<!DOCTYPE html>

<html xmlns="http://www.w3.org/1999/xhtml">

<head>

<meta charset="utf-8" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />




<title>CSBC/PS-ON Portal ETL</title>

<script>/*! jQuery v1.11.3 | (c) 2005, 2015 jQuery Foundation, Inc. | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=c.slice,e=c.concat,f=c.push,g=c.indexOf,h={},i=h.toString,j=h.hasOwnProperty,k={},l="1.11.3",m=function(a,b){return new m.fn.init(a,b)},n=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,o=/^-ms-/,p=/-([\da-z])/gi,q=function(a,b){return b.toUpperCase()};m.fn=m.prototype={jquery:l,constructor:m,selector:"",length:0,toArray:function(){return d.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:d.call(this)},pushStack:function(a){var b=m.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a,b){return m.each(this,a,b)},map:function(a){return this.pushStack(m.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(d.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor(null)},push:f,sort:c.sort,splice:c.splice},m.extend=m.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||m.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(m.isPlainObject(c)||(b=m.isArray(c)))?(b?(b=!1,f=a&&m.isArray(a)?a:[]):f=a&&m.isPlainObject(a)?a:{},g[d]=m.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},m.extend({expando:"jQuery"+(l+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===m.type(a)},isArray:Array.isArray||function(a){return"array"===m.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){return!m.isArray(a)&&a-parseFloat(a)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==m.type(a)||a.nodeType||m.isWindow(a))return!1;try{if(a.constructor&&!j.call(a,"constructor")&&!j.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(k.ownLast)for(b in a)return j.call(a,b);for(b in a);return void 0===b||j.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?h[i.call(a)]||"object":typeof a},globalEval:function(b){b&&m.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(o,"ms-").replace(p,q)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b,c){var d,e=0,f=a.length,g=r(a);if(c){if(g){for(;f>e;e++)if(d=b.apply(a[e],c),d===!1)break}else for(e in a)if(d=b.apply(a[e],c),d===!1)break}else if(g){for(;f>e;e++)if(d=b.call(a[e],e,a[e]),d===!1)break}else for(e in a)if(d=b.call(a[e],e,a[e]),d===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(n,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(r(Object(a))?m.merge(c,"string"==typeof a?[a]:a):f.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(g)return g.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,f=0,g=a.length,h=r(a),i=[];if(h)for(;g>f;f++)d=b(a[f],f,c),null!=d&&i.push(d);else for(f in a)d=b(a[f],f,c),null!=d&&i.push(d);return e.apply([],i)},guid:1,proxy:function(a,b){var c,e,f;return"string"==typeof b&&(f=a[b],b=a,a=f),m.isFunction(a)?(c=d.call(arguments,2),e=function(){return a.apply(b||this,c.concat(d.call(arguments)))},e.guid=a.guid=a.guid||m.guid++,e):void 0},now:function(){return+new Date},support:k}),m.each("Boolean Number String Function Array Date RegExp Object Error".split(" "),function(a,b){h["[object "+b+"]"]=b.toLowerCase()});function r(a){var b="length"in a&&a.length,c=m.type(a);return"function"===c||m.isWindow(a)?!1:1===a.nodeType&&b?!0:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var s=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ha(),z=ha(),A=ha(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N=M.replace("w","w#"),O="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+N+"))|)"+L+"*\\]",P=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+O+")*)|.*)\\)|)",Q=new RegExp(L+"+","g"),R=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),S=new RegExp("^"+L+"*,"+L+"*"),T=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),U=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),V=new RegExp(P),W=new RegExp("^"+N+"$"),X={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M.replace("w","w*")+")"),ATTR:new RegExp("^"+O),PSEUDO:new RegExp("^"+P),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},Y=/^(?:input|select|textarea|button)$/i,Z=/^h\d$/i,$=/^[^{]+\{\s*\[native \w/,_=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,aa=/[+~]/,ba=/'|\\/g,ca=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),da=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},ea=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(fa){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function ga(a,b,d,e){var f,h,j,k,l,o,r,s,w,x;if((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,d=d||[],k=b.nodeType,"string"!=typeof a||!a||1!==k&&9!==k&&11!==k)return d;if(!e&&p){if(11!==k&&(f=_.exec(a)))if(j=f[1]){if(9===k){if(h=b.getElementById(j),!h||!h.parentNode)return d;if(h.id===j)return d.push(h),d}else if(b.ownerDocument&&(h=b.ownerDocument.getElementById(j))&&t(b,h)&&h.id===j)return d.push(h),d}else{if(f[2])return H.apply(d,b.getElementsByTagName(a)),d;if((j=f[3])&&c.getElementsByClassName)return H.apply(d,b.getElementsByClassName(j)),d}if(c.qsa&&(!q||!q.test(a))){if(s=r=u,w=b,x=1!==k&&a,1===k&&"object"!==b.nodeName.toLowerCase()){o=g(a),(r=b.getAttribute("id"))?s=r.replace(ba,"\\$&"):b.setAttribute("id",s),s="[id='"+s+"'] ",l=o.length;while(l--)o[l]=s+ra(o[l]);w=aa.test(a)&&pa(b.parentNode)||b,x=o.join(",")}if(x)try{return H.apply(d,w.querySelectorAll(x)),d}catch(y){}finally{r||b.removeAttribute("id")}}}return i(a.replace(R,"$1"),b,d,e)}function ha(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ia(a){return a[u]=!0,a}function ja(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ka(a,b){var c=a.split("|"),e=a.length;while(e--)d.attrHandle[c[e]]=b}function la(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function na(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function oa(a){return ia(function(b){return b=+b,ia(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function pa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=ga.support={},f=ga.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=ga.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=g.documentElement,e=g.defaultView,e&&e!==e.top&&(e.addEventListener?e.addEventListener("unload",ea,!1):e.attachEvent&&e.attachEvent("onunload",ea)),p=!f(g),c.attributes=ja(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ja(function(a){return a.appendChild(g.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=$.test(g.getElementsByClassName),c.getById=ja(function(a){return o.appendChild(a).id=u,!g.getElementsByName||!g.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c&&c.parentNode?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=$.test(g.querySelectorAll))&&(ja(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\f]' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ja(function(a){var b=g.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=$.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ja(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",P)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=$.test(o.compareDocumentPosition),t=b||$.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===g||a.ownerDocument===v&&t(v,a)?-1:b===g||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,h=[a],i=[b];if(!e||!f)return a===g?-1:b===g?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return la(a,b);c=a;while(c=c.parentNode)h.unshift(c);c=b;while(c=c.parentNode)i.unshift(c);while(h[d]===i[d])d++;return d?la(h[d],i[d]):h[d]===v?-1:i[d]===v?1:0},g):n},ga.matches=function(a,b){return ga(a,null,null,b)},ga.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(U,"='$1']"),!(!c.matchesSelector||!p||r&&r.test(b)||q&&q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return ga(b,n,null,[a]).length>0},ga.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},ga.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},ga.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},ga.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=ga.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=ga.selectors={cacheLength:50,createPseudo:ia,match:X,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ca,da),a[3]=(a[3]||a[4]||a[5]||"").replace(ca,da),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||ga.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&ga.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return X.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&V.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ca,da).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=ga.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(Q," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h;if(q){if(f){while(p){l=b;while(l=l[p])if(h?l.nodeName.toLowerCase()===r:1===l.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){k=q[u]||(q[u]={}),j=k[a]||[],n=j[0]===w&&j[1],m=j[0]===w&&j[2],l=n&&q.childNodes[n];while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if(1===l.nodeType&&++m&&l===b){k[a]=[w,n,m];break}}else if(s&&(j=(b[u]||(b[u]={}))[a])&&j[0]===w)m=j[1];else while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if((h?l.nodeName.toLowerCase()===r:1===l.nodeType)&&++m&&(s&&((l[u]||(l[u]={}))[a]=[w,m]),l===b))break;return m-=e,m===d||m%d===0&&m/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||ga.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ia(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ia(function(a){var b=[],c=[],d=h(a.replace(R,"$1"));return d[u]?ia(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ia(function(a){return function(b){return ga(a,b).length>0}}),contains:ia(function(a){return a=a.replace(ca,da),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ia(function(a){return W.test(a||"")||ga.error("unsupported lang: "+a),a=a.replace(ca,da).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Z.test(a.nodeName)},input:function(a){return Y.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:oa(function(){return[0]}),last:oa(function(a,b){return[b-1]}),eq:oa(function(a,b,c){return[0>c?c+b:c]}),even:oa(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:oa(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:oa(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:oa(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=ma(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=na(b);function qa(){}qa.prototype=d.filters=d.pseudos,d.setFilters=new qa,g=ga.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){(!c||(e=S.exec(h)))&&(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=T.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(R," ")}),h=h.slice(c.length));for(g in d.filter)!(e=X[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?ga.error(a):z(a,i).slice(0)};function ra(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function sa(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(i=b[u]||(b[u]={}),(h=i[d])&&h[0]===w&&h[1]===f)return j[2]=h[2];if(i[d]=j,j[2]=a(b,c,g))return!0}}}function ta(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ua(a,b,c){for(var d=0,e=b.length;e>d;d++)ga(a,b[d],c);return c}function va(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(!c||c(f,d,e))&&(g.push(f),j&&b.push(h));return g}function wa(a,b,c,d,e,f){return d&&!d[u]&&(d=wa(d)),e&&!e[u]&&(e=wa(e,f)),ia(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ua(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:va(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=va(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=va(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function xa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=sa(function(a){return a===b},h,!0),l=sa(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[sa(ta(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return wa(i>1&&ta(m),i>1&&ra(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(R,"$1"),c,e>i&&xa(a.slice(i,e)),f>e&&xa(a=a.slice(e)),f>e&&ra(a))}m.push(c)}return ta(m)}function ya(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,m,o,p=0,q="0",r=f&&[],s=[],t=j,u=f||e&&d.find.TAG("*",k),v=w+=null==t?1:Math.random()||.1,x=u.length;for(k&&(j=g!==n&&g);q!==x&&null!=(l=u[q]);q++){if(e&&l){m=0;while(o=a[m++])if(o(l,g,h)){i.push(l);break}k&&(w=v)}c&&((l=!o&&l)&&p--,f&&r.push(l))}if(p+=q,c&&q!==p){m=0;while(o=b[m++])o(r,s,g,h);if(f){if(p>0)while(q--)r[q]||s[q]||(s[q]=F.call(i));s=va(s)}H.apply(i,s),k&&!f&&s.length>0&&p+b.length>1&&ga.uniqueSort(i)}return k&&(w=v,j=t),r};return c?ia(f):f}return h=ga.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=xa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,ya(e,d)),f.selector=a}return f},i=ga.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ca,da),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=X.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ca,da),aa.test(j[0].type)&&pa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&ra(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,aa.test(a)&&pa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ja(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ja(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ka("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ja(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ka("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ja(function(a){return null==a.getAttribute("disabled")})||ka(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),ga}(a);m.find=s,m.expr=s.selectors,m.expr[":"]=m.expr.pseudos,m.unique=s.uniqueSort,m.text=s.getText,m.isXMLDoc=s.isXML,m.contains=s.contains;var t=m.expr.match.needsContext,u=/^<(\w+)\s*\/?>(?:<\/\1>|)$/,v=/^.[^:#\[\.,]*$/;function w(a,b,c){if(m.isFunction(b))return m.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return m.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(v.test(b))return m.filter(b,a,c);b=m.filter(b,a)}return m.grep(a,function(a){return m.inArray(a,b)>=0!==c})}m.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?m.find.matchesSelector(d,a)?[d]:[]:m.find.matches(a,m.grep(b,function(a){return 1===a.nodeType}))},m.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(m(a).filter(function(){for(b=0;e>b;b++)if(m.contains(d[b],this))return!0}));for(b=0;e>b;b++)m.find(a,d[b],c);return c=this.pushStack(e>1?m.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(w(this,a||[],!1))},not:function(a){return this.pushStack(w(this,a||[],!0))},is:function(a){return!!w(this,"string"==typeof a&&t.test(a)?m(a):a||[],!1).length}});var x,y=a.document,z=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,A=m.fn.init=function(a,b){var c,d;if(!a)return this;if("string"==typeof a){if(c="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:z.exec(a),!c||!c[1]&&b)return!b||b.jquery?(b||x).find(a):this.constructor(b).find(a);if(c[1]){if(b=b instanceof m?b[0]:b,m.merge(this,m.parseHTML(c[1],b&&b.nodeType?b.ownerDocument||b:y,!0)),u.test(c[1])&&m.isPlainObject(b))for(c in b)m.isFunction(this[c])?this[c](b[c]):this.attr(c,b[c]);return this}if(d=y.getElementById(c[2]),d&&d.parentNode){if(d.id!==c[2])return x.find(a);this.length=1,this[0]=d}return this.context=y,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):m.isFunction(a)?"undefined"!=typeof x.ready?x.ready(a):a(m):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),m.makeArray(a,this))};A.prototype=m.fn,x=m(y);var B=/^(?:parents|prev(?:Until|All))/,C={children:!0,contents:!0,next:!0,prev:!0};m.extend({dir:function(a,b,c){var d=[],e=a[b];while(e&&9!==e.nodeType&&(void 0===c||1!==e.nodeType||!m(e).is(c)))1===e.nodeType&&d.push(e),e=e[b];return d},sibling:function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c}}),m.fn.extend({has:function(a){var b,c=m(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(m.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=t.test(a)||"string"!=typeof a?m(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&m.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?m.unique(f):f)},index:function(a){return a?"string"==typeof a?m.inArray(this[0],m(a)):m.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(m.unique(m.merge(this.get(),m(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function D(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}m.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return m.dir(a,"parentNode")},parentsUntil:function(a,b,c){return m.dir(a,"parentNode",c)},next:function(a){return D(a,"nextSibling")},prev:function(a){return D(a,"previousSibling")},nextAll:function(a){return m.dir(a,"nextSibling")},prevAll:function(a){return m.dir(a,"previousSibling")},nextUntil:function(a,b,c){return m.dir(a,"nextSibling",c)},prevUntil:function(a,b,c){return m.dir(a,"previousSibling",c)},siblings:function(a){return m.sibling((a.parentNode||{}).firstChild,a)},children:function(a){return m.sibling(a.firstChild)},contents:function(a){return m.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:m.merge([],a.childNodes)}},function(a,b){m.fn[a]=function(c,d){var e=m.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=m.filter(d,e)),this.length>1&&(C[a]||(e=m.unique(e)),B.test(a)&&(e=e.reverse())),this.pushStack(e)}});var E=/\S+/g,F={};function G(a){var b=F[a]={};return m.each(a.match(E)||[],function(a,c){b[c]=!0}),b}m.Callbacks=function(a){a="string"==typeof a?F[a]||G(a):m.extend({},a);var b,c,d,e,f,g,h=[],i=!a.once&&[],j=function(l){for(c=a.memory&&l,d=!0,f=g||0,g=0,e=h.length,b=!0;h&&e>f;f++)if(h[f].apply(l[0],l[1])===!1&&a.stopOnFalse){c=!1;break}b=!1,h&&(i?i.length&&j(i.shift()):c?h=[]:k.disable())},k={add:function(){if(h){var d=h.length;!function f(b){m.each(b,function(b,c){var d=m.type(c);"function"===d?a.unique&&k.has(c)||h.push(c):c&&c.length&&"string"!==d&&f(c)})}(arguments),b?e=h.length:c&&(g=d,j(c))}return this},remove:function(){return h&&m.each(arguments,function(a,c){var d;while((d=m.inArray(c,h,d))>-1)h.splice(d,1),b&&(e>=d&&e--,f>=d&&f--)}),this},has:function(a){return a?m.inArray(a,h)>-1:!(!h||!h.length)},empty:function(){return h=[],e=0,this},disable:function(){return h=i=c=void 0,this},disabled:function(){return!h},lock:function(){return i=void 0,c||k.disable(),this},locked:function(){return!i},fireWith:function(a,c){return!h||d&&!i||(c=c||[],c=[a,c.slice?c.slice():c],b?i.push(c):j(c)),this},fire:function(){return k.fireWith(this,arguments),this},fired:function(){return!!d}};return k},m.extend({Deferred:function(a){var b=[["resolve","done",m.Callbacks("once memory"),"resolved"],["reject","fail",m.Callbacks("once memory"),"rejected"],["notify","progress",m.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return m.Deferred(function(c){m.each(b,function(b,f){var g=m.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&m.isFunction(a.promise)?a.promise().done(c.resolve).fail(c.reject).progress(c.notify):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?m.extend(a,d):d}},e={};return d.pipe=d.then,m.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=d.call(arguments),e=c.length,f=1!==e||a&&m.isFunction(a.promise)?e:0,g=1===f?a:m.Deferred(),h=function(a,b,c){return function(e){b[a]=this,c[a]=arguments.length>1?d.call(arguments):e,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(e>1)for(i=new Array(e),j=new Array(e),k=new Array(e);e>b;b++)c[b]&&m.isFunction(c[b].promise)?c[b].promise().done(h(b,k,c)).fail(g.reject).progress(h(b,j,i)):--f;return f||g.resolveWith(k,c),g.promise()}});var H;m.fn.ready=function(a){return m.ready.promise().done(a),this},m.extend({isReady:!1,readyWait:1,holdReady:function(a){a?m.readyWait++:m.ready(!0)},ready:function(a){if(a===!0?!--m.readyWait:!m.isReady){if(!y.body)return setTimeout(m.ready);m.isReady=!0,a!==!0&&--m.readyWait>0||(H.resolveWith(y,[m]),m.fn.triggerHandler&&(m(y).triggerHandler("ready"),m(y).off("ready")))}}});function I(){y.addEventListener?(y.removeEventListener("DOMContentLoaded",J,!1),a.removeEventListener("load",J,!1)):(y.detachEvent("onreadystatechange",J),a.detachEvent("onload",J))}function J(){(y.addEventListener||"load"===event.type||"complete"===y.readyState)&&(I(),m.ready())}m.ready.promise=function(b){if(!H)if(H=m.Deferred(),"complete"===y.readyState)setTimeout(m.ready);else if(y.addEventListener)y.addEventListener("DOMContentLoaded",J,!1),a.addEventListener("load",J,!1);else{y.attachEvent("onreadystatechange",J),a.attachEvent("onload",J);var c=!1;try{c=null==a.frameElement&&y.documentElement}catch(d){}c&&c.doScroll&&!function e(){if(!m.isReady){try{c.doScroll("left")}catch(a){return setTimeout(e,50)}I(),m.ready()}}()}return H.promise(b)};var K="undefined",L;for(L in m(k))break;k.ownLast="0"!==L,k.inlineBlockNeedsLayout=!1,m(function(){var a,b,c,d;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",k.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(d))}),function(){var a=y.createElement("div");if(null==k.deleteExpando){k.deleteExpando=!0;try{delete a.test}catch(b){k.deleteExpando=!1}}a=null}(),m.acceptData=function(a){var b=m.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b};var M=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,N=/([A-Z])/g;function O(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(N,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:M.test(c)?m.parseJSON(c):c}catch(e){}m.data(a,b,c)}else c=void 0}return c}function P(a){var b;for(b in a)if(("data"!==b||!m.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;

return!0}function Q(a,b,d,e){if(m.acceptData(a)){var f,g,h=m.expando,i=a.nodeType,j=i?m.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||m.guid++:h),j[k]||(j[k]=i?{}:{toJSON:m.noop}),("object"==typeof b||"function"==typeof b)&&(e?j[k]=m.extend(j[k],b):j[k].data=m.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[m.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[m.camelCase(b)])):f=g,f}}function R(a,b,c){if(m.acceptData(a)){var d,e,f=a.nodeType,g=f?m.cache:a,h=f?a[m.expando]:m.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){m.isArray(b)?b=b.concat(m.map(b,m.camelCase)):b in d?b=[b]:(b=m.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!P(d):!m.isEmptyObject(d))return}(c||(delete g[h].data,P(g[h])))&&(f?m.cleanData([a],!0):k.deleteExpando||g!=g.window?delete g[h]:g[h]=null)}}}m.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?m.cache[a[m.expando]]:a[m.expando],!!a&&!P(a)},data:function(a,b,c){return Q(a,b,c)},removeData:function(a,b){return R(a,b)},_data:function(a,b,c){return Q(a,b,c,!0)},_removeData:function(a,b){return R(a,b,!0)}}),m.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=m.data(f),1===f.nodeType&&!m._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=m.camelCase(d.slice(5)),O(f,d,e[d])));m._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){m.data(this,a)}):arguments.length>1?this.each(function(){m.data(this,a,b)}):f?O(f,a,m.data(f,a)):void 0},removeData:function(a){return this.each(function(){m.removeData(this,a)})}}),m.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=m._data(a,b),c&&(!d||m.isArray(c)?d=m._data(a,b,m.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=m.queue(a,b),d=c.length,e=c.shift(),f=m._queueHooks(a,b),g=function(){m.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return m._data(a,c)||m._data(a,c,{empty:m.Callbacks("once memory").add(function(){m._removeData(a,b+"queue"),m._removeData(a,c)})})}}),m.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?m.queue(this[0],a):void 0===b?this:this.each(function(){var c=m.queue(this,a,b);m._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&m.dequeue(this,a)})},dequeue:function(a){return this.each(function(){m.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=m.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=m._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}});var S=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,T=["Top","Right","Bottom","Left"],U=function(a,b){return a=b||a,"none"===m.css(a,"display")||!m.contains(a.ownerDocument,a)},V=m.access=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===m.type(c)){e=!0;for(h in c)m.access(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,m.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(m(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},W=/^(?:checkbox|radio)$/i;!function(){var a=y.createElement("input"),b=y.createElement("div"),c=y.createDocumentFragment();if(b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",k.leadingWhitespace=3===b.firstChild.nodeType,k.tbody=!b.getElementsByTagName("tbody").length,k.htmlSerialize=!!b.getElementsByTagName("link").length,k.html5Clone="<:nav></:nav>"!==y.createElement("nav").cloneNode(!0).outerHTML,a.type="checkbox",a.checked=!0,c.appendChild(a),k.appendChecked=a.checked,b.innerHTML="<textarea>x</textarea>",k.noCloneChecked=!!b.cloneNode(!0).lastChild.defaultValue,c.appendChild(b),b.innerHTML="<input type='radio' checked='checked' name='t'/>",k.checkClone=b.cloneNode(!0).cloneNode(!0).lastChild.checked,k.noCloneEvent=!0,b.attachEvent&&(b.attachEvent("onclick",function(){k.noCloneEvent=!1}),b.cloneNode(!0).click()),null==k.deleteExpando){k.deleteExpando=!0;try{delete b.test}catch(d){k.deleteExpando=!1}}}(),function(){var b,c,d=y.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(k[b+"Bubbles"]=c in a)||(d.setAttribute(c,"t"),k[b+"Bubbles"]=d.attributes[c].expando===!1);d=null}();var X=/^(?:input|select|textarea)$/i,Y=/^key/,Z=/^(?:mouse|pointer|contextmenu)|click/,$=/^(?:focusinfocus|focusoutblur)$/,_=/^([^.]*)(?:\.(.+)|)$/;function aa(){return!0}function ba(){return!1}function ca(){try{return y.activeElement}catch(a){}}m.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=m.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return typeof m===K||a&&m.event.triggered===a.type?void 0:m.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(E)||[""],h=b.length;while(h--)f=_.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=m.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=m.event.special[o]||{},l=m.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&m.expr.match.needsContext.test(e),namespace:p.join(".")},i),(n=g[o])||(n=g[o]=[],n.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?n.splice(n.delegateCount++,0,l):n.push(l),m.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m.hasData(a)&&m._data(a);if(r&&(k=r.events)){b=(b||"").match(E)||[""],j=b.length;while(j--)if(h=_.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=m.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,n=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=n.length;while(f--)g=n[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(n.splice(f,1),g.selector&&n.delegateCount--,l.remove&&l.remove.call(a,g));i&&!n.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||m.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)m.event.remove(a,o+b[j],c,d,!0);m.isEmptyObject(k)&&(delete r.handle,m._removeData(a,"events"))}},trigger:function(b,c,d,e){var f,g,h,i,k,l,n,o=[d||y],p=j.call(b,"type")?b.type:b,q=j.call(b,"namespace")?b.namespace.split("."):[];if(h=l=d=d||y,3!==d.nodeType&&8!==d.nodeType&&!$.test(p+m.event.triggered)&&(p.indexOf(".")>=0&&(q=p.split("."),p=q.shift(),q.sort()),g=p.indexOf(":")<0&&"on"+p,b=b[m.expando]?b:new m.Event(p,"object"==typeof b&&b),b.isTrigger=e?2:3,b.namespace=q.join("."),b.namespace_re=b.namespace?new RegExp("(^|\\.)"+q.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=d),c=null==c?[b]:m.makeArray(c,[b]),k=m.event.special[p]||{},e||!k.trigger||k.trigger.apply(d,c)!==!1)){if(!e&&!k.noBubble&&!m.isWindow(d)){for(i=k.delegateType||p,$.test(i+p)||(h=h.parentNode);h;h=h.parentNode)o.push(h),l=h;l===(d.ownerDocument||y)&&o.push(l.defaultView||l.parentWindow||a)}n=0;while((h=o[n++])&&!b.isPropagationStopped())b.type=n>1?i:k.bindType||p,f=(m._data(h,"events")||{})[b.type]&&m._data(h,"handle"),f&&f.apply(h,c),f=g&&h[g],f&&f.apply&&m.acceptData(h)&&(b.result=f.apply(h,c),b.result===!1&&b.preventDefault());if(b.type=p,!e&&!b.isDefaultPrevented()&&(!k._default||k._default.apply(o.pop(),c)===!1)&&m.acceptData(d)&&g&&d[p]&&!m.isWindow(d)){l=d[g],l&&(d[g]=null),m.event.triggered=p;try{d[p]()}catch(r){}m.event.triggered=void 0,l&&(d[g]=l)}return b.result}},dispatch:function(a){a=m.event.fix(a);var b,c,e,f,g,h=[],i=d.call(arguments),j=(m._data(this,"events")||{})[a.type]||[],k=m.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=m.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,g=0;while((e=f.handlers[g++])&&!a.isImmediatePropagationStopped())(!a.namespace_re||a.namespace_re.test(e.namespace))&&(a.handleObj=e,a.data=e.data,c=((m.event.special[e.origType]||{}).handle||e.handler).apply(f.elem,i),void 0!==c&&(a.result=c)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&(!a.button||"click"!==a.type))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(e=[],f=0;h>f;f++)d=b[f],c=d.selector+" ",void 0===e[c]&&(e[c]=d.needsContext?m(c,this).index(i)>=0:m.find(c,this,null,[i]).length),e[c]&&e.push(d);e.length&&g.push({elem:i,handlers:e})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[m.expando])return a;var b,c,d,e=a.type,f=a,g=this.fixHooks[e];g||(this.fixHooks[e]=g=Z.test(e)?this.mouseHooks:Y.test(e)?this.keyHooks:{}),d=g.props?this.props.concat(g.props):this.props,a=new m.Event(f),b=d.length;while(b--)c=d[b],a[c]=f[c];return a.target||(a.target=f.srcElement||y),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,g.filter?g.filter(a,f):a},props:"altKey bubbles cancelable ctrlKey currentTarget eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,d,e,f=b.button,g=b.fromElement;return null==a.pageX&&null!=b.clientX&&(d=a.target.ownerDocument||y,e=d.documentElement,c=d.body,a.pageX=b.clientX+(e&&e.scrollLeft||c&&c.scrollLeft||0)-(e&&e.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(e&&e.scrollTop||c&&c.scrollTop||0)-(e&&e.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&g&&(a.relatedTarget=g===a.target?b.toElement:g),a.which||void 0===f||(a.which=1&f?1:2&f?3:4&f?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ca()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ca()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return m.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return m.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c,d){var e=m.extend(new m.Event,c,{type:a,isSimulated:!0,originalEvent:{}});d?m.event.trigger(e,null,b):m.event.dispatch.call(b,e),e.isDefaultPrevented()&&c.preventDefault()}},m.removeEvent=y.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c,!1)}:function(a,b,c){var d="on"+b;a.detachEvent&&(typeof a[d]===K&&(a[d]=null),a.detachEvent(d,c))},m.Event=function(a,b){return this instanceof m.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?aa:ba):this.type=a,b&&m.extend(this,b),this.timeStamp=a&&a.timeStamp||m.now(),void(this[m.expando]=!0)):new m.Event(a,b)},m.Event.prototype={isDefaultPrevented:ba,isPropagationStopped:ba,isImmediatePropagationStopped:ba,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=aa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=aa,a&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=aa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},m.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){m.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return(!e||e!==d&&!m.contains(d,e))&&(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),k.submitBubbles||(m.event.special.submit={setup:function(){return m.nodeName(this,"form")?!1:void m.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=m.nodeName(b,"input")||m.nodeName(b,"button")?b.form:void 0;c&&!m._data(c,"submitBubbles")&&(m.event.add(c,"submit._submit",function(a){a._submit_bubble=!0}),m._data(c,"submitBubbles",!0))})},postDispatch:function(a){a._submit_bubble&&(delete a._submit_bubble,this.parentNode&&!a.isTrigger&&m.event.simulate("submit",this.parentNode,a,!0))},teardown:function(){return m.nodeName(this,"form")?!1:void m.event.remove(this,"._submit")}}),k.changeBubbles||(m.event.special.change={setup:function(){return X.test(this.nodeName)?(("checkbox"===this.type||"radio"===this.type)&&(m.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._just_changed=!0)}),m.event.add(this,"click._change",function(a){this._just_changed&&!a.isTrigger&&(this._just_changed=!1),m.event.simulate("change",this,a,!0)})),!1):void m.event.add(this,"beforeactivate._change",function(a){var b=a.target;X.test(b.nodeName)&&!m._data(b,"changeBubbles")&&(m.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||m.event.simulate("change",this.parentNode,a,!0)}),m._data(b,"changeBubbles",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return m.event.remove(this,"._change"),!X.test(this.nodeName)}}),k.focusinBubbles||m.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){m.event.simulate(b,a.target,m.event.fix(a),!0)};m.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=m._data(d,b);e||d.addEventListener(a,c,!0),m._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=m._data(d,b)-1;e?m._data(d,b,e):(d.removeEventListener(a,c,!0),m._removeData(d,b))}}}),m.fn.extend({on:function(a,b,c,d,e){var f,g;if("object"==typeof a){"string"!=typeof b&&(c=c||b,b=void 0);for(f in a)this.on(f,b,c,a[f],e);return this}if(null==c&&null==d?(d=b,c=b=void 0):null==d&&("string"==typeof b?(d=c,c=void 0):(d=c,c=b,b=void 0)),d===!1)d=ba;else if(!d)return this;return 1===e&&(g=d,d=function(a){return m().off(a),g.apply(this,arguments)},d.guid=g.guid||(g.guid=m.guid++)),this.each(function(){m.event.add(this,a,d,c,b)})},one:function(a,b,c,d){return this.on(a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,m(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return(b===!1||"function"==typeof b)&&(c=b,b=void 0),c===!1&&(c=ba),this.each(function(){m.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){m.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?m.event.trigger(a,b,c,!0):void 0}});function da(a){var b=ea.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}var ea="abbr|article|aside|audio|bdi|canvas|data|datalist|details|figcaption|figure|footer|header|hgroup|mark|meter|nav|output|progress|section|summary|time|video",fa=/ jQuery\d+="(?:null|\d+)"/g,ga=new RegExp("<(?:"+ea+")[\\s/>]","i"),ha=/^\s+/,ia=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/gi,ja=/<([\w:]+)/,ka=/<tbody/i,la=/<|&#?\w+;/,ma=/<(?:script|style|link)/i,na=/checked\s*(?:[^=]|=\s*.checked.)/i,oa=/^$|\/(?:java|ecma)script/i,pa=/^true\/(.*)/,qa=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,ra={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:k.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]},sa=da(y),ta=sa.appendChild(y.createElement("div"));ra.optgroup=ra.option,ra.tbody=ra.tfoot=ra.colgroup=ra.caption=ra.thead,ra.th=ra.td;function ua(a,b){var c,d,e=0,f=typeof a.getElementsByTagName!==K?a.getElementsByTagName(b||"*"):typeof a.querySelectorAll!==K?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||m.nodeName(d,b)?f.push(d):m.merge(f,ua(d,b));return void 0===b||b&&m.nodeName(a,b)?m.merge([a],f):f}function va(a){W.test(a.type)&&(a.defaultChecked=a.checked)}function wa(a,b){return m.nodeName(a,"table")&&m.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function xa(a){return a.type=(null!==m.find.attr(a,"type"))+"/"+a.type,a}function ya(a){var b=pa.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function za(a,b){for(var c,d=0;null!=(c=a[d]);d++)m._data(c,"globalEval",!b||m._data(b[d],"globalEval"))}function Aa(a,b){if(1===b.nodeType&&m.hasData(a)){var c,d,e,f=m._data(a),g=m._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)m.event.add(b,c,h[c][d])}g.data&&(g.data=m.extend({},g.data))}}function Ba(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!k.noCloneEvent&&b[m.expando]){e=m._data(b);for(d in e.events)m.removeEvent(b,d,e.handle);b.removeAttribute(m.expando)}"script"===c&&b.text!==a.text?(xa(b).text=a.text,ya(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),k.html5Clone&&a.innerHTML&&!m.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&W.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:("input"===c||"textarea"===c)&&(b.defaultValue=a.defaultValue)}}m.extend({clone:function(a,b,c){var d,e,f,g,h,i=m.contains(a.ownerDocument,a);if(k.html5Clone||m.isXMLDoc(a)||!ga.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(ta.innerHTML=a.outerHTML,ta.removeChild(f=ta.firstChild)),!(k.noCloneEvent&&k.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||m.isXMLDoc(a)))for(d=ua(f),h=ua(a),g=0;null!=(e=h[g]);++g)d[g]&&Ba(e,d[g]);if(b)if(c)for(h=h||ua(a),d=d||ua(f),g=0;null!=(e=h[g]);g++)Aa(e,d[g]);else Aa(a,f);return d=ua(f,"script"),d.length>0&&za(d,!i&&ua(a,"script")),d=h=e=null,f},buildFragment:function(a,b,c,d){for(var e,f,g,h,i,j,l,n=a.length,o=da(b),p=[],q=0;n>q;q++)if(f=a[q],f||0===f)if("object"===m.type(f))m.merge(p,f.nodeType?[f]:f);else if(la.test(f)){h=h||o.appendChild(b.createElement("div")),i=(ja.exec(f)||["",""])[1].toLowerCase(),l=ra[i]||ra._default,h.innerHTML=l[1]+f.replace(ia,"<$1></$2>")+l[2],e=l[0];while(e--)h=h.lastChild;if(!k.leadingWhitespace&&ha.test(f)&&p.push(b.createTextNode(ha.exec(f)[0])),!k.tbody){f="table"!==i||ka.test(f)?"<table>"!==l[1]||ka.test(f)?0:h:h.firstChild,e=f&&f.childNodes.length;while(e--)m.nodeName(j=f.childNodes[e],"tbody")&&!j.childNodes.length&&f.removeChild(j)}m.merge(p,h.childNodes),h.textContent="";while(h.firstChild)h.removeChild(h.firstChild);h=o.lastChild}else p.push(b.createTextNode(f));h&&o.removeChild(h),k.appendChecked||m.grep(ua(p,"input"),va),q=0;while(f=p[q++])if((!d||-1===m.inArray(f,d))&&(g=m.contains(f.ownerDocument,f),h=ua(o.appendChild(f),"script"),g&&za(h),c)){e=0;while(f=h[e++])oa.test(f.type||"")&&c.push(f)}return h=null,o},cleanData:function(a,b){for(var d,e,f,g,h=0,i=m.expando,j=m.cache,l=k.deleteExpando,n=m.event.special;null!=(d=a[h]);h++)if((b||m.acceptData(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)n[e]?m.event.remove(d,e):m.removeEvent(d,e,g.handle);j[f]&&(delete j[f],l?delete d[i]:typeof d.removeAttribute!==K?d.removeAttribute(i):d[i]=null,c.push(f))}}}),m.fn.extend({text:function(a){return V(this,function(a){return void 0===a?m.text(this):this.empty().append((this[0]&&this[0].ownerDocument||y).createTextNode(a))},null,a,arguments.length)},append:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.appendChild(a)}})},prepend:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},remove:function(a,b){for(var c,d=a?m.filter(a,this):this,e=0;null!=(c=d[e]);e++)b||1!==c.nodeType||m.cleanData(ua(c)),c.parentNode&&(b&&m.contains(c.ownerDocument,c)&&za(ua(c,"script")),c.parentNode.removeChild(c));return this},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&m.cleanData(ua(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&m.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return m.clone(this,a,b)})},html:function(a){return V(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(fa,""):void 0;if(!("string"!=typeof a||ma.test(a)||!k.htmlSerialize&&ga.test(a)||!k.leadingWhitespace&&ha.test(a)||ra[(ja.exec(a)||["",""])[1].toLowerCase()])){a=a.replace(ia,"<$1></$2>");try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(m.cleanData(ua(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=arguments[0];return this.domManip(arguments,function(b){a=this.parentNode,m.cleanData(ua(this)),a&&a.replaceChild(b,this)}),a&&(a.length||a.nodeType)?this:this.remove()},detach:function(a){return this.remove(a,!0)},domManip:function(a,b){a=e.apply([],a);var c,d,f,g,h,i,j=0,l=this.length,n=this,o=l-1,p=a[0],q=m.isFunction(p);if(q||l>1&&"string"==typeof p&&!k.checkClone&&na.test(p))return this.each(function(c){var d=n.eq(c);q&&(a[0]=p.call(this,c,d.html())),d.domManip(a,b)});if(l&&(i=m.buildFragment(a,this[0].ownerDocument,!1,this),c=i.firstChild,1===i.childNodes.length&&(i=c),c)){for(g=m.map(ua(i,"script"),xa),f=g.length;l>j;j++)d=i,j!==o&&(d=m.clone(d,!0,!0),f&&m.merge(g,ua(d,"script"))),b.call(this[j],d,j);if(f)for(h=g[g.length-1].ownerDocument,m.map(g,ya),j=0;f>j;j++)d=g[j],oa.test(d.type||"")&&!m._data(d,"globalEval")&&m.contains(h,d)&&(d.src?m._evalUrl&&m._evalUrl(d.src):m.globalEval((d.text||d.textContent||d.innerHTML||"").replace(qa,"")));i=c=null}return this}}),m.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){m.fn[a]=function(a){for(var c,d=0,e=[],g=m(a),h=g.length-1;h>=d;d++)c=d===h?this:this.clone(!0),m(g[d])[b](c),f.apply(e,c.get());return this.pushStack(e)}});var Ca,Da={};function Ea(b,c){var d,e=m(c.createElement(b)).appendTo(c.body),f=a.getDefaultComputedStyle&&(d=a.getDefaultComputedStyle(e[0]))?d.display:m.css(e[0],"display");return e.detach(),f}function Fa(a){var b=y,c=Da[a];return c||(c=Ea(a,b),"none"!==c&&c||(Ca=(Ca||m("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ca[0].contentWindow||Ca[0].contentDocument).document,b.write(),b.close(),c=Ea(a,b),Ca.detach()),Da[a]=c),c}!function(){var a;k.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,d;return c=y.getElementsByTagName("body")[0],c&&c.style?(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(y.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(d),a):void 0}}();var Ga=/^margin/,Ha=new RegExp("^("+S+")(?!px)[a-z%]+$","i"),Ia,Ja,Ka=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ia=function(b){return b.ownerDocument.defaultView.opener?b.ownerDocument.defaultView.getComputedStyle(b,null):a.getComputedStyle(b,null)},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c.getPropertyValue(b)||c[b]:void 0,c&&(""!==g||m.contains(a.ownerDocument,a)||(g=m.style(a,b)),Ha.test(g)&&Ga.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f)),void 0===g?g:g+""}):y.documentElement.currentStyle&&(Ia=function(a){return a.currentStyle},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Ha.test(g)&&!Ka.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function La(a,b){return{get:function(){var c=a();if(null!=c)return c?void delete this.get:(this.get=b).apply(this,arguments)}}}!function(){var b,c,d,e,f,g,h;if(b=y.createElement("div"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=d&&d.style){c.cssText="float:left;opacity:.5",k.opacity="0.5"===c.opacity,k.cssFloat=!!c.cssFloat,b.style.backgroundClip="content-box",b.cloneNode(!0).style.backgroundClip="",k.clearCloneStyle="content-box"===b.style.backgroundClip,k.boxSizing=""===c.boxSizing||""===c.MozBoxSizing||""===c.WebkitBoxSizing,m.extend(k,{reliableHiddenOffsets:function(){return null==g&&i(),g},boxSizingReliable:function(){return null==f&&i(),f},pixelPosition:function(){return null==e&&i(),e},reliableMarginRight:function(){return null==h&&i(),h}});function i(){var b,c,d,i;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),b.style.cssText="-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;display:block;margin-top:1%;top:1%;border:1px;padding:1px;width:4px;position:absolute",e=f=!1,h=!0,a.getComputedStyle&&(e="1%"!==(a.getComputedStyle(b,null)||{}).top,f="4px"===(a.getComputedStyle(b,null)||{width:"4px"}).width,i=b.appendChild(y.createElement("div")),i.style.cssText=b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",i.style.marginRight=i.style.width="0",b.style.width="1px",h=!parseFloat((a.getComputedStyle(i,null)||{}).marginRight),b.removeChild(i)),b.innerHTML="<table><tr><td></td><td>t</td></tr></table>",i=b.getElementsByTagName("td"),i[0].style.cssText="margin:0;border:0;padding:0;display:none",g=0===i[0].offsetHeight,g&&(i[0].style.display="",i[1].style.display="none",g=0===i[0].offsetHeight),c.removeChild(d))}}}(),m.swap=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e};var Ma=/alpha\([^)]*\)/i,Na=/opacity\s*=\s*([^)]*)/,Oa=/^(none|table(?!-c[ea]).+)/,Pa=new RegExp("^("+S+")(.*)$","i"),Qa=new RegExp("^([+-])=("+S+")","i"),Ra={position:"absolute",visibility:"hidden",display:"block"},Sa={letterSpacing:"0",fontWeight:"400"},Ta=["Webkit","O","Moz","ms"];function Ua(a,b){if(b in a)return b;var c=b.charAt(0).toUpperCase()+b.slice(1),d=b,e=Ta.length;while(e--)if(b=Ta[e]+c,b in a)return b;return d}function Va(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=m._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&U(d)&&(f[g]=m._data(d,"olddisplay",Fa(d.nodeName)))):(e=U(d),(c&&"none"!==c||!e)&&m._data(d,"olddisplay",e?c:m.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function Wa(a,b,c){var d=Pa.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function Xa(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=m.css(a,c+T[f],!0,e)),d?("content"===c&&(g-=m.css(a,"padding"+T[f],!0,e)),"margin"!==c&&(g-=m.css(a,"border"+T[f]+"Width",!0,e))):(g+=m.css(a,"padding"+T[f],!0,e),"padding"!==c&&(g+=m.css(a,"border"+T[f]+"Width",!0,e)));return g}function Ya(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ia(a),g=k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Ja(a,b,f),(0>e||null==e)&&(e=a.style[b]),Ha.test(e))return e;d=g&&(k.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+Xa(a,b,c||(g?"border":"content"),d,f)+"px"}m.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Ja(a,"opacity");return""===c?"1":c}}}},cssNumber:{columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":k.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=m.camelCase(b),i=a.style;if(b=m.cssProps[h]||(m.cssProps[h]=Ua(i,h)),g=m.cssHooks[b]||m.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=Qa.exec(c))&&(c=(e[1]+1)*e[2]+parseFloat(m.css(a,b)),f="number"),null!=c&&c===c&&("number"!==f||m.cssNumber[h]||(c+="px"),k.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=m.camelCase(b);return b=m.cssProps[h]||(m.cssProps[h]=Ua(a.style,h)),g=m.cssHooks[b]||m.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Ja(a,b,d)),"normal"===f&&b in Sa&&(f=Sa[b]),""===c||c?(e=parseFloat(f),c===!0||m.isNumeric(e)?e||0:f):f}}),m.each(["height","width"],function(a,b){m.cssHooks[b]={get:function(a,c,d){return c?Oa.test(m.css(a,"display"))&&0===a.offsetWidth?m.swap(a,Ra,function(){return Ya(a,b,d)}):Ya(a,b,d):void 0},set:function(a,c,d){var e=d&&Ia(a);return Wa(a,c,d?Xa(a,b,d,k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,e),e):0)}}}),k.opacity||(m.cssHooks.opacity={get:function(a,b){return Na.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=m.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===m.trim(f.replace(Ma,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Ma.test(f)?f.replace(Ma,e):f+" "+e)}}),m.cssHooks.marginRight=La(k.reliableMarginRight,function(a,b){return b?m.swap(a,{display:"inline-block"},Ja,[a,"marginRight"]):void 0}),m.each({margin:"",padding:"",border:"Width"},function(a,b){m.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+T[d]+b]=f[d]||f[d-2]||f[0];return e}},Ga.test(a)||(m.cssHooks[a+b].set=Wa)}),m.fn.extend({css:function(a,b){return V(this,function(a,b,c){var d,e,f={},g=0;if(m.isArray(b)){for(d=Ia(a),e=b.length;e>g;g++)f[b[g]]=m.css(a,b[g],!1,d);return f}return void 0!==c?m.style(a,b,c):m.css(a,b)},a,b,arguments.length>1)},show:function(){return Va(this,!0)},hide:function(){return Va(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){U(this)?m(this).show():m(this).hide()})}});function Za(a,b,c,d,e){
return new Za.prototype.init(a,b,c,d,e)}m.Tween=Za,Za.prototype={constructor:Za,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||"swing",this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(m.cssNumber[c]?"":"px")},cur:function(){var a=Za.propHooks[this.prop];return a&&a.get?a.get(this):Za.propHooks._default.get(this)},run:function(a){var b,c=Za.propHooks[this.prop];return this.options.duration?this.pos=b=m.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):Za.propHooks._default.set(this),this}},Za.prototype.init.prototype=Za.prototype,Za.propHooks={_default:{get:function(a){var b;return null==a.elem[a.prop]||a.elem.style&&null!=a.elem.style[a.prop]?(b=m.css(a.elem,a.prop,""),b&&"auto"!==b?b:0):a.elem[a.prop]},set:function(a){m.fx.step[a.prop]?m.fx.step[a.prop](a):a.elem.style&&(null!=a.elem.style[m.cssProps[a.prop]]||m.cssHooks[a.prop])?m.style(a.elem,a.prop,a.now+a.unit):a.elem[a.prop]=a.now}}},Za.propHooks.scrollTop=Za.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},m.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2}},m.fx=Za.prototype.init,m.fx.step={};var $a,_a,ab=/^(?:toggle|show|hide)$/,bb=new RegExp("^(?:([+-])=|)("+S+")([a-z%]*)$","i"),cb=/queueHooks$/,db=[ib],eb={"*":[function(a,b){var c=this.createTween(a,b),d=c.cur(),e=bb.exec(b),f=e&&e[3]||(m.cssNumber[a]?"":"px"),g=(m.cssNumber[a]||"px"!==f&&+d)&&bb.exec(m.css(c.elem,a)),h=1,i=20;if(g&&g[3]!==f){f=f||g[3],e=e||[],g=+d||1;do h=h||".5",g/=h,m.style(c.elem,a,g+f);while(h!==(h=c.cur()/d)&&1!==h&&--i)}return e&&(g=c.start=+g||+d||0,c.unit=f,c.end=e[1]?g+(e[1]+1)*e[2]:+e[2]),c}]};function fb(){return setTimeout(function(){$a=void 0}),$a=m.now()}function gb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=T[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function hb(a,b,c){for(var d,e=(eb[b]||[]).concat(eb["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ib(a,b,c){var d,e,f,g,h,i,j,l,n=this,o={},p=a.style,q=a.nodeType&&U(a),r=m._data(a,"fxshow");c.queue||(h=m._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,n.always(function(){n.always(function(){h.unqueued--,m.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=m.css(a,"display"),l="none"===j?m._data(a,"olddisplay")||Fa(a.nodeName):j,"inline"===l&&"none"===m.css(a,"float")&&(k.inlineBlockNeedsLayout&&"inline"!==Fa(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",k.shrinkWrapBlocks()||n.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],ab.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||m.style(a,d)}else j=void 0;if(m.isEmptyObject(o))"inline"===("none"===j?Fa(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=m._data(a,"fxshow",{}),f&&(r.hidden=!q),q?m(a).show():n.done(function(){m(a).hide()}),n.done(function(){var b;m._removeData(a,"fxshow");for(b in o)m.style(a,b,o[b])});for(d in o)g=hb(q?r[d]:0,d,n),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function jb(a,b){var c,d,e,f,g;for(c in a)if(d=m.camelCase(c),e=b[d],f=a[c],m.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=m.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function kb(a,b,c){var d,e,f=0,g=db.length,h=m.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=$a||fb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:m.extend({},b),opts:m.extend(!0,{specialEasing:{}},c),originalProperties:b,originalOptions:c,startTime:$a||fb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=m.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?h.resolveWith(a,[j,b]):h.rejectWith(a,[j,b]),this}}),k=j.props;for(jb(k,j.opts.specialEasing);g>f;f++)if(d=db[f].call(j,a,k,j.opts))return d;return m.map(k,hb,j),m.isFunction(j.opts.start)&&j.opts.start.call(a,j),m.fx.timer(m.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}m.Animation=m.extend(kb,{tweener:function(a,b){m.isFunction(a)?(b=a,a=["*"]):a=a.split(" ");for(var c,d=0,e=a.length;e>d;d++)c=a[d],eb[c]=eb[c]||[],eb[c].unshift(b)},prefilter:function(a,b){b?db.unshift(a):db.push(a)}}),m.speed=function(a,b,c){var d=a&&"object"==typeof a?m.extend({},a):{complete:c||!c&&b||m.isFunction(a)&&a,duration:a,easing:c&&b||b&&!m.isFunction(b)&&b};return d.duration=m.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in m.fx.speeds?m.fx.speeds[d.duration]:m.fx.speeds._default,(null==d.queue||d.queue===!0)&&(d.queue="fx"),d.old=d.complete,d.complete=function(){m.isFunction(d.old)&&d.old.call(this),d.queue&&m.dequeue(this,d.queue)},d},m.fn.extend({fadeTo:function(a,b,c,d){return this.filter(U).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=m.isEmptyObject(a),f=m.speed(b,c,d),g=function(){var b=kb(this,m.extend({},a),f);(e||m._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=m.timers,g=m._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&cb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));(b||!c)&&m.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=m._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=m.timers,g=d?d.length:0;for(c.finish=!0,m.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),m.each(["toggle","show","hide"],function(a,b){var c=m.fn[b];m.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(gb(b,!0),a,d,e)}}),m.each({slideDown:gb("show"),slideUp:gb("hide"),slideToggle:gb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){m.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),m.timers=[],m.fx.tick=function(){var a,b=m.timers,c=0;for($a=m.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||m.fx.stop(),$a=void 0},m.fx.timer=function(a){m.timers.push(a),a()?m.fx.start():m.timers.pop()},m.fx.interval=13,m.fx.start=function(){_a||(_a=setInterval(m.fx.tick,m.fx.interval))},m.fx.stop=function(){clearInterval(_a),_a=null},m.fx.speeds={slow:600,fast:200,_default:400},m.fn.delay=function(a,b){return a=m.fx?m.fx.speeds[a]||a:a,b=b||"fx",this.queue(b,function(b,c){var d=setTimeout(b,a);c.stop=function(){clearTimeout(d)}})},function(){var a,b,c,d,e;b=y.createElement("div"),b.setAttribute("className","t"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=y.createElement("select"),e=c.appendChild(y.createElement("option")),a=b.getElementsByTagName("input")[0],d.style.cssText="top:1px",k.getSetAttribute="t"!==b.className,k.style=/top/.test(d.getAttribute("style")),k.hrefNormalized="/a"===d.getAttribute("href"),k.checkOn=!!a.value,k.optSelected=e.selected,k.enctype=!!y.createElement("form").enctype,c.disabled=!0,k.optDisabled=!e.disabled,a=y.createElement("input"),a.setAttribute("value",""),k.input=""===a.getAttribute("value"),a.value="t",a.setAttribute("type","radio"),k.radioValue="t"===a.value}();var lb=/\r/g;m.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=m.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,m(this).val()):a,null==e?e="":"number"==typeof e?e+="":m.isArray(e)&&(e=m.map(e,function(a){return null==a?"":a+""})),b=m.valHooks[this.type]||m.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=m.valHooks[e.type]||m.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(lb,""):null==c?"":c)}}}),m.extend({valHooks:{option:{get:function(a){var b=m.find.attr(a,"value");return null!=b?b:m.trim(m.text(a))}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],!(!c.selected&&i!==e||(k.optDisabled?c.disabled:null!==c.getAttribute("disabled"))||c.parentNode.disabled&&m.nodeName(c.parentNode,"optgroup"))){if(b=m(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=m.makeArray(b),g=e.length;while(g--)if(d=e[g],m.inArray(m.valHooks.option.get(d),f)>=0)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),m.each(["radio","checkbox"],function(){m.valHooks[this]={set:function(a,b){return m.isArray(b)?a.checked=m.inArray(m(a).val(),b)>=0:void 0}},k.checkOn||(m.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var mb,nb,ob=m.expr.attrHandle,pb=/^(?:checked|selected)$/i,qb=k.getSetAttribute,rb=k.input;m.fn.extend({attr:function(a,b){return V(this,m.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){m.removeAttr(this,a)})}}),m.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(a&&3!==f&&8!==f&&2!==f)return typeof a.getAttribute===K?m.prop(a,b,c):(1===f&&m.isXMLDoc(a)||(b=b.toLowerCase(),d=m.attrHooks[b]||(m.expr.match.bool.test(b)?nb:mb)),void 0===c?d&&"get"in d&&null!==(e=d.get(a,b))?e:(e=m.find.attr(a,b),null==e?void 0:e):null!==c?d&&"set"in d&&void 0!==(e=d.set(a,c,b))?e:(a.setAttribute(b,c+""),c):void m.removeAttr(a,b))},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(E);if(f&&1===a.nodeType)while(c=f[e++])d=m.propFix[c]||c,m.expr.match.bool.test(c)?rb&&qb||!pb.test(c)?a[d]=!1:a[m.camelCase("default-"+c)]=a[d]=!1:m.attr(a,c,""),a.removeAttribute(qb?c:d)},attrHooks:{type:{set:function(a,b){if(!k.radioValue&&"radio"===b&&m.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}}}),nb={set:function(a,b,c){return b===!1?m.removeAttr(a,c):rb&&qb||!pb.test(c)?a.setAttribute(!qb&&m.propFix[c]||c,c):a[m.camelCase("default-"+c)]=a[c]=!0,c}},m.each(m.expr.match.bool.source.match(/\w+/g),function(a,b){var c=ob[b]||m.find.attr;ob[b]=rb&&qb||!pb.test(b)?function(a,b,d){var e,f;return d||(f=ob[b],ob[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,ob[b]=f),e}:function(a,b,c){return c?void 0:a[m.camelCase("default-"+b)]?b.toLowerCase():null}}),rb&&qb||(m.attrHooks.value={set:function(a,b,c){return m.nodeName(a,"input")?void(a.defaultValue=b):mb&&mb.set(a,b,c)}}),qb||(mb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},ob.id=ob.name=ob.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},m.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:mb.set},m.attrHooks.contenteditable={set:function(a,b,c){mb.set(a,""===b?!1:b,c)}},m.each(["width","height"],function(a,b){m.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),k.style||(m.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var sb=/^(?:input|select|textarea|button|object)$/i,tb=/^(?:a|area)$/i;m.fn.extend({prop:function(a,b){return V(this,m.prop,a,b,arguments.length>1)},removeProp:function(a){return a=m.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),m.extend({propFix:{"for":"htmlFor","class":"className"},prop:function(a,b,c){var d,e,f,g=a.nodeType;if(a&&3!==g&&8!==g&&2!==g)return f=1!==g||!m.isXMLDoc(a),f&&(b=m.propFix[b]||b,e=m.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=m.find.attr(a,"tabindex");return b?parseInt(b,10):sb.test(a.nodeName)||tb.test(a.nodeName)&&a.href?0:-1}}}}),k.hrefNormalized||m.each(["href","src"],function(a,b){m.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),k.optSelected||(m.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null}}),m.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){m.propFix[this.toLowerCase()]=this}),k.enctype||(m.propFix.enctype="encoding");var ub=/[\t\r\n\f]/g;m.fn.extend({addClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j="string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).addClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):" ")){f=0;while(e=b[f++])d.indexOf(" "+e+" ")<0&&(d+=e+" ");g=m.trim(d),c.className!==g&&(c.className=g)}return this},removeClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j=0===arguments.length||"string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).removeClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):"")){f=0;while(e=b[f++])while(d.indexOf(" "+e+" ")>=0)d=d.replace(" "+e+" "," ");g=a?m.trim(d):"",c.className!==g&&(c.className=g)}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):this.each(m.isFunction(a)?function(c){m(this).toggleClass(a.call(this,c,this.className,b),b)}:function(){if("string"===c){var b,d=0,e=m(this),f=a.match(E)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else(c===K||"boolean"===c)&&(this.className&&m._data(this,"__className__",this.className),this.className=this.className||a===!1?"":m._data(this,"__className__")||"")})},hasClass:function(a){for(var b=" "+a+" ",c=0,d=this.length;d>c;c++)if(1===this[c].nodeType&&(" "+this[c].className+" ").replace(ub," ").indexOf(b)>=0)return!0;return!1}}),m.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){m.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),m.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)},bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}});var vb=m.now(),wb=/\?/,xb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;m.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=m.trim(b+"");return e&&!m.trim(e.replace(xb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():m.error("Invalid JSON: "+b)},m.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new DOMParser,c=d.parseFromString(b,"text/xml")):(c=new ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||m.error("Invalid XML: "+b),c};var yb,zb,Ab=/#.*$/,Bb=/([?&])_=[^&]*/,Cb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Db=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Eb=/^(?:GET|HEAD)$/,Fb=/^\/\//,Gb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Hb={},Ib={},Jb="*/".concat("*");try{zb=location.href}catch(Kb){zb=y.createElement("a"),zb.href="",zb=zb.href}yb=Gb.exec(zb.toLowerCase())||[];function Lb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(E)||[];if(m.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Mb(a,b,c,d){var e={},f=a===Ib;function g(h){var i;return e[h]=!0,m.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Nb(a,b){var c,d,e=m.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&m.extend(!0,a,c),a}function Ob(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Pb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}m.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:zb,type:"GET",isLocal:Db.test(yb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Jb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":m.parseJSON,"text xml":m.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Nb(Nb(a,m.ajaxSettings),b):Nb(m.ajaxSettings,a)},ajaxPrefilter:Lb(Hb),ajaxTransport:Lb(Ib),ajax:function(a,b){"object"==typeof a&&(b=a,a=void 0),b=b||{};var c,d,e,f,g,h,i,j,k=m.ajaxSetup({},b),l=k.context||k,n=k.context&&(l.nodeType||l.jquery)?m(l):m.event,o=m.Deferred(),p=m.Callbacks("once memory"),q=k.statusCode||{},r={},s={},t=0,u="canceled",v={readyState:0,getResponseHeader:function(a){var b;if(2===t){if(!j){j={};while(b=Cb.exec(f))j[b[1].toLowerCase()]=b[2]}b=j[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===t?f:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return t||(a=s[c]=s[c]||a,r[a]=b),this},overrideMimeType:function(a){return t||(k.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>t)for(b in a)q[b]=[q[b],a[b]];else v.always(a[v.status]);return this},abort:function(a){var b=a||u;return i&&i.abort(b),x(0,b),this}};if(o.promise(v).complete=p.add,v.success=v.done,v.error=v.fail,k.url=((a||k.url||zb)+"").replace(Ab,"").replace(Fb,yb[1]+"//"),k.type=b.method||b.type||k.method||k.type,k.dataTypes=m.trim(k.dataType||"*").toLowerCase().match(E)||[""],null==k.crossDomain&&(c=Gb.exec(k.url.toLowerCase()),k.crossDomain=!(!c||c[1]===yb[1]&&c[2]===yb[2]&&(c[3]||("http:"===c[1]?"80":"443"))===(yb[3]||("http:"===yb[1]?"80":"443")))),k.data&&k.processData&&"string"!=typeof k.data&&(k.data=m.param(k.data,k.traditional)),Mb(Hb,k,b,v),2===t)return v;h=m.event&&k.global,h&&0===m.active++&&m.event.trigger("ajaxStart"),k.type=k.type.toUpperCase(),k.hasContent=!Eb.test(k.type),e=k.url,k.hasContent||(k.data&&(e=k.url+=(wb.test(e)?"&":"?")+k.data,delete k.data),k.cache===!1&&(k.url=Bb.test(e)?e.replace(Bb,"$1_="+vb++):e+(wb.test(e)?"&":"?")+"_="+vb++)),k.ifModified&&(m.lastModified[e]&&v.setRequestHeader("If-Modified-Since",m.lastModified[e]),m.etag[e]&&v.setRequestHeader("If-None-Match",m.etag[e])),(k.data&&k.hasContent&&k.contentType!==!1||b.contentType)&&v.setRequestHeader("Content-Type",k.contentType),v.setRequestHeader("Accept",k.dataTypes[0]&&k.accepts[k.dataTypes[0]]?k.accepts[k.dataTypes[0]]+("*"!==k.dataTypes[0]?", "+Jb+"; q=0.01":""):k.accepts["*"]);for(d in k.headers)v.setRequestHeader(d,k.headers[d]);if(k.beforeSend&&(k.beforeSend.call(l,v,k)===!1||2===t))return v.abort();u="abort";for(d in{success:1,error:1,complete:1})v[d](k[d]);if(i=Mb(Ib,k,b,v)){v.readyState=1,h&&n.trigger("ajaxSend",[v,k]),k.async&&k.timeout>0&&(g=setTimeout(function(){v.abort("timeout")},k.timeout));try{t=1,i.send(r,x)}catch(w){if(!(2>t))throw w;x(-1,w)}}else x(-1,"No Transport");function x(a,b,c,d){var j,r,s,u,w,x=b;2!==t&&(t=2,g&&clearTimeout(g),i=void 0,f=d||"",v.readyState=a>0?4:0,j=a>=200&&300>a||304===a,c&&(u=Ob(k,v,c)),u=Pb(k,u,v,j),j?(k.ifModified&&(w=v.getResponseHeader("Last-Modified"),w&&(m.lastModified[e]=w),w=v.getResponseHeader("etag"),w&&(m.etag[e]=w)),204===a||"HEAD"===k.type?x="nocontent":304===a?x="notmodified":(x=u.state,r=u.data,s=u.error,j=!s)):(s=x,(a||!x)&&(x="error",0>a&&(a=0))),v.status=a,v.statusText=(b||x)+"",j?o.resolveWith(l,[r,x,v]):o.rejectWith(l,[v,x,s]),v.statusCode(q),q=void 0,h&&n.trigger(j?"ajaxSuccess":"ajaxError",[v,k,j?r:s]),p.fireWith(l,[v,x]),h&&(n.trigger("ajaxComplete",[v,k]),--m.active||m.event.trigger("ajaxStop")))}return v},getJSON:function(a,b,c){return m.get(a,b,c,"json")},getScript:function(a,b){return m.get(a,void 0,b,"script")}}),m.each(["get","post"],function(a,b){m[b]=function(a,c,d,e){return m.isFunction(c)&&(e=e||d,d=c,c=void 0),m.ajax({url:a,type:b,dataType:e,data:c,success:d})}}),m._evalUrl=function(a){return m.ajax({url:a,type:"GET",dataType:"script",async:!1,global:!1,"throws":!0})},m.fn.extend({wrapAll:function(a){if(m.isFunction(a))return this.each(function(b){m(this).wrapAll(a.call(this,b))});if(this[0]){var b=m(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return this.each(m.isFunction(a)?function(b){m(this).wrapInner(a.call(this,b))}:function(){var b=m(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=m.isFunction(a);return this.each(function(c){m(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){m.nodeName(this,"body")||m(this).replaceWith(this.childNodes)}).end()}}),m.expr.filters.hidden=function(a){return a.offsetWidth<=0&&a.offsetHeight<=0||!k.reliableHiddenOffsets()&&"none"===(a.style&&a.style.display||m.css(a,"display"))},m.expr.filters.visible=function(a){return!m.expr.filters.hidden(a)};var Qb=/%20/g,Rb=/\[\]$/,Sb=/\r?\n/g,Tb=/^(?:submit|button|image|reset|file)$/i,Ub=/^(?:input|select|textarea|keygen)/i;function Vb(a,b,c,d){var e;if(m.isArray(b))m.each(b,function(b,e){c||Rb.test(a)?d(a,e):Vb(a+"["+("object"==typeof e?b:"")+"]",e,c,d)});else if(c||"object"!==m.type(b))d(a,b);else for(e in b)Vb(a+"["+e+"]",b[e],c,d)}m.param=function(a,b){var c,d=[],e=function(a,b){b=m.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=m.ajaxSettings&&m.ajaxSettings.traditional),m.isArray(a)||a.jquery&&!m.isPlainObject(a))m.each(a,function(){e(this.name,this.value)});else for(c in a)Vb(c,a[c],b,e);return d.join("&").replace(Qb,"+")},m.fn.extend({serialize:function(){return m.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=m.prop(this,"elements");return a?m.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!m(this).is(":disabled")&&Ub.test(this.nodeName)&&!Tb.test(a)&&(this.checked||!W.test(a))}).map(function(a,b){var c=m(this).val();return null==c?null:m.isArray(c)?m.map(c,function(a){return{name:b.name,value:a.replace(Sb,"\r\n")}}):{name:b.name,value:c.replace(Sb,"\r\n")}}).get()}}),m.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return!this.isLocal&&/^(get|post|head|put|delete|options)$/i.test(this.type)&&Zb()||$b()}:Zb;var Wb=0,Xb={},Yb=m.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in Xb)Xb[a](void 0,!0)}),k.cors=!!Yb&&"withCredentials"in Yb,Yb=k.ajax=!!Yb,Yb&&m.ajaxTransport(function(a){if(!a.crossDomain||k.cors){var b;return{send:function(c,d){var e,f=a.xhr(),g=++Wb;if(f.open(a.type,a.url,a.async,a.username,a.password),a.xhrFields)for(e in a.xhrFields)f[e]=a.xhrFields[e];a.mimeType&&f.overrideMimeType&&f.overrideMimeType(a.mimeType),a.crossDomain||c["X-Requested-With"]||(c["X-Requested-With"]="XMLHttpRequest");for(e in c)void 0!==c[e]&&f.setRequestHeader(e,c[e]+"");f.send(a.hasContent&&a.data||null),b=function(c,e){var h,i,j;if(b&&(e||4===f.readyState))if(delete Xb[g],b=void 0,f.onreadystatechange=m.noop,e)4!==f.readyState&&f.abort();else{j={},h=f.status,"string"==typeof f.responseText&&(j.text=f.responseText);try{i=f.statusText}catch(k){i=""}h||!a.isLocal||a.crossDomain?1223===h&&(h=204):h=j.text?200:404}j&&d(h,i,j,f.getAllResponseHeaders())},a.async?4===f.readyState?setTimeout(b):f.onreadystatechange=Xb[g]=b:b()},abort:function(){b&&b(void 0,!0)}}}});function Zb(){try{return new a.XMLHttpRequest}catch(b){}}function $b(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}m.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/(?:java|ecma)script/},converters:{"text script":function(a){return m.globalEval(a),a}}}),m.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),m.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=y.head||m("head")[0]||y.documentElement;return{send:function(d,e){b=y.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||e(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var _b=[],ac=/(=)\?(?=&|$)|\?\?/;m.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=_b.pop()||m.expando+"_"+vb++;return this[a]=!0,a}}),m.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(ac.test(b.url)?"url":"string"==typeof b.data&&!(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&ac.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=m.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(ac,"$1"+e):b.jsonp!==!1&&(b.url+=(wb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||m.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,_b.push(e)),g&&m.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),m.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||y;var d=u.exec(a),e=!c&&[];return d?[b.createElement(d[1])]:(d=m.buildFragment([a],b,e),e&&e.length&&m(e).remove(),m.merge([],d.childNodes))};var bc=m.fn.load;m.fn.load=function(a,b,c){if("string"!=typeof a&&bc)return bc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>=0&&(d=m.trim(a.slice(h,a.length)),a=a.slice(0,h)),m.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(f="POST"),g.length>0&&m.ajax({url:a,type:f,dataType:"html",data:b}).done(function(a){e=arguments,g.html(d?m("<div>").append(m.parseHTML(a)).find(d):a)}).complete(c&&function(a,b){g.each(c,e||[a.responseText,b,a])}),this},m.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){m.fn[b]=function(a){return this.on(b,a)}}),m.expr.filters.animated=function(a){return m.grep(m.timers,function(b){return a===b.elem}).length};var cc=a.document.documentElement;function dc(a){return m.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}m.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=m.css(a,"position"),l=m(a),n={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=m.css(a,"top"),i=m.css(a,"left"),j=("absolute"===k||"fixed"===k)&&m.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),m.isFunction(b)&&(b=b.call(a,c,h)),null!=b.top&&(n.top=b.top-h.top+g),null!=b.left&&(n.left=b.left-h.left+e),"using"in b?b.using.call(a,n):l.css(n)}},m.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){m.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,m.contains(b,e)?(typeof e.getBoundingClientRect!==K&&(d=e.getBoundingClientRect()),c=dc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===m.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),m.nodeName(a[0],"html")||(c=a.offset()),c.top+=m.css(a[0],"borderTopWidth",!0),c.left+=m.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-m.css(d,"marginTop",!0),left:b.left-c.left-m.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent||cc;while(a&&!m.nodeName(a,"html")&&"static"===m.css(a,"position"))a=a.offsetParent;return a||cc})}}),m.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);m.fn[a]=function(d){return V(this,function(a,d,e){var f=dc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?m(f).scrollLeft():e,c?e:m(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),m.each(["top","left"],function(a,b){m.cssHooks[b]=La(k.pixelPosition,function(a,c){return c?(c=Ja(a,b),Ha.test(c)?m(a).position()[b]+"px":c):void 0})}),m.each({Height:"height",Width:"width"},function(a,b){m.each({padding:"inner"+a,content:b,"":"outer"+a},function(c,d){m.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return V(this,function(b,c,d){var e;return m.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?m.css(b,c,g):m.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),m.fn.size=function(){return this.length},m.fn.andSelf=m.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return m});var ec=a.jQuery,fc=a.$;return m.noConflict=function(b){return a.$===m&&(a.$=fc),b&&a.jQuery===m&&(a.jQuery=ec),m},typeof b===K&&(a.jQuery=a.$=m),m});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/x-font-truetype;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style type="text/css">.pagedtable {
overflow: auto;
padding-left: 8px;
padding-right: 8px;
}
.pagedtable-wrapper {
border: 1px solid #ccc;
border-radius: 4px;
margin-bottom: 10px;
}
.pagedtable table {
width: 100%;
max-width: 100%;
margin: 0;
}
.pagedtable th {
padding: 0 5px 0 5px;
border: none;
border-bottom: 2px solid #dddddd;
min-width: 45px;
}
.pagedtable-empty th {
display: none;
}
.pagedtable td {
padding: 0 4px 0 4px;
}
.pagedtable .even {
background-color: rgba(140, 140, 140, 0.1);
}
.pagedtable-padding-col {
display: none;
}
.pagedtable a {
-webkit-touch-callout: none;
-webkit-user-select: none;
-khtml-user-select: none;
-moz-user-select: none;
-ms-user-select: none;
user-select: none;
}
.pagedtable-index-nav {
cursor: pointer;
padding: 0 5px 0 5px;
float: right;
border: 0;
}
.pagedtable-index-nav-disabled {
cursor: default;
text-decoration: none;
color: #999;
}
a.pagedtable-index-nav-disabled:hover {
text-decoration: none;
color: #999;
}
.pagedtable-indexes {
cursor: pointer;
float: right;
border: 0;
}
.pagedtable-index-current {
cursor: default;
text-decoration: none;
font-weight: bold;
color: #333;
border: 0;
}
a.pagedtable-index-current:hover {
text-decoration: none;
font-weight: bold;
color: #333;
}
.pagedtable-index {
width: 30px;
display: inline-block;
text-align: center;
border: 0;
}
.pagedtable-index-separator-left {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 0 0 0;
cursor: default;
}
.pagedtable-index-separator-right {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 4px 0 0;
cursor: default;
}
.pagedtable-footer {
padding-top: 4px;
padding-bottom: 5px;
}
.pagedtable-not-empty .pagedtable-footer {
border-top: 2px solid #dddddd;
}
.pagedtable-info {
overflow: hidden;
color: #999;
white-space: nowrap;
text-overflow: ellipsis;
}
.pagedtable-header-name {
overflow: hidden;
text-overflow: ellipsis;
}
.pagedtable-header-type {
color: #999;
font-weight: 400;
}
.pagedtable-na-cell {
font-style: italic;
opacity: 0.3;
}
</style>
<script>// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<script>
window.initializeCodeFolding = function(show) {

  // handlers for show-all and hide all
  $("#rmd-show-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('show');
    });
  });
  $("#rmd-hide-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('hide');
    });
  });

  // index for unique code element ids
  var currentIndex = 1;

  // select all R code blocks
  var rCodeBlocks = $('pre.r, pre.python, pre.bash, pre.sql, pre.cpp, pre.stan, pre.julia');
  rCodeBlocks.each(function() {

    // create a collapsable div to wrap the code in
    var div = $('<div class="collapse r-code-collapse"></div>');
    if (show)
      div.addClass('in');
    var id = 'rcode-643E0F36' + currentIndex++;
    div.attr('id', id);
    $(this).before(div);
    $(this).detach().appendTo(div);

    // add a show code button right above
    var showCodeText = $('<span>' + (show ? 'Hide' : 'Code') + '</span>');
    var showCodeButton = $('<button type="button" class="btn btn-default btn-xs code-folding-btn pull-right"></button>');
    showCodeButton.append(showCodeText);
    showCodeButton
        .attr('data-toggle', 'collapse')
        .attr('data-target', '#' + id)
        .attr('aria-expanded', show)
        .attr('aria-controls', id);

    var buttonRow = $('<div class="row"></div>');
    var buttonCol = $('<div class="col-md-12"></div>');

    buttonCol.append(showCodeButton);
    buttonRow.append(buttonCol);

    div.before(buttonRow);

    // update state of button on show/hide
    div.on('hidden.bs.collapse', function () {
      showCodeText.text('Code');
    });
    div.on('show.bs.collapse', function () {
      showCodeText.text('Hide');
    });
  });

}
</script>
<script>
window.initializeSourceEmbed = function(filename) {
  $("#rmd-download-source").click(function() {
    var src = $("#rmd-source-code").html();
    var a = document.createElement('a');
    a.href = "data:text/x-r-markdown;base64," + src;
    a.download = filename;
    document.body.appendChild(a);
    a.click();
    document.body.removeChild(a);
  });
};
</script>
<style type="text/css">.hljs-literal {
color: rgb(88, 72, 246);
}
.hljs-number {
color: rgb(0, 0, 205);
}
.hljs-comment {
color: rgb(76, 136, 107);
}
.hljs-keyword {
color: rgb(0, 0, 255);
}
.hljs-string {
color: rgb(3, 106, 7);
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>



<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
#rmd-source-code {
  display: none;
}
</style>




<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
  height: auto;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
</style>

<style type="text/css">
.kable-table {
  border: 1px solid #ccc;
  border-radius: 4px;
  overflow: auto;
  padding-left: 8px;
  padding-right: 8px;
  margin-bottom: 20px;
  max-height: 350px;
}

.kable-table table {
  margin-bottom: 0px;
}

.kable-table table>thead>tr>th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.kable-table table>thead {
  background-color: #fff;
}
</style>


<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  background: white;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open')
  });
});
</script>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>
<script>
$(document).ready(function () {
  window.initializeSourceEmbed("portal_etl.Rmd");
  window.initializeCodeFolding("show" === "show");
});
</script>




</head>

<body>


<div class="container-fluid main-container">




<div class="fluid-row" id="header">

<div class="btn-group pull-right">
<button type="button" class="btn btn-default btn-xs dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu" style="min-width: 50px;">
<li><a id="rmd-show-all-code" href="#">Show All Code</a></li>
<li><a id="rmd-hide-all-code" href="#">Hide All Code</a></li>
<li role="separator" class="divider"></li>
<li><a id="rmd-download-source" href="#">Download Rmd</a></li>
</ul>
</div>



<h1 class="title toc-ignore">CSBC/PS-ON Portal ETL</h1>

</div>


<!-- rnb-text-begin -->
<p>The code in this notebook is used to take data from tables in the <a href="https://www.synapse.org/#!Synapse:syn21498902/wiki/600349">CSBC/PS-ON Portal DB</a> and recombine them into denormalized, production tables hosted in the <a href="https://www.synapse.org/csbcpson">CSBC/PS-ON Knowledge Portal Synapse project</a>.</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeShzeW5hcHNlcilcbmBgYCJ9 -->
<pre class="r"><code>library(synapser)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>
TERMS OF USE NOTICE:
  When using Synapse, remember that the terms and conditions of use require that you:
  1) Attribute data contributors when discussing these data or results from these data.
  2) Not discriminate, identify, or recontact individuals or groups represented by the data.
  3) Use and contribute only data de-identified to HIPAA standards.
  4) Redistribute data only under these same terms of use.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeShzeW5kY2N1dGlscylcbiMgU3lzLnNldGVudihSRVRJQ1VMQVRFX1BZVEhPTj1cIn4vYW5hY29uZGEvZW52cy9jc2JjLXBzb24tZGNjL2Jpbi9weXRob25cIilcbiMgbGlicmFyeShyZXRpY3VsYXRlKVxubGlicmFyeSh0aWR5dmVyc2UpXG5gYGAifQ== -->
<pre class="r"><code>library(syndccutils)
# Sys.setenv(RETICULATE_PYTHON=&quot;~/anaconda/envs/csbc-pson-dcc/bin/python&quot;)
# library(reticulate)
library(tidyverse)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>[37m [1mAttaching packages[22m  tidyverse 1.2.1 [39m
[37m[32m[37m [34mggplot2[37m 3.2.0     [32m[37m [34mpurrr  [37m 0.3.2
[32m[37m [34mtibble [37m 2.1.3     [32m[37m [34mdplyr  [37m 0.8.3
[32m[37m [34mtidyr  [37m 1.0.0     [32m[37m [34mstringr[37m 1.4.0
[32m[37m [34mreadr  [37m 1.3.1     [32m[37m [34mforcats[37m 0.4.0[39m
[37m [1mConflicts[22m  tidyverse_conflicts() 
[31m[37m [34mdplyr[37m::[32mfilter()[37m masks [34mstats[37m::filter()
[31m[37m [34mdplyr[37m::[32mlag()[37m    masks [34mstats[37m::lag()[39m</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuc291cmNlKFwiLi4vUi9zdW1tYXJ5X3Zpei5SXCIpXG5zb3VyY2UoXCIuLi9SL3N5bmFwc2VfZGIuUlwiKVxuXG5zeW5Mb2dpbigpXG5gYGAifQ== -->
<pre class="r"><code>source(&quot;../R/summary_viz.R&quot;)
source(&quot;../R/synapse_db.R&quot;)

synLogin()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiV2VsY29tZSwgSmFtZXMgRWRkeSFOVUxMXG4ifQ== -->
<pre><code>Welcome, James Eddy!NULL</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyB1c2VfY29uZGFlbnYoXCJjc2JjLXBzb24tZGNjXCIpXG4jIHN5bmFwc2VjbGllbnQgPC0gcmV0aWN1bGF0ZTo6aW1wb3J0KFwic3luYXBzZWNsaWVudFwiKVxuIyBzeW4gPC0gc3luYXBzZWNsaWVudCRTeW5hcHNlKClcbiMgc3luJGxvZ2luKClcbmBgYCJ9 -->
<pre class="r"><code># use_condaenv(&quot;csbc-pson-dcc&quot;)
# synapseclient &lt;- reticulate::import(&quot;synapseclient&quot;)
# syn &lt;- synapseclient$Synapse()
# syn$login()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGJfaW5zdGl0dXRpb25fZGYgPC0gZ2V0X3RhYmxlX2RmKFwic3luMjE5MDU4OTFcIiwgY2FjaGUgPSBGQUxTRSlcblxuYGBgIn0= -->
<pre class="r"><code>db_institution_df &lt;- get_table_df(&quot;syn21905891&quot;, cache = FALSE)
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiXG4gWyMjIyMjIyMjIyMjIyMjIyMjIyMjXTEwMC4wMCUgICAxLzEgICBEb25lLi4uICAgIFxuRG93bmxvYWRpbmcgIFsjIyMjIyMjIyMjIyMjIyMjIyMjI10xMDAuMDAlICAgNi44a0IvNi44a0IgKDMuMk1CL3MpIEpvYi0xMTIwNjI0MDEzMzU3NTMxMzMzNTU0MTExODcuY3N2IERvbmUuLi4gICAgXG4ifQ== -->
<pre><code>
 [####################]100.00%   1/1   Done...    
Downloading  [####################]100.00%   6.8kB/6.8kB (3.2MB/s) Job-112062401335753133355411187.csv Done...    </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<div id="grants---merged-table" class="section level2">
<h2>Grants - merged table</h2>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_grant_df &lt;- db_grant_df %&gt;% 
  select(-one_of(property_cols)) %&gt;% 
  rename(grantId = id, grantName = name) %&gt;%
  left_join(db_theme_grant, by = &quot;grantId&quot;) %&gt;% 
  left_join(db_institution_grant, by = &quot;grantId&quot;) %&gt;% 
  left_join(db_person_grant, by = &quot;grantId&quot;) %&gt;% 
  left_join(
    db_theme_df %&gt;% 
      select(themeId = id, theme = displayName),
    by = &quot;themeId&quot;
  ) %&gt;% 
  left_join(
    db_consortium_df %&gt;% 
      select(consortiumId = id, consortium = displayName)
  ) %&gt;% 
  left_join(
    db_institution_df %&gt;% 
      select(institutionId = id, institution = fullName)
  ) %&gt;% 
  select(grantId, grantName, grantNumber, consortium, theme,
         institution, investigator = person,
         abstract = description, grantType) %&gt;% 
  distinct() %&gt;% 
  I</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiSm9pbmluZywgYnkgPSBcImNvbnNvcnRpdW1JZFwiXG5Kb2luaW5nLCBieSA9IFwiaW5zdGl0dXRpb25JZFwiXG4ifQ== -->
<pre><code>Joining, by = &quot;consortiumId&quot;
Joining, by = &quot;institutionId&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWVyZ2VkX2dyYW50X2RmXG5gYGAifQ== -->
<pre class="r"><code>merged_grant_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"ncol":9,"nrow":556},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["grantId"],"name":[1],"type":["chr"],"align":["left"]},{"label":["grantName"],"name":[2],"type":["chr"],"align":["left"]},{"label":["grantNumber"],"name":[3],"type":["chr"],"align":["left"]},{"label":["consortium"],"name":[4],"type":["chr"],"align":["left"]},{"label":["theme"],"name":[5],"type":["chr"],"align":["left"]},{"label":["institution"],"name":[6],"type":["chr"],"align":["left"]},{"label":["investigator"],"name":[7],"type":["chr"],"align":["left"]},{"label":["abstract"],"name":[8],"type":["chr"],"align":["left"]},{"label":["grantType"],"name":[9],"type":["chr"],"align":["left"]}],"data":[{"1":"syn7080714","2":"CSBC PS-ON Knowledge Portal","3":"CA209923","4":"CSBC","5":"Computational Resource","6":"Sage Bionetworks","7":"NA","8":"NA","9":"U24","_rn_":"1"},{"1":"syn7315802","2":"Center for Cancer Systems Therapeutics (CaST)","3":"CA209997","4":"CSBC","5":"Heterogeneity","6":"Columbia University","7":"Andrea Califano","8":"Instead of focusing on the highly diverse, patient-specific spectrum of mutations that can initiate cancer, CaST is concentrating on the regulatory machinery found within cancer cells responsible for tumor homeostasis canalization.","9":"U54","_rn_":"2"},{"1":"syn7315802","2":"Center for Cancer Systems Therapeutics (CaST)","3":"CA209997","4":"CSBC","5":"Heterogeneity","6":"Columbia University","7":"Barry Honig","8":"Instead of focusing on the highly diverse, patient-specific spectrum of mutations that can initiate cancer, CaST is concentrating on the regulatory machinery found within cancer cells responsible for tumor homeostasis canalization.","9":"U54","_rn_":"3"},{"1":"syn7315802","2":"Center for Cancer Systems Therapeutics (CaST)","3":"CA209997","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Columbia University","7":"Andrea Califano","8":"Instead of focusing on the highly diverse, patient-specific spectrum of mutations that can initiate cancer, CaST is concentrating on the regulatory machinery found within cancer cells responsible for tumor homeostasis canalization.","9":"U54","_rn_":"4"},{"1":"syn7315802","2":"Center for Cancer Systems Therapeutics (CaST)","3":"CA209997","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Columbia University","7":"Barry Honig","8":"Instead of focusing on the highly diverse, patient-specific spectrum of mutations that can initiate cancer, CaST is concentrating on the regulatory machinery found within cancer cells responsible for tumor homeostasis canalization.","9":"U54","_rn_":"5"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Tumor-Immune","6":"Memorial Sloan Kettering Cancer Center","7":"Christina Leslie","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"6"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Tumor-Immune","6":"Memorial Sloan Kettering Cancer Center","7":"Alexander Rudensky","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"7"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Microenvironment","6":"Memorial Sloan Kettering Cancer Center","7":"Christina Leslie","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"8"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Microenvironment","6":"Memorial Sloan Kettering Cancer Center","7":"Alexander Rudensky","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"9"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Memorial Sloan Kettering Cancer Center","7":"Christina Leslie","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"10"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Memorial Sloan Kettering Cancer Center","7":"Alexander Rudensky","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"11"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Metastasis","6":"Memorial Sloan Kettering Cancer Center","7":"Christina Leslie","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"12"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"CSBC","5":"Metastasis","6":"Memorial Sloan Kettering Cancer Center","7":"Alexander Rudensky","8":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","9":"U54","_rn_":"13"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Tumor-Immune","6":"Stanford University","7":"Sylvia Plevritis","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"14"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Tumor-Immune","6":"Stanford University","7":"Garry Nolan","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"15"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Tumor-Immune","6":"Stanford University","7":"Ed Engleman","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"16"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Tumor-Immune","6":"Stanford University","7":"John Sunwoo","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"17"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Metastasis","6":"Stanford University","7":"Sylvia Plevritis","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"18"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Metastasis","6":"Stanford University","7":"Garry Nolan","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"19"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Metastasis","6":"Stanford University","7":"Ed Engleman","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"20"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Metastasis","6":"Stanford University","7":"John Sunwoo","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"21"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Microenvironment","6":"Stanford University","7":"Sylvia Plevritis","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"22"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Microenvironment","6":"Stanford University","7":"Garry Nolan","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"23"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Microenvironment","6":"Stanford University","7":"Ed Engleman","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"24"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"CSBC","5":"Microenvironment","6":"Stanford University","7":"John Sunwoo","8":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","9":"U54","_rn_":"25"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Andre Levchenko","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"26"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Mark Lemmon","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"27"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Gutner Wagner","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"28"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Murat Acar","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"29"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Jesse Rinehart","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"30"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Farren Isaacs","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"31"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Michael Murrell","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"32"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Rong Fan","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"33"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Sidi Chen","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"34"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Lynne Regan","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"35"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Adam Marcus","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"36"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Kshitiz Gupta","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"37"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Anatoly Kiyatkin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"38"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Metastasis","6":"Yale University","7":"Maria Apostolidi","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"39"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Andre Levchenko","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"40"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Mark Lemmon","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"41"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Gutner Wagner","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"42"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Murat Acar","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"43"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Jesse Rinehart","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"44"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Farren Isaacs","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"45"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Michael Murrell","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"46"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Rong Fan","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"47"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Sidi Chen","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"48"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Lynne Regan","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"49"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Adam Marcus","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"50"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Kshitiz Gupta","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"51"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Anatoly Kiyatkin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"52"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"CSBC","5":"Microenvironment","6":"Yale University","7":"Maria Apostolidi","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"53"},{"1":"syn7349742","2":"Chicago Region Physical Science Oncology Center","3":"CA193419","4":"PS-ON","5":"Metabolism","6":"Northwestern University","7":"Thomas V. O'Halloran","8":"The Chicago Region-Physical Science Oncology Center (CR-PSOC) is organized around the conceptual framework that addresses the spatio-temporal organization of chromatin and information transfer in cancer. This organizing framework integrates the strengths of chemistry, genetics, and physics to address chromatin dynamics in cancer.","9":"U54","_rn_":"54"},{"1":"syn7349742","2":"Chicago Region Physical Science Oncology Center","3":"CA193419","4":"PS-ON","5":"Metabolism","6":"Northwestern University","7":"Jonathan D. Licht","8":"The Chicago Region-Physical Science Oncology Center (CR-PSOC) is organized around the conceptual framework that addresses the spatio-temporal organization of chromatin and information transfer in cancer. This organizing framework integrates the strengths of chemistry, genetics, and physics to address chromatin dynamics in cancer.","9":"U54","_rn_":"55"},{"1":"syn7349742","2":"Chicago Region Physical Science Oncology Center","3":"CA193419","4":"PS-ON","5":"Heterogeneity","6":"Northwestern University","7":"Thomas V. O'Halloran","8":"The Chicago Region-Physical Science Oncology Center (CR-PSOC) is organized around the conceptual framework that addresses the spatio-temporal organization of chromatin and information transfer in cancer. This organizing framework integrates the strengths of chemistry, genetics, and physics to address chromatin dynamics in cancer.","9":"U54","_rn_":"56"},{"1":"syn7349742","2":"Chicago Region Physical Science Oncology Center","3":"CA193419","4":"PS-ON","5":"Heterogeneity","6":"Northwestern University","7":"Jonathan D. Licht","8":"The Chicago Region-Physical Science Oncology Center (CR-PSOC) is organized around the conceptual framework that addresses the spatio-temporal organization of chromatin and information transfer in cancer. This organizing framework integrates the strengths of chemistry, genetics, and physics to address chromatin dynamics in cancer.","9":"U54","_rn_":"57"},{"1":"syn7349742","2":"Chicago Region Physical Science Oncology Center","3":"CA193419","4":"PS-ON","5":"Evolution","6":"Northwestern University","7":"Thomas V. O'Halloran","8":"The Chicago Region-Physical Science Oncology Center (CR-PSOC) is organized around the conceptual framework that addresses the spatio-temporal organization of chromatin and information transfer in cancer. This organizing framework integrates the strengths of chemistry, genetics, and physics to address chromatin dynamics in cancer.","9":"U54","_rn_":"58"},{"1":"syn7349742","2":"Chicago Region Physical Science Oncology Center","3":"CA193419","4":"PS-ON","5":"Evolution","6":"Northwestern University","7":"Jonathan D. Licht","8":"The Chicago Region-Physical Science Oncology Center (CR-PSOC) is organized around the conceptual framework that addresses the spatio-temporal organization of chromatin and information transfer in cancer. This organizing framework integrates the strengths of chemistry, genetics, and physics to address chromatin dynamics in cancer.","9":"U54","_rn_":"59"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Microenvironment","6":"University of Minnesota","7":"David Odde","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"60"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Microenvironment","6":"University of Minnesota","7":"David Largaespada","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"61"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Microenvironment","6":"University of Minnesota","7":"Steven Rosenfeld","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"62"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Metastasis","6":"University of Minnesota","7":"David Odde","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"63"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Metastasis","6":"University of Minnesota","7":"David Largaespada","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"64"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Metastasis","6":"University of Minnesota","7":"Steven Rosenfeld","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"65"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Tumor-Immune","6":"University of Minnesota","7":"David Odde","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"66"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Tumor-Immune","6":"University of Minnesota","7":"David Largaespada","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"67"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"PS-ON","5":"Tumor-Immune","6":"University of Minnesota","7":"Steven Rosenfeld","8":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","9":"U54","_rn_":"68"},{"1":"syn7349747","2":"Physical Science Oncology Center at Penn","3":"CA193417","4":"PS-ON","5":"Microenvironment","6":"University of Pennsylvania","7":"Dennis Discher","8":"The PSOC@Penn focuses on physical changes of tissues, cells, and nuclei that contribute to cancer growth and initiation. As tumor cells divide, invade, and displace normal cells, the tissue often changes physically, frequently getting stiffer, sometimes softer, often heterogeneously. Physical changes sometimes occur even before the cancer is detectable.","9":"U54","_rn_":"69"},{"1":"syn7349747","2":"Physical Science Oncology Center at Penn","3":"CA193417","4":"PS-ON","5":"Evolution","6":"University of Pennsylvania","7":"Dennis Discher","8":"The PSOC@Penn focuses on physical changes of tissues, cells, and nuclei that contribute to cancer growth and initiation. As tumor cells divide, invade, and displace normal cells, the tissue often changes physically, frequently getting stiffer, sometimes softer, often heterogeneously. Physical changes sometimes occur even before the cancer is detectable.","9":"U54","_rn_":"70"},{"1":"syn7349747","2":"Physical Science Oncology Center at Penn","3":"CA193417","4":"PS-ON","5":"Metastasis","6":"University of Pennsylvania","7":"Dennis Discher","8":"The PSOC@Penn focuses on physical changes of tissues, cells, and nuclei that contribute to cancer growth and initiation. As tumor cells divide, invade, and displace normal cells, the tissue often changes physically, frequently getting stiffer, sometimes softer, often heterogeneously. Physical changes sometimes occur even before the cancer is detectable.","9":"U54","_rn_":"71"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Evolution","6":"Moffitt Cancer Center","7":"Robert A. Gatenby","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"72"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Evolution","6":"Moffitt Cancer Center","7":"Robert J. Gillies","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"73"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Evolution","6":"Moffitt Cancer Center","7":"Alexander R. A. Anderson","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"74"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Robert A. Gatenby","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"75"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Robert J. Gillies","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"76"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Alexander R. A. Anderson","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"77"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Microenvironment","6":"Moffitt Cancer Center","7":"Robert A. Gatenby","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"78"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Microenvironment","6":"Moffitt Cancer Center","7":"Robert J. Gillies","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"79"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Microenvironment","6":"Moffitt Cancer Center","7":"Alexander R. A. Anderson","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"80"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Tumor-Immune","6":"Moffitt Cancer Center","7":"Robert A. Gatenby","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"81"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Tumor-Immune","6":"Moffitt Cancer Center","7":"Robert J. Gillies","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"82"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"PS-ON","5":"Tumor-Immune","6":"Moffitt Cancer Center","7":"Alexander R. A. Anderson","8":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U54","_rn_":"83"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Evolution","6":"Dana-Farber Cancer Institute","7":"Franziska Michor","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"84"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Evolution","6":"Dana-Farber Cancer Institute","7":"Eric C. Holland","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"85"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"Dana-Farber Cancer Institute","7":"Franziska Michor","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"86"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"Dana-Farber Cancer Institute","7":"Eric C. Holland","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"87"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Microenvironment","6":"Dana-Farber Cancer Institute","7":"Franziska Michor","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"88"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Microenvironment","6":"Dana-Farber Cancer Institute","7":"Eric C. Holland","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"89"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Heterogeneity","6":"Dana-Farber Cancer Institute","7":"Franziska Michor","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"90"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"PS-ON","5":"Heterogeneity","6":"Dana-Farber Cancer Institute","7":"Eric C. Holland","8":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","9":"U54","_rn_":"91"},{"1":"syn7349759","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","3":"CA193313","4":"PS-ON","5":"Heterogeneity","6":"Columbia University","7":"Raul Rabadan","8":"The Center for Topology of Cancer Evolution and Heterogeneity opened in May 2015 as an interdisciplinary center formed to develop an integrated experimental and computational pipeline for characterizing the evolution of subclonal populations within solid tumors. Our experimental techniques include novel organoid systems for tracing cellular lineages, as well as innovative single-cell sequencing technologies.","9":"U54","_rn_":"92"},{"1":"syn7349759","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","3":"CA193313","4":"PS-ON","5":"Heterogeneity","6":"Columbia University","7":"Antonio Iavarone","8":"The Center for Topology of Cancer Evolution and Heterogeneity opened in May 2015 as an interdisciplinary center formed to develop an integrated experimental and computational pipeline for characterizing the evolution of subclonal populations within solid tumors. Our experimental techniques include novel organoid systems for tracing cellular lineages, as well as innovative single-cell sequencing technologies.","9":"U54","_rn_":"93"},{"1":"syn7349759","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","3":"CA193313","4":"PS-ON","5":"Evolution","6":"Columbia University","7":"Raul Rabadan","8":"The Center for Topology of Cancer Evolution and Heterogeneity opened in May 2015 as an interdisciplinary center formed to develop an integrated experimental and computational pipeline for characterizing the evolution of subclonal populations within solid tumors. Our experimental techniques include novel organoid systems for tracing cellular lineages, as well as innovative single-cell sequencing technologies.","9":"U54","_rn_":"94"},{"1":"syn7349759","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","3":"CA193313","4":"PS-ON","5":"Evolution","6":"Columbia University","7":"Antonio Iavarone","8":"The Center for Topology of Cancer Evolution and Heterogeneity opened in May 2015 as an interdisciplinary center formed to develop an integrated experimental and computational pipeline for characterizing the evolution of subclonal populations within solid tumors. Our experimental techniques include novel organoid systems for tracing cellular lineages, as well as innovative single-cell sequencing technologies.","9":"U54","_rn_":"95"},{"1":"syn7349759","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","3":"CA193313","4":"PS-ON","5":"Metastasis","6":"Columbia University","7":"Raul Rabadan","8":"The Center for Topology of Cancer Evolution and Heterogeneity opened in May 2015 as an interdisciplinary center formed to develop an integrated experimental and computational pipeline for characterizing the evolution of subclonal populations within solid tumors. Our experimental techniques include novel organoid systems for tracing cellular lineages, as well as innovative single-cell sequencing technologies.","9":"U54","_rn_":"96"},{"1":"syn7349759","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","3":"CA193313","4":"PS-ON","5":"Metastasis","6":"Columbia University","7":"Antonio Iavarone","8":"The Center for Topology of Cancer Evolution and Heterogeneity opened in May 2015 as an interdisciplinary center formed to develop an integrated experimental and computational pipeline for characterizing the evolution of subclonal populations within solid tumors. Our experimental techniques include novel organoid systems for tracing cellular lineages, as well as innovative single-cell sequencing technologies.","9":"U54","_rn_":"97"},{"1":"syn7349762","2":"The Center for Immunotherapeutic Transport Oncophysics","3":"CA210181","4":"PS-ON","5":"Heterogeneity","6":"Houston Methodist","7":"Mauro Ferrari","8":"The use of FDA-approved immunotherapies to treat metastatic melanoma and lung cancer has reignited the interest and examination of similar approaches for other cancers, including breast and pancreatic cancer, both considered <U+201C>immunologically cold<U+201D> and for which immunotherapy treatments have achieved limited success.","9":"U54","_rn_":"98"},{"1":"syn7349762","2":"The Center for Immunotherapeutic Transport Oncophysics","3":"CA210181","4":"PS-ON","5":"Tumor-Immune","6":"Houston Methodist","7":"Mauro Ferrari","8":"The use of FDA-approved immunotherapies to treat metastatic melanoma and lung cancer has reignited the interest and examination of similar approaches for other cancers, including breast and pancreatic cancer, both considered <U+201C>immunologically cold<U+201D> and for which immunotherapy treatments have achieved limited success.","9":"U54","_rn_":"99"},{"1":"syn7349762","2":"The Center for Immunotherapeutic Transport Oncophysics","3":"CA210181","4":"PS-ON","5":"Microenvironment","6":"Houston Methodist","7":"Mauro Ferrari","8":"The use of FDA-approved immunotherapies to treat metastatic melanoma and lung cancer has reignited the interest and examination of similar approaches for other cancers, including breast and pancreatic cancer, both considered <U+201C>immunologically cold<U+201D> and for which immunotherapy treatments have achieved limited success.","9":"U54","_rn_":"100"},{"1":"syn7349764","2":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","3":"CA210180","4":"PS-ON","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Forest M. White","8":"A central goal of the MIT/Mayo PS-OC is to model the physical and physico-chemical factors that govern drug distribution into brain tumors.","9":"U54","_rn_":"101"},{"1":"syn7349764","2":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","3":"CA210180","4":"PS-ON","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Jann Sarkaria","8":"A central goal of the MIT/Mayo PS-OC is to model the physical and physico-chemical factors that govern drug distribution into brain tumors.","9":"U54","_rn_":"102"},{"1":"syn7349764","2":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","3":"CA210180","4":"PS-ON","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Forest M. White","8":"A central goal of the MIT/Mayo PS-OC is to model the physical and physico-chemical factors that govern drug distribution into brain tumors.","9":"U54","_rn_":"103"},{"1":"syn7349764","2":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","3":"CA210180","4":"PS-ON","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Jann Sarkaria","8":"A central goal of the MIT/Mayo PS-OC is to model the physical and physico-chemical factors that govern drug distribution into brain tumors.","9":"U54","_rn_":"104"},{"1":"syn7349764","2":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","3":"CA210180","4":"PS-ON","5":"Evolution","6":"Massachusetts Institute of Technology","7":"Forest M. White","8":"A central goal of the MIT/Mayo PS-OC is to model the physical and physico-chemical factors that govern drug distribution into brain tumors.","9":"U54","_rn_":"105"},{"1":"syn7349764","2":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","3":"CA210180","4":"PS-ON","5":"Evolution","6":"Massachusetts Institute of Technology","7":"Jann Sarkaria","8":"A central goal of the MIT/Mayo PS-OC is to model the physical and physico-chemical factors that govern drug distribution into brain tumors.","9":"U54","_rn_":"106"},{"1":"syn7349766","2":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","3":"CA210173","4":"PS-ON","5":"Microenvironment","6":"Johns Hopkins University","7":"Denis Wirtz","8":"Johns Hopkins University Physical Sciences-Oncology Center will explore the mechanical forces in cancer that bolster the tumor metastatic cascade. Metastatic disease is the cause for the preponderance of deaths related to cancer.","9":"U54","_rn_":"107"},{"1":"syn7349766","2":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","3":"CA210173","4":"PS-ON","5":"Metastasis","6":"Johns Hopkins University","7":"Denis Wirtz","8":"Johns Hopkins University Physical Sciences-Oncology Center will explore the mechanical forces in cancer that bolster the tumor metastatic cascade. Metastatic disease is the cause for the preponderance of deaths related to cancer.","9":"U54","_rn_":"108"},{"1":"syn7349766","2":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","3":"CA210173","4":"PS-ON","5":"Metabolism","6":"Johns Hopkins University","7":"Denis Wirtz","8":"Johns Hopkins University Physical Sciences-Oncology Center will explore the mechanical forces in cancer that bolster the tumor metastatic cascade. Metastatic disease is the cause for the preponderance of deaths related to cancer.","9":"U54","_rn_":"109"},{"1":"syn7349770","2":"Center on the Physics of Cancer Metabolism","3":"CA210184","4":"PS-ON","5":"Metabolism","6":"Cornell University","7":"Claudia Fischbach-Teschl","8":"Despite advances in breast cancer treatment, metastatic disease remains incurable and is of particular concern in patients with triple negative breast cancer. Both aberrant metabolic signaling and physical properties of the microenvironment have been independently defined as hallmarks of cancers, and experimental evidence suggests that they may be functionally linked.","9":"U54","_rn_":"110"},{"1":"syn7349770","2":"Center on the Physics of Cancer Metabolism","3":"CA210184","4":"PS-ON","5":"Metabolism","6":"Cornell University","7":"Lewis C. Cantley","8":"Despite advances in breast cancer treatment, metastatic disease remains incurable and is of particular concern in patients with triple negative breast cancer. Both aberrant metabolic signaling and physical properties of the microenvironment have been independently defined as hallmarks of cancers, and experimental evidence suggests that they may be functionally linked.","9":"U54","_rn_":"111"},{"1":"syn7349770","2":"Center on the Physics of Cancer Metabolism","3":"CA210184","4":"PS-ON","5":"Microenvironment","6":"Cornell University","7":"Claudia Fischbach-Teschl","8":"Despite advances in breast cancer treatment, metastatic disease remains incurable and is of particular concern in patients with triple negative breast cancer. Both aberrant metabolic signaling and physical properties of the microenvironment have been independently defined as hallmarks of cancers, and experimental evidence suggests that they may be functionally linked.","9":"U54","_rn_":"112"},{"1":"syn7349770","2":"Center on the Physics of Cancer Metabolism","3":"CA210184","4":"PS-ON","5":"Microenvironment","6":"Cornell University","7":"Lewis C. Cantley","8":"Despite advances in breast cancer treatment, metastatic disease remains incurable and is of particular concern in patients with triple negative breast cancer. Both aberrant metabolic signaling and physical properties of the microenvironment have been independently defined as hallmarks of cancers, and experimental evidence suggests that they may be functionally linked.","9":"U54","_rn_":"113"},{"1":"syn7349770","2":"Center on the Physics of Cancer Metabolism","3":"CA210184","4":"PS-ON","5":"Metastasis","6":"Cornell University","7":"Claudia Fischbach-Teschl","8":"Despite advances in breast cancer treatment, metastatic disease remains incurable and is of particular concern in patients with triple negative breast cancer. Both aberrant metabolic signaling and physical properties of the microenvironment have been independently defined as hallmarks of cancers, and experimental evidence suggests that they may be functionally linked.","9":"U54","_rn_":"114"},{"1":"syn7349770","2":"Center on the Physics of Cancer Metabolism","3":"CA210184","4":"PS-ON","5":"Metastasis","6":"Cornell University","7":"Lewis C. Cantley","8":"Despite advances in breast cancer treatment, metastatic disease remains incurable and is of particular concern in patients with triple negative breast cancer. Both aberrant metabolic signaling and physical properties of the microenvironment have been independently defined as hallmarks of cancers, and experimental evidence suggests that they may be functionally linked.","9":"U54","_rn_":"115"},{"1":"syn7416702","2":"Epithelial layer jamming in breast cancer cell migration","3":"CA202123","4":"PS-ON","5":"Metastasis","6":"Harvard University","7":"Jeffrey J. Fredberg","8":"NA","9":"U01","_rn_":"116"},{"1":"syn7416702","2":"Epithelial layer jamming in breast cancer cell migration","3":"CA202123","4":"PS-ON","5":"Metastasis","6":"Boston University","7":"Jeffrey J. Fredberg","8":"NA","9":"U01","_rn_":"117"},{"1":"syn7416702","2":"Epithelial layer jamming in breast cancer cell migration","3":"CA202123","4":"PS-ON","5":"Metastasis","6":"Dartmouth College","7":"Jeffrey J. Fredberg","8":"NA","9":"U01","_rn_":"118"},{"1":"syn7416702","2":"Epithelial layer jamming in breast cancer cell migration","3":"CA202123","4":"PS-ON","5":"Heterogeneity","6":"Harvard University","7":"Jeffrey J. Fredberg","8":"NA","9":"U01","_rn_":"119"},{"1":"syn7416702","2":"Epithelial layer jamming in breast cancer cell migration","3":"CA202123","4":"PS-ON","5":"Heterogeneity","6":"Boston University","7":"Jeffrey J. Fredberg","8":"NA","9":"U01","_rn_":"120"},{"1":"syn7416702","2":"Epithelial layer jamming in breast cancer cell migration","3":"CA202123","4":"PS-ON","5":"Heterogeneity","6":"Dartmouth College","7":"Jeffrey J. Fredberg","8":"NA","9":"U01","_rn_":"121"},{"1":"syn7416707","2":"Quantitative analyses of tumor cell extravasation","3":"CA202177","4":"PS-ON","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Roger D. Kamm","8":"Over the past several years, we have developed microfluidic systems that are capable of simulating many steps of metastasis including tumor cell invasion, intravasation, etc. The object of our study is to employ these assays with new measurement methods to interrogate the changes in cell mechanics during the process of extravasation and understand the nature of the cell-cell and cell-matrix force interactions.","9":"U01","_rn_":"122"},{"1":"syn7416707","2":"Quantitative analyses of tumor cell extravasation","3":"CA202177","4":"PS-ON","5":"Metastasis","6":"Massachusetts Institute of Technology","7":"Roger D. Kamm","8":"Over the past several years, we have developed microfluidic systems that are capable of simulating many steps of metastasis including tumor cell invasion, intravasation, etc. The object of our study is to employ these assays with new measurement methods to interrogate the changes in cell mechanics during the process of extravasation and understand the nature of the cell-cell and cell-matrix force interactions.","9":"U01","_rn_":"123"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Heterogeneity","6":"University of California, Berkeley","7":"Jay T. Groves","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"124"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Heterogeneity","6":"University of California, Berkeley","7":"Valerie M. Weaver","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"125"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Heterogeneity","6":"University of California, San Francisco","7":"Jay T. Groves","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"126"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Heterogeneity","6":"University of California, San Francisco","7":"Valerie M. Weaver","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"127"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Microenvironment","6":"University of California, Berkeley","7":"Jay T. Groves","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"128"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Microenvironment","6":"University of California, Berkeley","7":"Valerie M. Weaver","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"129"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Microenvironment","6":"University of California, San Francisco","7":"Jay T. Groves","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"130"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"PS-ON","5":"Microenvironment","6":"University of California, San Francisco","7":"Valerie M. Weaver","8":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","9":"U01","_rn_":"131"},{"1":"syn7416712","2":"Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics","3":"CA202144","4":"PS-ON","5":"Heterogeneity","6":"University of Utah","7":"Orly Alter","8":"The University of Utah is developing new mathematical frameworks to create a single coherent model from multiple high-dimensional datasets, or tensors. The frameworks <U+2013> comparative spectral decompositions <U+2013> generalize those that underlie the theoretical description of the physical world.","9":"U01","_rn_":"132"},{"1":"syn7416712","2":"Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics","3":"CA202144","4":"PS-ON","5":"Evolution","6":"University of Utah","7":"Orly Alter","8":"The University of Utah is developing new mathematical frameworks to create a single coherent model from multiple high-dimensional datasets, or tensors. The frameworks <U+2013> comparative spectral decompositions <U+2013> generalize those that underlie the theoretical description of the physical world.","9":"U01","_rn_":"133"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Microenvironment","6":"Vanderbilt University","7":"Lisa J. McCawley","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"134"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Microenvironment","6":"Vanderbilt University","7":"Katarzyna Rejniak","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"135"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Microenvironment","6":"Vanderbilt University","7":"Dmitry Markov","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"136"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Microenvironment","6":"Moffitt Cancer Center","7":"Lisa J. McCawley","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"137"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Microenvironment","6":"Moffitt Cancer Center","7":"Katarzyna Rejniak","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"138"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Microenvironment","6":"Moffitt Cancer Center","7":"Dmitry Markov","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"139"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Heterogeneity","6":"Vanderbilt University","7":"Lisa J. McCawley","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"140"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Heterogeneity","6":"Vanderbilt University","7":"Katarzyna Rejniak","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"141"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Heterogeneity","6":"Vanderbilt University","7":"Dmitry Markov","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"142"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Heterogeneity","6":"Moffitt Cancer Center","7":"Lisa J. McCawley","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"143"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Heterogeneity","6":"Moffitt Cancer Center","7":"Katarzyna Rejniak","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"144"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"PS-ON","5":"Heterogeneity","6":"Moffitt Cancer Center","7":"Dmitry Markov","8":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","9":"U01","_rn_":"145"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"City Of Hope National Medical Center","7":"Andrea Bild","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"146"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"City Of Hope National Medical Center","7":"Fred Adler","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"147"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"City Of Hope National Medical Center","7":"David Bowtell","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"148"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"City Of Hope National Medical Center","7":"Jeffrey Chang","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"149"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"City Of Hope National Medical Center","7":"Gabor Marth","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"150"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"City Of Hope National Medical Center","7":"Suni Sharma","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"151"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Heterogeneity","6":"City Of Hope National Medical Center","7":"Andrea Bild","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"152"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Heterogeneity","6":"City Of Hope National Medical Center","7":"Fred Adler","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"153"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Heterogeneity","6":"City Of Hope National Medical Center","7":"David Bowtell","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"154"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Heterogeneity","6":"City Of Hope National Medical Center","7":"Jeffrey Chang","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"155"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Heterogeneity","6":"City Of Hope National Medical Center","7":"Gabor Marth","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"156"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Heterogeneity","6":"City Of Hope National Medical Center","7":"Suni Sharma","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"157"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Evolution","6":"City Of Hope National Medical Center","7":"Andrea Bild","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"158"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Evolution","6":"City Of Hope National Medical Center","7":"Fred Adler","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"159"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Evolution","6":"City Of Hope National Medical Center","7":"David Bowtell","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"160"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Evolution","6":"City Of Hope National Medical Center","7":"Jeffrey Chang","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"161"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Evolution","6":"City Of Hope National Medical Center","7":"Gabor Marth","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"162"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Evolution","6":"City Of Hope National Medical Center","7":"Suni Sharma","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"163"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Metastasis","6":"City Of Hope National Medical Center","7":"Andrea Bild","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"164"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Metastasis","6":"City Of Hope National Medical Center","7":"Fred Adler","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"165"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Metastasis","6":"City Of Hope National Medical Center","7":"David Bowtell","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"166"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Metastasis","6":"City Of Hope National Medical Center","7":"Jeffrey Chang","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"167"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Metastasis","6":"City Of Hope National Medical Center","7":"Gabor Marth","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"168"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"CSBC","5":"Metastasis","6":"City Of Hope National Medical Center","7":"Suni Sharma","8":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","9":"U54","_rn_":"169"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Jill P. Mesirov","8":"NA","9":"U01","_rn_":"170"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Ernest Fraenkel","8":"NA","9":"U01","_rn_":"171"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Scott L. Pomeroy","8":"NA","9":"U01","_rn_":"172"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"Harvard University","7":"Jill P. Mesirov","8":"NA","9":"U01","_rn_":"173"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"Harvard University","7":"Ernest Fraenkel","8":"NA","9":"U01","_rn_":"174"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"Harvard University","7":"Scott L. Pomeroy","8":"NA","9":"U01","_rn_":"175"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Jill P. Mesirov","8":"NA","9":"U01","_rn_":"176"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Ernest Fraenkel","8":"NA","9":"U01","_rn_":"177"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Scott L. Pomeroy","8":"NA","9":"U01","_rn_":"178"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Scott Manalis","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"179"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Douglas A. Lauffenburger","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"180"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"William Hahn","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"181"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Alex K. Shalek","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"182"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"David Weinstock","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"183"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Christopher Love","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"184"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Kristen Stevenson","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"185"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Scott Manalis","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"186"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Douglas A. Lauffenburger","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"187"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"William Hahn","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"188"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Alex K. Shalek","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"189"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"David Weinstock","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"190"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Christopher Love","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"191"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"CSBC","5":"Microenvironment","6":"Massachusetts Institute of Technology","7":"Kristen Stevenson","8":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","9":"U54","_rn_":"192"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Oregon Health & Science University","7":"Joe W. Gray","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"193"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Oregon Health & Science University","7":"Rosalie Sears","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"194"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Oregon Health & Science University","7":"Claire Tomlin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"195"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Berkeley","7":"Joe W. Gray","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"196"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Berkeley","7":"Rosalie Sears","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"197"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Berkeley","7":"Claire Tomlin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"198"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Heterogeneity","6":"Oregon Health & Science University","7":"Joe W. Gray","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"199"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Heterogeneity","6":"Oregon Health & Science University","7":"Rosalie Sears","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"200"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Heterogeneity","6":"Oregon Health & Science University","7":"Claire Tomlin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"201"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Heterogeneity","6":"University of California, Berkeley","7":"Joe W. Gray","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"202"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Heterogeneity","6":"University of California, Berkeley","7":"Rosalie Sears","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"203"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Heterogeneity","6":"University of California, Berkeley","7":"Claire Tomlin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"204"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Microenvironment","6":"Oregon Health & Science University","7":"Joe W. Gray","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"205"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Microenvironment","6":"Oregon Health & Science University","7":"Rosalie Sears","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"206"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Microenvironment","6":"Oregon Health & Science University","7":"Claire Tomlin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"207"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Microenvironment","6":"University of California, Berkeley","7":"Joe W. Gray","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"208"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Microenvironment","6":"University of California, Berkeley","7":"Rosalie Sears","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"209"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"CSBC","5":"Microenvironment","6":"University of California, Berkeley","7":"Claire Tomlin","8":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","9":"U54","_rn_":"210"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"The University of Texas Health Science Center at San Antonio","7":"Tim Huang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"211"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"The University of Texas Health Science Center at San Antonio","7":"Victor Jin","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"212"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"The University of Texas Health Science Center at San Antonio","7":"Qianben Wang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"213"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Duke University","7":"Tim Huang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"214"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Duke University","7":"Victor Jin","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"215"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Duke University","7":"Qianben Wang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"216"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Epigenetics","6":"The University of Texas Health Science Center at San Antonio","7":"Tim Huang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"217"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Epigenetics","6":"The University of Texas Health Science Center at San Antonio","7":"Victor Jin","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"218"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Epigenetics","6":"The University of Texas Health Science Center at San Antonio","7":"Qianben Wang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"219"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Epigenetics","6":"Duke University","7":"Tim Huang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"220"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Epigenetics","6":"Duke University","7":"Victor Jin","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"221"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"CSBC","5":"Epigenetics","6":"Duke University","7":"Qianben Wang","8":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","9":"U54","_rn_":"222"},{"1":"syn9774783","2":"Integrative approach to heterogeneity in breast cancer metastasis","3":"CA199315","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"NA","8":"NA","9":"U01","_rn_":"223"},{"1":"syn9774783","2":"Integrative approach to heterogeneity in breast cancer metastasis","3":"CA199315","4":"CSBC","5":"Microenvironment","6":"University of California, San Francisco","7":"NA","8":"NA","9":"U01","_rn_":"224"},{"1":"syn9774959","2":"From Mechanism to Population - Modeling HPV-related Oropharyngeal Carcinogenesis","3":"CA182915","4":"CSBC","5":"NA","6":"University of Michigan","7":"NA","8":"NA","9":"U01","_rn_":"225"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Heterogeneity","6":"Houston Methodist","7":"Allen W. Tsang","8":"NA","9":"U01","_rn_":"226"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Heterogeneity","6":"Houston Methodist","7":"Vivek Mittal","8":"NA","9":"U01","_rn_":"227"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Heterogeneity","6":"Weill Cornell Medicine","7":"Allen W. Tsang","8":"NA","9":"U01","_rn_":"228"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Heterogeneity","6":"Weill Cornell Medicine","7":"Vivek Mittal","8":"NA","9":"U01","_rn_":"229"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Microenvironment","6":"Houston Methodist","7":"Allen W. Tsang","8":"NA","9":"U01","_rn_":"230"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Microenvironment","6":"Houston Methodist","7":"Vivek Mittal","8":"NA","9":"U01","_rn_":"231"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Microenvironment","6":"Weill Cornell Medicine","7":"Allen W. Tsang","8":"NA","9":"U01","_rn_":"232"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"CSBC","5":"Microenvironment","6":"Weill Cornell Medicine","7":"Vivek Mittal","8":"NA","9":"U01","_rn_":"233"},{"1":"syn9775651","2":"Phenotype Transitions in Small Cell Lung Cancer","3":"CA182915","4":"CSBC","5":"NA","6":"Vanderbilt University","7":"NA","8":"NA","9":"U01","_rn_":"234"},{"1":"syn9775665","2":"CSBC U01 Project Boston University","3":"CA182898","4":"CSBC","5":"NA","6":"Boston University","7":"NA","8":"NA","9":"U01","_rn_":"235"},{"1":"syn9775689","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"CA184897","4":"CSBC","5":"Metastasis","6":"Massachusetts Institute of Technology","7":"NA","8":"NA","9":"U01","_rn_":"236"},{"1":"syn9775689","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"CA184897","4":"CSBC","5":"Metastasis","6":"Beth Israel Deaconess Hospital","7":"NA","8":"NA","9":"U01","_rn_":"237"},{"1":"syn9775689","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"CA184897","4":"CSBC","5":"Metastasis","6":"Massachusetts General Hospital","7":"NA","8":"NA","9":"U01","_rn_":"238"},{"1":"syn9775689","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"CA184897","4":"CSBC","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"NA","8":"NA","9":"U01","_rn_":"239"},{"1":"syn9775689","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"CA184897","4":"CSBC","5":"Heterogeneity","6":"Beth Israel Deaconess Hospital","7":"NA","8":"NA","9":"U01","_rn_":"240"},{"1":"syn9775689","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"CA184897","4":"CSBC","5":"Heterogeneity","6":"Massachusetts General Hospital","7":"NA","8":"NA","9":"U01","_rn_":"241"},{"1":"syn9775704","2":"Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors","3":"CA195469","4":"CSBC","5":"Evolution","6":"Dana-Farber Cancer Institute","7":"NA","8":"NA","9":"U01","_rn_":"242"},{"1":"syn9775704","2":"Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors","3":"CA195469","4":"CSBC","5":"Heterogeneity","6":"Dana-Farber Cancer Institute","7":"NA","8":"NA","9":"U01","_rn_":"243"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Nevan Krogan","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"244"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Trey Ideker","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"245"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"David Agard","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"246"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Prashant Mali","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"247"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Jill P. Mesirov","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"248"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Alan Ashworth","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"249"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Jennifer Grandis","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"250"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Silvio Gutkind","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"251"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Laura Esserman","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"252"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Francisco","7":"Laura van't Veer","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"253"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Nevan Krogan","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"254"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Trey Ideker","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"255"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"David Agard","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"256"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Prashant Mali","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"257"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Jill P. Mesirov","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"258"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Alan Ashworth","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"259"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Jennifer Grandis","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"260"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Silvio Gutkind","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"261"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Laura Esserman","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"262"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Heterogeneity","6":"University of California, San Diego","7":"Laura van't Veer","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"263"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Nevan Krogan","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"264"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Trey Ideker","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"265"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"David Agard","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"266"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Prashant Mali","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"267"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Jill P. Mesirov","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"268"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Alan Ashworth","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"269"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Jennifer Grandis","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"270"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Silvio Gutkind","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"271"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Laura Esserman","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"272"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Francisco","7":"Laura van't Veer","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"273"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Nevan Krogan","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"274"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Trey Ideker","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"275"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"David Agard","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"276"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Prashant Mali","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"277"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Jill P. Mesirov","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"278"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Alan Ashworth","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"279"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Jennifer Grandis","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"280"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Silvio Gutkind","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"281"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Laura Esserman","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"282"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Evolution","6":"University of California, San Diego","7":"Laura van't Veer","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"283"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Nevan Krogan","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"284"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Trey Ideker","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"285"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"David Agard","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"286"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Prashant Mali","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"287"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Jill P. Mesirov","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"288"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Alan Ashworth","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"289"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Jennifer Grandis","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"290"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Silvio Gutkind","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"291"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Laura Esserman","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"292"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Francisco","7":"Laura van't Veer","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"293"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Nevan Krogan","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"294"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Trey Ideker","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"295"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"David Agard","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"296"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Prashant Mali","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"297"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Jill P. Mesirov","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"298"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Alan Ashworth","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"299"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Jennifer Grandis","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"300"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Silvio Gutkind","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"301"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Laura Esserman","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"302"},{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, San Diego","7":"Laura van't Veer","8":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","9":"U54","_rn_":"303"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Peter Sorger","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"304"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Sameer Chopra","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"305"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Conor Evans","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"306"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Keith Flaherty","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"307"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Jennifer Guerriero","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"308"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Marcia Haigis","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"309"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Steve Hodi","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"310"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Benjamin Izar","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"311"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Darrell Irvine","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"312"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Douglas A. Lauffenburger","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"313"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Nicole Leboeuf","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"314"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Patrick Ott","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"315"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Sandro Santagata","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"316"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Arlene Sharpe","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"317"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Peter Sorger","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"318"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Sameer Chopra","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"319"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Conor Evans","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"320"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Keith Flaherty","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"321"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Jennifer Guerriero","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"322"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Marcia Haigis","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"323"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Steve Hodi","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"324"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Benjamin Izar","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"325"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Darrell Irvine","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"326"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Douglas A. Lauffenburger","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"327"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Nicole Leboeuf","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"328"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Patrick Ott","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"329"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Sandro Santagata","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"330"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"CSBC","5":"Microenvironment","6":"Harvard University","7":"Arlene Sharpe","8":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","9":"U54","_rn_":"331"},{"1":"syn17023185","2":"ISB Heath Lab","3":"CA202165","4":"PS-ON","5":"NA","6":"Institute for Systems Biology","7":"NA","8":"NA","9":"U01","_rn_":"332"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"Institute for Systems Biology","7":"James Heath","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"333"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"Institute for Systems Biology","7":"Wei Wei","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"334"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"University of California, Los Angeles","7":"James Heath","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"335"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Drug Resistance/Sensitivity","6":"University of California, Los Angeles","7":"Wei Wei","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"336"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Tumor-Immune","6":"Institute for Systems Biology","7":"James Heath","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"337"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Tumor-Immune","6":"Institute for Systems Biology","7":"Wei Wei","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"338"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Tumor-Immune","6":"University of California, Los Angeles","7":"James Heath","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"339"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Tumor-Immune","6":"University of California, Los Angeles","7":"Wei Wei","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"340"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Metabolism","6":"Institute for Systems Biology","7":"James Heath","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"341"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Metabolism","6":"Institute for Systems Biology","7":"Wei Wei","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"342"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Metabolism","6":"University of California, Los Angeles","7":"James Heath","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"343"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"PS-ON","5":"Metabolism","6":"University of California, Los Angeles","7":"Wei Wei","8":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","9":"U01","_rn_":"344"},{"1":"syn17083789","2":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","3":"CA210152","4":"PS-ON","5":"Metastasis","6":"University of Michigan","7":"Gary Luker","8":"Studies of plasticity in cancer stem cells have focused predominantly on primary tumors, in part due to technological challenges. To overcome these challenges, we will develop engineered environments for three key sites in tumor progression: primary tumor, intravascular compartment, and bone.","9":"U01","_rn_":"345"},{"1":"syn17083789","2":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","3":"CA210152","4":"PS-ON","5":"Metastasis","6":"University of Michigan","7":"Joerg Lahann","8":"Studies of plasticity in cancer stem cells have focused predominantly on primary tumors, in part due to technological challenges. To overcome these challenges, we will develop engineered environments for three key sites in tumor progression: primary tumor, intravascular compartment, and bone.","9":"U01","_rn_":"346"},{"1":"syn17083789","2":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","3":"CA210152","4":"PS-ON","5":"Microenvironment","6":"University of Michigan","7":"Gary Luker","8":"Studies of plasticity in cancer stem cells have focused predominantly on primary tumors, in part due to technological challenges. To overcome these challenges, we will develop engineered environments for three key sites in tumor progression: primary tumor, intravascular compartment, and bone.","9":"U01","_rn_":"347"},{"1":"syn17083789","2":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","3":"CA210152","4":"PS-ON","5":"Microenvironment","6":"University of Michigan","7":"Joerg Lahann","8":"Studies of plasticity in cancer stem cells have focused predominantly on primary tumors, in part due to technological challenges. To overcome these challenges, we will develop engineered environments for three key sites in tumor progression: primary tumor, intravascular compartment, and bone.","9":"U01","_rn_":"348"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"Wake Forest","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"349"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"Wake Forest","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"350"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"University of North Carolina at Chapel Hill","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"351"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"University of North Carolina at Chapel Hill","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"352"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"Indiana University  Purdue University Indianapolis","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"353"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"Indiana University  Purdue University Indianapolis","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"354"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"University of Minnesota","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"355"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Heterogeneity","6":"University of Minnesota","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"356"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"Wake Forest","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"357"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"Wake Forest","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"358"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"University of North Carolina at Chapel Hill","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"359"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"University of North Carolina at Chapel Hill","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"360"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"Indiana University  Purdue University Indianapolis","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"361"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"Indiana University  Purdue University Indianapolis","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"362"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"University of Minnesota","7":"Pierre Vidi","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"363"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"PS-ON","5":"Evolution","6":"University of Minnesota","7":"Keith Bonin","8":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","9":"U01","_rn_":"364"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Tumor-Immune","6":"Georgia Institute of Technology","7":"Cheng Zhu","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"365"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Tumor-Immune","6":"Georgia Institute of Technology","7":"Michelle Krogsgaard","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"366"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Tumor-Immune","6":"Georgia Institute of Technology","7":"Susan Napier Thomas","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"367"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Tumor-Immune","6":"New York University School of Medicine","7":"Cheng Zhu","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"368"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Tumor-Immune","6":"New York University School of Medicine","7":"Michelle Krogsgaard","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"369"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Tumor-Immune","6":"New York University School of Medicine","7":"Susan Napier Thomas","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"370"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Microenvironment","6":"Georgia Institute of Technology","7":"Cheng Zhu","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"371"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Microenvironment","6":"Georgia Institute of Technology","7":"Michelle Krogsgaard","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"372"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Microenvironment","6":"Georgia Institute of Technology","7":"Susan Napier Thomas","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"373"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Microenvironment","6":"New York University School of Medicine","7":"Cheng Zhu","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"374"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Microenvironment","6":"New York University School of Medicine","7":"Michelle Krogsgaard","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"375"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"PS-ON","5":"Microenvironment","6":"New York University School of Medicine","7":"Susan Napier Thomas","8":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","9":"U01","_rn_":"376"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Douglas A. Lauffenburger","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"377"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Kevin M. Haigis","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"378"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Wilhelm Haas","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"379"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Ken Lau","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"380"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Kimmie Ng","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"381"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Douglas A. Lauffenburger","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"382"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Kevin M. Haigis","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"383"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Wilhelm Haas","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"384"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Ken Lau","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"385"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Harvard University","7":"Kimmie Ng","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"386"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Douglas A. Lauffenburger","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"387"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Kevin M. Haigis","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"388"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Wilhelm Haas","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"389"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Ken Lau","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"390"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Kimmie Ng","8":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","9":"U01","_rn_":"391"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"University of California, Los Angeles","7":"Aaron Meyer","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"392"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"University of California, Los Angeles","7":"Eric Haura","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"393"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"University of California, Los Angeles","7":"Forest M. White","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"394"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"Moffitt Cancer Center","7":"Aaron Meyer","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"395"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"Moffitt Cancer Center","7":"Eric Haura","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"396"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"Moffitt Cancer Center","7":"Forest M. White","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"397"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Aaron Meyer","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"398"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Eric Haura","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"399"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Heterogeneity","6":"Massachusetts Institute of Technology","7":"Forest M. White","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"400"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Los Angeles","7":"Aaron Meyer","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"401"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Los Angeles","7":"Eric Haura","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"402"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Los Angeles","7":"Forest M. White","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"403"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Aaron Meyer","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"404"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Eric Haura","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"405"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Forest M. White","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"406"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Aaron Meyer","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"407"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Eric Haura","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"408"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Massachusetts Institute of Technology","7":"Forest M. White","8":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","9":"U01","_rn_":"409"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Heterogeneity","6":"University of Virginia","7":"Kevin Janes","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"410"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Heterogeneity","6":"University of Virginia","7":"Fabian Theis","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"411"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Heterogeneity","6":"University of Virginia","7":"Christiane Fuchs","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"412"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Heterogeneity","6":"University of Virginia","7":"Kristen Atkins","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"413"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Heterogeneity","6":"University of Virginia","7":"Jennifer Harvey","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"414"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Evolution","6":"University of Virginia","7":"Kevin Janes","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"415"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Evolution","6":"University of Virginia","7":"Fabian Theis","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"416"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Evolution","6":"University of Virginia","7":"Christiane Fuchs","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"417"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Evolution","6":"University of Virginia","7":"Kristen Atkins","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"418"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"CSBC","5":"Evolution","6":"University of Virginia","7":"Jennifer Harvey","8":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","9":"U01","_rn_":"419"},{"1":"syn17084070","2":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","3":"CA215845","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Vito Quaranta","8":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies.","9":"U01","_rn_":"420"},{"1":"syn17084070","2":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","3":"CA215845","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Carlos F. Lopez","8":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies.","9":"U01","_rn_":"421"},{"1":"syn17084070","2":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","3":"CA215845","4":"CSBC","5":"Heterogeneity","6":"Vanderbilt University","7":"Vito Quaranta","8":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies.","9":"U01","_rn_":"422"},{"1":"syn17084070","2":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","3":"CA215845","4":"CSBC","5":"Heterogeneity","6":"Vanderbilt University","7":"Carlos F. Lopez","8":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies.","9":"U01","_rn_":"423"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Georgia Institute of Technology","7":"Melissa Kemp","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"424"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Georgia Institute of Technology","7":"Cristina Furdui","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"425"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Georgia Institute of Technology","7":"David Boothman","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"426"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Georgia Institute of Technology","7":"Baran D. Sumer","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"427"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Georgia Institute of Technology","7":"Noelle Williams","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"428"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Georgia Institute of Technology","7":"Merecedes Porosnicu","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"429"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Georgia Institute of Technology","7":"Allen W. Tsang","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"430"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Melissa Kemp","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"431"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Cristina Furdui","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"432"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"David Boothman","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"433"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Baran D. Sumer","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"434"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Noelle Williams","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"435"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Merecedes Porosnicu","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"436"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Allen W. Tsang","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"437"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Wake Forest","7":"Melissa Kemp","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"438"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Wake Forest","7":"Cristina Furdui","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"439"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Wake Forest","7":"David Boothman","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"440"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Wake Forest","7":"Baran D. Sumer","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"441"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Wake Forest","7":"Noelle Williams","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"442"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Wake Forest","7":"Merecedes Porosnicu","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"443"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Metabolism","6":"Wake Forest","7":"Allen W. Tsang","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"444"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Georgia Institute of Technology","7":"Melissa Kemp","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"445"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Georgia Institute of Technology","7":"Cristina Furdui","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"446"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Georgia Institute of Technology","7":"David Boothman","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"447"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Georgia Institute of Technology","7":"Baran D. Sumer","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"448"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Georgia Institute of Technology","7":"Noelle Williams","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"449"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Georgia Institute of Technology","7":"Merecedes Porosnicu","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"450"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Georgia Institute of Technology","7":"Allen W. Tsang","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"451"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Indiana University","7":"Melissa Kemp","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"452"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Indiana University","7":"Cristina Furdui","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"453"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Indiana University","7":"David Boothman","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"454"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Indiana University","7":"Baran D. Sumer","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"455"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Indiana University","7":"Noelle Williams","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"456"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Indiana University","7":"Merecedes Porosnicu","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"457"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Indiana University","7":"Allen W. Tsang","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"458"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wake Forest","7":"Melissa Kemp","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"459"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wake Forest","7":"Cristina Furdui","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"460"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wake Forest","7":"David Boothman","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"461"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wake Forest","7":"Baran D. Sumer","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"462"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wake Forest","7":"Noelle Williams","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"463"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wake Forest","7":"Merecedes Porosnicu","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"464"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wake Forest","7":"Allen W. Tsang","8":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","9":"U01","_rn_":"465"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Mayo Clinic","7":"Kristin R. Swanson","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"466"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Mayo Clinic","7":"Leland S. Hu","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"467"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Mayo Clinic","7":"J. Ross Mitchell","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"468"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Mayo Clinic","7":"Nhan L. Tran","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"469"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Arizona State University","7":"Kristin R. Swanson","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"470"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Arizona State University","7":"Leland S. Hu","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"471"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Arizona State University","7":"J. Ross Mitchell","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"472"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Arizona State University","7":"Nhan L. Tran","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"473"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Barrow Neurological Institute","7":"Kristin R. Swanson","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"474"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Barrow Neurological Institute","7":"Leland S. Hu","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"475"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Barrow Neurological Institute","7":"J. Ross Mitchell","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"476"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Heterogeneity","6":"Barrow Neurological Institute","7":"Nhan L. Tran","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"477"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Mayo Clinic","7":"Kristin R. Swanson","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"478"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Mayo Clinic","7":"Leland S. Hu","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"479"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Mayo Clinic","7":"J. Ross Mitchell","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"480"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Mayo Clinic","7":"Nhan L. Tran","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"481"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Arizona State University","7":"Kristin R. Swanson","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"482"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Arizona State University","7":"Leland S. Hu","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"483"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Arizona State University","7":"J. Ross Mitchell","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"484"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Arizona State University","7":"Nhan L. Tran","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"485"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Barrow Neurological Institute","7":"Kristin R. Swanson","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"486"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Barrow Neurological Institute","7":"Leland S. Hu","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"487"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Barrow Neurological Institute","7":"J. Ross Mitchell","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"488"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"CSBC","5":"Evolution","6":"Barrow Neurological Institute","7":"Nhan L. Tran","8":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","9":"U01","_rn_":"489"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of Pennsylvania","7":"Arjun Raj","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"490"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of Pennsylvania","7":"Ravi Radhakrishnan","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"491"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of Pennsylvania","7":"Junwei Shi","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"492"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of Pennsylvania","7":"Abhyudai Singh","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"493"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of Pennsylvania","7":"Ashani T. Weeraratna","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"494"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wistar Institute","7":"Arjun Raj","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"495"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wistar Institute","7":"Ravi Radhakrishnan","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"496"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wistar Institute","7":"Junwei Shi","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"497"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wistar Institute","7":"Abhyudai Singh","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"498"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Wistar Institute","7":"Ashani T. Weeraratna","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"499"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"University of Pennsylvania","7":"Arjun Raj","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"500"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"University of Pennsylvania","7":"Ravi Radhakrishnan","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"501"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"University of Pennsylvania","7":"Junwei Shi","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"502"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"University of Pennsylvania","7":"Abhyudai Singh","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"503"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"University of Pennsylvania","7":"Ashani T. Weeraratna","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"504"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"Wistar Institute","7":"Arjun Raj","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"505"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"Wistar Institute","7":"Ravi Radhakrishnan","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"506"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"Wistar Institute","7":"Junwei Shi","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"507"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"Wistar Institute","7":"Abhyudai Singh","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"508"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"CSBC","5":"Heterogeneity","6":"Wistar Institute","7":"Ashani T. Weeraratna","8":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","9":"U01","_rn_":"509"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Metabolism","6":"University of Southern California","7":"Stacey Finley","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"510"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Metabolism","6":"University of Southern California","7":"Paul Macklin","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"511"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Metabolism","6":"University of Southern California","7":"Shannon Mumenthaler","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"512"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Stacey Finley","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"513"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Paul Macklin","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"514"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Metabolism","6":"Indiana University","7":"Shannon Mumenthaler","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"515"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Heterogeneity","6":"University of Southern California","7":"Stacey Finley","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"516"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Heterogeneity","6":"University of Southern California","7":"Paul Macklin","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"517"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Heterogeneity","6":"University of Southern California","7":"Shannon Mumenthaler","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"518"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Heterogeneity","6":"Indiana University","7":"Stacey Finley","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"519"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Heterogeneity","6":"Indiana University","7":"Paul Macklin","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"520"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Heterogeneity","6":"Indiana University","7":"Shannon Mumenthaler","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"521"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Microenvironment","6":"University of Southern California","7":"Stacey Finley","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"522"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Microenvironment","6":"University of Southern California","7":"Paul Macklin","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"523"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Microenvironment","6":"University of Southern California","7":"Shannon Mumenthaler","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"524"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Microenvironment","6":"Indiana University","7":"Stacey Finley","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"525"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Microenvironment","6":"Indiana University","7":"Paul Macklin","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"526"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"CSBC","5":"Microenvironment","6":"Indiana University","7":"Shannon Mumenthaler","8":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","9":"U01","_rn_":"527"},{"1":"syn17084104","2":"Rewiring of regulatory networks in breast cancer by transcription factor isoforms","3":"CA232161","4":"CSBC","5":"Heterogeneity","6":"Dana-Farber Cancer Institute","7":"Martha Bulyk","8":"We aim to combine network modeling and high-throughput systematic experimental strategies at the level of molecular protein-protein and protein-DNA interactions to predict cancer drivers and suppressors. The resulting hypotheses will be tested experimentally using various large-scale functional assays in breast cancer as a model system.","9":"U01","_rn_":"528"},{"1":"syn17084104","2":"Rewiring of regulatory networks in breast cancer by transcription factor isoforms","3":"CA232161","4":"CSBC","5":"Heterogeneity","6":"Dana-Farber Cancer Institute","7":"Juan Fuxman","8":"We aim to combine network modeling and high-throughput systematic experimental strategies at the level of molecular protein-protein and protein-DNA interactions to predict cancer drivers and suppressors. The resulting hypotheses will be tested experimentally using various large-scale functional assays in breast cancer as a model system.","9":"U01","_rn_":"529"},{"1":"syn17084104","2":"Rewiring of regulatory networks in breast cancer by transcription factor isoforms","3":"CA232161","4":"CSBC","5":"Heterogeneity","6":"Dana-Farber Cancer Institute","7":"Marc Vidal","8":"We aim to combine network modeling and high-throughput systematic experimental strategies at the level of molecular protein-protein and protein-DNA interactions to predict cancer drivers and suppressors. The resulting hypotheses will be tested experimentally using various large-scale functional assays in breast cancer as a model system.","9":"U01","_rn_":"530"},{"1":"syn17084109","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"CA232382","4":"CSBC","5":"Tumor-Immune","6":"Moffitt Cancer Center","7":"Robert A. Gatenby","8":"The Moffitt PSOC embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U01","_rn_":"531"},{"1":"syn17084109","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"CA232382","4":"CSBC","5":"Tumor-Immune","6":"Moffitt Cancer Center","7":"Scott Antonia","8":"The Moffitt PSOC embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U01","_rn_":"532"},{"1":"syn17084109","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"CA232382","4":"CSBC","5":"Tumor-Immune","6":"Moffitt Cancer Center","7":"Alexander R. A. Anderson","8":"The Moffitt PSOC embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U01","_rn_":"533"},{"1":"syn17084109","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"CA232382","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Robert A. Gatenby","8":"The Moffitt PSOC embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U01","_rn_":"534"},{"1":"syn17084109","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"CA232382","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Scott Antonia","8":"The Moffitt PSOC embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U01","_rn_":"535"},{"1":"syn17084109","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"CA232382","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Moffitt Cancer Center","7":"Alexander R. A. Anderson","8":"The Moffitt PSOC embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","9":"U01","_rn_":"536"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Heterogeneity","6":"University of California, Irvine","7":"John Lowengrub","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"537"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Heterogeneity","6":"University of California, Irvine","7":"Arthur Lander","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"538"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Heterogeneity","6":"University of California, Irvine","7":"Marian Waterman","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"539"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Evolution","6":"University of California, Irvine","7":"John Lowengrub","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"540"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Evolution","6":"University of California, Irvine","7":"Arthur Lander","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"541"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Evolution","6":"University of California, Irvine","7":"Marian Waterman","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"542"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Irvine","7":"John Lowengrub","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"543"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Irvine","7":"Arthur Lander","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"544"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"University of California, Irvine","7":"Marian Waterman","8":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","9":"U54","_rn_":"545"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Evolution","6":"Arizona State University","7":"Carlo Maley","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"546"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Evolution","6":"Arizona State University","7":"Darryl Shibata","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"547"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Heterogeneity","6":"Arizona State University","7":"Carlo Maley","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"548"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Heterogeneity","6":"Arizona State University","7":"Darryl Shibata","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"549"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Epigenetics","6":"Arizona State University","7":"Carlo Maley","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"550"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Epigenetics","6":"Arizona State University","7":"Darryl Shibata","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"551"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Microenvironment","6":"Arizona State University","7":"Carlo Maley","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"552"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"CSBC","5":"Microenvironment","6":"Arizona State University","7":"Darryl Shibata","8":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","9":"U54","_rn_":"553"},{"1":"syn18435914","2":"Phenotype Heterogeneity and Dynamics in SCLC","3":"CA217450","4":"CSBC","5":"Heterogeneity","6":"Vanderbilt University","7":"Vito Quaranta","8":"NA","9":"U54","_rn_":"554"},{"1":"syn18435914","2":"Phenotype Heterogeneity and Dynamics in SCLC","3":"CA217450","4":"CSBC","5":"Drug Resistance/Sensitivity","6":"Vanderbilt University","7":"Vito Quaranta","8":"NA","9":"U54","_rn_":"555"},{"1":"syn18435914","2":"Phenotype Heterogeneity and Dynamics in SCLC","3":"CA217450","4":"CSBC","5":"Microenvironment","6":"Vanderbilt University","7":"Vito Quaranta","8":"NA","9":"U54","_rn_":"556"}],"options":{"columns":{"min":{},"max":[10],"total":[9]},"rows":{"min":[10],"max":[10],"total":[556]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_formatted_grant_df &lt;- merged_grant_df %&gt;%
  filter(!is.na(grantName)) %&gt;%
  group_by(grantId, grantName, grantNumber, abstract, grantType) %&gt;%
  summarize(institution = str_c(unique(institution), collapse = &quot; | &quot;),
            investigator = str_c(unique(investigator), collapse = &quot;, &quot;),
            theme = str_c(unique(theme), collapse = &quot;, &quot;),
            consortium = str_c(unique(consortium), collapse = &quot;, &quot;)) %&gt;%
  ungroup() %&gt;%
  distinct()

merged_formatted_grant_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["tbl_df","tbl","data.frame"],"ncol":9,"nrow":52},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["grantId"],"name":[1],"type":["chr"],"align":["left"]},{"label":["grantName"],"name":[2],"type":["chr"],"align":["left"]},{"label":["grantNumber"],"name":[3],"type":["chr"],"align":["left"]},{"label":["abstract"],"name":[4],"type":["chr"],"align":["left"]},{"label":["grantType"],"name":[5],"type":["chr"],"align":["left"]},{"label":["institution"],"name":[6],"type":["chr"],"align":["left"]},{"label":["investigator"],"name":[7],"type":["chr"],"align":["left"]},{"label":["theme"],"name":[8],"type":["chr"],"align":["left"]},{"label":["consortium"],"name":[9],"type":["chr"],"align":["left"]}],"data":[{"1":"syn10140998","2":"The Cancer Cell Map Initiative","3":"CA209891","4":"What is now needed is an integrated computational and experimental strategy that will help place these alterations into context of the higher order biological mechanisms in cancer cells. This is the goal of the Cancer Cell Map Initiative, which will create a resource that can be used for cancer genome interpretation.","5":"U54","6":"University of California, San Francisco | University of California, San Diego","7":"Nevan Krogan, Trey Ideker, David Agard, Prashant Mali, Jill P. Mesirov, Alan Ashworth, Jennifer Grandis, Silvio Gutkind, Laura Esserman, Laura van't Veer","8":"Heterogeneity, Evolution, Drug Resistance/Sensitivity","9":"CSBC"},{"1":"syn12051865","2":"Center for Cancer Systems Pharmacology","3":"CA225088","4":"The Center for Cancer Systems Pharmacology (CCSP) based at Harvard Medical School focuses on constructing and validating network-level models of responsiveness and resistance (innate and acquired) to immune checkpoint inhibitor (ICI) and small molecule (targeted) therapies in human cancer.","5":"U54","6":"Harvard University","7":"Peter Sorger, Sameer Chopra, Conor Evans, Keith Flaherty, Jennifer Guerriero, Marcia Haigis, Steve Hodi, Benjamin Izar, Darrell Irvine, Douglas A. Lauffenburger, Nicole Leboeuf, Patrick Ott, Sandro Santagata, Arlene Sharpe","8":"Drug Resistance/Sensitivity, Microenvironment","9":"CSBC"},{"1":"syn17023185","2":"ISB Heath Lab","3":"CA202165","4":"NA","5":"U01","6":"Institute for Systems Biology","7":"NA","8":"NA","9":"PS-ON"},{"1":"syn17083754","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"CA217655","4":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. We seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes.","5":"U01","6":"Institute for Systems Biology | University of California, Los Angeles","7":"James Heath, Wei Wei","8":"Drug Resistance/Sensitivity, Tumor-Immune, Metabolism","9":"PS-ON"},{"1":"syn17083789","2":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","3":"CA210152","4":"Studies of plasticity in cancer stem cells have focused predominantly on primary tumors, in part due to technological challenges. To overcome these challenges, we will develop engineered environments for three key sites in tumor progression: primary tumor, intravascular compartment, and bone.","5":"U01","6":"University of Michigan","7":"Gary Luker, Joerg Lahann","8":"Metastasis, Microenvironment","9":"PS-ON"},{"1":"syn17083844","2":"Chromatin Mobility in Response to DNA Damage","3":"CA214282","4":"We developed a method based on diffractive optical elements to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact genomic translocations frequencies in cells with DNA damage.","5":"U01","6":"Wake Forest | University of North Carolina at Chapel Hill | Indiana University  Purdue University Indianapolis | University of Minnesota","7":"Pierre Vidi, Keith Bonin","8":"Heterogeneity, Evolution","9":"PS-ON"},{"1":"syn17083914","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"CA214354","4":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity.","5":"U01","6":"Georgia Institute of Technology | New York University School of Medicine","7":"Cheng Zhu, Michelle Krogsgaard, Susan Napier Thomas","8":"Tumor-Immune, Microenvironment","9":"PS-ON"},{"1":"syn17084053","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"CA215798","4":"Three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of precision medicine is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation.","5":"U01","6":"Massachusetts Institute of Technology | Harvard University | Vanderbilt University","7":"Douglas A. Lauffenburger, Kevin M. Haigis, Wilhelm Haas, Ken Lau, Kimmie Ng","8":"Drug Resistance/Sensitivity","9":"CSBC"},{"1":"syn17084058","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"CA215709","4":"Tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.","5":"U01","6":"University of California, Los Angeles | Moffitt Cancer Center | Massachusetts Institute of Technology","7":"Aaron Meyer, Eric Haura, Forest M. White","8":"Heterogeneity, Drug Resistance/Sensitivity","9":"CSBC"},{"1":"syn17084062","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"CA215794","4":"The goals are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype.","5":"U01","6":"University of Virginia","7":"Kevin Janes, Fabian Theis, Christiane Fuchs, Kristen Atkins, Jennifer Harvey","8":"Heterogeneity, Evolution","9":"CSBC"},{"1":"syn17084070","2":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","3":"CA215845","4":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies.","5":"U01","6":"Vanderbilt University","7":"Vito Quaranta, Carlos F. Lopez","8":"Drug Resistance/Sensitivity, Heterogeneity","9":"CSBC"},{"1":"syn17084080","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"CA215848","4":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof.","5":"U01","6":"Georgia Institute of Technology | Indiana University | Wake Forest","7":"Melissa Kemp, Cristina Furdui, David Boothman, Baran D. Sumer, Noelle Williams, Merecedes Porosnicu, Allen W. Tsang","8":"Metabolism, Drug Resistance/Sensitivity","9":"CSBC"},{"1":"syn17084088","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"CA220378","4":"Glioblastoma (GBM) exhibits molecular heterogeneity that contributes to treatment resistance and poor survival. A significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions.","5":"U01","6":"Mayo Clinic | Arizona State University | Barrow Neurological Institute","7":"Kristin R. Swanson, Leland S. Hu, J. Ross Mitchell, Nhan L. Tran","8":"Heterogeneity, Evolution","9":"CSBC"},{"1":"syn17084095","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"CA227550","4":"Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma.","5":"U01","6":"University of Pennsylvania | Wistar Institute","7":"Arjun Raj, Ravi Radhakrishnan, Junwei Shi, Abhyudai Singh, Ashani T. Weeraratna","8":"Drug Resistance/Sensitivity, Heterogeneity","9":"CSBC"},{"1":"syn17084099","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"CA232137","4":"We addresses low the survival rate for patients with metastatic colorectal cancer (CRC) by applying a systems biology approach of novel mathematical frameworks, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming occurring between tumor cells and CAFs.","5":"U01","6":"University of Southern California | Indiana University","7":"Stacey Finley, Paul Macklin, Shannon Mumenthaler","8":"Metabolism, Heterogeneity, Microenvironment","9":"CSBC"},{"1":"syn17084104","2":"Rewiring of regulatory networks in breast cancer by transcription factor isoforms","3":"CA232161","4":"We aim to combine network modeling and high-throughput systematic experimental strategies at the level of molecular protein-protein and protein-DNA interactions to predict cancer drivers and suppressors. The resulting hypotheses will be tested experimentally using various large-scale functional assays in breast cancer as a model system.","5":"U01","6":"Dana-Farber Cancer Institute","7":"Martha Bulyk, Juan Fuxman, Marc Vidal","8":"Heterogeneity","9":"CSBC"},{"1":"syn17084109","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"CA232382","4":"The Moffitt PSOC embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","5":"U01","6":"Moffitt Cancer Center","7":"Robert A. Gatenby, Scott Antonia, Alexander R. A. Anderson","8":"Tumor-Immune, Drug Resistance/Sensitivity","9":"CSBC"},{"1":"syn18145018","2":"Cancer Systems Biology at UC Irvine","3":"CA217378","4":"The UCI Center for Cancer Systems Biology (CaSB@UCI) is carrying out three projects on the role of context, cooperation and community in the initiation and progression of cancer. They seek to understand how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","5":"U54","6":"University of California, Irvine","7":"John Lowengrub, Arthur Lander, Marian Waterman","8":"Heterogeneity, Evolution, Drug Resistance/Sensitivity","9":"CSBC"},{"1":"syn18435688","2":"Arizona Cancer and Evolution Center","3":"CA217376","4":"Regulatory mechanisms determine evolutionary parameters at the cell level such as the somatic mutation rate and response to DNA damage. Cancer circumvents those constraints and changes the parameters of cell-level evolution, leading to malignancy and eventual host death. Thus, organismal and cell-level evolution feed back upon each other. This opens an opportunity.","5":"U54","6":"Arizona State University","7":"Carlo Maley, Darryl Shibata","8":"Evolution, Heterogeneity, Epigenetics, Microenvironment","9":"CSBC"},{"1":"syn18435914","2":"Phenotype Heterogeneity and Dynamics in SCLC","3":"CA217450","4":"NA","5":"U54","6":"Vanderbilt University","7":"Vito Quaranta","8":"Heterogeneity, Drug Resistance/Sensitivity, Microenvironment","9":"CSBC"},{"1":"syn7080714","2":"CSBC PS-ON Knowledge Portal","3":"CA209923","4":"NA","5":"U24","6":"Sage Bionetworks","7":"NA","8":"Computational Resource","9":"CSBC"},{"1":"syn7315802","2":"Center for Cancer Systems Therapeutics (CaST)","3":"CA209997","4":"Instead of focusing on the highly diverse, patient-specific spectrum of mutations that can initiate cancer, CaST is concentrating on the regulatory machinery found within cancer cells responsible for tumor homeostasis canalization.","5":"U54","6":"Columbia University","7":"Andrea Califano, Barry Honig","8":"Heterogeneity, Drug Resistance/Sensitivity","9":"CSBC"},{"1":"syn7315805","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC","3":"CA209975","4":"The overarching goal of the proposed CSBC Research Center for Cancer Systems Immunology at MSKCC is to bring the tools of systems biology to advance our fundamental understanding of the role of the immune system during three critical steps of tumor development: cancer initiation and early tumorigenesis; tumor progression and established tumors; and invasion and metastasis.","5":"U54","6":"Memorial Sloan Kettering Cancer Center","7":"Christina Leslie, Alexander Rudensky","8":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","9":"CSBC"},{"1":"syn7315808","2":"Stanford University Center for Cancer Systems Biology","3":"CA209971","4":"Our Research Center aims to identify the mechanisms in which tumor cells instruct the immune system to tolerant them by focusing on the understudied role of lymph node invasion in tumor-mediated immunosuppression. Distant metastasis is the primary cause of cancer-related death. To colonize distant tissues, cancer cells must migrate while evading elimination by the immune system.","5":"U54","6":"Stanford University","7":"Sylvia Plevritis, Garry Nolan, Ed Engleman, John Sunwoo","8":"Tumor-Immune, Metastasis, Microenvironment","9":"CSBC"},{"1":"syn7315810","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","3":"CA209992","4":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","5":"U54","6":"Yale University","7":"Andre Levchenko, Mark Lemmon, Gutner Wagner, Murat Acar, Jesse Rinehart, Farren Isaacs, Michael Murrell, Rong Fan, Sidi Chen, Lynne Regan, Adam Marcus, Kshitiz Gupta, Anatoly Kiyatkin, Maria Apostolidi","8":"Metastasis, Microenvironment","9":"CSBC"},{"1":"syn7349742","2":"Chicago Region Physical Science Oncology Center","3":"CA193419","4":"The Chicago Region-Physical Science Oncology Center (CR-PSOC) is organized around the conceptual framework that addresses the spatio-temporal organization of chromatin and information transfer in cancer. This organizing framework integrates the strengths of chemistry, genetics, and physics to address chromatin dynamics in cancer.","5":"U54","6":"Northwestern University","7":"Thomas V. O'Halloran, Jonathan D. Licht","8":"Metabolism, Heterogeneity, Evolution","9":"PS-ON"},{"1":"syn7349745","2":"Center for Modeling Tumor Cell Migration Mechanics","3":"CA210190","4":"Our Center will focus on understanding the fundamental mechanics and chemistry of how cells generate forces to move through complex and mechanically challenging tumor microenvironments. The organizing framework of our Center is to then directly target the mechanical machinery and structural elements that drive cell migration.","5":"U54","6":"University of Minnesota","7":"David Odde, David Largaespada, Steven Rosenfeld","8":"Microenvironment, Metastasis, Tumor-Immune","9":"PS-ON"},{"1":"syn7349747","2":"Physical Science Oncology Center at Penn","3":"CA193417","4":"The PSOC@Penn focuses on physical changes of tissues, cells, and nuclei that contribute to cancer growth and initiation. As tumor cells divide, invade, and displace normal cells, the tissue often changes physically, frequently getting stiffer, sometimes softer, often heterogeneously. Physical changes sometimes occur even before the cancer is detectable.","5":"U54","6":"University of Pennsylvania","7":"Dennis Discher","8":"Microenvironment, Evolution, Metastasis","9":"PS-ON"},{"1":"syn7349753","2":"H Lee Moffitt Cancer Center and Research Institute","3":"CA193489","4":"The Moffitt PSOC (1 of 10 current PSOC centers nationwide) embraces the physical science research paradigm that has combined empirical studies with mathematically-based theoretical models that integrate and organize diverse data. We view cancer as an open, complex, dynamic, adaptive system. <U+201C>Complex<U+201D> because it contains a large number of components linked through a variety of mostly non-linear interactions.","5":"U54","6":"Moffitt Cancer Center","7":"Robert A. Gatenby, Robert J. Gillies, Alexander R. A. Anderson","8":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Tumor-Immune","9":"PS-ON"},{"1":"syn7349757","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","3":"CA193461","4":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center will intertwine the physical sciences with cancer biology and oncology by engaging evolutionary theory to address several critical issues concerning modern cancer research. This center aspires to institute evolutionary modeling of cancer as a new field of study. The center has brought together scientists from theoretical biology, cancer biology, oncology, physics and engineering.","5":"U54","6":"Dana-Farber Cancer Institute","7":"Franziska Michor, Eric C. Holland","8":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","9":"PS-ON"},{"1":"syn7349759","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","3":"CA193313","4":"The Center for Topology of Cancer Evolution and Heterogeneity opened in May 2015 as an interdisciplinary center formed to develop an integrated experimental and computational pipeline for characterizing the evolution of subclonal populations within solid tumors. Our experimental techniques include novel organoid systems for tracing cellular lineages, as well as innovative single-cell sequencing technologies.","5":"U54","6":"Columbia University","7":"Raul Rabadan, Antonio Iavarone","8":"Heterogeneity, Evolution, Metastasis","9":"PS-ON"},{"1":"syn7349762","2":"The Center for Immunotherapeutic Transport Oncophysics","3":"CA210181","4":"The use of FDA-approved immunotherapies to treat metastatic melanoma and lung cancer has reignited the interest and examination of similar approaches for other cancers, including breast and pancreatic cancer, both considered <U+201C>immunologically cold<U+201D> and for which immunotherapy treatments have achieved limited success.","5":"U54","6":"Houston Methodist","7":"Mauro Ferrari","8":"Heterogeneity, Tumor-Immune, Microenvironment","9":"PS-ON"},{"1":"syn7349764","2":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","3":"CA210180","4":"A central goal of the MIT/Mayo PS-OC is to model the physical and physico-chemical factors that govern drug distribution into brain tumors.","5":"U54","6":"Massachusetts Institute of Technology","7":"Forest M. White, Jann Sarkaria","8":"Heterogeneity, Microenvironment, Evolution","9":"PS-ON"},{"1":"syn7349766","2":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","3":"CA210173","4":"Johns Hopkins University Physical Sciences-Oncology Center will explore the mechanical forces in cancer that bolster the tumor metastatic cascade. Metastatic disease is the cause for the preponderance of deaths related to cancer.","5":"U54","6":"Johns Hopkins University","7":"Denis Wirtz","8":"Microenvironment, Metastasis, Metabolism","9":"PS-ON"},{"1":"syn7349770","2":"Center on the Physics of Cancer Metabolism","3":"CA210184","4":"Despite advances in breast cancer treatment, metastatic disease remains incurable and is of particular concern in patients with triple negative breast cancer. Both aberrant metabolic signaling and physical properties of the microenvironment have been independently defined as hallmarks of cancers, and experimental evidence suggests that they may be functionally linked.","5":"U54","6":"Cornell University","7":"Claudia Fischbach-Teschl, Lewis C. Cantley","8":"Metabolism, Microenvironment, Metastasis","9":"PS-ON"},{"1":"syn7416702","2":"Epithelial layer jamming in breast cancer cell migration","3":"CA202123","4":"NA","5":"U01","6":"Harvard University | Boston University | Dartmouth College","7":"Jeffrey J. Fredberg","8":"Metastasis, Heterogeneity","9":"PS-ON"},{"1":"syn7416707","2":"Quantitative analyses of tumor cell extravasation","3":"CA202177","4":"Over the past several years, we have developed microfluidic systems that are capable of simulating many steps of metastasis including tumor cell invasion, intravasation, etc. The object of our study is to employ these assays with new measurement methods to interrogate the changes in cell mechanics during the process of extravasation and understand the nature of the cell-cell and cell-matrix force interactions.","5":"U01","6":"Massachusetts Institute of Technology","7":"Roger D. Kamm","8":"Microenvironment, Metastasis","9":"PS-ON"},{"1":"syn7416710","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"CA202241","4":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs.","5":"U01","6":"University of California, Berkeley | University of California, San Francisco","7":"Jay T. Groves, Valerie M. Weaver","8":"Heterogeneity, Microenvironment","9":"PS-ON"},{"1":"syn7416712","2":"Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics","3":"CA202144","4":"The University of Utah is developing new mathematical frameworks to create a single coherent model from multiple high-dimensional datasets, or tensors. The frameworks <U+2013> comparative spectral decompositions <U+2013> generalize those that underlie the theoretical description of the physical world.","5":"U01","6":"University of Utah","7":"Orly Alter","8":"Heterogeneity, Evolution","9":"PS-ON"},{"1":"syn7416714","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"CA202229","4":"Our project aims to develop a new computational platform to examine physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response. Malignant breast tumors are highly heterogeneous and complex.","5":"U01","6":"Vanderbilt University | Moffitt Cancer Center","7":"Lisa J. McCawley, Katarzyna Rejniak, Dmitry Markov","8":"Microenvironment, Heterogeneity","9":"PS-ON"},{"1":"syn9771796","2":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","3":"CA209978","4":"We will integrate dynamic models with clinical trials to evaluate if these phenotypic changes can be targeted for therapy. We hypothesize that acquired resistance emerges from selection acting on phenotypes during tumor evolution, and simultaneously measuring and modeling subclone genotypes and phenotypes will identify new testable therapeutic targets.","5":"U54","6":"City Of Hope National Medical Center","7":"Andrea Bild, Fred Adler, David Bowtell, Jeffrey Chang, Gabor Marth, Suni Sharma","8":"Drug Resistance/Sensitivity, Heterogeneity, Evolution, Metastasis","9":"CSBC"},{"1":"syn9772917","2":"Embryonal Brain Tumor Networks","3":"CA184898","4":"NA","5":"U01","6":"Massachusetts Institute of Technology | Harvard University | University of California, San Diego","7":"Jill P. Mesirov, Ernest Fraenkel, Scott L. Pomeroy","8":"Heterogeneity","9":"CSBC"},{"1":"syn9773338","2":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","3":"CA217377","4":"Treatment of patients with conventional chemotherapy or targeted agents remains highly empiric. Our center will establish a framework that enables an iterative cycle between novel single-cell measurements from clinically-relevant specimens and computational approaches that result in testable predictions. Phenotypic properties include physical parameters and molecular markers.","5":"U54","6":"Massachusetts Institute of Technology","7":"Scott Manalis, Douglas A. Lauffenburger, William Hahn, Alex K. Shalek, David Weinstock, Christopher Love, Kristen Stevenson","8":"Drug Resistance/Sensitivity, Microenvironment","9":"CSBC"},{"1":"syn9773345","2":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","3":"CA209988","4":"M2CH Center for Cancer Systems Biology seeks to improve management of triple negative breast cancer (TNBC) by developing strategies to prevent the emergence of cancer subpopulations resistant to treatment. We postulate that heterogeneity arising from epigenomic instability intrinsic to cancer cells and diverse signals from extrinsic microenvironments that cancer cells reside are root causes of resistance.","5":"U54","6":"Oregon Health & Science University | University of California, Berkeley","7":"Joe W. Gray, Rosalie Sears, Claire Tomlin","8":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","9":"CSBC"},{"1":"syn9773346","2":"Systems Analysis of Epigenomic Architecture in Cancer Progression","3":"CA217297","4":"Despite anti-hormone therapies in patients, the cognate receptors ER<U+03B1> and AR can remain functional to support oncogenic signaling for advanced progression of breast and prostate cancers. Intensive studies have uncovered cellular and biochemical changes underlying the development of hormone resistance. However, epigenetic mechanisms for establishing and maintaining a hormone-resistant phenotype remain to be explored.","5":"U54","6":"The University of Texas Health Science Center at San Antonio | Duke University","7":"Tim Huang, Victor Jin, Qianben Wang","8":"Drug Resistance/Sensitivity, Epigenetics","9":"CSBC"},{"1":"syn9774783","2":"Integrative approach to heterogeneity in breast cancer metastasis","3":"CA199315","4":"NA","5":"U01","6":"University of California, San Francisco","7":"NA","8":"Heterogeneity, Microenvironment","9":"CSBC"},{"1":"syn9774959","2":"From Mechanism to Population - Modeling HPV-related Oropharyngeal Carcinogenesis","3":"CA182915","4":"NA","5":"U01","6":"University of Michigan","7":"NA","8":"NA","9":"CSBC"},{"1":"syn9775595","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"CA188388","4":"NA","5":"U01","6":"Houston Methodist | Weill Cornell Medicine","7":"Allen W. Tsang, Vivek Mittal","8":"Heterogeneity, Microenvironment","9":"CSBC"},{"1":"syn9775651","2":"Phenotype Transitions in Small Cell Lung Cancer","3":"CA182915","4":"NA","5":"U01","6":"Vanderbilt University","7":"NA","8":"NA","9":"CSBC"},{"1":"syn9775665","2":"CSBC U01 Project Boston University","3":"CA182898","4":"NA","5":"U01","6":"Boston University","7":"NA","8":"NA","9":"CSBC"},{"1":"syn9775689","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"CA184897","4":"NA","5":"U01","6":"Massachusetts Institute of Technology | Beth Israel Deaconess Hospital | Massachusetts General Hospital","7":"NA","8":"Metastasis, Heterogeneity","9":"CSBC"},{"1":"syn9775704","2":"Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors","3":"CA195469","4":"NA","5":"U01","6":"Dana-Farber Cancer Institute","7":"NA","8":"Evolution, Heterogeneity","9":"CSBC"}],"options":{"columns":{"min":{},"max":[10],"total":[9]},"rows":{"min":[10],"max":[10],"total":[52]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code># initial table creation (synIDs need to be integers)
# merged_grant_syntable &lt;- merged_formatted_grant_df %&gt;% 
#   mutate_at(vars(contains(&quot;Id&quot;)), ~ str_replace(., &quot;syn&quot;, &quot;&quot;)) %&gt;% 
#   synBuildTable(&quot;Portal - Grants Merged&quot;, &quot;syn7080714&quot;, .) %&gt;% 
#   synStore()

# update/overwrite the table
merged_grant_syntable &lt;- merged_formatted_grant_df %&gt;% 
  # mutate(id = grantName) %&gt;% 
  update_table(&quot;syn21918972&quot;, .)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>
 [####################]100.00%   1/1   Done...    
Downloading  [####################]100.00%   25.5kB/25.5kB (278.9kB/s) Job-112110311742636298619267553.csv Done...    
Uploading [--------------------]0.00%   0.0bytes/338.0bytes  tmpx_4zifra.csv     
Uploading [####################]100.00%   338.0bytes/338.0bytes (380.2bytes/s) tmpx_4zifra.csv Done...    
 [####################]100.00%   1/1   Done...    
Uploading [--------------------]0.00%   0.0bytes/25.5kB  file6565b3ab2e3     
Uploading [####################]100.00%   25.5kB/25.5kB (10.9kB/s) file6565b3ab2e3 Done...    
 [####################]100.00%   1/1   Done...    </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
<div id="projects---merged-table" class="section level2">
<h2>Projects - merged table</h2>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGJfcHJvamVjdF9kZiA8LSBnZXRfdGFibGVfZGYoXCJzeW4yMTY0NTE0N1wiLCBjYWNoZSA9IEZBTFNFKVxuYGBgIn0= -->
<pre class="r"><code>db_project_df &lt;- get_table_df(&quot;syn21645147&quot;, cache = FALSE)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiXG4gWyMjIyMjIyMjIyMjIyMjIyMjIyMjXTEwMC4wMCUgICAxLzEgICBEb25lLi4uICAgIFxuRG93bmxvYWRpbmcgIFsjIyMjIyMjIyMjIyMjIyMjIyMjI10xMDAuMDAlICAgMzQuM2tCLzM0LjNrQiAoMzc2LjFrQi9zKSBKb2ItMTEyMDY1Mzg4ODIyOTAzNzIyMjE5NDE5ODczLmNzdiBEb25lLi4uICAgIFxuIn0= -->
<pre><code>
 [####################]100.00%   1/1   Done...    
Downloading  [####################]100.00%   34.3kB/34.3kB (376.1kB/s) Job-112065388822903722219419873.csv Done...    </code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGJfZGVzY3JpcHRpb25fcHJvamVjdCA8LSBnZXRfdGFibGVfZGYoXCJzeW4yMTg2ODQwN1wiLCBjYWNoZSA9IEZBTFNFKVxuYGBgIn0= -->
<pre class="r"><code>db_description_project &lt;- get_table_df(&quot;syn21868407&quot;, cache = FALSE)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiXG4gWyMjIyMjIyMjIyMjIyMjIyMjIyMjXTEwMC4wMCUgICAxLzEgICBEb25lLi4uICAgIFxuRG93bmxvYWRpbmcgIFsjIyMjIyMjIyMjIyMjIyMjIyMjI10xMDAuMDAlICAgMjU1LjhrQi8yNTUuOGtCICgxLjNNQi9zKSBKb2ItMTEyMDY1MzkyMDYxMTQzNTgwMTY4MjA5NDMyLmNzdiBEb25lLi4uICAgIFxuIn0= -->
<pre><code>
 [####################]100.00%   1/1   Done...    
Downloading  [####################]100.00%   255.8kB/255.8kB (1.3MB/s) Job-112065392061143580168209432.csv Done...    </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_project_df &lt;- db_project_df %&gt;% 
  rename(projectId = id, projectName = name) %&gt;%
  left_join(
    db_description_project, by = &quot;projectId&quot;
  ) %&gt;% 
  left_join(
    db_grant_df %&gt;% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = &quot;grantId&quot;
  ) %&gt;% 
  left_join(db_theme_grant, by = &quot;grantId&quot;) %&gt;% 
  left_join(
    db_theme_df %&gt;% 
      select(themeId = id, theme = displayName),
    by = &quot;themeId&quot;
  ) %&gt;% 
  left_join(
    db_consortium_df %&gt;% 
      select(consortiumId = id, consortium = displayName)
  ) %&gt;% 
  select(projectId, projectName = displayName, description, 
         theme, grantName, consortium, grantType) %&gt;%
  distinct()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiSm9pbmluZywgYnkgPSBcImNvbnNvcnRpdW1JZFwiXG4ifQ== -->
<pre><code>Joining, by = &quot;consortiumId&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWVyZ2VkX3Byb2plY3RfZGZcbmBgYCJ9 -->
<pre class="r"><code>merged_project_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"ncol":7,"nrow":359},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["projectId"],"name":[1],"type":["chr"],"align":["left"]},{"label":["projectName"],"name":[2],"type":["chr"],"align":["left"]},{"label":["description"],"name":[3],"type":["chr"],"align":["left"]},{"label":["theme"],"name":[4],"type":["chr"],"align":["left"]},{"label":["grantName"],"name":[5],"type":["chr"],"align":["left"]},{"label":["consortium"],"name":[6],"type":["chr"],"align":["left"]},{"label":["grantType"],"name":[7],"type":["chr"],"align":["left"]}],"data":[{"1":"syn21645005","2":"Elucidating the regulatory logic that is responsible for maintaining cancer cell state, independent of specific initiating events and endogenous/exogenous perturbations","3":"[In project 1](https://systemsbiology.columbia.edu/cast-project-1), CaST is attempting to move beyond current approaches for elucidating tumor checkpoints and master regulators, which are largely static and not designed to predict how tumors respond to pharmacological and genomic perturbations over time. Thus, we are developing novel methodologies to mechanistically uncover the regulatory machinery that maintains cancer cell state and governs cell state transition. We are also working to define the role of regulatory networks in implementing distinct tumor phenotypes, from metastatic progression, to immunoevasion, to drug resistance. This effort will leverage and integrate time-course data from gene expression and computationally inferred protein activity profiles, generated by small molecules and RNAi/CRISPR perturbations.","4":"Heterogeneity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645005","2":"Elucidating the regulatory logic that is responsible for maintaining cancer cell state, independent of specific initiating events and endogenous/exogenous perturbations","3":"[In project 1](https://systemsbiology.columbia.edu/cast-project-1), CaST is attempting to move beyond current approaches for elucidating tumor checkpoints and master regulators, which are largely static and not designed to predict how tumors respond to pharmacological and genomic perturbations over time. Thus, we are developing novel methodologies to mechanistically uncover the regulatory machinery that maintains cancer cell state and governs cell state transition. We are also working to define the role of regulatory networks in implementing distinct tumor phenotypes, from metastatic progression, to immunoevasion, to drug resistance. This effort will leverage and integrate time-course data from gene expression and computationally inferred protein activity profiles, generated by small molecules and RNAi/CRISPR perturbations.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645006","2":"Elucidating time-dependent mechanisms of genetic and epigenetic reprogramming of individual cancer cells underlying cancer-state transitions to drug resistance and progression","3":"[In project 2](https://systemsbiology.columbia.edu/cast-project-2), we are investigating cell state plasticity and tumor/microenvironment heterogeneity, which represent formidable obstacles to successful treatment of human malignancies. This interest is driven by a growing awareness that tumors can harbor distinct niches that include genetically distinct subclones (which have identical or distinct tumor checkpoints), as well as isogenic niches (which present with orthogonal checkpoints). Our goal is to compile a comprehensive inventory of tumor dependencies among such heterogeneous niches that can be targeted pharmacologically, We are studying these mechanisms by developing new methods to identify distinct tumor compartments and heterogeneity at the single-cell level.","4":"Heterogeneity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645006","2":"Elucidating time-dependent mechanisms of genetic and epigenetic reprogramming of individual cancer cells underlying cancer-state transitions to drug resistance and progression","3":"[In project 2](https://systemsbiology.columbia.edu/cast-project-2), we are investigating cell state plasticity and tumor/microenvironment heterogeneity, which represent formidable obstacles to successful treatment of human malignancies. This interest is driven by a growing awareness that tumors can harbor distinct niches that include genetically distinct subclones (which have identical or distinct tumor checkpoints), as well as isogenic niches (which present with orthogonal checkpoints). Our goal is to compile a comprehensive inventory of tumor dependencies among such heterogeneous niches that can be targeted pharmacologically, We are studying these mechanisms by developing new methods to identify distinct tumor compartments and heterogeneity at the single-cell level.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645007","2":"Developing novel methodologies for the systematic prioritization of compounds and compound combinations capable of abrogating tumorigenesis in vivo","3":"[In project 3](https://systemsbiology.columbia.edu/cast-project-3), we are developing and validating computational methods for the prioritization of master regulator-targeting drugs and drug combinations to either implement or prevent specific tumor state transitions. This includes inducing irreversible commitment to cell death, preventing progression to a malignant tumor stage, and rescuing drug sensitivity. In addition, we are attempting to address a broad range of questions related to the heterogeneity of tumor response, including mechanisms that allow tumor cells to compensate for MR-targeted therapy. We propose that addressing tumor plasticity and potential escape routes implemented by tumor state reprograming is going to be critically relevant for the chronic management of cancer in patients.","4":"Heterogeneity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645007","2":"Developing novel methodologies for the systematic prioritization of compounds and compound combinations capable of abrogating tumorigenesis in vivo","3":"[In project 3](https://systemsbiology.columbia.edu/cast-project-3), we are developing and validating computational methods for the prioritization of master regulator-targeting drugs and drug combinations to either implement or prevent specific tumor state transitions. This includes inducing irreversible commitment to cell death, preventing progression to a malignant tumor stage, and rescuing drug sensitivity. In addition, we are attempting to address a broad range of questions related to the heterogeneity of tumor response, including mechanisms that allow tumor cells to compensate for MR-targeted therapy. We propose that addressing tumor plasticity and potential escape routes implemented by tumor state reprograming is going to be critically relevant for the chronic management of cancer in patients.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645008","2":"Center for Cancer Systems Therapeutics (CaST) Molecular Profiling","3":"A technical requirement for achieving CaST<U+201A><U+00C4><U+00F4>s scientific goals is access to cost-effective, cutting-edge [molecular profiling](https://systemsbiology.columbia.edu/cast-molecular-profiling-core), high-throughput screening, and single-cell analysis tools utilizing robotics and microfluidics. The Molecular Profiling Core (MPC) provides three key capabilities: nn1) PLATESeq: a novel platform for integrating high-throughput screening with genome-wide expression profiling; n2) microfluidics: a highly multiplexed, microfluidic implementation of PLATESeq that produces expression profiles across hundreds of single cells in parallel; n3) single-cell whole genome sequencing: a pipeline that combines microscopy-based single cell isolation with whole genome amplification for single-cell whole genome sequencing.","4":"Heterogeneity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645008","2":"Center for Cancer Systems Therapeutics (CaST) Molecular Profiling","3":"A technical requirement for achieving CaST<U+201A><U+00C4><U+00F4>s scientific goals is access to cost-effective, cutting-edge [molecular profiling](https://systemsbiology.columbia.edu/cast-molecular-profiling-core), high-throughput screening, and single-cell analysis tools utilizing robotics and microfluidics. The Molecular Profiling Core (MPC) provides three key capabilities: nn1) PLATESeq: a novel platform for integrating high-throughput screening with genome-wide expression profiling; n2) microfluidics: a highly multiplexed, microfluidic implementation of PLATESeq that produces expression profiles across hundreds of single cells in parallel; n3) single-cell whole genome sequencing: a pipeline that combines microscopy-based single cell isolation with whole genome amplification for single-cell whole genome sequencing.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645009","2":"Center for Cancer Systems Therapeutics (CaST) Outreach","3":"In addition to pursuing research, CaST conducts [outreach](https://systemsbiology.columbia.edu/cast-outreach-core) to disseminate the software and methods developed by the Center, foster discussion on related issues within the larger scientific community, support community-based research efforts, and mentor young scientists. These activities include:nn1) supporting the DREAM challenges; n2) a cross-training program to help investigators gain experience with complementary methods and perspectives; n3) a <U+201A><U+00C4><U+00FA>CaST Scholars<U+201A><U+00C4><U+00F9> program that enables undergraduate students to participate in our research; n4) organizing scientific meetings on related topics in cooperation with the New York Academy of Sciences Systems Biology Discussion Group.","4":"Heterogeneity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645009","2":"Center for Cancer Systems Therapeutics (CaST) Outreach","3":"In addition to pursuing research, CaST conducts [outreach](https://systemsbiology.columbia.edu/cast-outreach-core) to disseminate the software and methods developed by the Center, foster discussion on related issues within the larger scientific community, support community-based research efforts, and mentor young scientists. These activities include:nn1) supporting the DREAM challenges; n2) a cross-training program to help investigators gain experience with complementary methods and perspectives; n3) a <U+201A><U+00C4><U+00FA>CaST Scholars<U+201A><U+00C4><U+00F9> program that enables undergraduate students to participate in our research; n4) organizing scientific meetings on related topics in cooperation with the New York Academy of Sciences Systems Biology Discussion Group.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Therapeutics (CaST)","6":"CSBC","7":"U54"},{"1":"syn21645010","2":"Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis","3":"CD8 T cells are powerful components of the immune system that have the potential to selectively eradicate cancer cells. However, in most patients, tumors progress relentlessly despite the presence of tumor-specific CD8 T cells. We developed a genetic cancer mouse model that faithfully mirrors cancer development in patients and revealed that tumor-specific CD8 T cells enter a state of dysfunction early during tumorigenesis. These T cells exhibited the hallmarks of dysfunctional T cells from late-stage human tumors. Early after tumor initiation, T cell dysfunction was plastic, but at later times, became fixed. Breakthrough therapies (immune checkpoint blockade) have emerged to reverse T cell dysfunction but these strategies have only worked in a subset of patients and a subset of tumor types. The goal of Project 1 is to understand the co-evolutionary cancer cell, stromal and immune population dynamics that control T cell differentiation to different functional states and consequently, T cell sensitivity to immunotherapeutic interventions. We will leverage the power of clinically-relevant genetic cancer mouse models to dissect the complex interplay of cancer genomic evolution, immune and stromal cell population dynamics, and the molecular mechanisms controlling CD8 T cell differentiation using innovative single-cell transcriptional and epigenetic analytic tools and powerful mathematical modeling approaches. By bringing together considerable expertise in cancer immune mouse modeling, computational methods, and clinical immune checkpoint blockade therapy, these approaches will provide new insights into T cell differentiation and could reveal novel strategies to unleash the precise power of tumor-specific CD8 T cells for cancer immunotherapy.","4":"Tumor-Immune","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645010","2":"Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis","3":"CD8 T cells are powerful components of the immune system that have the potential to selectively eradicate cancer cells. However, in most patients, tumors progress relentlessly despite the presence of tumor-specific CD8 T cells. We developed a genetic cancer mouse model that faithfully mirrors cancer development in patients and revealed that tumor-specific CD8 T cells enter a state of dysfunction early during tumorigenesis. These T cells exhibited the hallmarks of dysfunctional T cells from late-stage human tumors. Early after tumor initiation, T cell dysfunction was plastic, but at later times, became fixed. Breakthrough therapies (immune checkpoint blockade) have emerged to reverse T cell dysfunction but these strategies have only worked in a subset of patients and a subset of tumor types. The goal of Project 1 is to understand the co-evolutionary cancer cell, stromal and immune population dynamics that control T cell differentiation to different functional states and consequently, T cell sensitivity to immunotherapeutic interventions. We will leverage the power of clinically-relevant genetic cancer mouse models to dissect the complex interplay of cancer genomic evolution, immune and stromal cell population dynamics, and the molecular mechanisms controlling CD8 T cell differentiation using innovative single-cell transcriptional and epigenetic analytic tools and powerful mathematical modeling approaches. By bringing together considerable expertise in cancer immune mouse modeling, computational methods, and clinical immune checkpoint blockade therapy, these approaches will provide new insights into T cell differentiation and could reveal novel strategies to unleash the precise power of tumor-specific CD8 T cells for cancer immunotherapy.","4":"Microenvironment","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645010","2":"Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis","3":"CD8 T cells are powerful components of the immune system that have the potential to selectively eradicate cancer cells. However, in most patients, tumors progress relentlessly despite the presence of tumor-specific CD8 T cells. We developed a genetic cancer mouse model that faithfully mirrors cancer development in patients and revealed that tumor-specific CD8 T cells enter a state of dysfunction early during tumorigenesis. These T cells exhibited the hallmarks of dysfunctional T cells from late-stage human tumors. Early after tumor initiation, T cell dysfunction was plastic, but at later times, became fixed. Breakthrough therapies (immune checkpoint blockade) have emerged to reverse T cell dysfunction but these strategies have only worked in a subset of patients and a subset of tumor types. The goal of Project 1 is to understand the co-evolutionary cancer cell, stromal and immune population dynamics that control T cell differentiation to different functional states and consequently, T cell sensitivity to immunotherapeutic interventions. We will leverage the power of clinically-relevant genetic cancer mouse models to dissect the complex interplay of cancer genomic evolution, immune and stromal cell population dynamics, and the molecular mechanisms controlling CD8 T cell differentiation using innovative single-cell transcriptional and epigenetic analytic tools and powerful mathematical modeling approaches. By bringing together considerable expertise in cancer immune mouse modeling, computational methods, and clinical immune checkpoint blockade therapy, these approaches will provide new insights into T cell differentiation and could reveal novel strategies to unleash the precise power of tumor-specific CD8 T cells for cancer immunotherapy.","4":"Drug Resistance/Sensitivity","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645010","2":"Tumor-specific T cell state dynamics and heterogeneity in early tumorigenesis","3":"CD8 T cells are powerful components of the immune system that have the potential to selectively eradicate cancer cells. However, in most patients, tumors progress relentlessly despite the presence of tumor-specific CD8 T cells. We developed a genetic cancer mouse model that faithfully mirrors cancer development in patients and revealed that tumor-specific CD8 T cells enter a state of dysfunction early during tumorigenesis. These T cells exhibited the hallmarks of dysfunctional T cells from late-stage human tumors. Early after tumor initiation, T cell dysfunction was plastic, but at later times, became fixed. Breakthrough therapies (immune checkpoint blockade) have emerged to reverse T cell dysfunction but these strategies have only worked in a subset of patients and a subset of tumor types. The goal of Project 1 is to understand the co-evolutionary cancer cell, stromal and immune population dynamics that control T cell differentiation to different functional states and consequently, T cell sensitivity to immunotherapeutic interventions. We will leverage the power of clinically-relevant genetic cancer mouse models to dissect the complex interplay of cancer genomic evolution, immune and stromal cell population dynamics, and the molecular mechanisms controlling CD8 T cell differentiation using innovative single-cell transcriptional and epigenetic analytic tools and powerful mathematical modeling approaches. By bringing together considerable expertise in cancer immune mouse modeling, computational methods, and clinical immune checkpoint blockade therapy, these approaches will provide new insights into T cell differentiation and could reveal novel strategies to unleash the precise power of tumor-specific CD8 T cells for cancer immunotherapy.","4":"Metastasis","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645011","2":"The tumor ecosystem in cancer progression and immunotherapeutic response","3":"The goal of Project 2 is to identify the ecological interactions between cancer and immune cells that govern cancer dynamics and response to therapy. We start from the idea that a tumor can be considered an ecosystem or organ, where multiple accessory cell types are interconnected and communicate with each other and with tumor cells, which serve as their clients. Through systems analysis and modeling of functional interactions in the tumor ecosystem on different scales including cellular, protein, metabolite, and gene expression dynamics at a population and single cell levels this proposal will seek to identify key cellular and molecular regulatory elements in the tumor microenvironment and potential means of their manipulation for therapeutic benefit. We will a) explore features of, and relationships between, multiple accessory cell types and tumor cells, in experimental models of skin and lung cancer in mice and in human cancer patients; b) use perturbation of the tumor ecology impacting its progression in mice and human patients by established and novel immunotherapeutic modalities including PD-1 and CTLA-4 blockade and Treg cell depletion; c) validate key interaction components in the tumor ecosystem by modeling cell-cell interactions _in vitro_ using tissue mimetic systems and _in silico_ using agent-based models.","4":"Tumor-Immune","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645011","2":"The tumor ecosystem in cancer progression and immunotherapeutic response","3":"The goal of Project 2 is to identify the ecological interactions between cancer and immune cells that govern cancer dynamics and response to therapy. We start from the idea that a tumor can be considered an ecosystem or organ, where multiple accessory cell types are interconnected and communicate with each other and with tumor cells, which serve as their clients. Through systems analysis and modeling of functional interactions in the tumor ecosystem on different scales including cellular, protein, metabolite, and gene expression dynamics at a population and single cell levels this proposal will seek to identify key cellular and molecular regulatory elements in the tumor microenvironment and potential means of their manipulation for therapeutic benefit. We will a) explore features of, and relationships between, multiple accessory cell types and tumor cells, in experimental models of skin and lung cancer in mice and in human cancer patients; b) use perturbation of the tumor ecology impacting its progression in mice and human patients by established and novel immunotherapeutic modalities including PD-1 and CTLA-4 blockade and Treg cell depletion; c) validate key interaction components in the tumor ecosystem by modeling cell-cell interactions _in vitro_ using tissue mimetic systems and _in silico_ using agent-based models.","4":"Microenvironment","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645011","2":"The tumor ecosystem in cancer progression and immunotherapeutic response","3":"The goal of Project 2 is to identify the ecological interactions between cancer and immune cells that govern cancer dynamics and response to therapy. We start from the idea that a tumor can be considered an ecosystem or organ, where multiple accessory cell types are interconnected and communicate with each other and with tumor cells, which serve as their clients. Through systems analysis and modeling of functional interactions in the tumor ecosystem on different scales including cellular, protein, metabolite, and gene expression dynamics at a population and single cell levels this proposal will seek to identify key cellular and molecular regulatory elements in the tumor microenvironment and potential means of their manipulation for therapeutic benefit. We will a) explore features of, and relationships between, multiple accessory cell types and tumor cells, in experimental models of skin and lung cancer in mice and in human cancer patients; b) use perturbation of the tumor ecology impacting its progression in mice and human patients by established and novel immunotherapeutic modalities including PD-1 and CTLA-4 blockade and Treg cell depletion; c) validate key interaction components in the tumor ecosystem by modeling cell-cell interactions _in vitro_ using tissue mimetic systems and _in silico_ using agent-based models.","4":"Drug Resistance/Sensitivity","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645011","2":"The tumor ecosystem in cancer progression and immunotherapeutic response","3":"The goal of Project 2 is to identify the ecological interactions between cancer and immune cells that govern cancer dynamics and response to therapy. We start from the idea that a tumor can be considered an ecosystem or organ, where multiple accessory cell types are interconnected and communicate with each other and with tumor cells, which serve as their clients. Through systems analysis and modeling of functional interactions in the tumor ecosystem on different scales including cellular, protein, metabolite, and gene expression dynamics at a population and single cell levels this proposal will seek to identify key cellular and molecular regulatory elements in the tumor microenvironment and potential means of their manipulation for therapeutic benefit. We will a) explore features of, and relationships between, multiple accessory cell types and tumor cells, in experimental models of skin and lung cancer in mice and in human cancer patients; b) use perturbation of the tumor ecology impacting its progression in mice and human patients by established and novel immunotherapeutic modalities including PD-1 and CTLA-4 blockade and Treg cell depletion; c) validate key interaction components in the tumor ecosystem by modeling cell-cell interactions _in vitro_ using tissue mimetic systems and _in silico_ using agent-based models.","4":"Metastasis","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645012","2":"Latent metastasis: immune regulation of disseminated cancer stem cells","3":"The goal of Project 3 is to discover mechanisms that critically regulate immune evasion by disseminated tumor cells (DTCs) and their evolution as latent metastatic entities. We will use an integrated approach that combines single-cell interrogation methods with unique biological models of latent metastasis from breast cancer and lung adenocarcinoma, and novel computational strategies. Distant metastasis underlies the overwhelming majority of cancer-related deaths and its inception is exceedingly variable. Residual DTCs may outgrow immediately or, more frequently, linger in a viable state of replicative quiescence or mass dormancy for months to years after infiltrating distant organs. This latency state of DTCs is accompanied with significant resistance to anti-neoplastic therapy, which typically targets actively dividing tumor cells. Moreover, latent DTCs somehow evade immune surveillance. The biology underlying these adaptive abilities remains poorly understood and factors governing DTC population dynamics, whether stochastic or deterministic, remain unknown. We aim to address this significant knowledge gap by combining massively parallel, single-cell RNA expression profiling using a bead-based molecular barcoding technology with unsupervised learning methods to identify stable/transitory cell states within latent, residual disease and their molecular control mechanisms. As a complementary approach, individual cell responses to molecular perturbations will be dynamically tracked by live cell imaging.","4":"Tumor-Immune","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645012","2":"Latent metastasis: immune regulation of disseminated cancer stem cells","3":"The goal of Project 3 is to discover mechanisms that critically regulate immune evasion by disseminated tumor cells (DTCs) and their evolution as latent metastatic entities. We will use an integrated approach that combines single-cell interrogation methods with unique biological models of latent metastasis from breast cancer and lung adenocarcinoma, and novel computational strategies. Distant metastasis underlies the overwhelming majority of cancer-related deaths and its inception is exceedingly variable. Residual DTCs may outgrow immediately or, more frequently, linger in a viable state of replicative quiescence or mass dormancy for months to years after infiltrating distant organs. This latency state of DTCs is accompanied with significant resistance to anti-neoplastic therapy, which typically targets actively dividing tumor cells. Moreover, latent DTCs somehow evade immune surveillance. The biology underlying these adaptive abilities remains poorly understood and factors governing DTC population dynamics, whether stochastic or deterministic, remain unknown. We aim to address this significant knowledge gap by combining massively parallel, single-cell RNA expression profiling using a bead-based molecular barcoding technology with unsupervised learning methods to identify stable/transitory cell states within latent, residual disease and their molecular control mechanisms. As a complementary approach, individual cell responses to molecular perturbations will be dynamically tracked by live cell imaging.","4":"Microenvironment","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645012","2":"Latent metastasis: immune regulation of disseminated cancer stem cells","3":"The goal of Project 3 is to discover mechanisms that critically regulate immune evasion by disseminated tumor cells (DTCs) and their evolution as latent metastatic entities. We will use an integrated approach that combines single-cell interrogation methods with unique biological models of latent metastasis from breast cancer and lung adenocarcinoma, and novel computational strategies. Distant metastasis underlies the overwhelming majority of cancer-related deaths and its inception is exceedingly variable. Residual DTCs may outgrow immediately or, more frequently, linger in a viable state of replicative quiescence or mass dormancy for months to years after infiltrating distant organs. This latency state of DTCs is accompanied with significant resistance to anti-neoplastic therapy, which typically targets actively dividing tumor cells. Moreover, latent DTCs somehow evade immune surveillance. The biology underlying these adaptive abilities remains poorly understood and factors governing DTC population dynamics, whether stochastic or deterministic, remain unknown. We aim to address this significant knowledge gap by combining massively parallel, single-cell RNA expression profiling using a bead-based molecular barcoding technology with unsupervised learning methods to identify stable/transitory cell states within latent, residual disease and their molecular control mechanisms. As a complementary approach, individual cell responses to molecular perturbations will be dynamically tracked by live cell imaging.","4":"Drug Resistance/Sensitivity","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645012","2":"Latent metastasis: immune regulation of disseminated cancer stem cells","3":"The goal of Project 3 is to discover mechanisms that critically regulate immune evasion by disseminated tumor cells (DTCs) and their evolution as latent metastatic entities. We will use an integrated approach that combines single-cell interrogation methods with unique biological models of latent metastasis from breast cancer and lung adenocarcinoma, and novel computational strategies. Distant metastasis underlies the overwhelming majority of cancer-related deaths and its inception is exceedingly variable. Residual DTCs may outgrow immediately or, more frequently, linger in a viable state of replicative quiescence or mass dormancy for months to years after infiltrating distant organs. This latency state of DTCs is accompanied with significant resistance to anti-neoplastic therapy, which typically targets actively dividing tumor cells. Moreover, latent DTCs somehow evade immune surveillance. The biology underlying these adaptive abilities remains poorly understood and factors governing DTC population dynamics, whether stochastic or deterministic, remain unknown. We aim to address this significant knowledge gap by combining massively parallel, single-cell RNA expression profiling using a bead-based molecular barcoding technology with unsupervised learning methods to identify stable/transitory cell states within latent, residual disease and their molecular control mechanisms. As a complementary approach, individual cell responses to molecular perturbations will be dynamically tracked by live cell imaging.","4":"Metastasis","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645013","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Single-cell sequencing technology and computational analysis","3":"The Research Center<U+201A><U+00C4><U+00F4>s Shared Resource Core will provide a broadly applicable set of experimental technologies and computational tools for high-throughput single-cell RNA-seq (scRNA-seq) of heterogeneous populations. xa0Single-cell resolution is crucial for elucidating the functional cell subpopulations in both the tumor and its immune microenvironment and moreover can be harnessed to elucidate regulatory relationships within and between these cell subpopulations. The Shared Resource will provide the computation, visualization and analysis methods needed to interpret the collected single cell data and integrate it with other measurement modalities.","4":"Tumor-Immune","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645013","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Single-cell sequencing technology and computational analysis","3":"The Research Center<U+201A><U+00C4><U+00F4>s Shared Resource Core will provide a broadly applicable set of experimental technologies and computational tools for high-throughput single-cell RNA-seq (scRNA-seq) of heterogeneous populations. xa0Single-cell resolution is crucial for elucidating the functional cell subpopulations in both the tumor and its immune microenvironment and moreover can be harnessed to elucidate regulatory relationships within and between these cell subpopulations. The Shared Resource will provide the computation, visualization and analysis methods needed to interpret the collected single cell data and integrate it with other measurement modalities.","4":"Microenvironment","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645013","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Single-cell sequencing technology and computational analysis","3":"The Research Center<U+201A><U+00C4><U+00F4>s Shared Resource Core will provide a broadly applicable set of experimental technologies and computational tools for high-throughput single-cell RNA-seq (scRNA-seq) of heterogeneous populations. xa0Single-cell resolution is crucial for elucidating the functional cell subpopulations in both the tumor and its immune microenvironment and moreover can be harnessed to elucidate regulatory relationships within and between these cell subpopulations. The Shared Resource will provide the computation, visualization and analysis methods needed to interpret the collected single cell data and integrate it with other measurement modalities.","4":"Drug Resistance/Sensitivity","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645013","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Single-cell sequencing technology and computational analysis","3":"The Research Center<U+201A><U+00C4><U+00F4>s Shared Resource Core will provide a broadly applicable set of experimental technologies and computational tools for high-throughput single-cell RNA-seq (scRNA-seq) of heterogeneous populations. xa0Single-cell resolution is crucial for elucidating the functional cell subpopulations in both the tumor and its immune microenvironment and moreover can be harnessed to elucidate regulatory relationships within and between these cell subpopulations. The Shared Resource will provide the computation, visualization and analysis methods needed to interpret the collected single cell data and integrate it with other measurement modalities.","4":"Metastasis","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645014","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Outreach","3":"The CSBC Research Center for Cancer Systems Immunology at MSKCC outreach program will encompass undergraduate and graduate education and cross-training in systems biology and immunology, computational biology, and bioinformatics, and will focus on scientific outreach within the local, national and international scientific communities. Our local scientific community is strengthened by MSKCC<U+201A><U+00C4><U+00F4>s close relationship with Weill Cornell Medical College and Rockefeller University under the Tri-Institutional partnership. Our Center will include this unique community in nearly all of our education and outreach efforts. The broad aim of the Outreach Core is to disseminate the importance of cancer-immune interactions in cancer progression and immunotherapy, both to the public as well as to the broad scientific community, with particular focus on students that will become the next generation of cancer systems biologists.","4":"Tumor-Immune","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645014","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Outreach","3":"The CSBC Research Center for Cancer Systems Immunology at MSKCC outreach program will encompass undergraduate and graduate education and cross-training in systems biology and immunology, computational biology, and bioinformatics, and will focus on scientific outreach within the local, national and international scientific communities. Our local scientific community is strengthened by MSKCC<U+201A><U+00C4><U+00F4>s close relationship with Weill Cornell Medical College and Rockefeller University under the Tri-Institutional partnership. Our Center will include this unique community in nearly all of our education and outreach efforts. The broad aim of the Outreach Core is to disseminate the importance of cancer-immune interactions in cancer progression and immunotherapy, both to the public as well as to the broad scientific community, with particular focus on students that will become the next generation of cancer systems biologists.","4":"Microenvironment","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645014","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Outreach","3":"The CSBC Research Center for Cancer Systems Immunology at MSKCC outreach program will encompass undergraduate and graduate education and cross-training in systems biology and immunology, computational biology, and bioinformatics, and will focus on scientific outreach within the local, national and international scientific communities. Our local scientific community is strengthened by MSKCC<U+201A><U+00C4><U+00F4>s close relationship with Weill Cornell Medical College and Rockefeller University under the Tri-Institutional partnership. Our Center will include this unique community in nearly all of our education and outreach efforts. The broad aim of the Outreach Core is to disseminate the importance of cancer-immune interactions in cancer progression and immunotherapy, both to the public as well as to the broad scientific community, with particular focus on students that will become the next generation of cancer systems biologists.","4":"Drug Resistance/Sensitivity","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645014","2":"CSBC Research Center for Cancer Systems Immunology at MSKCC Outreach","3":"The CSBC Research Center for Cancer Systems Immunology at MSKCC outreach program will encompass undergraduate and graduate education and cross-training in systems biology and immunology, computational biology, and bioinformatics, and will focus on scientific outreach within the local, national and international scientific communities. Our local scientific community is strengthened by MSKCC<U+201A><U+00C4><U+00F4>s close relationship with Weill Cornell Medical College and Rockefeller University under the Tri-Institutional partnership. Our Center will include this unique community in nearly all of our education and outreach efforts. The broad aim of the Outreach Core is to disseminate the importance of cancer-immune interactions in cancer progression and immunotherapy, both to the public as well as to the broad scientific community, with particular focus on students that will become the next generation of cancer systems biologists.","4":"Metastasis","5":"CSBC Research Center for Cancer Systems Immunology at MSKCC","6":"CSBC","7":"U54"},{"1":"syn21645015","2":"Murine modeling of tumor-mediated immunosuppression","3":"We hypothesize that lymph node (LN) metastasis constitutes an essential step in the metastatic cascade of melanomas and head and neck tumors in that such metastases act locally upon the adaptive immune system within the nodes to induce tolerance to the tumor and that leukocytes recirculating from these nodes carry the tolerance to distant sites. Our objectives are to establish whether LN metastases induce perturbations in anti-tumor immunity and to identify the mechanisms of these perturbations. We will a) characterize differences in local and systemic immune responses to metastatic tumors; b) identify differential regulators of tolerance induction by metastatic cells through the use of genomic profiling; and c) identify the molecular mediators of metastatic tolerance induction in mice and humans. Through the use of serial in vivo passaging, we have developed a panel of syngeneic melanoma cell lines that exhibit enhanced LN metastatic potential. We will compare the activation states of these immune cells, cytokine profiles, T cell polarization, and cytolytic activity toward tumor cells using single cell proteomic methods (Project 2). Using cytokine profiling and RNA sequencing on the lines, we will apply computational systems biology approaches (Project 3) to identify the molecules relevant for induction of tolerance. If our hypothesis is proven correct that LN metastasis is an obligate step in the generation of systemic disease due to tolerance induction, targeting the molecules responsible for LN metastasis induced tolerance could prevent and treat metastatic disease.","4":"Tumor-Immune","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645015","2":"Murine modeling of tumor-mediated immunosuppression","3":"We hypothesize that lymph node (LN) metastasis constitutes an essential step in the metastatic cascade of melanomas and head and neck tumors in that such metastases act locally upon the adaptive immune system within the nodes to induce tolerance to the tumor and that leukocytes recirculating from these nodes carry the tolerance to distant sites. Our objectives are to establish whether LN metastases induce perturbations in anti-tumor immunity and to identify the mechanisms of these perturbations. We will a) characterize differences in local and systemic immune responses to metastatic tumors; b) identify differential regulators of tolerance induction by metastatic cells through the use of genomic profiling; and c) identify the molecular mediators of metastatic tolerance induction in mice and humans. Through the use of serial in vivo passaging, we have developed a panel of syngeneic melanoma cell lines that exhibit enhanced LN metastatic potential. We will compare the activation states of these immune cells, cytokine profiles, T cell polarization, and cytolytic activity toward tumor cells using single cell proteomic methods (Project 2). Using cytokine profiling and RNA sequencing on the lines, we will apply computational systems biology approaches (Project 3) to identify the molecules relevant for induction of tolerance. If our hypothesis is proven correct that LN metastasis is an obligate step in the generation of systemic disease due to tolerance induction, targeting the molecules responsible for LN metastasis induced tolerance could prevent and treat metastatic disease.","4":"Metastasis","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645015","2":"Murine modeling of tumor-mediated immunosuppression","3":"We hypothesize that lymph node (LN) metastasis constitutes an essential step in the metastatic cascade of melanomas and head and neck tumors in that such metastases act locally upon the adaptive immune system within the nodes to induce tolerance to the tumor and that leukocytes recirculating from these nodes carry the tolerance to distant sites. Our objectives are to establish whether LN metastases induce perturbations in anti-tumor immunity and to identify the mechanisms of these perturbations. We will a) characterize differences in local and systemic immune responses to metastatic tumors; b) identify differential regulators of tolerance induction by metastatic cells through the use of genomic profiling; and c) identify the molecular mediators of metastatic tolerance induction in mice and humans. Through the use of serial in vivo passaging, we have developed a panel of syngeneic melanoma cell lines that exhibit enhanced LN metastatic potential. We will compare the activation states of these immune cells, cytokine profiles, T cell polarization, and cytolytic activity toward tumor cells using single cell proteomic methods (Project 2). Using cytokine profiling and RNA sequencing on the lines, we will apply computational systems biology approaches (Project 3) to identify the molecules relevant for induction of tolerance. If our hypothesis is proven correct that LN metastasis is an obligate step in the generation of systemic disease due to tolerance induction, targeting the molecules responsible for LN metastasis induced tolerance could prevent and treat metastatic disease.","4":"Microenvironment","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645016","2":"Spatial architecture of tumor-mediated immunosuppression","3":"Beyond the internal genomic and epigenetic events that occur to drive a cell towards outright carcinogenesis and then metastasis, there co-exist the ordered events a cancer imposes on immune cells it encounters on its progression towards advanced disease. Induction of tolerance, avoidance of apoptosis, and even recruitment of the immune system to aid a tumor<U+201A><U+00C4><U+00F4>s growth are all poorly understood processes. We propose to undertake deep phenotyping of the 2D and 3D architecture of tumour-lymph node micro-environment<U+201A><U+00C4><U+00EE>wherein it is expected some of the initial phases of the tumor<U+201A><U+00C4><U+00F4>s avoidance and recruitment mechanisms are implemented. How is the architecture of the immune environment disrupted in the face of tumor metastasis? Are their micro-communities (as defined by particular cell-cell interactions) whose presence or absence defines an outcome in progression of the tumor? To this end we have developed a technology (ABSeq) that enables us to sensitively and quantitatively image tumors with 60 markers per 3 hours (scalable to 480 in a time-dependent manner) with markers selected from a range of intracellular or surface epitopes (recognized by antibodies) or RNAs. The hypothesis is that an orchestrated corruption of immune surveillance is initiated by cancers as they progress, and that the micro-scale architecture of the lymph node (by way of which cells are talking to whom and what broader effects occur across the lymph node and beyond) is disrupted in a defined manner. A major aim of the research is to, with ABSeq, define the 2D and 3D architecture and communities of immune and cancer cells in draining lymph nodes from 2 cancers (melanoma and head and neck cancer) in murine models and with human samples. Databases of 2D and 3D microenvironments will be publicly created and mined for associations that define the architectural changes that occur as tumors progress and initiate tolerance.","4":"Tumor-Immune","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645016","2":"Spatial architecture of tumor-mediated immunosuppression","3":"Beyond the internal genomic and epigenetic events that occur to drive a cell towards outright carcinogenesis and then metastasis, there co-exist the ordered events a cancer imposes on immune cells it encounters on its progression towards advanced disease. Induction of tolerance, avoidance of apoptosis, and even recruitment of the immune system to aid a tumor<U+201A><U+00C4><U+00F4>s growth are all poorly understood processes. We propose to undertake deep phenotyping of the 2D and 3D architecture of tumour-lymph node micro-environment<U+201A><U+00C4><U+00EE>wherein it is expected some of the initial phases of the tumor<U+201A><U+00C4><U+00F4>s avoidance and recruitment mechanisms are implemented. How is the architecture of the immune environment disrupted in the face of tumor metastasis? Are their micro-communities (as defined by particular cell-cell interactions) whose presence or absence defines an outcome in progression of the tumor? To this end we have developed a technology (ABSeq) that enables us to sensitively and quantitatively image tumors with 60 markers per 3 hours (scalable to 480 in a time-dependent manner) with markers selected from a range of intracellular or surface epitopes (recognized by antibodies) or RNAs. The hypothesis is that an orchestrated corruption of immune surveillance is initiated by cancers as they progress, and that the micro-scale architecture of the lymph node (by way of which cells are talking to whom and what broader effects occur across the lymph node and beyond) is disrupted in a defined manner. A major aim of the research is to, with ABSeq, define the 2D and 3D architecture and communities of immune and cancer cells in draining lymph nodes from 2 cancers (melanoma and head and neck cancer) in murine models and with human samples. Databases of 2D and 3D microenvironments will be publicly created and mined for associations that define the architectural changes that occur as tumors progress and initiate tolerance.","4":"Metastasis","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645016","2":"Spatial architecture of tumor-mediated immunosuppression","3":"Beyond the internal genomic and epigenetic events that occur to drive a cell towards outright carcinogenesis and then metastasis, there co-exist the ordered events a cancer imposes on immune cells it encounters on its progression towards advanced disease. Induction of tolerance, avoidance of apoptosis, and even recruitment of the immune system to aid a tumor<U+201A><U+00C4><U+00F4>s growth are all poorly understood processes. We propose to undertake deep phenotyping of the 2D and 3D architecture of tumour-lymph node micro-environment<U+201A><U+00C4><U+00EE>wherein it is expected some of the initial phases of the tumor<U+201A><U+00C4><U+00F4>s avoidance and recruitment mechanisms are implemented. How is the architecture of the immune environment disrupted in the face of tumor metastasis? Are their micro-communities (as defined by particular cell-cell interactions) whose presence or absence defines an outcome in progression of the tumor? To this end we have developed a technology (ABSeq) that enables us to sensitively and quantitatively image tumors with 60 markers per 3 hours (scalable to 480 in a time-dependent manner) with markers selected from a range of intracellular or surface epitopes (recognized by antibodies) or RNAs. The hypothesis is that an orchestrated corruption of immune surveillance is initiated by cancers as they progress, and that the micro-scale architecture of the lymph node (by way of which cells are talking to whom and what broader effects occur across the lymph node and beyond) is disrupted in a defined manner. A major aim of the research is to, with ABSeq, define the 2D and 3D architecture and communities of immune and cancer cells in draining lymph nodes from 2 cancers (melanoma and head and neck cancer) in murine models and with human samples. Databases of 2D and 3D microenvironments will be publicly created and mined for associations that define the architectural changes that occur as tumors progress and initiate tolerance.","4":"Microenvironment","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645017","2":"Integrative computational modeling of tumor-mediated immunosuppression","3":"We will develop and apply computational tools to integrate the complex datasets generated by our Center in order to identify candidate mediators of tumor-immune interactions that induce immunosuppression for functional validation. To enrich our ability for interpretation, we will explore signatures of the immune system in a pan-cancer analysis using the TCGA datasets annotated with time to distant metastasis, in the context of node-negative and nodepositive patients. We hypothesize that pan-cancer genes whose expression is strongly associated with time to distant metastasis are more likely to be associated with tumor-intrinsic or microenvironmental processes driving metastasis progression, thus we will prioritize these genes in our integrative computational analysis of our melanoma and head and neck squamous cell carcinoma datasets. Using the RNAseq data generated by our study, we will develop and apply novel network-based computational methods for reconstructing the interactions between malignant and immune subpopulations. Moreover, we will develop and apply new approaches to integrate the spatial information from high dimensional single cell in situ images from Project 2 with the gene expression datasets to further refine our inferences of candidate mediators of immunosuppression. The datasets and computational resources developed by our Project, and Center at large, will not only enable use to deeply explore the role of lymph nodes in tumor-mediated immunosuppression, but will also provide the community with powerful resources for understanding systemic influences on the forces governing metastatic dissemination.","4":"Tumor-Immune","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645017","2":"Integrative computational modeling of tumor-mediated immunosuppression","3":"We will develop and apply computational tools to integrate the complex datasets generated by our Center in order to identify candidate mediators of tumor-immune interactions that induce immunosuppression for functional validation. To enrich our ability for interpretation, we will explore signatures of the immune system in a pan-cancer analysis using the TCGA datasets annotated with time to distant metastasis, in the context of node-negative and nodepositive patients. We hypothesize that pan-cancer genes whose expression is strongly associated with time to distant metastasis are more likely to be associated with tumor-intrinsic or microenvironmental processes driving metastasis progression, thus we will prioritize these genes in our integrative computational analysis of our melanoma and head and neck squamous cell carcinoma datasets. Using the RNAseq data generated by our study, we will develop and apply novel network-based computational methods for reconstructing the interactions between malignant and immune subpopulations. Moreover, we will develop and apply new approaches to integrate the spatial information from high dimensional single cell in situ images from Project 2 with the gene expression datasets to further refine our inferences of candidate mediators of immunosuppression. The datasets and computational resources developed by our Project, and Center at large, will not only enable use to deeply explore the role of lymph nodes in tumor-mediated immunosuppression, but will also provide the community with powerful resources for understanding systemic influences on the forces governing metastatic dissemination.","4":"Metastasis","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645017","2":"Integrative computational modeling of tumor-mediated immunosuppression","3":"We will develop and apply computational tools to integrate the complex datasets generated by our Center in order to identify candidate mediators of tumor-immune interactions that induce immunosuppression for functional validation. To enrich our ability for interpretation, we will explore signatures of the immune system in a pan-cancer analysis using the TCGA datasets annotated with time to distant metastasis, in the context of node-negative and nodepositive patients. We hypothesize that pan-cancer genes whose expression is strongly associated with time to distant metastasis are more likely to be associated with tumor-intrinsic or microenvironmental processes driving metastasis progression, thus we will prioritize these genes in our integrative computational analysis of our melanoma and head and neck squamous cell carcinoma datasets. Using the RNAseq data generated by our study, we will develop and apply novel network-based computational methods for reconstructing the interactions between malignant and immune subpopulations. Moreover, we will develop and apply new approaches to integrate the spatial information from high dimensional single cell in situ images from Project 2 with the gene expression datasets to further refine our inferences of candidate mediators of immunosuppression. The datasets and computational resources developed by our Project, and Center at large, will not only enable use to deeply explore the role of lymph nodes in tumor-mediated immunosuppression, but will also provide the community with powerful resources for understanding systemic influences on the forces governing metastatic dissemination.","4":"Microenvironment","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645018","2":"Stanford University Center for Cancer Systems Biology Biospecimen and Data Management","3":"Our Biospecimen and Data Management Core will be utilized by all the Research Projects in our Center. All three Research Projects aim to identify mechanisms by which tumor cells, metastatic to regional lymph nodes, interface with the host immune system to perturb systemic immunity to induce global immune tolerance. While we will methodically study this process in murine models (Project 1), analysis of human tumor and lymph node specimens is paramount for two primary reasons. The first reason is to ensure the translation of the murine discovery approach to human disease. The second reason is to facilitate the discovery of critical mediators of tumor-induced immunosuppression directly from the human samples, then follow with functional validation in our murine models. Hence it is critical that we establish the necessary infrastructure to procure viable human tumor specimens and autologous immune tumorinfiltrating immune cells. Importantly, matched sets of fresh primary tumor cells, metastatic tumor cells, tumor-infiltrating immune cells (from the primary tumor and the lymph nodes) and circulating immune cells will be collected to address the hypotheses and goals of the Research Projects. Furthermore, in this shared core, a database of clinical annotation (aka clinical metadata) for these matched samples will be created and maintained. This clinical metadata is critical for interpretation of our molecular and imaging data given tumor and patient heterogeneity and will likely provide important insight into how the data generated by the proposed projects may be used to guide treatment and predict outcome. Our proposed Biospecimen and Data Management Core that will focus on collecting tissue and collating all the molecular data on our two index cancer models: melanoma and head and neck squamous cell carcinoma (HNSCC).","4":"Tumor-Immune","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645018","2":"Stanford University Center for Cancer Systems Biology Biospecimen and Data Management","3":"Our Biospecimen and Data Management Core will be utilized by all the Research Projects in our Center. All three Research Projects aim to identify mechanisms by which tumor cells, metastatic to regional lymph nodes, interface with the host immune system to perturb systemic immunity to induce global immune tolerance. While we will methodically study this process in murine models (Project 1), analysis of human tumor and lymph node specimens is paramount for two primary reasons. The first reason is to ensure the translation of the murine discovery approach to human disease. The second reason is to facilitate the discovery of critical mediators of tumor-induced immunosuppression directly from the human samples, then follow with functional validation in our murine models. Hence it is critical that we establish the necessary infrastructure to procure viable human tumor specimens and autologous immune tumorinfiltrating immune cells. Importantly, matched sets of fresh primary tumor cells, metastatic tumor cells, tumor-infiltrating immune cells (from the primary tumor and the lymph nodes) and circulating immune cells will be collected to address the hypotheses and goals of the Research Projects. Furthermore, in this shared core, a database of clinical annotation (aka clinical metadata) for these matched samples will be created and maintained. This clinical metadata is critical for interpretation of our molecular and imaging data given tumor and patient heterogeneity and will likely provide important insight into how the data generated by the proposed projects may be used to guide treatment and predict outcome. Our proposed Biospecimen and Data Management Core that will focus on collecting tissue and collating all the molecular data on our two index cancer models: melanoma and head and neck squamous cell carcinoma (HNSCC).","4":"Metastasis","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645018","2":"Stanford University Center for Cancer Systems Biology Biospecimen and Data Management","3":"Our Biospecimen and Data Management Core will be utilized by all the Research Projects in our Center. All three Research Projects aim to identify mechanisms by which tumor cells, metastatic to regional lymph nodes, interface with the host immune system to perturb systemic immunity to induce global immune tolerance. While we will methodically study this process in murine models (Project 1), analysis of human tumor and lymph node specimens is paramount for two primary reasons. The first reason is to ensure the translation of the murine discovery approach to human disease. The second reason is to facilitate the discovery of critical mediators of tumor-induced immunosuppression directly from the human samples, then follow with functional validation in our murine models. Hence it is critical that we establish the necessary infrastructure to procure viable human tumor specimens and autologous immune tumorinfiltrating immune cells. Importantly, matched sets of fresh primary tumor cells, metastatic tumor cells, tumor-infiltrating immune cells (from the primary tumor and the lymph nodes) and circulating immune cells will be collected to address the hypotheses and goals of the Research Projects. Furthermore, in this shared core, a database of clinical annotation (aka clinical metadata) for these matched samples will be created and maintained. This clinical metadata is critical for interpretation of our molecular and imaging data given tumor and patient heterogeneity and will likely provide important insight into how the data generated by the proposed projects may be used to guide treatment and predict outcome. Our proposed Biospecimen and Data Management Core that will focus on collecting tissue and collating all the molecular data on our two index cancer models: melanoma and head and neck squamous cell carcinoma (HNSCC).","4":"Microenvironment","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645019","2":"Stanford University Center for Cancer Systems Biology Outreach","3":"Stanford University has a diverse range of faculty in biostatistics, computer science, applied mathematics, cancer biology, immunology, biomedical engineering and many other disciplines. A number of transformative technologies such as DNA microarrays, flow cytometry, single cell transcriptomics, and applications of next generation sequencing had their genesis in labs here. We are therefore in a unique environment for promoting cancer systems biology to a wide audience of researchers, the relevance of whose expertise to the field may not be obvious a priori. We envisage that our efforts to promote our research and those of others to the Stanford community will seed new collaborations across disciplines. We will conduct outreach through regular seminar series and meetings, an annual symposium, funding for pilot projects, as well as participation in the CSBC Postdoctoral Exchange Program that will place researchers at reciprocal institutions to have short-term dense exposure to relevant research objectives and expertise at other institutions. And finally, important collaborative possibilities with the other CSBC Research Centers will be facilitated by their updates provided at annual meetings, as well as in our newsletter. The great value of this new NCI Consortium will be harnessed by ongoing building of an expansive investigator network across universities and research centers.","4":"Tumor-Immune","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645019","2":"Stanford University Center for Cancer Systems Biology Outreach","3":"Stanford University has a diverse range of faculty in biostatistics, computer science, applied mathematics, cancer biology, immunology, biomedical engineering and many other disciplines. A number of transformative technologies such as DNA microarrays, flow cytometry, single cell transcriptomics, and applications of next generation sequencing had their genesis in labs here. We are therefore in a unique environment for promoting cancer systems biology to a wide audience of researchers, the relevance of whose expertise to the field may not be obvious a priori. We envisage that our efforts to promote our research and those of others to the Stanford community will seed new collaborations across disciplines. We will conduct outreach through regular seminar series and meetings, an annual symposium, funding for pilot projects, as well as participation in the CSBC Postdoctoral Exchange Program that will place researchers at reciprocal institutions to have short-term dense exposure to relevant research objectives and expertise at other institutions. And finally, important collaborative possibilities with the other CSBC Research Centers will be facilitated by their updates provided at annual meetings, as well as in our newsletter. The great value of this new NCI Consortium will be harnessed by ongoing building of an expansive investigator network across universities and research centers.","4":"Metastasis","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645019","2":"Stanford University Center for Cancer Systems Biology Outreach","3":"Stanford University has a diverse range of faculty in biostatistics, computer science, applied mathematics, cancer biology, immunology, biomedical engineering and many other disciplines. A number of transformative technologies such as DNA microarrays, flow cytometry, single cell transcriptomics, and applications of next generation sequencing had their genesis in labs here. We are therefore in a unique environment for promoting cancer systems biology to a wide audience of researchers, the relevance of whose expertise to the field may not be obvious a priori. We envisage that our efforts to promote our research and those of others to the Stanford community will seed new collaborations across disciplines. We will conduct outreach through regular seminar series and meetings, an annual symposium, funding for pilot projects, as well as participation in the CSBC Postdoctoral Exchange Program that will place researchers at reciprocal institutions to have short-term dense exposure to relevant research objectives and expertise at other institutions. And finally, important collaborative possibilities with the other CSBC Research Centers will be facilitated by their updates provided at annual meetings, as well as in our newsletter. The great value of this new NCI Consortium will be harnessed by ongoing building of an expansive investigator network across universities and research centers.","4":"Microenvironment","5":"Stanford University Center for Cancer Systems Biology","6":"CSBC","7":"U54"},{"1":"syn21645020","2":"Analysis of Cell Autonomous Mechanisms of Phenotypic Plasticity in Invasive Cell Spread","3":"The goal of this project is to obtain a better quantitative understanding of the complex regulation and characteristic of the invasive phenotypic state. The analysis in the project is aimed at the cell autonomous view of regulation, without explicit emphasis of cell-cell interactions. We will combine a variety of tools and approaches, including combining experimentation and mathematical modeling.nn&nbsp;nnWe are able to separate slow moving, proliferative cells from fast moving, migratory cells (and enrich each phenotype) using a <U+201A><U+00C4><U+00FA>phenotypic filter<U+201A><U+00C4><U+00F9> through an assay called Rapid Analysis of Cell migration Enhancement (RACE). This assay employs nano-fabricated surfaces that result in rapid and highly oriented cell migration. Preliminary results using RACE not only suggest that the assay can help identify molecular mechanisms of the Proliferative-to-Aggressive phenotypic switch but have also led us to develop a preliminary mathematical model describing how specific kinases, thought to be activated by the same growth factors, can be differentially active in different cell sub-populations. In addition, using synthetic biology techniques, we have created a new platform for generating novel kinase inhibitors that can be used to, for the first time, target kinases considered to be <U+201A><U+00C4><U+00FA>difficult<U+201A><U+00C4><U+00F9> to target due to their orphan status and unclear regulation mechanisms. When possible, the mechanistic significance in cancer invasion and spreading of newly identified and targeted kinases will be examined using biophysical approaches that can determine whether and how cytoskeletally-mediated processes leading to cell migration have been triggered.","4":"Metastasis","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645020","2":"Analysis of Cell Autonomous Mechanisms of Phenotypic Plasticity in Invasive Cell Spread","3":"The goal of this project is to obtain a better quantitative understanding of the complex regulation and characteristic of the invasive phenotypic state. The analysis in the project is aimed at the cell autonomous view of regulation, without explicit emphasis of cell-cell interactions. We will combine a variety of tools and approaches, including combining experimentation and mathematical modeling.nn&nbsp;nnWe are able to separate slow moving, proliferative cells from fast moving, migratory cells (and enrich each phenotype) using a <U+201A><U+00C4><U+00FA>phenotypic filter<U+201A><U+00C4><U+00F9> through an assay called Rapid Analysis of Cell migration Enhancement (RACE). This assay employs nano-fabricated surfaces that result in rapid and highly oriented cell migration. Preliminary results using RACE not only suggest that the assay can help identify molecular mechanisms of the Proliferative-to-Aggressive phenotypic switch but have also led us to develop a preliminary mathematical model describing how specific kinases, thought to be activated by the same growth factors, can be differentially active in different cell sub-populations. In addition, using synthetic biology techniques, we have created a new platform for generating novel kinase inhibitors that can be used to, for the first time, target kinases considered to be <U+201A><U+00C4><U+00FA>difficult<U+201A><U+00C4><U+00F9> to target due to their orphan status and unclear regulation mechanisms. When possible, the mechanistic significance in cancer invasion and spreading of newly identified and targeted kinases will be examined using biophysical approaches that can determine whether and how cytoskeletally-mediated processes leading to cell migration have been triggered.","4":"Microenvironment","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645021","2":"Analysis of Non-Cell-Autonomous (Cell Communication-Dependent) Mechanisms of Phenotypic Plasticity in Invasive Cell Spread","3":"Preliminary data from the RACE assay (see Project 1) combined with additional evidence suggests that both cancer cell-cancer cell and cancer cell-stroma interactions are critically important for controlling the Proliferative-to-Aggressive phenotypic switch and the ensuing invasive cancer spread. Therefore, in Project 2, our goal is to identify and analyze novel targets as possible regulators of invasive cancer phenotype, particularly ones involved in cell-cell interactions. The key novelty in this project is in the realization that invasive cancer migration has many similarities with normal, invasive processes occurring in developmental or physiological processes, such as wound healing or development of the placental tissue.nn&nbsp;nnWe will examine, in a species-dependent fashion, whether stromal cells exert differential resistance to or cooperation with the invasive cancer spread. A focus will be on the differential expression of specific chemo-attractants and chemo-repellents that are frequently associated with angigogenesis or neuronal migration. We will study the mechanisms regulating communication and putative interaction between cells adopting a more proliferative phenotype with cells adopting a more migratory phenotype. We will use novel techniques and approaches in Project 2 to perturb and validate possible novel targets as regulators of invasive cancer phenotype. Analysis of such targets will be conducted in collaboration with Project 1, since many of the techniques used in these projects are compatible and mutually enriching.","4":"Metastasis","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645021","2":"Analysis of Non-Cell-Autonomous (Cell Communication-Dependent) Mechanisms of Phenotypic Plasticity in Invasive Cell Spread","3":"Preliminary data from the RACE assay (see Project 1) combined with additional evidence suggests that both cancer cell-cancer cell and cancer cell-stroma interactions are critically important for controlling the Proliferative-to-Aggressive phenotypic switch and the ensuing invasive cancer spread. Therefore, in Project 2, our goal is to identify and analyze novel targets as possible regulators of invasive cancer phenotype, particularly ones involved in cell-cell interactions. The key novelty in this project is in the realization that invasive cancer migration has many similarities with normal, invasive processes occurring in developmental or physiological processes, such as wound healing or development of the placental tissue.nn&nbsp;nnWe will examine, in a species-dependent fashion, whether stromal cells exert differential resistance to or cooperation with the invasive cancer spread. A focus will be on the differential expression of specific chemo-attractants and chemo-repellents that are frequently associated with angigogenesis or neuronal migration. We will study the mechanisms regulating communication and putative interaction between cells adopting a more proliferative phenotype with cells adopting a more migratory phenotype. We will use novel techniques and approaches in Project 2 to perturb and validate possible novel targets as regulators of invasive cancer phenotype. Analysis of such targets will be conducted in collaboration with Project 1, since many of the techniques used in these projects are compatible and mutually enriching.","4":"Microenvironment","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645022","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion Microfabrication","3":"Core 1 will offer two key microfabricated platforms and assays to enable two different measurements. First, to measure at the scale of a single cancer cell, the migration and invasiveness of melanoma and glioblastoma cell populations in response to combinations of external cues. This will enable the RACE assay, analysis of the cell migration in different types of channels, and a new assay aimed at investigation of heterotypic cell communication. Second, to measure a panel of paracrine signals mediating heterotypic cell-cell communication that drive non-autonomous cancer progression.","4":"Metastasis","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645022","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion Microfabrication","3":"Core 1 will offer two key microfabricated platforms and assays to enable two different measurements. First, to measure at the scale of a single cancer cell, the migration and invasiveness of melanoma and glioblastoma cell populations in response to combinations of external cues. This will enable the RACE assay, analysis of the cell migration in different types of channels, and a new assay aimed at investigation of heterotypic cell communication. Second, to measure a panel of paracrine signals mediating heterotypic cell-cell communication that drive non-autonomous cancer progression.","4":"Microenvironment","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645023","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion Animal","3":"Core 2 will focus on the validation of the molecular targets and mechanisms involved in phenotypic switching between proliferative and invasive cancer phenotypes. This will be achieved using novel CRISPR-based models of cancer invasion and metastasis. This will allow us to explore the progression of disease following genetic perturbation of molecules of interest identified in the RACE assay, for example, in the analysis of homo- and hetero-typic cell interactions. Viral libraries generated by Core 2 will be used to perform in vivo high throughput analysis, aimed at assaying multiple genetic perturbations, ultimately mimicking the RACE assay in vivo. Both animal models and virus libraries will be of immense utility to researchers both at Yale and elsewhere, representing a valuable resource within the Consortium.","4":"Metastasis","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645023","2":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion Animal","3":"Core 2 will focus on the validation of the molecular targets and mechanisms involved in phenotypic switching between proliferative and invasive cancer phenotypes. This will be achieved using novel CRISPR-based models of cancer invasion and metastasis. This will allow us to explore the progression of disease following genetic perturbation of molecules of interest identified in the RACE assay, for example, in the analysis of homo- and hetero-typic cell interactions. Viral libraries generated by Core 2 will be used to perform in vivo high throughput analysis, aimed at assaying multiple genetic perturbations, ultimately mimicking the RACE assay in vivo. Both animal models and virus libraries will be of immense utility to researchers both at Yale and elsewhere, representing a valuable resource within the Consortium.","4":"Microenvironment","5":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","6":"CSBC","7":"U54"},{"1":"syn21645024","2":"Ionic modulation of chromatin in cancer","3":"[Project 1 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-1-ionic-modulation-of-chromatin-in-cancer/): Cellular potassium levels play a central role in regulating physiological processes and are maintained within narrow limits.  Recent studies reveal that aggressive and highly metastatic breast and multiple myeloma cancer cells maintain potassium concentrations that are several fold higher than matched non-tumorigenic cells. Since the strongest physiochemical interactions involved in reversible chromatin condensation are electrostatic, any perturbations in the ionic environment of the nucleus, such as those driven by a pathophysiological elevation of cellular K+ content, are anticipated to have profound effects on chromatin structure and access to transcriptional machinery.   Thus this discovery has global physiological implications.  It also has the potential to provide a mechanistic framework for a variety of reports showing that elevated potassium levels suppress cell death signaling pathways and may account for the large number of potassium channels that have been shown to play a role in cancer progression.  In this proposal we test the hypothesis that alterations in intracellular K+ and ionic strength alter chromatin structure and nuclear organization, and consequently global gene expression. These experiments will be performed across many length scales using Partial Wave Spectroscopy and STORM methods in the Nanocytometry Core: from intact living cells, to isolated nuclei and metaphase chromosomes and finally on nucleosome core particles.  To address our hypothesis we will develop new physical methods to: (a) understand the impact of potassium concentration on chromatin structure at the physical level in tumor cells; (b) probe the relationship between elevated potassium and clinical stage and grade of human tumors; and (c) probe whether this facet of cancer cell physiology can be exploited in the design of new combination chemotherapies. These advances in understanding ion imbalances in cancer may allow for the repurposing of current FDA-approved agents, such as diuretics that work by modulating intracellular potassium levels.  This project is central to the overarching framework of the CR-PSOC <U+201A><U+00C4><U+00FA>Spatio-Temporal Dynamics of Chromatin and Information Transfer in Cancer<U+201A><U+00C4><U+00F9> because it addresses physical changes in the nuclear environment that are important in cancer progression.  In collaboration with the Project 3 team we will determine the extent of chromatin compaction in intact nuclei, and with the Project 2 team, we will test roles for potassium accumulation in leukemia.  The role of this Project in the Center is to resolve key electrostatic aspects of chromatin and its environment in the cancer cell nucleus. These new ideas and insights will be applied to understand and ultimately intervene in disease progression. This physical chemistry approach may lead to more effective therapeutic interventions using existing drugs.","4":"Metabolism","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645024","2":"Ionic modulation of chromatin in cancer","3":"[Project 1 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-1-ionic-modulation-of-chromatin-in-cancer/): Cellular potassium levels play a central role in regulating physiological processes and are maintained within narrow limits.  Recent studies reveal that aggressive and highly metastatic breast and multiple myeloma cancer cells maintain potassium concentrations that are several fold higher than matched non-tumorigenic cells. Since the strongest physiochemical interactions involved in reversible chromatin condensation are electrostatic, any perturbations in the ionic environment of the nucleus, such as those driven by a pathophysiological elevation of cellular K+ content, are anticipated to have profound effects on chromatin structure and access to transcriptional machinery.   Thus this discovery has global physiological implications.  It also has the potential to provide a mechanistic framework for a variety of reports showing that elevated potassium levels suppress cell death signaling pathways and may account for the large number of potassium channels that have been shown to play a role in cancer progression.  In this proposal we test the hypothesis that alterations in intracellular K+ and ionic strength alter chromatin structure and nuclear organization, and consequently global gene expression. These experiments will be performed across many length scales using Partial Wave Spectroscopy and STORM methods in the Nanocytometry Core: from intact living cells, to isolated nuclei and metaphase chromosomes and finally on nucleosome core particles.  To address our hypothesis we will develop new physical methods to: (a) understand the impact of potassium concentration on chromatin structure at the physical level in tumor cells; (b) probe the relationship between elevated potassium and clinical stage and grade of human tumors; and (c) probe whether this facet of cancer cell physiology can be exploited in the design of new combination chemotherapies. These advances in understanding ion imbalances in cancer may allow for the repurposing of current FDA-approved agents, such as diuretics that work by modulating intracellular potassium levels.  This project is central to the overarching framework of the CR-PSOC <U+201A><U+00C4><U+00FA>Spatio-Temporal Dynamics of Chromatin and Information Transfer in Cancer<U+201A><U+00C4><U+00F9> because it addresses physical changes in the nuclear environment that are important in cancer progression.  In collaboration with the Project 3 team we will determine the extent of chromatin compaction in intact nuclei, and with the Project 2 team, we will test roles for potassium accumulation in leukemia.  The role of this Project in the Center is to resolve key electrostatic aspects of chromatin and its environment in the cancer cell nucleus. These new ideas and insights will be applied to understand and ultimately intervene in disease progression. This physical chemistry approach may lead to more effective therapeutic interventions using existing drugs.","4":"Heterogeneity","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645024","2":"Ionic modulation of chromatin in cancer","3":"[Project 1 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-1-ionic-modulation-of-chromatin-in-cancer/): Cellular potassium levels play a central role in regulating physiological processes and are maintained within narrow limits.  Recent studies reveal that aggressive and highly metastatic breast and multiple myeloma cancer cells maintain potassium concentrations that are several fold higher than matched non-tumorigenic cells. Since the strongest physiochemical interactions involved in reversible chromatin condensation are electrostatic, any perturbations in the ionic environment of the nucleus, such as those driven by a pathophysiological elevation of cellular K+ content, are anticipated to have profound effects on chromatin structure and access to transcriptional machinery.   Thus this discovery has global physiological implications.  It also has the potential to provide a mechanistic framework for a variety of reports showing that elevated potassium levels suppress cell death signaling pathways and may account for the large number of potassium channels that have been shown to play a role in cancer progression.  In this proposal we test the hypothesis that alterations in intracellular K+ and ionic strength alter chromatin structure and nuclear organization, and consequently global gene expression. These experiments will be performed across many length scales using Partial Wave Spectroscopy and STORM methods in the Nanocytometry Core: from intact living cells, to isolated nuclei and metaphase chromosomes and finally on nucleosome core particles.  To address our hypothesis we will develop new physical methods to: (a) understand the impact of potassium concentration on chromatin structure at the physical level in tumor cells; (b) probe the relationship between elevated potassium and clinical stage and grade of human tumors; and (c) probe whether this facet of cancer cell physiology can be exploited in the design of new combination chemotherapies. These advances in understanding ion imbalances in cancer may allow for the repurposing of current FDA-approved agents, such as diuretics that work by modulating intracellular potassium levels.  This project is central to the overarching framework of the CR-PSOC <U+201A><U+00C4><U+00FA>Spatio-Temporal Dynamics of Chromatin and Information Transfer in Cancer<U+201A><U+00C4><U+00F9> because it addresses physical changes in the nuclear environment that are important in cancer progression.  In collaboration with the Project 3 team we will determine the extent of chromatin compaction in intact nuclei, and with the Project 2 team, we will test roles for potassium accumulation in leukemia.  The role of this Project in the Center is to resolve key electrostatic aspects of chromatin and its environment in the cancer cell nucleus. These new ideas and insights will be applied to understand and ultimately intervene in disease progression. This physical chemistry approach may lead to more effective therapeutic interventions using existing drugs.","4":"Evolution","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645025","2":"Molecular modulation of chromatin and nuclear structure in cancer","3":"[Project 2 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-2-molecular-modulation-of-chromatin-and-nuclear-structure-in-cancer/): This project seeks to elucidate the role of enhancer dysfunction in modulating the spatio-temporal organization of chromatin and information transfer in cancer.  Genome sequencing efforts in recent years have revealed the presence of recurrent somatic mutations in epigenetic regulators in myelodysplasia (MDS) and acute myeloid leukemia (AML), such as loss of function mutations in EZH2 and TET2.  The effects of these mutations on chromatin structure and function are beginning to be elucidated.  Meanwhile with the advent of the ENCODE data and genome wide chromatin precipitation-sequencing studies it has become apparent that a large fraction of gene regulatory events are governed at enhancer sites located tens to hundreds of kilobases away from the start site of transcription.  Such sites are brought into apposition to gene promoters to stimulate gene expression through the formation of chromatin loops.  More recently, genomic surveys showed the presence of mutations in proteins linked to enhancer function, such as loss of function mutations of MLL3 (found within the common chromosome 7q36.1 deletion region in MDS and AML).  These enzymes encode histone methyltransferases that lead to the monomethylation of histone 3 lysine 4, a modification characteristic of enhancers.  p300, a histone acetyltransferase that acetylates these enhancers is mutated in MDS as well.  Mutation of TET2 in MDS signifies the importance of the hydroxymethylation modification, which our data indicate is present in enhancer sequences.  Finally the cohesin complex allows promoters and enhancers to loop together, facilitating gene expression.  Mutations in the genes of the cohesin assembly such as SMC3, STAG2, and RAD21 are found in MDS and AML. Collectively these data suggest that a subset of cases of AML and MDS suffers from enhancer dysfunction.nn&nbsp;nnWe hypothesize that enhancer dysfunction leads to an altered physical state of chromatin, including an abnormal state of 3-D looping, leading to aberrant formation of transcriptional, initiating and elongating complexes and destroying the normal regulation of gene expression in the cell.  This leads to the ineffective hematopoiesis and clonal expansion characteristic of MDS precursors.  We will use emerging CRISPR technology, advanced imaging (PWS/STORM microscopy) to visualize and monitor chromatin loop formation in response to oncogenic stimuli. We will use sophisticated chromatin confirmation capture and bioinformatics methods to create models of the physical state of chromatin in response to loss of key chromatin regulators.  Genome wide chromatin surveys will elucidate the aberrant structure and function of chromatin in hematologic malignancies.  Our work on the functional consequences of changes in chromatin structure at the kilobase-scale will interlock with an understanding of how ion concentrations alter chromatin structure and how folding mediated by condensins and cohesins affects chromatin structure and function at the megabase and chromosomal scale. We will use genetically edited cell models, genetically faithful animal models of AML and human specimens in xenografts to cross validate our work.  Finally we will determine if aberrant chromatin configurations lead to enhanced susceptibility to epigenetically targeted drugs.","4":"Metabolism","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645025","2":"Molecular modulation of chromatin and nuclear structure in cancer","3":"[Project 2 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-2-molecular-modulation-of-chromatin-and-nuclear-structure-in-cancer/): This project seeks to elucidate the role of enhancer dysfunction in modulating the spatio-temporal organization of chromatin and information transfer in cancer.  Genome sequencing efforts in recent years have revealed the presence of recurrent somatic mutations in epigenetic regulators in myelodysplasia (MDS) and acute myeloid leukemia (AML), such as loss of function mutations in EZH2 and TET2.  The effects of these mutations on chromatin structure and function are beginning to be elucidated.  Meanwhile with the advent of the ENCODE data and genome wide chromatin precipitation-sequencing studies it has become apparent that a large fraction of gene regulatory events are governed at enhancer sites located tens to hundreds of kilobases away from the start site of transcription.  Such sites are brought into apposition to gene promoters to stimulate gene expression through the formation of chromatin loops.  More recently, genomic surveys showed the presence of mutations in proteins linked to enhancer function, such as loss of function mutations of MLL3 (found within the common chromosome 7q36.1 deletion region in MDS and AML).  These enzymes encode histone methyltransferases that lead to the monomethylation of histone 3 lysine 4, a modification characteristic of enhancers.  p300, a histone acetyltransferase that acetylates these enhancers is mutated in MDS as well.  Mutation of TET2 in MDS signifies the importance of the hydroxymethylation modification, which our data indicate is present in enhancer sequences.  Finally the cohesin complex allows promoters and enhancers to loop together, facilitating gene expression.  Mutations in the genes of the cohesin assembly such as SMC3, STAG2, and RAD21 are found in MDS and AML. Collectively these data suggest that a subset of cases of AML and MDS suffers from enhancer dysfunction.nn&nbsp;nnWe hypothesize that enhancer dysfunction leads to an altered physical state of chromatin, including an abnormal state of 3-D looping, leading to aberrant formation of transcriptional, initiating and elongating complexes and destroying the normal regulation of gene expression in the cell.  This leads to the ineffective hematopoiesis and clonal expansion characteristic of MDS precursors.  We will use emerging CRISPR technology, advanced imaging (PWS/STORM microscopy) to visualize and monitor chromatin loop formation in response to oncogenic stimuli. We will use sophisticated chromatin confirmation capture and bioinformatics methods to create models of the physical state of chromatin in response to loss of key chromatin regulators.  Genome wide chromatin surveys will elucidate the aberrant structure and function of chromatin in hematologic malignancies.  Our work on the functional consequences of changes in chromatin structure at the kilobase-scale will interlock with an understanding of how ion concentrations alter chromatin structure and how folding mediated by condensins and cohesins affects chromatin structure and function at the megabase and chromosomal scale. We will use genetically edited cell models, genetically faithful animal models of AML and human specimens in xenografts to cross validate our work.  Finally we will determine if aberrant chromatin configurations lead to enhanced susceptibility to epigenetically targeted drugs.","4":"Heterogeneity","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645025","2":"Molecular modulation of chromatin and nuclear structure in cancer","3":"[Project 2 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-2-molecular-modulation-of-chromatin-and-nuclear-structure-in-cancer/): This project seeks to elucidate the role of enhancer dysfunction in modulating the spatio-temporal organization of chromatin and information transfer in cancer.  Genome sequencing efforts in recent years have revealed the presence of recurrent somatic mutations in epigenetic regulators in myelodysplasia (MDS) and acute myeloid leukemia (AML), such as loss of function mutations in EZH2 and TET2.  The effects of these mutations on chromatin structure and function are beginning to be elucidated.  Meanwhile with the advent of the ENCODE data and genome wide chromatin precipitation-sequencing studies it has become apparent that a large fraction of gene regulatory events are governed at enhancer sites located tens to hundreds of kilobases away from the start site of transcription.  Such sites are brought into apposition to gene promoters to stimulate gene expression through the formation of chromatin loops.  More recently, genomic surveys showed the presence of mutations in proteins linked to enhancer function, such as loss of function mutations of MLL3 (found within the common chromosome 7q36.1 deletion region in MDS and AML).  These enzymes encode histone methyltransferases that lead to the monomethylation of histone 3 lysine 4, a modification characteristic of enhancers.  p300, a histone acetyltransferase that acetylates these enhancers is mutated in MDS as well.  Mutation of TET2 in MDS signifies the importance of the hydroxymethylation modification, which our data indicate is present in enhancer sequences.  Finally the cohesin complex allows promoters and enhancers to loop together, facilitating gene expression.  Mutations in the genes of the cohesin assembly such as SMC3, STAG2, and RAD21 are found in MDS and AML. Collectively these data suggest that a subset of cases of AML and MDS suffers from enhancer dysfunction.nn&nbsp;nnWe hypothesize that enhancer dysfunction leads to an altered physical state of chromatin, including an abnormal state of 3-D looping, leading to aberrant formation of transcriptional, initiating and elongating complexes and destroying the normal regulation of gene expression in the cell.  This leads to the ineffective hematopoiesis and clonal expansion characteristic of MDS precursors.  We will use emerging CRISPR technology, advanced imaging (PWS/STORM microscopy) to visualize and monitor chromatin loop formation in response to oncogenic stimuli. We will use sophisticated chromatin confirmation capture and bioinformatics methods to create models of the physical state of chromatin in response to loss of key chromatin regulators.  Genome wide chromatin surveys will elucidate the aberrant structure and function of chromatin in hematologic malignancies.  Our work on the functional consequences of changes in chromatin structure at the kilobase-scale will interlock with an understanding of how ion concentrations alter chromatin structure and how folding mediated by condensins and cohesins affects chromatin structure and function at the megabase and chromosomal scale. We will use genetically edited cell models, genetically faithful animal models of AML and human specimens in xenografts to cross validate our work.  Finally we will determine if aberrant chromatin configurations lead to enhanced susceptibility to epigenetically targeted drugs.","4":"Evolution","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645026","2":"Mechanics of nuclei, chromosomes and chromatin in cancer","3":"[Project 3 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-3-mechanics-of-nuclei-chromosomes-and-chromatin-in-cancer/): The large-scale structure of chromosomes is being increasingly appreciated as crucial to the regulation of genes, and dysregulation of higher-order chromosome organization is a hallmark of most cancers.  The overarching hypothesis driving this Project is that there are profound changes in organization of nuclei and chromosomes with cell type, particularly for rapidly growing cancer cells.   Preliminary data show strong effects of cell cycle timing on the structure and mechanics of metaphase chromosomes, and strong changes in nuclear organization in cancer cells, including changes driven by post-translational modifications of histones.","4":"Metabolism","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645026","2":"Mechanics of nuclei, chromosomes and chromatin in cancer","3":"[Project 3 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-3-mechanics-of-nuclei-chromosomes-and-chromatin-in-cancer/): The large-scale structure of chromosomes is being increasingly appreciated as crucial to the regulation of genes, and dysregulation of higher-order chromosome organization is a hallmark of most cancers.  The overarching hypothesis driving this Project is that there are profound changes in organization of nuclei and chromosomes with cell type, particularly for rapidly growing cancer cells.   Preliminary data show strong effects of cell cycle timing on the structure and mechanics of metaphase chromosomes, and strong changes in nuclear organization in cancer cells, including changes driven by post-translational modifications of histones.","4":"Heterogeneity","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645026","2":"Mechanics of nuclei, chromosomes and chromatin in cancer","3":"[Project 3 summary](https://www.psoc.northwestern.edu/research/core-research-projects/project-3-mechanics-of-nuclei-chromosomes-and-chromatin-in-cancer/): The large-scale structure of chromosomes is being increasingly appreciated as crucial to the regulation of genes, and dysregulation of higher-order chromosome organization is a hallmark of most cancers.  The overarching hypothesis driving this Project is that there are profound changes in organization of nuclei and chromosomes with cell type, particularly for rapidly growing cancer cells.   Preliminary data show strong effects of cell cycle timing on the structure and mechanics of metaphase chromosomes, and strong changes in nuclear organization in cancer cells, including changes driven by post-translational modifications of histones.","4":"Evolution","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645027","2":"Chicago Region Physical Science Oncology Center Nanocytometry","3":"Higher-order/large-scale chromatin structure plays a critical role in gene regulation, and its dysregulation is a hallmark of most cancers. This involves a hierarchy of length scales from a few tens of nanometers for nucleosomes to hundreds of nanometers for chromatin loops. The Nanocytometry Core provides quantitative analysis of the physical structure of chromatin with a custom designed and built microscope capable of both nanoscale sensitivity and super-resolution imaging. This unique instrument does not exist anywhere else in the world.nn&nbsp;nnThe instrument combines two complementary micro/nanoscopic techniques: partial wave spectroscopic (PWS) nanocytometry, which quantifies the statistical properties of molecular density distribution within live or fixed cells for length scales from 10 to 200 nm, and Stochastic Optical Reconstruction Microscope (STORM), a super-resolution microscopy offering molecular-specific images with resolution as high as ~20-60 nm.  The core staff is developing a combined STORM-nanocytology software system that allows for seamless integration of the microscopy techniques with a co-registration capability.nn&nbsp;nnThe application of this instrument to the Chicago Region Physical Oncology Sciences Center studies allows investigators the ability to image and sense the chromatin structure with sensitivity down to 10-20 nm in live as well as fixed cells, and can work with individual cells as well as able to analyze thousands of cells across an entire slide within minutes. CR-PSOC Investigators anticipate that this cutting-edge microscopy system will open up new directions for basic science as well as translational research.","4":"Metabolism","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645027","2":"Chicago Region Physical Science Oncology Center Nanocytometry","3":"Higher-order/large-scale chromatin structure plays a critical role in gene regulation, and its dysregulation is a hallmark of most cancers. This involves a hierarchy of length scales from a few tens of nanometers for nucleosomes to hundreds of nanometers for chromatin loops. The Nanocytometry Core provides quantitative analysis of the physical structure of chromatin with a custom designed and built microscope capable of both nanoscale sensitivity and super-resolution imaging. This unique instrument does not exist anywhere else in the world.nn&nbsp;nnThe instrument combines two complementary micro/nanoscopic techniques: partial wave spectroscopic (PWS) nanocytometry, which quantifies the statistical properties of molecular density distribution within live or fixed cells for length scales from 10 to 200 nm, and Stochastic Optical Reconstruction Microscope (STORM), a super-resolution microscopy offering molecular-specific images with resolution as high as ~20-60 nm.  The core staff is developing a combined STORM-nanocytology software system that allows for seamless integration of the microscopy techniques with a co-registration capability.nn&nbsp;nnThe application of this instrument to the Chicago Region Physical Oncology Sciences Center studies allows investigators the ability to image and sense the chromatin structure with sensitivity down to 10-20 nm in live as well as fixed cells, and can work with individual cells as well as able to analyze thousands of cells across an entire slide within minutes. CR-PSOC Investigators anticipate that this cutting-edge microscopy system will open up new directions for basic science as well as translational research.","4":"Heterogeneity","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645027","2":"Chicago Region Physical Science Oncology Center Nanocytometry","3":"Higher-order/large-scale chromatin structure plays a critical role in gene regulation, and its dysregulation is a hallmark of most cancers. This involves a hierarchy of length scales from a few tens of nanometers for nucleosomes to hundreds of nanometers for chromatin loops. The Nanocytometry Core provides quantitative analysis of the physical structure of chromatin with a custom designed and built microscope capable of both nanoscale sensitivity and super-resolution imaging. This unique instrument does not exist anywhere else in the world.nn&nbsp;nnThe instrument combines two complementary micro/nanoscopic techniques: partial wave spectroscopic (PWS) nanocytometry, which quantifies the statistical properties of molecular density distribution within live or fixed cells for length scales from 10 to 200 nm, and Stochastic Optical Reconstruction Microscope (STORM), a super-resolution microscopy offering molecular-specific images with resolution as high as ~20-60 nm.  The core staff is developing a combined STORM-nanocytology software system that allows for seamless integration of the microscopy techniques with a co-registration capability.nn&nbsp;nnThe application of this instrument to the Chicago Region Physical Oncology Sciences Center studies allows investigators the ability to image and sense the chromatin structure with sensitivity down to 10-20 nm in live as well as fixed cells, and can work with individual cells as well as able to analyze thousands of cells across an entire slide within minutes. CR-PSOC Investigators anticipate that this cutting-edge microscopy system will open up new directions for basic science as well as translational research.","4":"Evolution","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645028","2":"Chicago Region Physical Science Oncology Center PDX Human Tumor","3":"Patient-derived xenograft tumors retain histological characteristics that are similar to the patient tumors from which they were derived. Thus, these models are thought to be closer to the clinical situation than traditional xenograft models.  The Patient-Derived Xenograft (PDX) Core provides a valuable model of human cancer that enables investigators to extend their observations to actual patient tumor cells.nn&nbsp;nnThe Core creates and maintains carefully delineated, in vivo human tumor models from a broad range of histologies that retain the characteristics of fresh human tumors.  These PDX models are passaged continuously in vivo and are never exposed to tissue culture plastic and the limitations imposed by tissue culture selection of certain tumor cell clones.nn&nbsp;nnThe Core builds on an already established PDX repository infrastructure that currently maintains sixty-two models covering ten different tumor histologies, with 2-3 new models created each week. Early passage cell lines are created in parallel from these in vivo PDX models and are available to the Physical Sciences Oncology Network investigators.nn&nbsp;nnThese early passage cell lines will be utilized for in vitro experiments by all three CR-PSOC research projects. The phenotypic and genotypic uniformity of these cells enables the integration of data across all three projects. In addition, the Core creates new PDX models of human multiple myeloma and medulloblastoma since potassium imbalances have been implicated in the tumorigenicity and progression of these tumor types.","4":"Metabolism","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645028","2":"Chicago Region Physical Science Oncology Center PDX Human Tumor","3":"Patient-derived xenograft tumors retain histological characteristics that are similar to the patient tumors from which they were derived. Thus, these models are thought to be closer to the clinical situation than traditional xenograft models.  The Patient-Derived Xenograft (PDX) Core provides a valuable model of human cancer that enables investigators to extend their observations to actual patient tumor cells.nn&nbsp;nnThe Core creates and maintains carefully delineated, in vivo human tumor models from a broad range of histologies that retain the characteristics of fresh human tumors.  These PDX models are passaged continuously in vivo and are never exposed to tissue culture plastic and the limitations imposed by tissue culture selection of certain tumor cell clones.nn&nbsp;nnThe Core builds on an already established PDX repository infrastructure that currently maintains sixty-two models covering ten different tumor histologies, with 2-3 new models created each week. Early passage cell lines are created in parallel from these in vivo PDX models and are available to the Physical Sciences Oncology Network investigators.nn&nbsp;nnThese early passage cell lines will be utilized for in vitro experiments by all three CR-PSOC research projects. The phenotypic and genotypic uniformity of these cells enables the integration of data across all three projects. In addition, the Core creates new PDX models of human multiple myeloma and medulloblastoma since potassium imbalances have been implicated in the tumorigenicity and progression of these tumor types.","4":"Heterogeneity","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645028","2":"Chicago Region Physical Science Oncology Center PDX Human Tumor","3":"Patient-derived xenograft tumors retain histological characteristics that are similar to the patient tumors from which they were derived. Thus, these models are thought to be closer to the clinical situation than traditional xenograft models.  The Patient-Derived Xenograft (PDX) Core provides a valuable model of human cancer that enables investigators to extend their observations to actual patient tumor cells.nn&nbsp;nnThe Core creates and maintains carefully delineated, in vivo human tumor models from a broad range of histologies that retain the characteristics of fresh human tumors.  These PDX models are passaged continuously in vivo and are never exposed to tissue culture plastic and the limitations imposed by tissue culture selection of certain tumor cell clones.nn&nbsp;nnThe Core builds on an already established PDX repository infrastructure that currently maintains sixty-two models covering ten different tumor histologies, with 2-3 new models created each week. Early passage cell lines are created in parallel from these in vivo PDX models and are available to the Physical Sciences Oncology Network investigators.nn&nbsp;nnThese early passage cell lines will be utilized for in vitro experiments by all three CR-PSOC research projects. The phenotypic and genotypic uniformity of these cells enables the integration of data across all three projects. In addition, the Core creates new PDX models of human multiple myeloma and medulloblastoma since potassium imbalances have been implicated in the tumorigenicity and progression of these tumor types.","4":"Evolution","5":"Chicago Region Physical Science Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645029","2":"Physical modeling and dynamics of tumor cell migration mechanics","3":"A key feature of highly aggressive cancers is their invasiveness, where transformed cells disseminate by crawling through the local micro-environment, ultimately causing death as the tumor invades and metastasizes. If these processes of cell motility could be suppressed, it would potentially extend lifespan and increase the potential effectiveness for local and global therapeutic treatments. However, we do not adequately understand the mechanical and chemical basis of cancer cell migration in complex and mechanically challenging microenvironments. The goal of this project is to develop and use a mathematical/computational model that will allow us to simulate cancer migration on a computer, and, in the longer-term, perform virtual in silico drug screening. Specifically, during this project we will mechanically parameterize glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDA) tumor cell migration so that patient outcomes can be predicted and new therapeutic strategies identified. Employing physical modeling for whole cell model migration, we have developed a <U+201A><U+00C4><U+00FA>Cell Migration Simulator, v1.0,<U+201A><U+00C4><U+00F9> (CMS1.0) to capture fundamental intracellular and extracellular mechanical processes regulating cell migration. Here, CMS1.0 will be used to 1) mechanically parameterize tumor heterogeneity, 2) bias immune-cancer cell interaction away from suppression and toward killing, and 3) elucidate proto-oncogene mechanism. Finally, we will also further develop the CMS1.0 to include more explicit F-actin dynamics, cell mechanics, and environmental fiber mechanics. In the process, we will build a physical sciences-based, patient-oriented approach toward understanding and controlling a key driver of cancer progression, cell migration. Thus, the project will establish the quantitative framework necessary to develop a model-driven approach to brain and pancreatic cancer invasion, so that therapies can be designed and engineered for better, more predictable outcomes.","4":"Microenvironment","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645029","2":"Physical modeling and dynamics of tumor cell migration mechanics","3":"A key feature of highly aggressive cancers is their invasiveness, where transformed cells disseminate by crawling through the local micro-environment, ultimately causing death as the tumor invades and metastasizes. If these processes of cell motility could be suppressed, it would potentially extend lifespan and increase the potential effectiveness for local and global therapeutic treatments. However, we do not adequately understand the mechanical and chemical basis of cancer cell migration in complex and mechanically challenging microenvironments. The goal of this project is to develop and use a mathematical/computational model that will allow us to simulate cancer migration on a computer, and, in the longer-term, perform virtual in silico drug screening. Specifically, during this project we will mechanically parameterize glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDA) tumor cell migration so that patient outcomes can be predicted and new therapeutic strategies identified. Employing physical modeling for whole cell model migration, we have developed a <U+201A><U+00C4><U+00FA>Cell Migration Simulator, v1.0,<U+201A><U+00C4><U+00F9> (CMS1.0) to capture fundamental intracellular and extracellular mechanical processes regulating cell migration. Here, CMS1.0 will be used to 1) mechanically parameterize tumor heterogeneity, 2) bias immune-cancer cell interaction away from suppression and toward killing, and 3) elucidate proto-oncogene mechanism. Finally, we will also further develop the CMS1.0 to include more explicit F-actin dynamics, cell mechanics, and environmental fiber mechanics. In the process, we will build a physical sciences-based, patient-oriented approach toward understanding and controlling a key driver of cancer progression, cell migration. Thus, the project will establish the quantitative framework necessary to develop a model-driven approach to brain and pancreatic cancer invasion, so that therapies can be designed and engineered for better, more predictable outcomes.","4":"Metastasis","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645029","2":"Physical modeling and dynamics of tumor cell migration mechanics","3":"A key feature of highly aggressive cancers is their invasiveness, where transformed cells disseminate by crawling through the local micro-environment, ultimately causing death as the tumor invades and metastasizes. If these processes of cell motility could be suppressed, it would potentially extend lifespan and increase the potential effectiveness for local and global therapeutic treatments. However, we do not adequately understand the mechanical and chemical basis of cancer cell migration in complex and mechanically challenging microenvironments. The goal of this project is to develop and use a mathematical/computational model that will allow us to simulate cancer migration on a computer, and, in the longer-term, perform virtual in silico drug screening. Specifically, during this project we will mechanically parameterize glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDA) tumor cell migration so that patient outcomes can be predicted and new therapeutic strategies identified. Employing physical modeling for whole cell model migration, we have developed a <U+201A><U+00C4><U+00FA>Cell Migration Simulator, v1.0,<U+201A><U+00C4><U+00F9> (CMS1.0) to capture fundamental intracellular and extracellular mechanical processes regulating cell migration. Here, CMS1.0 will be used to 1) mechanically parameterize tumor heterogeneity, 2) bias immune-cancer cell interaction away from suppression and toward killing, and 3) elucidate proto-oncogene mechanism. Finally, we will also further develop the CMS1.0 to include more explicit F-actin dynamics, cell mechanics, and environmental fiber mechanics. In the process, we will build a physical sciences-based, patient-oriented approach toward understanding and controlling a key driver of cancer progression, cell migration. Thus, the project will establish the quantitative framework necessary to develop a model-driven approach to brain and pancreatic cancer invasion, so that therapies can be designed and engineered for better, more predictable outcomes.","4":"Tumor-Immune","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645030","2":"Cell Migration in Mechanically Complex Microenvironments","3":"Cancers are complex systems commonly associated with a robust fibroinflammatory stromal response, or desmoplastic reaction. This is highly relevant as it is now recognized that, in many solid tumors, the stromal compartment and its local microenvironments significantly influence disease progression. Through disease progression this desmoplastic reaction continues and often intensifies, offering critical support to malignant cells as they progress to invasive and often fully metastastic disease while also providing drug-free sanctuaries that limit access of small molecule therapies. Likewise, even the earliest stages of disease are associated with a robust immune reaction that evolves with disease progression. Here tumor microenvironments appear to form sanctuaries for immune evasion and in fact are comprised, in part, of infiltrated immune cells that have been subverted to act as active collaborators that enable tumor progression. Interestingly, while robust biochemical stimuli are present in tumors, they are not the only factor. These microenvironments also provide robust physical cues that conspire to promote disease progression. For instance, in solid tumors there are fundamental roles of extracellular matrix stiffness, composition and architecture that profoundly influence outcome. However, to date, the molecular and physical mechanisms by which matrix stiffness and architecture, and their relative contributions, influence tumor cell behavior are not well known. Here, we propose specific and integrated experiments and modeling to explicitly investigate the physical and molecular mechanisms by which the tumor microenvironment regulates disease progression as a function of the underlying carcinoma genetics. Quantitative analysis and parameterization of data will facilitate model development and model predictions will be tested experimentally. Specifically, we will employ a series of 2D and 3D assays with varying stiffness and architecture of increasing complexity, and multiscale network modeling, to parse out the relative contributions of contact guidance cues and durotactic effects in complex microenvironments. Integration of chemical gradients will be used to parse out dominance, antagonism or synergy between chemical and physical cues. Further, we hypothesize that physical cues in the cellular microenvironment drive communication between different tumor cell populations and regulate immune cell infiltration and function. Thus, we seek to identify regimes where manipulating operant physical characteristics of a tumor reduces carcinoma cell advancement while simultaneously hampering immune evasion and promoting the antitumor response.","4":"Microenvironment","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645030","2":"Cell Migration in Mechanically Complex Microenvironments","3":"Cancers are complex systems commonly associated with a robust fibroinflammatory stromal response, or desmoplastic reaction. This is highly relevant as it is now recognized that, in many solid tumors, the stromal compartment and its local microenvironments significantly influence disease progression. Through disease progression this desmoplastic reaction continues and often intensifies, offering critical support to malignant cells as they progress to invasive and often fully metastastic disease while also providing drug-free sanctuaries that limit access of small molecule therapies. Likewise, even the earliest stages of disease are associated with a robust immune reaction that evolves with disease progression. Here tumor microenvironments appear to form sanctuaries for immune evasion and in fact are comprised, in part, of infiltrated immune cells that have been subverted to act as active collaborators that enable tumor progression. Interestingly, while robust biochemical stimuli are present in tumors, they are not the only factor. These microenvironments also provide robust physical cues that conspire to promote disease progression. For instance, in solid tumors there are fundamental roles of extracellular matrix stiffness, composition and architecture that profoundly influence outcome. However, to date, the molecular and physical mechanisms by which matrix stiffness and architecture, and their relative contributions, influence tumor cell behavior are not well known. Here, we propose specific and integrated experiments and modeling to explicitly investigate the physical and molecular mechanisms by which the tumor microenvironment regulates disease progression as a function of the underlying carcinoma genetics. Quantitative analysis and parameterization of data will facilitate model development and model predictions will be tested experimentally. Specifically, we will employ a series of 2D and 3D assays with varying stiffness and architecture of increasing complexity, and multiscale network modeling, to parse out the relative contributions of contact guidance cues and durotactic effects in complex microenvironments. Integration of chemical gradients will be used to parse out dominance, antagonism or synergy between chemical and physical cues. Further, we hypothesize that physical cues in the cellular microenvironment drive communication between different tumor cell populations and regulate immune cell infiltration and function. Thus, we seek to identify regimes where manipulating operant physical characteristics of a tumor reduces carcinoma cell advancement while simultaneously hampering immune evasion and promoting the antitumor response.","4":"Metastasis","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645030","2":"Cell Migration in Mechanically Complex Microenvironments","3":"Cancers are complex systems commonly associated with a robust fibroinflammatory stromal response, or desmoplastic reaction. This is highly relevant as it is now recognized that, in many solid tumors, the stromal compartment and its local microenvironments significantly influence disease progression. Through disease progression this desmoplastic reaction continues and often intensifies, offering critical support to malignant cells as they progress to invasive and often fully metastastic disease while also providing drug-free sanctuaries that limit access of small molecule therapies. Likewise, even the earliest stages of disease are associated with a robust immune reaction that evolves with disease progression. Here tumor microenvironments appear to form sanctuaries for immune evasion and in fact are comprised, in part, of infiltrated immune cells that have been subverted to act as active collaborators that enable tumor progression. Interestingly, while robust biochemical stimuli are present in tumors, they are not the only factor. These microenvironments also provide robust physical cues that conspire to promote disease progression. For instance, in solid tumors there are fundamental roles of extracellular matrix stiffness, composition and architecture that profoundly influence outcome. However, to date, the molecular and physical mechanisms by which matrix stiffness and architecture, and their relative contributions, influence tumor cell behavior are not well known. Here, we propose specific and integrated experiments and modeling to explicitly investigate the physical and molecular mechanisms by which the tumor microenvironment regulates disease progression as a function of the underlying carcinoma genetics. Quantitative analysis and parameterization of data will facilitate model development and model predictions will be tested experimentally. Specifically, we will employ a series of 2D and 3D assays with varying stiffness and architecture of increasing complexity, and multiscale network modeling, to parse out the relative contributions of contact guidance cues and durotactic effects in complex microenvironments. Integration of chemical gradients will be used to parse out dominance, antagonism or synergy between chemical and physical cues. Further, we hypothesize that physical cues in the cellular microenvironment drive communication between different tumor cell populations and regulate immune cell infiltration and function. Thus, we seek to identify regimes where manipulating operant physical characteristics of a tumor reduces carcinoma cell advancement while simultaneously hampering immune evasion and promoting the antitumor response.","4":"Tumor-Immune","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645031","2":"Center for Modeling Tumor Cell Migration Mechanics Cellular Microenvironment Engineering","3":"The Cell Microenvironment core will provide enabling technologies and develop new methods for controlling the cellular microenvironment and measuring its effect on cancer cell migration. The primary goals of the core will be to probe microenvironmental regulators of cell migration to inform mathematical models, probe cell migration within a physiologically relevant context, and develop highly parallelized platforms for high throughput studies. Technologies will include, but not be limited to, tools for controlling the mechanical environment, controlling cell and environment architecture, controlling cell organization within the microenvironment, controlling chemical gradients, controlling extracellular chemistry, measuring cell migration, and measuring cell force generation. In addition, tools will be developed for high-throughput cell migration measurement and high-throughput tissue isolation. The Cell Microenvironment core will support both Project 1 and Project 2 within this center as well as any applicable pilot projects.","4":"Microenvironment","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645031","2":"Center for Modeling Tumor Cell Migration Mechanics Cellular Microenvironment Engineering","3":"The Cell Microenvironment core will provide enabling technologies and develop new methods for controlling the cellular microenvironment and measuring its effect on cancer cell migration. The primary goals of the core will be to probe microenvironmental regulators of cell migration to inform mathematical models, probe cell migration within a physiologically relevant context, and develop highly parallelized platforms for high throughput studies. Technologies will include, but not be limited to, tools for controlling the mechanical environment, controlling cell and environment architecture, controlling cell organization within the microenvironment, controlling chemical gradients, controlling extracellular chemistry, measuring cell migration, and measuring cell force generation. In addition, tools will be developed for high-throughput cell migration measurement and high-throughput tissue isolation. The Cell Microenvironment core will support both Project 1 and Project 2 within this center as well as any applicable pilot projects.","4":"Metastasis","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645031","2":"Center for Modeling Tumor Cell Migration Mechanics Cellular Microenvironment Engineering","3":"The Cell Microenvironment core will provide enabling technologies and develop new methods for controlling the cellular microenvironment and measuring its effect on cancer cell migration. The primary goals of the core will be to probe microenvironmental regulators of cell migration to inform mathematical models, probe cell migration within a physiologically relevant context, and develop highly parallelized platforms for high throughput studies. Technologies will include, but not be limited to, tools for controlling the mechanical environment, controlling cell and environment architecture, controlling cell organization within the microenvironment, controlling chemical gradients, controlling extracellular chemistry, measuring cell migration, and measuring cell force generation. In addition, tools will be developed for high-throughput cell migration measurement and high-throughput tissue isolation. The Cell Microenvironment core will support both Project 1 and Project 2 within this center as well as any applicable pilot projects.","4":"Tumor-Immune","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645032","2":"Center for Modeling Tumor Cell Migration Mechanics Cell and Whole Animal Genome Engineering","3":"The Cell and Whole Animal Genetic Engineering core will provide both projects with genetically engineered cell lines and mice for analyzing cell and/or tumor behavior under a variety of conditions. The core brings together expertise from two highly trained mouse and somatic cell geneticists, Dr. David Largaespada and Dr. Anindya Bagchi, both with expertise in modeling cancer in mice and with a wide array of cells. Thus, this core will generate two specific resources for both projects #1 and #2. The first is cohorts of mice that reliably develop pancreatic, glioma or medulloblastoma tumors due to the inheritance of germline transgenes, mutant alleles in their endogenous locus, or due to transposon-mediated gene delivery to the brain. Likewise, Core 2 will support studies perturbing the genetic events examined in each project. Additional models will be developed as needed. The models will be provided to project #1 and #2 scientists in age-matched cohorts and of both genders. Specifically, these will be models of glioma and medulloblastoma initiated in mice by transposon delivery of shRNA and cDNAs. A second resource is to provide genetically altered human cancer cell lines for project #1 and #2. These cell lines will harbor loss of function mutations, or specific single nucleotide variants (SNV), in genes of interest. They will be produced using TAL endonuclease or CRISPR/Cas9 gene targeting, without or with oligonucleotide substrates, to create <U+201A><U+00C4><U+00FA>knockout<U+201A><U+00C4><U+00F9> cell lines due to imprecise non-homologous end joining (NHEJ) in the former case, or SNVs via homology directed repair (HDR) in the latter case.","4":"Microenvironment","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645032","2":"Center for Modeling Tumor Cell Migration Mechanics Cell and Whole Animal Genome Engineering","3":"The Cell and Whole Animal Genetic Engineering core will provide both projects with genetically engineered cell lines and mice for analyzing cell and/or tumor behavior under a variety of conditions. The core brings together expertise from two highly trained mouse and somatic cell geneticists, Dr. David Largaespada and Dr. Anindya Bagchi, both with expertise in modeling cancer in mice and with a wide array of cells. Thus, this core will generate two specific resources for both projects #1 and #2. The first is cohorts of mice that reliably develop pancreatic, glioma or medulloblastoma tumors due to the inheritance of germline transgenes, mutant alleles in their endogenous locus, or due to transposon-mediated gene delivery to the brain. Likewise, Core 2 will support studies perturbing the genetic events examined in each project. Additional models will be developed as needed. The models will be provided to project #1 and #2 scientists in age-matched cohorts and of both genders. Specifically, these will be models of glioma and medulloblastoma initiated in mice by transposon delivery of shRNA and cDNAs. A second resource is to provide genetically altered human cancer cell lines for project #1 and #2. These cell lines will harbor loss of function mutations, or specific single nucleotide variants (SNV), in genes of interest. They will be produced using TAL endonuclease or CRISPR/Cas9 gene targeting, without or with oligonucleotide substrates, to create <U+201A><U+00C4><U+00FA>knockout<U+201A><U+00C4><U+00F9> cell lines due to imprecise non-homologous end joining (NHEJ) in the former case, or SNVs via homology directed repair (HDR) in the latter case.","4":"Metastasis","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645032","2":"Center for Modeling Tumor Cell Migration Mechanics Cell and Whole Animal Genome Engineering","3":"The Cell and Whole Animal Genetic Engineering core will provide both projects with genetically engineered cell lines and mice for analyzing cell and/or tumor behavior under a variety of conditions. The core brings together expertise from two highly trained mouse and somatic cell geneticists, Dr. David Largaespada and Dr. Anindya Bagchi, both with expertise in modeling cancer in mice and with a wide array of cells. Thus, this core will generate two specific resources for both projects #1 and #2. The first is cohorts of mice that reliably develop pancreatic, glioma or medulloblastoma tumors due to the inheritance of germline transgenes, mutant alleles in their endogenous locus, or due to transposon-mediated gene delivery to the brain. Likewise, Core 2 will support studies perturbing the genetic events examined in each project. Additional models will be developed as needed. The models will be provided to project #1 and #2 scientists in age-matched cohorts and of both genders. Specifically, these will be models of glioma and medulloblastoma initiated in mice by transposon delivery of shRNA and cDNAs. A second resource is to provide genetically altered human cancer cell lines for project #1 and #2. These cell lines will harbor loss of function mutations, or specific single nucleotide variants (SNV), in genes of interest. They will be produced using TAL endonuclease or CRISPR/Cas9 gene targeting, without or with oligonucleotide substrates, to create <U+201A><U+00C4><U+00FA>knockout<U+201A><U+00C4><U+00F9> cell lines due to imprecise non-homologous end joining (NHEJ) in the former case, or SNVs via homology directed repair (HDR) in the latter case.","4":"Tumor-Immune","5":"Center for Modeling Tumor Cell Migration Mechanics","6":"PS-ON","7":"U54"},{"1":"syn21645033","2":"Liver cancer pre-malignant stiffening","3":"NA","4":"Microenvironment","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645033","2":"Liver cancer pre-malignant stiffening","3":"NA","4":"Evolution","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645033","2":"Liver cancer pre-malignant stiffening","3":"NA","4":"Metastasis","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645034","2":"Can Soft Signals Turn Oncogenic?","3":"In project 2 of Penn PSOC, we test the overall hypothesis (Figure 1), <U+201C>Can Soft Signals Turn Oncogenic?<U+201D> Can persistent <U+201C>soft<U+201D> signals (i.e. triggered through stiffness changes in the extracellular environment and changes in tension/ curvature distribution on the cell membrane) rewire the cell signaling to reflect the hallmarks of cancer in hepatocellular carcinoma (HCC)? The project is a collaboration between physical scientists Ravi Radhakrishnan, Tobias Baumgart, John Crocker, and Cell/Cancer Biologists Wei Guo and Mark Lemmon. The project investigators closely coordinate their studies with the clinical core investigators and the investigators of the theory core.","4":"Microenvironment","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645034","2":"Can Soft Signals Turn Oncogenic?","3":"In project 2 of Penn PSOC, we test the overall hypothesis (Figure 1), <U+201C>Can Soft Signals Turn Oncogenic?<U+201D> Can persistent <U+201C>soft<U+201D> signals (i.e. triggered through stiffness changes in the extracellular environment and changes in tension/ curvature distribution on the cell membrane) rewire the cell signaling to reflect the hallmarks of cancer in hepatocellular carcinoma (HCC)? The project is a collaboration between physical scientists Ravi Radhakrishnan, Tobias Baumgart, John Crocker, and Cell/Cancer Biologists Wei Guo and Mark Lemmon. The project investigators closely coordinate their studies with the clinical core investigators and the investigators of the theory core.","4":"Evolution","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645034","2":"Can Soft Signals Turn Oncogenic?","3":"In project 2 of Penn PSOC, we test the overall hypothesis (Figure 1), <U+201C>Can Soft Signals Turn Oncogenic?<U+201D> Can persistent <U+201C>soft<U+201D> signals (i.e. triggered through stiffness changes in the extracellular environment and changes in tension/ curvature distribution on the cell membrane) rewire the cell signaling to reflect the hallmarks of cancer in hepatocellular carcinoma (HCC)? The project is a collaboration between physical scientists Ravi Radhakrishnan, Tobias Baumgart, John Crocker, and Cell/Cancer Biologists Wei Guo and Mark Lemmon. The project investigators closely coordinate their studies with the clinical core investigators and the investigators of the theory core.","4":"Metastasis","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645035","2":"Nuclear rheology and stability in cancer","3":"Many different types of soft and solid tumors have now been sequenced, and meta-analyses suggest that genomic variation across tumors scales with the stiffness of the tumors<U+2019> tissues of origin. Vogelstein and Tomasetti recently suggested cancer risk scales sub-linearly with the normal rate of stem cell divisions in the tissue of origin, suggesting a key role for DNA replication in mutation processes, and multiple <U+2018>mechanogenomics<U+2019> mechanisms might explain the additional scaling of mutation rate with tissue stiffness. Since stiff solid tissues have higher density of fibrous collagen matrix, which should decrease tissue porosity, processes in proliferation could be affected and so could invasion into stiff tissues as the nucleus is squeezed sufficiently to enhance DNA damage. Although careful analyses continue to be required for rigorous conclusions about such DNA damage, diversification of a cancer genome after constricted migration is now clear in vitro. Understanding genome changes that give rise to neo-antigens is important to selection of cancer cell subpopulations (immunoediting) as well as to the development of immunotherapies. Monocytes/macrophages that might now be engineered to effectively attack cancer cells seem particularly relevant to understanding infiltration into solid tumors and the effects of microenvironment stiffness on genes such as the nuclear lamins.  [Pfiefer CR et al., 2017](https://www.sciencedirect.com/science/article/pii/S245231001730080X?via%3Dihub) [FigM](https://psoc.seas.upenn.edu/wp-content/uploads/2018/04/Mutation-vs-stiffness.jpg) Migration through micron-size constrictions has been seen to rupture the nucleus, release nuclear localized GFP, and cause localized accumulations of ectopic 53BP1<U+2014>a DNA repair protein. Here, constricted migration of two human cancer cell types and primary mesenchymal stem cells (MSCs) increases DNA breaks throughout the nucleoplasm as assessed by endogenous damage markers and by electrophoretic <U+2018><U+2018>comet<U+2019><U+2019> measurements. Migration also causes multiple DNA repair proteins to segregate away from DNA, with cytoplasmic mis-localization sustained for many hours as is relevant to delayed repair. Partial knockdown of repair factors that also regulate chromosome copy numbers is seen to increase DNA breaks in U2OS osteosarcoma cells without affecting migration and with nucleoplasmic patterns of damage similar to constricted migration. Such depletion also causes aberrant levels of DNA. Migration-induced nuclear damage is nonetheless reversible for wild-type and sub-cloned U2OS cells, except for lasting genomic differences between stable clones as revealed by DNA arrays and sequencing. Gains and losses of hundreds of megabases in many chromosomes are typical of the changes and heterogeneity in bone cancer. Phenotypic differences that arise from constricted migration of U2OS clones are further illustrated by a clone with a highly elongated and stable MSC-like shape that depends on microtubule assembly downstream of the transcription factor GATA4. Such changes are consistent with reversion to a more stem-like state upstream of cancerous osteoblastic cells. Migration-induced genomic instability can thus associate with heritable changes. [Irianto J et al., 2017](http://www.cell.com/current-biology/fulltext/S0960-9822(16)31403-8)","4":"Microenvironment","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645035","2":"Nuclear rheology and stability in cancer","3":"Many different types of soft and solid tumors have now been sequenced, and meta-analyses suggest that genomic variation across tumors scales with the stiffness of the tumors<U+2019> tissues of origin. Vogelstein and Tomasetti recently suggested cancer risk scales sub-linearly with the normal rate of stem cell divisions in the tissue of origin, suggesting a key role for DNA replication in mutation processes, and multiple <U+2018>mechanogenomics<U+2019> mechanisms might explain the additional scaling of mutation rate with tissue stiffness. Since stiff solid tissues have higher density of fibrous collagen matrix, which should decrease tissue porosity, processes in proliferation could be affected and so could invasion into stiff tissues as the nucleus is squeezed sufficiently to enhance DNA damage. Although careful analyses continue to be required for rigorous conclusions about such DNA damage, diversification of a cancer genome after constricted migration is now clear in vitro. Understanding genome changes that give rise to neo-antigens is important to selection of cancer cell subpopulations (immunoediting) as well as to the development of immunotherapies. Monocytes/macrophages that might now be engineered to effectively attack cancer cells seem particularly relevant to understanding infiltration into solid tumors and the effects of microenvironment stiffness on genes such as the nuclear lamins.  [Pfiefer CR et al., 2017](https://www.sciencedirect.com/science/article/pii/S245231001730080X?via%3Dihub) [FigM](https://psoc.seas.upenn.edu/wp-content/uploads/2018/04/Mutation-vs-stiffness.jpg) Migration through micron-size constrictions has been seen to rupture the nucleus, release nuclear localized GFP, and cause localized accumulations of ectopic 53BP1<U+2014>a DNA repair protein. Here, constricted migration of two human cancer cell types and primary mesenchymal stem cells (MSCs) increases DNA breaks throughout the nucleoplasm as assessed by endogenous damage markers and by electrophoretic <U+2018><U+2018>comet<U+2019><U+2019> measurements. Migration also causes multiple DNA repair proteins to segregate away from DNA, with cytoplasmic mis-localization sustained for many hours as is relevant to delayed repair. Partial knockdown of repair factors that also regulate chromosome copy numbers is seen to increase DNA breaks in U2OS osteosarcoma cells without affecting migration and with nucleoplasmic patterns of damage similar to constricted migration. Such depletion also causes aberrant levels of DNA. Migration-induced nuclear damage is nonetheless reversible for wild-type and sub-cloned U2OS cells, except for lasting genomic differences between stable clones as revealed by DNA arrays and sequencing. Gains and losses of hundreds of megabases in many chromosomes are typical of the changes and heterogeneity in bone cancer. Phenotypic differences that arise from constricted migration of U2OS clones are further illustrated by a clone with a highly elongated and stable MSC-like shape that depends on microtubule assembly downstream of the transcription factor GATA4. Such changes are consistent with reversion to a more stem-like state upstream of cancerous osteoblastic cells. Migration-induced genomic instability can thus associate with heritable changes. [Irianto J et al., 2017](http://www.cell.com/current-biology/fulltext/S0960-9822(16)31403-8)","4":"Evolution","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645035","2":"Nuclear rheology and stability in cancer","3":"Many different types of soft and solid tumors have now been sequenced, and meta-analyses suggest that genomic variation across tumors scales with the stiffness of the tumors<U+2019> tissues of origin. Vogelstein and Tomasetti recently suggested cancer risk scales sub-linearly with the normal rate of stem cell divisions in the tissue of origin, suggesting a key role for DNA replication in mutation processes, and multiple <U+2018>mechanogenomics<U+2019> mechanisms might explain the additional scaling of mutation rate with tissue stiffness. Since stiff solid tissues have higher density of fibrous collagen matrix, which should decrease tissue porosity, processes in proliferation could be affected and so could invasion into stiff tissues as the nucleus is squeezed sufficiently to enhance DNA damage. Although careful analyses continue to be required for rigorous conclusions about such DNA damage, diversification of a cancer genome after constricted migration is now clear in vitro. Understanding genome changes that give rise to neo-antigens is important to selection of cancer cell subpopulations (immunoediting) as well as to the development of immunotherapies. Monocytes/macrophages that might now be engineered to effectively attack cancer cells seem particularly relevant to understanding infiltration into solid tumors and the effects of microenvironment stiffness on genes such as the nuclear lamins.  [Pfiefer CR et al., 2017](https://www.sciencedirect.com/science/article/pii/S245231001730080X?via%3Dihub) [FigM](https://psoc.seas.upenn.edu/wp-content/uploads/2018/04/Mutation-vs-stiffness.jpg) Migration through micron-size constrictions has been seen to rupture the nucleus, release nuclear localized GFP, and cause localized accumulations of ectopic 53BP1<U+2014>a DNA repair protein. Here, constricted migration of two human cancer cell types and primary mesenchymal stem cells (MSCs) increases DNA breaks throughout the nucleoplasm as assessed by endogenous damage markers and by electrophoretic <U+2018><U+2018>comet<U+2019><U+2019> measurements. Migration also causes multiple DNA repair proteins to segregate away from DNA, with cytoplasmic mis-localization sustained for many hours as is relevant to delayed repair. Partial knockdown of repair factors that also regulate chromosome copy numbers is seen to increase DNA breaks in U2OS osteosarcoma cells without affecting migration and with nucleoplasmic patterns of damage similar to constricted migration. Such depletion also causes aberrant levels of DNA. Migration-induced nuclear damage is nonetheless reversible for wild-type and sub-cloned U2OS cells, except for lasting genomic differences between stable clones as revealed by DNA arrays and sequencing. Gains and losses of hundreds of megabases in many chromosomes are typical of the changes and heterogeneity in bone cancer. Phenotypic differences that arise from constricted migration of U2OS clones are further illustrated by a clone with a highly elongated and stable MSC-like shape that depends on microtubule assembly downstream of the transcription factor GATA4. Such changes are consistent with reversion to a more stem-like state upstream of cancerous osteoblastic cells. Migration-induced genomic instability can thus associate with heritable changes. [Irianto J et al., 2017](http://www.cell.com/current-biology/fulltext/S0960-9822(16)31403-8)","4":"Metastasis","5":"Physical Science Oncology Center at Penn","6":"PS-ON","7":"U54"},{"1":"syn21645036","2":"Evolutionary and ecological dynamics of tumor-host interactions","3":"Cancer is an open and complex adaptive system evolves at is grows. This evolution is driven by phenotypic/genomic plasticity in combination with highly selective microenvironments.  As cancers grow they can, in turn, alter the microenvironment and hence, can influence the trajectory of their own evolutionary dynamics.  These microenvironments occur in spatially distinct regions within tumors that can be characterized as distinct <U+201C>habitats<U+201D>, which can be identified by modern imaging at multiple scales.  The goal of Project 1 is to characterize the evolutionary dynamics using mathematical models informed by multi-scalar imaging and molecular analyses.  The choice of model systems is driven by those with high translational potential, in consultation with Project 2 and the Bench-to-Bedside Core.  We will focus our initial efforts on characterizing the evolutionary dynamics of prostate and breast cancers.  Specifically, both prostate and breast cancers can be effectively treated with anti-hormonal therapies, but in current clinical practice, these approaches inevitably select for resistance.  Forestalling the emergence of resistance using treatments based on evolutionary principles is a goal of the whole PSOC.  In support of current and planned clinical trials, we will generate in vitro and in vivo data from co-cultures of hormone-receptor positive and -negative cells grown in 3-D culture and in mouse xenografts, and use these data to inform models being developed within the B2B core.   In addition, we have identified distinct sub-types of cancer cells that co-exist within prostate cancers that are adapted to growth and survival under distinct microenvironmental conditions of pH and oxygenation.   Importantly, these sub-types have distinct prognostic characteristic, i.e. some are more indolent while others are aggressive and invasive.  We have observed in preliminary in vitro and in vivo studies that the evolutionary trajectory of some cancers can be altered towards a more benign phenotype by subtle microenvironmental perturbations.  Hence, we will continue to investigate these approaches in a broader array of animal models in vivo and 3-D culture system in vitro with the ultimate goal of developing math model-driven clinical trials using this approach.  A substantial effort will be expended to identify clinically achievable biomarkers to predict and monitor response to such approaches.  Finally, in recognition of the fact that the immune system plays a critical role in the establishment and therapeutic response of cancers, we will undertake the above studies in immune competent mouse models and investigate the evolutionary trajectory of immune system components during treatment of the animal patients, and these will be followed up with targeted in vitro studies with isolated immune cells.","4":"Evolution","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645036","2":"Evolutionary and ecological dynamics of tumor-host interactions","3":"Cancer is an open and complex adaptive system evolves at is grows. This evolution is driven by phenotypic/genomic plasticity in combination with highly selective microenvironments.  As cancers grow they can, in turn, alter the microenvironment and hence, can influence the trajectory of their own evolutionary dynamics.  These microenvironments occur in spatially distinct regions within tumors that can be characterized as distinct <U+201C>habitats<U+201D>, which can be identified by modern imaging at multiple scales.  The goal of Project 1 is to characterize the evolutionary dynamics using mathematical models informed by multi-scalar imaging and molecular analyses.  The choice of model systems is driven by those with high translational potential, in consultation with Project 2 and the Bench-to-Bedside Core.  We will focus our initial efforts on characterizing the evolutionary dynamics of prostate and breast cancers.  Specifically, both prostate and breast cancers can be effectively treated with anti-hormonal therapies, but in current clinical practice, these approaches inevitably select for resistance.  Forestalling the emergence of resistance using treatments based on evolutionary principles is a goal of the whole PSOC.  In support of current and planned clinical trials, we will generate in vitro and in vivo data from co-cultures of hormone-receptor positive and -negative cells grown in 3-D culture and in mouse xenografts, and use these data to inform models being developed within the B2B core.   In addition, we have identified distinct sub-types of cancer cells that co-exist within prostate cancers that are adapted to growth and survival under distinct microenvironmental conditions of pH and oxygenation.   Importantly, these sub-types have distinct prognostic characteristic, i.e. some are more indolent while others are aggressive and invasive.  We have observed in preliminary in vitro and in vivo studies that the evolutionary trajectory of some cancers can be altered towards a more benign phenotype by subtle microenvironmental perturbations.  Hence, we will continue to investigate these approaches in a broader array of animal models in vivo and 3-D culture system in vitro with the ultimate goal of developing math model-driven clinical trials using this approach.  A substantial effort will be expended to identify clinically achievable biomarkers to predict and monitor response to such approaches.  Finally, in recognition of the fact that the immune system plays a critical role in the establishment and therapeutic response of cancers, we will undertake the above studies in immune competent mouse models and investigate the evolutionary trajectory of immune system components during treatment of the animal patients, and these will be followed up with targeted in vitro studies with isolated immune cells.","4":"Drug Resistance/Sensitivity","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645036","2":"Evolutionary and ecological dynamics of tumor-host interactions","3":"Cancer is an open and complex adaptive system evolves at is grows. This evolution is driven by phenotypic/genomic plasticity in combination with highly selective microenvironments.  As cancers grow they can, in turn, alter the microenvironment and hence, can influence the trajectory of their own evolutionary dynamics.  These microenvironments occur in spatially distinct regions within tumors that can be characterized as distinct <U+201C>habitats<U+201D>, which can be identified by modern imaging at multiple scales.  The goal of Project 1 is to characterize the evolutionary dynamics using mathematical models informed by multi-scalar imaging and molecular analyses.  The choice of model systems is driven by those with high translational potential, in consultation with Project 2 and the Bench-to-Bedside Core.  We will focus our initial efforts on characterizing the evolutionary dynamics of prostate and breast cancers.  Specifically, both prostate and breast cancers can be effectively treated with anti-hormonal therapies, but in current clinical practice, these approaches inevitably select for resistance.  Forestalling the emergence of resistance using treatments based on evolutionary principles is a goal of the whole PSOC.  In support of current and planned clinical trials, we will generate in vitro and in vivo data from co-cultures of hormone-receptor positive and -negative cells grown in 3-D culture and in mouse xenografts, and use these data to inform models being developed within the B2B core.   In addition, we have identified distinct sub-types of cancer cells that co-exist within prostate cancers that are adapted to growth and survival under distinct microenvironmental conditions of pH and oxygenation.   Importantly, these sub-types have distinct prognostic characteristic, i.e. some are more indolent while others are aggressive and invasive.  We have observed in preliminary in vitro and in vivo studies that the evolutionary trajectory of some cancers can be altered towards a more benign phenotype by subtle microenvironmental perturbations.  Hence, we will continue to investigate these approaches in a broader array of animal models in vivo and 3-D culture system in vitro with the ultimate goal of developing math model-driven clinical trials using this approach.  A substantial effort will be expended to identify clinically achievable biomarkers to predict and monitor response to such approaches.  Finally, in recognition of the fact that the immune system plays a critical role in the establishment and therapeutic response of cancers, we will undertake the above studies in immune competent mouse models and investigate the evolutionary trajectory of immune system components during treatment of the animal patients, and these will be followed up with targeted in vitro studies with isolated immune cells.","4":"Microenvironment","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645036","2":"Evolutionary and ecological dynamics of tumor-host interactions","3":"Cancer is an open and complex adaptive system evolves at is grows. This evolution is driven by phenotypic/genomic plasticity in combination with highly selective microenvironments.  As cancers grow they can, in turn, alter the microenvironment and hence, can influence the trajectory of their own evolutionary dynamics.  These microenvironments occur in spatially distinct regions within tumors that can be characterized as distinct <U+201C>habitats<U+201D>, which can be identified by modern imaging at multiple scales.  The goal of Project 1 is to characterize the evolutionary dynamics using mathematical models informed by multi-scalar imaging and molecular analyses.  The choice of model systems is driven by those with high translational potential, in consultation with Project 2 and the Bench-to-Bedside Core.  We will focus our initial efforts on characterizing the evolutionary dynamics of prostate and breast cancers.  Specifically, both prostate and breast cancers can be effectively treated with anti-hormonal therapies, but in current clinical practice, these approaches inevitably select for resistance.  Forestalling the emergence of resistance using treatments based on evolutionary principles is a goal of the whole PSOC.  In support of current and planned clinical trials, we will generate in vitro and in vivo data from co-cultures of hormone-receptor positive and -negative cells grown in 3-D culture and in mouse xenografts, and use these data to inform models being developed within the B2B core.   In addition, we have identified distinct sub-types of cancer cells that co-exist within prostate cancers that are adapted to growth and survival under distinct microenvironmental conditions of pH and oxygenation.   Importantly, these sub-types have distinct prognostic characteristic, i.e. some are more indolent while others are aggressive and invasive.  We have observed in preliminary in vitro and in vivo studies that the evolutionary trajectory of some cancers can be altered towards a more benign phenotype by subtle microenvironmental perturbations.  Hence, we will continue to investigate these approaches in a broader array of animal models in vivo and 3-D culture system in vitro with the ultimate goal of developing math model-driven clinical trials using this approach.  A substantial effort will be expended to identify clinically achievable biomarkers to predict and monitor response to such approaches.  Finally, in recognition of the fact that the immune system plays a critical role in the establishment and therapeutic response of cancers, we will undertake the above studies in immune competent mouse models and investigate the evolutionary trajectory of immune system components during treatment of the animal patients, and these will be followed up with targeted in vitro studies with isolated immune cells.","4":"Tumor-Immune","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645037","2":"Clinical translation","3":"In the Moffitt PSOC, we view cancer as an open complex adaptive system that can be characterized using necessary and sufficient data, eco-evolutionary first principles and sophisticated computational methods. In Project 2, we examine the clinical application of that conceptual model. Here, we will build computational models of the system dynamics in individual cancer patients undergoing therapy with the ultimate goal of using those models to optimize the outcomes of increasingly complex cancer treatments   We will focus our initial efforts on three active clinical trials in different tumors (multiple myeloma, prostate cancer and glioblastoma) treated with three different therapeutic strategies (multidrug chemotherapy, hormonal treatment, and immunotherapy). In each trial a multidisciplinary team will develop a patient-specific computational model of the intratumoral evolutionary and ecological dynamics, based on available clinical data, which govern response and resistance to therapy in each patient. Using an iterative approach, each team will work with the Bench-to-Bedside (B2B) core and Project 1 to optimize the models<U+2019> predictive power by exploring alternative mathematical methods and inclusion of novel data elements from each trial (e.g. molecular analysis of primary tumors and circulating tumor cells). In follow-on trials using the same tumors and treatment strategies, we will both validate model predictions and apply variations in the treatment approaches (or combinations of approaches) suggested by pre-clinical experiments in Project 1 and model simulations in the B2B core.  Finally, we will develop the infrastructure necessary to develop and oversee evolutionarily-informed, computationally guided clinical trials at Moffitt.","4":"Evolution","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645037","2":"Clinical translation","3":"In the Moffitt PSOC, we view cancer as an open complex adaptive system that can be characterized using necessary and sufficient data, eco-evolutionary first principles and sophisticated computational methods. In Project 2, we examine the clinical application of that conceptual model. Here, we will build computational models of the system dynamics in individual cancer patients undergoing therapy with the ultimate goal of using those models to optimize the outcomes of increasingly complex cancer treatments   We will focus our initial efforts on three active clinical trials in different tumors (multiple myeloma, prostate cancer and glioblastoma) treated with three different therapeutic strategies (multidrug chemotherapy, hormonal treatment, and immunotherapy). In each trial a multidisciplinary team will develop a patient-specific computational model of the intratumoral evolutionary and ecological dynamics, based on available clinical data, which govern response and resistance to therapy in each patient. Using an iterative approach, each team will work with the Bench-to-Bedside (B2B) core and Project 1 to optimize the models<U+2019> predictive power by exploring alternative mathematical methods and inclusion of novel data elements from each trial (e.g. molecular analysis of primary tumors and circulating tumor cells). In follow-on trials using the same tumors and treatment strategies, we will both validate model predictions and apply variations in the treatment approaches (or combinations of approaches) suggested by pre-clinical experiments in Project 1 and model simulations in the B2B core.  Finally, we will develop the infrastructure necessary to develop and oversee evolutionarily-informed, computationally guided clinical trials at Moffitt.","4":"Drug Resistance/Sensitivity","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645037","2":"Clinical translation","3":"In the Moffitt PSOC, we view cancer as an open complex adaptive system that can be characterized using necessary and sufficient data, eco-evolutionary first principles and sophisticated computational methods. In Project 2, we examine the clinical application of that conceptual model. Here, we will build computational models of the system dynamics in individual cancer patients undergoing therapy with the ultimate goal of using those models to optimize the outcomes of increasingly complex cancer treatments   We will focus our initial efforts on three active clinical trials in different tumors (multiple myeloma, prostate cancer and glioblastoma) treated with three different therapeutic strategies (multidrug chemotherapy, hormonal treatment, and immunotherapy). In each trial a multidisciplinary team will develop a patient-specific computational model of the intratumoral evolutionary and ecological dynamics, based on available clinical data, which govern response and resistance to therapy in each patient. Using an iterative approach, each team will work with the Bench-to-Bedside (B2B) core and Project 1 to optimize the models<U+2019> predictive power by exploring alternative mathematical methods and inclusion of novel data elements from each trial (e.g. molecular analysis of primary tumors and circulating tumor cells). In follow-on trials using the same tumors and treatment strategies, we will both validate model predictions and apply variations in the treatment approaches (or combinations of approaches) suggested by pre-clinical experiments in Project 1 and model simulations in the B2B core.  Finally, we will develop the infrastructure necessary to develop and oversee evolutionarily-informed, computationally guided clinical trials at Moffitt.","4":"Microenvironment","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645037","2":"Clinical translation","3":"In the Moffitt PSOC, we view cancer as an open complex adaptive system that can be characterized using necessary and sufficient data, eco-evolutionary first principles and sophisticated computational methods. In Project 2, we examine the clinical application of that conceptual model. Here, we will build computational models of the system dynamics in individual cancer patients undergoing therapy with the ultimate goal of using those models to optimize the outcomes of increasingly complex cancer treatments   We will focus our initial efforts on three active clinical trials in different tumors (multiple myeloma, prostate cancer and glioblastoma) treated with three different therapeutic strategies (multidrug chemotherapy, hormonal treatment, and immunotherapy). In each trial a multidisciplinary team will develop a patient-specific computational model of the intratumoral evolutionary and ecological dynamics, based on available clinical data, which govern response and resistance to therapy in each patient. Using an iterative approach, each team will work with the Bench-to-Bedside (B2B) core and Project 1 to optimize the models<U+2019> predictive power by exploring alternative mathematical methods and inclusion of novel data elements from each trial (e.g. molecular analysis of primary tumors and circulating tumor cells). In follow-on trials using the same tumors and treatment strategies, we will both validate model predictions and apply variations in the treatment approaches (or combinations of approaches) suggested by pre-clinical experiments in Project 1 and model simulations in the B2B core.  Finally, we will develop the infrastructure necessary to develop and oversee evolutionarily-informed, computationally guided clinical trials at Moffitt.","4":"Tumor-Immune","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645038","2":"H Lee Moffitt Cancer Center and Research Institute: Bench-to-Bedside","3":"The process of using mechanistic models to assist with understanding experimental results and informing clinical decisions depends on a suitable framework for developing, analyzing, implementing, adjusting and presenting the models and results. Furthermore, models must be calibrated so that they recapitulate experimental and clinical observations both in terms of their range of behavior as well as the intrinsic variability of outcomes before they can be used to specifically impact one or more clinical decisions (e.g. predict novel treatment strategies). There is also a practical aspect of turning theoretical predictions into actionable clinical decisions that requires tools to generate patient cohorts, mimic clinical trials and present results in a visual and easy to use manner such that clinicians can immediately understand and manipulate them. The central focus of the Bench-to-Bedside Core is therefore to integrate experiments, clinical data, and models to assist with hypothesis generation, testing, and validation (Project 1), and translate successes into a clinical setting using clinically-relevant tools (Project 2). This will be accomplished through: Core models that explore unifying principles of evolution, heterogeneity, and response to treatment; Core tools, Radiomics, Pathomics, and a generalized set of analysis tools for integrating experimental and clinical data to facilitate mathematical model development and calibration; Core decision support tools including Phase i trials and dynamically optimized therapy for use in clinical trials. The tools and methods we develop here are generalized and therefore suitable to a wider class of experimental and clinical data and will serve as a key legacy from this project to drive bench-to-beside science.","4":"Evolution","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645038","2":"H Lee Moffitt Cancer Center and Research Institute: Bench-to-Bedside","3":"The process of using mechanistic models to assist with understanding experimental results and informing clinical decisions depends on a suitable framework for developing, analyzing, implementing, adjusting and presenting the models and results. Furthermore, models must be calibrated so that they recapitulate experimental and clinical observations both in terms of their range of behavior as well as the intrinsic variability of outcomes before they can be used to specifically impact one or more clinical decisions (e.g. predict novel treatment strategies). There is also a practical aspect of turning theoretical predictions into actionable clinical decisions that requires tools to generate patient cohorts, mimic clinical trials and present results in a visual and easy to use manner such that clinicians can immediately understand and manipulate them. The central focus of the Bench-to-Bedside Core is therefore to integrate experiments, clinical data, and models to assist with hypothesis generation, testing, and validation (Project 1), and translate successes into a clinical setting using clinically-relevant tools (Project 2). This will be accomplished through: Core models that explore unifying principles of evolution, heterogeneity, and response to treatment; Core tools, Radiomics, Pathomics, and a generalized set of analysis tools for integrating experimental and clinical data to facilitate mathematical model development and calibration; Core decision support tools including Phase i trials and dynamically optimized therapy for use in clinical trials. The tools and methods we develop here are generalized and therefore suitable to a wider class of experimental and clinical data and will serve as a key legacy from this project to drive bench-to-beside science.","4":"Drug Resistance/Sensitivity","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645038","2":"H Lee Moffitt Cancer Center and Research Institute: Bench-to-Bedside","3":"The process of using mechanistic models to assist with understanding experimental results and informing clinical decisions depends on a suitable framework for developing, analyzing, implementing, adjusting and presenting the models and results. Furthermore, models must be calibrated so that they recapitulate experimental and clinical observations both in terms of their range of behavior as well as the intrinsic variability of outcomes before they can be used to specifically impact one or more clinical decisions (e.g. predict novel treatment strategies). There is also a practical aspect of turning theoretical predictions into actionable clinical decisions that requires tools to generate patient cohorts, mimic clinical trials and present results in a visual and easy to use manner such that clinicians can immediately understand and manipulate them. The central focus of the Bench-to-Bedside Core is therefore to integrate experiments, clinical data, and models to assist with hypothesis generation, testing, and validation (Project 1), and translate successes into a clinical setting using clinically-relevant tools (Project 2). This will be accomplished through: Core models that explore unifying principles of evolution, heterogeneity, and response to treatment; Core tools, Radiomics, Pathomics, and a generalized set of analysis tools for integrating experimental and clinical data to facilitate mathematical model development and calibration; Core decision support tools including Phase i trials and dynamically optimized therapy for use in clinical trials. The tools and methods we develop here are generalized and therefore suitable to a wider class of experimental and clinical data and will serve as a key legacy from this project to drive bench-to-beside science.","4":"Microenvironment","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645038","2":"H Lee Moffitt Cancer Center and Research Institute: Bench-to-Bedside","3":"The process of using mechanistic models to assist with understanding experimental results and informing clinical decisions depends on a suitable framework for developing, analyzing, implementing, adjusting and presenting the models and results. Furthermore, models must be calibrated so that they recapitulate experimental and clinical observations both in terms of their range of behavior as well as the intrinsic variability of outcomes before they can be used to specifically impact one or more clinical decisions (e.g. predict novel treatment strategies). There is also a practical aspect of turning theoretical predictions into actionable clinical decisions that requires tools to generate patient cohorts, mimic clinical trials and present results in a visual and easy to use manner such that clinicians can immediately understand and manipulate them. The central focus of the Bench-to-Bedside Core is therefore to integrate experiments, clinical data, and models to assist with hypothesis generation, testing, and validation (Project 1), and translate successes into a clinical setting using clinically-relevant tools (Project 2). This will be accomplished through: Core models that explore unifying principles of evolution, heterogeneity, and response to treatment; Core tools, Radiomics, Pathomics, and a generalized set of analysis tools for integrating experimental and clinical data to facilitate mathematical model development and calibration; Core decision support tools including Phase i trials and dynamically optimized therapy for use in clinical trials. The tools and methods we develop here are generalized and therefore suitable to a wider class of experimental and clinical data and will serve as a key legacy from this project to drive bench-to-beside science.","4":"Tumor-Immune","5":"H Lee Moffitt Cancer Center and Research Institute","6":"PS-ON","7":"U54"},{"1":"syn21645039","2":"Developing a Mathematical Framework to Uncover the Sequence of Genetic Events during Tumor Development","3":"The recognition of cancer as a disease caused by the accumulation of genetic alterations has motivated large-scale efforts to annotate the cancer genome for all human cancers. Of special importance are changes that occur early during malignant transformation since they may result in oncogene addiction and represent promising targets for therapeutic intervention. In this project, we will link these emerging, large cross-sectional datasets with a novel mathematical model to predict the sequence of genetic events during tumorigenesis and then apply it to genomic datasets for primary glioblastoma, predict the sequence of associated genetic events, and examine in mice how the sequence of these genetic events affects tumor formation.","4":"Evolution","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645039","2":"Developing a Mathematical Framework to Uncover the Sequence of Genetic Events during Tumor Development","3":"The recognition of cancer as a disease caused by the accumulation of genetic alterations has motivated large-scale efforts to annotate the cancer genome for all human cancers. Of special importance are changes that occur early during malignant transformation since they may result in oncogene addiction and represent promising targets for therapeutic intervention. In this project, we will link these emerging, large cross-sectional datasets with a novel mathematical model to predict the sequence of genetic events during tumorigenesis and then apply it to genomic datasets for primary glioblastoma, predict the sequence of associated genetic events, and examine in mice how the sequence of these genetic events affects tumor formation.","4":"Drug Resistance/Sensitivity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645039","2":"Developing a Mathematical Framework to Uncover the Sequence of Genetic Events during Tumor Development","3":"The recognition of cancer as a disease caused by the accumulation of genetic alterations has motivated large-scale efforts to annotate the cancer genome for all human cancers. Of special importance are changes that occur early during malignant transformation since they may result in oncogene addiction and represent promising targets for therapeutic intervention. In this project, we will link these emerging, large cross-sectional datasets with a novel mathematical model to predict the sequence of genetic events during tumorigenesis and then apply it to genomic datasets for primary glioblastoma, predict the sequence of associated genetic events, and examine in mice how the sequence of these genetic events affects tumor formation.","4":"Microenvironment","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645039","2":"Developing a Mathematical Framework to Uncover the Sequence of Genetic Events during Tumor Development","3":"The recognition of cancer as a disease caused by the accumulation of genetic alterations has motivated large-scale efforts to annotate the cancer genome for all human cancers. Of special importance are changes that occur early during malignant transformation since they may result in oncogene addiction and represent promising targets for therapeutic intervention. In this project, we will link these emerging, large cross-sectional datasets with a novel mathematical model to predict the sequence of genetic events during tumorigenesis and then apply it to genomic datasets for primary glioblastoma, predict the sequence of associated genetic events, and examine in mice how the sequence of these genetic events affects tumor formation.","4":"Heterogeneity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645040","2":"The Cell-of-Origin of Human Cancers","3":"Although knowledge of the target of transformation is important for an understanding of the natural history of cancers and has therapeutic implications, the cell of origin of most cancers is still unknown. In this project, we aim to design mathematical frameworks to investigate the cell of origin of Myeloproliferative Neoplasms (MPNs) as well as PDGF-driven gliomas, and validate the predictions and further refine the mathematical model with data derived from murine models of MPNs and glioma which allow for expression of the known pathogenic mutations in the appropriate stem/progenitor cell compartments. These interdisciplinary approaches will enable us to identify the cell of origin of MPN and glioma and will also have relevance to other tumor types arising in tissues that are organized as a differentiation hierarchy.","4":"Evolution","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645040","2":"The Cell-of-Origin of Human Cancers","3":"Although knowledge of the target of transformation is important for an understanding of the natural history of cancers and has therapeutic implications, the cell of origin of most cancers is still unknown. In this project, we aim to design mathematical frameworks to investigate the cell of origin of Myeloproliferative Neoplasms (MPNs) as well as PDGF-driven gliomas, and validate the predictions and further refine the mathematical model with data derived from murine models of MPNs and glioma which allow for expression of the known pathogenic mutations in the appropriate stem/progenitor cell compartments. These interdisciplinary approaches will enable us to identify the cell of origin of MPN and glioma and will also have relevance to other tumor types arising in tissues that are organized as a differentiation hierarchy.","4":"Drug Resistance/Sensitivity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645040","2":"The Cell-of-Origin of Human Cancers","3":"Although knowledge of the target of transformation is important for an understanding of the natural history of cancers and has therapeutic implications, the cell of origin of most cancers is still unknown. In this project, we aim to design mathematical frameworks to investigate the cell of origin of Myeloproliferative Neoplasms (MPNs) as well as PDGF-driven gliomas, and validate the predictions and further refine the mathematical model with data derived from murine models of MPNs and glioma which allow for expression of the known pathogenic mutations in the appropriate stem/progenitor cell compartments. These interdisciplinary approaches will enable us to identify the cell of origin of MPN and glioma and will also have relevance to other tumor types arising in tissues that are organized as a differentiation hierarchy.","4":"Microenvironment","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645040","2":"The Cell-of-Origin of Human Cancers","3":"Although knowledge of the target of transformation is important for an understanding of the natural history of cancers and has therapeutic implications, the cell of origin of most cancers is still unknown. In this project, we aim to design mathematical frameworks to investigate the cell of origin of Myeloproliferative Neoplasms (MPNs) as well as PDGF-driven gliomas, and validate the predictions and further refine the mathematical model with data derived from murine models of MPNs and glioma which allow for expression of the known pathogenic mutations in the appropriate stem/progenitor cell compartments. These interdisciplinary approaches will enable us to identify the cell of origin of MPN and glioma and will also have relevance to other tumor types arising in tissues that are organized as a differentiation hierarchy.","4":"Heterogeneity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645041","2":"Novel Tools to Predict and Prevent the Emergence of Resistance against Targeted Drugs and Radiation Therapy.","3":"Since acquired resistance to either targeted or radiation therapies represent severe limitations, and since existing treatment schedules were established empirically, we propose an interdisciplinary approach utilizing mathematical modeling and unique experimental systems to predict and prevent the emergence of resistance against targeted drugs and radiation therapy. We will develop a mathematical framework for the general scenario of drug resistance emerging during therapy with targeted drugs, apply the models to minimize the risk of resistance to EGFR tyrosine kinase inhibitors in lung cancer, using quantitative measurements obtained from appropriate isogenic cell lines and in vivo transgenic lung tumor models, and apply the models to minimize the risk of resistance to radiation in medulloblastoma, using quantitative measurements obtained from a novel transgenic mouse model. Collectively, these studies are expected to lead to the rational design of clinical trials to prevent the emergence of resistance in patients treated with targeted drugs or radiation therapy.","4":"Evolution","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645041","2":"Novel Tools to Predict and Prevent the Emergence of Resistance against Targeted Drugs and Radiation Therapy.","3":"Since acquired resistance to either targeted or radiation therapies represent severe limitations, and since existing treatment schedules were established empirically, we propose an interdisciplinary approach utilizing mathematical modeling and unique experimental systems to predict and prevent the emergence of resistance against targeted drugs and radiation therapy. We will develop a mathematical framework for the general scenario of drug resistance emerging during therapy with targeted drugs, apply the models to minimize the risk of resistance to EGFR tyrosine kinase inhibitors in lung cancer, using quantitative measurements obtained from appropriate isogenic cell lines and in vivo transgenic lung tumor models, and apply the models to minimize the risk of resistance to radiation in medulloblastoma, using quantitative measurements obtained from a novel transgenic mouse model. Collectively, these studies are expected to lead to the rational design of clinical trials to prevent the emergence of resistance in patients treated with targeted drugs or radiation therapy.","4":"Drug Resistance/Sensitivity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645041","2":"Novel Tools to Predict and Prevent the Emergence of Resistance against Targeted Drugs and Radiation Therapy.","3":"Since acquired resistance to either targeted or radiation therapies represent severe limitations, and since existing treatment schedules were established empirically, we propose an interdisciplinary approach utilizing mathematical modeling and unique experimental systems to predict and prevent the emergence of resistance against targeted drugs and radiation therapy. We will develop a mathematical framework for the general scenario of drug resistance emerging during therapy with targeted drugs, apply the models to minimize the risk of resistance to EGFR tyrosine kinase inhibitors in lung cancer, using quantitative measurements obtained from appropriate isogenic cell lines and in vivo transgenic lung tumor models, and apply the models to minimize the risk of resistance to radiation in medulloblastoma, using quantitative measurements obtained from a novel transgenic mouse model. Collectively, these studies are expected to lead to the rational design of clinical trials to prevent the emergence of resistance in patients treated with targeted drugs or radiation therapy.","4":"Microenvironment","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645041","2":"Novel Tools to Predict and Prevent the Emergence of Resistance against Targeted Drugs and Radiation Therapy.","3":"Since acquired resistance to either targeted or radiation therapies represent severe limitations, and since existing treatment schedules were established empirically, we propose an interdisciplinary approach utilizing mathematical modeling and unique experimental systems to predict and prevent the emergence of resistance against targeted drugs and radiation therapy. We will develop a mathematical framework for the general scenario of drug resistance emerging during therapy with targeted drugs, apply the models to minimize the risk of resistance to EGFR tyrosine kinase inhibitors in lung cancer, using quantitative measurements obtained from appropriate isogenic cell lines and in vivo transgenic lung tumor models, and apply the models to minimize the risk of resistance to radiation in medulloblastoma, using quantitative measurements obtained from a novel transgenic mouse model. Collectively, these studies are expected to lead to the rational design of clinical trials to prevent the emergence of resistance in patients treated with targeted drugs or radiation therapy.","4":"Heterogeneity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645042","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center: Single cell phospho-profiling core facility","3":"Dr. Fan anticipates developing five single cell platforms to facilitate all three projects in the DFCI PSOC. These platforms include:\\n \\n1). single cell secretomic profiling\\n2). single cell phospho-protein profiling\\n3). single cell whole genome amplification\\n4). single cell epigenome amplification\\n5). high-content laser imaging cytometry\\n \\nIn addition, the core will be equipped with the state-of-the-art single cell analysis tools such as flow cytometer and motorized fluorescence microscope. These platforms together will enable a suite of functional evaluation ranging from genomics, epigenomics to proteomics of single primary tumor cells and examine phenotypic variability, functional state of activation and/or the response to drugs in heterogeneous populations of cells. For example, they will provide approaches to measure phospho-profiles of drug-sensitive pathways (e.g. EGFR), downstream signaling cascades (e.g. AKT and MAPK pathways), cell-cycle phases, and apoptotic response at the single cell level. Special emphasis is given to quantification of parameters for the dynamics of tumor cell proliferation and death (e.g. during drug treatment with varying concentration). This core contributes to the PS-OC by providing quantitative measurements that parameterize cellular fitness (as a convolution of cell cycle and apoptosis dynamics) and signaling events in colorectal/gliomaneurospheres/leukemia lines of the relevant genotypes; these measurements are then inserted into the modeling framework of the PS-OC. To achieve these core's objectives (i.e. to establish a facility dedicated to providing quantitative measurements of cancer growth, signaling, and response to drugs in single-cell resolution for animal and cell line models of tumorigenesis), we 1) establish validated quantitative measurements of proliferation and death rates of primary tumors and associated molecular signatures; 2) provide single-cell resolution of the variability of cellular signaling response during varying conditions (such as exposure to growth factors, cytokines, drugs, radiation therapy etc); and 3) establish systematic protocols to test the drug response of primary tumor cells.","4":"Evolution","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645042","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center: Single cell phospho-profiling core facility","3":"Dr. Fan anticipates developing five single cell platforms to facilitate all three projects in the DFCI PSOC. These platforms include:\\n \\n1). single cell secretomic profiling\\n2). single cell phospho-protein profiling\\n3). single cell whole genome amplification\\n4). single cell epigenome amplification\\n5). high-content laser imaging cytometry\\n \\nIn addition, the core will be equipped with the state-of-the-art single cell analysis tools such as flow cytometer and motorized fluorescence microscope. These platforms together will enable a suite of functional evaluation ranging from genomics, epigenomics to proteomics of single primary tumor cells and examine phenotypic variability, functional state of activation and/or the response to drugs in heterogeneous populations of cells. For example, they will provide approaches to measure phospho-profiles of drug-sensitive pathways (e.g. EGFR), downstream signaling cascades (e.g. AKT and MAPK pathways), cell-cycle phases, and apoptotic response at the single cell level. Special emphasis is given to quantification of parameters for the dynamics of tumor cell proliferation and death (e.g. during drug treatment with varying concentration). This core contributes to the PS-OC by providing quantitative measurements that parameterize cellular fitness (as a convolution of cell cycle and apoptosis dynamics) and signaling events in colorectal/gliomaneurospheres/leukemia lines of the relevant genotypes; these measurements are then inserted into the modeling framework of the PS-OC. To achieve these core's objectives (i.e. to establish a facility dedicated to providing quantitative measurements of cancer growth, signaling, and response to drugs in single-cell resolution for animal and cell line models of tumorigenesis), we 1) establish validated quantitative measurements of proliferation and death rates of primary tumors and associated molecular signatures; 2) provide single-cell resolution of the variability of cellular signaling response during varying conditions (such as exposure to growth factors, cytokines, drugs, radiation therapy etc); and 3) establish systematic protocols to test the drug response of primary tumor cells.","4":"Drug Resistance/Sensitivity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645042","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center: Single cell phospho-profiling core facility","3":"Dr. Fan anticipates developing five single cell platforms to facilitate all three projects in the DFCI PSOC. These platforms include:\\n \\n1). single cell secretomic profiling\\n2). single cell phospho-protein profiling\\n3). single cell whole genome amplification\\n4). single cell epigenome amplification\\n5). high-content laser imaging cytometry\\n \\nIn addition, the core will be equipped with the state-of-the-art single cell analysis tools such as flow cytometer and motorized fluorescence microscope. These platforms together will enable a suite of functional evaluation ranging from genomics, epigenomics to proteomics of single primary tumor cells and examine phenotypic variability, functional state of activation and/or the response to drugs in heterogeneous populations of cells. For example, they will provide approaches to measure phospho-profiles of drug-sensitive pathways (e.g. EGFR), downstream signaling cascades (e.g. AKT and MAPK pathways), cell-cycle phases, and apoptotic response at the single cell level. Special emphasis is given to quantification of parameters for the dynamics of tumor cell proliferation and death (e.g. during drug treatment with varying concentration). This core contributes to the PS-OC by providing quantitative measurements that parameterize cellular fitness (as a convolution of cell cycle and apoptosis dynamics) and signaling events in colorectal/gliomaneurospheres/leukemia lines of the relevant genotypes; these measurements are then inserted into the modeling framework of the PS-OC. To achieve these core's objectives (i.e. to establish a facility dedicated to providing quantitative measurements of cancer growth, signaling, and response to drugs in single-cell resolution for animal and cell line models of tumorigenesis), we 1) establish validated quantitative measurements of proliferation and death rates of primary tumors and associated molecular signatures; 2) provide single-cell resolution of the variability of cellular signaling response during varying conditions (such as exposure to growth factors, cytokines, drugs, radiation therapy etc); and 3) establish systematic protocols to test the drug response of primary tumor cells.","4":"Microenvironment","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645042","2":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center: Single cell phospho-profiling core facility","3":"Dr. Fan anticipates developing five single cell platforms to facilitate all three projects in the DFCI PSOC. These platforms include:\\n \\n1). single cell secretomic profiling\\n2). single cell phospho-protein profiling\\n3). single cell whole genome amplification\\n4). single cell epigenome amplification\\n5). high-content laser imaging cytometry\\n \\nIn addition, the core will be equipped with the state-of-the-art single cell analysis tools such as flow cytometer and motorized fluorescence microscope. These platforms together will enable a suite of functional evaluation ranging from genomics, epigenomics to proteomics of single primary tumor cells and examine phenotypic variability, functional state of activation and/or the response to drugs in heterogeneous populations of cells. For example, they will provide approaches to measure phospho-profiles of drug-sensitive pathways (e.g. EGFR), downstream signaling cascades (e.g. AKT and MAPK pathways), cell-cycle phases, and apoptotic response at the single cell level. Special emphasis is given to quantification of parameters for the dynamics of tumor cell proliferation and death (e.g. during drug treatment with varying concentration). This core contributes to the PS-OC by providing quantitative measurements that parameterize cellular fitness (as a convolution of cell cycle and apoptosis dynamics) and signaling events in colorectal/gliomaneurospheres/leukemia lines of the relevant genotypes; these measurements are then inserted into the modeling framework of the PS-OC. To achieve these core's objectives (i.e. to establish a facility dedicated to providing quantitative measurements of cancer growth, signaling, and response to drugs in single-cell resolution for animal and cell line models of tumorigenesis), we 1) establish validated quantitative measurements of proliferation and death rates of primary tumors and associated molecular signatures; 2) provide single-cell resolution of the variability of cellular signaling response during varying conditions (such as exposure to growth factors, cytokines, drugs, radiation therapy etc); and 3) establish systematic protocols to test the drug response of primary tumor cells.","4":"Heterogeneity","5":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","6":"PS-ON","7":"U54"},{"1":"syn21645043","2":"Modeling tumor evolution in mouse and organoid models.","3":"In previous work at Columbia University Medical Center, we developed a reductionist model system for investigating clonal histories and demonstrated its feasibility for tracing clonal evolution. Preliminary studies showed that multi-color lineage-tracing can be used to follow clonal fates in genetically-engineered mouse models of prostate cancer, and that a novel organoid culture approach, in which three-dimensional buds of organs are grown in the laboratory, can be used to assess clonal growth and response to therapy across multiple time points. In ongoing work at the Center, we will combine such approaches with single-cell transcriptome analyses of tumor heterogeneity. This project has **three specific aims**: \\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Confetti-image-1.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Confetti-image-1.jpg)\\n&nbsp;\\n1. Investigation of clonal evolution during tissue homeostasis and regeneration. We are using multi-color lineage-tracing and organoid culture to follow clonal histories.\\n2. Analysis of clonal evolution during cancer progression. We are using multi-color lineage tracing in mouse models of prostate cancer together with organoid culture for longitudinal analyses, with data analyzed by single-cell transcriptomics and mathematical modeling.\\n3. Investigation of the clonal response to therapy. This involves longitudinal analyses of clonal evolution in organoid culture after drug treatments.\\n&nbsp;\\nThese studies will be greatly facilitated by the analyses of evolutionary moduli spaces and topological data analyses performed in collaboration with the Mathematical Core, as well as by interactions with Projects 2 and 3.","4":"Heterogeneity","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645043","2":"Modeling tumor evolution in mouse and organoid models.","3":"In previous work at Columbia University Medical Center, we developed a reductionist model system for investigating clonal histories and demonstrated its feasibility for tracing clonal evolution. Preliminary studies showed that multi-color lineage-tracing can be used to follow clonal fates in genetically-engineered mouse models of prostate cancer, and that a novel organoid culture approach, in which three-dimensional buds of organs are grown in the laboratory, can be used to assess clonal growth and response to therapy across multiple time points. In ongoing work at the Center, we will combine such approaches with single-cell transcriptome analyses of tumor heterogeneity. This project has **three specific aims**: \\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Confetti-image-1.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Confetti-image-1.jpg)\\n&nbsp;\\n1. Investigation of clonal evolution during tissue homeostasis and regeneration. We are using multi-color lineage-tracing and organoid culture to follow clonal histories.\\n2. Analysis of clonal evolution during cancer progression. We are using multi-color lineage tracing in mouse models of prostate cancer together with organoid culture for longitudinal analyses, with data analyzed by single-cell transcriptomics and mathematical modeling.\\n3. Investigation of the clonal response to therapy. This involves longitudinal analyses of clonal evolution in organoid culture after drug treatments.\\n&nbsp;\\nThese studies will be greatly facilitated by the analyses of evolutionary moduli spaces and topological data analyses performed in collaboration with the Mathematical Core, as well as by interactions with Projects 2 and 3.","4":"Evolution","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645043","2":"Modeling tumor evolution in mouse and organoid models.","3":"In previous work at Columbia University Medical Center, we developed a reductionist model system for investigating clonal histories and demonstrated its feasibility for tracing clonal evolution. Preliminary studies showed that multi-color lineage-tracing can be used to follow clonal fates in genetically-engineered mouse models of prostate cancer, and that a novel organoid culture approach, in which three-dimensional buds of organs are grown in the laboratory, can be used to assess clonal growth and response to therapy across multiple time points. In ongoing work at the Center, we will combine such approaches with single-cell transcriptome analyses of tumor heterogeneity. This project has **three specific aims**: \\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Confetti-image-1.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Confetti-image-1.jpg)\\n&nbsp;\\n1. Investigation of clonal evolution during tissue homeostasis and regeneration. We are using multi-color lineage-tracing and organoid culture to follow clonal histories.\\n2. Analysis of clonal evolution during cancer progression. We are using multi-color lineage tracing in mouse models of prostate cancer together with organoid culture for longitudinal analyses, with data analyzed by single-cell transcriptomics and mathematical modeling.\\n3. Investigation of the clonal response to therapy. This involves longitudinal analyses of clonal evolution in organoid culture after drug treatments.\\n&nbsp;\\nThese studies will be greatly facilitated by the analyses of evolutionary moduli spaces and topological data analyses performed in collaboration with the Mathematical Core, as well as by interactions with Projects 2 and 3.","4":"Metastasis","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645044","2":"Dissecting clonal architecture and evolution in solid tumors.","3":"Focusing on human glioblastoma, one of the most incurable and genetically heterogeneous tumors, we will predict and validate the landscape of driver alterations that mark initiation, founder evolution, and therapy adaptation within individual patients. To do so, we will develop and apply novel technologies for high-throughput transcriptomic and genomic analysis of individual cells within malignant glioma tissues.\\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Ayasdi12.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Ayasdi12.jpg)\\n&nbsp;\\nOur current system is capable of single-cell mRNA capture, cDNA barcoding, and on-chip amplification, generating amplicons for direct conversion into a standard, pooled sequencing library. We will adapt the same device for massively parallel, on-chip capture of genomic DNA from individual cells for whole genome amplification and exome capture. Next, we will functionally validate the single-cell glioma models in orthotopic mouse and human systems in vitro and in vivo.\\n&nbsp;\\nIf successful, this project will deliver an integrated computational-experimental pipeline that will be able to predict forthcoming evolutionary changes of any solid tumor in the presence of a defined set of selective pressures. This information will be invaluable for deciphering evolving tumor dependencies and should enable highly accurate therapeutic predictions.","4":"Heterogeneity","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645044","2":"Dissecting clonal architecture and evolution in solid tumors.","3":"Focusing on human glioblastoma, one of the most incurable and genetically heterogeneous tumors, we will predict and validate the landscape of driver alterations that mark initiation, founder evolution, and therapy adaptation within individual patients. To do so, we will develop and apply novel technologies for high-throughput transcriptomic and genomic analysis of individual cells within malignant glioma tissues.\\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Ayasdi12.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Ayasdi12.jpg)\\n&nbsp;\\nOur current system is capable of single-cell mRNA capture, cDNA barcoding, and on-chip amplification, generating amplicons for direct conversion into a standard, pooled sequencing library. We will adapt the same device for massively parallel, on-chip capture of genomic DNA from individual cells for whole genome amplification and exome capture. Next, we will functionally validate the single-cell glioma models in orthotopic mouse and human systems in vitro and in vivo.\\n&nbsp;\\nIf successful, this project will deliver an integrated computational-experimental pipeline that will be able to predict forthcoming evolutionary changes of any solid tumor in the presence of a defined set of selective pressures. This information will be invaluable for deciphering evolving tumor dependencies and should enable highly accurate therapeutic predictions.","4":"Evolution","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645044","2":"Dissecting clonal architecture and evolution in solid tumors.","3":"Focusing on human glioblastoma, one of the most incurable and genetically heterogeneous tumors, we will predict and validate the landscape of driver alterations that mark initiation, founder evolution, and therapy adaptation within individual patients. To do so, we will develop and apply novel technologies for high-throughput transcriptomic and genomic analysis of individual cells within malignant glioma tissues.\\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Ayasdi12.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/Ayasdi12.jpg)\\n&nbsp;\\nOur current system is capable of single-cell mRNA capture, cDNA barcoding, and on-chip amplification, generating amplicons for direct conversion into a standard, pooled sequencing library. We will adapt the same device for massively parallel, on-chip capture of genomic DNA from individual cells for whole genome amplification and exome capture. Next, we will functionally validate the single-cell glioma models in orthotopic mouse and human systems in vitro and in vivo.\\n&nbsp;\\nIf successful, this project will deliver an integrated computational-experimental pipeline that will be able to predict forthcoming evolutionary changes of any solid tumor in the presence of a defined set of selective pressures. This information will be invaluable for deciphering evolving tumor dependencies and should enable highly accurate therapeutic predictions.","4":"Metastasis","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645045","2":"Predicting therapeutic sensitivity in cancer.","3":"Somatic genetic alterations in cancer have been linked with how tumors respond to targeted therapeutics and develop resistance to therapy. Therefore, the development of methods that model and predict therapeutic sensitivity of cancer should be extremely useful in the development of more effective treatments.\\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/tumor-fusion.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/tumor-fusion.jpg)\\n&nbsp;\\ntumor-fusionIn this project, our goal is to model, predict, and target therapeutic sensitivity and resistance of cancer. To do so, we will utilize three-dimensional models of glioblastoma (gliomaspheres) that recapitulate the nature of genetic lesions in primary tumors to experimentally validate computational machine learning predictions based on genomic information.\\n&nbsp;\\nWe will first build a computational framework that incorporates genomic data, drug properties and responses, and known drug targets and network models of pathways and protein complexes to predict the therapeutic response of 80 genomically annotated gliomaspheres. Then, we will experimentally validate our computational predictions of therapeutic sensitivity across the library of gliomaspheres, test combinatorial predictions, and examine the molecular mechanisms by which candidate genes alter drug responses. We will evaluate single- or multi-lesion sensitivity using RNA interference or cDNA overexpression. Finally, we will investigate the role of cell heterogeneity in the mechanism of drug resistance at the single-cell level using topological methods, developed in Project 2 and in the Mathematical Core.\\n&nbsp;\\nThe ultimate goal of this project will be to uncover mechanistic insights into genotype-dependent sensitivity to drugs or synthetic lethal relationships. Ultimately, our studies will deliver key information for the development of multiple gene- and pathway-based biomarkers for personalized cancer therapies.","4":"Heterogeneity","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645045","2":"Predicting therapeutic sensitivity in cancer.","3":"Somatic genetic alterations in cancer have been linked with how tumors respond to targeted therapeutics and develop resistance to therapy. Therefore, the development of methods that model and predict therapeutic sensitivity of cancer should be extremely useful in the development of more effective treatments.\\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/tumor-fusion.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/tumor-fusion.jpg)\\n&nbsp;\\ntumor-fusionIn this project, our goal is to model, predict, and target therapeutic sensitivity and resistance of cancer. To do so, we will utilize three-dimensional models of glioblastoma (gliomaspheres) that recapitulate the nature of genetic lesions in primary tumors to experimentally validate computational machine learning predictions based on genomic information.\\n&nbsp;\\nWe will first build a computational framework that incorporates genomic data, drug properties and responses, and known drug targets and network models of pathways and protein complexes to predict the therapeutic response of 80 genomically annotated gliomaspheres. Then, we will experimentally validate our computational predictions of therapeutic sensitivity across the library of gliomaspheres, test combinatorial predictions, and examine the molecular mechanisms by which candidate genes alter drug responses. We will evaluate single- or multi-lesion sensitivity using RNA interference or cDNA overexpression. Finally, we will investigate the role of cell heterogeneity in the mechanism of drug resistance at the single-cell level using topological methods, developed in Project 2 and in the Mathematical Core.\\n&nbsp;\\nThe ultimate goal of this project will be to uncover mechanistic insights into genotype-dependent sensitivity to drugs or synthetic lethal relationships. Ultimately, our studies will deliver key information for the development of multiple gene- and pathway-based biomarkers for personalized cancer therapies.","4":"Evolution","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645045","2":"Predicting therapeutic sensitivity in cancer.","3":"Somatic genetic alterations in cancer have been linked with how tumors respond to targeted therapeutics and develop resistance to therapy. Therefore, the development of methods that model and predict therapeutic sensitivity of cancer should be extremely useful in the development of more effective treatments.\\n&nbsp;\\n![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/tumor-fusion.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/tumor-fusion.jpg)\\n&nbsp;\\ntumor-fusionIn this project, our goal is to model, predict, and target therapeutic sensitivity and resistance of cancer. To do so, we will utilize three-dimensional models of glioblastoma (gliomaspheres) that recapitulate the nature of genetic lesions in primary tumors to experimentally validate computational machine learning predictions based on genomic information.\\n&nbsp;\\nWe will first build a computational framework that incorporates genomic data, drug properties and responses, and known drug targets and network models of pathways and protein complexes to predict the therapeutic response of 80 genomically annotated gliomaspheres. Then, we will experimentally validate our computational predictions of therapeutic sensitivity across the library of gliomaspheres, test combinatorial predictions, and examine the molecular mechanisms by which candidate genes alter drug responses. We will evaluate single- or multi-lesion sensitivity using RNA interference or cDNA overexpression. Finally, we will investigate the role of cell heterogeneity in the mechanism of drug resistance at the single-cell level using topological methods, developed in Project 2 and in the Mathematical Core.\\n&nbsp;\\nThe ultimate goal of this project will be to uncover mechanistic insights into genotype-dependent sensitivity to drugs or synthetic lethal relationships. Ultimately, our studies will deliver key information for the development of multiple gene- and pathway-based biomarkers for personalized cancer therapies.","4":"Metastasis","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645051","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity Mathematical Cores","3":"The Center for Topology of Cancer Evolution and Heterogeneity is pioneering the development and large-scale genomic application of topological data analysis (TDA), a new mathematical framework for capturing global structural properties of large data sets that is particularly well suited for high-dimensional, high-throughput biological data. (Topology is the branch of mathematics that characterizes robust global properties of spaces.)nn&nbsp;nn![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/fluspace.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/fluspace.jpg)nn&nbsp;nnPrevious work in the Center labs has shown that TDA offers unique capabilities for analyzing high-dimensional data sets. In particular, single-cell analyses put into question the standard bulk expression-based classification approaches and uncover a much more complex structure that is missed by consensus-based sequencing and standard clustering techniques. The Center for Topology of Cancer Evolution and Heterogeneity aims to extend this work and to develop and implement mathematical approaches to tackle the inherent complexity and biological interpretability of single-cell approaches to cancer evolution and heterogeneity. In order to develop an appropriately expressive language, we rely on ideas from geometry and topology (phylogenetic moduli spaces and TDA), modal logic, model-checking algorithms, and a probabilistic theory of causality. These tools complement each other and will be further developed in the context of single-cell data and applied in the specific research projects undertaken at the Center.","4":"Heterogeneity","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645051","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity Mathematical Cores","3":"The Center for Topology of Cancer Evolution and Heterogeneity is pioneering the development and large-scale genomic application of topological data analysis (TDA), a new mathematical framework for capturing global structural properties of large data sets that is particularly well suited for high-dimensional, high-throughput biological data. (Topology is the branch of mathematics that characterizes robust global properties of spaces.)nn&nbsp;nn![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/fluspace.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/fluspace.jpg)nn&nbsp;nnPrevious work in the Center labs has shown that TDA offers unique capabilities for analyzing high-dimensional data sets. In particular, single-cell analyses put into question the standard bulk expression-based classification approaches and uncover a much more complex structure that is missed by consensus-based sequencing and standard clustering techniques. The Center for Topology of Cancer Evolution and Heterogeneity aims to extend this work and to develop and implement mathematical approaches to tackle the inherent complexity and biological interpretability of single-cell approaches to cancer evolution and heterogeneity. In order to develop an appropriately expressive language, we rely on ideas from geometry and topology (phylogenetic moduli spaces and TDA), modal logic, model-checking algorithms, and a probabilistic theory of causality. These tools complement each other and will be further developed in the context of single-cell data and applied in the specific research projects undertaken at the Center.","4":"Evolution","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645051","2":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity Mathematical Cores","3":"The Center for Topology of Cancer Evolution and Heterogeneity is pioneering the development and large-scale genomic application of topological data analysis (TDA), a new mathematical framework for capturing global structural properties of large data sets that is particularly well suited for high-dimensional, high-throughput biological data. (Topology is the branch of mathematics that characterizes robust global properties of spaces.)nn&nbsp;nn![https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/fluspace.jpg](https://psoc.c2b2.columbia.edu/wp-content/uploads/2015/05/fluspace.jpg)nn&nbsp;nnPrevious work in the Center labs has shown that TDA offers unique capabilities for analyzing high-dimensional data sets. In particular, single-cell analyses put into question the standard bulk expression-based classification approaches and uncover a much more complex structure that is missed by consensus-based sequencing and standard clustering techniques. The Center for Topology of Cancer Evolution and Heterogeneity aims to extend this work and to develop and implement mathematical approaches to tackle the inherent complexity and biological interpretability of single-cell approaches to cancer evolution and heterogeneity. In order to develop an appropriately expressive language, we rely on ideas from geometry and topology (phylogenetic moduli spaces and TDA), modal logic, model-checking algorithms, and a probabilistic theory of causality. These tools complement each other and will be further developed in the context of single-cell data and applied in the specific research projects undertaken at the Center.","4":"Metastasis","5":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","6":"PS-ON","7":"U54"},{"1":"syn21645057","2":"Transport of Effector T cells and Nano-DC vaccine in Breast Cancer","3":"Dendritic cells (DCs) are professional antigen-presenting cells that can process and present tumor antigen to T cells to initiate immune responses. Therefore, DC vaccines are a logical choice for therapeutic intervention. In order for a DC vaccine to elicit the proper immune responses, a sequence of physical and biological events must occur:nn&nbsp;nn1. the DC vaccine must migrate from the injection site to lymphoid tissues;n2. the DC vaccine must maintain a mature stimulatory status to persistently process and present the immunizing antigen to T cells; andn3. the antigen-specific T cells must travel to the tumor-bearing organ and infiltrate into the tumor microenvironment to exert their antitumor activity. These events are often insurmountable hurdles for most DC vaccines.nn&nbsp;nnClinical studies have shown that less than 5% of intradermally injected DCs can reach the lymph nodes. The stimulatory signals of ex vivo-matured DCs cannot be maintained in vivo. Furthermore, the tumor microenvironment prevents infiltration of the cytotoxic T cells. Overcoming these sequential barriers is critical for developing an effective DC vaccine. Accumulation of DC vaccines in the lymph nodes, especially tumor-draining lymph nodes, may depend on successful negotiation of the sequential physical and biological barriers. In addition, modification of the tumor microenvironment will potentially facilitate transport of effector T cells and drugs, which combined with our Nano-DC vaccine, would significantly improve cancer therapy.nn&nbsp;nn${image?fileName=Overview%2Dcircles%2Dv3%5F2%2D768x621%2Epng&align=None&scale=50&responsive=true}","4":"Heterogeneity","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645057","2":"Transport of Effector T cells and Nano-DC vaccine in Breast Cancer","3":"Dendritic cells (DCs) are professional antigen-presenting cells that can process and present tumor antigen to T cells to initiate immune responses. Therefore, DC vaccines are a logical choice for therapeutic intervention. In order for a DC vaccine to elicit the proper immune responses, a sequence of physical and biological events must occur:nn&nbsp;nn1. the DC vaccine must migrate from the injection site to lymphoid tissues;n2. the DC vaccine must maintain a mature stimulatory status to persistently process and present the immunizing antigen to T cells; andn3. the antigen-specific T cells must travel to the tumor-bearing organ and infiltrate into the tumor microenvironment to exert their antitumor activity. These events are often insurmountable hurdles for most DC vaccines.nn&nbsp;nnClinical studies have shown that less than 5% of intradermally injected DCs can reach the lymph nodes. The stimulatory signals of ex vivo-matured DCs cannot be maintained in vivo. Furthermore, the tumor microenvironment prevents infiltration of the cytotoxic T cells. Overcoming these sequential barriers is critical for developing an effective DC vaccine. Accumulation of DC vaccines in the lymph nodes, especially tumor-draining lymph nodes, may depend on successful negotiation of the sequential physical and biological barriers. In addition, modification of the tumor microenvironment will potentially facilitate transport of effector T cells and drugs, which combined with our Nano-DC vaccine, would significantly improve cancer therapy.nn&nbsp;nn${image?fileName=Overview%2Dcircles%2Dv3%5F2%2D768x621%2Epng&align=None&scale=50&responsive=true}","4":"Tumor-Immune","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645057","2":"Transport of Effector T cells and Nano-DC vaccine in Breast Cancer","3":"Dendritic cells (DCs) are professional antigen-presenting cells that can process and present tumor antigen to T cells to initiate immune responses. Therefore, DC vaccines are a logical choice for therapeutic intervention. In order for a DC vaccine to elicit the proper immune responses, a sequence of physical and biological events must occur:nn&nbsp;nn1. the DC vaccine must migrate from the injection site to lymphoid tissues;n2. the DC vaccine must maintain a mature stimulatory status to persistently process and present the immunizing antigen to T cells; andn3. the antigen-specific T cells must travel to the tumor-bearing organ and infiltrate into the tumor microenvironment to exert their antitumor activity. These events are often insurmountable hurdles for most DC vaccines.nn&nbsp;nnClinical studies have shown that less than 5% of intradermally injected DCs can reach the lymph nodes. The stimulatory signals of ex vivo-matured DCs cannot be maintained in vivo. Furthermore, the tumor microenvironment prevents infiltration of the cytotoxic T cells. Overcoming these sequential barriers is critical for developing an effective DC vaccine. Accumulation of DC vaccines in the lymph nodes, especially tumor-draining lymph nodes, may depend on successful negotiation of the sequential physical and biological barriers. In addition, modification of the tumor microenvironment will potentially facilitate transport of effector T cells and drugs, which combined with our Nano-DC vaccine, would significantly improve cancer therapy.nn&nbsp;nn${image?fileName=Overview%2Dcircles%2Dv3%5F2%2D768x621%2Epng&align=None&scale=50&responsive=true}","4":"Microenvironment","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645058","2":"Microenvironmental Transport for Immunotherapy in Pancreatic Cancer","3":"Current immunotherapy strategies have limited efficacy in treating pancreatic ductal adenocarcinoma (PDAC), a non-T cell inflamed tumor. Immune suppression of PDAC occurs due to the presence of myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and M2 macrophages in the tumor microenvironment. While tremendous effort has focused on deciphering the biological pathways that regulate these immunosuppressive cells so that more effector T cells can infiltrate and kill cancer cells, little attention has been focused on the contribution of the multi-scale physical aberrations that are inherent in PDAC.nn&nbsp;nnWe believe that immunotherapy response and resistance in primary and metastatic sites are dependent on both the molecular and heterogeneous multi-scale physical properties of a specific PDAC tumor. In the CITO, we examine these phenomena, based on the notion that the efficacy of immunotherapy is limited by the spatial distribution of nutrients in the tumor microenvironment, as its disorganization restricts access of effector T cells to the cancer cells.nn&nbsp;nn${image?fileName=Project%2D2%2Dinset%2Dlarge%2D768x618%2Ejpg&align=None&scale=50&responsive=true}","4":"Heterogeneity","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645058","2":"Microenvironmental Transport for Immunotherapy in Pancreatic Cancer","3":"Current immunotherapy strategies have limited efficacy in treating pancreatic ductal adenocarcinoma (PDAC), a non-T cell inflamed tumor. Immune suppression of PDAC occurs due to the presence of myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and M2 macrophages in the tumor microenvironment. While tremendous effort has focused on deciphering the biological pathways that regulate these immunosuppressive cells so that more effector T cells can infiltrate and kill cancer cells, little attention has been focused on the contribution of the multi-scale physical aberrations that are inherent in PDAC.nn&nbsp;nnWe believe that immunotherapy response and resistance in primary and metastatic sites are dependent on both the molecular and heterogeneous multi-scale physical properties of a specific PDAC tumor. In the CITO, we examine these phenomena, based on the notion that the efficacy of immunotherapy is limited by the spatial distribution of nutrients in the tumor microenvironment, as its disorganization restricts access of effector T cells to the cancer cells.nn&nbsp;nn${image?fileName=Project%2D2%2Dinset%2Dlarge%2D768x618%2Ejpg&align=None&scale=50&responsive=true}","4":"Tumor-Immune","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645058","2":"Microenvironmental Transport for Immunotherapy in Pancreatic Cancer","3":"Current immunotherapy strategies have limited efficacy in treating pancreatic ductal adenocarcinoma (PDAC), a non-T cell inflamed tumor. Immune suppression of PDAC occurs due to the presence of myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and M2 macrophages in the tumor microenvironment. While tremendous effort has focused on deciphering the biological pathways that regulate these immunosuppressive cells so that more effector T cells can infiltrate and kill cancer cells, little attention has been focused on the contribution of the multi-scale physical aberrations that are inherent in PDAC.nn&nbsp;nnWe believe that immunotherapy response and resistance in primary and metastatic sites are dependent on both the molecular and heterogeneous multi-scale physical properties of a specific PDAC tumor. In the CITO, we examine these phenomena, based on the notion that the efficacy of immunotherapy is limited by the spatial distribution of nutrients in the tumor microenvironment, as its disorganization restricts access of effector T cells to the cancer cells.nn&nbsp;nn${image?fileName=Project%2D2%2Dinset%2Dlarge%2D768x618%2Ejpg&align=None&scale=50&responsive=true}","4":"Microenvironment","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645059","2":"The Center for Immunotherapeutic Transport Oncophysics: Transport Oncophysics Core","3":"In the Transport Oncophysics Core (TOC), our computational and modeling approach takes into consideration the biophysical properties of tissues, cells, and molecules that control the efficiency of transport processes. The transport process of immune cells, biomolecules, and other drugs involves many barriers, including systemic and within the tumor microenvironment. We believe opportunities exist to improve the delivery and efficacy of immunotherapeutics, by optimizing the transport and penetration of drugs and immune cells, to improve the immune response against breast and pancreatic cancers.nn&nbsp;nnThe TOC supports both research projects of the CITO by providing imaging, data analysis, quantification, and unique oncophysical computational tools to rationalize the delivery and transport of immunotherapies, based on the oncophysical modeling framework and Transport and Biodistribution Theory (TBT). The TBT moves boundaries from classical tools used to study pharmacokinetic and efficacy relations, to the creation of novel precision immunotherapeutic tools used to rationally tailor individual treatments to patients.nn&nbsp;nn${image?fileName=Core%2Dv2%2D768x594%2Ejpg&align=None&scale=50&responsive=true}","4":"Heterogeneity","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645059","2":"The Center for Immunotherapeutic Transport Oncophysics: Transport Oncophysics Core","3":"In the Transport Oncophysics Core (TOC), our computational and modeling approach takes into consideration the biophysical properties of tissues, cells, and molecules that control the efficiency of transport processes. The transport process of immune cells, biomolecules, and other drugs involves many barriers, including systemic and within the tumor microenvironment. We believe opportunities exist to improve the delivery and efficacy of immunotherapeutics, by optimizing the transport and penetration of drugs and immune cells, to improve the immune response against breast and pancreatic cancers.nn&nbsp;nnThe TOC supports both research projects of the CITO by providing imaging, data analysis, quantification, and unique oncophysical computational tools to rationalize the delivery and transport of immunotherapies, based on the oncophysical modeling framework and Transport and Biodistribution Theory (TBT). The TBT moves boundaries from classical tools used to study pharmacokinetic and efficacy relations, to the creation of novel precision immunotherapeutic tools used to rationally tailor individual treatments to patients.nn&nbsp;nn${image?fileName=Core%2Dv2%2D768x594%2Ejpg&align=None&scale=50&responsive=true}","4":"Tumor-Immune","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645059","2":"The Center for Immunotherapeutic Transport Oncophysics: Transport Oncophysics Core","3":"In the Transport Oncophysics Core (TOC), our computational and modeling approach takes into consideration the biophysical properties of tissues, cells, and molecules that control the efficiency of transport processes. The transport process of immune cells, biomolecules, and other drugs involves many barriers, including systemic and within the tumor microenvironment. We believe opportunities exist to improve the delivery and efficacy of immunotherapeutics, by optimizing the transport and penetration of drugs and immune cells, to improve the immune response against breast and pancreatic cancers.nn&nbsp;nnThe TOC supports both research projects of the CITO by providing imaging, data analysis, quantification, and unique oncophysical computational tools to rationalize the delivery and transport of immunotherapies, based on the oncophysical modeling framework and Transport and Biodistribution Theory (TBT). The TBT moves boundaries from classical tools used to study pharmacokinetic and efficacy relations, to the creation of novel precision immunotherapeutic tools used to rationally tailor individual treatments to patients.nn&nbsp;nn${image?fileName=Core%2Dv2%2D768x594%2Ejpg&align=None&scale=50&responsive=true}","4":"Microenvironment","5":"The Center for Immunotherapeutic Transport Oncophysics","6":"PS-ON","7":"U54"},{"1":"syn21645060","2":"Modeling the Interface between Non-invasive Imaging and Drug Distribution","3":"Dogma in clinical neuro-oncology holds that Gadolinium (Gd) contrast on magnetic resonance imaging (MRI) in tumor regions confirms that the blood-brain barrier (BBB) is locally compromised, and thus sufficient levels of drug are being distributed within these tumor regions. However, drug distribution data indicate the importance of the local microenvironmental heterogeneity and other physical factors that lead to differential distribution of therapeutic agents relative to Gd contrast. Non-invasively acquired imaging features can provide a snapshot of tumor microenvironment and ultimately a better understanding of drug distribution. The goal of this project is to develop and validate a <U+201A><U+00C4><U+00FA>minimal<U+201A><U+00C4><U+00F9> model that will capture intra- and inter-tumor heterogeneity to predict clinically relevant levels of drug distribution using routine imaging. In this project, we will use a combination of patient data, GBM patient-derived xenografts (PDXs), matrix-assisted laser desorption/ionization mass spectroscopy imaging (MALDI-MSI), and stimulated raman spectroscopy (SRS) to quantify the differences in drug distribution within and across tumors and, in doing so, develop a computational framework for predicting the efficacy of BBB-penetrant and BBB-impenetrant drugs for the treatment of GBMs.nn&nbsp;nnOur hypothesis is that mathematical models based on multiparametric high content imaging techniques will predict spatially distinct drug distribution patterns in invasive primary and metastatic brain tumor models for both small molecule and macromolecular therapeutics, and therefore be pivotal to predicting the in vivo efficacy of targeted therapies. In the first phase of the project we will build a computational framework that quantitatively connects imaging features with differences in drug distribution within and across tumors.  This part of the project involves experiments to quantify differences in drug distribution across tumors in a series of PDXs with MALDI mass spectrometry imaging (MSI), physical tissue features with stimulated Raman scattering (SRS), development/calibration of imaging-driven models for drug distribution incorporating BBB permeability, and extending our results to patients through a Phase 0 trial. In the second phase of the project we will construct a computational framework that quantitatively connects differences in drug distribution with imageable response within and across tumors.  The second phase will include the investigatation of treatment response using BLI imaging, development/calibration of models of treatment response connecting drug distribution and tumor kinetics, and extension of our results to patients by determining sub-cohorts of patients most likely to respond to therapies. Overall, this project will provide a quantitative connection between imaging features and drug distribution at levels sufficient to predict heterogeneous treatment response across patients. The ultimate vision is to provide clinicians an accessible decision-making tool to help choose relevant targeted therapies that will be tailored for an individual GBM patient.","4":"Heterogeneity","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645060","2":"Modeling the Interface between Non-invasive Imaging and Drug Distribution","3":"Dogma in clinical neuro-oncology holds that Gadolinium (Gd) contrast on magnetic resonance imaging (MRI) in tumor regions confirms that the blood-brain barrier (BBB) is locally compromised, and thus sufficient levels of drug are being distributed within these tumor regions. However, drug distribution data indicate the importance of the local microenvironmental heterogeneity and other physical factors that lead to differential distribution of therapeutic agents relative to Gd contrast. Non-invasively acquired imaging features can provide a snapshot of tumor microenvironment and ultimately a better understanding of drug distribution. The goal of this project is to develop and validate a <U+201A><U+00C4><U+00FA>minimal<U+201A><U+00C4><U+00F9> model that will capture intra- and inter-tumor heterogeneity to predict clinically relevant levels of drug distribution using routine imaging. In this project, we will use a combination of patient data, GBM patient-derived xenografts (PDXs), matrix-assisted laser desorption/ionization mass spectroscopy imaging (MALDI-MSI), and stimulated raman spectroscopy (SRS) to quantify the differences in drug distribution within and across tumors and, in doing so, develop a computational framework for predicting the efficacy of BBB-penetrant and BBB-impenetrant drugs for the treatment of GBMs.nn&nbsp;nnOur hypothesis is that mathematical models based on multiparametric high content imaging techniques will predict spatially distinct drug distribution patterns in invasive primary and metastatic brain tumor models for both small molecule and macromolecular therapeutics, and therefore be pivotal to predicting the in vivo efficacy of targeted therapies. In the first phase of the project we will build a computational framework that quantitatively connects imaging features with differences in drug distribution within and across tumors.  This part of the project involves experiments to quantify differences in drug distribution across tumors in a series of PDXs with MALDI mass spectrometry imaging (MSI), physical tissue features with stimulated Raman scattering (SRS), development/calibration of imaging-driven models for drug distribution incorporating BBB permeability, and extending our results to patients through a Phase 0 trial. In the second phase of the project we will construct a computational framework that quantitatively connects differences in drug distribution with imageable response within and across tumors.  The second phase will include the investigatation of treatment response using BLI imaging, development/calibration of models of treatment response connecting drug distribution and tumor kinetics, and extension of our results to patients by determining sub-cohorts of patients most likely to respond to therapies. Overall, this project will provide a quantitative connection between imaging features and drug distribution at levels sufficient to predict heterogeneous treatment response across patients. The ultimate vision is to provide clinicians an accessible decision-making tool to help choose relevant targeted therapies that will be tailored for an individual GBM patient.","4":"Microenvironment","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645060","2":"Modeling the Interface between Non-invasive Imaging and Drug Distribution","3":"Dogma in clinical neuro-oncology holds that Gadolinium (Gd) contrast on magnetic resonance imaging (MRI) in tumor regions confirms that the blood-brain barrier (BBB) is locally compromised, and thus sufficient levels of drug are being distributed within these tumor regions. However, drug distribution data indicate the importance of the local microenvironmental heterogeneity and other physical factors that lead to differential distribution of therapeutic agents relative to Gd contrast. Non-invasively acquired imaging features can provide a snapshot of tumor microenvironment and ultimately a better understanding of drug distribution. The goal of this project is to develop and validate a <U+201A><U+00C4><U+00FA>minimal<U+201A><U+00C4><U+00F9> model that will capture intra- and inter-tumor heterogeneity to predict clinically relevant levels of drug distribution using routine imaging. In this project, we will use a combination of patient data, GBM patient-derived xenografts (PDXs), matrix-assisted laser desorption/ionization mass spectroscopy imaging (MALDI-MSI), and stimulated raman spectroscopy (SRS) to quantify the differences in drug distribution within and across tumors and, in doing so, develop a computational framework for predicting the efficacy of BBB-penetrant and BBB-impenetrant drugs for the treatment of GBMs.nn&nbsp;nnOur hypothesis is that mathematical models based on multiparametric high content imaging techniques will predict spatially distinct drug distribution patterns in invasive primary and metastatic brain tumor models for both small molecule and macromolecular therapeutics, and therefore be pivotal to predicting the in vivo efficacy of targeted therapies. In the first phase of the project we will build a computational framework that quantitatively connects imaging features with differences in drug distribution within and across tumors.  This part of the project involves experiments to quantify differences in drug distribution across tumors in a series of PDXs with MALDI mass spectrometry imaging (MSI), physical tissue features with stimulated Raman scattering (SRS), development/calibration of imaging-driven models for drug distribution incorporating BBB permeability, and extending our results to patients through a Phase 0 trial. In the second phase of the project we will construct a computational framework that quantitatively connects differences in drug distribution with imageable response within and across tumors.  The second phase will include the investigatation of treatment response using BLI imaging, development/calibration of models of treatment response connecting drug distribution and tumor kinetics, and extension of our results to patients by determining sub-cohorts of patients most likely to respond to therapies. Overall, this project will provide a quantitative connection between imaging features and drug distribution at levels sufficient to predict heterogeneous treatment response across patients. The ultimate vision is to provide clinicians an accessible decision-making tool to help choose relevant targeted therapies that will be tailored for an individual GBM patient.","4":"Evolution","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645061","2":"Defining the relationship between tumor composition, spatial heterogeneity, drug delivery, and drug efficacy","3":"Cancer genomic analysis enables the selection of therapeutic targets for precision medicine based on the detection of oncogenic events in a patient tumor. Despite significant advances in the field, there remains a daunting challenge in identifying optimal therapeutic agents that will be well distributed throughout the tumor and efficacious in their target inhibition. This challenge is exacerbated in brain tumors due to the blood-brain and blood-tumor barriers (collectively referred to subsequently as the BBB) that can limit distribution into the central nervous system of otherwise highly effective therapies and likely contribute to the failure of many therapies targeting brain pathologies. The spatially heterogeneous distribution of targeted therapy throughout a patient tumor significantly impacts the molecular and cellular response. Local concentrations above a critical threshold can lead to target inhibition and cell death, but may also generate an adaptive response and activation of compensatory resistance pathways. At sub-threshold concentrations, our preliminary data indicate a paradoxical signaling network activation resulting in increased proliferation. For any given therapeutic agent and any given tumor, the tumor physical parameters and physico-chemical properties of the therapeutic agent that regulate drug distribution and efficacy are currently poorly understood.nn&nbsp;nnDetermining the physical factors regulating therapeutic distribution and efficacy in vivo is a daunting challenge. Therapeutic distribution may be affected by its size, affinity, and molecular composition in combination with multiple physical factors of the tumor, such as vascular distribution and integrity along with spatial cellular and molecular heterogeneity.nn&nbsp;nnIn the first phase of this project, we will define the tumor tissue architecture and determine its effect on drug distribution.  Previous models, including those developed by the Wittrup lab, have focused on the effect of diffusion and distance from vasculature, to predict therapeutic delivery. While these models have worked well for many tumors, they are limited in predicting drug distribution into CNS tumors, due to the effect of the blood-brain barrier (intact in native vessels; aberrant in neovasculature), hypoxia, necrosis, edema, tumor growth kinetics, and the different dispersion behaviors of these tumors relative to non-CNS tumors. Using a variety of latest- generation bio-physical imaging and analytical techniques, combined with computational models provided by the Data Handling and Integration Core, we will generate improved computational models quantifying the physical properties of the tumor tissue architecture and their effect on drug distribution.nn&nbsp;nnIn the second phase of this project, we will quantify the adaptive molecular response to different therapeutic doses. To understand the overall tumor response to therapy it is necessary to quantify drug distribution and drug efficacy, including target inhibition and the systems-level signaling network-wide response to this inhibition. To quantify dynamic responses to different therapeutic concentrations for different durations, we propose to utilize cutting-edge systems biology analytical techniques, including next-gen RNA sequencing and mass spectrometry based proteomics and phosphoproteomics. To connect this data to cellular biology outcome, we will quantify tumor size, apoptosis, senescence, and proliferation under each condition. Multivariate data driven computational modeling in the Data Handling and Integration Core will identify the transcript and signaling nodes regulating cell response to therapy. Mechanistic pharmacodynamics modeling will then be used to predict the dynamic molecular and cellular response to spatially heterogeneous drug distribution. Models will be validated by IHC, PLA, and LCM-RNASeq to obtain spatially resolved response to therapy with approximately cellular resolution.","4":"Heterogeneity","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645061","2":"Defining the relationship between tumor composition, spatial heterogeneity, drug delivery, and drug efficacy","3":"Cancer genomic analysis enables the selection of therapeutic targets for precision medicine based on the detection of oncogenic events in a patient tumor. Despite significant advances in the field, there remains a daunting challenge in identifying optimal therapeutic agents that will be well distributed throughout the tumor and efficacious in their target inhibition. This challenge is exacerbated in brain tumors due to the blood-brain and blood-tumor barriers (collectively referred to subsequently as the BBB) that can limit distribution into the central nervous system of otherwise highly effective therapies and likely contribute to the failure of many therapies targeting brain pathologies. The spatially heterogeneous distribution of targeted therapy throughout a patient tumor significantly impacts the molecular and cellular response. Local concentrations above a critical threshold can lead to target inhibition and cell death, but may also generate an adaptive response and activation of compensatory resistance pathways. At sub-threshold concentrations, our preliminary data indicate a paradoxical signaling network activation resulting in increased proliferation. For any given therapeutic agent and any given tumor, the tumor physical parameters and physico-chemical properties of the therapeutic agent that regulate drug distribution and efficacy are currently poorly understood.nn&nbsp;nnDetermining the physical factors regulating therapeutic distribution and efficacy in vivo is a daunting challenge. Therapeutic distribution may be affected by its size, affinity, and molecular composition in combination with multiple physical factors of the tumor, such as vascular distribution and integrity along with spatial cellular and molecular heterogeneity.nn&nbsp;nnIn the first phase of this project, we will define the tumor tissue architecture and determine its effect on drug distribution.  Previous models, including those developed by the Wittrup lab, have focused on the effect of diffusion and distance from vasculature, to predict therapeutic delivery. While these models have worked well for many tumors, they are limited in predicting drug distribution into CNS tumors, due to the effect of the blood-brain barrier (intact in native vessels; aberrant in neovasculature), hypoxia, necrosis, edema, tumor growth kinetics, and the different dispersion behaviors of these tumors relative to non-CNS tumors. Using a variety of latest- generation bio-physical imaging and analytical techniques, combined with computational models provided by the Data Handling and Integration Core, we will generate improved computational models quantifying the physical properties of the tumor tissue architecture and their effect on drug distribution.nn&nbsp;nnIn the second phase of this project, we will quantify the adaptive molecular response to different therapeutic doses. To understand the overall tumor response to therapy it is necessary to quantify drug distribution and drug efficacy, including target inhibition and the systems-level signaling network-wide response to this inhibition. To quantify dynamic responses to different therapeutic concentrations for different durations, we propose to utilize cutting-edge systems biology analytical techniques, including next-gen RNA sequencing and mass spectrometry based proteomics and phosphoproteomics. To connect this data to cellular biology outcome, we will quantify tumor size, apoptosis, senescence, and proliferation under each condition. Multivariate data driven computational modeling in the Data Handling and Integration Core will identify the transcript and signaling nodes regulating cell response to therapy. Mechanistic pharmacodynamics modeling will then be used to predict the dynamic molecular and cellular response to spatially heterogeneous drug distribution. Models will be validated by IHC, PLA, and LCM-RNASeq to obtain spatially resolved response to therapy with approximately cellular resolution.","4":"Microenvironment","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645061","2":"Defining the relationship between tumor composition, spatial heterogeneity, drug delivery, and drug efficacy","3":"Cancer genomic analysis enables the selection of therapeutic targets for precision medicine based on the detection of oncogenic events in a patient tumor. Despite significant advances in the field, there remains a daunting challenge in identifying optimal therapeutic agents that will be well distributed throughout the tumor and efficacious in their target inhibition. This challenge is exacerbated in brain tumors due to the blood-brain and blood-tumor barriers (collectively referred to subsequently as the BBB) that can limit distribution into the central nervous system of otherwise highly effective therapies and likely contribute to the failure of many therapies targeting brain pathologies. The spatially heterogeneous distribution of targeted therapy throughout a patient tumor significantly impacts the molecular and cellular response. Local concentrations above a critical threshold can lead to target inhibition and cell death, but may also generate an adaptive response and activation of compensatory resistance pathways. At sub-threshold concentrations, our preliminary data indicate a paradoxical signaling network activation resulting in increased proliferation. For any given therapeutic agent and any given tumor, the tumor physical parameters and physico-chemical properties of the therapeutic agent that regulate drug distribution and efficacy are currently poorly understood.nn&nbsp;nnDetermining the physical factors regulating therapeutic distribution and efficacy in vivo is a daunting challenge. Therapeutic distribution may be affected by its size, affinity, and molecular composition in combination with multiple physical factors of the tumor, such as vascular distribution and integrity along with spatial cellular and molecular heterogeneity.nn&nbsp;nnIn the first phase of this project, we will define the tumor tissue architecture and determine its effect on drug distribution.  Previous models, including those developed by the Wittrup lab, have focused on the effect of diffusion and distance from vasculature, to predict therapeutic delivery. While these models have worked well for many tumors, they are limited in predicting drug distribution into CNS tumors, due to the effect of the blood-brain barrier (intact in native vessels; aberrant in neovasculature), hypoxia, necrosis, edema, tumor growth kinetics, and the different dispersion behaviors of these tumors relative to non-CNS tumors. Using a variety of latest- generation bio-physical imaging and analytical techniques, combined with computational models provided by the Data Handling and Integration Core, we will generate improved computational models quantifying the physical properties of the tumor tissue architecture and their effect on drug distribution.nn&nbsp;nnIn the second phase of this project, we will quantify the adaptive molecular response to different therapeutic doses. To understand the overall tumor response to therapy it is necessary to quantify drug distribution and drug efficacy, including target inhibition and the systems-level signaling network-wide response to this inhibition. To quantify dynamic responses to different therapeutic concentrations for different durations, we propose to utilize cutting-edge systems biology analytical techniques, including next-gen RNA sequencing and mass spectrometry based proteomics and phosphoproteomics. To connect this data to cellular biology outcome, we will quantify tumor size, apoptosis, senescence, and proliferation under each condition. Multivariate data driven computational modeling in the Data Handling and Integration Core will identify the transcript and signaling nodes regulating cell response to therapy. Mechanistic pharmacodynamics modeling will then be used to predict the dynamic molecular and cellular response to spatially heterogeneous drug distribution. Models will be validated by IHC, PLA, and LCM-RNASeq to obtain spatially resolved response to therapy with approximately cellular resolution.","4":"Evolution","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645062","2":"Data Handling and Integration","3":"The ultimate goal of the MIT/Mayo PS-OC is to develop a multiscale predictive model connecting non-invasive imaging (tissue scale) to predicted therapeutic distribution (tissue-cellular scale) and dynamic molecular cellular response (cellular-molecular scale). To achieve this highly innovative and ambitious goal, we have assembled an interdisciplinary team with expertise in a wide range of cutting-edge analytical, imaging, and computational modeling tools. Although the measurements and some initial data handling and modeling will be performed in each project, the main tasks of the Data Handling and Integration Core include management of the large amounts of diverse data that will be generated in Project 1 and Project 2, extraction of key parameters from these large-scale data sets and images, integration of this information across platforms and scales to identify the key physical parameters governing therapeutic distribution and efficacy, and finally integration of multiple computational models at different scales to develop a multi-scale model linking non-invasive imaging to spatially heterogeneous drug distribution and drug efficacy. To achieve a robust model capable of predicting distribution for a range of therapies across a range of tumors with different parameters, we will utilize therapies ranging from small molecules to drug-conjugated antibodies, and will evaluate these therapies on a diverse set of patient-derived tumor models.","4":"Heterogeneity","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645062","2":"Data Handling and Integration","3":"The ultimate goal of the MIT/Mayo PS-OC is to develop a multiscale predictive model connecting non-invasive imaging (tissue scale) to predicted therapeutic distribution (tissue-cellular scale) and dynamic molecular cellular response (cellular-molecular scale). To achieve this highly innovative and ambitious goal, we have assembled an interdisciplinary team with expertise in a wide range of cutting-edge analytical, imaging, and computational modeling tools. Although the measurements and some initial data handling and modeling will be performed in each project, the main tasks of the Data Handling and Integration Core include management of the large amounts of diverse data that will be generated in Project 1 and Project 2, extraction of key parameters from these large-scale data sets and images, integration of this information across platforms and scales to identify the key physical parameters governing therapeutic distribution and efficacy, and finally integration of multiple computational models at different scales to develop a multi-scale model linking non-invasive imaging to spatially heterogeneous drug distribution and drug efficacy. To achieve a robust model capable of predicting distribution for a range of therapies across a range of tumors with different parameters, we will utilize therapies ranging from small molecules to drug-conjugated antibodies, and will evaluate these therapies on a diverse set of patient-derived tumor models.","4":"Microenvironment","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645062","2":"Data Handling and Integration","3":"The ultimate goal of the MIT/Mayo PS-OC is to develop a multiscale predictive model connecting non-invasive imaging (tissue scale) to predicted therapeutic distribution (tissue-cellular scale) and dynamic molecular cellular response (cellular-molecular scale). To achieve this highly innovative and ambitious goal, we have assembled an interdisciplinary team with expertise in a wide range of cutting-edge analytical, imaging, and computational modeling tools. Although the measurements and some initial data handling and modeling will be performed in each project, the main tasks of the Data Handling and Integration Core include management of the large amounts of diverse data that will be generated in Project 1 and Project 2, extraction of key parameters from these large-scale data sets and images, integration of this information across platforms and scales to identify the key physical parameters governing therapeutic distribution and efficacy, and finally integration of multiple computational models at different scales to develop a multi-scale model linking non-invasive imaging to spatially heterogeneous drug distribution and drug efficacy. To achieve a robust model capable of predicting distribution for a range of therapies across a range of tumors with different parameters, we will utilize therapies ranging from small molecules to drug-conjugated antibodies, and will evaluate these therapies on a diverse set of patient-derived tumor models.","4":"Evolution","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645063","2":"Animal and Pharmacology","3":"The focus of the MIT/Mayo PS-OC is to understand the physical and biological features of primary and metastatic brain tumors that result in heterogeneous drug delivery and how sub-therapeutic delivery may impact treatment failure and resistance emergence. The studies in this PSOC will focus on evaluating a spectrum of EGFR- and RAF-targeted therapies in patient-derived xenograft (PDX) orthotopic models of glioblastoma (GBM) and melanoma brain metastases. The Animal and Pharmacology Core will provide critical infrastructure, expertise and experience to support these studies. The Core will be led by Dr. Jann Sarkaria, who has extensive expertise in animal tumor models and by his long-time collaborator, Dr. William Elmquist, who is an expert in pharmacokinetic modeling of drug delivery into the brain.nn&nbsp;nnGlioblastoma (GBM) patient-derived xenograft (PDX) models have been developed to overcome the limitations of more traditional glioma models and have become one of the gold-standards for both basic and translational studies in GBM. The Sarkaria laboratory has developed a panel of 79 GBM xenografts that were established by implanting patient tumor specimens directly into the flank of nude mice. Maintenance of these xenograft lines by serial transplantation in mice preserves key genetic features of the corresponding patient tumor, such as EGFR amplification, and whole exome sequencing and RNAseq analysis demonstrates that these models are broadly representative of common molecular variants observed within GBM. We used a similar strategy to xenograft freshly resected brain tumor metastases to develop highly translational relevant models for brain metastases. To date, we have developed 38 brain metastasis PDX models, including 11 from melanoma metastases. These melanoma PDX models demonstrate robust intracranial growth when directly implanted into the brain, significant brain tropism following intracardiac injection, and similar to the glioma PDX models, we are completing our RNAseq analysis of these models. Overall, the extensive phenotypic and molecular characterization of these models greatly enhances our ability to select appropriate tumor models to test the EGFR and RAF-targeted therapies in the planned MIT/Mayo PS-OC projects.nn&nbsp;nnThe Animal and Pharmacology Core will provide essential services to the MIT/Mayo PS-OC in support of both Project 1 and Project 2. The Core will manage all aspects of the experiments that involve live animals and, in collaboration with the Administrative Core, manage distribution of biospecimens and imaging data to the appropriate investigators.","4":"Heterogeneity","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645063","2":"Animal and Pharmacology","3":"The focus of the MIT/Mayo PS-OC is to understand the physical and biological features of primary and metastatic brain tumors that result in heterogeneous drug delivery and how sub-therapeutic delivery may impact treatment failure and resistance emergence. The studies in this PSOC will focus on evaluating a spectrum of EGFR- and RAF-targeted therapies in patient-derived xenograft (PDX) orthotopic models of glioblastoma (GBM) and melanoma brain metastases. The Animal and Pharmacology Core will provide critical infrastructure, expertise and experience to support these studies. The Core will be led by Dr. Jann Sarkaria, who has extensive expertise in animal tumor models and by his long-time collaborator, Dr. William Elmquist, who is an expert in pharmacokinetic modeling of drug delivery into the brain.nn&nbsp;nnGlioblastoma (GBM) patient-derived xenograft (PDX) models have been developed to overcome the limitations of more traditional glioma models and have become one of the gold-standards for both basic and translational studies in GBM. The Sarkaria laboratory has developed a panel of 79 GBM xenografts that were established by implanting patient tumor specimens directly into the flank of nude mice. Maintenance of these xenograft lines by serial transplantation in mice preserves key genetic features of the corresponding patient tumor, such as EGFR amplification, and whole exome sequencing and RNAseq analysis demonstrates that these models are broadly representative of common molecular variants observed within GBM. We used a similar strategy to xenograft freshly resected brain tumor metastases to develop highly translational relevant models for brain metastases. To date, we have developed 38 brain metastasis PDX models, including 11 from melanoma metastases. These melanoma PDX models demonstrate robust intracranial growth when directly implanted into the brain, significant brain tropism following intracardiac injection, and similar to the glioma PDX models, we are completing our RNAseq analysis of these models. Overall, the extensive phenotypic and molecular characterization of these models greatly enhances our ability to select appropriate tumor models to test the EGFR and RAF-targeted therapies in the planned MIT/Mayo PS-OC projects.nn&nbsp;nnThe Animal and Pharmacology Core will provide essential services to the MIT/Mayo PS-OC in support of both Project 1 and Project 2. The Core will manage all aspects of the experiments that involve live animals and, in collaboration with the Administrative Core, manage distribution of biospecimens and imaging data to the appropriate investigators.","4":"Microenvironment","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645063","2":"Animal and Pharmacology","3":"The focus of the MIT/Mayo PS-OC is to understand the physical and biological features of primary and metastatic brain tumors that result in heterogeneous drug delivery and how sub-therapeutic delivery may impact treatment failure and resistance emergence. The studies in this PSOC will focus on evaluating a spectrum of EGFR- and RAF-targeted therapies in patient-derived xenograft (PDX) orthotopic models of glioblastoma (GBM) and melanoma brain metastases. The Animal and Pharmacology Core will provide critical infrastructure, expertise and experience to support these studies. The Core will be led by Dr. Jann Sarkaria, who has extensive expertise in animal tumor models and by his long-time collaborator, Dr. William Elmquist, who is an expert in pharmacokinetic modeling of drug delivery into the brain.nn&nbsp;nnGlioblastoma (GBM) patient-derived xenograft (PDX) models have been developed to overcome the limitations of more traditional glioma models and have become one of the gold-standards for both basic and translational studies in GBM. The Sarkaria laboratory has developed a panel of 79 GBM xenografts that were established by implanting patient tumor specimens directly into the flank of nude mice. Maintenance of these xenograft lines by serial transplantation in mice preserves key genetic features of the corresponding patient tumor, such as EGFR amplification, and whole exome sequencing and RNAseq analysis demonstrates that these models are broadly representative of common molecular variants observed within GBM. We used a similar strategy to xenograft freshly resected brain tumor metastases to develop highly translational relevant models for brain metastases. To date, we have developed 38 brain metastasis PDX models, including 11 from melanoma metastases. These melanoma PDX models demonstrate robust intracranial growth when directly implanted into the brain, significant brain tropism following intracardiac injection, and similar to the glioma PDX models, we are completing our RNAseq analysis of these models. Overall, the extensive phenotypic and molecular characterization of these models greatly enhances our ability to select appropriate tumor models to test the EGFR and RAF-targeted therapies in the planned MIT/Mayo PS-OC projects.nn&nbsp;nnThe Animal and Pharmacology Core will provide essential services to the MIT/Mayo PS-OC in support of both Project 1 and Project 2. The Core will manage all aspects of the experiments that involve live animals and, in collaboration with the Administrative Core, manage distribution of biospecimens and imaging data to the appropriate investigators.","4":"Evolution","5":"MIT Mayo Physical Sciences Center for Drug Distribution and Drug Efficacy in Brain Tumors","6":"PS-ON","7":"U54"},{"1":"syn21645064","2":"Functional Interactions between HIF-1 and ECM in Cancer","3":"This project focuses on analyzing the makeup and physical properties of the extracellular matrix (ECM) in which cells live. Normal cells live in a flexible scaffold, but cancer cells create a rigid scaffold that they climb through to invade normal tissue. This project will study how this change occurs and how it is affected by the amount of oxygen to which cancer cells are exposed.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-1.jpg](https://physics.cancer.gov/images/centers/JHU-project-1.jpg)","4":"Microenvironment","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645064","2":"Functional Interactions between HIF-1 and ECM in Cancer","3":"This project focuses on analyzing the makeup and physical properties of the extracellular matrix (ECM) in which cells live. Normal cells live in a flexible scaffold, but cancer cells create a rigid scaffold that they climb through to invade normal tissue. This project will study how this change occurs and how it is affected by the amount of oxygen to which cancer cells are exposed.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-1.jpg](https://physics.cancer.gov/images/centers/JHU-project-1.jpg)","4":"Metastasis","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645064","2":"Functional Interactions between HIF-1 and ECM in Cancer","3":"This project focuses on analyzing the makeup and physical properties of the extracellular matrix (ECM) in which cells live. Normal cells live in a flexible scaffold, but cancer cells create a rigid scaffold that they climb through to invade normal tissue. This project will study how this change occurs and how it is affected by the amount of oxygen to which cancer cells are exposed.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-1.jpg](https://physics.cancer.gov/images/centers/JHU-project-1.jpg)","4":"Metabolism","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645065","2":"The Physics of Cadherin-Mediated Intercellular Adhesion and 3D Migration in Cancer","3":"Cancer cells are able to modulate proteins on the surface almost like a protein brake that allows them to adhere or de-adhere in response to mechanical forces. This project will examine the physical basis for cancer cell adhesion and de-adhesion and how it increases the likelihood that cancer cells will break free, move into the bloodstream and migrate to other tissues.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-2.jpg](https://physics.cancer.gov/images/centers/JHU-project-2.jpg)","4":"Microenvironment","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645065","2":"The Physics of Cadherin-Mediated Intercellular Adhesion and 3D Migration in Cancer","3":"Cancer cells are able to modulate proteins on the surface almost like a protein brake that allows them to adhere or de-adhere in response to mechanical forces. This project will examine the physical basis for cancer cell adhesion and de-adhesion and how it increases the likelihood that cancer cells will break free, move into the bloodstream and migrate to other tissues.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-2.jpg](https://physics.cancer.gov/images/centers/JHU-project-2.jpg)","4":"Metastasis","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645065","2":"The Physics of Cadherin-Mediated Intercellular Adhesion and 3D Migration in Cancer","3":"Cancer cells are able to modulate proteins on the surface almost like a protein brake that allows them to adhere or de-adhere in response to mechanical forces. This project will examine the physical basis for cancer cell adhesion and de-adhesion and how it increases the likelihood that cancer cells will break free, move into the bloodstream and migrate to other tissues.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-2.jpg](https://physics.cancer.gov/images/centers/JHU-project-2.jpg)","4":"Metabolism","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645066","2":"Mechanochemical Effects on Tumor Cell Signaling, Adhesion and Migration","3":"Fluid flow in and around tumor tissue modulates the mechanical microenvironment, including the forces acting on the cell surface and the tethering force on cell-substrate connections. Cells in the interior of a tumor mass experience a lower oxygen tension microenvironment and lower fluid velocities than those at the edges in proximity with a functional blood vessel, and are prompted to produce different biochemical signals. These differential responses affect tumor cell fate that is, whether a cell will live or die, and whether it will be able to detach and migrate to secondary sites in the body.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-3.jpg](https://physics.cancer.gov/images/centers/JHU-project-3.jpg)","4":"Microenvironment","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645066","2":"Mechanochemical Effects on Tumor Cell Signaling, Adhesion and Migration","3":"Fluid flow in and around tumor tissue modulates the mechanical microenvironment, including the forces acting on the cell surface and the tethering force on cell-substrate connections. Cells in the interior of a tumor mass experience a lower oxygen tension microenvironment and lower fluid velocities than those at the edges in proximity with a functional blood vessel, and are prompted to produce different biochemical signals. These differential responses affect tumor cell fate that is, whether a cell will live or die, and whether it will be able to detach and migrate to secondary sites in the body.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-3.jpg](https://physics.cancer.gov/images/centers/JHU-project-3.jpg)","4":"Metastasis","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645066","2":"Mechanochemical Effects on Tumor Cell Signaling, Adhesion and Migration","3":"Fluid flow in and around tumor tissue modulates the mechanical microenvironment, including the forces acting on the cell surface and the tethering force on cell-substrate connections. Cells in the interior of a tumor mass experience a lower oxygen tension microenvironment and lower fluid velocities than those at the edges in proximity with a functional blood vessel, and are prompted to produce different biochemical signals. These differential responses affect tumor cell fate that is, whether a cell will live or die, and whether it will be able to detach and migrate to secondary sites in the body.nn&nbsp;nn![https://physics.cancer.gov/images/centers/JHU-project-3.jpg](https://physics.cancer.gov/images/centers/JHU-project-3.jpg)","4":"Metabolism","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645067","2":"PS-OC Imaging Core","3":"This core has capabilities in epifluorescence/atomic force microscopy, ultra-fast/sensitive dynamic live-cell imaging, and total internal reflectance fluorescence microscopy. In addition, confocal/ multi-photon microscopy, fluorescence correlation spectroscopy, multi-mode scanning electron microscopy, high- vacuum, low-vacuum, and environmental-SEM, and conventional and high-resolution analytical transmission electron microscopy will be utilized. This core will also perform fluorescence-activated cell sorting and analysis.","4":"Microenvironment","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645067","2":"PS-OC Imaging Core","3":"This core has capabilities in epifluorescence/atomic force microscopy, ultra-fast/sensitive dynamic live-cell imaging, and total internal reflectance fluorescence microscopy. In addition, confocal/ multi-photon microscopy, fluorescence correlation spectroscopy, multi-mode scanning electron microscopy, high- vacuum, low-vacuum, and environmental-SEM, and conventional and high-resolution analytical transmission electron microscopy will be utilized. This core will also perform fluorescence-activated cell sorting and analysis.","4":"Metastasis","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645067","2":"PS-OC Imaging Core","3":"This core has capabilities in epifluorescence/atomic force microscopy, ultra-fast/sensitive dynamic live-cell imaging, and total internal reflectance fluorescence microscopy. In addition, confocal/ multi-photon microscopy, fluorescence correlation spectroscopy, multi-mode scanning electron microscopy, high- vacuum, low-vacuum, and environmental-SEM, and conventional and high-resolution analytical transmission electron microscopy will be utilized. This core will also perform fluorescence-activated cell sorting and analysis.","4":"Metabolism","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645068","2":"PS-OC Microfabrication Core","3":"This core is housed in a 600-sq. ft. facility and retains the following equipment for photolithography: spin coater; UV lamp; e-beam evaporator; mask aligner; and wet chemical equipment. Adhesive micropatterned surfaces will be used to study the influence of geometry on motility. In another example, microfluidic<U+201A><U+00C4><U+00EA>based devices will be fabricated to study the influence of steric forces, extracellular matrix, cell compliance, and adhesiveness on tumor cell migration.","4":"Microenvironment","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645068","2":"PS-OC Microfabrication Core","3":"This core is housed in a 600-sq. ft. facility and retains the following equipment for photolithography: spin coater; UV lamp; e-beam evaporator; mask aligner; and wet chemical equipment. Adhesive micropatterned surfaces will be used to study the influence of geometry on motility. In another example, microfluidic<U+201A><U+00C4><U+00EA>based devices will be fabricated to study the influence of steric forces, extracellular matrix, cell compliance, and adhesiveness on tumor cell migration.","4":"Metastasis","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645068","2":"PS-OC Microfabrication Core","3":"This core is housed in a 600-sq. ft. facility and retains the following equipment for photolithography: spin coater; UV lamp; e-beam evaporator; mask aligner; and wet chemical equipment. Adhesive micropatterned surfaces will be used to study the influence of geometry on motility. In another example, microfluidic<U+201A><U+00C4><U+00EA>based devices will be fabricated to study the influence of steric forces, extracellular matrix, cell compliance, and adhesiveness on tumor cell migration.","4":"Metabolism","5":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","6":"PS-ON","7":"U54"},{"1":"syn21645069","2":"Effects of the Physical Microenvironment on Metabolism","3":"Triple negative breast cancer (TNBC) and obesity lead to physical changes in the microenvironment, including aberrant multiscale structure and mechanics of the extracellular matrix, disturbed distributions of soluble factors, and population-level abnormalities in collective cell behavior. However, the functional interconnections between these physical variations and tumor metabolism remain unclear. This gap in understanding can be attributed to a lack of computational and experimental models that permit reliable prediction, recapitulation, and study of tumor and obesity-associated physical mechanisms in TNBC. By integrating biomaterials, tissue engineering, microfabrication, and computational models, Project 1 will investigate the hypothesis that physical changes in the microenvironment regulate malignancy by perturbing cellular metabolism. Furthermore, we will test whether obesity primes for tumorigenesis through similar mechanisms. To address these hypotheses, engineering-centric approaches will be integrated with transgenic mouse models, patient-derives xenografts, patient-derived organoid cultures, and drug testing. This approach will reveal novel mechanisms in tumor metabolic reprogramming for clinical translation.nn&nbsp;nn${image?fileName=Tumor%2Dspheroid1%2Dshtpe8%2Ejpg&align=None&scale=60&responsive=true}","4":"Metabolism","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645069","2":"Effects of the Physical Microenvironment on Metabolism","3":"Triple negative breast cancer (TNBC) and obesity lead to physical changes in the microenvironment, including aberrant multiscale structure and mechanics of the extracellular matrix, disturbed distributions of soluble factors, and population-level abnormalities in collective cell behavior. However, the functional interconnections between these physical variations and tumor metabolism remain unclear. This gap in understanding can be attributed to a lack of computational and experimental models that permit reliable prediction, recapitulation, and study of tumor and obesity-associated physical mechanisms in TNBC. By integrating biomaterials, tissue engineering, microfabrication, and computational models, Project 1 will investigate the hypothesis that physical changes in the microenvironment regulate malignancy by perturbing cellular metabolism. Furthermore, we will test whether obesity primes for tumorigenesis through similar mechanisms. To address these hypotheses, engineering-centric approaches will be integrated with transgenic mouse models, patient-derives xenografts, patient-derived organoid cultures, and drug testing. This approach will reveal novel mechanisms in tumor metabolic reprogramming for clinical translation.nn&nbsp;nn${image?fileName=Tumor%2Dspheroid1%2Dshtpe8%2Ejpg&align=None&scale=60&responsive=true}","4":"Microenvironment","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645069","2":"Effects of the Physical Microenvironment on Metabolism","3":"Triple negative breast cancer (TNBC) and obesity lead to physical changes in the microenvironment, including aberrant multiscale structure and mechanics of the extracellular matrix, disturbed distributions of soluble factors, and population-level abnormalities in collective cell behavior. However, the functional interconnections between these physical variations and tumor metabolism remain unclear. This gap in understanding can be attributed to a lack of computational and experimental models that permit reliable prediction, recapitulation, and study of tumor and obesity-associated physical mechanisms in TNBC. By integrating biomaterials, tissue engineering, microfabrication, and computational models, Project 1 will investigate the hypothesis that physical changes in the microenvironment regulate malignancy by perturbing cellular metabolism. Furthermore, we will test whether obesity primes for tumorigenesis through similar mechanisms. To address these hypotheses, engineering-centric approaches will be integrated with transgenic mouse models, patient-derives xenografts, patient-derived organoid cultures, and drug testing. This approach will reveal novel mechanisms in tumor metabolic reprogramming for clinical translation.nn&nbsp;nn${image?fileName=Tumor%2Dspheroid1%2Dshtpe8%2Ejpg&align=None&scale=60&responsive=true}","4":"Metastasis","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645070","2":"Metabolism-Mediated Changes of Microvesicle Biogenesis","3":"Focus on a key outcome of cancer cell metabolism: the generation of microvesicles (MVs), which are shed from the plasma membranes of cancer cells. MVs have been implicated in the metastatic process by changing the tumor microenvironment and stimulating tumor angiogenesis. Although we understand some of the biochemical signals triggering MV production, we know little about the physical determinants driving their formation, or how the physical microenvironment influences their biogenesis and function. We will probe these issues as follows: 1) Determine the physical relationships governing MV biogenesis and size distribution; 2) determine the reciprocal relationship between the physical properties of the extracellular matrix and MV formation; 3) establish physical read-outs such as vesicle size as indicators of MV function in tumor-stroma and reciprocal stroma-tumor vesicle transfer. These studies should shed new light on how cancer cell metabolism stimulates MV biogenesis, and ultimately lead to novel therapeutic strategies.nn&nbsp;nn${image?fileName=nih%2Dcancer%2Dcells%2Dattachment%2Dx876on%2D768x770%2Ejpg&align=None&scale=40&responsive=true}","4":"Metabolism","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645070","2":"Metabolism-Mediated Changes of Microvesicle Biogenesis","3":"Focus on a key outcome of cancer cell metabolism: the generation of microvesicles (MVs), which are shed from the plasma membranes of cancer cells. MVs have been implicated in the metastatic process by changing the tumor microenvironment and stimulating tumor angiogenesis. Although we understand some of the biochemical signals triggering MV production, we know little about the physical determinants driving their formation, or how the physical microenvironment influences their biogenesis and function. We will probe these issues as follows: 1) Determine the physical relationships governing MV biogenesis and size distribution; 2) determine the reciprocal relationship between the physical properties of the extracellular matrix and MV formation; 3) establish physical read-outs such as vesicle size as indicators of MV function in tumor-stroma and reciprocal stroma-tumor vesicle transfer. These studies should shed new light on how cancer cell metabolism stimulates MV biogenesis, and ultimately lead to novel therapeutic strategies.nn&nbsp;nn${image?fileName=nih%2Dcancer%2Dcells%2Dattachment%2Dx876on%2D768x770%2Ejpg&align=None&scale=40&responsive=true}","4":"Microenvironment","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645070","2":"Metabolism-Mediated Changes of Microvesicle Biogenesis","3":"Focus on a key outcome of cancer cell metabolism: the generation of microvesicles (MVs), which are shed from the plasma membranes of cancer cells. MVs have been implicated in the metastatic process by changing the tumor microenvironment and stimulating tumor angiogenesis. Although we understand some of the biochemical signals triggering MV production, we know little about the physical determinants driving their formation, or how the physical microenvironment influences their biogenesis and function. We will probe these issues as follows: 1) Determine the physical relationships governing MV biogenesis and size distribution; 2) determine the reciprocal relationship between the physical properties of the extracellular matrix and MV formation; 3) establish physical read-outs such as vesicle size as indicators of MV function in tumor-stroma and reciprocal stroma-tumor vesicle transfer. These studies should shed new light on how cancer cell metabolism stimulates MV biogenesis, and ultimately lead to novel therapeutic strategies.nn&nbsp;nn${image?fileName=nih%2Dcancer%2Dcells%2Dattachment%2Dx876on%2D768x770%2Ejpg&align=None&scale=40&responsive=true}","4":"Metastasis","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645071","2":"Physical and Metabolic Constraints of Cancer Cell Invasion","3":"Cell invasion from the primary tumor into surrounding tissues is a crucial step of the metastatic cascade, which is responsible for the vast majority of cancer deaths. We propose that invading cancer cells must expend significant energy to penetrate through tight interstitial spaces, and adopt migration modes that minimize metabolic cost. The research in this project will address how the interaction between invading cells and the physical microenvironment determine energy consumption; how physical factors intrinsic to the cell, particularly nuclear deformability and the physical properties of the cell surface, modulate metabolic cost and migration efficiency; and how metabolic reprogramming in cancer cells affects migration efficiency by fueling biosynthetic pathways that alter cellular mechanics. The experimental work will be complemented by modeling of cancer cell metabolism and physical interaction with the microenvironment, with the objective to predict outcomes of therapeutic metabolic interventions and to identify strategies to counter adaptive responses.nn&nbsp;nn![https://psoc.engineering.cornell.edu/files/2016/09/tumormcroenvironmentfriedl-10uz9ct-281x300.jpg](https://psoc.engineering.cornell.edu/files/2016/09/tumormcroenvironmentfriedl-10uz9ct-281x300.jpg)","4":"Metabolism","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645071","2":"Physical and Metabolic Constraints of Cancer Cell Invasion","3":"Cell invasion from the primary tumor into surrounding tissues is a crucial step of the metastatic cascade, which is responsible for the vast majority of cancer deaths. We propose that invading cancer cells must expend significant energy to penetrate through tight interstitial spaces, and adopt migration modes that minimize metabolic cost. The research in this project will address how the interaction between invading cells and the physical microenvironment determine energy consumption; how physical factors intrinsic to the cell, particularly nuclear deformability and the physical properties of the cell surface, modulate metabolic cost and migration efficiency; and how metabolic reprogramming in cancer cells affects migration efficiency by fueling biosynthetic pathways that alter cellular mechanics. The experimental work will be complemented by modeling of cancer cell metabolism and physical interaction with the microenvironment, with the objective to predict outcomes of therapeutic metabolic interventions and to identify strategies to counter adaptive responses.nn&nbsp;nn![https://psoc.engineering.cornell.edu/files/2016/09/tumormcroenvironmentfriedl-10uz9ct-281x300.jpg](https://psoc.engineering.cornell.edu/files/2016/09/tumormcroenvironmentfriedl-10uz9ct-281x300.jpg)","4":"Microenvironment","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645071","2":"Physical and Metabolic Constraints of Cancer Cell Invasion","3":"Cell invasion from the primary tumor into surrounding tissues is a crucial step of the metastatic cascade, which is responsible for the vast majority of cancer deaths. We propose that invading cancer cells must expend significant energy to penetrate through tight interstitial spaces, and adopt migration modes that minimize metabolic cost. The research in this project will address how the interaction between invading cells and the physical microenvironment determine energy consumption; how physical factors intrinsic to the cell, particularly nuclear deformability and the physical properties of the cell surface, modulate metabolic cost and migration efficiency; and how metabolic reprogramming in cancer cells affects migration efficiency by fueling biosynthetic pathways that alter cellular mechanics. The experimental work will be complemented by modeling of cancer cell metabolism and physical interaction with the microenvironment, with the objective to predict outcomes of therapeutic metabolic interventions and to identify strategies to counter adaptive responses.nn&nbsp;nn![https://psoc.engineering.cornell.edu/files/2016/09/tumormcroenvironmentfriedl-10uz9ct-281x300.jpg](https://psoc.engineering.cornell.edu/files/2016/09/tumormcroenvironmentfriedl-10uz9ct-281x300.jpg)","4":"Metastasis","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645072","2":"Tissue Microfabrication Core","3":"The elucidation of biophysical mechanisms that lead to metabolic aberrations in tumors and, in turn, impact cancer progression, requires specialized capabilities for the manipulation of cells, biological materials, and tissues and for the development of computational models to evaluate hypotheses and interpret experimental data. Additionally, the assessment of the clinical relevance of these mechanisms and their translation toward therapeutic applications requires coordinated access to patient-derived samples with thorough clinical and genetic profiling and data basing. The Tissue Microfabrication Core will provide project investigators a shared infrastructure that satisfies these requirements organized into three aims: 1) management of the acquisition, clinical and genomic characterization, data banking, and distribution of patient derived tissues; 2) development and fabrication of advanced culture platforms and microfluidic devices for the characterization of cells and biomaterials; and 3) hierarchy of computational models to support metabolic analysis and the design and interpretation of experiments.nn&nbsp;nn![https://psoc.engineering.cornell.edu/files/2016/09/cropped-Microvascular-Image-1kgdsig-300x200.jpeg](https://psoc.engineering.cornell.edu/files/2016/09/cropped-Microvascular-Image-1kgdsig-300x200.jpeg)","4":"Metabolism","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645072","2":"Tissue Microfabrication Core","3":"The elucidation of biophysical mechanisms that lead to metabolic aberrations in tumors and, in turn, impact cancer progression, requires specialized capabilities for the manipulation of cells, biological materials, and tissues and for the development of computational models to evaluate hypotheses and interpret experimental data. Additionally, the assessment of the clinical relevance of these mechanisms and their translation toward therapeutic applications requires coordinated access to patient-derived samples with thorough clinical and genetic profiling and data basing. The Tissue Microfabrication Core will provide project investigators a shared infrastructure that satisfies these requirements organized into three aims: 1) management of the acquisition, clinical and genomic characterization, data banking, and distribution of patient derived tissues; 2) development and fabrication of advanced culture platforms and microfluidic devices for the characterization of cells and biomaterials; and 3) hierarchy of computational models to support metabolic analysis and the design and interpretation of experiments.nn&nbsp;nn![https://psoc.engineering.cornell.edu/files/2016/09/cropped-Microvascular-Image-1kgdsig-300x200.jpeg](https://psoc.engineering.cornell.edu/files/2016/09/cropped-Microvascular-Image-1kgdsig-300x200.jpeg)","4":"Microenvironment","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645072","2":"Tissue Microfabrication Core","3":"The elucidation of biophysical mechanisms that lead to metabolic aberrations in tumors and, in turn, impact cancer progression, requires specialized capabilities for the manipulation of cells, biological materials, and tissues and for the development of computational models to evaluate hypotheses and interpret experimental data. Additionally, the assessment of the clinical relevance of these mechanisms and their translation toward therapeutic applications requires coordinated access to patient-derived samples with thorough clinical and genetic profiling and data basing. The Tissue Microfabrication Core will provide project investigators a shared infrastructure that satisfies these requirements organized into three aims: 1) management of the acquisition, clinical and genomic characterization, data banking, and distribution of patient derived tissues; 2) development and fabrication of advanced culture platforms and microfluidic devices for the characterization of cells and biomaterials; and 3) hierarchy of computational models to support metabolic analysis and the design and interpretation of experiments.nn&nbsp;nn![https://psoc.engineering.cornell.edu/files/2016/09/cropped-Microvascular-Image-1kgdsig-300x200.jpeg](https://psoc.engineering.cornell.edu/files/2016/09/cropped-Microvascular-Image-1kgdsig-300x200.jpeg)","4":"Metastasis","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645073","2":"Biophysics and Metabolic Imaging Core","3":"The Biophysical and Metabolic Imaging Core provides the optical imaging instrumentation, facilities and expertise for the high resolution imaging, biophysical analysis and image processing tasks required by the three PSOC projects, as well as any pilot or trans-network projects that may develop. We provide high-end microscopy instrumentation for dynamic measurements of the cellular metabolic state using both fluorescent metabolic sensors and intrinsic sources such as NADH and FAD containing proteins, for the visualization of tissue morphology, microvesicle shedding and for quantitative imaging of cellular nanoscale mechanical properties using several forms of super-resolution microscopy.  The Biophysical and Metabolic Imaging Core leverages both state-of-art commercial instrumentation, as well as custom-built instruments specifically optimized for the research needs of PSOC investigators and their projects.nn&nbsp;nn${image?fileName=3D%5FLaconic%2D2%2Dolsq20%2Ejpg&align=None&scale=60&responsive=true}","4":"Metabolism","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645073","2":"Biophysics and Metabolic Imaging Core","3":"The Biophysical and Metabolic Imaging Core provides the optical imaging instrumentation, facilities and expertise for the high resolution imaging, biophysical analysis and image processing tasks required by the three PSOC projects, as well as any pilot or trans-network projects that may develop. We provide high-end microscopy instrumentation for dynamic measurements of the cellular metabolic state using both fluorescent metabolic sensors and intrinsic sources such as NADH and FAD containing proteins, for the visualization of tissue morphology, microvesicle shedding and for quantitative imaging of cellular nanoscale mechanical properties using several forms of super-resolution microscopy.  The Biophysical and Metabolic Imaging Core leverages both state-of-art commercial instrumentation, as well as custom-built instruments specifically optimized for the research needs of PSOC investigators and their projects.nn&nbsp;nn${image?fileName=3D%5FLaconic%2D2%2Dolsq20%2Ejpg&align=None&scale=60&responsive=true}","4":"Microenvironment","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645073","2":"Biophysics and Metabolic Imaging Core","3":"The Biophysical and Metabolic Imaging Core provides the optical imaging instrumentation, facilities and expertise for the high resolution imaging, biophysical analysis and image processing tasks required by the three PSOC projects, as well as any pilot or trans-network projects that may develop. We provide high-end microscopy instrumentation for dynamic measurements of the cellular metabolic state using both fluorescent metabolic sensors and intrinsic sources such as NADH and FAD containing proteins, for the visualization of tissue morphology, microvesicle shedding and for quantitative imaging of cellular nanoscale mechanical properties using several forms of super-resolution microscopy.  The Biophysical and Metabolic Imaging Core leverages both state-of-art commercial instrumentation, as well as custom-built instruments specifically optimized for the research needs of PSOC investigators and their projects.nn&nbsp;nn${image?fileName=3D%5FLaconic%2D2%2Dolsq20%2Ejpg&align=None&scale=60&responsive=true}","4":"Metastasis","5":"Center on the Physics of Cancer Metabolism","6":"PS-ON","7":"U54"},{"1":"syn21645074","2":"Epithelial layer jamming in breast cancer cell migration","3":"If cancer cells did not migrate <U+201A><U+00C4><U+00EC>and instead just stayed put<U+201A><U+00C4><U+00EC> then cancer in most instances would be a more manageable disease. But cancer cells do migrate, and that migration accounts for much of cancer<U+201A><U+00C4><U+00F4>s morbidity and mortality. Unfortunately, we understand little about how, why, and when this aberrant cellular migration plays out. Cancer cells tend to migrate not as individual units but rather as a cellular collective <U+201A><U+00C4><U+00EC>in multicellular strings, ducts, strands and clusters. We propose that a controlling factor in that collective cellular migration is a newly discovered phenomenon called <U+201A><U+00C4><U+00FA>cell jamming<U+201A><U+00C4><U+00F9>. From cars streaming in highway traffic to coffee beans flowing in a chute at the supermarket to cells migrating within a living tissue, a wide variety of collective systems <U+201A><U+00C4><U+00EC>both inert and living<U+201A><U+00C4><U+00EC> are now known to have the capacity to jam. Within a living cell cluster, in particular, cells can jam to become quiescent, solid-like, and virtually frozen in place, or instead can unjam to become mobilized, fluid-like, and migratory. In the physiological case of healthy tissues, we do not yet know if the transition from a jammed to an unjammed state is an essential part of organogenesis, pattern formation, and wound healing. And in the pathophysiological case of malignant tissues, neither do we know if the transition from a jammed to an unjammed state is a prerequisite for invasion or metastasis. We do know, however, that the discovery of cell jamming suggests a physical picture of collective cellular migration that is substantially richer than previously recognized, and we propose here to investigate cell jamming in the context of early stages of breast tumor progression. Breast cancer is representative of the wider class of cancers of epithelial origin <U+201A><U+00C4><U+00EC>carcinomas<U+201A><U+00C4><U+00EC> that account for the vast majority of cancers and cancer deaths.nn&nbsp;nnDo epithelial cells in some circumstances behave in one way <U+201A><U+00C4><U+00EC>jammed, solid-like and aggregated with little possibility of mutual cell rearrangement, escape or invasion<U+201A><U+00C4><U+00EC> while in other circumstances they behave in another <U+201A><U+00C4><U+00EC>unjammed, fluid-like, disaggregated and invasive? We address this question in selected breast cancer cell lines, in a variety of extracellular environments that mimic native environments, and across graded stages of the epithelial-to-mesenchymal transition. Data derived from a comprehensive suite of novel experimental probes <U+201A><U+00C4><U+00EC>cellular motions, traction stresses, intercellular stresses and cellular shapes (Figure)<U+201A><U+00C4><U+00EC> will be critically examined through the lens of a novel quantitative theory of cell jamming. Specific questions include:   nn&nbsp;nnDo cell populations that are jammed correspond to quiescent, lower risk states whereas populations that are unjammed correspond to states that are more motile, more invasive, or more likely to metastasize?nConventional wisdom holds that adhesion molecules tether a cell to its immediate neighbors and thus tend to impede cellular migration. The theory of cell jamming and supporting preliminary data suggest the opposite interpretation <U+201A><U+00C4><U+00EC>increased cell-cell adhesion facilitates cell unjamming and thereby promotes cellular migration. Is the conventional wisdom overly simplistic and perhaps even misleading?  Does the jamming hypothesis force a fundamental rethinking of the mechano-biology of cancer cell migration and metastasis?nn&nbsp;nnHow does the presence of stem-like features within cancer cell sub-populations alter the propensity for cell unjamming?nImportantly, the cell jamming hypothesis makes predictions that are mechanistic, non-trivial, and counterintuitive. If supported by the data in the instances of the particular breast cancers to be addressed here, the hope is that the concept of cell jamming may improve understanding and guide novel therapeutic approaches <U+201A><U+00C4><U+00EC>not only in those particular instances, but also more generally in other cancers of epithelial origin.nn&nbsp;n![image](https://physics.cancer.gov/images/network/HarvardUniversity-slide1.jpg)","4":"Metastasis","5":"Epithelial layer jamming in breast cancer cell migration","6":"PS-ON","7":"U01"},{"1":"syn21645074","2":"Epithelial layer jamming in breast cancer cell migration","3":"If cancer cells did not migrate <U+201A><U+00C4><U+00EC>and instead just stayed put<U+201A><U+00C4><U+00EC> then cancer in most instances would be a more manageable disease. But cancer cells do migrate, and that migration accounts for much of cancer<U+201A><U+00C4><U+00F4>s morbidity and mortality. Unfortunately, we understand little about how, why, and when this aberrant cellular migration plays out. Cancer cells tend to migrate not as individual units but rather as a cellular collective <U+201A><U+00C4><U+00EC>in multicellular strings, ducts, strands and clusters. We propose that a controlling factor in that collective cellular migration is a newly discovered phenomenon called <U+201A><U+00C4><U+00FA>cell jamming<U+201A><U+00C4><U+00F9>. From cars streaming in highway traffic to coffee beans flowing in a chute at the supermarket to cells migrating within a living tissue, a wide variety of collective systems <U+201A><U+00C4><U+00EC>both inert and living<U+201A><U+00C4><U+00EC> are now known to have the capacity to jam. Within a living cell cluster, in particular, cells can jam to become quiescent, solid-like, and virtually frozen in place, or instead can unjam to become mobilized, fluid-like, and migratory. In the physiological case of healthy tissues, we do not yet know if the transition from a jammed to an unjammed state is an essential part of organogenesis, pattern formation, and wound healing. And in the pathophysiological case of malignant tissues, neither do we know if the transition from a jammed to an unjammed state is a prerequisite for invasion or metastasis. We do know, however, that the discovery of cell jamming suggests a physical picture of collective cellular migration that is substantially richer than previously recognized, and we propose here to investigate cell jamming in the context of early stages of breast tumor progression. Breast cancer is representative of the wider class of cancers of epithelial origin <U+201A><U+00C4><U+00EC>carcinomas<U+201A><U+00C4><U+00EC> that account for the vast majority of cancers and cancer deaths.nn&nbsp;nnDo epithelial cells in some circumstances behave in one way <U+201A><U+00C4><U+00EC>jammed, solid-like and aggregated with little possibility of mutual cell rearrangement, escape or invasion<U+201A><U+00C4><U+00EC> while in other circumstances they behave in another <U+201A><U+00C4><U+00EC>unjammed, fluid-like, disaggregated and invasive? We address this question in selected breast cancer cell lines, in a variety of extracellular environments that mimic native environments, and across graded stages of the epithelial-to-mesenchymal transition. Data derived from a comprehensive suite of novel experimental probes <U+201A><U+00C4><U+00EC>cellular motions, traction stresses, intercellular stresses and cellular shapes (Figure)<U+201A><U+00C4><U+00EC> will be critically examined through the lens of a novel quantitative theory of cell jamming. Specific questions include:   nn&nbsp;nnDo cell populations that are jammed correspond to quiescent, lower risk states whereas populations that are unjammed correspond to states that are more motile, more invasive, or more likely to metastasize?nConventional wisdom holds that adhesion molecules tether a cell to its immediate neighbors and thus tend to impede cellular migration. The theory of cell jamming and supporting preliminary data suggest the opposite interpretation <U+201A><U+00C4><U+00EC>increased cell-cell adhesion facilitates cell unjamming and thereby promotes cellular migration. Is the conventional wisdom overly simplistic and perhaps even misleading?  Does the jamming hypothesis force a fundamental rethinking of the mechano-biology of cancer cell migration and metastasis?nn&nbsp;nnHow does the presence of stem-like features within cancer cell sub-populations alter the propensity for cell unjamming?nImportantly, the cell jamming hypothesis makes predictions that are mechanistic, non-trivial, and counterintuitive. If supported by the data in the instances of the particular breast cancers to be addressed here, the hope is that the concept of cell jamming may improve understanding and guide novel therapeutic approaches <U+201A><U+00C4><U+00EC>not only in those particular instances, but also more generally in other cancers of epithelial origin.nn&nbsp;n![image](https://physics.cancer.gov/images/network/HarvardUniversity-slide1.jpg)","4":"Heterogeneity","5":"Epithelial layer jamming in breast cancer cell migration","6":"PS-ON","7":"U01"},{"1":"syn21645075","2":"Quantitative analyses of tumor cell extravasation","3":"Understanding the fundamental mechanisms leading to metastatic cancer has been hampered by the need for models that replicate the in vivo situation, yet are amenable to tight control and facilitate high-resolution, time-lapse imaging and quantitative analysis of cell behavior. Over the past several years, we have developed microfluidic systems that are capable of simulating many steps of metastasis including tumor cell invasion, intravasation, trapping in the microcirculation or adhesion to the vessel walls, and extravasation into surrounding extracellular matrix. This prior work has shed new light on the interactions between a transmigrating tumor cell and the endothelium, the role of specific adhesion molecules, and the deformations of the cell and especially the cell nucleus, experience during the transmigration process. The object of our current study is to employ these assays in combination with new measurement methods to interrogate the changes in cell mechanics during the process of extravasation, and understand the nature of the cell-cell and cell-matrix force interactions. We are also investigating the nuclear deformations, changes in chromatin structure and the resulting changes in the transcriptome, which could have important implications for the subsequent ability of extravasated cells to form a new tumor. In close coordination with these experiments, computational models are being developed to simulate tumor cell / endothelial cell interactions, nuclear deformation, and the resulting changes in gene expression. We anticipate that these studies will provide new insights, and enhance our ability to identify and screen for new therapies to inhibit the tendency for metastatic spread of disease.nn&nbsp;nn![https://physics.cancer.gov/images/network/MassachusettsInstituteofTechnology-slide1.jpg](https://physics.cancer.gov/images/network/MassachusettsInstituteofTechnology-slide1.jpg)nnA tumor cell (green) in the process of transmigrating across an endothelial monolayer (pink), as observed in a three-dimensional model of tumor cell extravasation.  The vessel lumen is on the left and the extracellular matrix on the right.  Blue indicates cell nuclei.  Note the highly deformed state of the tumor cell nucleus at this stage.","4":"Microenvironment","5":"Quantitative analyses of tumor cell extravasation","6":"PS-ON","7":"U01"},{"1":"syn21645075","2":"Quantitative analyses of tumor cell extravasation","3":"Understanding the fundamental mechanisms leading to metastatic cancer has been hampered by the need for models that replicate the in vivo situation, yet are amenable to tight control and facilitate high-resolution, time-lapse imaging and quantitative analysis of cell behavior. Over the past several years, we have developed microfluidic systems that are capable of simulating many steps of metastasis including tumor cell invasion, intravasation, trapping in the microcirculation or adhesion to the vessel walls, and extravasation into surrounding extracellular matrix. This prior work has shed new light on the interactions between a transmigrating tumor cell and the endothelium, the role of specific adhesion molecules, and the deformations of the cell and especially the cell nucleus, experience during the transmigration process. The object of our current study is to employ these assays in combination with new measurement methods to interrogate the changes in cell mechanics during the process of extravasation, and understand the nature of the cell-cell and cell-matrix force interactions. We are also investigating the nuclear deformations, changes in chromatin structure and the resulting changes in the transcriptome, which could have important implications for the subsequent ability of extravasated cells to form a new tumor. In close coordination with these experiments, computational models are being developed to simulate tumor cell / endothelial cell interactions, nuclear deformation, and the resulting changes in gene expression. We anticipate that these studies will provide new insights, and enhance our ability to identify and screen for new therapies to inhibit the tendency for metastatic spread of disease.nn&nbsp;nn![https://physics.cancer.gov/images/network/MassachusettsInstituteofTechnology-slide1.jpg](https://physics.cancer.gov/images/network/MassachusettsInstituteofTechnology-slide1.jpg)nnA tumor cell (green) in the process of transmigrating across an endothelial monolayer (pink), as observed in a three-dimensional model of tumor cell extravasation.  The vessel lumen is on the left and the extracellular matrix on the right.  Blue indicates cell nuclei.  Note the highly deformed state of the tumor cell nucleus at this stage.","4":"Metastasis","5":"Quantitative analyses of tumor cell extravasation","6":"PS-ON","7":"U01"},{"1":"syn21645076","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs. A combination of discoveries from the Groves lab (physical chemistry, UCB) and the Weaver lab (cancer biology, UCSF) have lead to a new insight into how cancer cells acquire this resistance and how we might be able to stop this deadly process.nn&nbsp;nnReceptor tyrosine kinase (RTK) somatic mutations and overexpression are found in many aggressive diseases such as non-small cell lung carcinoma (NSCLC), breast cancer, and colorectal cancer. RTKs are thus important targets for cancer therapy. However, patients often develop resistance to RTK inhibitors, despite initially robust tumor regression. While this could be due to the emergence of mutated clones, stromal-epithelial interactions also regulate tumor progression and treatment response. In particular, there is a striking heterogeneity in extracellular matrix (ECM) mechanical properties in diseased tissue. Recent work from our groups suggests that ECM modulation of tumor behavior occurs through RTK signaling assemblies (Weaver et al., Cell, 2009; Nature, 2014; Cancer Res., 2014; Groves et al., Science, 2010), extending the mechanistic features of the mechano-signal initiation beyond the well-characterized effect of integrin-mediated adhesion and signaling. It is our thesis that in addition to genetic variation, external spatio-mechanical factors from the ECM are critical contributors to RTK therapy resistance. In this program, we will utilize the expertise of both of our groups to quantitatively characterize and manipulate the mechanical and topographical properties of the cellular microenvironment to understand the effects on RTK signaling (Figure), and its therapeutic inhibition. This study will provide actionable insights by pinpointing the molecular mechanisms by which ECM modulates RTK signaling and contributes to RTK inhibitor resistance.nn&nbsp;nn![https://physics.cancer.gov/images/network/UniversityofCaliforniaBerkeley-slide1.jpg](https://physics.cancer.gov/images/network/UniversityofCaliforniaBerkeley-slide1.jpg)nFigure: Schematic of proposed research to study how the mechanical and topographical properties of the cellular microenvironment modulate RTK signaling and contribute to RTK inhibitor resistance in cancer treatment.","4":"Heterogeneity","5":"ECM geometrical and mechanical properties modulate RTK signaling","6":"PS-ON","7":"U01"},{"1":"syn21645076","2":"ECM geometrical and mechanical properties modulate RTK signaling","3":"A serious problem with cancer treatment today is the tendency of cancer cells to develop resistance to the drugs we use to destroy them. The devastating result is that all too many cancer patients see their cancer at first respond positively to drug treatment, only to return later with a newfound resistance to the cancer drugs. A combination of discoveries from the Groves lab (physical chemistry, UCB) and the Weaver lab (cancer biology, UCSF) have lead to a new insight into how cancer cells acquire this resistance and how we might be able to stop this deadly process.nn&nbsp;nnReceptor tyrosine kinase (RTK) somatic mutations and overexpression are found in many aggressive diseases such as non-small cell lung carcinoma (NSCLC), breast cancer, and colorectal cancer. RTKs are thus important targets for cancer therapy. However, patients often develop resistance to RTK inhibitors, despite initially robust tumor regression. While this could be due to the emergence of mutated clones, stromal-epithelial interactions also regulate tumor progression and treatment response. In particular, there is a striking heterogeneity in extracellular matrix (ECM) mechanical properties in diseased tissue. Recent work from our groups suggests that ECM modulation of tumor behavior occurs through RTK signaling assemblies (Weaver et al., Cell, 2009; Nature, 2014; Cancer Res., 2014; Groves et al., Science, 2010), extending the mechanistic features of the mechano-signal initiation beyond the well-characterized effect of integrin-mediated adhesion and signaling. It is our thesis that in addition to genetic variation, external spatio-mechanical factors from the ECM are critical contributors to RTK therapy resistance. In this program, we will utilize the expertise of both of our groups to quantitatively characterize and manipulate the mechanical and topographical properties of the cellular microenvironment to understand the effects on RTK signaling (Figure), and its therapeutic inhibition. This study will provide actionable insights by pinpointing the molecular mechanisms by which ECM modulates RTK signaling and contributes to RTK inhibitor resistance.nn&nbsp;nn![https://physics.cancer.gov/images/network/UniversityofCaliforniaBerkeley-slide1.jpg](https://physics.cancer.gov/images/network/UniversityofCaliforniaBerkeley-slide1.jpg)nFigure: Schematic of proposed research to study how the mechanical and topographical properties of the cellular microenvironment modulate RTK signaling and contribute to RTK inhibitor resistance in cancer treatment.","4":"Microenvironment","5":"ECM geometrical and mechanical properties modulate RTK signaling","6":"PS-ON","7":"U01"},{"1":"syn21645077","2":"Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics","3":"The University of Utah team is developing new mathematical frameworks to do what no others currently can, that is, create a single coherent model from multiple high-dimensional datasets, known as tensors. The frameworks <U+201A><U+00C4><U+00EC> comparative spectral decompositions <U+201A><U+00C4><U+00EC> generalize those that underlie the theoretical description of the physical world. The team is using the frameworks to compare and contrast datasets recording different aspects of a single disease, such as genomic profiles of multiple cell types from the same set of patients, measured more than once by several different methods. By using the complex structure of the datasets, rather than simplifying them as is commonly done, the frameworks enable the separation of patterns of DNA alterations <U+201A><U+00C4><U+00EC> which occur only in the tumor genomes <U+201A><U+00C4><U+00EC> from those that occur in the genomes of normal cells in the body, and from variations caused by experimental inconsistencies. The patterns that the team uncovers in the data are expected to offer answers to the open question of the relation between a tumor's genome and a patient's outcome.nn&nbsp;nnFor example, recent comparisons of the genomes of tumor and normal cells from the same sets of ovarian and, separately, glioblastoma brain cancer patients uncovered patterns of DNA copy-number alterations that were found to be correlated with a patient's survival and response to chemotherapy. For three decades prior, the best predictor of ovarian cancer survival was the tumor's stage; more than a quarter of ovarian tumors are resistant to the platinum-based chemotherapy, the first-line treatment, yet no diagnostic existed to distinguish resistant from sensitive tumors before the treatment. For five decades prior, the best prognostic indicator of glioblastoma was the patient's age at diagnosis. The ovarian and brain cancer data were published, but the patterns remained unknown until the team applied their comparative spectral decompositions.nn&nbsp;nnPending experimental revalidation, the team will bring the patterns that they uncover to the clinic, to be used in personalized diagnostic and prognostic pathology laboratory tests. The tests would predict a patient's survival and response to therapy, and doctors could tailor treatment accordingly.nn&nbsp;nn![http://www.alterlab.org/physics_of_cancer/jpgs/Image_1.jpg](http://www.alterlab.org/physics_of_cancer/jpgs/Image_1.jpg)nn&nbsp;nn&nbsp;nn#####Physics-inspired mathematical frameworks. nThe team develops mathematical frameworks to uncover patterns in datasets arranged in two or more third- or higher-dimensional tables, known as tensors. Rather than simplifying the datasets, as is commonly done, the frameworks make use of their complex structure in order to tease out the patterns within them.nn&nbsp;nn![http://www.alterlab.org/physics_of_cancer/jpgs/Image_2.jpg](http://www.alterlab.org/physics_of_cancer/jpgs/Image_2.jpg)nn&nbsp;nn&nbsp;nn#####Genomic predictors of a patient's outcome.nA recent comparison of the genomes of tumor and normal cells from the same sets of ovarian serous cystadenocarcinoma patients uncovered patterns of DNA copy-number alterations that were found to be correlated with a patient's survival and response to platinum-based chemotherapy. Among patients that were diagnosed at late stages, the DNA patterns distinguished short-term survivors, with a median survival time of three years, from long-term survivors, with a median survival time almost twice as long. Among patients treated with platinum, the DNA patterns distinguished those with platinum-resistant tumors, with a median survival time of three years, from those with platinum-sensitive tumors, with a median survival time of more than seven years.nn&nbsp;nn![http://www.alterlab.org/physics_of_cancer/jpgs/Image_3.jpg](http://www.alterlab.org/physics_of_cancer/jpgs/Image_3.jpg)nn&nbsp;nn&nbsp;nn#####Patterns of DNA copy-number alterations in personalized diagnostic and prognostic tests.nPending experimental revalidation, the team will bring the patterns that they uncover to the clinic, to be used in personalized diagnostic and prognostic pathology laboratory tests. The tests would predict a patient's survival and response to therapy, and doctors could tailor treatment accordingly. The specific genes found to be perturbed may be actively involved in cancer development and progression, and could be the basis for drug therapies.","4":"Heterogeneity","5":"Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics","6":"PS-ON","7":"U01"},{"1":"syn21645077","2":"Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics","3":"The University of Utah team is developing new mathematical frameworks to do what no others currently can, that is, create a single coherent model from multiple high-dimensional datasets, known as tensors. The frameworks <U+201A><U+00C4><U+00EC> comparative spectral decompositions <U+201A><U+00C4><U+00EC> generalize those that underlie the theoretical description of the physical world. The team is using the frameworks to compare and contrast datasets recording different aspects of a single disease, such as genomic profiles of multiple cell types from the same set of patients, measured more than once by several different methods. By using the complex structure of the datasets, rather than simplifying them as is commonly done, the frameworks enable the separation of patterns of DNA alterations <U+201A><U+00C4><U+00EC> which occur only in the tumor genomes <U+201A><U+00C4><U+00EC> from those that occur in the genomes of normal cells in the body, and from variations caused by experimental inconsistencies. The patterns that the team uncovers in the data are expected to offer answers to the open question of the relation between a tumor's genome and a patient's outcome.nn&nbsp;nnFor example, recent comparisons of the genomes of tumor and normal cells from the same sets of ovarian and, separately, glioblastoma brain cancer patients uncovered patterns of DNA copy-number alterations that were found to be correlated with a patient's survival and response to chemotherapy. For three decades prior, the best predictor of ovarian cancer survival was the tumor's stage; more than a quarter of ovarian tumors are resistant to the platinum-based chemotherapy, the first-line treatment, yet no diagnostic existed to distinguish resistant from sensitive tumors before the treatment. For five decades prior, the best prognostic indicator of glioblastoma was the patient's age at diagnosis. The ovarian and brain cancer data were published, but the patterns remained unknown until the team applied their comparative spectral decompositions.nn&nbsp;nnPending experimental revalidation, the team will bring the patterns that they uncover to the clinic, to be used in personalized diagnostic and prognostic pathology laboratory tests. The tests would predict a patient's survival and response to therapy, and doctors could tailor treatment accordingly.nn&nbsp;nn![http://www.alterlab.org/physics_of_cancer/jpgs/Image_1.jpg](http://www.alterlab.org/physics_of_cancer/jpgs/Image_1.jpg)nn&nbsp;nn&nbsp;nn#####Physics-inspired mathematical frameworks. nThe team develops mathematical frameworks to uncover patterns in datasets arranged in two or more third- or higher-dimensional tables, known as tensors. Rather than simplifying the datasets, as is commonly done, the frameworks make use of their complex structure in order to tease out the patterns within them.nn&nbsp;nn![http://www.alterlab.org/physics_of_cancer/jpgs/Image_2.jpg](http://www.alterlab.org/physics_of_cancer/jpgs/Image_2.jpg)nn&nbsp;nn&nbsp;nn#####Genomic predictors of a patient's outcome.nA recent comparison of the genomes of tumor and normal cells from the same sets of ovarian serous cystadenocarcinoma patients uncovered patterns of DNA copy-number alterations that were found to be correlated with a patient's survival and response to platinum-based chemotherapy. Among patients that were diagnosed at late stages, the DNA patterns distinguished short-term survivors, with a median survival time of three years, from long-term survivors, with a median survival time almost twice as long. Among patients treated with platinum, the DNA patterns distinguished those with platinum-resistant tumors, with a median survival time of three years, from those with platinum-sensitive tumors, with a median survival time of more than seven years.nn&nbsp;nn![http://www.alterlab.org/physics_of_cancer/jpgs/Image_3.jpg](http://www.alterlab.org/physics_of_cancer/jpgs/Image_3.jpg)nn&nbsp;nn&nbsp;nn#####Patterns of DNA copy-number alterations in personalized diagnostic and prognostic tests.nPending experimental revalidation, the team will bring the patterns that they uncover to the clinic, to be used in personalized diagnostic and prognostic pathology laboratory tests. The tests would predict a patient's survival and response to therapy, and doctors could tailor treatment accordingly. The specific genes found to be perturbed may be actively involved in cancer development and progression, and could be the basis for drug therapies.","4":"Evolution","5":"Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics","6":"PS-ON","7":"U01"},{"1":"syn21645078","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"Our project aims to develop a new computationally driven platform to examine complex physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response.  Malignant breast tumors are highly heterogeneous in terms of their cellular composition, varying levels of oxygenation, acidity, and nutrients, as well as local changes in the extracellular matrix. Furthermore, tumor tissue and tumor microenvironment properties can dynamically evolve not only during tumor growth but also when anticancer treatments are administered.  Despite this, nearly all pre-clinical assessments of drug efficacy and optimal dosing are performed using homogeneous 2D cell cultures that do not resemble the cellular, metabolic, and physical features manifest in tumors in vivo. Such approach suffered from overly reductionist ex vivo/in vitro and studies may not fully recapitulate the complexity of cancers, especially their physical and chemical microenvironments. To address these issues, we concentrate on developing an integrated quantitative platform that combines the power of organ-on-chip 3D tissue bioreactor, developed to include non-uniform fully controlled physical and chemical microenvironments, together with a 3DMultiCell math model that allows predictive testing of a broad range of microenvironmental combinations around the experimentally validated baseline.nn#### Goals:nn1. Develop a predictive methodology to assess effects of defined microenvironments on the dynamics of normal and tumorigenic breast organoids and their sensitivity to therapeutics.n2. Construct and validate in silico model-guided complex spatial and temporal microenvironmental gradients established within TTb-G reactor, and assess breast tumor organoids response to chemotherapeuticsn3. Apply our integrated computational/engineering approach to guide therapy and predict therapeutic response ex vivo and in vivonn&nbsp;nnMammary on chip bioreactor for studying complex physical and chemical microenvironments in breast cancer coupled with a predictive mathematical model of tumor growth and therapeutic response. A) Thick Tissue bioreactor diagram.  B) Selected confocal slices of the mammospheres produced by MCF cell variants cultured within TTB for 21 days. C) Mammosphere formation after proteinase inhibitor treatments. D) Inhibition of proteinase activity. (A-D: Taken from Markov et al, Lab Chip, 21:4560-8, 2012). E) An example of the growth of 3D in silico spheroids (grey) under the heterogeneous microenvironmental gradient (high concentration in red, low concentration in blue).","4":"Microenvironment","5":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","6":"PS-ON","7":"U01"},{"1":"syn21645078","2":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","3":"Our project aims to develop a new computationally driven platform to examine complex physical and chemical microenvironments utilizing organ-on-chip microfluidic bioreactor technology coupled with a predictive mathematical model of tumor growth and therapeutic response.  Malignant breast tumors are highly heterogeneous in terms of their cellular composition, varying levels of oxygenation, acidity, and nutrients, as well as local changes in the extracellular matrix. Furthermore, tumor tissue and tumor microenvironment properties can dynamically evolve not only during tumor growth but also when anticancer treatments are administered.  Despite this, nearly all pre-clinical assessments of drug efficacy and optimal dosing are performed using homogeneous 2D cell cultures that do not resemble the cellular, metabolic, and physical features manifest in tumors in vivo. Such approach suffered from overly reductionist ex vivo/in vitro and studies may not fully recapitulate the complexity of cancers, especially their physical and chemical microenvironments. To address these issues, we concentrate on developing an integrated quantitative platform that combines the power of organ-on-chip 3D tissue bioreactor, developed to include non-uniform fully controlled physical and chemical microenvironments, together with a 3DMultiCell math model that allows predictive testing of a broad range of microenvironmental combinations around the experimentally validated baseline.nn#### Goals:nn1. Develop a predictive methodology to assess effects of defined microenvironments on the dynamics of normal and tumorigenic breast organoids and their sensitivity to therapeutics.n2. Construct and validate in silico model-guided complex spatial and temporal microenvironmental gradients established within TTb-G reactor, and assess breast tumor organoids response to chemotherapeuticsn3. Apply our integrated computational/engineering approach to guide therapy and predict therapeutic response ex vivo and in vivonn&nbsp;nnMammary on chip bioreactor for studying complex physical and chemical microenvironments in breast cancer coupled with a predictive mathematical model of tumor growth and therapeutic response. A) Thick Tissue bioreactor diagram.  B) Selected confocal slices of the mammospheres produced by MCF cell variants cultured within TTB for 21 days. C) Mammosphere formation after proteinase inhibitor treatments. D) Inhibition of proteinase activity. (A-D: Taken from Markov et al, Lab Chip, 21:4560-8, 2012). E) An example of the growth of 3D in silico spheroids (grey) under the heterogeneous microenvironmental gradient (high concentration in red, low concentration in blue).","4":"Heterogeneity","5":"Physical Dynamics of Cancer Response to Chemotherapy in 3D Microenvironments","6":"PS-ON","7":"U01"},{"1":"syn21645079","2":"Dynamic genomic and microenvironmental models of chemoresistance","3":"Breast and ovarian cancers are heterogeneous diseases, as a typical tumor contains multiple <U+201A><U+00C4><U+00FA>subclones<U+201A><U+00C4><U+00F9>, which are defined as evolutionarily related subpopulations of cells with a different complement of somatically acquired DNA mutations and phenotypes. When chemotherapeutic agents are administered to the patient, some of these subclones may gain a selective advantage and develop resistance to the treatment, resulting in cancer relapse and progression. For this reason, it is imperative to identify these subclones and their evolution across treatment; and to understand how the genomic aberrations within these subclones drive resistance to chemotherapy. We will integrate experimental biology and computational models across temporal samples of patient tumors as they develop a resistant state in order to better understand and combat refractory and terminal cancer. To enable the study of tumor heterogeneity evolution in patients, we will utilize a highly unique collection of metastatic tumor cells from breast and ovarian cancer patients before, during, and after treatments, often across multiple courses of chemotherapy, as well as tumors from a clinical trial taken before and after therapy. We use deep sequencing to find genomic aberrations at each of these time points, and develop systems models to identify the subclones and follow phenotypic changes and their functional impacts of subclone evolution in response to chemotherapy. We hypothesize that 1) Dynamical systems models based on the evolution of subclone structure and acquisition of oncogenic phenotypes during treatment can identify key factors in the development of a chemo-resistant state; and 2) We can delay development of a chemo-resistant cancer state by inhibiting development of phenotypes that emerge over time commonly during treatment. We will model resistant cancer cell populations and both extrinsic and immune microenvironmental factors to identify critical features of acquired resistance and apply these models to a clinical trial aimed at blocking transition to a resistant cancer state. While these components can exhibit co-dependencies, by their nature they can also have vulnerabilities based on these interactive features, and if one can inhibit dependent relationships within a population it may be possible to shift the equilibrium of a tumor from a chemoresistant state to a sensitive state. The algorithms and procedures we are developing in this proposal will for a rational basis for real-time patient monitoring and making treatment choices for refractory patients. The outcomes of this research will deliver approaches to block or reverse the transition to a resistant state for advanced stage breast and ovarian cancer patients.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645079","2":"Dynamic genomic and microenvironmental models of chemoresistance","3":"Breast and ovarian cancers are heterogeneous diseases, as a typical tumor contains multiple <U+201A><U+00C4><U+00FA>subclones<U+201A><U+00C4><U+00F9>, which are defined as evolutionarily related subpopulations of cells with a different complement of somatically acquired DNA mutations and phenotypes. When chemotherapeutic agents are administered to the patient, some of these subclones may gain a selective advantage and develop resistance to the treatment, resulting in cancer relapse and progression. For this reason, it is imperative to identify these subclones and their evolution across treatment; and to understand how the genomic aberrations within these subclones drive resistance to chemotherapy. We will integrate experimental biology and computational models across temporal samples of patient tumors as they develop a resistant state in order to better understand and combat refractory and terminal cancer. To enable the study of tumor heterogeneity evolution in patients, we will utilize a highly unique collection of metastatic tumor cells from breast and ovarian cancer patients before, during, and after treatments, often across multiple courses of chemotherapy, as well as tumors from a clinical trial taken before and after therapy. We use deep sequencing to find genomic aberrations at each of these time points, and develop systems models to identify the subclones and follow phenotypic changes and their functional impacts of subclone evolution in response to chemotherapy. We hypothesize that 1) Dynamical systems models based on the evolution of subclone structure and acquisition of oncogenic phenotypes during treatment can identify key factors in the development of a chemo-resistant state; and 2) We can delay development of a chemo-resistant cancer state by inhibiting development of phenotypes that emerge over time commonly during treatment. We will model resistant cancer cell populations and both extrinsic and immune microenvironmental factors to identify critical features of acquired resistance and apply these models to a clinical trial aimed at blocking transition to a resistant cancer state. While these components can exhibit co-dependencies, by their nature they can also have vulnerabilities based on these interactive features, and if one can inhibit dependent relationships within a population it may be possible to shift the equilibrium of a tumor from a chemoresistant state to a sensitive state. The algorithms and procedures we are developing in this proposal will for a rational basis for real-time patient monitoring and making treatment choices for refractory patients. The outcomes of this research will deliver approaches to block or reverse the transition to a resistant state for advanced stage breast and ovarian cancer patients.","4":"Heterogeneity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645079","2":"Dynamic genomic and microenvironmental models of chemoresistance","3":"Breast and ovarian cancers are heterogeneous diseases, as a typical tumor contains multiple <U+201A><U+00C4><U+00FA>subclones<U+201A><U+00C4><U+00F9>, which are defined as evolutionarily related subpopulations of cells with a different complement of somatically acquired DNA mutations and phenotypes. When chemotherapeutic agents are administered to the patient, some of these subclones may gain a selective advantage and develop resistance to the treatment, resulting in cancer relapse and progression. For this reason, it is imperative to identify these subclones and their evolution across treatment; and to understand how the genomic aberrations within these subclones drive resistance to chemotherapy. We will integrate experimental biology and computational models across temporal samples of patient tumors as they develop a resistant state in order to better understand and combat refractory and terminal cancer. To enable the study of tumor heterogeneity evolution in patients, we will utilize a highly unique collection of metastatic tumor cells from breast and ovarian cancer patients before, during, and after treatments, often across multiple courses of chemotherapy, as well as tumors from a clinical trial taken before and after therapy. We use deep sequencing to find genomic aberrations at each of these time points, and develop systems models to identify the subclones and follow phenotypic changes and their functional impacts of subclone evolution in response to chemotherapy. We hypothesize that 1) Dynamical systems models based on the evolution of subclone structure and acquisition of oncogenic phenotypes during treatment can identify key factors in the development of a chemo-resistant state; and 2) We can delay development of a chemo-resistant cancer state by inhibiting development of phenotypes that emerge over time commonly during treatment. We will model resistant cancer cell populations and both extrinsic and immune microenvironmental factors to identify critical features of acquired resistance and apply these models to a clinical trial aimed at blocking transition to a resistant cancer state. While these components can exhibit co-dependencies, by their nature they can also have vulnerabilities based on these interactive features, and if one can inhibit dependent relationships within a population it may be possible to shift the equilibrium of a tumor from a chemoresistant state to a sensitive state. The algorithms and procedures we are developing in this proposal will for a rational basis for real-time patient monitoring and making treatment choices for refractory patients. The outcomes of this research will deliver approaches to block or reverse the transition to a resistant state for advanced stage breast and ovarian cancer patients.","4":"Evolution","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645079","2":"Dynamic genomic and microenvironmental models of chemoresistance","3":"Breast and ovarian cancers are heterogeneous diseases, as a typical tumor contains multiple <U+201A><U+00C4><U+00FA>subclones<U+201A><U+00C4><U+00F9>, which are defined as evolutionarily related subpopulations of cells with a different complement of somatically acquired DNA mutations and phenotypes. When chemotherapeutic agents are administered to the patient, some of these subclones may gain a selective advantage and develop resistance to the treatment, resulting in cancer relapse and progression. For this reason, it is imperative to identify these subclones and their evolution across treatment; and to understand how the genomic aberrations within these subclones drive resistance to chemotherapy. We will integrate experimental biology and computational models across temporal samples of patient tumors as they develop a resistant state in order to better understand and combat refractory and terminal cancer. To enable the study of tumor heterogeneity evolution in patients, we will utilize a highly unique collection of metastatic tumor cells from breast and ovarian cancer patients before, during, and after treatments, often across multiple courses of chemotherapy, as well as tumors from a clinical trial taken before and after therapy. We use deep sequencing to find genomic aberrations at each of these time points, and develop systems models to identify the subclones and follow phenotypic changes and their functional impacts of subclone evolution in response to chemotherapy. We hypothesize that 1) Dynamical systems models based on the evolution of subclone structure and acquisition of oncogenic phenotypes during treatment can identify key factors in the development of a chemo-resistant state; and 2) We can delay development of a chemo-resistant cancer state by inhibiting development of phenotypes that emerge over time commonly during treatment. We will model resistant cancer cell populations and both extrinsic and immune microenvironmental factors to identify critical features of acquired resistance and apply these models to a clinical trial aimed at blocking transition to a resistant cancer state. While these components can exhibit co-dependencies, by their nature they can also have vulnerabilities based on these interactive features, and if one can inhibit dependent relationships within a population it may be possible to shift the equilibrium of a tumor from a chemoresistant state to a sensitive state. The algorithms and procedures we are developing in this proposal will for a rational basis for real-time patient monitoring and making treatment choices for refractory patients. The outcomes of this research will deliver approaches to block or reverse the transition to a resistant state for advanced stage breast and ovarian cancer patients.","4":"Metastasis","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645080","2":"Targeting cooperative phenotypes common in spatial heterogeneity","3":"Recent studies in primary tumors have found a remarkable degree of intratumor heterogeneity, where a single tumor is comprised of a range of subclones exhibiting a diversity of phenotypes, including molecular profiles, proliferation capacity, and response to therapies. Although heterogeneity is now widely reported, few studies have investigated the heterogeneity of metastatic tumors at the end stage, despite the fact that metastatic cancer is estimated to be responsible for over 90% of cancer deaths. For breast and ovarian cancer, tumors that progress to metastasis are refractory to treatment. Therefore, there is a great need to determine the mechanisms by which subclonal diversity can affect the metastatic phenotype and underlie the difficulties in treatment. Studying metastatic tumors is difficult due to the challenges in collecting patient tissues. While primary tissues are typically obtained through biopsy, this is rarely performed for metastatic sites. To address this difficulty, we have developed both a rapid autopsy strategy where we collect fresh samples of metastatic tumors within hours of patient death, as well as collections of metastatic tumor biopsies in the clinical trial setting prior to and after drug treatment. These collections enable us to profile multiple metastatic sites and investigate the association between metastatic sites and subclonal evolution in an isogenic background. We propose to leverage this unique data set to investigate the relationship between evolution of tumor subclones during metastatic progression and the phenotypic profiles of these tumors. We hypothesize that, despite the diversity in their genetic mutation profiles, metastatic tumors exhibit clonal dynamics that ultimately leads to convergence on more common cooperative phenotypic networks, and that targeting the key dependencies within this network will lead to increased collapse of the metastatic tumor population. To investigate this, we will profile the tumors by whole genome sequencing, whole exome sequencing, and single cell RNA sequencing. This data, coupled with our newly developed algorithms for dissecting subclonal populations using tree reconstruction algorithms, for eliciting phenotypes from gene expression profiles using Bayesian statistics, and for simulating phenotypic evolution using mathematical models from ecology; will enable us to understand (Aim 1) the subclonal heterogeneity that underlies metastatic initiation and progression; (Aim 2) how cooperative functions evolve to a chemo-refractory signaling network, and therapeutic strategies to target it; and (Aim 3) how these dynamics are manifested human tumors in a clinical trial. Our investigations represent the first characterization of the clonal dynamics of a large multisite metastatic cohort, and will provide a new framework for understanding and treating end-stage tumors based on the evolution of cooperative phenotypes. We will develop these models on patient samples and test them in a unique clinical trial, ensuring the physiological, if not clinical, relevance of our findings.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645080","2":"Targeting cooperative phenotypes common in spatial heterogeneity","3":"Recent studies in primary tumors have found a remarkable degree of intratumor heterogeneity, where a single tumor is comprised of a range of subclones exhibiting a diversity of phenotypes, including molecular profiles, proliferation capacity, and response to therapies. Although heterogeneity is now widely reported, few studies have investigated the heterogeneity of metastatic tumors at the end stage, despite the fact that metastatic cancer is estimated to be responsible for over 90% of cancer deaths. For breast and ovarian cancer, tumors that progress to metastasis are refractory to treatment. Therefore, there is a great need to determine the mechanisms by which subclonal diversity can affect the metastatic phenotype and underlie the difficulties in treatment. Studying metastatic tumors is difficult due to the challenges in collecting patient tissues. While primary tissues are typically obtained through biopsy, this is rarely performed for metastatic sites. To address this difficulty, we have developed both a rapid autopsy strategy where we collect fresh samples of metastatic tumors within hours of patient death, as well as collections of metastatic tumor biopsies in the clinical trial setting prior to and after drug treatment. These collections enable us to profile multiple metastatic sites and investigate the association between metastatic sites and subclonal evolution in an isogenic background. We propose to leverage this unique data set to investigate the relationship between evolution of tumor subclones during metastatic progression and the phenotypic profiles of these tumors. We hypothesize that, despite the diversity in their genetic mutation profiles, metastatic tumors exhibit clonal dynamics that ultimately leads to convergence on more common cooperative phenotypic networks, and that targeting the key dependencies within this network will lead to increased collapse of the metastatic tumor population. To investigate this, we will profile the tumors by whole genome sequencing, whole exome sequencing, and single cell RNA sequencing. This data, coupled with our newly developed algorithms for dissecting subclonal populations using tree reconstruction algorithms, for eliciting phenotypes from gene expression profiles using Bayesian statistics, and for simulating phenotypic evolution using mathematical models from ecology; will enable us to understand (Aim 1) the subclonal heterogeneity that underlies metastatic initiation and progression; (Aim 2) how cooperative functions evolve to a chemo-refractory signaling network, and therapeutic strategies to target it; and (Aim 3) how these dynamics are manifested human tumors in a clinical trial. Our investigations represent the first characterization of the clonal dynamics of a large multisite metastatic cohort, and will provide a new framework for understanding and treating end-stage tumors based on the evolution of cooperative phenotypes. We will develop these models on patient samples and test them in a unique clinical trial, ensuring the physiological, if not clinical, relevance of our findings.","4":"Heterogeneity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645080","2":"Targeting cooperative phenotypes common in spatial heterogeneity","3":"Recent studies in primary tumors have found a remarkable degree of intratumor heterogeneity, where a single tumor is comprised of a range of subclones exhibiting a diversity of phenotypes, including molecular profiles, proliferation capacity, and response to therapies. Although heterogeneity is now widely reported, few studies have investigated the heterogeneity of metastatic tumors at the end stage, despite the fact that metastatic cancer is estimated to be responsible for over 90% of cancer deaths. For breast and ovarian cancer, tumors that progress to metastasis are refractory to treatment. Therefore, there is a great need to determine the mechanisms by which subclonal diversity can affect the metastatic phenotype and underlie the difficulties in treatment. Studying metastatic tumors is difficult due to the challenges in collecting patient tissues. While primary tissues are typically obtained through biopsy, this is rarely performed for metastatic sites. To address this difficulty, we have developed both a rapid autopsy strategy where we collect fresh samples of metastatic tumors within hours of patient death, as well as collections of metastatic tumor biopsies in the clinical trial setting prior to and after drug treatment. These collections enable us to profile multiple metastatic sites and investigate the association between metastatic sites and subclonal evolution in an isogenic background. We propose to leverage this unique data set to investigate the relationship between evolution of tumor subclones during metastatic progression and the phenotypic profiles of these tumors. We hypothesize that, despite the diversity in their genetic mutation profiles, metastatic tumors exhibit clonal dynamics that ultimately leads to convergence on more common cooperative phenotypic networks, and that targeting the key dependencies within this network will lead to increased collapse of the metastatic tumor population. To investigate this, we will profile the tumors by whole genome sequencing, whole exome sequencing, and single cell RNA sequencing. This data, coupled with our newly developed algorithms for dissecting subclonal populations using tree reconstruction algorithms, for eliciting phenotypes from gene expression profiles using Bayesian statistics, and for simulating phenotypic evolution using mathematical models from ecology; will enable us to understand (Aim 1) the subclonal heterogeneity that underlies metastatic initiation and progression; (Aim 2) how cooperative functions evolve to a chemo-refractory signaling network, and therapeutic strategies to target it; and (Aim 3) how these dynamics are manifested human tumors in a clinical trial. Our investigations represent the first characterization of the clonal dynamics of a large multisite metastatic cohort, and will provide a new framework for understanding and treating end-stage tumors based on the evolution of cooperative phenotypes. We will develop these models on patient samples and test them in a unique clinical trial, ensuring the physiological, if not clinical, relevance of our findings.","4":"Evolution","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645080","2":"Targeting cooperative phenotypes common in spatial heterogeneity","3":"Recent studies in primary tumors have found a remarkable degree of intratumor heterogeneity, where a single tumor is comprised of a range of subclones exhibiting a diversity of phenotypes, including molecular profiles, proliferation capacity, and response to therapies. Although heterogeneity is now widely reported, few studies have investigated the heterogeneity of metastatic tumors at the end stage, despite the fact that metastatic cancer is estimated to be responsible for over 90% of cancer deaths. For breast and ovarian cancer, tumors that progress to metastasis are refractory to treatment. Therefore, there is a great need to determine the mechanisms by which subclonal diversity can affect the metastatic phenotype and underlie the difficulties in treatment. Studying metastatic tumors is difficult due to the challenges in collecting patient tissues. While primary tissues are typically obtained through biopsy, this is rarely performed for metastatic sites. To address this difficulty, we have developed both a rapid autopsy strategy where we collect fresh samples of metastatic tumors within hours of patient death, as well as collections of metastatic tumor biopsies in the clinical trial setting prior to and after drug treatment. These collections enable us to profile multiple metastatic sites and investigate the association between metastatic sites and subclonal evolution in an isogenic background. We propose to leverage this unique data set to investigate the relationship between evolution of tumor subclones during metastatic progression and the phenotypic profiles of these tumors. We hypothesize that, despite the diversity in their genetic mutation profiles, metastatic tumors exhibit clonal dynamics that ultimately leads to convergence on more common cooperative phenotypic networks, and that targeting the key dependencies within this network will lead to increased collapse of the metastatic tumor population. To investigate this, we will profile the tumors by whole genome sequencing, whole exome sequencing, and single cell RNA sequencing. This data, coupled with our newly developed algorithms for dissecting subclonal populations using tree reconstruction algorithms, for eliciting phenotypes from gene expression profiles using Bayesian statistics, and for simulating phenotypic evolution using mathematical models from ecology; will enable us to understand (Aim 1) the subclonal heterogeneity that underlies metastatic initiation and progression; (Aim 2) how cooperative functions evolve to a chemo-refractory signaling network, and therapeutic strategies to target it; and (Aim 3) how these dynamics are manifested human tumors in a clinical trial. Our investigations represent the first characterization of the clonal dynamics of a large multisite metastatic cohort, and will provide a new framework for understanding and treating end-stage tumors based on the evolution of cooperative phenotypes. We will develop these models on patient samples and test them in a unique clinical trial, ensuring the physiological, if not clinical, relevance of our findings.","4":"Metastasis","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645081","2":"Translational Shared Resource Core (Moos)","3":"The Translational Shared Resource Core will provide services for both research projects. This core is central to the proposal<U+201A><U+00C4><U+00F4>s mission as it directly facilitates: 1) collection, processing, pharmacological testing and use of samples from our patient cohorts; and 2) generation and collection of DNA- and RNA-sequencing data, including single-cell sequencing. Specifically, we will collect, process, and maintain patient-derived cells for temporal and spatial samples from the patients we profile. In preparation for sequencing, we will enrich for tumor cells, and separate white blood cells and other normal cell types. For single-cell experiments, we will use microfluidics to isolate individual cells, prior to extracting DNA or RNA that will be amplified for sequencing. The core will also be responsible for comparing sequencing results for bulk tumors with results from single-cell sequencing, which will enable us to continue optimizing our single-cell sequencing process and to perform comparisons that help us better understand temporal and spatial tumor evolution, which is central to the success of the scientific projects.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645081","2":"Translational Shared Resource Core (Moos)","3":"The Translational Shared Resource Core will provide services for both research projects. This core is central to the proposal<U+201A><U+00C4><U+00F4>s mission as it directly facilitates: 1) collection, processing, pharmacological testing and use of samples from our patient cohorts; and 2) generation and collection of DNA- and RNA-sequencing data, including single-cell sequencing. Specifically, we will collect, process, and maintain patient-derived cells for temporal and spatial samples from the patients we profile. In preparation for sequencing, we will enrich for tumor cells, and separate white blood cells and other normal cell types. For single-cell experiments, we will use microfluidics to isolate individual cells, prior to extracting DNA or RNA that will be amplified for sequencing. The core will also be responsible for comparing sequencing results for bulk tumors with results from single-cell sequencing, which will enable us to continue optimizing our single-cell sequencing process and to perform comparisons that help us better understand temporal and spatial tumor evolution, which is central to the success of the scientific projects.","4":"Heterogeneity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645081","2":"Translational Shared Resource Core (Moos)","3":"The Translational Shared Resource Core will provide services for both research projects. This core is central to the proposal<U+201A><U+00C4><U+00F4>s mission as it directly facilitates: 1) collection, processing, pharmacological testing and use of samples from our patient cohorts; and 2) generation and collection of DNA- and RNA-sequencing data, including single-cell sequencing. Specifically, we will collect, process, and maintain patient-derived cells for temporal and spatial samples from the patients we profile. In preparation for sequencing, we will enrich for tumor cells, and separate white blood cells and other normal cell types. For single-cell experiments, we will use microfluidics to isolate individual cells, prior to extracting DNA or RNA that will be amplified for sequencing. The core will also be responsible for comparing sequencing results for bulk tumors with results from single-cell sequencing, which will enable us to continue optimizing our single-cell sequencing process and to perform comparisons that help us better understand temporal and spatial tumor evolution, which is central to the success of the scientific projects.","4":"Evolution","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645081","2":"Translational Shared Resource Core (Moos)","3":"The Translational Shared Resource Core will provide services for both research projects. This core is central to the proposal<U+201A><U+00C4><U+00F4>s mission as it directly facilitates: 1) collection, processing, pharmacological testing and use of samples from our patient cohorts; and 2) generation and collection of DNA- and RNA-sequencing data, including single-cell sequencing. Specifically, we will collect, process, and maintain patient-derived cells for temporal and spatial samples from the patients we profile. In preparation for sequencing, we will enrich for tumor cells, and separate white blood cells and other normal cell types. For single-cell experiments, we will use microfluidics to isolate individual cells, prior to extracting DNA or RNA that will be amplified for sequencing. The core will also be responsible for comparing sequencing results for bulk tumors with results from single-cell sequencing, which will enable us to continue optimizing our single-cell sequencing process and to perform comparisons that help us better understand temporal and spatial tumor evolution, which is central to the success of the scientific projects.","4":"Metastasis","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645082","2":"Computational Core (Chang)","3":"The main purpose of the Computational Core is to support the scientific goals of the center by ensuring correct and reproducible analysis of next generation sequencing data. This will be accomplished through five tasks. 1) Data management: we will store and maintain provenance of the raw and pre-processed data in archives that track relevant metadata, such as creation data and checks on secured servers. 2) Data Preprocessing: we will develop standardized approaches to pre-processing the data, and create reference versions of the pre-processed data ready for further analysis. 3) Algorithm Development: We will coordinate with investigators to develop algorithms for the modeling of tumor heterogeneity and its evolution. The Core will maintain the source code in a git repository and will identify stable working versions that are then tagged and archived. 4) Develop Pipelines: to facilitate the processing of the data, and to ensure its reproducibility, we will develop standardized pipelines for the preprocessing and analysis of the data. 5) Standardize Environments: The processing of next generation sequencing data requires a multitude of software programs, each of which can affect the final result. To mitigate variation due to differences in software, versions, or libraries, we will create standardized analysis environments equipped with validated software and libraries and distribute them as Docker containers.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645082","2":"Computational Core (Chang)","3":"The main purpose of the Computational Core is to support the scientific goals of the center by ensuring correct and reproducible analysis of next generation sequencing data. This will be accomplished through five tasks. 1) Data management: we will store and maintain provenance of the raw and pre-processed data in archives that track relevant metadata, such as creation data and checks on secured servers. 2) Data Preprocessing: we will develop standardized approaches to pre-processing the data, and create reference versions of the pre-processed data ready for further analysis. 3) Algorithm Development: We will coordinate with investigators to develop algorithms for the modeling of tumor heterogeneity and its evolution. The Core will maintain the source code in a git repository and will identify stable working versions that are then tagged and archived. 4) Develop Pipelines: to facilitate the processing of the data, and to ensure its reproducibility, we will develop standardized pipelines for the preprocessing and analysis of the data. 5) Standardize Environments: The processing of next generation sequencing data requires a multitude of software programs, each of which can affect the final result. To mitigate variation due to differences in software, versions, or libraries, we will create standardized analysis environments equipped with validated software and libraries and distribute them as Docker containers.","4":"Heterogeneity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645082","2":"Computational Core (Chang)","3":"The main purpose of the Computational Core is to support the scientific goals of the center by ensuring correct and reproducible analysis of next generation sequencing data. This will be accomplished through five tasks. 1) Data management: we will store and maintain provenance of the raw and pre-processed data in archives that track relevant metadata, such as creation data and checks on secured servers. 2) Data Preprocessing: we will develop standardized approaches to pre-processing the data, and create reference versions of the pre-processed data ready for further analysis. 3) Algorithm Development: We will coordinate with investigators to develop algorithms for the modeling of tumor heterogeneity and its evolution. The Core will maintain the source code in a git repository and will identify stable working versions that are then tagged and archived. 4) Develop Pipelines: to facilitate the processing of the data, and to ensure its reproducibility, we will develop standardized pipelines for the preprocessing and analysis of the data. 5) Standardize Environments: The processing of next generation sequencing data requires a multitude of software programs, each of which can affect the final result. To mitigate variation due to differences in software, versions, or libraries, we will create standardized analysis environments equipped with validated software and libraries and distribute them as Docker containers.","4":"Evolution","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645082","2":"Computational Core (Chang)","3":"The main purpose of the Computational Core is to support the scientific goals of the center by ensuring correct and reproducible analysis of next generation sequencing data. This will be accomplished through five tasks. 1) Data management: we will store and maintain provenance of the raw and pre-processed data in archives that track relevant metadata, such as creation data and checks on secured servers. 2) Data Preprocessing: we will develop standardized approaches to pre-processing the data, and create reference versions of the pre-processed data ready for further analysis. 3) Algorithm Development: We will coordinate with investigators to develop algorithms for the modeling of tumor heterogeneity and its evolution. The Core will maintain the source code in a git repository and will identify stable working versions that are then tagged and archived. 4) Develop Pipelines: to facilitate the processing of the data, and to ensure its reproducibility, we will develop standardized pipelines for the preprocessing and analysis of the data. 5) Standardize Environments: The processing of next generation sequencing data requires a multitude of software programs, each of which can affect the final result. To mitigate variation due to differences in software, versions, or libraries, we will create standardized analysis environments equipped with validated software and libraries and distribute them as Docker containers.","4":"Metastasis","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645083","2":"Education and Outreach Core (Moos and Werner)","3":"This core are to build a singular research community within the consortium, educate students and the community on the latest advances in systems biology, and reach out to cancer advocates and patients regarding the impact of systems biology and cancer heterogeneity on treatment strategies to build excitement for future developments. We will sponsor student exchange programs, seminars, and courses on systems biology, as well as participate in organizations that promote health and cancer awareness. We will invite leaders in systems biology<U+201A><U+00C4><U+00EE>whose expertise and research interests complement and expand our own<U+201A><U+00C4><U+00EE>to visit our center sites; meet with our faculty, postdocs, and students; and participate in workshops that encourage spirited dialog and broad participation. We will assess the effectiveness of our outreach efforts through surveys that will provide the feedback necessary to ensure we are meeting our goals.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645083","2":"Education and Outreach Core (Moos and Werner)","3":"This core are to build a singular research community within the consortium, educate students and the community on the latest advances in systems biology, and reach out to cancer advocates and patients regarding the impact of systems biology and cancer heterogeneity on treatment strategies to build excitement for future developments. We will sponsor student exchange programs, seminars, and courses on systems biology, as well as participate in organizations that promote health and cancer awareness. We will invite leaders in systems biology<U+201A><U+00C4><U+00EE>whose expertise and research interests complement and expand our own<U+201A><U+00C4><U+00EE>to visit our center sites; meet with our faculty, postdocs, and students; and participate in workshops that encourage spirited dialog and broad participation. We will assess the effectiveness of our outreach efforts through surveys that will provide the feedback necessary to ensure we are meeting our goals.","4":"Heterogeneity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645083","2":"Education and Outreach Core (Moos and Werner)","3":"This core are to build a singular research community within the consortium, educate students and the community on the latest advances in systems biology, and reach out to cancer advocates and patients regarding the impact of systems biology and cancer heterogeneity on treatment strategies to build excitement for future developments. We will sponsor student exchange programs, seminars, and courses on systems biology, as well as participate in organizations that promote health and cancer awareness. We will invite leaders in systems biology<U+201A><U+00C4><U+00EE>whose expertise and research interests complement and expand our own<U+201A><U+00C4><U+00EE>to visit our center sites; meet with our faculty, postdocs, and students; and participate in workshops that encourage spirited dialog and broad participation. We will assess the effectiveness of our outreach efforts through surveys that will provide the feedback necessary to ensure we are meeting our goals.","4":"Evolution","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645083","2":"Education and Outreach Core (Moos and Werner)","3":"This core are to build a singular research community within the consortium, educate students and the community on the latest advances in systems biology, and reach out to cancer advocates and patients regarding the impact of systems biology and cancer heterogeneity on treatment strategies to build excitement for future developments. We will sponsor student exchange programs, seminars, and courses on systems biology, as well as participate in organizations that promote health and cancer awareness. We will invite leaders in systems biology<U+201A><U+00C4><U+00EE>whose expertise and research interests complement and expand our own<U+201A><U+00C4><U+00EE>to visit our center sites; meet with our faculty, postdocs, and students; and participate in workshops that encourage spirited dialog and broad participation. We will assess the effectiveness of our outreach efforts through surveys that will provide the feedback necessary to ensure we are meeting our goals.","4":"Metastasis","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645084","2":"Administrative Core","3":"The key to our ongoing collaboration has been communication between groups on our weekly to bi-weekly calls and discussions, focused on coordinated project planning and discussion of experiments and results. The Administrative Core will provide oversight of the Center and will manage its day-to-day operations. Specifically, this Core will: 1) schedule and organize meetings among investigators twice a month; 2) provide monthly and yearly summaries of work accomplished, results, and to-do items; 3) manage the budget; 4) plan internal and external advisory panel meetings and implementation of feedback; 5) manage developmental research project selection and support; and 6) perform administrative tasks related to center management.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645084","2":"Administrative Core","3":"The key to our ongoing collaboration has been communication between groups on our weekly to bi-weekly calls and discussions, focused on coordinated project planning and discussion of experiments and results. The Administrative Core will provide oversight of the Center and will manage its day-to-day operations. Specifically, this Core will: 1) schedule and organize meetings among investigators twice a month; 2) provide monthly and yearly summaries of work accomplished, results, and to-do items; 3) manage the budget; 4) plan internal and external advisory panel meetings and implementation of feedback; 5) manage developmental research project selection and support; and 6) perform administrative tasks related to center management.","4":"Heterogeneity","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645084","2":"Administrative Core","3":"The key to our ongoing collaboration has been communication between groups on our weekly to bi-weekly calls and discussions, focused on coordinated project planning and discussion of experiments and results. The Administrative Core will provide oversight of the Center and will manage its day-to-day operations. Specifically, this Core will: 1) schedule and organize meetings among investigators twice a month; 2) provide monthly and yearly summaries of work accomplished, results, and to-do items; 3) manage the budget; 4) plan internal and external advisory panel meetings and implementation of feedback; 5) manage developmental research project selection and support; and 6) perform administrative tasks related to center management.","4":"Evolution","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645084","2":"Administrative Core","3":"The key to our ongoing collaboration has been communication between groups on our weekly to bi-weekly calls and discussions, focused on coordinated project planning and discussion of experiments and results. The Administrative Core will provide oversight of the Center and will manage its day-to-day operations. Specifically, this Core will: 1) schedule and organize meetings among investigators twice a month; 2) provide monthly and yearly summaries of work accomplished, results, and to-do items; 3) manage the budget; 4) plan internal and external advisory panel meetings and implementation of feedback; 5) manage developmental research project selection and support; and 6) perform administrative tasks related to center management.","4":"Metastasis","5":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","6":"CSBC","7":"U54"},{"1":"syn21645085","2":"Embryonal Brain Tumor Networks","3":"Our U01 is an innovative, systems biology approach designed to uncover new therapeutic strategies for childhood embryonal tumors. These tumors are the most common central nervous system malignancies in childhood, and there is a pressing need for better therapies. Current survival rates range from 30 <U+201A><U+00C4><U+00EC> 80% depending on subgroup, and nearly all survivors have impaired neurological and neurocognitive function. Extensive genomic analysis of medulloblastomas, the most common embryonal tumors, failed to identify <U+201A><U+00C4><U+00FA>driver genes<U+201A><U+00C4><U+00F9> that could explain the origin of most tumors or suggest new strategies. Nevertheless, these tumors can be grouped into a small number of subtypes that share transcriptional patterns and clinical outcomes.nn&nbsp;nnWe believe that it is time for a fundamentally new approach that seeks oncogenic <U+201A><U+00C4><U+00FA>driver pathways<U+201A><U+00C4><U+00F9> rather than <U+201A><U+00C4><U+00FA>driver genes.<U+201A><U+00C4><U+00F9> As many different genomic changes can all affect the same driver pathway, such pathways cannot be uncovered by looking for recurring genomic changes alone. Rather, we use a systems biology approach based on a wide variety of omic methods to identify these oncogenic driver pathways.nn&nbsp;nnWe are creating comprehensive, genome-wide datasets from human medulloblastoma tumors and cell lines by measuring mutations, copy number variations, mRNA expression, proteomic (including enrichment for several types of post-translational modifications), metabolomic, and epigenomic data. We have developed innovative network models methods to unite these diverse data and thereby identify shared pathways altered across many patients within a subtype. Finally, we will test driver pathways nominated from the network modeling.nn&nbsp;nnBy merging these diverse data collected from tumors of individual patients, we will have an unprecedented ability to uncover the root causes of cancer, providing new therapeutic strategies. Concurrent with publication, we make all data and software tools developed during the course of this project available to the scientific community to further spark innovation and scientific advancements.","4":"Heterogeneity","5":"Embryonal Brain Tumor Networks","6":"CSBC","7":"U01"},{"1":"syn21645086","2":"Systematic discovery of cell-intrinsic mechanisms of cancer drug resistance","3":"We aim to utilize high precision single-cell growth measurements together with single-cell RNA-Seq (scRNA-Seq) to profile the intrinsic factors that inform the responses of individual cancer cells to therapeutic interventions. We will ask to what extent paired phenotypic and transcriptomic measurements can identify pathways that mediate cell autonomous resistance and highlight therapeutic approaches to overcome that resistance. Cancer cells will be isolated from primary tumors or from patient-derived cell lines/xenografts of both leukemias (as a liquid tumor model) and colon/pancreatic cancers (as a solid tumor model). In contrast to Project 2, cells will be measured in isolation without mimicking aspects of the microenvironment. Over a period of many hours, we will examine distinct phenotypic attributes of the cells (mass and mass accumulation rate) and link these attributes to the transcriptome at the single-cell level. We will then determine cell intrinsic mechanisms for resistance by analyzing transcriptomic features of responding and non-responding tumor cells.","4":"Drug Resistance/Sensitivity","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645086","2":"Systematic discovery of cell-intrinsic mechanisms of cancer drug resistance","3":"We aim to utilize high precision single-cell growth measurements together with single-cell RNA-Seq (scRNA-Seq) to profile the intrinsic factors that inform the responses of individual cancer cells to therapeutic interventions. We will ask to what extent paired phenotypic and transcriptomic measurements can identify pathways that mediate cell autonomous resistance and highlight therapeutic approaches to overcome that resistance. Cancer cells will be isolated from primary tumors or from patient-derived cell lines/xenografts of both leukemias (as a liquid tumor model) and colon/pancreatic cancers (as a solid tumor model). In contrast to Project 2, cells will be measured in isolation without mimicking aspects of the microenvironment. Over a period of many hours, we will examine distinct phenotypic attributes of the cells (mass and mass accumulation rate) and link these attributes to the transcriptome at the single-cell level. We will then determine cell intrinsic mechanisms for resistance by analyzing transcriptomic features of responding and non-responding tumor cells.","4":"Microenvironment","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645087","2":"Systematic discovery of cell-extrinsic mechanisms of cancer drug resistance","3":"We aim to utilize high precision single-cell growth measurements and single-cell RNA-Seq (scRNA-Seq) together with nanowells to systematically examine how the extracellular factors present in leukemias and colon and pancreatic cancers influence drug responses. First, we will identify the signals and non-malignant cells present in each tumor type by performing scRNA-Seq on primary biopsies. We will then generate an atlas of implicated cell types/states and putative signaling molecules that may influence cancer cell drug responses in vivo. Second, we will use high precision single-cell growth measurement and nanowells to systematically uncover how these soluble factors and tumor cells inform on cancer cell drug responses; we will similarly examine the impact of previously implicated environmental factors as well as other cancer cells (of the same and different intrinsic states; from Project 1). By analyzing and modeling our results, we will uncover previously unknown microenvironmental synergies (e.g., cytokines, receptor-ligand pairing) that may modulate cancer cell drug responses in vivo. Collectively, these aims will afford an unprecedented view of the tumor microenvironment and shed light on current therapeutic bottlenecks, while suggesting potential new and more effect therapeutic inroads for treating cancer.","4":"Drug Resistance/Sensitivity","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645087","2":"Systematic discovery of cell-extrinsic mechanisms of cancer drug resistance","3":"We aim to utilize high precision single-cell growth measurements and single-cell RNA-Seq (scRNA-Seq) together with nanowells to systematically examine how the extracellular factors present in leukemias and colon and pancreatic cancers influence drug responses. First, we will identify the signals and non-malignant cells present in each tumor type by performing scRNA-Seq on primary biopsies. We will then generate an atlas of implicated cell types/states and putative signaling molecules that may influence cancer cell drug responses in vivo. Second, we will use high precision single-cell growth measurement and nanowells to systematically uncover how these soluble factors and tumor cells inform on cancer cell drug responses; we will similarly examine the impact of previously implicated environmental factors as well as other cancer cells (of the same and different intrinsic states; from Project 1). By analyzing and modeling our results, we will uncover previously unknown microenvironmental synergies (e.g., cytokines, receptor-ligand pairing) that may modulate cancer cell drug responses in vivo. Collectively, these aims will afford an unprecedented view of the tumor microenvironment and shed light on current therapeutic bottlenecks, while suggesting potential new and more effect therapeutic inroads for treating cancer.","4":"Microenvironment","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645088","2":"Biospecimens and Patient-derived xenografts","3":"The overarching goal of Core 1 is to provide the infrastructure and professional expertise needed to bank primary leukemia, colon, and pancreatic cancer specimens, establish patient-derived xenograft (PDX), organoid, and cell models, and make these patient-derived resources available to all Program investigators, thereby facilitating the translational and laboratory-based research performed by CSBC investigators in Projects 1 and 2. Both projects will require access to patient samples and cells derived from PDX and organoid models. The core supports 3 functions: (1) cryopreservation and distribution of primary cells from patients with leukemia, colon, and pancreatic cancer, (2) establishment, characterization, and distribution of xenograft, organoid, and cell culture models of these diseases, and (3) isolation of cell populations from primary tumor samples and tissue models for single cell analysis. The functions of the core include documentation and tracking of informed consent, isolation and cryopreservation of viable tissue, plasma or serum, and genomic DNA from patient samples and distribution of samples to CSBC investigators. A large number of primary leukemia, colon and pancreatic tumor samples are currently available in our existing repositories for use by Project Investigators. Additional samples will be acquired from patients routinely evaluated in our gastrointestinal oncologic and hematologic malignancies clinics. In addition to distributing primary cells to program investigators, Core 1 will also maintain and distribute a bank of well characterized PDXs selected for passage in immunocompromised mice. Methods for engrafting leukemia cells and primary epithelial tumor tissues in immunodeficient mice are now well established, and we and others have successfully used PDX models for drug testing. Organoid culture approaches will be used to complement the PDX effort, and will provide an additional way of propagating and segregating patient-derived epithelial tumor cells and stromal cells. Core 1 will maintain a bank of PDX models and organoids and distribute to program investigators as needed. Overall, Core 1 has extensive experience in the processing, cryopreservation, flow cytometric analysis, purification, propagation, banking, and genomic characterization of primary specimens and tumor models, as well as their use in preclinical drug evaluation.","4":"Drug Resistance/Sensitivity","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645088","2":"Biospecimens and Patient-derived xenografts","3":"The overarching goal of Core 1 is to provide the infrastructure and professional expertise needed to bank primary leukemia, colon, and pancreatic cancer specimens, establish patient-derived xenograft (PDX), organoid, and cell models, and make these patient-derived resources available to all Program investigators, thereby facilitating the translational and laboratory-based research performed by CSBC investigators in Projects 1 and 2. Both projects will require access to patient samples and cells derived from PDX and organoid models. The core supports 3 functions: (1) cryopreservation and distribution of primary cells from patients with leukemia, colon, and pancreatic cancer, (2) establishment, characterization, and distribution of xenograft, organoid, and cell culture models of these diseases, and (3) isolation of cell populations from primary tumor samples and tissue models for single cell analysis. The functions of the core include documentation and tracking of informed consent, isolation and cryopreservation of viable tissue, plasma or serum, and genomic DNA from patient samples and distribution of samples to CSBC investigators. A large number of primary leukemia, colon and pancreatic tumor samples are currently available in our existing repositories for use by Project Investigators. Additional samples will be acquired from patients routinely evaluated in our gastrointestinal oncologic and hematologic malignancies clinics. In addition to distributing primary cells to program investigators, Core 1 will also maintain and distribute a bank of well characterized PDXs selected for passage in immunocompromised mice. Methods for engrafting leukemia cells and primary epithelial tumor tissues in immunodeficient mice are now well established, and we and others have successfully used PDX models for drug testing. Organoid culture approaches will be used to complement the PDX effort, and will provide an additional way of propagating and segregating patient-derived epithelial tumor cells and stromal cells. Core 1 will maintain a bank of PDX models and organoids and distribute to program investigators as needed. Overall, Core 1 has extensive experience in the processing, cryopreservation, flow cytometric analysis, purification, propagation, banking, and genomic characterization of primary specimens and tumor models, as well as their use in preclinical drug evaluation.","4":"Microenvironment","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645089","2":"Computational Analysis Core","3":"The Computational Analysis Core (Core 2) will support Projects 1 & 2 by bringing necessary bioinformatics and computational methods to bear on the questions addressed by each project. More specifically, we will apply established computational pipelines to perform quality control on, and extract maximal information (cell types, states, circuits, and drivers) from, our rich data sets. We will help our CSBC team identify the cell types, states, and circuits active in the Leukemia and Colon and Pancreatic tumor models of Core 1 from the single-cell RNA-Seq data collected in Projects 1 & 2, as well as the molecular drivers of interesting behaviors. We will deploy numerical algorithms to uncover the predictive power of phenotypic measurements, alone or in combination, made via our Nanowell (NW) and Suspended Microchannel Resonator (SMR) platforms to explain cancer cell drug responses. When necessary, we will identify and/or develop new algorithms, enhancing our CSBC<U+201A><U+00C4><U+00F4>s quantitative and multivariate capabilities. Finally, we will work closely with our CSBC team members to help with experimental design, ensuring that an appropriate number of cells/samples are processed to test hypotheses of interest and that appropriate statistical testing is performed. By providing comprehensive analysis (QC, power, gene set enrichment) and modeling capabilities, we will dramatically enhance our ability to draw crucial insights from our data. This will lead to new hypotheses that can be tested by designing new experiments.","4":"Drug Resistance/Sensitivity","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645089","2":"Computational Analysis Core","3":"The Computational Analysis Core (Core 2) will support Projects 1 & 2 by bringing necessary bioinformatics and computational methods to bear on the questions addressed by each project. More specifically, we will apply established computational pipelines to perform quality control on, and extract maximal information (cell types, states, circuits, and drivers) from, our rich data sets. We will help our CSBC team identify the cell types, states, and circuits active in the Leukemia and Colon and Pancreatic tumor models of Core 1 from the single-cell RNA-Seq data collected in Projects 1 & 2, as well as the molecular drivers of interesting behaviors. We will deploy numerical algorithms to uncover the predictive power of phenotypic measurements, alone or in combination, made via our Nanowell (NW) and Suspended Microchannel Resonator (SMR) platforms to explain cancer cell drug responses. When necessary, we will identify and/or develop new algorithms, enhancing our CSBC<U+201A><U+00C4><U+00F4>s quantitative and multivariate capabilities. Finally, we will work closely with our CSBC team members to help with experimental design, ensuring that an appropriate number of cells/samples are processed to test hypotheses of interest and that appropriate statistical testing is performed. By providing comprehensive analysis (QC, power, gene set enrichment) and modeling capabilities, we will dramatically enhance our ability to draw crucial insights from our data. This will lead to new hypotheses that can be tested by designing new experiments.","4":"Microenvironment","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645090","2":"Education and Outreach Core","3":"The mentorship of current and future trainees who can tackle cancer-related problems with computational systems biology approaches is an integral part of fulfilling our commitment to catalyze and generate new bodies of knowledge and fields of cancer study. To achieve this goal, we will: 1) Establish graduate student fellowships for students jointly mentored in computational systems biology, precision measurement or oncology. 2) Provide undergraduate research opportunities for MIT students to work in laboratories at DFCI. 3) Provide outreach to the biotech/pharmaceutical industry. 4) Establish an NCI CSBC Junior Investigators program. 5) Facilitate monthly meetings and annual retreats that will be open to the MIT/DFCI community. 6) Offer mini-courses and training in experimental and computational methods. 8) Provide outreach to the community. and 7) Establish and maintain a website for disseminating research activities of our center as well as relevant techniques and applications.","4":"Drug Resistance/Sensitivity","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645090","2":"Education and Outreach Core","3":"The mentorship of current and future trainees who can tackle cancer-related problems with computational systems biology approaches is an integral part of fulfilling our commitment to catalyze and generate new bodies of knowledge and fields of cancer study. To achieve this goal, we will: 1) Establish graduate student fellowships for students jointly mentored in computational systems biology, precision measurement or oncology. 2) Provide undergraduate research opportunities for MIT students to work in laboratories at DFCI. 3) Provide outreach to the biotech/pharmaceutical industry. 4) Establish an NCI CSBC Junior Investigators program. 5) Facilitate monthly meetings and annual retreats that will be open to the MIT/DFCI community. 6) Offer mini-courses and training in experimental and computational methods. 8) Provide outreach to the community. and 7) Establish and maintain a website for disseminating research activities of our center as well as relevant techniques and applications.","4":"Microenvironment","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645091","2":"Administrative Core","3":"The overall mission of the Administrative Unit is to provide oversight and coordination on administrative and fiscal aspects of the MIT/DFCI CSBC.","4":"Drug Resistance/Sensitivity","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645091","2":"Administrative Core","3":"The overall mission of the Administrative Unit is to provide oversight and coordination on administrative and fiscal aspects of the MIT/DFCI CSBC.","4":"Microenvironment","5":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","6":"CSBC","7":"U54"},{"1":"syn21645092","2":"Therapeutic Management of Lineage- and Differentiation-state Plasticity","3":"Heterogeneity in differentiation state in a TNBC tumor and cell line demonstrated by immunofluorescence staining for differentiation-associated proteins.nn&nbsp;nnTNBC is an aggressive disease characterized by high intratumor heterogeneity and poor patient outcome. In preliminary experiments, we identified subpopulations of tumor cells in primary TNBC as well as in basal-like TNBC cell lines that are characterized by differential expression of luminal, basal, and mesenchymal differentiation-state markers. We have observed that distinct classes of targeted therapeutics have the capacity to eliminate or enrich specific differentiation-state subpopulations within these lines, steering heterogeneous cancer cell populations toward increased homogeneity. Importantly, we identified synergistic combinatorial treatments that targeted either pathway dependencies predicted by master regulator analysis of residual cells or epigenetic regulators found to contribute to a cell<U+201A><U+00C4><U+00F4>s transition to a resistant state. The overall goal of this project, therefore, is to understand cell intrinsic regulation of therapeutic response in phenotypically heterogeneous TNBC in order to develop targeting strategies to kill all co-existing subpopulations. We focus on phenotypic heterogeneity, as this can represent the combination of genetic and epigenetic factors, and we take advantage of clinically relevant therapeutics that drive heterogeneous populations toward homogeneity. We hypothesize that a systems biology approach of measuring and computationally modeling the functional pathways underlying phenotypic state changes in response to state-aggregating therapeutics will reveal common escape routes and regulators of cell plasticity, which allow us to predict effective combinatorial therapeutic strategies that eliminate all cancer subpopulations. We address this hypothesis by (1) examining and computationally modeling phenotype state changes in multiple genetically diverse, heterogeneous TNBC cell lines in response to targeted therapeutics that induce homogeneity using high-content imaging and single cell expression analysis, (2) determining whether clonal expansion or differentiation state plasticity drives the dynamic phenotype changes following targeted therapy and modeling the molecular network changes that underlie these transitions, and (3) determining epigenetic regulation underlying state transitions and developing combinatorial strategies that overcome therapeutic resistance in heterogeneous TNBC cells in vitro and in vivo. Together, these aims support our goal to measure and model cell intrinsic responses to clinically relevant targeted therapeutics and to predict synergistic drug combinations that more effectively control heterogeneous TNBC. Integration of this work with Projects 2 and 3 allows us to incorporate extrinsic regulators of these intrinsic mechanisms and to iteratively refine control strategies for this devastating disease.","4":"Drug Resistance/Sensitivity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645092","2":"Therapeutic Management of Lineage- and Differentiation-state Plasticity","3":"Heterogeneity in differentiation state in a TNBC tumor and cell line demonstrated by immunofluorescence staining for differentiation-associated proteins.nn&nbsp;nnTNBC is an aggressive disease characterized by high intratumor heterogeneity and poor patient outcome. In preliminary experiments, we identified subpopulations of tumor cells in primary TNBC as well as in basal-like TNBC cell lines that are characterized by differential expression of luminal, basal, and mesenchymal differentiation-state markers. We have observed that distinct classes of targeted therapeutics have the capacity to eliminate or enrich specific differentiation-state subpopulations within these lines, steering heterogeneous cancer cell populations toward increased homogeneity. Importantly, we identified synergistic combinatorial treatments that targeted either pathway dependencies predicted by master regulator analysis of residual cells or epigenetic regulators found to contribute to a cell<U+201A><U+00C4><U+00F4>s transition to a resistant state. The overall goal of this project, therefore, is to understand cell intrinsic regulation of therapeutic response in phenotypically heterogeneous TNBC in order to develop targeting strategies to kill all co-existing subpopulations. We focus on phenotypic heterogeneity, as this can represent the combination of genetic and epigenetic factors, and we take advantage of clinically relevant therapeutics that drive heterogeneous populations toward homogeneity. We hypothesize that a systems biology approach of measuring and computationally modeling the functional pathways underlying phenotypic state changes in response to state-aggregating therapeutics will reveal common escape routes and regulators of cell plasticity, which allow us to predict effective combinatorial therapeutic strategies that eliminate all cancer subpopulations. We address this hypothesis by (1) examining and computationally modeling phenotype state changes in multiple genetically diverse, heterogeneous TNBC cell lines in response to targeted therapeutics that induce homogeneity using high-content imaging and single cell expression analysis, (2) determining whether clonal expansion or differentiation state plasticity drives the dynamic phenotype changes following targeted therapy and modeling the molecular network changes that underlie these transitions, and (3) determining epigenetic regulation underlying state transitions and developing combinatorial strategies that overcome therapeutic resistance in heterogeneous TNBC cells in vitro and in vivo. Together, these aims support our goal to measure and model cell intrinsic responses to clinically relevant targeted therapeutics and to predict synergistic drug combinations that more effectively control heterogeneous TNBC. Integration of this work with Projects 2 and 3 allows us to incorporate extrinsic regulators of these intrinsic mechanisms and to iteratively refine control strategies for this devastating disease.","4":"Heterogeneity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645092","2":"Therapeutic Management of Lineage- and Differentiation-state Plasticity","3":"Heterogeneity in differentiation state in a TNBC tumor and cell line demonstrated by immunofluorescence staining for differentiation-associated proteins.nn&nbsp;nnTNBC is an aggressive disease characterized by high intratumor heterogeneity and poor patient outcome. In preliminary experiments, we identified subpopulations of tumor cells in primary TNBC as well as in basal-like TNBC cell lines that are characterized by differential expression of luminal, basal, and mesenchymal differentiation-state markers. We have observed that distinct classes of targeted therapeutics have the capacity to eliminate or enrich specific differentiation-state subpopulations within these lines, steering heterogeneous cancer cell populations toward increased homogeneity. Importantly, we identified synergistic combinatorial treatments that targeted either pathway dependencies predicted by master regulator analysis of residual cells or epigenetic regulators found to contribute to a cell<U+201A><U+00C4><U+00F4>s transition to a resistant state. The overall goal of this project, therefore, is to understand cell intrinsic regulation of therapeutic response in phenotypically heterogeneous TNBC in order to develop targeting strategies to kill all co-existing subpopulations. We focus on phenotypic heterogeneity, as this can represent the combination of genetic and epigenetic factors, and we take advantage of clinically relevant therapeutics that drive heterogeneous populations toward homogeneity. We hypothesize that a systems biology approach of measuring and computationally modeling the functional pathways underlying phenotypic state changes in response to state-aggregating therapeutics will reveal common escape routes and regulators of cell plasticity, which allow us to predict effective combinatorial therapeutic strategies that eliminate all cancer subpopulations. We address this hypothesis by (1) examining and computationally modeling phenotype state changes in multiple genetically diverse, heterogeneous TNBC cell lines in response to targeted therapeutics that induce homogeneity using high-content imaging and single cell expression analysis, (2) determining whether clonal expansion or differentiation state plasticity drives the dynamic phenotype changes following targeted therapy and modeling the molecular network changes that underlie these transitions, and (3) determining epigenetic regulation underlying state transitions and developing combinatorial strategies that overcome therapeutic resistance in heterogeneous TNBC cells in vitro and in vivo. Together, these aims support our goal to measure and model cell intrinsic responses to clinically relevant targeted therapeutics and to predict synergistic drug combinations that more effectively control heterogeneous TNBC. Integration of this work with Projects 2 and 3 allows us to incorporate extrinsic regulators of these intrinsic mechanisms and to iteratively refine control strategies for this devastating disease.","4":"Microenvironment","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645093","2":"Managing Microenvironment-mediated Heterogeneity and Resistance","3":"Schematic illustration of the process used to use microenvironment microarrays to interrogate the effects of microenvironmental proteins on therapeutic responses. The inability to effectively treat TNBC is thought to be in part due to its heterogeneity, as cells are highly plastic and able to respond rapidly to therapeutic insults to steer into drug resistant states. One aspect that is likely to strongly influence TNBC plasticity, heterogeneity, and response to therapy is the microenvironment (ME) in which cells reside. Interactions with extracellular matrix proteins or soluble factors like growth factors and cytokines can profoundly change phenotypic properties of TNBC cells, and mounting evidence suggests that such ME factors also influence response to therapy. We hypothesize that the ME impacts therapeutic response of TNBC, and that consideration of signals from the ME in treatment decisions are likely to lead to improved therapeutic control and patient outcomes. We couple experimental assessment of TNBC response to targeted therapeutics in the presence of defined combinatorial ME perturbations (MEPs) with concomitant expression profiling and computational approaches to define underlying pathway signatures to identify vulnerabilities in residual cancer cells that could be exploited for therapeutic benefit. This is accomplished using microenvironment microarrays to identify MEPs that confer resistance to six targeted therapeutics in TNBC cell lines and primary patient-derived xenograft (PDX) samples. We perform expression profiling by RNA-Seq at fixed time points on TNBC cells grown in the presence of resistance conferring MEPs plus therapeutic and use computational approaches to identify underlying reduced dimensionality network signatures (PREdictors of CEllular Phenotypes to guide Therapeutic Strategies, PRECEPTS) that are altered as a result of interactions of cells with MEP and drug. These altered PRECEPTS signatures represent candidates for therapeutic intervention, and are tested using drug combinations in an attempt to overcome ME-mediated resistance. We perform dynamic imaging and expression profiling of the response of TNBC cells to resistance conferring MEPs plus drug and identify PRECEPTS signatures that are dynamically altered. Such PRECEPTS signatures represent potential transition vulnerabilities that could be targeted for therapeutic intervention, which we test experimentally using drug combination treatments of TNBC cells. These approaches are closely coordinated with those of Projects 1 and 3 in the use of common cell lines, drugs, and reagents and to maximize the information that we derive from the experiments. This approach enables the discovery of new drug combinations that could be deployed clinically to improve outcome in TNBC patients with primary and disseminated disease.","4":"Drug Resistance/Sensitivity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645093","2":"Managing Microenvironment-mediated Heterogeneity and Resistance","3":"Schematic illustration of the process used to use microenvironment microarrays to interrogate the effects of microenvironmental proteins on therapeutic responses. The inability to effectively treat TNBC is thought to be in part due to its heterogeneity, as cells are highly plastic and able to respond rapidly to therapeutic insults to steer into drug resistant states. One aspect that is likely to strongly influence TNBC plasticity, heterogeneity, and response to therapy is the microenvironment (ME) in which cells reside. Interactions with extracellular matrix proteins or soluble factors like growth factors and cytokines can profoundly change phenotypic properties of TNBC cells, and mounting evidence suggests that such ME factors also influence response to therapy. We hypothesize that the ME impacts therapeutic response of TNBC, and that consideration of signals from the ME in treatment decisions are likely to lead to improved therapeutic control and patient outcomes. We couple experimental assessment of TNBC response to targeted therapeutics in the presence of defined combinatorial ME perturbations (MEPs) with concomitant expression profiling and computational approaches to define underlying pathway signatures to identify vulnerabilities in residual cancer cells that could be exploited for therapeutic benefit. This is accomplished using microenvironment microarrays to identify MEPs that confer resistance to six targeted therapeutics in TNBC cell lines and primary patient-derived xenograft (PDX) samples. We perform expression profiling by RNA-Seq at fixed time points on TNBC cells grown in the presence of resistance conferring MEPs plus therapeutic and use computational approaches to identify underlying reduced dimensionality network signatures (PREdictors of CEllular Phenotypes to guide Therapeutic Strategies, PRECEPTS) that are altered as a result of interactions of cells with MEP and drug. These altered PRECEPTS signatures represent candidates for therapeutic intervention, and are tested using drug combinations in an attempt to overcome ME-mediated resistance. We perform dynamic imaging and expression profiling of the response of TNBC cells to resistance conferring MEPs plus drug and identify PRECEPTS signatures that are dynamically altered. Such PRECEPTS signatures represent potential transition vulnerabilities that could be targeted for therapeutic intervention, which we test experimentally using drug combination treatments of TNBC cells. These approaches are closely coordinated with those of Projects 1 and 3 in the use of common cell lines, drugs, and reagents and to maximize the information that we derive from the experiments. This approach enables the discovery of new drug combinations that could be deployed clinically to improve outcome in TNBC patients with primary and disseminated disease.","4":"Heterogeneity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645093","2":"Managing Microenvironment-mediated Heterogeneity and Resistance","3":"Schematic illustration of the process used to use microenvironment microarrays to interrogate the effects of microenvironmental proteins on therapeutic responses. The inability to effectively treat TNBC is thought to be in part due to its heterogeneity, as cells are highly plastic and able to respond rapidly to therapeutic insults to steer into drug resistant states. One aspect that is likely to strongly influence TNBC plasticity, heterogeneity, and response to therapy is the microenvironment (ME) in which cells reside. Interactions with extracellular matrix proteins or soluble factors like growth factors and cytokines can profoundly change phenotypic properties of TNBC cells, and mounting evidence suggests that such ME factors also influence response to therapy. We hypothesize that the ME impacts therapeutic response of TNBC, and that consideration of signals from the ME in treatment decisions are likely to lead to improved therapeutic control and patient outcomes. We couple experimental assessment of TNBC response to targeted therapeutics in the presence of defined combinatorial ME perturbations (MEPs) with concomitant expression profiling and computational approaches to define underlying pathway signatures to identify vulnerabilities in residual cancer cells that could be exploited for therapeutic benefit. This is accomplished using microenvironment microarrays to identify MEPs that confer resistance to six targeted therapeutics in TNBC cell lines and primary patient-derived xenograft (PDX) samples. We perform expression profiling by RNA-Seq at fixed time points on TNBC cells grown in the presence of resistance conferring MEPs plus therapeutic and use computational approaches to identify underlying reduced dimensionality network signatures (PREdictors of CEllular Phenotypes to guide Therapeutic Strategies, PRECEPTS) that are altered as a result of interactions of cells with MEP and drug. These altered PRECEPTS signatures represent candidates for therapeutic intervention, and are tested using drug combinations in an attempt to overcome ME-mediated resistance. We perform dynamic imaging and expression profiling of the response of TNBC cells to resistance conferring MEPs plus drug and identify PRECEPTS signatures that are dynamically altered. Such PRECEPTS signatures represent potential transition vulnerabilities that could be targeted for therapeutic intervention, which we test experimentally using drug combination treatments of TNBC cells. These approaches are closely coordinated with those of Projects 1 and 3 in the use of common cell lines, drugs, and reagents and to maximize the information that we derive from the experiments. This approach enables the discovery of new drug combinations that could be deployed clinically to improve outcome in TNBC patients with primary and disseminated disease.","4":"Microenvironment","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645094","2":"Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance","3":"Integration of omic and spatial features to identify molecular networks that control molecular heterogeneity. We use a spatial systems approach to identify molecular networks that control development of resistance-associated heterogeneity in TNBCs and to use this information to devise multidrug treatments that are effective in heterogeneous TNBCs. Our focus is on heterogeneity that arises from epigenomic plasticity intrinsic to cancer cells and from extrinsic signals from the diverse microenvironments into which TNBC cells disperse. Individual cells within a TNBC exhibit variable phenotypes and respond variably to treatment so that establishing durable control of TNBCs is notoriously difficult. We explore the mechanisms by which individual cells in TNBC tissues respond to perturbations induced by microenvironment interactions and/or drugs. Our approach is based on the concept that the phenotype and response to therapy of every cell in a heterogeneous TNBC tissue is influenced by its intrinsic epigenomic status and by the microenvironmental signals it receives. In short, every cancer cell-microenvironment-drug interaction in a heterogeneous experimental tissue or clinical specimen is an independent experiment of nature. We analyze ensembles of such interactions in TNBC tissues before and after treatment to determine the impact of local environmental signals on cancer cell phenotype and therapeutic response. We accomplish this using cyclic multiplex immunofluorescence to stain cancer cells for quantitative analysis of proliferative status, differentiation state, and expression levels of proteins that report on control network activity. We quantify cancer cell-microenvironment interactions at the microscale using multicolor fluorescence microscopy and at the nanoscale using multispectral super resolution fluorescence microscopy and 3D scanning electron microscopy. We use custom image analysis techniques developed in the Imaging Core to quantify cell and microenvironment components and machine/deep learning strategies to identify microenvironment-cancer cell interactions that influence phenotype. This work guides development of dynamic models of spatially dependent control network-microenvironment interactions that can be used to devise therapeutic strategies to control TNBCs. The approach is statistically powerful since every tissue section contains details about tens of thousands of cell-microenvironment interactions. We accomplish this by; (1) developing cyclic multiplex immunofluorescence, multiscale image analysis, and machine learning procedures needed to identify molecular control networks in individual cells in TNBC tissues that respond to signals from microenvironmental cells and proteins (MEPs) and that influence phenotype and/or therapeutic response, (2) elucidating the effects of microenvironmental cells and high impact proteins on TNBC control network activity, phenotype, and therapeutic response in bioprinted tissues. (3) assessing the effects of microenvironmental cells and high impact proteins on TNBC control network activity, phenotype, and therapeutic response in TNBC xenografts and clinical TNBC specimens.","4":"Drug Resistance/Sensitivity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645094","2":"Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance","3":"Integration of omic and spatial features to identify molecular networks that control molecular heterogeneity. We use a spatial systems approach to identify molecular networks that control development of resistance-associated heterogeneity in TNBCs and to use this information to devise multidrug treatments that are effective in heterogeneous TNBCs. Our focus is on heterogeneity that arises from epigenomic plasticity intrinsic to cancer cells and from extrinsic signals from the diverse microenvironments into which TNBC cells disperse. Individual cells within a TNBC exhibit variable phenotypes and respond variably to treatment so that establishing durable control of TNBCs is notoriously difficult. We explore the mechanisms by which individual cells in TNBC tissues respond to perturbations induced by microenvironment interactions and/or drugs. Our approach is based on the concept that the phenotype and response to therapy of every cell in a heterogeneous TNBC tissue is influenced by its intrinsic epigenomic status and by the microenvironmental signals it receives. In short, every cancer cell-microenvironment-drug interaction in a heterogeneous experimental tissue or clinical specimen is an independent experiment of nature. We analyze ensembles of such interactions in TNBC tissues before and after treatment to determine the impact of local environmental signals on cancer cell phenotype and therapeutic response. We accomplish this using cyclic multiplex immunofluorescence to stain cancer cells for quantitative analysis of proliferative status, differentiation state, and expression levels of proteins that report on control network activity. We quantify cancer cell-microenvironment interactions at the microscale using multicolor fluorescence microscopy and at the nanoscale using multispectral super resolution fluorescence microscopy and 3D scanning electron microscopy. We use custom image analysis techniques developed in the Imaging Core to quantify cell and microenvironment components and machine/deep learning strategies to identify microenvironment-cancer cell interactions that influence phenotype. This work guides development of dynamic models of spatially dependent control network-microenvironment interactions that can be used to devise therapeutic strategies to control TNBCs. The approach is statistically powerful since every tissue section contains details about tens of thousands of cell-microenvironment interactions. We accomplish this by; (1) developing cyclic multiplex immunofluorescence, multiscale image analysis, and machine learning procedures needed to identify molecular control networks in individual cells in TNBC tissues that respond to signals from microenvironmental cells and proteins (MEPs) and that influence phenotype and/or therapeutic response, (2) elucidating the effects of microenvironmental cells and high impact proteins on TNBC control network activity, phenotype, and therapeutic response in bioprinted tissues. (3) assessing the effects of microenvironmental cells and high impact proteins on TNBC control network activity, phenotype, and therapeutic response in TNBC xenografts and clinical TNBC specimens.","4":"Heterogeneity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645094","2":"Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance","3":"Integration of omic and spatial features to identify molecular networks that control molecular heterogeneity. We use a spatial systems approach to identify molecular networks that control development of resistance-associated heterogeneity in TNBCs and to use this information to devise multidrug treatments that are effective in heterogeneous TNBCs. Our focus is on heterogeneity that arises from epigenomic plasticity intrinsic to cancer cells and from extrinsic signals from the diverse microenvironments into which TNBC cells disperse. Individual cells within a TNBC exhibit variable phenotypes and respond variably to treatment so that establishing durable control of TNBCs is notoriously difficult. We explore the mechanisms by which individual cells in TNBC tissues respond to perturbations induced by microenvironment interactions and/or drugs. Our approach is based on the concept that the phenotype and response to therapy of every cell in a heterogeneous TNBC tissue is influenced by its intrinsic epigenomic status and by the microenvironmental signals it receives. In short, every cancer cell-microenvironment-drug interaction in a heterogeneous experimental tissue or clinical specimen is an independent experiment of nature. We analyze ensembles of such interactions in TNBC tissues before and after treatment to determine the impact of local environmental signals on cancer cell phenotype and therapeutic response. We accomplish this using cyclic multiplex immunofluorescence to stain cancer cells for quantitative analysis of proliferative status, differentiation state, and expression levels of proteins that report on control network activity. We quantify cancer cell-microenvironment interactions at the microscale using multicolor fluorescence microscopy and at the nanoscale using multispectral super resolution fluorescence microscopy and 3D scanning electron microscopy. We use custom image analysis techniques developed in the Imaging Core to quantify cell and microenvironment components and machine/deep learning strategies to identify microenvironment-cancer cell interactions that influence phenotype. This work guides development of dynamic models of spatially dependent control network-microenvironment interactions that can be used to devise therapeutic strategies to control TNBCs. The approach is statistically powerful since every tissue section contains details about tens of thousands of cell-microenvironment interactions. We accomplish this by; (1) developing cyclic multiplex immunofluorescence, multiscale image analysis, and machine learning procedures needed to identify molecular control networks in individual cells in TNBC tissues that respond to signals from microenvironmental cells and proteins (MEPs) and that influence phenotype and/or therapeutic response, (2) elucidating the effects of microenvironmental cells and high impact proteins on TNBC control network activity, phenotype, and therapeutic response in bioprinted tissues. (3) assessing the effects of microenvironmental cells and high impact proteins on TNBC control network activity, phenotype, and therapeutic response in TNBC xenografts and clinical TNBC specimens.","4":"Microenvironment","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645095","2":"Imaging Management and Analysis Core","3":"The Imaging Management and Analysis Core (Imaging Core) provides a common infrastructure for image acquisition, efficient image data management, and quantitative analysis for all projects. It deploys and integrates images from multiple platforms including multiwell high content imaging, microenvironment microarrays, cyclic immunofluorescence workflows and correlative light/electron microscopy. This includes: (1) developing customized workflows for the three high-content microscope systems to acquire and store images and metadata and all derived and associated measurement data, using an open source OMERO image database and our Annot experiment tracking database, (b) providing automated scene segmentation and feature extraction solutions, and (c) developing novel visualization methods to interactively analyze quantitative imaging data, metadata, and externally linked data. These tools and methods are integrated into a highly efficient workflow for acquiring, managing, analyzing, and visualizing the types of high-content imaging data that are generated in Project 1 for assessing phenotypic state changes from drug therapy, and in Project 2 for analyzing the effects of the microenvironment, alone and in combination with drugs, on differentiation state. These data and visualization tools are made available to the community through the Outreach Core in close collaboration with Sage Synapse. The Imaging Core supports Project 3 and image analysis and visualization requirements in all projects by further developing our Dynamic Visualization Engine framework for visualization methods that integrate image data at the level of individual cells, images, and assays; experimental metadata and external annotations; image analysis features such as segmentation results; and interactive quantitative graphs that allow drilling down to all levels of underlying data.","4":"Drug Resistance/Sensitivity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645095","2":"Imaging Management and Analysis Core","3":"The Imaging Management and Analysis Core (Imaging Core) provides a common infrastructure for image acquisition, efficient image data management, and quantitative analysis for all projects. It deploys and integrates images from multiple platforms including multiwell high content imaging, microenvironment microarrays, cyclic immunofluorescence workflows and correlative light/electron microscopy. This includes: (1) developing customized workflows for the three high-content microscope systems to acquire and store images and metadata and all derived and associated measurement data, using an open source OMERO image database and our Annot experiment tracking database, (b) providing automated scene segmentation and feature extraction solutions, and (c) developing novel visualization methods to interactively analyze quantitative imaging data, metadata, and externally linked data. These tools and methods are integrated into a highly efficient workflow for acquiring, managing, analyzing, and visualizing the types of high-content imaging data that are generated in Project 1 for assessing phenotypic state changes from drug therapy, and in Project 2 for analyzing the effects of the microenvironment, alone and in combination with drugs, on differentiation state. These data and visualization tools are made available to the community through the Outreach Core in close collaboration with Sage Synapse. The Imaging Core supports Project 3 and image analysis and visualization requirements in all projects by further developing our Dynamic Visualization Engine framework for visualization methods that integrate image data at the level of individual cells, images, and assays; experimental metadata and external annotations; image analysis features such as segmentation results; and interactive quantitative graphs that allow drilling down to all levels of underlying data.","4":"Heterogeneity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645095","2":"Imaging Management and Analysis Core","3":"The Imaging Management and Analysis Core (Imaging Core) provides a common infrastructure for image acquisition, efficient image data management, and quantitative analysis for all projects. It deploys and integrates images from multiple platforms including multiwell high content imaging, microenvironment microarrays, cyclic immunofluorescence workflows and correlative light/electron microscopy. This includes: (1) developing customized workflows for the three high-content microscope systems to acquire and store images and metadata and all derived and associated measurement data, using an open source OMERO image database and our Annot experiment tracking database, (b) providing automated scene segmentation and feature extraction solutions, and (c) developing novel visualization methods to interactively analyze quantitative imaging data, metadata, and externally linked data. These tools and methods are integrated into a highly efficient workflow for acquiring, managing, analyzing, and visualizing the types of high-content imaging data that are generated in Project 1 for assessing phenotypic state changes from drug therapy, and in Project 2 for analyzing the effects of the microenvironment, alone and in combination with drugs, on differentiation state. These data and visualization tools are made available to the community through the Outreach Core in close collaboration with Sage Synapse. The Imaging Core supports Project 3 and image analysis and visualization requirements in all projects by further developing our Dynamic Visualization Engine framework for visualization methods that integrate image data at the level of individual cells, images, and assays; experimental metadata and external annotations; image analysis features such as segmentation results; and interactive quantitative graphs that allow drilling down to all levels of underlying data.","4":"Microenvironment","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645096","2":"Outreach Core","3":"The Outreach Core disseminates results, methods and tools from the Center to the broader research community. It accomplishes this by; (a) hosting symposia, workshops, and think tanks that present, train, and extend the state of the art in techniques useful for understanding heterogeneity in cancer, (b) providing access to the bioimaging and genomic data using a custom portal for access, visualization, and interactive analysis based on OMERO (Open Microscopy Environment image database) and Sage Synapse; and (c) conducting DREAM crowd-sourcing activities to seek analytical solutions to spatial systems biology questions, and to identify new methods and approaches for analyzing these data.","4":"Drug Resistance/Sensitivity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645096","2":"Outreach Core","3":"The Outreach Core disseminates results, methods and tools from the Center to the broader research community. It accomplishes this by; (a) hosting symposia, workshops, and think tanks that present, train, and extend the state of the art in techniques useful for understanding heterogeneity in cancer, (b) providing access to the bioimaging and genomic data using a custom portal for access, visualization, and interactive analysis based on OMERO (Open Microscopy Environment image database) and Sage Synapse; and (c) conducting DREAM crowd-sourcing activities to seek analytical solutions to spatial systems biology questions, and to identify new methods and approaches for analyzing these data.","4":"Heterogeneity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645096","2":"Outreach Core","3":"The Outreach Core disseminates results, methods and tools from the Center to the broader research community. It accomplishes this by; (a) hosting symposia, workshops, and think tanks that present, train, and extend the state of the art in techniques useful for understanding heterogeneity in cancer, (b) providing access to the bioimaging and genomic data using a custom portal for access, visualization, and interactive analysis based on OMERO (Open Microscopy Environment image database) and Sage Synapse; and (c) conducting DREAM crowd-sourcing activities to seek analytical solutions to spatial systems biology questions, and to identify new methods and approaches for analyzing these data.","4":"Microenvironment","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645097","2":"Administrative Core","3":"The Administrative Core provides leadership and supports and coordinates: (a) communications and interactions within the Center and across the CSBC, (b) proposal preparation, management, reporting, and compliance activities, (c) oversight of budgetary and intellectual property issues, (d) oversight of the M2CH-CCSB computational infrastructure and the Resource Sharing Plan, (e) project integration and evaluation (including pilot projects), and (f) external review of the Center, including assembly of an External Advisory Committee (EAC).","4":"Drug Resistance/Sensitivity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645097","2":"Administrative Core","3":"The Administrative Core provides leadership and supports and coordinates: (a) communications and interactions within the Center and across the CSBC, (b) proposal preparation, management, reporting, and compliance activities, (c) oversight of budgetary and intellectual property issues, (d) oversight of the M2CH-CCSB computational infrastructure and the Resource Sharing Plan, (e) project integration and evaluation (including pilot projects), and (f) external review of the Center, including assembly of an External Advisory Committee (EAC).","4":"Heterogeneity","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645097","2":"Administrative Core","3":"The Administrative Core provides leadership and supports and coordinates: (a) communications and interactions within the Center and across the CSBC, (b) proposal preparation, management, reporting, and compliance activities, (c) oversight of budgetary and intellectual property issues, (d) oversight of the M2CH-CCSB computational infrastructure and the Resource Sharing Plan, (e) project integration and evaluation (including pilot projects), and (f) external review of the Center, including assembly of an External Advisory Committee (EAC).","4":"Microenvironment","5":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","6":"CSBC","7":"U54"},{"1":"syn21645098","2":"High-order assembly of MegaTrans complexes for hormone-independent enhancer activation","3":"Endocrine therapy is commonly used in hormone-driven breast and prostate cancers. A persistent challenge is disease progression caused by hormone resistance during the treatment. Studies for the past 25 years have revealed an essential role of hormones (i.e., estrogen and androgen) and their receptors, ER<U+0152><U+00B1> and AR, in cancer progression. Increased evidence indicates that epigenetic deregulation of ER<U+0152><U+00B1>/AR-bound enhancers profoundly alters hormone-mediated transcription machineries, leading to the development of hormone resistance. However, the molecular mechanisms underlying this hormone-resistance transition of enhancer function are largely unknown. We have recently discovered that the most active and functionally important ER<U+0152><U+00B1>-bound enhancers can recruit a large number of DNA-binding transcription factors through protein-protein interactions. These newly identified ER<U+0152><U+00B1> <U+201A><U+00C4><U+00F2>co-activators<U+201A><U+00C4><U+00F4>, termed MegaTrans transcription factors (TFs), are required to activate ER<U+0152><U+00B1>-bound enhancers and also serve as a signature of functional enhancers. Our preliminary data additionally show the presence of MegaTrans TFs in AR-bound enhancers. Because most MegaTrans TFs are signaling-dependent molecules, they may receive other signals from tumor microenvironments to alter enhancer functions. Thus, combinatorial interactions between ER<U+0152><U+00B1>/AR and MegaTrans TFs make their enhancers respond not only to estrogen or androgen, but also to other microenvironmental signals. The composition and interaction of MegaTrans TFs undergo dynamic changes during cancer progression, resulting in alterations of ER<U+0152><U+00B1>/AR enhancer functions that promote hormone-resistance in breast and prostate cancer cells.nn&nbsp;nn${image?fileName=u54%5Futhscsa%5Fosu%5Fimage2%2Epng&align=None&scale=100&responsive=true}nCis- and trans-binding transcription factor","4":"Drug Resistance/Sensitivity","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645098","2":"High-order assembly of MegaTrans complexes for hormone-independent enhancer activation","3":"Endocrine therapy is commonly used in hormone-driven breast and prostate cancers. A persistent challenge is disease progression caused by hormone resistance during the treatment. Studies for the past 25 years have revealed an essential role of hormones (i.e., estrogen and androgen) and their receptors, ER<U+0152><U+00B1> and AR, in cancer progression. Increased evidence indicates that epigenetic deregulation of ER<U+0152><U+00B1>/AR-bound enhancers profoundly alters hormone-mediated transcription machineries, leading to the development of hormone resistance. However, the molecular mechanisms underlying this hormone-resistance transition of enhancer function are largely unknown. We have recently discovered that the most active and functionally important ER<U+0152><U+00B1>-bound enhancers can recruit a large number of DNA-binding transcription factors through protein-protein interactions. These newly identified ER<U+0152><U+00B1> <U+201A><U+00C4><U+00F2>co-activators<U+201A><U+00C4><U+00F4>, termed MegaTrans transcription factors (TFs), are required to activate ER<U+0152><U+00B1>-bound enhancers and also serve as a signature of functional enhancers. Our preliminary data additionally show the presence of MegaTrans TFs in AR-bound enhancers. Because most MegaTrans TFs are signaling-dependent molecules, they may receive other signals from tumor microenvironments to alter enhancer functions. Thus, combinatorial interactions between ER<U+0152><U+00B1>/AR and MegaTrans TFs make their enhancers respond not only to estrogen or androgen, but also to other microenvironmental signals. The composition and interaction of MegaTrans TFs undergo dynamic changes during cancer progression, resulting in alterations of ER<U+0152><U+00B1>/AR enhancer functions that promote hormone-resistance in breast and prostate cancer cells.nn&nbsp;nn${image?fileName=u54%5Futhscsa%5Fosu%5Fimage2%2Epng&align=None&scale=100&responsive=true}nCis- and trans-binding transcription factor","4":"Epigenetics","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645099","2":"Fine-scale nucleosome repositioning of enhancers for hormone-independent genomic function","3":"The cognate receptors AR and ER<U+0152><U+00B1> can remain active for tumor progression after anti-hormone treatment for patients with prostate and breast cancers. Despite intensive efforts to elucidate the underlying mechanisms, little information is available concerning AR/ER<U+0152><U+00B1> genomic function for promoting hormone resistance at the nucleosome level. In recent studies, we observed this genomic function is well orchestrated, relying on precise nucleosome organization within cis-bound enhancers for hormone-dependent transcription. Interestingly, we also found that this epigenetic mechanism can be hijacked by hormone-resistant cells to gain their growth and invasion advantages. Therefore, we hypothesize that altered nucleosome positions, or nucleosome repositioning, in and near AR/ER<U+0152><U+00B1>-bound enhancers is being exploited for hormone-independent genomic function in advanced cancers. In Aim 1, we will conduct ChIP-ePENS and MNase-seq to comprehensively map nucleosome boundaries of AR/ER<U+0152><U+00B1>-bound enhancers in a panel of hormone-sensitive and -resistant cancer cells. RNA-seq will be conducted to determine differential expression patterns of corresponding genes in these cell lines. The NucPat computational pipeline will be deployed to seamlessly process complex omics-seq data (Aim 2). We will use a Kernel Density Estimation algorithm to determine nucleosome positioning and spacing when AR or ER<U+0152><U+00B1> establishes direct contact with its binding motif. Using a Hidden Markov model, we will identify active nucleosome states that maximize DNA-protein contact for AR/ER<U+0152><U+00B1> genomic functions. In addition, pioneer factor FOXA1 and chromatin remodelers participate in this nucleosome repositioning even in the absence of agonists or in the presence of antagonists. To confirm this computational modeling in vivo, ChIP-ePENS and MNase-seq will be conducted in patient-derived xenograft (PDX) lines carrying hormone-sensitive and -resistant tumors (Aim 3). A nucleosome-phasing index (NPI) will be established to quantitatively assess the nucleosome states of AR/ER<U+0152><U+00B1> redeployment in different PDX lines. This integrative omics analysis will be extended to a cohort of primary tumors, categorized into high- and low-risk groups. Again, we will calculate individual NPIs and correlate the data with clinicopathological features of patients. This translational study is intended to determine whether nucleosome phasing for AR/ER<U+0152><U+00B1> redeployment is already present in high-risk primary tumors. Patients with this intrinsic phenotype are expected to have an adverse clinical outcome, irrespective of their anti-hormone treatments. Therefore, our study will address a previously uncharacterized mechanism of hormone resistance and provide experimental evidence that nucleosome repositioning plays an integral role in redefining AR/ER<U+0152><U+00B1> genomic function for advanced development of prostate and breast cancers.nn&nbsp;nn${image?fileName=u54%5Futhscsa%5Fosu%5Fimage3%2Epng&align=None&scale=100&responsive=true}nPre-existing nucleosome phasing (N2) promotes androgen-independent AR transcription in cancer cells treated with antagonist ENZ, compared to those stimulated with agonist DHT","4":"Drug Resistance/Sensitivity","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645099","2":"Fine-scale nucleosome repositioning of enhancers for hormone-independent genomic function","3":"The cognate receptors AR and ER<U+0152><U+00B1> can remain active for tumor progression after anti-hormone treatment for patients with prostate and breast cancers. Despite intensive efforts to elucidate the underlying mechanisms, little information is available concerning AR/ER<U+0152><U+00B1> genomic function for promoting hormone resistance at the nucleosome level. In recent studies, we observed this genomic function is well orchestrated, relying on precise nucleosome organization within cis-bound enhancers for hormone-dependent transcription. Interestingly, we also found that this epigenetic mechanism can be hijacked by hormone-resistant cells to gain their growth and invasion advantages. Therefore, we hypothesize that altered nucleosome positions, or nucleosome repositioning, in and near AR/ER<U+0152><U+00B1>-bound enhancers is being exploited for hormone-independent genomic function in advanced cancers. In Aim 1, we will conduct ChIP-ePENS and MNase-seq to comprehensively map nucleosome boundaries of AR/ER<U+0152><U+00B1>-bound enhancers in a panel of hormone-sensitive and -resistant cancer cells. RNA-seq will be conducted to determine differential expression patterns of corresponding genes in these cell lines. The NucPat computational pipeline will be deployed to seamlessly process complex omics-seq data (Aim 2). We will use a Kernel Density Estimation algorithm to determine nucleosome positioning and spacing when AR or ER<U+0152><U+00B1> establishes direct contact with its binding motif. Using a Hidden Markov model, we will identify active nucleosome states that maximize DNA-protein contact for AR/ER<U+0152><U+00B1> genomic functions. In addition, pioneer factor FOXA1 and chromatin remodelers participate in this nucleosome repositioning even in the absence of agonists or in the presence of antagonists. To confirm this computational modeling in vivo, ChIP-ePENS and MNase-seq will be conducted in patient-derived xenograft (PDX) lines carrying hormone-sensitive and -resistant tumors (Aim 3). A nucleosome-phasing index (NPI) will be established to quantitatively assess the nucleosome states of AR/ER<U+0152><U+00B1> redeployment in different PDX lines. This integrative omics analysis will be extended to a cohort of primary tumors, categorized into high- and low-risk groups. Again, we will calculate individual NPIs and correlate the data with clinicopathological features of patients. This translational study is intended to determine whether nucleosome phasing for AR/ER<U+0152><U+00B1> redeployment is already present in high-risk primary tumors. Patients with this intrinsic phenotype are expected to have an adverse clinical outcome, irrespective of their anti-hormone treatments. Therefore, our study will address a previously uncharacterized mechanism of hormone resistance and provide experimental evidence that nucleosome repositioning plays an integral role in redefining AR/ER<U+0152><U+00B1> genomic function for advanced development of prostate and breast cancers.nn&nbsp;nn${image?fileName=u54%5Futhscsa%5Fosu%5Fimage3%2Epng&align=None&scale=100&responsive=true}nPre-existing nucleosome phasing (N2) promotes androgen-independent AR transcription in cancer cells treated with antagonist ENZ, compared to those stimulated with agonist DHT","4":"Epigenetics","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645100","2":"Topological mapping of chromatin architectures for hormone-independent gene transcription","3":"Long-range chromatin interactions between ER<U+0152><U+00B1>/AR-bound enhancers and promoters are necessary for coordinated gene regulation in breast and prostate cancer cells. These interactions occur via the formation of 3D chromatin architecture that brings enhancers and transcription factor complexes into close contact with target genes. To decode this complex regulation, we and other investigators have previously used Hi-C to map topologically associated domains (TADs) in different cell types. In a further study, we have identified a cancer-specific TAD on chromosome 17q23 that can be partitioned into an ER<U+0152><U+00B1>-regulated transcription hub. Concordant up-regulation of its target genes is found to be associated with short disease-free survival in a subgroup of ER<U+0152><U+00B1>-positive breast cancer patients, irrespective of their anti-hormone treatments. Emerging evidence has also shown AR-specific TADs are present in the prostate cancer cell genome. Therefore, we hypothesize that 1) frequent hormone (i.e., estrogen or androgen) stimulation leads to the formation of ER<U+0152><U+00B1>/AR-related TADs that dynamically regulate transcription of multiple genes for aberrant proliferation of breast and prostate cancer cells and 2) in the presence of antagonists, a subset of these chromatin domains, herein termed transition TADs, continue to be exploited through chromatin redeployment for hormone-independent transcription. Whereas the majority of ER<U+0152><U+00B1>/AR-related TADs are functionally suppressed by antagonists, transition TADs may partially escape this blockade for constitutive regulation of gene transcription. To test these hypotheses, we will use a modified Hi-C method, called tethered conformation capture (TCC), to investigate dynamic changes of TAD structures in hormone-sensitive and -resistant cancer cell lines exposed to agonists or antagonists (Aim 1). ChIP-seq of repressive, active, and gene-body histone marks and CTCF insulator will also be conducted in this cell line panel. MNase-seq and MBDCap-seq datasets will be acquired to map euchromatinized and heterochromatinized TADs. To integrate omics-seq data, we will develop a computational model, PRAM3D, which applies a Poisson Random effect Architecture Model (PRAM) to recapitulate 3D chromatin architectures (Aim 2). A Bayesian hierarchical model will predict putative transition TADs that concordantly regulate hormone-independent transcription of target genes. Furthermore, we will use a nucleosome density method to classify transition TAD subdomains into different regulatory categories, i.e., active, repressive, or bivalent transcription hubs. CRISPR/Cas9 genome-editing of critical chromatin regions may functionally disassemble spatiotemporal organization of these TAD-associated hubs (Aim 3). Proliferation and invasion/migration assays will determine whether this genome editing partially re-sensitizes cancer cells to anti-hormone treatments. We will also interrogate mechanistic contribution of histone modifications and other epigenetic modulators for the establishment of transition TAD structures. In silico expression profiling and single-cell RNA seq will be conducted in primary tumors of TCGA cohorts and in cancer cell subpopulations, respectively, and determine whether concordant regulation of TAD-associated target genes is intrinsic predictors of hormone resistance in breast or prostate cancer.nn&nbsp;nn${image?fileName=u54%5Futhscsa%5Fosu%5Fimage4%2Epng&align=None&scale=100&responsive=true}nER<U+0152><U+00B1>-mediated transcription of a TAD located on 17q23 in breast cancer cell","4":"Drug Resistance/Sensitivity","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645100","2":"Topological mapping of chromatin architectures for hormone-independent gene transcription","3":"Long-range chromatin interactions between ER<U+0152><U+00B1>/AR-bound enhancers and promoters are necessary for coordinated gene regulation in breast and prostate cancer cells. These interactions occur via the formation of 3D chromatin architecture that brings enhancers and transcription factor complexes into close contact with target genes. To decode this complex regulation, we and other investigators have previously used Hi-C to map topologically associated domains (TADs) in different cell types. In a further study, we have identified a cancer-specific TAD on chromosome 17q23 that can be partitioned into an ER<U+0152><U+00B1>-regulated transcription hub. Concordant up-regulation of its target genes is found to be associated with short disease-free survival in a subgroup of ER<U+0152><U+00B1>-positive breast cancer patients, irrespective of their anti-hormone treatments. Emerging evidence has also shown AR-specific TADs are present in the prostate cancer cell genome. Therefore, we hypothesize that 1) frequent hormone (i.e., estrogen or androgen) stimulation leads to the formation of ER<U+0152><U+00B1>/AR-related TADs that dynamically regulate transcription of multiple genes for aberrant proliferation of breast and prostate cancer cells and 2) in the presence of antagonists, a subset of these chromatin domains, herein termed transition TADs, continue to be exploited through chromatin redeployment for hormone-independent transcription. Whereas the majority of ER<U+0152><U+00B1>/AR-related TADs are functionally suppressed by antagonists, transition TADs may partially escape this blockade for constitutive regulation of gene transcription. To test these hypotheses, we will use a modified Hi-C method, called tethered conformation capture (TCC), to investigate dynamic changes of TAD structures in hormone-sensitive and -resistant cancer cell lines exposed to agonists or antagonists (Aim 1). ChIP-seq of repressive, active, and gene-body histone marks and CTCF insulator will also be conducted in this cell line panel. MNase-seq and MBDCap-seq datasets will be acquired to map euchromatinized and heterochromatinized TADs. To integrate omics-seq data, we will develop a computational model, PRAM3D, which applies a Poisson Random effect Architecture Model (PRAM) to recapitulate 3D chromatin architectures (Aim 2). A Bayesian hierarchical model will predict putative transition TADs that concordantly regulate hormone-independent transcription of target genes. Furthermore, we will use a nucleosome density method to classify transition TAD subdomains into different regulatory categories, i.e., active, repressive, or bivalent transcription hubs. CRISPR/Cas9 genome-editing of critical chromatin regions may functionally disassemble spatiotemporal organization of these TAD-associated hubs (Aim 3). Proliferation and invasion/migration assays will determine whether this genome editing partially re-sensitizes cancer cells to anti-hormone treatments. We will also interrogate mechanistic contribution of histone modifications and other epigenetic modulators for the establishment of transition TAD structures. In silico expression profiling and single-cell RNA seq will be conducted in primary tumors of TCGA cohorts and in cancer cell subpopulations, respectively, and determine whether concordant regulation of TAD-associated target genes is intrinsic predictors of hormone resistance in breast or prostate cancer.nn&nbsp;nn${image?fileName=u54%5Futhscsa%5Fosu%5Fimage4%2Epng&align=None&scale=100&responsive=true}nER<U+0152><U+00B1>-mediated transcription of a TAD located on 17q23 in breast cancer cell","4":"Epigenetics","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645101","2":"Data Analysis and Management Core","3":"A huge amount of high-throughput sequencing data is expected to be generated from TCC, ChIP-ePENS, BirA-BLRP-seq, ChIP-seq, MBDCap-seq, CLIP-seq, GRO-seq, and population-cell or single-cell RNA-seq assays and proteomic analysis in the three projects of the SA-OSU Research Center for Cancer Systems Biology (SA-OSU RCCSB). Thus, it is critical to establishing a central data process hub in order to meet the scientific missions and goals of our center. The Data Analysis and Management Core (DAMC) will ensure a unified approach to data analysis and management for all three projects, including the following tasks: 1) implementing and maintaining new software tools for computational models developed in the three projects and intra-center pilot projects; 2) designing and supporting the data analysis flow using existing public or our own software tools; 3) managing data submission to public archives, maintaining data repository and exploring data visualization; and 4) coordinating with the Data Coordination Center (DCC) within the Research Centers for Cancer Systems Biology (RCCSB) Consortium. To accomplish these tasks, the DAMC will leverage existing infrastructure and computational expertise at University of Texas at San Antonio of both Health Science Center (UTHSCSA) and Academics (UTSA), the Ohio State University, and Baylor College of Medicine. We will establish a leadership team to develop and coordinate ongoing support of cancer omics research and to communicate monthly with the Executive Committee in the Administrative Core. Members of the DAMC leadership team include the leader of the DAMC and senior investigators of the three projects <U+201A><U+00C4><U+00EC> Drs. Jin (Chair), Ruan, Weintraub, and Li who have extensive experience in large-scale data management, computational, statistical, genomic and proteomic analyses, and coordination of data analytic efforts within multi-project centers. Members of the DAMC will also be involved in all phases of project planning, from design to execution, to ensure that the flow of data from projects to the relevant cores and is well-coordinated.","4":"Drug Resistance/Sensitivity","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645101","2":"Data Analysis and Management Core","3":"A huge amount of high-throughput sequencing data is expected to be generated from TCC, ChIP-ePENS, BirA-BLRP-seq, ChIP-seq, MBDCap-seq, CLIP-seq, GRO-seq, and population-cell or single-cell RNA-seq assays and proteomic analysis in the three projects of the SA-OSU Research Center for Cancer Systems Biology (SA-OSU RCCSB). Thus, it is critical to establishing a central data process hub in order to meet the scientific missions and goals of our center. The Data Analysis and Management Core (DAMC) will ensure a unified approach to data analysis and management for all three projects, including the following tasks: 1) implementing and maintaining new software tools for computational models developed in the three projects and intra-center pilot projects; 2) designing and supporting the data analysis flow using existing public or our own software tools; 3) managing data submission to public archives, maintaining data repository and exploring data visualization; and 4) coordinating with the Data Coordination Center (DCC) within the Research Centers for Cancer Systems Biology (RCCSB) Consortium. To accomplish these tasks, the DAMC will leverage existing infrastructure and computational expertise at University of Texas at San Antonio of both Health Science Center (UTHSCSA) and Academics (UTSA), the Ohio State University, and Baylor College of Medicine. We will establish a leadership team to develop and coordinate ongoing support of cancer omics research and to communicate monthly with the Executive Committee in the Administrative Core. Members of the DAMC leadership team include the leader of the DAMC and senior investigators of the three projects <U+201A><U+00C4><U+00EC> Drs. Jin (Chair), Ruan, Weintraub, and Li who have extensive experience in large-scale data management, computational, statistical, genomic and proteomic analyses, and coordination of data analytic efforts within multi-project centers. Members of the DAMC will also be involved in all phases of project planning, from design to execution, to ensure that the flow of data from projects to the relevant cores and is well-coordinated.","4":"Epigenetics","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645102","2":"Outreach Core","3":"The goals of the Core are to enhance the awareness and knowledge of cancer systems biology, recruit next- generation trainees interested in epigenomics, and expand the scope of early-stage and established investigators to engage in omics analysis as part of their research portfolio. Two experienced Core leaders, Dr. Nameer Kirma (UTHSCSA) and Dr. Pearlly Yan (OSU), will coordinate outreach/training activities within the two center sites. In Aim 1, knowledge of advances in cancer systems biology will be disseminated through seminar series and annual symposium. Workshops will provide practical training of novel omics technologies. To maximize exposure and capitalize on our existing expertise, these symposia and workshops will be held every year alternating between the two center sites. In Aim 2, we plan to train new scientists and retool established investigators in systems epigenomics. Postdoctoral fellows and early-stage investigators will have the opportunity to participate in cross-pollination training beyond their current expertise, facilitating a more rounded understanding of systems biology. Early-stage and established investigators will have the opportunity to re-sharpen their research skills in omics analyses through the three projects in our center and the release of annual RFA for supporting two Intra-center Pilot Projects (IPPs). In addition, the Core will organize summer programs for at least six undergraduate students and visiting scientists who will have the opportunity to engage in short-term research projects using omics approaches. Given that both sites have access to a great pool of minority and underserved students in South Texas and Appalachia, we will encourage them to apply for these programs. In Aim 3, we plan to interact with investigators in the RCCSB Consortium and other genomics communities. Working with the leaders of our Administrative Core, we will send a delegation consisting of 10 senior and early-stage investigators and IPP awardees to participate in the annual RCCSB Consortium Steering Committee meeting. Through platform and poster presentations and face-to-face meetings, our investigators will find opportunities and niches for collaboration and data sharing with scientists in the Consortium. Furthermore, we will make contact with members of the NIH-funded 4D nucleome programs and other genomics forums, such as the Cold Spring Harbor Nuclear Organization and Function Symposium, to share our epigenomic findings. To disseminate knowledge on epigenomic advances, we will work with the staff in the Data Analysis and Management Core to set up searchable databases. Ongoing and to-be-developed toolkits will be made available to researchers through our website portal. Collectively, these integrative efforts are expected to nurture next-generation trainees in the area of systems biology and to foster a collaborative spirit with investigators in the RCCSB Consortium and other genomics communities.","4":"Drug Resistance/Sensitivity","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645102","2":"Outreach Core","3":"The goals of the Core are to enhance the awareness and knowledge of cancer systems biology, recruit next- generation trainees interested in epigenomics, and expand the scope of early-stage and established investigators to engage in omics analysis as part of their research portfolio. Two experienced Core leaders, Dr. Nameer Kirma (UTHSCSA) and Dr. Pearlly Yan (OSU), will coordinate outreach/training activities within the two center sites. In Aim 1, knowledge of advances in cancer systems biology will be disseminated through seminar series and annual symposium. Workshops will provide practical training of novel omics technologies. To maximize exposure and capitalize on our existing expertise, these symposia and workshops will be held every year alternating between the two center sites. In Aim 2, we plan to train new scientists and retool established investigators in systems epigenomics. Postdoctoral fellows and early-stage investigators will have the opportunity to participate in cross-pollination training beyond their current expertise, facilitating a more rounded understanding of systems biology. Early-stage and established investigators will have the opportunity to re-sharpen their research skills in omics analyses through the three projects in our center and the release of annual RFA for supporting two Intra-center Pilot Projects (IPPs). In addition, the Core will organize summer programs for at least six undergraduate students and visiting scientists who will have the opportunity to engage in short-term research projects using omics approaches. Given that both sites have access to a great pool of minority and underserved students in South Texas and Appalachia, we will encourage them to apply for these programs. In Aim 3, we plan to interact with investigators in the RCCSB Consortium and other genomics communities. Working with the leaders of our Administrative Core, we will send a delegation consisting of 10 senior and early-stage investigators and IPP awardees to participate in the annual RCCSB Consortium Steering Committee meeting. Through platform and poster presentations and face-to-face meetings, our investigators will find opportunities and niches for collaboration and data sharing with scientists in the Consortium. Furthermore, we will make contact with members of the NIH-funded 4D nucleome programs and other genomics forums, such as the Cold Spring Harbor Nuclear Organization and Function Symposium, to share our epigenomic findings. To disseminate knowledge on epigenomic advances, we will work with the staff in the Data Analysis and Management Core to set up searchable databases. Ongoing and to-be-developed toolkits will be made available to researchers through our website portal. Collectively, these integrative efforts are expected to nurture next-generation trainees in the area of systems biology and to foster a collaborative spirit with investigators in the RCCSB Consortium and other genomics communities.","4":"Epigenetics","5":"Systems Analysis of Epigenomic Architecture in Cancer Progression","6":"CSBC","7":"U54"},{"1":"syn21645103","2":"Integrative approach to heterogeneity in breast cancer metastasis","3":"Despite major advances in understanding the molecular and genetic basis of cancer, disease progression to metastasis remains the cause of >90% of cancer-related mortality. Understanding the mechanisms underlying metastasis initiation is critical for the development of new therapeutic strategies specifically to diagnose, target and prevent progression to metastatic disease. However, the identity of metastasis-initiating cells in human breast cancer remains elusive. We propose to use an integrative approach using a variety of state-of-the-art single cell multi-parametric, analytical techniques to probe heterogeneity during metastasis of human breast cancer at single cell resolution. We have previously found heterogeneity in micro- and macro-metastatic cells from human patient-derived xenografts (PDXs) and .we will exploit these PDXs grown in immunodeficient mice to probe heterogeneity in triple negative, estrogen receptor-positive and HER2-positive human breast cancers and their metastases. We propose to determine differentiation states for triple negative breast cancers and their early and advanced metastasis using single cell profiling techniques to test the hypothesis that distinct states confer therapeutic resistance and metastatic capabilities. We will compare the differentiation states of the triple negative cancers with those of estrogen receptor positive and HER2 positive breast cancers and their early and advanced metastases at the single cell level to determine the properties of states that confer therapeutic resistance and metastatic capabilities. The RNA studies will be complemented by protein analysis using single cell mass cytometry. After determining the self-renewal and differentiation properties of the metastatic cells, we will test their response to targeted therapy by transplantation in vivo and by tumor cell sphere assays in culture. We will then validate the predictions by examining human breast cancer specimens. Through this systems biology approach we plan to develop a global understanding of the events leading to breast cancer metastasis. Understanding these functions in molecular detail could lead to prevention regimes for patients at high risk of developing breast cancer so that their tumors do not metastasize, biomarkers of progression for patients who are newly diagnosed with cancer and new therapeutic approaches for patients at high risk of developing metastases by either suppressing the outgrowth of micro-metastases or by killing them outright.","4":"Heterogeneity","5":"Integrative approach to heterogeneity in breast cancer metastasis","6":"CSBC","7":"U01"},{"1":"syn21645103","2":"Integrative approach to heterogeneity in breast cancer metastasis","3":"Despite major advances in understanding the molecular and genetic basis of cancer, disease progression to metastasis remains the cause of >90% of cancer-related mortality. Understanding the mechanisms underlying metastasis initiation is critical for the development of new therapeutic strategies specifically to diagnose, target and prevent progression to metastatic disease. However, the identity of metastasis-initiating cells in human breast cancer remains elusive. We propose to use an integrative approach using a variety of state-of-the-art single cell multi-parametric, analytical techniques to probe heterogeneity during metastasis of human breast cancer at single cell resolution. We have previously found heterogeneity in micro- and macro-metastatic cells from human patient-derived xenografts (PDXs) and .we will exploit these PDXs grown in immunodeficient mice to probe heterogeneity in triple negative, estrogen receptor-positive and HER2-positive human breast cancers and their metastases. We propose to determine differentiation states for triple negative breast cancers and their early and advanced metastasis using single cell profiling techniques to test the hypothesis that distinct states confer therapeutic resistance and metastatic capabilities. We will compare the differentiation states of the triple negative cancers with those of estrogen receptor positive and HER2 positive breast cancers and their early and advanced metastases at the single cell level to determine the properties of states that confer therapeutic resistance and metastatic capabilities. The RNA studies will be complemented by protein analysis using single cell mass cytometry. After determining the self-renewal and differentiation properties of the metastatic cells, we will test their response to targeted therapy by transplantation in vivo and by tumor cell sphere assays in culture. We will then validate the predictions by examining human breast cancer specimens. Through this systems biology approach we plan to develop a global understanding of the events leading to breast cancer metastasis. Understanding these functions in molecular detail could lead to prevention regimes for patients at high risk of developing breast cancer so that their tumors do not metastasize, biomarkers of progression for patients who are newly diagnosed with cancer and new therapeutic approaches for patients at high risk of developing metastases by either suppressing the outgrowth of micro-metastases or by killing them outright.","4":"Microenvironment","5":"Integrative approach to heterogeneity in breast cancer metastasis","6":"CSBC","7":"U01"},{"1":"syn21645104","2":"From Mechanism to Population: Modeling HPV-related Oropharyngeal Carcinogenesis","3":"While cervical and other genital cancers are primarily caused by Human Papilloma Virus (HPV) infections, recent studies have demonstrated that HPV is also associated with head and neck (HN) cancers. The prevalence of oral HPV infection among men and women aged 14 to 69 years in the US is about 7%, however, 90% of University of Michigan (UM) oropharyngeal squamous cancer (OPSC) patients carry high-risk HPV. Indeed, the incidence of HPV- associated OPSCs is increasing and OPSC has become the most common HPV-related cancer in the US. HPV has been shown to disrupt several key cancer pathways in oropharyngeal squamous cell lines, including p53 and Rb, but many open questions remain regarding oral HPV transmission epidemiology, infection and persistence, the mechanisms of HPV HN carcinogenesis, and the connection between the ongoing oral HPV epidemic and the rising OPSC incidence. The overarching goal of this proposal is to understand the mechanistic effects of HPV infection on the regulatory pathways of oropharyngeal carcinogenesis, and how these effects in turn shape the observed age-specific incidence and mortality of OPSCs. This problem is inherently multi-scale, as population level HPV transmission drives dynamic, ongoing changes to intracellular cancer regulatory pathways, which in turn drives population-level trends in cancer incidence and mortality. Thus, understanding the rising incidence in OPSC necessitates tying together both the population level processes of infectious disease and the population-level cancer incidence through the mechanistic interactions between HPV and carcinogenesis. Toward this goal, we will develop systems biology models of the main proliferation regulatory networks affected by HPV, and assess the consequences of HPV infection, integration and alternate transcripts on the dynamics of HPV-positive tumor cell proliferation. We will integrate these mechanistic infection and cancer models into multistage models of carcinogenesis to gauge the impacts of HPV infection on the population-level age-specific incidence and mortality of OPSC. We will use these integrated multiscale cancer models in combination with population-level oral HPV transmission models to predict the effects of current HPV prevalence trends on future rates of OPSCs and the potential impact of vaccination and other prevention strategies. Our systems models will be based on multiscale inference using mechanistic infection and cancer data.","4":"NA","5":"From Mechanism to Population - Modeling HPV-related Oropharyngeal Carcinogenesis","6":"CSBC","7":"U01"},{"1":"syn21645105","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"Our research is aimed at finding molecularly targeted therapies for the treatment of non-small cell lung cancer (NSCLC). Taking into account the emerging paradigm that the reprogrammed intratumoral stromal cells contribute to carcinogenesis, we are employing integrated experimental and computational approaches to identify tumor-stromal crosstalk pathways that drive NSCLC progression in mice and humans. We are developing a multicellular crosstalk signaling network modeling and visualization tool, which is being applied to multicellular RNAseq data to identify tumor-stroma crosstalk pathways. Genes involved in these signaling mechanisms constitute potential candidates, which are being validated in rapid in vitro coculture assays, and their mechanistic and therapeutic potential is being assessed in genetically engineered NSCLC models. This study explores the relatively understudied tumor-stroma crosstalk pathways as a largely untapped source of drug targets. It has tremendous potential for the development of novel therapeutic strategies that will target tumor-stroma interactions and may complement existing treatments that target cancer cells.nn&nbsp;nn${image?fileName=Capture%2EPNG&align=Center&scale=100&responsive=true}nn&nbsp;nnTo date, we have developed a computational model, P2GWAS, to identify both autocrine and paracrine pathways. We have made significant progress in refining our crosstalk discovery algorithms and developing a graphic interactive interface for crosstalk signaling network discovery. Early results have indicated roles for the HGF-MET pathway and the OPN pathway, for which we have made significant progress in experimentally assessing their tumor-stroma crosstalk contributions both in vitro and in vivo.","4":"Heterogeneity","5":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","6":"CSBC","7":"U01"},{"1":"syn21645105","2":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","3":"Our research is aimed at finding molecularly targeted therapies for the treatment of non-small cell lung cancer (NSCLC). Taking into account the emerging paradigm that the reprogrammed intratumoral stromal cells contribute to carcinogenesis, we are employing integrated experimental and computational approaches to identify tumor-stromal crosstalk pathways that drive NSCLC progression in mice and humans. We are developing a multicellular crosstalk signaling network modeling and visualization tool, which is being applied to multicellular RNAseq data to identify tumor-stroma crosstalk pathways. Genes involved in these signaling mechanisms constitute potential candidates, which are being validated in rapid in vitro coculture assays, and their mechanistic and therapeutic potential is being assessed in genetically engineered NSCLC models. This study explores the relatively understudied tumor-stroma crosstalk pathways as a largely untapped source of drug targets. It has tremendous potential for the development of novel therapeutic strategies that will target tumor-stroma interactions and may complement existing treatments that target cancer cells.nn&nbsp;nn${image?fileName=Capture%2EPNG&align=Center&scale=100&responsive=true}nn&nbsp;nnTo date, we have developed a computational model, P2GWAS, to identify both autocrine and paracrine pathways. We have made significant progress in refining our crosstalk discovery algorithms and developing a graphic interactive interface for crosstalk signaling network discovery. Early results have indicated roles for the HGF-MET pathway and the OPN pathway, for which we have made significant progress in experimentally assessing their tumor-stroma crosstalk contributions both in vitro and in vivo.","4":"Microenvironment","5":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","6":"CSBC","7":"U01"},{"1":"syn21645106","2":"Phenotype Transitions in Small Cell Lung Cancer","3":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies. We seek to decode the gene-regulatory processes that underlie SCLC<U+201A><U+00C4><U+00F4>s phenotypic response to treatment, and develop clinically viable strategies to reprogram those circuits, while keeping cells locked into drug-sensitive states. Our major driving questions are: How does SCLC heterogeneity contribute dynamic adaptation to treatment? What regulatory mechanisms govern this response, and how are they coordinated? How can these regulatory mechanisms be manipulated to drive SCLC cells toward therapeutically desirable phenotypes? What molecular species can be targeted therapeutically to affect these mechanisms? To this end we will integrate bioinformatics, mathematical modeling, and experimentation to provide a systems-level understanding of SCLC drug response and optimal treatment strategies.nn&nbsp;nn####Our project is articulated into two Aims:nn#####Aim 1 <U+201A><U+00C4><U+00EC> Identify key transcriptional regulators of phenotypic transitions and drug-sensitivity in neuroendocrine (NE), mesenchymal-like (ML), and hybrid SCLC phenotypes.nnThe goal of this Aim is to reverse-engineer the regulatory circuits underlying SCLC heterogeneity and drug response, and develop intervention strategies to control the circuit<U+201A><U+00C4><U+00F4>s dynamics. TFs induce and maintain cell identity and can be used to reprogram cells by activation and/or inhibition of small groups of TFs (such as in induced pluripotent stem cells). In previous work (Udyavar et al, 2016), we showed that canonical neuroendocrine/epithelial (NE) and mesenchymal-like (ML) SCLC phenotypes correspond to attractors (stable states, as in the bottoms of energy wells) of a core TF regulatory network, as well as identifying novel <U+201A><U+00C4><U+00FA>Hybrid<U+201A><U+00C4><U+00F9> single-cell phenotypes (Figure 1). Here, we will expand our TF network to describe these hybrid phenotypes, and integrate data from multiple sources including human tumors and tissue microarrays (TMAs). Based on publically available transcriptomic datasets and TMAs, we employ bioinformatic techniques including Consensus Clustering, WGCNA, ARACNe, and Gabi (manuscript in preparation), as well as database mining, to identify molecular processes characterizing heterogeneous SCLC phenotypes, and uncover networks for TFs which regulate expression of those processes. Single-cell experiments are used to validate the phenotypic character of individual SCLC cells.nn&nbsp;nn${image?fileName=u10%5Fvanderbilt%5Fpic1%2Epng&align=None&scale=100&responsive=true}nFigure 1. The hypothesized SCLC heterogeneity landscape comprised of multiple phenotypic states (distinguished by color) grouped in attractor basins. Arrows indicate phenotype transitions.nn&nbsp;nnBoolean simulations of this TF network will reveal underlying regulatory mechanisms which stabilize single-cell heterogeneous SCLC phenotypes, and provide an in silico representaiton which we will explore to find cocktails transcription factors which reprogram cells from untreatable attractors into treatable ones. This is a computationally expensive task which must take into account uncertainty in the network topology, TF regulatory interaction rules, and stochastic effects in order to prioritize the most likely candidate reprogramming targets. We have therefore developed GPU/CPU hybrid algorithms to address this need and run the simulations in high-performance computing environments.nn&nbsp;nnThe final outcome of this Aim will be a mechanistic model that describes the regulation of NE, ML, and hybrid phenotypes based on TF gene regulatory dynamics, that will guide further exploration and experimental validation.nn#####Aim 2 <U+201A><U+00C4><U+00EC> Identify signaling perturbations that promote SCLC shifting to phenotypes maximally susceptible to killing under drug treatment.nnWhile Aim 1 seeks to uncover underlying regulatory mechanisms of SCLC phenotypic heterogeneity and drug response, it is well-known that TFs are difficult, and often impossible, to target directly in the clinic. Here we exploit the fact that intracellular signaling pathways, which are commonly targeted in the clinic, can be used to indirectly manipulate the activity of TF networks.nn&nbsp;nn${image?fileName=u10%5Fvanderbilt%5Fpic2%2Epng&align=None&scale=100&responsive=true}nTable 1. Biological features in the SCLC modules identified by WGCNA, which distinguish NE, ML, and hybrid states.nn&nbsp;nnTo attain this goal, we will first identify and experimentally validate signaling pathways which are heterogeneously active across distinct SCLC phenotypes. Heterogeneous WGCNA gene co-expression modules are found which are enriched for expression of distinct signaling pathways (Table 1). CyTOF will be used to validate the activity of these at the single-cell level, providing a high resolution map of SCLC signaling pathway activity. Using this map, we will track the single-cell response of SCLC cells to drug treatment. Our group has developed a metric of drug sensitivity based on the net Drug Induced Proliferation rate (DIP rate), which we will use to estimate the effects of selection for distinct phenotypes. Coupled with this, we have implemented a Stochastic Phenotype Transition Proliferation (SPTP) model to quantify relative roles of selection and plasticity, by tracking single-cell drug response population shifts. We will complement this with unsupervised and semi-supervised logistic regression algorithms to link molecular drivers to cellular drug response. This information, will enable us to prioritize optimal combinations of chemotherapy, paired with signaling perturbations which drive cells toward states sensitive to that specific chemo-agent. These combinations will be tested in vitro, and the best candidates will be validated in in vivo mouse models.nn&nbsp;nnWith the completion of this Aim, we will have developed of a map of SCLC phenotypic heterogeneity, coupled with signaling-induced transition paths and chemo-agent sensitivity. This map will provide clinically actionable signaling drivers which can push SCLC cells toward states which maximize chemotherapy efficacy.","4":"NA","5":"Phenotype Transitions in Small Cell Lung Cancer","6":"CSBC","7":"U01"},{"1":"syn21645107","2":"Uncoupling obesity from breast cancer in African American women","3":"The mechanistic relationship between immunometabolic complications of obesity and breast cancer is not understood, particularly in African American women, a group that is disproportionately affected. Insulin- resistant obesity features chronic systemic and local inflammation of fat, which has been linked to breast cancer outcomes. However, not all obesity conveys the same risk of cancer. About a quarter of obese African American adults are 'metabolically-healthy'despite their obesity and show reduced cardiovascular and diabetes risks. Recent analyses of Framingham Study population-based data show that risks for obesity- associated cancers, including breast cancer, are also reduced in these subjects. A key feature of these healthy obese adults is a reduced inflammatory profile, both locally in fat and systemically in blood. These data set up our long-term goal: to understand and use the relationships between obesity, inflammation and breast cancer outcomes to reduce the effects of obesity on cancer mortality. We do not know whether 'metabolically-healthy'obese African American women have less inflammation in breast tissue or systemically, or whether immunometabolic status associates with reduced breast cancer risk. Many 'metabolically-abnormal'obese African American women are given metformin to control blood glucose, but we do not know if metformin protects them against breast cancer;the critical studies simply have not been performed. It is urgent to resolve these questions, given the numbers of Americans affected and the high mortality arising from obesity and cancer. Our approach will investigate immunometabolic status and breast cancer in the Black Women's Health Study and use both basic laboratory and epidemiological population data to identify critical mechanisms and pharmacological solutions. Our overall objective is to define the critical immunometabolic mechanisms that stratify cancer risk in obese women, and test hypothesized relationships in cell culture models of breast cancer. Based on new preliminary data, we hypothesize that reduced inflammation in certain obese women protects against breast cancer;and that the standard of care for insulin-resistant obesity, metformin, has value for prevention of breast cancer in African American women. The hypothesis is formulated on the basis of preliminary and published studies of Framingham and BWHS subjects. We undertake three Aims: 1. Determine the immunometabolic factors that stratify obesity-related risk of breast cancer in BWHS subjects. 2. Determine whether inflammatory markers, including crown-like structures in breast adipose tissue and plasma cytokine levels, are associated with 'metabolically-abnormal'obesity as opposed to 'metabolically-healthy'obesity. 3. Determine whether novel inhibitors of inflammation and cancer diminish tumor cell aggressiveness in models of human breast cancer. The proposed research is innovative and important because we are the first to disentangle mechanisms that couple obesity to breast cancer risk. The investigation will have important public health impact because our results will help reduce cancer mortality in a disadvantaged population.\\nPublic Health Relevance\\nNot all obesity is the same: 'metabolically healthy obese'women, who have normal glucose tolerance and lack metabolic syndrome despite sometimes severe obesity, exhibit reduced risks for obesity-associated cancers, including breast cancer. African American women are more likely to be obese and to experience its inflammatory complications. Therefore, new methods to stratify risk using immunometabolic profiling will have important benefits for improved cancer outcomes in this disadvantaged group, including reduced breast cancer mortality.","4":"NA","5":"CSBC U01 Project Boston University","6":"CSBC","7":"U01"},{"1":"syn21645108","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"The epithelial-mesenchymal transition (EMT) is a complex cell-biological program that operates during the progression of carcinoma cells to high-grade malignancy, conferring on these cells many of the attributes associated with aggressive tumors, including the ability to disseminate to distant sites and to seed metastatic colonies. This program is orchestrated by a series of pleiotropically acting master transcription factors (EMT- TFs) that organize the complex changes in gene expression causing the replacement of a large cohort of epithelial cell proteins with those associated with the mesenchymal cell state. A major, critical level of control required for expression of the aggressive mesenchymal state is poorly understood however: the precursors of many of the mRNAs whose expression changes during the EMT also undergo alternative splicing (AS) that confer on resulting mature, processed mRNAs altered properties, including changes in stability, protein-coding information, and responsiveness to microRNA-mediated inhibition. The current fragmentary insights into the effects of AS on the execution of the EMT program make it impossible to form a reasonably complete understanding of how this critical cell-biological program is effected. The proposed research will begin by enumerating the hundreds of AS events that occur in response to several alternative mechanisms of inducing an EMT program both in cultured cells and in a living tissue. Having done so, bioinformatics algorithms will be employed to determine the sequences adjacent to involved splice sites. Thereafter, using the known nucleotide-recognizing properties of the large array of already-characterized RNA- binding, splice-regulating proteins, predictions will be made by these algorithms about the identities of the splice-regulators that are likely to b responsible for the observed large-scale shifts in AS occurring during passage through an EMT. This experimental strategy should yield the identities of key regulators of AS that are likely to b as important functionally as the EMT-TFs in executing the EMT program. Experimental tests designed to functionally test the candidacies of these AS factors will be performed. These tests will gauge whether the forced or blocked expression of these factors affect execution of critical components of the EMT program, and whether, as predicted, such imposed changes in AS factor expression affect the production of key EMT-associated proteins, i.e., proteins that play key roles in the expression of the epithelial versus mesenchymal cell phenotypes observed during malignant progression. This work also has the potential to identify novel biomarkers of the EMT program that are applicable, for example, for the detections of stem cells in a variety of epithelial tissues.","4":"Metastasis","5":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","6":"CSBC","7":"U01"},{"1":"syn21645108","2":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","3":"The epithelial-mesenchymal transition (EMT) is a complex cell-biological program that operates during the progression of carcinoma cells to high-grade malignancy, conferring on these cells many of the attributes associated with aggressive tumors, including the ability to disseminate to distant sites and to seed metastatic colonies. This program is orchestrated by a series of pleiotropically acting master transcription factors (EMT- TFs) that organize the complex changes in gene expression causing the replacement of a large cohort of epithelial cell proteins with those associated with the mesenchymal cell state. A major, critical level of control required for expression of the aggressive mesenchymal state is poorly understood however: the precursors of many of the mRNAs whose expression changes during the EMT also undergo alternative splicing (AS) that confer on resulting mature, processed mRNAs altered properties, including changes in stability, protein-coding information, and responsiveness to microRNA-mediated inhibition. The current fragmentary insights into the effects of AS on the execution of the EMT program make it impossible to form a reasonably complete understanding of how this critical cell-biological program is effected. The proposed research will begin by enumerating the hundreds of AS events that occur in response to several alternative mechanisms of inducing an EMT program both in cultured cells and in a living tissue. Having done so, bioinformatics algorithms will be employed to determine the sequences adjacent to involved splice sites. Thereafter, using the known nucleotide-recognizing properties of the large array of already-characterized RNA- binding, splice-regulating proteins, predictions will be made by these algorithms about the identities of the splice-regulators that are likely to b responsible for the observed large-scale shifts in AS occurring during passage through an EMT. This experimental strategy should yield the identities of key regulators of AS that are likely to b as important functionally as the EMT-TFs in executing the EMT program. Experimental tests designed to functionally test the candidacies of these AS factors will be performed. These tests will gauge whether the forced or blocked expression of these factors affect execution of critical components of the EMT program, and whether, as predicted, such imposed changes in AS factor expression affect the production of key EMT-associated proteins, i.e., proteins that play key roles in the expression of the epithelial versus mesenchymal cell phenotypes observed during malignant progression. This work also has the potential to identify novel biomarkers of the EMT program that are applicable, for example, for the detections of stem cells in a variety of epithelial tissues.","4":"Heterogeneity","5":"Dynamics of Gene and Isoform Regulation during EMT and tumor progression","6":"CSBC","7":"U01"},{"1":"syn21645109","2":"Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors","3":"Despite improved treatment strategies, inherent and acquired resistance to HER2-targeted therapies is common and inevitably lead to disease progression and cancer-related deaths. PIK3CA mutations occur in ~40% of HER2+ tumors and have been associated with resistance to treatment. To explore intratumor heterogeneity for HER2 and PIK3CA mutation in HER2+ tumors and the potential role of this in treatment resistance, we have developed a technique, STAR-FISH (Specific To Allele pcR FISH) that allows for the combined detection of point mutations and copy number gain in intact tissue samples at the single cell level. By applying STAR-FISH to HER2+ tumors before and after neoadjuvant therapy, we found that PIK3CA mutation and HER2 amplification do not always co-occur in the same cell but can be present in distinct subpopulations within tumors. Post-treatment residual tumors have higher fraction of mutant PIK3CA cells with a concomitant decrease in the relative ratio of cells with HER2 amplification. Patients with significant differene in cell type diversity between pre and post-treatment samples have shorter disease-specific survival than those with no change. Based on our preliminary data, we hypothesize that 1) not all somatic mutations that have been reported to occur in a given tumor are present in the same tumor cell but some may represent genetically divergent clones within tumors, (2) the combination of mutations within the same cell and within the same tumor is not random, but reflect cooperation among pathways and among clones, and (3) the presence of a combination of mutations within the same cell versus in different clones in the same tumor will have different functional and clinical consequences. We propose three specific aims to test these hypotheses:\\nAim 1. Analyze intratumor subclonal and cellular genetic diversity in HER2+ breast tumors.\\nAim 2. Develop and characterize experimental models of intratumor heterogeneity in HER2+ breast cancer.\\nAim 3. Develop mathematical models to infer the evolution of HER2+ tumors during treatment. Our goal is to translate our findings into future clinical trials.\\nPublic Health Relevance\\nIntratumor heterogeneity is a major obstacle in the understanding and treatment of cancer, yet it can also be used to predict tumor evolution. The application aims to develop individualized treatment strategies using a combination of predictive mathematical modeling and experimental approaches both in models of HER2+ breast cancer and in clinical samples.","4":"Evolution","5":"Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors","6":"CSBC","7":"U01"},{"1":"syn21645109","2":"Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors","3":"Despite improved treatment strategies, inherent and acquired resistance to HER2-targeted therapies is common and inevitably lead to disease progression and cancer-related deaths. PIK3CA mutations occur in ~40% of HER2+ tumors and have been associated with resistance to treatment. To explore intratumor heterogeneity for HER2 and PIK3CA mutation in HER2+ tumors and the potential role of this in treatment resistance, we have developed a technique, STAR-FISH (Specific To Allele pcR FISH) that allows for the combined detection of point mutations and copy number gain in intact tissue samples at the single cell level. By applying STAR-FISH to HER2+ tumors before and after neoadjuvant therapy, we found that PIK3CA mutation and HER2 amplification do not always co-occur in the same cell but can be present in distinct subpopulations within tumors. Post-treatment residual tumors have higher fraction of mutant PIK3CA cells with a concomitant decrease in the relative ratio of cells with HER2 amplification. Patients with significant differene in cell type diversity between pre and post-treatment samples have shorter disease-specific survival than those with no change. Based on our preliminary data, we hypothesize that 1) not all somatic mutations that have been reported to occur in a given tumor are present in the same tumor cell but some may represent genetically divergent clones within tumors, (2) the combination of mutations within the same cell and within the same tumor is not random, but reflect cooperation among pathways and among clones, and (3) the presence of a combination of mutations within the same cell versus in different clones in the same tumor will have different functional and clinical consequences. We propose three specific aims to test these hypotheses:\\nAim 1. Analyze intratumor subclonal and cellular genetic diversity in HER2+ breast tumors.\\nAim 2. Develop and characterize experimental models of intratumor heterogeneity in HER2+ breast cancer.\\nAim 3. Develop mathematical models to infer the evolution of HER2+ tumors during treatment. Our goal is to translate our findings into future clinical trials.\\nPublic Health Relevance\\nIntratumor heterogeneity is a major obstacle in the understanding and treatment of cancer, yet it can also be used to predict tumor evolution. The application aims to develop individualized treatment strategies using a combination of predictive mathematical modeling and experimental approaches both in models of HER2+ breast cancer and in clinical samples.","4":"Heterogeneity","5":"Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors","6":"CSBC","7":"U01"},{"1":"syn21645110","2":"Systematic Identification of Driver Networks in Cancer","3":"A vast number of mutations contribute to cancer, but the observed non-random combinations of those leading to transformation highlight the importance of hallmark pathways and networks in cancer progression. While many pathways have been implicated in cancer, attributes such as tumor heterogeneity, tissue of origin, and degree of progression lead to each case exhibiting a unique subset of altered pathways. Taken together, this diversity among cancer types and their origins has complicated the development of targeted cancer treatments. We propose to systematically identify the protein networks driving cancer, across a range of tumor types starting with head and neck squamous cell carcinoma and breast cancer. Coupled with functional validation and high-resolution structural analysis of the key protein interactions and complexes, we anticipate major insights into the underlying tumor biology as well as the potential to unravel genetic vulnerabilities of therapeutic relevance.","4":"Heterogeneity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645110","2":"Systematic Identification of Driver Networks in Cancer","3":"A vast number of mutations contribute to cancer, but the observed non-random combinations of those leading to transformation highlight the importance of hallmark pathways and networks in cancer progression. While many pathways have been implicated in cancer, attributes such as tumor heterogeneity, tissue of origin, and degree of progression lead to each case exhibiting a unique subset of altered pathways. Taken together, this diversity among cancer types and their origins has complicated the development of targeted cancer treatments. We propose to systematically identify the protein networks driving cancer, across a range of tumor types starting with head and neck squamous cell carcinoma and breast cancer. Coupled with functional validation and high-resolution structural analysis of the key protein interactions and complexes, we anticipate major insights into the underlying tumor biology as well as the potential to unravel genetic vulnerabilities of therapeutic relevance.","4":"Evolution","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645110","2":"Systematic Identification of Driver Networks in Cancer","3":"A vast number of mutations contribute to cancer, but the observed non-random combinations of those leading to transformation highlight the importance of hallmark pathways and networks in cancer progression. While many pathways have been implicated in cancer, attributes such as tumor heterogeneity, tissue of origin, and degree of progression lead to each case exhibiting a unique subset of altered pathways. Taken together, this diversity among cancer types and their origins has complicated the development of targeted cancer treatments. We propose to systematically identify the protein networks driving cancer, across a range of tumor types starting with head and neck squamous cell carcinoma and breast cancer. Coupled with functional validation and high-resolution structural analysis of the key protein interactions and complexes, we anticipate major insights into the underlying tumor biology as well as the potential to unravel genetic vulnerabilities of therapeutic relevance.","4":"Drug Resistance/Sensitivity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645111","2":"Mapping the Pharmacogenetic Landscape for Precision Medicine","3":"It is well known that cancer is tremendously heterogeneous with few tumors having the same set of mutated, amplified, or deleted genes. Clearly these molecular differences alter a tumor<U+201A><U+00C4><U+00F4>s responsiveness to chemotherapy, but current knowledge of how the tumor genotype influences drug sensitivity is poor. We will seek to vastly increase our understanding of pharmacogenetic interactions in cancer (gene-gene and gene-drug interactions). Recognizing that oncogenic transformation requires alteration of the function of many genes, we will use state-of-the-art high-throughput epistasis mapping and data analysis pipelines to systematically interrogate the function and pairwise interactions of a panel cancer driver genes and therapeutic targets in both head and neck squamous cell carcinoma and breast cancer, expecting to identify many new synthetic lethal relationships. Anticipating the discovery of multiple therapeutically relevant synthetic lethal interactions, we have already formulated a plan for rapid clinical testing of the most promising hits as new treatment arms on the I-SPY 2 trial in breast cancer. Through this work, we expect to develop fundamental new insights into the genetic logic and functional synergies underlying cancer pathways as well as to greatly expand the ability of clinicians to practice precision oncology.","4":"Heterogeneity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645111","2":"Mapping the Pharmacogenetic Landscape for Precision Medicine","3":"It is well known that cancer is tremendously heterogeneous with few tumors having the same set of mutated, amplified, or deleted genes. Clearly these molecular differences alter a tumor<U+201A><U+00C4><U+00F4>s responsiveness to chemotherapy, but current knowledge of how the tumor genotype influences drug sensitivity is poor. We will seek to vastly increase our understanding of pharmacogenetic interactions in cancer (gene-gene and gene-drug interactions). Recognizing that oncogenic transformation requires alteration of the function of many genes, we will use state-of-the-art high-throughput epistasis mapping and data analysis pipelines to systematically interrogate the function and pairwise interactions of a panel cancer driver genes and therapeutic targets in both head and neck squamous cell carcinoma and breast cancer, expecting to identify many new synthetic lethal relationships. Anticipating the discovery of multiple therapeutically relevant synthetic lethal interactions, we have already formulated a plan for rapid clinical testing of the most promising hits as new treatment arms on the I-SPY 2 trial in breast cancer. Through this work, we expect to develop fundamental new insights into the genetic logic and functional synergies underlying cancer pathways as well as to greatly expand the ability of clinicians to practice precision oncology.","4":"Evolution","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645111","2":"Mapping the Pharmacogenetic Landscape for Precision Medicine","3":"It is well known that cancer is tremendously heterogeneous with few tumors having the same set of mutated, amplified, or deleted genes. Clearly these molecular differences alter a tumor<U+201A><U+00C4><U+00F4>s responsiveness to chemotherapy, but current knowledge of how the tumor genotype influences drug sensitivity is poor. We will seek to vastly increase our understanding of pharmacogenetic interactions in cancer (gene-gene and gene-drug interactions). Recognizing that oncogenic transformation requires alteration of the function of many genes, we will use state-of-the-art high-throughput epistasis mapping and data analysis pipelines to systematically interrogate the function and pairwise interactions of a panel cancer driver genes and therapeutic targets in both head and neck squamous cell carcinoma and breast cancer, expecting to identify many new synthetic lethal relationships. Anticipating the discovery of multiple therapeutically relevant synthetic lethal interactions, we have already formulated a plan for rapid clinical testing of the most promising hits as new treatment arms on the I-SPY 2 trial in breast cancer. Through this work, we expect to develop fundamental new insights into the genetic logic and functional synergies underlying cancer pathways as well as to greatly expand the ability of clinicians to practice precision oncology.","4":"Drug Resistance/Sensitivity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645112","2":"Using Networks to Seed Hierarchical Whole-Cell Models of Cancer","3":"Knowledge of cell biology is often modeled in the form of molecular networks and interaction maps, consisting of sets of genes and gene-gene (or protein-protein) pairwise interactions. In reality, however, biological systems are not simply one large protein network, but consist of a deep and dynamic hierarchy of functional subsystems ranging across many orders of magnitude in scale. Here, we move beyond basic interaction maps to instead use molecular interaction data to develop hierarchical structure/function models of the cancer cell. This hierarchical structure will be developed using the protein-protein interaction data generated here and backstopped by public networks; it will provide an objective definition of a cancer cell by systematically identifying the hierarchical relations among its associated systems of genes and proteins. We will next use this descriptive hierarchy to seed a predictive whole-cell model of cancer. This hierarchical model will be validated and revised by applying it to predict therapeutic responses in PDXs of head and neck and breast tumors as well as inform an ongoing I-SPY 2 breast cancer clinical trial.","4":"Heterogeneity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645112","2":"Using Networks to Seed Hierarchical Whole-Cell Models of Cancer","3":"Knowledge of cell biology is often modeled in the form of molecular networks and interaction maps, consisting of sets of genes and gene-gene (or protein-protein) pairwise interactions. In reality, however, biological systems are not simply one large protein network, but consist of a deep and dynamic hierarchy of functional subsystems ranging across many orders of magnitude in scale. Here, we move beyond basic interaction maps to instead use molecular interaction data to develop hierarchical structure/function models of the cancer cell. This hierarchical structure will be developed using the protein-protein interaction data generated here and backstopped by public networks; it will provide an objective definition of a cancer cell by systematically identifying the hierarchical relations among its associated systems of genes and proteins. We will next use this descriptive hierarchy to seed a predictive whole-cell model of cancer. This hierarchical model will be validated and revised by applying it to predict therapeutic responses in PDXs of head and neck and breast tumors as well as inform an ongoing I-SPY 2 breast cancer clinical trial.","4":"Evolution","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645112","2":"Using Networks to Seed Hierarchical Whole-Cell Models of Cancer","3":"Knowledge of cell biology is often modeled in the form of molecular networks and interaction maps, consisting of sets of genes and gene-gene (or protein-protein) pairwise interactions. In reality, however, biological systems are not simply one large protein network, but consist of a deep and dynamic hierarchy of functional subsystems ranging across many orders of magnitude in scale. Here, we move beyond basic interaction maps to instead use molecular interaction data to develop hierarchical structure/function models of the cancer cell. This hierarchical structure will be developed using the protein-protein interaction data generated here and backstopped by public networks; it will provide an objective definition of a cancer cell by systematically identifying the hierarchical relations among its associated systems of genes and proteins. We will next use this descriptive hierarchy to seed a predictive whole-cell model of cancer. This hierarchical model will be validated and revised by applying it to predict therapeutic responses in PDXs of head and neck and breast tumors as well as inform an ongoing I-SPY 2 breast cancer clinical trial.","4":"Drug Resistance/Sensitivity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645113","2":"Functional Genomics","3":"The Functional Genomics Core provides cutting-edge innovative technologies for the functional characterization of the genome in a reliable, reproducible and cost-efficient manner. We provide combinatorial genetic knockout by CRISPR, CRISPRi and CRISPRa, mass spectrometry characterization, and expertise in data processing for these experimental platforms. This core is partnered with two well established facilities: the Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery located at the J. David Gladstone Institutes and the UCSD Institute for Genomic Medicine Genomics Center sequencing facility. We are also creating a new CRISPR screening core that leverages our foundational expertise in genome engineering.","4":"Heterogeneity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645113","2":"Functional Genomics","3":"The Functional Genomics Core provides cutting-edge innovative technologies for the functional characterization of the genome in a reliable, reproducible and cost-efficient manner. We provide combinatorial genetic knockout by CRISPR, CRISPRi and CRISPRa, mass spectrometry characterization, and expertise in data processing for these experimental platforms. This core is partnered with two well established facilities: the Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery located at the J. David Gladstone Institutes and the UCSD Institute for Genomic Medicine Genomics Center sequencing facility. We are also creating a new CRISPR screening core that leverages our foundational expertise in genome engineering.","4":"Evolution","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645113","2":"Functional Genomics","3":"The Functional Genomics Core provides cutting-edge innovative technologies for the functional characterization of the genome in a reliable, reproducible and cost-efficient manner. We provide combinatorial genetic knockout by CRISPR, CRISPRi and CRISPRa, mass spectrometry characterization, and expertise in data processing for these experimental platforms. This core is partnered with two well established facilities: the Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery located at the J. David Gladstone Institutes and the UCSD Institute for Genomic Medicine Genomics Center sequencing facility. We are also creating a new CRISPR screening core that leverages our foundational expertise in genome engineering.","4":"Drug Resistance/Sensitivity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645114","2":"Bioinformatics Infrastructure and Services","3":"The Bioinformatics Infrastructure and Services Core provides support to all three CCMI projects at all stages of research and publication. The Core is made up of three major components: Cytoscape and the Cytoscape Cyberinfrastructure (CI); the Network Data Exchange (NDEx); and the CCMI Data and Analysis Portal. Cytoscape provides a range of tools for the analysis and visualization of biological networks. NDEx provides the database infrastructure to support the sharing, review and dissemination of network data and models. It also enables a consolidated access point to public biological network resources for use by CCMI investigators. Finally, the CCMI Data and Analysis Portal provides a common access point for software tools and pipelines and for their associated data. This component will be supported by GenePattern Notebooks, which will facilitate the development of workflow pipelines and the sharing and reproducibility of analyses.","4":"Heterogeneity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645114","2":"Bioinformatics Infrastructure and Services","3":"The Bioinformatics Infrastructure and Services Core provides support to all three CCMI projects at all stages of research and publication. The Core is made up of three major components: Cytoscape and the Cytoscape Cyberinfrastructure (CI); the Network Data Exchange (NDEx); and the CCMI Data and Analysis Portal. Cytoscape provides a range of tools for the analysis and visualization of biological networks. NDEx provides the database infrastructure to support the sharing, review and dissemination of network data and models. It also enables a consolidated access point to public biological network resources for use by CCMI investigators. Finally, the CCMI Data and Analysis Portal provides a common access point for software tools and pipelines and for their associated data. This component will be supported by GenePattern Notebooks, which will facilitate the development of workflow pipelines and the sharing and reproducibility of analyses.","4":"Evolution","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645114","2":"Bioinformatics Infrastructure and Services","3":"The Bioinformatics Infrastructure and Services Core provides support to all three CCMI projects at all stages of research and publication. The Core is made up of three major components: Cytoscape and the Cytoscape Cyberinfrastructure (CI); the Network Data Exchange (NDEx); and the CCMI Data and Analysis Portal. Cytoscape provides a range of tools for the analysis and visualization of biological networks. NDEx provides the database infrastructure to support the sharing, review and dissemination of network data and models. It also enables a consolidated access point to public biological network resources for use by CCMI investigators. Finally, the CCMI Data and Analysis Portal provides a common access point for software tools and pipelines and for their associated data. This component will be supported by GenePattern Notebooks, which will facilitate the development of workflow pipelines and the sharing and reproducibility of analyses.","4":"Drug Resistance/Sensitivity","5":"The Cancer Cell Map Initiative","6":"CSBC","7":"U54"},{"1":"syn21645115","2":"Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma","3":"We are constructing families of computational models, at different levels of molecular detail, that capture and ultimately explain the diversity of phenomena associated with resistance to RAF/MEK inhibitors. This is accomplished by collecting time-series single-cell and population-level data from cells with diverse genotypes followed by time-resolved modeling using differential equations, logic-based models and supervised machine learning. These studies are performed initially in patient-derived cell lines and mouse models, but intended to provide hypotheses that can be tested in clinical trials.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645115","2":"Multi-scale modeling of adaptive drug resistance in BRAF-mutant melanoma","3":"We are constructing families of computational models, at different levels of molecular detail, that capture and ultimately explain the diversity of phenomena associated with resistance to RAF/MEK inhibitors. This is accomplished by collecting time-series single-cell and population-level data from cells with diverse genotypes followed by time-resolved modeling using differential equations, logic-based models and supervised machine learning. These studies are performed initially in patient-derived cell lines and mouse models, but intended to provide hypotheses that can be tested in clinical trials.","4":"Microenvironment","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645116","2":"Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance","3":"We study changes in the tumor ecosystem induced by ICIs or targeted therapy and predictive of therapeutic response. The precise proportions and spatiotemporal arrangements of tumor, stromal and immune cells will be determined in tissue biopsies, and single-cell features will be extracted and associated with disease progression and therapeutic response using machine learning, deep learning and high-dimensional data analysis. Adverse responses in the skin and gut will also be investigated and compared to therapeutic responses at a mechanistic and clinical level.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645116","2":"Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance","3":"We study changes in the tumor ecosystem induced by ICIs or targeted therapy and predictive of therapeutic response. The precise proportions and spatiotemporal arrangements of tumor, stromal and immune cells will be determined in tissue biopsies, and single-cell features will be extracted and associated with disease progression and therapeutic response using machine learning, deep learning and high-dimensional data analysis. Adverse responses in the skin and gut will also be investigated and compared to therapeutic responses at a mechanistic and clinical level.","4":"Microenvironment","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645117","2":"Mechanisms of immunotherapy action","3":"We study ICIs alone or in combination in tumor-bearing mice to evaluate whether highly efficacious responses arise from co-targeting cells of single lineages (e.g. CD8+ effector T cells) or concurrent targeting of multiple cell lineages (e.g. CD8+ T cells, regulatory T cells), and to identify the tumor settings in which either strategy might prove more effective. Metabolic, signaling, and transcriptional changes associated with cellular responses to ICIs are assessed and modeled. Agent-based models are then used to study non-cell autonomous mechanisms that mediate therapeutic and adverse drug effects. We hope to thereby discover combinations of ICIs and specific patient populations in which therapeutic responses are high and toxicity is minimal.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645117","2":"Mechanisms of immunotherapy action","3":"We study ICIs alone or in combination in tumor-bearing mice to evaluate whether highly efficacious responses arise from co-targeting cells of single lineages (e.g. CD8+ effector T cells) or concurrent targeting of multiple cell lineages (e.g. CD8+ T cells, regulatory T cells), and to identify the tumor settings in which either strategy might prove more effective. Metabolic, signaling, and transcriptional changes associated with cellular responses to ICIs are assessed and modeled. Agent-based models are then used to study non-cell autonomous mechanisms that mediate therapeutic and adverse drug effects. We hope to thereby discover combinations of ICIs and specific patient populations in which therapeutic responses are high and toxicity is minimal.","4":"Microenvironment","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645118","2":"Systems Pharmacology Core","3":"The Systems Pharmacology Core provides all CCSP members, as well as individuals selected for funded internal research projects, access to a central, high quality resource for molecular profiling of cells and tissues and for data analysis. The core will join together four approaches based in the Laboratory of Systems Pharmacology (LSP) (i) deep, high throughput, and single cell RNA-Seq (ii) targeted and shotgun mass-spectrometry based proteomics (iii) high dimensional single cell imaging and (iv) data analysis and data science based on supervised and unsupervised machine learning as well as two technologies based in the laboratories of CCSP investigators (i) metabolomics profiling (via Haigis lab) and (ii) immune profiling of blood using flow cytometry and multiplex cytokine assays (via the DFCI Immune Profiling Lab). These activities do not take place in isolation, and all of our platform technologies work closely with HMS core facilities in a hub and spoke model.","4":"Drug Resistance/Sensitivity","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645118","2":"Systems Pharmacology Core","3":"The Systems Pharmacology Core provides all CCSP members, as well as individuals selected for funded internal research projects, access to a central, high quality resource for molecular profiling of cells and tissues and for data analysis. The core will join together four approaches based in the Laboratory of Systems Pharmacology (LSP) (i) deep, high throughput, and single cell RNA-Seq (ii) targeted and shotgun mass-spectrometry based proteomics (iii) high dimensional single cell imaging and (iv) data analysis and data science based on supervised and unsupervised machine learning as well as two technologies based in the laboratories of CCSP investigators (i) metabolomics profiling (via Haigis lab) and (ii) immune profiling of blood using flow cytometry and multiplex cytokine assays (via the DFCI Immune Profiling Lab). These activities do not take place in isolation, and all of our platform technologies work closely with HMS core facilities in a hub and spoke model.","4":"Microenvironment","5":"Center for Cancer Systems Pharmacology","6":"CSBC","7":"U54"},{"1":"syn21645119","2":"ISB Heath Lab","3":"NA","4":"NA","5":"ISB Heath Lab","6":"PS-ON","7":"U01"},{"1":"syn21645120","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. Such transitions are broadly studied, but general models have been historically limited to qualitative descriptions. This contrasts with phase transitions in physical systems, such as the transition between ferro- and paramagnetic states, which are well characterized within the context of the physico-chemical laws, and can be partially understood, in a predictive capacity, using simple, precise models such as the Ising model. Such models are based upon a system of interacting lattice sites. A parameter (e.g. temperature) is varied, and the fluctuations of the lattice sites are analyzed as the system approaches and passes through a critical point. These models are largely independent of many details of the specific system under study; the critical system-specific details are captured in the interactions between the lattice sites. Nevertheless, they can yield specific predictions that can, in principle, be experimentally verified, such as increased fluctuations in the vicinity of the critical point, and the loss of one or more degrees of freedom at the critical point. Ising-like in silico models have guided theoretical studies of transitions in various gene or protein regulatory networks, although resultant predictions can be challenging to experimentally test.nnWe seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes. In an Ising model analogy, such measurements define the site interactions. These inputs permit straightforward theoretic models for resolving cellular steady states, transitions between steady states, and for making testable predictions. Studies of the chemically-induced-carcinogenesis transition are provided as preliminary data/proof of concept. For Aim 1 we develop a picture of cancer cell steady states using integrated metabolic and proteomic single cell assays. In Aims 2 and 3 we expand this approach to two apparent cellular transitions associated with cancer drug resistance: the adaptation of heterogeneous brain cancers to certain targeted inhibitors, and a drug-induced cellular de-differentiation observed in melanomas (and other tumors) in response to immunotherapy and targeted inhibitors. All aims are joint experiment/theory aims. Aims 2-3 involve in vivo testing of predictions.","4":"Drug Resistance/Sensitivity","5":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","6":"PS-ON","7":"U01"},{"1":"syn21645120","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. Such transitions are broadly studied, but general models have been historically limited to qualitative descriptions. This contrasts with phase transitions in physical systems, such as the transition between ferro- and paramagnetic states, which are well characterized within the context of the physico-chemical laws, and can be partially understood, in a predictive capacity, using simple, precise models such as the Ising model. Such models are based upon a system of interacting lattice sites. A parameter (e.g. temperature) is varied, and the fluctuations of the lattice sites are analyzed as the system approaches and passes through a critical point. These models are largely independent of many details of the specific system under study; the critical system-specific details are captured in the interactions between the lattice sites. Nevertheless, they can yield specific predictions that can, in principle, be experimentally verified, such as increased fluctuations in the vicinity of the critical point, and the loss of one or more degrees of freedom at the critical point. Ising-like in silico models have guided theoretical studies of transitions in various gene or protein regulatory networks, although resultant predictions can be challenging to experimentally test.nnWe seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes. In an Ising model analogy, such measurements define the site interactions. These inputs permit straightforward theoretic models for resolving cellular steady states, transitions between steady states, and for making testable predictions. Studies of the chemically-induced-carcinogenesis transition are provided as preliminary data/proof of concept. For Aim 1 we develop a picture of cancer cell steady states using integrated metabolic and proteomic single cell assays. In Aims 2 and 3 we expand this approach to two apparent cellular transitions associated with cancer drug resistance: the adaptation of heterogeneous brain cancers to certain targeted inhibitors, and a drug-induced cellular de-differentiation observed in melanomas (and other tumors) in response to immunotherapy and targeted inhibitors. All aims are joint experiment/theory aims. Aims 2-3 involve in vivo testing of predictions.","4":"Tumor-Immune","5":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","6":"PS-ON","7":"U01"},{"1":"syn21645120","2":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","3":"Cellular transitions between two distinct states are fundamental to many steps of carcinogenesis and tumor progression. Such transitions are broadly studied, but general models have been historically limited to qualitative descriptions. This contrasts with phase transitions in physical systems, such as the transition between ferro- and paramagnetic states, which are well characterized within the context of the physico-chemical laws, and can be partially understood, in a predictive capacity, using simple, precise models such as the Ising model. Such models are based upon a system of interacting lattice sites. A parameter (e.g. temperature) is varied, and the fluctuations of the lattice sites are analyzed as the system approaches and passes through a critical point. These models are largely independent of many details of the specific system under study; the critical system-specific details are captured in the interactions between the lattice sites. Nevertheless, they can yield specific predictions that can, in principle, be experimentally verified, such as increased fluctuations in the vicinity of the critical point, and the loss of one or more degrees of freedom at the critical point. Ising-like in silico models have guided theoretical studies of transitions in various gene or protein regulatory networks, although resultant predictions can be challenging to experimentally test.nnWe seek a potentially general approach where the experimental input is a statistically large number of single cell measurements, with many analytes quantitatively measured from each cell. From this data we capture the fluctuations and thereby determine the correlations of many analytes. In an Ising model analogy, such measurements define the site interactions. These inputs permit straightforward theoretic models for resolving cellular steady states, transitions between steady states, and for making testable predictions. Studies of the chemically-induced-carcinogenesis transition are provided as preliminary data/proof of concept. For Aim 1 we develop a picture of cancer cell steady states using integrated metabolic and proteomic single cell assays. In Aims 2 and 3 we expand this approach to two apparent cellular transitions associated with cancer drug resistance: the adaptation of heterogeneous brain cancers to certain targeted inhibitors, and a drug-induced cellular de-differentiation observed in melanomas (and other tumors) in response to immunotherapy and targeted inhibitors. All aims are joint experiment/theory aims. Aims 2-3 involve in vivo testing of predictions.","4":"Metabolism","5":"Steady States and Cellular Transitions Associated with Carcinogenesis and Tumorprogression","6":"PS-ON","7":"U01"},{"1":"syn21645121","2":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","3":"Emerging evidence suggests that the physical environment of tumors, including mechanical stress and physico-chemical properties of extracellular matrix, combines with genetics and cell signaling to control plasticity of cancer stem cells during metastasis, the cause of death for > 90% of patients with cancer. Metastasis encompasses processes associated with mesenchymal (invasion) and epithelial (proliferation) phenotypes. Epithelial to mesenchymal (EMT) and mesenchymal to epithelial (MET) transitions define subsets of cancer stem cells, which are implicated as critical drivers of metastasis. In particular, circulating tumor cells (CTCs) and other disseminated tumor cells commonly exhibit both epithelial and mesenchymal features, suggesting that cancer cells transition between these states. Studies of plasticity in cancer stem cells have focused predominantly on primary tumors, in part due to technological challenges of analyzing cell phenotypes and dynamics in other anatomic sites. To overcome these challenges, we will develop engineered environments for three key sites in tumor progression: primary tumor, intravascular compartment, and bone. We hypothesize that extracellular matrix and mechanical properties associated with distinct tumor environments in the metastatic cascade promote EMT and MET transitions of cancer stem cells in triple negative breast cancer. We will systematically interrogate this hypothesis using tunable 3D tissue-engineering technologies pioneered by our group. Specifically, we will develop (i) novel 3D scaffolds and protein matrices to engineer primary and metastatic tumor environments; (ii) microfluidic technologies to model the intravascular compartment; and (iii) new in vivo imaging technologies to measure environmental cues that drive EMT and MET transitions in cancer. Through this physical sciences approach, we will define tumor environments that drive stem cell state transitions in distinct phases of metastasis. EMT and MET transitions occur in almost all solid malignancies, so benefits of this research extend beyond breast cancer and ultimately will lead to better approaches to interrupt metastasis and improve outcomes for patients with multiple types of cancer.","4":"Metastasis","5":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","6":"PS-ON","7":"U01"},{"1":"syn21645121","2":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","3":"Emerging evidence suggests that the physical environment of tumors, including mechanical stress and physico-chemical properties of extracellular matrix, combines with genetics and cell signaling to control plasticity of cancer stem cells during metastasis, the cause of death for > 90% of patients with cancer. Metastasis encompasses processes associated with mesenchymal (invasion) and epithelial (proliferation) phenotypes. Epithelial to mesenchymal (EMT) and mesenchymal to epithelial (MET) transitions define subsets of cancer stem cells, which are implicated as critical drivers of metastasis. In particular, circulating tumor cells (CTCs) and other disseminated tumor cells commonly exhibit both epithelial and mesenchymal features, suggesting that cancer cells transition between these states. Studies of plasticity in cancer stem cells have focused predominantly on primary tumors, in part due to technological challenges of analyzing cell phenotypes and dynamics in other anatomic sites. To overcome these challenges, we will develop engineered environments for three key sites in tumor progression: primary tumor, intravascular compartment, and bone. We hypothesize that extracellular matrix and mechanical properties associated with distinct tumor environments in the metastatic cascade promote EMT and MET transitions of cancer stem cells in triple negative breast cancer. We will systematically interrogate this hypothesis using tunable 3D tissue-engineering technologies pioneered by our group. Specifically, we will develop (i) novel 3D scaffolds and protein matrices to engineer primary and metastatic tumor environments; (ii) microfluidic technologies to model the intravascular compartment; and (iii) new in vivo imaging technologies to measure environmental cues that drive EMT and MET transitions in cancer. Through this physical sciences approach, we will define tumor environments that drive stem cell state transitions in distinct phases of metastasis. EMT and MET transitions occur in almost all solid malignancies, so benefits of this research extend beyond breast cancer and ultimately will lead to better approaches to interrupt metastasis and improve outcomes for patients with multiple types of cancer.","4":"Microenvironment","5":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","6":"PS-ON","7":"U01"},{"1":"syn21645122","2":"Chromatin Mobility in Response to DNA Damage","3":"Genomic translocations are well-established drivers of therapy-related myeloid neoplasms (t-MNs). T-MNs have poor outcomes and affect survivors of primary malignancies. It is not possible to predict which patients treated for a primary cancer will develop t-MN, which constitutes a major clinical challenge. A method to assess the risk of translocations after patient exposures to DNA damaging chemotherapy and radiations would inform therapeutic decisions. Translocations depend on the movements of broken DNA ends on non-homologous chromosomes. We developed a method based on diffractive optical elements (DOE) to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Our preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact on genomic translocations frequencies in cells with DNA damage. The goals for this PS-OP are (1) to develop new methodology to measure chromatin mobility in the 3D nuclear space, (2) to identify the mechanisms controlling chromatin motions after DNA damage and assess their functional consequences for DNA repair efficacy, repair quality, and translocations frequencies, and (3) to test for clinically relevant associations between chromatin motions and genomic translocations using hematopoietic stem/progenitor cell samples from t-MN patients and healthy donors (translational goal). Characterizing the physical origins of genomic translocations may yield new methods to predict, and new targets to prevent, genomic rearrangements driving cancer initiation. Beyond the proposed research focused on chromatin motions during DNA repair, we anticipate broad applicability of our novel 3D imaging resources to study chromatin in multiple contexts.","4":"Heterogeneity","5":"Chromatin Mobility in Response to DNA Damage","6":"PS-ON","7":"U01"},{"1":"syn21645122","2":"Chromatin Mobility in Response to DNA Damage","3":"Genomic translocations are well-established drivers of therapy-related myeloid neoplasms (t-MNs). T-MNs have poor outcomes and affect survivors of primary malignancies. It is not possible to predict which patients treated for a primary cancer will develop t-MN, which constitutes a major clinical challenge. A method to assess the risk of translocations after patient exposures to DNA damaging chemotherapy and radiations would inform therapeutic decisions. Translocations depend on the movements of broken DNA ends on non-homologous chromosomes. We developed a method based on diffractive optical elements (DOE) to track photoactivated chromatin reporters and map chromatin motions in the cell nucleus. Our preliminary data show fluctuations in chromatin mobility in response to DNA damage, which may impact on genomic translocations frequencies in cells with DNA damage. The goals for this PS-OP are (1) to develop new methodology to measure chromatin mobility in the 3D nuclear space, (2) to identify the mechanisms controlling chromatin motions after DNA damage and assess their functional consequences for DNA repair efficacy, repair quality, and translocations frequencies, and (3) to test for clinically relevant associations between chromatin motions and genomic translocations using hematopoietic stem/progenitor cell samples from t-MN patients and healthy donors (translational goal). Characterizing the physical origins of genomic translocations may yield new methods to predict, and new targets to prevent, genomic rearrangements driving cancer initiation. Beyond the proposed research focused on chromatin motions during DNA repair, we anticipate broad applicability of our novel 3D imaging resources to study chromatin in multiple contexts.","4":"Evolution","5":"Chromatin Mobility in Response to DNA Damage","6":"PS-ON","7":"U01"},{"1":"syn21645123","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity. Detailed mechanistic understanding will be obtained by an integrated approach that combines physical science (PS) based tools with two complementary pre-clinical mouse models of melanoma T cell immunity, which will be further tested using bio specimens from melanoma patients. The molecular focus is the T-cell receptor (TCR) that initiates the T-cell antigen recognition upon binding to peptide-major histocompatibility complex (pMHC), and the coreceptor CD8 that co-ligates with the pMHC. The first PS tool is single-molecule force techniques for quantifying TCR mechanosensing through in situ kinetic analyses of molecular interactions with concurrent imaging of intracellular signals on a single cell. The second PS tool is DNA-based digital tension probes that report cell generated pulling forces on the TCR and CD8 via engaged pMHC. One animal model is a recognized standard that uses melanoma conjugated with a chicken ovalbumin antigen recognized by the OT-I TCR. The other animal model is a melanoma self-antigen gp100 in conjunction with JR209 humanized transgenic mice. By analyzing the mechanically regulated two-dimensional (2D) ligand binding of TCR and/or CD8 at the T-cell membrane, we observed that the TCR avidities for the pMHC of CD8 T cells infiltrating primary murine melanomas grown in vivo are significantly reduced relative to T cells within non-tumor associated tissues (spleen and blood). Such differential avidities were not detected by the conventional assay using pMHC tetramer, attesting to the power of our mechanics-based methods for analyzing TCR<U+201A><U+00C4><U+00EC>pMHC interactions. We also found melanomas to substantially alter the force-dependent TCR<U+201A><U+00C4><U+00EC>pMHC bond durability: in tumor-free animals, the TCR and pMHC formed a catch-slip bond whose lifetime first increased and then decreased with increasing force, which we have previously demonstrated to govern T cell signaling and effector function, whereas in melanoma-bearing animals, the TCR<U+201A><U+00C4><U+00EC>pMHC bond lifetime only decreased with increasing force, i.e., behaved as a slip bond and were associated with reduced T cell effector functions. We hypothesize that deficient CD8 T cell immunity in melanoma results, at least in part, from impaired antigen recognition within the TME, as manifested by the altered TCR mechanosensing of pMHC. Three specific aims are proposed to test our hypothesis: 1) Determine the molecular interactions crucial to T cell antigen recognition that are impaired by the TME; 2) Define the functional consequences of suppressed T cell antigen recognition; and 3) Elucidate the mechanisms underlying the TME suppression of T cell antigen recognition. Completing these aims has the potential to identify new immunotherapeutic targets for the treatment of melanoma to improve the outcomes of patients with advanced disease.","4":"Tumor-Immune","5":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","6":"PS-ON","7":"U01"},{"1":"syn21645123","2":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","3":"This project investigates how the tumor microenvironment (TME) impairs in situ interactions of T-cell surface molecules with counter-molecules on the melanoma cells to suppress anti-tumor immunity. Detailed mechanistic understanding will be obtained by an integrated approach that combines physical science (PS) based tools with two complementary pre-clinical mouse models of melanoma T cell immunity, which will be further tested using bio specimens from melanoma patients. The molecular focus is the T-cell receptor (TCR) that initiates the T-cell antigen recognition upon binding to peptide-major histocompatibility complex (pMHC), and the coreceptor CD8 that co-ligates with the pMHC. The first PS tool is single-molecule force techniques for quantifying TCR mechanosensing through in situ kinetic analyses of molecular interactions with concurrent imaging of intracellular signals on a single cell. The second PS tool is DNA-based digital tension probes that report cell generated pulling forces on the TCR and CD8 via engaged pMHC. One animal model is a recognized standard that uses melanoma conjugated with a chicken ovalbumin antigen recognized by the OT-I TCR. The other animal model is a melanoma self-antigen gp100 in conjunction with JR209 humanized transgenic mice. By analyzing the mechanically regulated two-dimensional (2D) ligand binding of TCR and/or CD8 at the T-cell membrane, we observed that the TCR avidities for the pMHC of CD8 T cells infiltrating primary murine melanomas grown in vivo are significantly reduced relative to T cells within non-tumor associated tissues (spleen and blood). Such differential avidities were not detected by the conventional assay using pMHC tetramer, attesting to the power of our mechanics-based methods for analyzing TCR<U+201A><U+00C4><U+00EC>pMHC interactions. We also found melanomas to substantially alter the force-dependent TCR<U+201A><U+00C4><U+00EC>pMHC bond durability: in tumor-free animals, the TCR and pMHC formed a catch-slip bond whose lifetime first increased and then decreased with increasing force, which we have previously demonstrated to govern T cell signaling and effector function, whereas in melanoma-bearing animals, the TCR<U+201A><U+00C4><U+00EC>pMHC bond lifetime only decreased with increasing force, i.e., behaved as a slip bond and were associated with reduced T cell effector functions. We hypothesize that deficient CD8 T cell immunity in melanoma results, at least in part, from impaired antigen recognition within the TME, as manifested by the altered TCR mechanosensing of pMHC. Three specific aims are proposed to test our hypothesis: 1) Determine the molecular interactions crucial to T cell antigen recognition that are impaired by the TME; 2) Define the functional consequences of suppressed T cell antigen recognition; and 3) Elucidate the mechanisms underlying the TME suppression of T cell antigen recognition. Completing these aims has the potential to identify new immunotherapeutic targets for the treatment of melanoma to improve the outcomes of patients with advanced disease.","4":"Microenvironment","5":"Mechanisms of Impaired T-Cell Mechanosensing of Melanoma Antiagents","6":"PS-ON","7":"U01"},{"1":"syn21645124","2":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","3":"The promise of precision medicine for cancer is a personalized therapeutic strategy based on the molecular features of an individual<U+201A><U+00C4><U+00F4>s tumor. This concept is most effectively demonstrated by the successes in targeting oncogenic kinases with small molecules or antibody inhibitors. But while successes have garnered significant attention in recent years, precision medicine has not made an impact for the vast majority of cancer patients. The high profile successes associated with inhibitors of kinases such as ABL, EGFR, ALK, and B-RAF bring to the forefront the major disappointment associated with efforts to establish precision medicine for cancers expressing mutant K-RAS. K-RAS mutations occur in 15% of all cancers, but are significantly enriched in three of the four most deadly forms: lung, colorectal, and pancreatic. Importantly, KRAS mutations are associated with resistance to conventional and targeted therapies, most notably therapies targeting the epidermal growth factor receptor. As such, three decades after the initial identification of KRAS mutations in human cancers, prospective knowledge of K-RAS mutation state in a given cancer is useful largely only for its ability to predict negative response to therapy. The major shortfall of the precision medicine movement is the lack of direct inhibitors for specific oncogenic events, such as K-RAS mutation. The alternative to direct inhibition of an activated oncoprotein is to target downstream pathways, but this requires an absolute understanding of contextual cues that influence oncogenic effector signaling. Lack of depth in our understanding of the relationship between genotype, network signaling state, and therapeutic response leads to ineffective precision medicine. With its focus on network-level biology and its ability to uncover molecular mechanisms through computational analysis, systems biology provides a means to overcome this lack of understanding. This project is designed to take advantage of the broad array of expertise within our research community in order to make precision medicine a realistic goal for patients with K-RAS mutant cancer.","4":"Drug Resistance/Sensitivity","5":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","6":"CSBC","7":"U01"},{"1":"syn21645125","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"Combination therapy holds considerable promise for overcoming intrinsic and acquired resistance to targeted therapies but will rely on our ability to precisely identify the best drug combination for particular tumors. While immense focus exists on using genomic information to direct therapeutic strategies, many resistance mechanisms do not rely on genetic changes and, in fact, can arise from entirely tumor-extrinsic factors within the microenvironment. For example, although the receptor tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.nnWe propose to study both downstream and receptor-proximal signaling during bypass resistance mediated by AXL, and then across a wider panel of RTKs. Integrating these measurements with quantitative modeling will identify the connectivity between receptors, interacting adapters, and downstream signaling events, thereby defining the essential set of signaling network changes required for tumor cell survival in response to targeted therapeutics. We will then apply this understanding by measuring RTK-adapter interaction using proximity ligation to predict the RTKs driving bypass resistance and test these predictions in a panel of patient-derived xenograft tumors.nnThis work will considerably improve our ability to identify effective drug combinations by (a) developing a mechanism-based assay for identifying which among many RTKs tumor cells are relying upon for survival, (b) improving our basic understanding of exactly how network-level bypass resistance arises due to activation of non-targeted RTKs both at the receptor-proximal and downstream signaling layer, and (c) expanding our understanding of the RTK AXL with links to resistance, tumor spread, and immune avoidance.","4":"Heterogeneity","5":"Precision lung cancer therapy design through multiplexed adapter measurement","6":"CSBC","7":"U01"},{"1":"syn21645125","2":"Precision lung cancer therapy design through multiplexed adapter measurement","3":"Combination therapy holds considerable promise for overcoming intrinsic and acquired resistance to targeted therapies but will rely on our ability to precisely identify the best drug combination for particular tumors. While immense focus exists on using genomic information to direct therapeutic strategies, many resistance mechanisms do not rely on genetic changes and, in fact, can arise from entirely tumor-extrinsic factors within the microenvironment. For example, although the receptor tyrosine kinase (RTK) AXL is widely implicated in resistance to targeted therapies such as those directed against EGFR, its regulation by phosphatidylserine, as opposed to mutation, amplification or autocrine ligand, make identifying the tumors that will respond to AXL-targeted therapy especially challenging.nnWe propose to study both downstream and receptor-proximal signaling during bypass resistance mediated by AXL, and then across a wider panel of RTKs. Integrating these measurements with quantitative modeling will identify the connectivity between receptors, interacting adapters, and downstream signaling events, thereby defining the essential set of signaling network changes required for tumor cell survival in response to targeted therapeutics. We will then apply this understanding by measuring RTK-adapter interaction using proximity ligation to predict the RTKs driving bypass resistance and test these predictions in a panel of patient-derived xenograft tumors.nnThis work will considerably improve our ability to identify effective drug combinations by (a) developing a mechanism-based assay for identifying which among many RTKs tumor cells are relying upon for survival, (b) improving our basic understanding of exactly how network-level bypass resistance arises due to activation of non-targeted RTKs both at the receptor-proximal and downstream signaling layer, and (c) expanding our understanding of the RTK AXL with links to resistance, tumor spread, and immune avoidance.","4":"Drug Resistance/Sensitivity","5":"Precision lung cancer therapy design through multiplexed adapter measurement","6":"CSBC","7":"U01"},{"1":"syn21645126","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"Perturbation of cancer cells often leads to heterogeneous outcomes, in that most cells exhibit a dominant phenotype, but the rest appear resistant or hypersensitive to the perturbation. If the penetrance of such a phenotype is heritably incomplete, then it becomes extremely difficult to decipher the upstream molecular events that heterogenize the population and cause response variability. By combining quantitative measurements with dynamical models, systems approaches should be useful if provided with a core network of important biomolecules. The daunting hurdle lies in identifying phenotype-relevant regulatory heterogeneities that define the network for penetrance at the single-cell level. Our proposal seeks to exploit a new approach, called stochastic frequency matching (SFM), for elaborating the molecular networks upstream of incompletely penetrant phenotypes. SFM identifies and parameterizes single-cell heterogeneities<U+201A><U+00C4><U+00EE>which emerge after a uniform perturbation but before the appearance of a variable phenotype<U+201A><U+00C4><U+00EE>to hone in on regulatory states corresponding to future penetrance. For an onco-phenotype incompletely triggered by ErbB receptor tyrosine kinase signaling in 3D cultured breast epithelia, we implemented SFM using microarrays to uncover a network of critical nucleocytoplasmic regulators. The goals of this proposal are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype. The aims are to: 1) Identify network-level mechanisms for the incompletely penetrant ErbB1:ErbB2 phenotype. 2) Determine whether drivers of incomplete penetrance in 3D define shuttling states in human cancers and promote ErbB2-driven mammary tumors in mice. 3) Sequence and parameterize regulatory-state heterogeneity in HER2+ breast cancers to assemble patient-specific network models of shuttling variability and sensitivity. Drivers of incomplete penetrance are important for understanding transitions during tumor initiation-progression and for developing therapeutic interventions with more reliable patient outcomes. SFM gives the Cancer Systems Biology Consortium a means to identify driver networks in a comprehensive and hypothesis-driven way.","4":"Heterogeneity","5":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","6":"CSBC","7":"U01"},{"1":"syn21645126","2":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","3":"Perturbation of cancer cells often leads to heterogeneous outcomes, in that most cells exhibit a dominant phenotype, but the rest appear resistant or hypersensitive to the perturbation. If the penetrance of such a phenotype is heritably incomplete, then it becomes extremely difficult to decipher the upstream molecular events that heterogenize the population and cause response variability. By combining quantitative measurements with dynamical models, systems approaches should be useful if provided with a core network of important biomolecules. The daunting hurdle lies in identifying phenotype-relevant regulatory heterogeneities that define the network for penetrance at the single-cell level. Our proposal seeks to exploit a new approach, called stochastic frequency matching (SFM), for elaborating the molecular networks upstream of incompletely penetrant phenotypes. SFM identifies and parameterizes single-cell heterogeneities<U+201A><U+00C4><U+00EE>which emerge after a uniform perturbation but before the appearance of a variable phenotype<U+201A><U+00C4><U+00EE>to hone in on regulatory states corresponding to future penetrance. For an onco-phenotype incompletely triggered by ErbB receptor tyrosine kinase signaling in 3D cultured breast epithelia, we implemented SFM using microarrays to uncover a network of critical nucleocytoplasmic regulators. The goals of this proposal are to apply systems approaches to the ErbB nucleocytoplasmic network and adapt SFM more broadly to RNA sequencing of breast cancer patients with ErbB amplification. Based on our provisional SFM results, we hypothesize that ErbB signaling heterogeneously reconfigures the nucleocytoplasmic shuttling state of cells to determine incomplete penetrance of the onco-phenotype. The aims are to: 1) Identify network-level mechanisms for the incompletely penetrant ErbB1:ErbB2 phenotype. 2) Determine whether drivers of incomplete penetrance in 3D define shuttling states in human cancers and promote ErbB2-driven mammary tumors in mice. 3) Sequence and parameterize regulatory-state heterogeneity in HER2+ breast cancers to assemble patient-specific network models of shuttling variability and sensitivity. Drivers of incomplete penetrance are important for understanding transitions during tumor initiation-progression and for developing therapeutic interventions with more reliable patient outcomes. SFM gives the Cancer Systems Biology Consortium a means to identify driver networks in a comprehensive and hypothesis-driven way.","4":"Evolution","5":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","6":"CSBC","7":"U01"},{"1":"syn21645127","2":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","3":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies. We seek to decode the gene-regulatory processes that underlie SCLC<U+201A><U+00C4><U+00F4>s phenotypic response to treatment, and develop clinically viable strategies to reprogram those circuits, while keeping cells locked into drug-sensitive states. Our major driving questions are: How does SCLC heterogeneity contribute dynamic adaptation to treatment? What regulatory mechanisms govern this response, and how are they coordinated? How can these regulatory mechanisms be manipulated to drive SCLC cells toward therapeutically desirable phenotypes? What molecular species can be targeted therapeutically to affect these mechanisms? To this end we will integrate bioinformatics, mathematical modeling, and experimentation to provide a systems-level understanding of SCLC drug response and optimal treatment strategies.","4":"Drug Resistance/Sensitivity","5":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","6":"CSBC","7":"U01"},{"1":"syn21645127","2":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","3":"The goal of our U01 project to develop rational systems approaches to treat cancer. Small-cell lung cancer (SCLC) is arguably the most aggressive form of lung cancer, and while modern treatment strategies are initially highly effective, tumors quickly relapse, resistant to further therapies. We seek to decode the gene-regulatory processes that underlie SCLC<U+201A><U+00C4><U+00F4>s phenotypic response to treatment, and develop clinically viable strategies to reprogram those circuits, while keeping cells locked into drug-sensitive states. Our major driving questions are: How does SCLC heterogeneity contribute dynamic adaptation to treatment? What regulatory mechanisms govern this response, and how are they coordinated? How can these regulatory mechanisms be manipulated to drive SCLC cells toward therapeutically desirable phenotypes? What molecular species can be targeted therapeutically to affect these mechanisms? To this end we will integrate bioinformatics, mathematical modeling, and experimentation to provide a systems-level understanding of SCLC drug response and optimal treatment strategies.","4":"Heterogeneity","5":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","6":"CSBC","7":"U01"},{"1":"syn21645128","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof. Compared to other cancers, the treatment options available for Head and Neck Squamous Cell Cancer (HNSCC) patients are particularly limited with only one targeted therapy currently approved by FDA for treatment; therefore, there is a need for new therapeutic strategies and methods to enable systematic/predictive selection of patients for treatment with targeted agents.nnSpecifically, we hypothesize that the response to a new class of redox-based chemotherapeutics can be predicted and enhanced by identifying specific metabolic network features contributing to the NAD(P)+/NAD(P)H redox balance and overall levels associated with the specific mechanism of action. We will be investigating the NAD(P)H-driven responses to the quinone-based chemotherapeutics, beta-lapachone (<U+221A><U+00FC>-Lap) and isobutyl-deoxynyboquinone (IB-DNQ) in laboratory models and clinical specimens of HNSCC. This project will require integration and expansion of our prior successful models of drug bioactivation networks and redox metabolic systems in a comprehensive systems-level approach to improve understanding and enhance prediction of phenotype-specific responses to chemotherapeutic strategies. Development and validation of predictive models of <U+0152><U+2264>-Lap or IB-DBQ lethality in HNSCC cell lines will rely upon novel genome-wide metabolomics approaches to identify key enzymatic contributors to NAD(P)H levels required for driving drug metabolism and DNA lesion repair. The predictive capabilities of our computational models will be enhanced by accounting for metabolic diversity across HNSCC tumors and RNAi manipulation of enzyme levels to extract predictive proteomic/metabolic signatures associated with quinone redox cycling. Finally, the model-based predictions of therapeutic outcomes will be tested with HNSCC clinical specimens via ex vivo assays and targeted metabolic profiling. We anticipate that our multi-disciplinary project <U+201A><U+00C4><U+00EC> relying on a team of investigators in pharmacology, oncology, redox biology, mass spectrometry, and computational modeling <U+201A><U+00C4><U+00EC> will identify metabolic regulatory features applicable to the treatment of other cancers by molecular or systemic chemotherapies.","4":"Metabolism","5":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","6":"CSBC","7":"U01"},{"1":"syn21645128","2":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","3":"The goal of our U01 project is to advance precision medicine through consideration of cancer redox metabolism when predicting patient-specific responses to therapies. While the arsenal of approaches to selectively killing cancer cells is increasing, the majority of treatments rely on redox alterations of tumor cells and their microenvironment through chemotherapy, radiation, or some combination thereof. Compared to other cancers, the treatment options available for Head and Neck Squamous Cell Cancer (HNSCC) patients are particularly limited with only one targeted therapy currently approved by FDA for treatment; therefore, there is a need for new therapeutic strategies and methods to enable systematic/predictive selection of patients for treatment with targeted agents.nnSpecifically, we hypothesize that the response to a new class of redox-based chemotherapeutics can be predicted and enhanced by identifying specific metabolic network features contributing to the NAD(P)+/NAD(P)H redox balance and overall levels associated with the specific mechanism of action. We will be investigating the NAD(P)H-driven responses to the quinone-based chemotherapeutics, beta-lapachone (<U+221A><U+00FC>-Lap) and isobutyl-deoxynyboquinone (IB-DNQ) in laboratory models and clinical specimens of HNSCC. This project will require integration and expansion of our prior successful models of drug bioactivation networks and redox metabolic systems in a comprehensive systems-level approach to improve understanding and enhance prediction of phenotype-specific responses to chemotherapeutic strategies. Development and validation of predictive models of <U+0152><U+2264>-Lap or IB-DBQ lethality in HNSCC cell lines will rely upon novel genome-wide metabolomics approaches to identify key enzymatic contributors to NAD(P)H levels required for driving drug metabolism and DNA lesion repair. The predictive capabilities of our computational models will be enhanced by accounting for metabolic diversity across HNSCC tumors and RNAi manipulation of enzyme levels to extract predictive proteomic/metabolic signatures associated with quinone redox cycling. Finally, the model-based predictions of therapeutic outcomes will be tested with HNSCC clinical specimens via ex vivo assays and targeted metabolic profiling. We anticipate that our multi-disciplinary project <U+201A><U+00C4><U+00EC> relying on a team of investigators in pharmacology, oncology, redox biology, mass spectrometry, and computational modeling <U+201A><U+00C4><U+00EC> will identify metabolic regulatory features applicable to the treatment of other cancers by molecular or systemic chemotherapies.","4":"Drug Resistance/Sensitivity","5":"Model-based Prediction of Redox-Modulated Responses to Cancer Treatments","6":"CSBC","7":"U01"},{"1":"syn21645129","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"Glioblastoma (GBM) exhibits profound intratumoral molecular heterogeneity that contributes to treatment resistance and poor survival. Specifically, each tumor comprises multiple molecularly-distinct subpopulations with different treatment sensitivities. This heterogeneity not only portends the pre-existence of resistant molecular subpopulations, but also the communications between neighboring subpopulations that further modulate tumorigenicity and resistance. In fact, a minority tumor subpopulation with EGFRvIII mutation has been shown to potentiate a majority subpopulation with wild-type EGFR to increase tumor growth, cell survival, and drug resistance. This type of cooperativity presents clear implications for improving GBM treatment. Yet compared to other tumor types, the interactions in GBM remain critically understudied.nnA significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. In particular, contrast-enhanced MRI (CE-MRI) routinely guides surgical biopsy and resection of the MRI enhancing core, but fails to address the diverse subpopulations of the surrounding non-enhancing parenchyma (so called <U+201A><U+00C4><U+00FA>brain around tumor<U+201A><U+00C4><U+00F9> or BAT). These unresected residual subpopulations in BAT represent the main contributors to tumor recurrence, which can exhibit different therapeutic targets (and interactions) compared with enhancing biopsies. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions. Our group has used multi-parametric MRI and image-guided biopsies to develop and validate machine-learning (ML) models of intratumoral genomic heterogeneity, with particular focus on the BAT zone.nnIn Aim 1, will we collect and molecularly profile a large set of image-recorded stereotactic biopsies in primary GBM patients to quantify the diversity of molecularly-distinct subpopulations, as well as their phenotypic niches, throughout the BAT zone. We will assess local heterogeneity at the biopsy level and also co-localize regional patterns and rates of recurrence on serial MRI. In Aim 2, we will use these biopsies and spatially matched MRI metrics to refine our existing ML predictive models. We will use these ML models to co-localize spatial patterns of molecularly-distinct subpopulations (and their phenotypic niches) to quantify their risk of regional recurrence. In Aim 3, we will functionally validate the subpopulation interactions observed in Aims 1 and 2 using patient derived xenograft (PDX) models. We will also validate these interactions in human GBM using a subset of spatially matched biopsies from primary and recurrent tumors in the same patients.nnThis proposal leverages our unique expertise in image-guided tissue analysis and MRI-based computational modeling to study the diversity of molecularly-distinct subpopulations and the evolving competitive landscapes in human GBM. This work will help risk stratify patients in future targeted clinical drug trials and should also facilitate new strategies (e.g., adaptive therapy) to exploit subpopulation co-dependency for therapeutic benefit.","4":"Heterogeneity","5":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","6":"CSBC","7":"U01"},{"1":"syn21645129","2":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","3":"Glioblastoma (GBM) exhibits profound intratumoral molecular heterogeneity that contributes to treatment resistance and poor survival. Specifically, each tumor comprises multiple molecularly-distinct subpopulations with different treatment sensitivities. This heterogeneity not only portends the pre-existence of resistant molecular subpopulations, but also the communications between neighboring subpopulations that further modulate tumorigenicity and resistance. In fact, a minority tumor subpopulation with EGFRvIII mutation has been shown to potentiate a majority subpopulation with wild-type EGFR to increase tumor growth, cell survival, and drug resistance. This type of cooperativity presents clear implications for improving GBM treatment. Yet compared to other tumor types, the interactions in GBM remain critically understudied.nnA significant barrier to studying the interactions between molecularly-distinct subpopulations is the challenge of tissue sampling in GBM. In particular, contrast-enhanced MRI (CE-MRI) routinely guides surgical biopsy and resection of the MRI enhancing core, but fails to address the diverse subpopulations of the surrounding non-enhancing parenchyma (so called <U+201A><U+00C4><U+00FA>brain around tumor<U+201A><U+00C4><U+00F9> or BAT). These unresected residual subpopulations in BAT represent the main contributors to tumor recurrence, which can exhibit different therapeutic targets (and interactions) compared with enhancing biopsies. To address the limitations of tissue sampling, imaging techniques can help quantitatively characterize tumors in their entirety, including unresected BAT regions. Our group has used multi-parametric MRI and image-guided biopsies to develop and validate machine-learning (ML) models of intratumoral genomic heterogeneity, with particular focus on the BAT zone.nnIn Aim 1, will we collect and molecularly profile a large set of image-recorded stereotactic biopsies in primary GBM patients to quantify the diversity of molecularly-distinct subpopulations, as well as their phenotypic niches, throughout the BAT zone. We will assess local heterogeneity at the biopsy level and also co-localize regional patterns and rates of recurrence on serial MRI. In Aim 2, we will use these biopsies and spatially matched MRI metrics to refine our existing ML predictive models. We will use these ML models to co-localize spatial patterns of molecularly-distinct subpopulations (and their phenotypic niches) to quantify their risk of regional recurrence. In Aim 3, we will functionally validate the subpopulation interactions observed in Aims 1 and 2 using patient derived xenograft (PDX) models. We will also validate these interactions in human GBM using a subset of spatially matched biopsies from primary and recurrent tumors in the same patients.nnThis proposal leverages our unique expertise in image-guided tissue analysis and MRI-based computational modeling to study the diversity of molecularly-distinct subpopulations and the evolving competitive landscapes in human GBM. This work will help risk stratify patients in future targeted clinical drug trials and should also facilitate new strategies (e.g., adaptive therapy) to exploit subpopulation co-dependency for therapeutic benefit.","4":"Evolution","5":"Quantifying Multiscale Competitive Landscapes of Clonal Diversity in Glioblastoma","6":"CSBC","7":"U01"},{"1":"syn21645130","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"Targeted therapies in melanoma have shown enormous promise in the sense that they can show dramatic reductions in tumor burden, with melanoma being a particularly stark example. However, this promise has failed to be fully realized because of the emergence of resistant tumor cells, which repopulate the tumor and are subsequently difficult or impossible to treat effectively. Typically, scientists have thought of therapy resistance as having genetic origins, with rare mutant tumor cells surviving therapy because of a mutation that causes resistance. Recent work from our labs using advanced single cell analysis, however, suggest that, at the point of attack, there may be other, complementary, non-genetic mechanisms that could also govern exactly why some rare cells are able to evade the effects of the therapy. Subsequently, the targeted therapy itself can reprogram these rare cells into a stably resistant population. This more nuanced <U+201A><U+00C4><U+00FA>plasticity and reprogramming<U+201A><U+00C4><U+00F9> view of resistance at the single cell level has opened the possibility of a far richer set of targets that can be exploited for forestalling therapy resistance; however, the current set of tools and models, both experimental and computational, for identifying these targets are underdeveloped and the origin of these biological processes remain mysterious. Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma. Our goal is to identify and validate the pathways that govern cellular plasticity in melanoma, develop computational tools to identify the gene networks that drive the formation of cellular plasticity, and ultimately test these interactions in in vivo mouse models. In conjunction, we developing tools for also specifically targeting the reprogramming phase of resistance, ultimately using all these data collectively to inform models of dosing regiments that we can test in in vivo systems. Collectively, our results may help shape treatment of melanoma to avoid the problem of resistance.","4":"Drug Resistance/Sensitivity","5":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","6":"CSBC","7":"U01"},{"1":"syn21645130","2":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","3":"Targeted therapies in melanoma have shown enormous promise in the sense that they can show dramatic reductions in tumor burden, with melanoma being a particularly stark example. However, this promise has failed to be fully realized because of the emergence of resistant tumor cells, which repopulate the tumor and are subsequently difficult or impossible to treat effectively. Typically, scientists have thought of therapy resistance as having genetic origins, with rare mutant tumor cells surviving therapy because of a mutation that causes resistance. Recent work from our labs using advanced single cell analysis, however, suggest that, at the point of attack, there may be other, complementary, non-genetic mechanisms that could also govern exactly why some rare cells are able to evade the effects of the therapy. Subsequently, the targeted therapy itself can reprogram these rare cells into a stably resistant population. This more nuanced <U+201A><U+00C4><U+00FA>plasticity and reprogramming<U+201A><U+00C4><U+00F9> view of resistance at the single cell level has opened the possibility of a far richer set of targets that can be exploited for forestalling therapy resistance; however, the current set of tools and models, both experimental and computational, for identifying these targets are underdeveloped and the origin of these biological processes remain mysterious. Here, we propose to develop and apply new concepts and methods in experimental and computational single cell biology to tackle the problem of non-genetic therapy resistance, translating our basic science results towards the clinic through the use of sophisticated in vivo models of melanoma. Our goal is to identify and validate the pathways that govern cellular plasticity in melanoma, develop computational tools to identify the gene networks that drive the formation of cellular plasticity, and ultimately test these interactions in in vivo mouse models. In conjunction, we developing tools for also specifically targeting the reprogramming phase of resistance, ultimately using all these data collectively to inform models of dosing regiments that we can test in in vivo systems. Collectively, our results may help shape treatment of melanoma to avoid the problem of resistance.","4":"Heterogeneity","5":"A plasticity and reprogramming paradigm for therapy resistance at the single cell level","6":"CSBC","7":"U01"},{"1":"syn21645131","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"The survival rate for patients with metastatic colorectal cancer (CRC) is less than 10%, and resistance to standard therapies is a key contributor to this high rate of morbidity and mortality. Cancer-associated fibroblasts (CAFs), a dominant cellular component of the tumor stroma, play a significant role in drug resistance by contributing to the altered metabolism that is a hallmark of CRC. Despite many computational models of colorectal cancer growth and progression, there is currently no quantitative spatiotemporal description of the interactions between colon cancer cells and CAF cells, or the metabolic dependencies of these two cell populations. Thus quantifying the collective cell dynamics (i.e. cooperation or competition) of tumor and CAF cells in their metabolic ecosystem may provide insight needed to develop optimal cancer therapies.nnOur U01 addresses this limitation by applying a systems biology approach comprised of novel mathematical frameworks across scales, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming that occurs between tumor cells and CAFs. We hypothesize that exploiting tumor-stromal metabolic dependencies will enhance the effects of therapeutic strategies to inhibit tumor growth. We will test this hypothesis by pursuing three aims that combine computational and experimental studies: (1) Develop computational models of intracellular metabolic pathways in CRC cells and CAFs that promote colon cancer proliferation; (2) Develop a spatial multiscale model of colon cancer cell growth, integrating the pathway models of tumor-CAF metabolic crosstalk; and (3) explore these data-driven models with supercomputing resources to identify and validate treatment strategies that exploit tumor and CAF metabolism.n![project description](https://csbconsortium.org/wp-content/uploads/2018/12/U01_website_schematic_USC_IU_final.png)","4":"Metabolism","5":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","6":"CSBC","7":"U01"},{"1":"syn21645131","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"The survival rate for patients with metastatic colorectal cancer (CRC) is less than 10%, and resistance to standard therapies is a key contributor to this high rate of morbidity and mortality. Cancer-associated fibroblasts (CAFs), a dominant cellular component of the tumor stroma, play a significant role in drug resistance by contributing to the altered metabolism that is a hallmark of CRC. Despite many computational models of colorectal cancer growth and progression, there is currently no quantitative spatiotemporal description of the interactions between colon cancer cells and CAF cells, or the metabolic dependencies of these two cell populations. Thus quantifying the collective cell dynamics (i.e. cooperation or competition) of tumor and CAF cells in their metabolic ecosystem may provide insight needed to develop optimal cancer therapies.nnOur U01 addresses this limitation by applying a systems biology approach comprised of novel mathematical frameworks across scales, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming that occurs between tumor cells and CAFs. We hypothesize that exploiting tumor-stromal metabolic dependencies will enhance the effects of therapeutic strategies to inhibit tumor growth. We will test this hypothesis by pursuing three aims that combine computational and experimental studies: (1) Develop computational models of intracellular metabolic pathways in CRC cells and CAFs that promote colon cancer proliferation; (2) Develop a spatial multiscale model of colon cancer cell growth, integrating the pathway models of tumor-CAF metabolic crosstalk; and (3) explore these data-driven models with supercomputing resources to identify and validate treatment strategies that exploit tumor and CAF metabolism.n![project description](https://csbconsortium.org/wp-content/uploads/2018/12/U01_website_schematic_USC_IU_final.png)","4":"Heterogeneity","5":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","6":"CSBC","7":"U01"},{"1":"syn21645131","2":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","3":"The survival rate for patients with metastatic colorectal cancer (CRC) is less than 10%, and resistance to standard therapies is a key contributor to this high rate of morbidity and mortality. Cancer-associated fibroblasts (CAFs), a dominant cellular component of the tumor stroma, play a significant role in drug resistance by contributing to the altered metabolism that is a hallmark of CRC. Despite many computational models of colorectal cancer growth and progression, there is currently no quantitative spatiotemporal description of the interactions between colon cancer cells and CAF cells, or the metabolic dependencies of these two cell populations. Thus quantifying the collective cell dynamics (i.e. cooperation or competition) of tumor and CAF cells in their metabolic ecosystem may provide insight needed to develop optimal cancer therapies.nnOur U01 addresses this limitation by applying a systems biology approach comprised of novel mathematical frameworks across scales, quantitative imaging techniques, and physiologically-relevant preclinical models to investigate reciprocal metabolic reprogramming that occurs between tumor cells and CAFs. We hypothesize that exploiting tumor-stromal metabolic dependencies will enhance the effects of therapeutic strategies to inhibit tumor growth. We will test this hypothesis by pursuing three aims that combine computational and experimental studies: (1) Develop computational models of intracellular metabolic pathways in CRC cells and CAFs that promote colon cancer proliferation; (2) Develop a spatial multiscale model of colon cancer cell growth, integrating the pathway models of tumor-CAF metabolic crosstalk; and (3) explore these data-driven models with supercomputing resources to identify and validate treatment strategies that exploit tumor and CAF metabolism.n![project description](https://csbconsortium.org/wp-content/uploads/2018/12/U01_website_schematic_USC_IU_final.png)","4":"Microenvironment","5":"Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer","6":"CSBC","7":"U01"},{"1":"syn21645132","2":"Rewiring of regulatory networks in breast cancer by transcription factor isoforms","3":"One of the ultimate goals of cancer systems biology is to generate predictive and dynamic models of tumorigenesis by identifying and quantifying all perturbed functional interactions in a cancerous cellular system. The central hypothesis of our CSBC is that functional perturbations emerging from cancer-specific gene expression of alternative isoforms are crucial for tumorigenesis. Genome alterations such as amplification, deletion, translocations and mutations, are often considered primary events of cancer progression. However, cancer-specific isoforms resulting from alternative splicing, alternative sites of transcriptional initiation, and/or alternative transcriptional termination sites, have also been shown to have functional impact on tumorigenesis. nChanges in gene regulatory networks (GRNs) by transcription factor (TF) isoforms have been shown to play a major role in tumorigenesis and metastasis in multiple types of cancer. What remains unclear is the extent to which differences in TF isoforms between normal and cancer tissue affect global GRNs and how such regulatory network rewiring leads to altered gene expression programs in cancer. In this CSBC project, we are characterizing and modeling the effect(s) of large numbers of breast cancer-specific TF isoforms in the context of cancer interactome networks. We will combine network modeling and high-throughput systematic experimental strategies at the level of molecular protein-protein and protein-DNA interactions to predict cancer drivers and suppressors. nAltogether, this project will contextualize and functionalize large numbers of TF isoforms implicated in breast cancer. Lessons learned from this project will lead to the identification of novel cancer drivers and suppressors, the generation of mechanistic models of GRN rewiring in cancer and provide a framework for the design of novel therapeutics. The resulting hypotheses will be tested experimentally using various large-scale functional assays in breast cancer cells as a model system. As part of the experimental testing, we will establish state-of-the-art genome editing methodologies for testing the effects of isoform-specific perturbations on GRNs in mammalian cells.","4":"Heterogeneity","5":"Rewiring of regulatory networks in breast cancer by transcription factor isoforms","6":"CSBC","7":"U01"},{"1":"syn21645133","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"The Moffitt Integrated Mathematical Oncology (IMO) Department, through collaborations with oncologists, cancer biologists, evolutionary biologists, and imaging scientists, has pioneered the integration of evolutionary dynamics into cancer treatment protocols. In pre-clinical experiments and now with ongoing clinical trials, we have demonstrated that therapies incorporating evolutionary dynamics can significantly improve outcomes using currently available treatments. Major <U+201A><U+00C4><U+00FA>lessons learned<U+201A><U+00C4><U+00F9> from this experience include 1) Optimal therapy design requires maximal understanding of the multiscale dynamics that provide the <U+201A><U+00C4><U+00FA>menu<U+201A><U+00C4><U+00F9> of resistance strategies for cancer cells undergoing treatment; 2) The eco-evolutionary forces that govern response and resistance in cancer therapy are dominated by non-linear dynamics that defy intuitive analysis and can only be predicted through mathematical models and computational simulation; and 3) Clinical data are typically sparse and can be obtained only in periodic <U+201A><U+00C4><U+00FA>snapshots<U+201A><U+00C4><U+00F9> from biopsies or imaging studies. Converting static information to evolutionary dynamics requires mathematical tools. In this U01 we will apply these investigational principles to immunotherapy for metastatic non-small cell lung cancer (NSCLC). During the past decade, the Moffitt Thoracic Oncology Department has pioneered new strategies using immunotherapy for NSCLC. In almost 500 patients treated with immunotherapy at Moffitt, the response rate (CR, PR, and SD) is 30 to 45%. Most responses are followed by evolution of resistance and progression but some patients in each category have experienced durable responses maintained for >1 year. nnOur underlying hypothesis is that the observed results from immunotherapy can be improved with sufficient understanding of the evolutionary (cellular and molecular) and ecological (tissue) dynamics that govern response and resistance of NSCLC to immunotherapy. There is clear evidence that integration of other agents can enhance NSCLC response to immunotherapy. But, as we have previously demonstrated, administration of cytotoxic drugs in heterogeneous cancers typically elicits complex, often non-intuitive evolutionary dynamics and integration of evolutionary mathematical models into the clinical protocols can significantly improve outcomes. nnTo develop such models we will analyze a Moffitt NSCLC immunotherapy cohort to investigate the evolutionary (molecular, cellular) as well as ecological (histological and radiological) dynamics that govern response and resistance to immunotherapy. These investigations will be supplemented with ex vivo studies in which tumor and immune cells obtained from resected primary tumors are dispersed in culture allowing the immediate response to immunotherapy agents to be assessed. We will also perform in vitro studies that dissect the wide range of cellular and tissue ecological engineering strategies available to NSCLC cells as well as the timescales of immunotherapy adaptation. Finally, we will test predictive power of our developed mathematical models to prospectively use pre-therapy data to predict outcomes from anti-PD-L1 immunotherapy and calibrate these results from ongoing clinical trials in NSCLC at Moffitt.","4":"Tumor-Immune","5":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","6":"CSBC","7":"U01"},{"1":"syn21645133","2":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","3":"The Moffitt Integrated Mathematical Oncology (IMO) Department, through collaborations with oncologists, cancer biologists, evolutionary biologists, and imaging scientists, has pioneered the integration of evolutionary dynamics into cancer treatment protocols. In pre-clinical experiments and now with ongoing clinical trials, we have demonstrated that therapies incorporating evolutionary dynamics can significantly improve outcomes using currently available treatments. Major <U+201A><U+00C4><U+00FA>lessons learned<U+201A><U+00C4><U+00F9> from this experience include 1) Optimal therapy design requires maximal understanding of the multiscale dynamics that provide the <U+201A><U+00C4><U+00FA>menu<U+201A><U+00C4><U+00F9> of resistance strategies for cancer cells undergoing treatment; 2) The eco-evolutionary forces that govern response and resistance in cancer therapy are dominated by non-linear dynamics that defy intuitive analysis and can only be predicted through mathematical models and computational simulation; and 3) Clinical data are typically sparse and can be obtained only in periodic <U+201A><U+00C4><U+00FA>snapshots<U+201A><U+00C4><U+00F9> from biopsies or imaging studies. Converting static information to evolutionary dynamics requires mathematical tools. In this U01 we will apply these investigational principles to immunotherapy for metastatic non-small cell lung cancer (NSCLC). During the past decade, the Moffitt Thoracic Oncology Department has pioneered new strategies using immunotherapy for NSCLC. In almost 500 patients treated with immunotherapy at Moffitt, the response rate (CR, PR, and SD) is 30 to 45%. Most responses are followed by evolution of resistance and progression but some patients in each category have experienced durable responses maintained for >1 year. nnOur underlying hypothesis is that the observed results from immunotherapy can be improved with sufficient understanding of the evolutionary (cellular and molecular) and ecological (tissue) dynamics that govern response and resistance of NSCLC to immunotherapy. There is clear evidence that integration of other agents can enhance NSCLC response to immunotherapy. But, as we have previously demonstrated, administration of cytotoxic drugs in heterogeneous cancers typically elicits complex, often non-intuitive evolutionary dynamics and integration of evolutionary mathematical models into the clinical protocols can significantly improve outcomes. nnTo develop such models we will analyze a Moffitt NSCLC immunotherapy cohort to investigate the evolutionary (molecular, cellular) as well as ecological (histological and radiological) dynamics that govern response and resistance to immunotherapy. These investigations will be supplemented with ex vivo studies in which tumor and immune cells obtained from resected primary tumors are dispersed in culture allowing the immediate response to immunotherapy agents to be assessed. We will also perform in vitro studies that dissect the wide range of cellular and tissue ecological engineering strategies available to NSCLC cells as well as the timescales of immunotherapy adaptation. Finally, we will test predictive power of our developed mathematical models to prospectively use pre-therapy data to predict outcomes from anti-PD-L1 immunotherapy and calibrate these results from ongoing clinical trials in NSCLC at Moffitt.","4":"Drug Resistance/Sensitivity","5":"Eco-Evolutionary dynamics of NSCLC to immunotherapy - Response and Resistance","6":"CSBC","7":"U01"},{"1":"syn21645134","2":"Patterned Heterogeneity in Colon Cancer","3":"Solid tumors are complex masses of cancer cells with a multitude of genetic, epigenetic, morphologic and metabolic phenotypes. This heterogeneous condition is a formidable barrier to treating cancer as it underlies the ability of tumors to adapt to nutrient starvation, immune challenges and to develop resistance to cancer treatments <U+201A><U+00C4><U+00EC> the most common cause of mortality. Non-genetic heterogeneity in gene expression, signaling and metabolism are considered to be some of the most dynamic forms of heterogeneity and the most responsive to the tumor microenvironment. But we currently understand little about such heterogeneity, both mechanistically (what drives it) and functionally (how it helps the tumor). Non-genetic heterogeneity is very challenging to study, partly because of a limited toolbox and partly for lack of tractable model systems. Consequently, there are fundamental unknowns about how such heterogeneity arises and what its role in tumor growth and drug resistance really is.nnIn preliminary and published work, we observed heterogeneity in a xenograft model of colon cancer where the heterogeneity is patterned in a manner suggestive of a spatially self-organizing process (such as Turing-patterning). What is heterogeneous in these tumors is both Wnt signaling (thought to be the essential driver of proliferation in these cells), and metabolism (the balance between glycolysis and oxidative phosphorylation). In particular, the pattern consists of cell clusters, or spots, in which biomarkers of Wnt signaling are higher than in surrounding regions. These spots also mark regions of glycolytic metabolism. These patterns are likely connected through Wnt regulation of the expression of genes that control metabolism, as identified in our earlier work, and possibly through Wnt-Turing patterning of cancer cell subpopulations. Interestingly, glycolytic heterogeneity has recently been proposed to serve as the basis for resistance to anti-angiogenic therapy, one of the most important clinical problems in colorectal cancer. The short time scale of the xenografting (14-21 days), the reproducibility of the heterogeneity across genetically identical cell lines, and sites of injection, all suggest that this heterogeneity is not genetic.nnIn this project, Hughes, Waterman and their team seek to understand the causes of the observed heterogeneity in colon cancer, the reason why spatial patterns of heterogeneity develop spontaneously, the consequences of such heterogeneity for the growth of tumor cells, and whether this, or possibly other, forms of heterogeneity indeed drive resistance to therapy (and if so, why). They are addressing these questions by 1) explaining the relationships between heterogeneity, patterning and growth of colon tumors; 2) defining the general principles linking heterogeneity, patterning and growth in colon tumors; and 3) defining the link between heterogeneity and drug resistance.nn![Fig1](https://casb.uci.edu/files/2018/08/project-1-figure-1.jpg)nFigure 1. Xenograft colon tumors reveal a spotted pattern of metabolic (A) and Wnt signaling (B) heterogeneity; concordant heterogeneity in metabolism and Wnt signaling is present in primary patient tumors (C). (D) shows a new vascularized microtumor (VMT) platform that supports human vessels (red) and colon tumors (green), NADH-fluorescence lifetime imaging (FLIM) of colon tumors in the VMT shows metabolic heterogeneity (D: lower right). (E) Single Cell Sequence analysis using Seurat/tSNE clustering reveals that SW480 xenograft tumors are strikingly heterogeneous with a cancer stem cell-like cluster (0: top left) that is missing in tumors expressing dominant negative LEF1 (dnLEF: bottom left). In (E/Middle Panel) Ligand and receptor pairs among several cell clusters of the human and mouse (right panels in E) cells are shown. (F) Candidate mathematical model for simulating SW480 tumors.nnnThe foundation of the project is multi-scale modeling of stochastic and self-organizing processes that potentially explains overt differences in tumor growth, patterning of heterogeneity and metabolism, and the most likely mechanisms for drug resistance. The experimental tools pair xenograft studies with a novel platform for generating fully vascularized micro-tumors in vitro; the use of fluorescence lifetime imaging to read out the metabolic states of unlabeled, living cells, and the use of single cell transcriptomicsnto identify cell states, the gene expression signatures that define them and signaling and adhesion molecules that mediate communication among the cells. Modeling predictions of strategies that re-establish drug sensitivity will be tested via genetic engineering (CRISPR/Cas9) or small molecule drug therapies. The overarching goal of the work is to discover deep insights into the origins and consequences of tumor heterogeneity in an especially manipulable, and clinically relevant tumor system. The integration of this work with Projects 2 and 3, which focus on different cancer types (melanoma and chronic myeloid leukemia, respectively), enables us to identify general principles that underlie how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","4":"Heterogeneity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645134","2":"Patterned Heterogeneity in Colon Cancer","3":"Solid tumors are complex masses of cancer cells with a multitude of genetic, epigenetic, morphologic and metabolic phenotypes. This heterogeneous condition is a formidable barrier to treating cancer as it underlies the ability of tumors to adapt to nutrient starvation, immune challenges and to develop resistance to cancer treatments <U+201A><U+00C4><U+00EC> the most common cause of mortality. Non-genetic heterogeneity in gene expression, signaling and metabolism are considered to be some of the most dynamic forms of heterogeneity and the most responsive to the tumor microenvironment. But we currently understand little about such heterogeneity, both mechanistically (what drives it) and functionally (how it helps the tumor). Non-genetic heterogeneity is very challenging to study, partly because of a limited toolbox and partly for lack of tractable model systems. Consequently, there are fundamental unknowns about how such heterogeneity arises and what its role in tumor growth and drug resistance really is.nnIn preliminary and published work, we observed heterogeneity in a xenograft model of colon cancer where the heterogeneity is patterned in a manner suggestive of a spatially self-organizing process (such as Turing-patterning). What is heterogeneous in these tumors is both Wnt signaling (thought to be the essential driver of proliferation in these cells), and metabolism (the balance between glycolysis and oxidative phosphorylation). In particular, the pattern consists of cell clusters, or spots, in which biomarkers of Wnt signaling are higher than in surrounding regions. These spots also mark regions of glycolytic metabolism. These patterns are likely connected through Wnt regulation of the expression of genes that control metabolism, as identified in our earlier work, and possibly through Wnt-Turing patterning of cancer cell subpopulations. Interestingly, glycolytic heterogeneity has recently been proposed to serve as the basis for resistance to anti-angiogenic therapy, one of the most important clinical problems in colorectal cancer. The short time scale of the xenografting (14-21 days), the reproducibility of the heterogeneity across genetically identical cell lines, and sites of injection, all suggest that this heterogeneity is not genetic.nnIn this project, Hughes, Waterman and their team seek to understand the causes of the observed heterogeneity in colon cancer, the reason why spatial patterns of heterogeneity develop spontaneously, the consequences of such heterogeneity for the growth of tumor cells, and whether this, or possibly other, forms of heterogeneity indeed drive resistance to therapy (and if so, why). They are addressing these questions by 1) explaining the relationships between heterogeneity, patterning and growth of colon tumors; 2) defining the general principles linking heterogeneity, patterning and growth in colon tumors; and 3) defining the link between heterogeneity and drug resistance.nn![Fig1](https://casb.uci.edu/files/2018/08/project-1-figure-1.jpg)nFigure 1. Xenograft colon tumors reveal a spotted pattern of metabolic (A) and Wnt signaling (B) heterogeneity; concordant heterogeneity in metabolism and Wnt signaling is present in primary patient tumors (C). (D) shows a new vascularized microtumor (VMT) platform that supports human vessels (red) and colon tumors (green), NADH-fluorescence lifetime imaging (FLIM) of colon tumors in the VMT shows metabolic heterogeneity (D: lower right). (E) Single Cell Sequence analysis using Seurat/tSNE clustering reveals that SW480 xenograft tumors are strikingly heterogeneous with a cancer stem cell-like cluster (0: top left) that is missing in tumors expressing dominant negative LEF1 (dnLEF: bottom left). In (E/Middle Panel) Ligand and receptor pairs among several cell clusters of the human and mouse (right panels in E) cells are shown. (F) Candidate mathematical model for simulating SW480 tumors.nnnThe foundation of the project is multi-scale modeling of stochastic and self-organizing processes that potentially explains overt differences in tumor growth, patterning of heterogeneity and metabolism, and the most likely mechanisms for drug resistance. The experimental tools pair xenograft studies with a novel platform for generating fully vascularized micro-tumors in vitro; the use of fluorescence lifetime imaging to read out the metabolic states of unlabeled, living cells, and the use of single cell transcriptomicsnto identify cell states, the gene expression signatures that define them and signaling and adhesion molecules that mediate communication among the cells. Modeling predictions of strategies that re-establish drug sensitivity will be tested via genetic engineering (CRISPR/Cas9) or small molecule drug therapies. The overarching goal of the work is to discover deep insights into the origins and consequences of tumor heterogeneity in an especially manipulable, and clinically relevant tumor system. The integration of this work with Projects 2 and 3, which focus on different cancer types (melanoma and chronic myeloid leukemia, respectively), enables us to identify general principles that underlie how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","4":"Evolution","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645134","2":"Patterned Heterogeneity in Colon Cancer","3":"Solid tumors are complex masses of cancer cells with a multitude of genetic, epigenetic, morphologic and metabolic phenotypes. This heterogeneous condition is a formidable barrier to treating cancer as it underlies the ability of tumors to adapt to nutrient starvation, immune challenges and to develop resistance to cancer treatments <U+201A><U+00C4><U+00EC> the most common cause of mortality. Non-genetic heterogeneity in gene expression, signaling and metabolism are considered to be some of the most dynamic forms of heterogeneity and the most responsive to the tumor microenvironment. But we currently understand little about such heterogeneity, both mechanistically (what drives it) and functionally (how it helps the tumor). Non-genetic heterogeneity is very challenging to study, partly because of a limited toolbox and partly for lack of tractable model systems. Consequently, there are fundamental unknowns about how such heterogeneity arises and what its role in tumor growth and drug resistance really is.nnIn preliminary and published work, we observed heterogeneity in a xenograft model of colon cancer where the heterogeneity is patterned in a manner suggestive of a spatially self-organizing process (such as Turing-patterning). What is heterogeneous in these tumors is both Wnt signaling (thought to be the essential driver of proliferation in these cells), and metabolism (the balance between glycolysis and oxidative phosphorylation). In particular, the pattern consists of cell clusters, or spots, in which biomarkers of Wnt signaling are higher than in surrounding regions. These spots also mark regions of glycolytic metabolism. These patterns are likely connected through Wnt regulation of the expression of genes that control metabolism, as identified in our earlier work, and possibly through Wnt-Turing patterning of cancer cell subpopulations. Interestingly, glycolytic heterogeneity has recently been proposed to serve as the basis for resistance to anti-angiogenic therapy, one of the most important clinical problems in colorectal cancer. The short time scale of the xenografting (14-21 days), the reproducibility of the heterogeneity across genetically identical cell lines, and sites of injection, all suggest that this heterogeneity is not genetic.nnIn this project, Hughes, Waterman and their team seek to understand the causes of the observed heterogeneity in colon cancer, the reason why spatial patterns of heterogeneity develop spontaneously, the consequences of such heterogeneity for the growth of tumor cells, and whether this, or possibly other, forms of heterogeneity indeed drive resistance to therapy (and if so, why). They are addressing these questions by 1) explaining the relationships between heterogeneity, patterning and growth of colon tumors; 2) defining the general principles linking heterogeneity, patterning and growth in colon tumors; and 3) defining the link between heterogeneity and drug resistance.nn![Fig1](https://casb.uci.edu/files/2018/08/project-1-figure-1.jpg)nFigure 1. Xenograft colon tumors reveal a spotted pattern of metabolic (A) and Wnt signaling (B) heterogeneity; concordant heterogeneity in metabolism and Wnt signaling is present in primary patient tumors (C). (D) shows a new vascularized microtumor (VMT) platform that supports human vessels (red) and colon tumors (green), NADH-fluorescence lifetime imaging (FLIM) of colon tumors in the VMT shows metabolic heterogeneity (D: lower right). (E) Single Cell Sequence analysis using Seurat/tSNE clustering reveals that SW480 xenograft tumors are strikingly heterogeneous with a cancer stem cell-like cluster (0: top left) that is missing in tumors expressing dominant negative LEF1 (dnLEF: bottom left). In (E/Middle Panel) Ligand and receptor pairs among several cell clusters of the human and mouse (right panels in E) cells are shown. (F) Candidate mathematical model for simulating SW480 tumors.nnnThe foundation of the project is multi-scale modeling of stochastic and self-organizing processes that potentially explains overt differences in tumor growth, patterning of heterogeneity and metabolism, and the most likely mechanisms for drug resistance. The experimental tools pair xenograft studies with a novel platform for generating fully vascularized micro-tumors in vitro; the use of fluorescence lifetime imaging to read out the metabolic states of unlabeled, living cells, and the use of single cell transcriptomicsnto identify cell states, the gene expression signatures that define them and signaling and adhesion molecules that mediate communication among the cells. Modeling predictions of strategies that re-establish drug sensitivity will be tested via genetic engineering (CRISPR/Cas9) or small molecule drug therapies. The overarching goal of the work is to discover deep insights into the origins and consequences of tumor heterogeneity in an especially manipulable, and clinically relevant tumor system. The integration of this work with Projects 2 and 3, which focus on different cancer types (melanoma and chronic myeloid leukemia, respectively), enables us to identify general principles that underlie how the in vivo behaviors of transformed cells are constrained by rules inherited from the communities of diverse, interacting cell types and lineage hierarchies within which those cells arise.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645135","2":"Understanding the Cellular Origins of Melanoma","3":"Melanoma, a tumor resistant to therapy in late stages, is curable by excision when caught early. Early melanomas can be difficult to distinguish from benign, pigmented <U+201A><U+00C4><U+00FA>moles<U+201A><U+00C4><U+00F9>, i.e. melanocytic nevi; this leads to unnecessary excision of many normal nevi while early melanomas are often missed. Nevi and melanomas share more than morphological features: Clinical and experimental data show that ~90% of nevi are initiated when melanocytes acquire an activating mutation in the BRAF oncogene, the same oncogenic mutation observed in >60% of melanomas. Yet nevi spontaneously stop growing. This is usually attributed to <U+201A><U+00C4><U+00FA>oncogene-induced senescence,<U+201A><U+00C4><U+00F9> but the fact that nevi readily re-grow after incomplete excision, or in response to UV-irradiation, and can sometimes evolve to melanoma, suggest nevi are not <U+201A><U+00C4><U+00FA>senescent<U+201A><U+00C4><U+00F9> but reversibly growth-arrested. Nevi also spontaneously regress, a process that appears to involve the immune system.nnIn preliminary work, we investigated nevus dynamics in a mouse model of inducible Braf activation, which mimics human nevus formation and also produces melanomas either at low frequency or when additional oncogenic mutations are added (e.g., in Pten). We found that as we activate Braf in more melanocytes, such that nevi become more numerous and closely-spaced, the smaller individual nevi become<U+201A><U+00C4><U+00EE>as if nevi, when close together enough, inhibit each other<U+201A><U+00C4><U+00F4>s growth. Such behavior is predicted by mathematical models of growth control based on feedback through diffusible signaling molecules. Such models achieve robust control when feedback regulates decisions between self-renewal and progression to alternate cell states or fates. Interestingly, when we look closely at the nevi in this model, we see that there are, in fact, two distinct cell types: highly pigmented nevus body cells and a scattered, lightly pigmented melanocyte population that forms a <U+201A><U+00C4><U+00FA>veil<U+201A><U+00C4><U+00F9> around the pigmented cells that had not been observed before. These veil cells are usually not seen unless the melanocyte lineage is fluorescently-labeled with GFP. Single cell RNA-sequencing suggests that these cells likely communicate through ligands and receptors they differentially express.nnIn this project, Ganesan, Lander and their team seek to understand the role of the nevus body and veil cell types in mouse models that produce both nevi and melanoma,nn![fig2](https://casb.uci.edu/files/2018/08/project-2-figure-2.jpg)nFigure 2. (A) BRAF-mutant (Tyrosinase::CreERT2; BraffloxV600E/+) mice are crossed with ROSAmT/mG mice (TCBR) to GFP-label BRAF-mutant melanocytes. (B) Fluorescence emission (confocal and MPM) 3-D imaging of skin of live mice (as in Fig. 1; total depth = 90, 115 and 190<U+0152><U+00BA>m for 1x, 2x, and 3x representative stacks, respectively). Green = GFP; red = td Tomato. (C,D). Continuum modeling, in which cells at an arrested (quiescent) lineage stage feedback on the self-renewal probability of dividing cells. Model snapshots (D) show cell density (see heatmap) as a function of time (T= cell cycles) and location. Top and bottom rows are for low and high seeding densities, respectively, that represent different levels of nevi induction. (E) Single Cell RNA-seq of melanocytic nevi. Control mice (Tyrosinase::CreERT2; ROSAmTmG; TCR) and TCBR mice, as labeled. Left: tSNE clustering of gene expression for individual cells. Right: A portion of the tSNE map, showing contributions of TCR and TCBR mice as well as expression of selected marker genes.nnand to identify both the nature of how growth is controlled in nevi and the means by which melanoma cells escape from it. The goal of the work is to build a solid molecular and cellular framework on which to base clinical decisions about melanoma prevention, detection and treatment. They are addressing these issues by 1) Explaining feedback growth dynamics in melanocytic nevi; 2) Elucidating how melanomas escape growth control mechanisms that arrest nevi; and 3) Revealing how the immune system targets nevi, and how this affects melanoma development.nnThis project integrates multiscale mathematical modeling with experiments in mice using a nevus-forming inducible activated Braf model, and a version of the same model that combines Braf activation with inducible loss of one allele of Pten, leading to the reliable production of both nevi and melanoma tumors. We are developing hypotheses that can explain the spatiotemporal dynamics and spatial statistics of nevus and melanoma development in these models, including potential bifurcations that account for the development of both nevi and melanoma in the same mouse. We are investigating the reasons why some cells escape from growth control, while others do not. We anticipate that this is unlikely to be due to a requirement for inactivation of the other Pten allele, and instead believe that escape may more likely be due to the spatial dynamics of collective feedback. The results are expected to shed light on signaling pathways that could be manipulated to prevent or treat melanoma. Live cell imaging, focused laser ablation, immunohistochemistry, and time-course single cell RNA-sequencing are used to identify potential positive and negative feedback regulators that drive the mathematical models, and experiments are used to test model-based predictions concerning the roles that such molecules play. Finally, an investigation of spontaneous regression, which occurs with both mouse and human nevi, provides clues into how the immune system efficiently recognizes melanocyte overgrowth. Since immunotherapy has recently emerged as a promising therapy for melanoma, this study is expected to reveal whether immunotherapy leverages an existing immune program for eliminating nevi, and if so, how that program is carried out, and how melanomas typically escape from it. Such information should aid in developing new prevention and therapeutic strategies for this devastating disease. The integration of this work with Projects 1 and 3 occurs through the use of scRNA-seq as a tool for hypothesis generation and development and through the application of mathematical models that have similar underlying structures (cell state transitions, proliferation and quiescence, positive and negative feedback), but differ in their context (e.g., spatial in Projects 1 and 2 vs. non-spatial in Project 3).","4":"Heterogeneity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645135","2":"Understanding the Cellular Origins of Melanoma","3":"Melanoma, a tumor resistant to therapy in late stages, is curable by excision when caught early. Early melanomas can be difficult to distinguish from benign, pigmented <U+201A><U+00C4><U+00FA>moles<U+201A><U+00C4><U+00F9>, i.e. melanocytic nevi; this leads to unnecessary excision of many normal nevi while early melanomas are often missed. Nevi and melanomas share more than morphological features: Clinical and experimental data show that ~90% of nevi are initiated when melanocytes acquire an activating mutation in the BRAF oncogene, the same oncogenic mutation observed in >60% of melanomas. Yet nevi spontaneously stop growing. This is usually attributed to <U+201A><U+00C4><U+00FA>oncogene-induced senescence,<U+201A><U+00C4><U+00F9> but the fact that nevi readily re-grow after incomplete excision, or in response to UV-irradiation, and can sometimes evolve to melanoma, suggest nevi are not <U+201A><U+00C4><U+00FA>senescent<U+201A><U+00C4><U+00F9> but reversibly growth-arrested. Nevi also spontaneously regress, a process that appears to involve the immune system.nnIn preliminary work, we investigated nevus dynamics in a mouse model of inducible Braf activation, which mimics human nevus formation and also produces melanomas either at low frequency or when additional oncogenic mutations are added (e.g., in Pten). We found that as we activate Braf in more melanocytes, such that nevi become more numerous and closely-spaced, the smaller individual nevi become<U+201A><U+00C4><U+00EE>as if nevi, when close together enough, inhibit each other<U+201A><U+00C4><U+00F4>s growth. Such behavior is predicted by mathematical models of growth control based on feedback through diffusible signaling molecules. Such models achieve robust control when feedback regulates decisions between self-renewal and progression to alternate cell states or fates. Interestingly, when we look closely at the nevi in this model, we see that there are, in fact, two distinct cell types: highly pigmented nevus body cells and a scattered, lightly pigmented melanocyte population that forms a <U+201A><U+00C4><U+00FA>veil<U+201A><U+00C4><U+00F9> around the pigmented cells that had not been observed before. These veil cells are usually not seen unless the melanocyte lineage is fluorescently-labeled with GFP. Single cell RNA-sequencing suggests that these cells likely communicate through ligands and receptors they differentially express.nnIn this project, Ganesan, Lander and their team seek to understand the role of the nevus body and veil cell types in mouse models that produce both nevi and melanoma,nn![fig2](https://casb.uci.edu/files/2018/08/project-2-figure-2.jpg)nFigure 2. (A) BRAF-mutant (Tyrosinase::CreERT2; BraffloxV600E/+) mice are crossed with ROSAmT/mG mice (TCBR) to GFP-label BRAF-mutant melanocytes. (B) Fluorescence emission (confocal and MPM) 3-D imaging of skin of live mice (as in Fig. 1; total depth = 90, 115 and 190<U+0152><U+00BA>m for 1x, 2x, and 3x representative stacks, respectively). Green = GFP; red = td Tomato. (C,D). Continuum modeling, in which cells at an arrested (quiescent) lineage stage feedback on the self-renewal probability of dividing cells. Model snapshots (D) show cell density (see heatmap) as a function of time (T= cell cycles) and location. Top and bottom rows are for low and high seeding densities, respectively, that represent different levels of nevi induction. (E) Single Cell RNA-seq of melanocytic nevi. Control mice (Tyrosinase::CreERT2; ROSAmTmG; TCR) and TCBR mice, as labeled. Left: tSNE clustering of gene expression for individual cells. Right: A portion of the tSNE map, showing contributions of TCR and TCBR mice as well as expression of selected marker genes.nnand to identify both the nature of how growth is controlled in nevi and the means by which melanoma cells escape from it. The goal of the work is to build a solid molecular and cellular framework on which to base clinical decisions about melanoma prevention, detection and treatment. They are addressing these issues by 1) Explaining feedback growth dynamics in melanocytic nevi; 2) Elucidating how melanomas escape growth control mechanisms that arrest nevi; and 3) Revealing how the immune system targets nevi, and how this affects melanoma development.nnThis project integrates multiscale mathematical modeling with experiments in mice using a nevus-forming inducible activated Braf model, and a version of the same model that combines Braf activation with inducible loss of one allele of Pten, leading to the reliable production of both nevi and melanoma tumors. We are developing hypotheses that can explain the spatiotemporal dynamics and spatial statistics of nevus and melanoma development in these models, including potential bifurcations that account for the development of both nevi and melanoma in the same mouse. We are investigating the reasons why some cells escape from growth control, while others do not. We anticipate that this is unlikely to be due to a requirement for inactivation of the other Pten allele, and instead believe that escape may more likely be due to the spatial dynamics of collective feedback. The results are expected to shed light on signaling pathways that could be manipulated to prevent or treat melanoma. Live cell imaging, focused laser ablation, immunohistochemistry, and time-course single cell RNA-sequencing are used to identify potential positive and negative feedback regulators that drive the mathematical models, and experiments are used to test model-based predictions concerning the roles that such molecules play. Finally, an investigation of spontaneous regression, which occurs with both mouse and human nevi, provides clues into how the immune system efficiently recognizes melanocyte overgrowth. Since immunotherapy has recently emerged as a promising therapy for melanoma, this study is expected to reveal whether immunotherapy leverages an existing immune program for eliminating nevi, and if so, how that program is carried out, and how melanomas typically escape from it. Such information should aid in developing new prevention and therapeutic strategies for this devastating disease. The integration of this work with Projects 1 and 3 occurs through the use of scRNA-seq as a tool for hypothesis generation and development and through the application of mathematical models that have similar underlying structures (cell state transitions, proliferation and quiescence, positive and negative feedback), but differ in their context (e.g., spatial in Projects 1 and 2 vs. non-spatial in Project 3).","4":"Evolution","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645135","2":"Understanding the Cellular Origins of Melanoma","3":"Melanoma, a tumor resistant to therapy in late stages, is curable by excision when caught early. Early melanomas can be difficult to distinguish from benign, pigmented <U+201A><U+00C4><U+00FA>moles<U+201A><U+00C4><U+00F9>, i.e. melanocytic nevi; this leads to unnecessary excision of many normal nevi while early melanomas are often missed. Nevi and melanomas share more than morphological features: Clinical and experimental data show that ~90% of nevi are initiated when melanocytes acquire an activating mutation in the BRAF oncogene, the same oncogenic mutation observed in >60% of melanomas. Yet nevi spontaneously stop growing. This is usually attributed to <U+201A><U+00C4><U+00FA>oncogene-induced senescence,<U+201A><U+00C4><U+00F9> but the fact that nevi readily re-grow after incomplete excision, or in response to UV-irradiation, and can sometimes evolve to melanoma, suggest nevi are not <U+201A><U+00C4><U+00FA>senescent<U+201A><U+00C4><U+00F9> but reversibly growth-arrested. Nevi also spontaneously regress, a process that appears to involve the immune system.nnIn preliminary work, we investigated nevus dynamics in a mouse model of inducible Braf activation, which mimics human nevus formation and also produces melanomas either at low frequency or when additional oncogenic mutations are added (e.g., in Pten). We found that as we activate Braf in more melanocytes, such that nevi become more numerous and closely-spaced, the smaller individual nevi become<U+201A><U+00C4><U+00EE>as if nevi, when close together enough, inhibit each other<U+201A><U+00C4><U+00F4>s growth. Such behavior is predicted by mathematical models of growth control based on feedback through diffusible signaling molecules. Such models achieve robust control when feedback regulates decisions between self-renewal and progression to alternate cell states or fates. Interestingly, when we look closely at the nevi in this model, we see that there are, in fact, two distinct cell types: highly pigmented nevus body cells and a scattered, lightly pigmented melanocyte population that forms a <U+201A><U+00C4><U+00FA>veil<U+201A><U+00C4><U+00F9> around the pigmented cells that had not been observed before. These veil cells are usually not seen unless the melanocyte lineage is fluorescently-labeled with GFP. Single cell RNA-sequencing suggests that these cells likely communicate through ligands and receptors they differentially express.nnIn this project, Ganesan, Lander and their team seek to understand the role of the nevus body and veil cell types in mouse models that produce both nevi and melanoma,nn![fig2](https://casb.uci.edu/files/2018/08/project-2-figure-2.jpg)nFigure 2. (A) BRAF-mutant (Tyrosinase::CreERT2; BraffloxV600E/+) mice are crossed with ROSAmT/mG mice (TCBR) to GFP-label BRAF-mutant melanocytes. (B) Fluorescence emission (confocal and MPM) 3-D imaging of skin of live mice (as in Fig. 1; total depth = 90, 115 and 190<U+0152><U+00BA>m for 1x, 2x, and 3x representative stacks, respectively). Green = GFP; red = td Tomato. (C,D). Continuum modeling, in which cells at an arrested (quiescent) lineage stage feedback on the self-renewal probability of dividing cells. Model snapshots (D) show cell density (see heatmap) as a function of time (T= cell cycles) and location. Top and bottom rows are for low and high seeding densities, respectively, that represent different levels of nevi induction. (E) Single Cell RNA-seq of melanocytic nevi. Control mice (Tyrosinase::CreERT2; ROSAmTmG; TCR) and TCBR mice, as labeled. Left: tSNE clustering of gene expression for individual cells. Right: A portion of the tSNE map, showing contributions of TCR and TCBR mice as well as expression of selected marker genes.nnand to identify both the nature of how growth is controlled in nevi and the means by which melanoma cells escape from it. The goal of the work is to build a solid molecular and cellular framework on which to base clinical decisions about melanoma prevention, detection and treatment. They are addressing these issues by 1) Explaining feedback growth dynamics in melanocytic nevi; 2) Elucidating how melanomas escape growth control mechanisms that arrest nevi; and 3) Revealing how the immune system targets nevi, and how this affects melanoma development.nnThis project integrates multiscale mathematical modeling with experiments in mice using a nevus-forming inducible activated Braf model, and a version of the same model that combines Braf activation with inducible loss of one allele of Pten, leading to the reliable production of both nevi and melanoma tumors. We are developing hypotheses that can explain the spatiotemporal dynamics and spatial statistics of nevus and melanoma development in these models, including potential bifurcations that account for the development of both nevi and melanoma in the same mouse. We are investigating the reasons why some cells escape from growth control, while others do not. We anticipate that this is unlikely to be due to a requirement for inactivation of the other Pten allele, and instead believe that escape may more likely be due to the spatial dynamics of collective feedback. The results are expected to shed light on signaling pathways that could be manipulated to prevent or treat melanoma. Live cell imaging, focused laser ablation, immunohistochemistry, and time-course single cell RNA-sequencing are used to identify potential positive and negative feedback regulators that drive the mathematical models, and experiments are used to test model-based predictions concerning the roles that such molecules play. Finally, an investigation of spontaneous regression, which occurs with both mouse and human nevi, provides clues into how the immune system efficiently recognizes melanocyte overgrowth. Since immunotherapy has recently emerged as a promising therapy for melanoma, this study is expected to reveal whether immunotherapy leverages an existing immune program for eliminating nevi, and if so, how that program is carried out, and how melanomas typically escape from it. Such information should aid in developing new prevention and therapeutic strategies for this devastating disease. The integration of this work with Projects 1 and 3 occurs through the use of scRNA-seq as a tool for hypothesis generation and development and through the application of mathematical models that have similar underlying structures (cell state transitions, proliferation and quiescence, positive and negative feedback), but differ in their context (e.g., spatial in Projects 1 and 2 vs. non-spatial in Project 3).","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645136","2":"Modeling malignant myelopoiesis to increase efficacy of targeted leukemia therapy","3":"Chronic myeloid leukemia (CML), one of the most prevalent of human leukemias, is a natural model of dysregulated granulopoiesis driven by a single genetic abnormality in a hematopoietic stem cell, the BCR-ABL1 gene fusion. Although therapy with tyrosine kinase inhibitors (TKIs) such as imatinib mesylate has dramatically lowered the death rate in CML, lifelong treatment is needed and the associated economic costs are significant. Two major unaddressed questions are to understand the mechanism of primary resistance to TKI therapy (affecting ~10-15% of newly diagnosed CML patients), and to identify strategies to increase the frequency of complete molecular remission (CMR) in patients treated with TKIs and subsequently the rate of treatment-free remission (TFR), which may represent a surrogate for permanent cure of the disease. The scientific premise of this project is that new and clinically relevant insights into the biology of CML and its response to therapy can be gained by a more physiologically accurate mathematical model of the disease.nnWhile mathematical models of CML have been developed by several groups, these models tend to be highly simplified and largely omit feedback interactions among the different hematopoietic components. These models are designed to fit clinical data sets of the response of patient populations to TKI therapy but unfortunately, they have not proven useful for understanding primary TKI resistance or for predicting TFR. In preliminary work, we found that nonlinear models that incorporate feedback are more robust, have a better fit to alternative patterns of patient response than simple linear models used previously, and allow predictions about the effects of interventions affecting parameters (such as cell cycle status) subject to feedback mechanisms on the response to TKI therapy. Preliminary analyses from prototype feedback models have already raised two provocative hypotheses about CML. The first is that the initial response to TKI therapy may depend on the relative size of the leukemic stem cell clone, which will be analyzed by TKI treatment of mice engrafted with different levels of BCR-ABL1+ stem cells. The second is that interventions that increase leukemic stem cell cycling may sensitize this population to killing by TKIs.nnIn this project, Van Etten and his team seek to develop improved mathematical models of chronic phase CML and the response to TKI therapy, to validate these models using data from a binary transgenic mouse model of CML and from human CML patients, and to utilize the models to test several hypotheses about the response of CML to therapy and to predict strategies for improving the treatment-free remission rate in CML. We address these issues by 1) Developing data-driven, dynamic models of CML hematopoiesis incorporating feedback control; 2) Measuring granulocytopoiesis parameters in a CML mouse model and in human CML patients; 3) Testing model-driven hypotheses about the response of CML to therapy and informing strategies for improving the treatment-free remission rate in CML.nn![fig3](https://casb.uci.edu/files/2018/08/project-3-figure-3.jpg)nFigure 3. (A) Illustrative nonlinear feedback models of hematopoiesis. The red box indicates the model used in (B). (B) Increased leukemic stem cell (LSC) cycling predicts faster LSC decline on TKI therapy. The results correspond to different LSC cycling parameters applied (expressed as ratio of LSC to multipotential progenitor (MPP) cycling rate). Note the increasing negative slope of the second linear phase with increased cycling. (C,D) Selective decrement of HSC compartment increases MPP proliferation. Mice were irradiated (50 cGy), injected 24h post-radiation with BrdU and analyzed 12h later. (C) 50 cGy irradiation significantly (P=0.018) decreased the size (%LSK) of the HSC compartment (right panel) at 36h without a significant effect on the MPP compartment (left panel). (D) Reduction in HSC pool by low-dose radiation dramatically increases proliferation of the MPP compartment, supporting the existence of a negative feedback loop in the model above. (E) t-SNE analysis of scRNA-seq data from the MPP population isolated from mice with BCR-ABL1-induced CML shows eight separate subpopulations. (F) Expression of sorted lineage markers mapped on the t-SNE plot from (E). (G) Expression of GFP (marking leukemic MPP) and MPP/HSC markers mapped onto the t-SNE plot from (E).nnMachine-based automated model selection methods are being utilized to arrive at a mathematical model that maintains appropriate stability and homeostasis, responds physiologically to stress and depletion of different cell compartments, and conforms to the limited existing qualitative data on CML hematopoiesis derived from mouse models and patient studies. To validate and inform potential models, binary/conditional BCR-ABL1 transgenic donor mice are being used to generate mixed BM chimeras via transplantation of high doses of unfractionated marrow cells without use of conditioning radiation. Recipients bearing a clone of BCR-ABL1+ cells have leukemia induced by withdrawal of doxycycline, leukemic mice are treated with BrdU or subjected to short-term stable isotope labeling with D2-glucose, marrow and spleen stem and progenitor compartments isolated by flow cytometry, and cell cycle and kinetic parameters estimated to inform the mathematical models. Single cell transcriptome profiling is used to investigate the heterogeneity of the MPP compartment and to discover potential regulatory mechanisms mediated by cytokine/receptor interactions. Feedback relationships are tested via direct in vivo manipulation using depleting monoclonal antibodies and through a novel mouse that targets metronidazole cytotoxicity to specific cell compartments. Parallel studies of human CML progenitor flux will be carried out through a clinical protocol of short-term D2-glucose labeling in patients presenting with suspected CML prior to diagnostic BM biopsy. The response to TKI therapy is also being analyzed. The integration of this work with Projects 1 and 2 occurs through the use of scRNA-seq as a tool for hypothesis generation and development and through the application of nonlinear mathematical models that have similar underlying structures (cell state transitions, proliferation and quiescence, positive and negative feedback), although the models in Project 3 are non-spatial.","4":"Heterogeneity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645136","2":"Modeling malignant myelopoiesis to increase efficacy of targeted leukemia therapy","3":"Chronic myeloid leukemia (CML), one of the most prevalent of human leukemias, is a natural model of dysregulated granulopoiesis driven by a single genetic abnormality in a hematopoietic stem cell, the BCR-ABL1 gene fusion. Although therapy with tyrosine kinase inhibitors (TKIs) such as imatinib mesylate has dramatically lowered the death rate in CML, lifelong treatment is needed and the associated economic costs are significant. Two major unaddressed questions are to understand the mechanism of primary resistance to TKI therapy (affecting ~10-15% of newly diagnosed CML patients), and to identify strategies to increase the frequency of complete molecular remission (CMR) in patients treated with TKIs and subsequently the rate of treatment-free remission (TFR), which may represent a surrogate for permanent cure of the disease. The scientific premise of this project is that new and clinically relevant insights into the biology of CML and its response to therapy can be gained by a more physiologically accurate mathematical model of the disease.nnWhile mathematical models of CML have been developed by several groups, these models tend to be highly simplified and largely omit feedback interactions among the different hematopoietic components. These models are designed to fit clinical data sets of the response of patient populations to TKI therapy but unfortunately, they have not proven useful for understanding primary TKI resistance or for predicting TFR. In preliminary work, we found that nonlinear models that incorporate feedback are more robust, have a better fit to alternative patterns of patient response than simple linear models used previously, and allow predictions about the effects of interventions affecting parameters (such as cell cycle status) subject to feedback mechanisms on the response to TKI therapy. Preliminary analyses from prototype feedback models have already raised two provocative hypotheses about CML. The first is that the initial response to TKI therapy may depend on the relative size of the leukemic stem cell clone, which will be analyzed by TKI treatment of mice engrafted with different levels of BCR-ABL1+ stem cells. The second is that interventions that increase leukemic stem cell cycling may sensitize this population to killing by TKIs.nnIn this project, Van Etten and his team seek to develop improved mathematical models of chronic phase CML and the response to TKI therapy, to validate these models using data from a binary transgenic mouse model of CML and from human CML patients, and to utilize the models to test several hypotheses about the response of CML to therapy and to predict strategies for improving the treatment-free remission rate in CML. We address these issues by 1) Developing data-driven, dynamic models of CML hematopoiesis incorporating feedback control; 2) Measuring granulocytopoiesis parameters in a CML mouse model and in human CML patients; 3) Testing model-driven hypotheses about the response of CML to therapy and informing strategies for improving the treatment-free remission rate in CML.nn![fig3](https://casb.uci.edu/files/2018/08/project-3-figure-3.jpg)nFigure 3. (A) Illustrative nonlinear feedback models of hematopoiesis. The red box indicates the model used in (B). (B) Increased leukemic stem cell (LSC) cycling predicts faster LSC decline on TKI therapy. The results correspond to different LSC cycling parameters applied (expressed as ratio of LSC to multipotential progenitor (MPP) cycling rate). Note the increasing negative slope of the second linear phase with increased cycling. (C,D) Selective decrement of HSC compartment increases MPP proliferation. Mice were irradiated (50 cGy), injected 24h post-radiation with BrdU and analyzed 12h later. (C) 50 cGy irradiation significantly (P=0.018) decreased the size (%LSK) of the HSC compartment (right panel) at 36h without a significant effect on the MPP compartment (left panel). (D) Reduction in HSC pool by low-dose radiation dramatically increases proliferation of the MPP compartment, supporting the existence of a negative feedback loop in the model above. (E) t-SNE analysis of scRNA-seq data from the MPP population isolated from mice with BCR-ABL1-induced CML shows eight separate subpopulations. (F) Expression of sorted lineage markers mapped on the t-SNE plot from (E). (G) Expression of GFP (marking leukemic MPP) and MPP/HSC markers mapped onto the t-SNE plot from (E).nnMachine-based automated model selection methods are being utilized to arrive at a mathematical model that maintains appropriate stability and homeostasis, responds physiologically to stress and depletion of different cell compartments, and conforms to the limited existing qualitative data on CML hematopoiesis derived from mouse models and patient studies. To validate and inform potential models, binary/conditional BCR-ABL1 transgenic donor mice are being used to generate mixed BM chimeras via transplantation of high doses of unfractionated marrow cells without use of conditioning radiation. Recipients bearing a clone of BCR-ABL1+ cells have leukemia induced by withdrawal of doxycycline, leukemic mice are treated with BrdU or subjected to short-term stable isotope labeling with D2-glucose, marrow and spleen stem and progenitor compartments isolated by flow cytometry, and cell cycle and kinetic parameters estimated to inform the mathematical models. Single cell transcriptome profiling is used to investigate the heterogeneity of the MPP compartment and to discover potential regulatory mechanisms mediated by cytokine/receptor interactions. Feedback relationships are tested via direct in vivo manipulation using depleting monoclonal antibodies and through a novel mouse that targets metronidazole cytotoxicity to specific cell compartments. Parallel studies of human CML progenitor flux will be carried out through a clinical protocol of short-term D2-glucose labeling in patients presenting with suspected CML prior to diagnostic BM biopsy. The response to TKI therapy is also being analyzed. The integration of this work with Projects 1 and 2 occurs through the use of scRNA-seq as a tool for hypothesis generation and development and through the application of nonlinear mathematical models that have similar underlying structures (cell state transitions, proliferation and quiescence, positive and negative feedback), although the models in Project 3 are non-spatial.","4":"Evolution","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645136","2":"Modeling malignant myelopoiesis to increase efficacy of targeted leukemia therapy","3":"Chronic myeloid leukemia (CML), one of the most prevalent of human leukemias, is a natural model of dysregulated granulopoiesis driven by a single genetic abnormality in a hematopoietic stem cell, the BCR-ABL1 gene fusion. Although therapy with tyrosine kinase inhibitors (TKIs) such as imatinib mesylate has dramatically lowered the death rate in CML, lifelong treatment is needed and the associated economic costs are significant. Two major unaddressed questions are to understand the mechanism of primary resistance to TKI therapy (affecting ~10-15% of newly diagnosed CML patients), and to identify strategies to increase the frequency of complete molecular remission (CMR) in patients treated with TKIs and subsequently the rate of treatment-free remission (TFR), which may represent a surrogate for permanent cure of the disease. The scientific premise of this project is that new and clinically relevant insights into the biology of CML and its response to therapy can be gained by a more physiologically accurate mathematical model of the disease.nnWhile mathematical models of CML have been developed by several groups, these models tend to be highly simplified and largely omit feedback interactions among the different hematopoietic components. These models are designed to fit clinical data sets of the response of patient populations to TKI therapy but unfortunately, they have not proven useful for understanding primary TKI resistance or for predicting TFR. In preliminary work, we found that nonlinear models that incorporate feedback are more robust, have a better fit to alternative patterns of patient response than simple linear models used previously, and allow predictions about the effects of interventions affecting parameters (such as cell cycle status) subject to feedback mechanisms on the response to TKI therapy. Preliminary analyses from prototype feedback models have already raised two provocative hypotheses about CML. The first is that the initial response to TKI therapy may depend on the relative size of the leukemic stem cell clone, which will be analyzed by TKI treatment of mice engrafted with different levels of BCR-ABL1+ stem cells. The second is that interventions that increase leukemic stem cell cycling may sensitize this population to killing by TKIs.nnIn this project, Van Etten and his team seek to develop improved mathematical models of chronic phase CML and the response to TKI therapy, to validate these models using data from a binary transgenic mouse model of CML and from human CML patients, and to utilize the models to test several hypotheses about the response of CML to therapy and to predict strategies for improving the treatment-free remission rate in CML. We address these issues by 1) Developing data-driven, dynamic models of CML hematopoiesis incorporating feedback control; 2) Measuring granulocytopoiesis parameters in a CML mouse model and in human CML patients; 3) Testing model-driven hypotheses about the response of CML to therapy and informing strategies for improving the treatment-free remission rate in CML.nn![fig3](https://casb.uci.edu/files/2018/08/project-3-figure-3.jpg)nFigure 3. (A) Illustrative nonlinear feedback models of hematopoiesis. The red box indicates the model used in (B). (B) Increased leukemic stem cell (LSC) cycling predicts faster LSC decline on TKI therapy. The results correspond to different LSC cycling parameters applied (expressed as ratio of LSC to multipotential progenitor (MPP) cycling rate). Note the increasing negative slope of the second linear phase with increased cycling. (C,D) Selective decrement of HSC compartment increases MPP proliferation. Mice were irradiated (50 cGy), injected 24h post-radiation with BrdU and analyzed 12h later. (C) 50 cGy irradiation significantly (P=0.018) decreased the size (%LSK) of the HSC compartment (right panel) at 36h without a significant effect on the MPP compartment (left panel). (D) Reduction in HSC pool by low-dose radiation dramatically increases proliferation of the MPP compartment, supporting the existence of a negative feedback loop in the model above. (E) t-SNE analysis of scRNA-seq data from the MPP population isolated from mice with BCR-ABL1-induced CML shows eight separate subpopulations. (F) Expression of sorted lineage markers mapped on the t-SNE plot from (E). (G) Expression of GFP (marking leukemic MPP) and MPP/HSC markers mapped onto the t-SNE plot from (E).nnMachine-based automated model selection methods are being utilized to arrive at a mathematical model that maintains appropriate stability and homeostasis, responds physiologically to stress and depletion of different cell compartments, and conforms to the limited existing qualitative data on CML hematopoiesis derived from mouse models and patient studies. To validate and inform potential models, binary/conditional BCR-ABL1 transgenic donor mice are being used to generate mixed BM chimeras via transplantation of high doses of unfractionated marrow cells without use of conditioning radiation. Recipients bearing a clone of BCR-ABL1+ cells have leukemia induced by withdrawal of doxycycline, leukemic mice are treated with BrdU or subjected to short-term stable isotope labeling with D2-glucose, marrow and spleen stem and progenitor compartments isolated by flow cytometry, and cell cycle and kinetic parameters estimated to inform the mathematical models. Single cell transcriptome profiling is used to investigate the heterogeneity of the MPP compartment and to discover potential regulatory mechanisms mediated by cytokine/receptor interactions. Feedback relationships are tested via direct in vivo manipulation using depleting monoclonal antibodies and through a novel mouse that targets metronidazole cytotoxicity to specific cell compartments. Parallel studies of human CML progenitor flux will be carried out through a clinical protocol of short-term D2-glucose labeling in patients presenting with suspected CML prior to diagnostic BM biopsy. The response to TKI therapy is also being analyzed. The integration of this work with Projects 1 and 2 occurs through the use of scRNA-seq as a tool for hypothesis generation and development and through the application of nonlinear mathematical models that have similar underlying structures (cell state transitions, proliferation and quiescence, positive and negative feedback), although the models in Project 3 are non-spatial.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645137","2":"Single Cell Analysis Core","3":"This core provides technical, bioinformatic, and training support for the Center. The goal of the Single Cell Analysis Core technical support is to make cost-effective high-throughput analysis of single cells optimal for and accessible to each of the three Projects. Technical support consists of providing staff and instrument infrastructure, as well as advising on design of experimental strategies, facilitating sharing of protocols for process development; providing single-cell services including microscopy, protein localization, cell sorting, library production, and sequencing; and working with investigators to innovate in these technologies.","4":"Heterogeneity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645137","2":"Single Cell Analysis Core","3":"This core provides technical, bioinformatic, and training support for the Center. The goal of the Single Cell Analysis Core technical support is to make cost-effective high-throughput analysis of single cells optimal for and accessible to each of the three Projects. Technical support consists of providing staff and instrument infrastructure, as well as advising on design of experimental strategies, facilitating sharing of protocols for process development; providing single-cell services including microscopy, protein localization, cell sorting, library production, and sequencing; and working with investigators to innovate in these technologies.","4":"Evolution","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645137","2":"Single Cell Analysis Core","3":"This core provides technical, bioinformatic, and training support for the Center. The goal of the Single Cell Analysis Core technical support is to make cost-effective high-throughput analysis of single cells optimal for and accessible to each of the three Projects. Technical support consists of providing staff and instrument infrastructure, as well as advising on design of experimental strategies, facilitating sharing of protocols for process development; providing single-cell services including microscopy, protein localization, cell sorting, library production, and sequencing; and working with investigators to innovate in these technologies.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645138","2":"Administrative Core","3":"The Administrative Core (AC) provides the administrative, communication and oversight needs for the three projects and the single cell analysis and outreach cores. The AC defines, approves and reviews membership in the Center and provides logistical support for Center members, including assisting investigators with meeting regulatory hurdles associated with research. In addition, the AC solicits, reviews and administers two types of pilot project grants: one directed at graduate students and postdocs and the other directed at faculty. The AC guides the integration of the Center into the Cancer Systems Biology Consortium by facilitating the sharing of Center resources and member expertise across the Consortium, by participating in the Annual Consortium meeting and by matching Center members with counterparts in the Consortium to foster new collaborations.","4":"Heterogeneity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645138","2":"Administrative Core","3":"The Administrative Core (AC) provides the administrative, communication and oversight needs for the three projects and the single cell analysis and outreach cores. The AC defines, approves and reviews membership in the Center and provides logistical support for Center members, including assisting investigators with meeting regulatory hurdles associated with research. In addition, the AC solicits, reviews and administers two types of pilot project grants: one directed at graduate students and postdocs and the other directed at faculty. The AC guides the integration of the Center into the Cancer Systems Biology Consortium by facilitating the sharing of Center resources and member expertise across the Consortium, by participating in the Annual Consortium meeting and by matching Center members with counterparts in the Consortium to foster new collaborations.","4":"Evolution","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645138","2":"Administrative Core","3":"The Administrative Core (AC) provides the administrative, communication and oversight needs for the three projects and the single cell analysis and outreach cores. The AC defines, approves and reviews membership in the Center and provides logistical support for Center members, including assisting investigators with meeting regulatory hurdles associated with research. In addition, the AC solicits, reviews and administers two types of pilot project grants: one directed at graduate students and postdocs and the other directed at faculty. The AC guides the integration of the Center into the Cancer Systems Biology Consortium by facilitating the sharing of Center resources and member expertise across the Consortium, by participating in the Annual Consortium meeting and by matching Center members with counterparts in the Consortium to foster new collaborations.","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645139","2":"Outreach Core","3":"The Outreach Core of the UCI cancer systems biology center promotes cancer systems biology to the research community, targeting researchers and trainees at all career stages, and disseminates advances and capabilities of cancer systems biology to the cancer research and broader communities. These goals are accomplished through a variety of activities including symposia, seminars, <U+201A><U+00C4><U+00FA>short courses<U+201A><U+00C4><U+00F9>, interest groups, <U+201A><U+00C4><U+00FA>bootcamps<U+201A><U+00C4><U+00F9>, a visiting scientist program, and an annual retreat. Included among the activities of the core are programs aimed at mentoring junior faculty, programs to provide undergraduate and pre-college students with exposure to cancer systems biology research, and activities to increase public awareness of the advances and capabilities of cancer systems biology. The core monitors its effectiveness through periodic evaluation, and coordinates and integrates with activities of the larger NCI Cancer Systems Biology consortium","4":"Heterogeneity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645139","2":"Outreach Core","3":"The Outreach Core of the UCI cancer systems biology center promotes cancer systems biology to the research community, targeting researchers and trainees at all career stages, and disseminates advances and capabilities of cancer systems biology to the cancer research and broader communities. These goals are accomplished through a variety of activities including symposia, seminars, <U+201A><U+00C4><U+00FA>short courses<U+201A><U+00C4><U+00F9>, interest groups, <U+201A><U+00C4><U+00FA>bootcamps<U+201A><U+00C4><U+00F9>, a visiting scientist program, and an annual retreat. Included among the activities of the core are programs aimed at mentoring junior faculty, programs to provide undergraduate and pre-college students with exposure to cancer systems biology research, and activities to increase public awareness of the advances and capabilities of cancer systems biology. The core monitors its effectiveness through periodic evaluation, and coordinates and integrates with activities of the larger NCI Cancer Systems Biology consortium","4":"Evolution","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645139","2":"Outreach Core","3":"The Outreach Core of the UCI cancer systems biology center promotes cancer systems biology to the research community, targeting researchers and trainees at all career stages, and disseminates advances and capabilities of cancer systems biology to the cancer research and broader communities. These goals are accomplished through a variety of activities including symposia, seminars, <U+201A><U+00C4><U+00FA>short courses<U+201A><U+00C4><U+00F9>, interest groups, <U+201A><U+00C4><U+00FA>bootcamps<U+201A><U+00C4><U+00F9>, a visiting scientist program, and an annual retreat. Included among the activities of the core are programs aimed at mentoring junior faculty, programs to provide undergraduate and pre-college students with exposure to cancer systems biology research, and activities to increase public awareness of the advances and capabilities of cancer systems biology. The core monitors its effectiveness through periodic evaluation, and coordinates and integrates with activities of the larger NCI Cancer Systems Biology consortium","4":"Drug Resistance/Sensitivity","5":"Cancer Systems Biology at UC Irvine","6":"CSBC","7":"U54"},{"1":"syn21645140","2":"Organismal Evolution and Cancer Defenses","3":"Cancer has been an important selective pressure for organisms and a great deal of variation in cancer rates exist across species. Why do species vary in their susceptibility to cancer and what mechanisms are responsible for this variation? Life history theory (LHT) may provide an explanation for these differences. LHT is an evolutionary and ecological approach that focuses on organism-level tradeoffs between growth, maintenance and reproduction. Organisms can either live fast and die young, or live slowly and die old, or anywhere in between. Cancer suppression is an important component of building a robust body that can live into old age. Our previous models show that lower levels of cancer defense can be favored by natural selection when there are tradeoffs with traits such as reproductive competitiveness, body size, and longevity. Here we use real life history parameters to predict cancer rates across animals and test the predictions with a highly curated comparative oncology dataset, including animals from major orders of reptiles, birds, fish, amphibians and mammals. Additionally, we will analyze the genomes of mammalian species to identify patterns of selection and mutation in tumor suppressor genes. Our approach combines mathematical modeling, comparative techniques, evolutionary theory, genomic sequencing, molecular evolution, and phylogenetics to study cancer suppression. We are particularly interested in identifying cancer resistant species, discovering how they prevent cancer, and translating that into better cancer prevention for humans.nn![img2](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_Elephant-mouse.jpg)nLife history strategies fall on a continuum from fast to slow, and organisms with a fast life history strategy allocate less energy to somatic maintenance (i.e. cancer defense), while slow life history organism have higher investment in cancer defenses, such as DNA damage sensitivitynImpact: More cancers could be prevented if we better understand the evolution of cancer defense mechanisms and other biological parameters that make humans more susceptible to cancer than other species. We can leverage these findings to develop novel tools for prevention and clinical management of human cancers. Comparative oncology offers a unique opportunity to see how evolution has, over millions of years, led to both cancer defense mechanisms and why certain forms of susceptibility remain.","4":"Evolution","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645140","2":"Organismal Evolution and Cancer Defenses","3":"Cancer has been an important selective pressure for organisms and a great deal of variation in cancer rates exist across species. Why do species vary in their susceptibility to cancer and what mechanisms are responsible for this variation? Life history theory (LHT) may provide an explanation for these differences. LHT is an evolutionary and ecological approach that focuses on organism-level tradeoffs between growth, maintenance and reproduction. Organisms can either live fast and die young, or live slowly and die old, or anywhere in between. Cancer suppression is an important component of building a robust body that can live into old age. Our previous models show that lower levels of cancer defense can be favored by natural selection when there are tradeoffs with traits such as reproductive competitiveness, body size, and longevity. Here we use real life history parameters to predict cancer rates across animals and test the predictions with a highly curated comparative oncology dataset, including animals from major orders of reptiles, birds, fish, amphibians and mammals. Additionally, we will analyze the genomes of mammalian species to identify patterns of selection and mutation in tumor suppressor genes. Our approach combines mathematical modeling, comparative techniques, evolutionary theory, genomic sequencing, molecular evolution, and phylogenetics to study cancer suppression. We are particularly interested in identifying cancer resistant species, discovering how they prevent cancer, and translating that into better cancer prevention for humans.nn![img2](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_Elephant-mouse.jpg)nLife history strategies fall on a continuum from fast to slow, and organisms with a fast life history strategy allocate less energy to somatic maintenance (i.e. cancer defense), while slow life history organism have higher investment in cancer defenses, such as DNA damage sensitivitynImpact: More cancers could be prevented if we better understand the evolution of cancer defense mechanisms and other biological parameters that make humans more susceptible to cancer than other species. We can leverage these findings to develop novel tools for prevention and clinical management of human cancers. Comparative oncology offers a unique opportunity to see how evolution has, over millions of years, led to both cancer defense mechanisms and why certain forms of susceptibility remain.","4":"Heterogeneity","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645140","2":"Organismal Evolution and Cancer Defenses","3":"Cancer has been an important selective pressure for organisms and a great deal of variation in cancer rates exist across species. Why do species vary in their susceptibility to cancer and what mechanisms are responsible for this variation? Life history theory (LHT) may provide an explanation for these differences. LHT is an evolutionary and ecological approach that focuses on organism-level tradeoffs between growth, maintenance and reproduction. Organisms can either live fast and die young, or live slowly and die old, or anywhere in between. Cancer suppression is an important component of building a robust body that can live into old age. Our previous models show that lower levels of cancer defense can be favored by natural selection when there are tradeoffs with traits such as reproductive competitiveness, body size, and longevity. Here we use real life history parameters to predict cancer rates across animals and test the predictions with a highly curated comparative oncology dataset, including animals from major orders of reptiles, birds, fish, amphibians and mammals. Additionally, we will analyze the genomes of mammalian species to identify patterns of selection and mutation in tumor suppressor genes. Our approach combines mathematical modeling, comparative techniques, evolutionary theory, genomic sequencing, molecular evolution, and phylogenetics to study cancer suppression. We are particularly interested in identifying cancer resistant species, discovering how they prevent cancer, and translating that into better cancer prevention for humans.nn![img2](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_Elephant-mouse.jpg)nLife history strategies fall on a continuum from fast to slow, and organisms with a fast life history strategy allocate less energy to somatic maintenance (i.e. cancer defense), while slow life history organism have higher investment in cancer defenses, such as DNA damage sensitivitynImpact: More cancers could be prevented if we better understand the evolution of cancer defense mechanisms and other biological parameters that make humans more susceptible to cancer than other species. We can leverage these findings to develop novel tools for prevention and clinical management of human cancers. Comparative oncology offers a unique opportunity to see how evolution has, over millions of years, led to both cancer defense mechanisms and why certain forms of susceptibility remain.","4":"Epigenetics","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645140","2":"Organismal Evolution and Cancer Defenses","3":"Cancer has been an important selective pressure for organisms and a great deal of variation in cancer rates exist across species. Why do species vary in their susceptibility to cancer and what mechanisms are responsible for this variation? Life history theory (LHT) may provide an explanation for these differences. LHT is an evolutionary and ecological approach that focuses on organism-level tradeoffs between growth, maintenance and reproduction. Organisms can either live fast and die young, or live slowly and die old, or anywhere in between. Cancer suppression is an important component of building a robust body that can live into old age. Our previous models show that lower levels of cancer defense can be favored by natural selection when there are tradeoffs with traits such as reproductive competitiveness, body size, and longevity. Here we use real life history parameters to predict cancer rates across animals and test the predictions with a highly curated comparative oncology dataset, including animals from major orders of reptiles, birds, fish, amphibians and mammals. Additionally, we will analyze the genomes of mammalian species to identify patterns of selection and mutation in tumor suppressor genes. Our approach combines mathematical modeling, comparative techniques, evolutionary theory, genomic sequencing, molecular evolution, and phylogenetics to study cancer suppression. We are particularly interested in identifying cancer resistant species, discovering how they prevent cancer, and translating that into better cancer prevention for humans.nn![img2](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_Elephant-mouse.jpg)nLife history strategies fall on a continuum from fast to slow, and organisms with a fast life history strategy allocate less energy to somatic maintenance (i.e. cancer defense), while slow life history organism have higher investment in cancer defenses, such as DNA damage sensitivitynImpact: More cancers could be prevented if we better understand the evolution of cancer defense mechanisms and other biological parameters that make humans more susceptible to cancer than other species. We can leverage these findings to develop novel tools for prevention and clinical management of human cancers. Comparative oncology offers a unique opportunity to see how evolution has, over millions of years, led to both cancer defense mechanisms and why certain forms of susceptibility remain.","4":"Microenvironment","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645141","2":"Somatic Cell Evolution in Small Human Replicative Units","3":"![img3](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_HumanCrypts.jpg)nThis Project will study somatic cell evolution in distinct, small human replicative units (intestinal crypts and tumor glands). The compartmentalization of cells into small replicative units can modify evolution because selection and drift (random cell turnover) is limited to immediately adjacent cells. The advantages of analyzing small replicative units are that experimentally they large enough to measure with conventional methods yet small enough to simulate in detail. Characterizing somatic cell evolution in replicative units can lead to better understanding of tumor evolution because selection or drift first occurs at the cell-cell level.nnWe will sample multiple colon crypts from different aged individuals and multiple tumor glands from opposite sides of 20 colorectal tumors (adenomas and CRCs). Crypts from different species will also be compared with the human data. For each crypt or gland we will document genetic alterations (whole genome sequencing), epigenetic alterations (ATAC-seq), and expression. Combining epigenetic and genetic evolution is important because phenotypic plasticity can mimic clonal evolution when epigenetic modulation allows a single genome to express multiple phenotypes. This data will be modeled through simulations to better understand somatic cell proliferation (division and death) within small replicative units, specifically to determine whether selection or neutral drift are more common during normal human aging and tumor progression.nnThis Project will also compare the evolutionary biology of fibroblasts. We will test the predictions of Project 1 for the mutation rates, proliferation rates, apoptosis rates, DNA damage response, and stress responses of early passage, primary fibroblasts from species with a wide variety of life history traits. We will also test for functional differences in cancer associated pathways that have evidence of selection in specific species identified by Project 1.","4":"Evolution","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645141","2":"Somatic Cell Evolution in Small Human Replicative Units","3":"![img3](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_HumanCrypts.jpg)nThis Project will study somatic cell evolution in distinct, small human replicative units (intestinal crypts and tumor glands). The compartmentalization of cells into small replicative units can modify evolution because selection and drift (random cell turnover) is limited to immediately adjacent cells. The advantages of analyzing small replicative units are that experimentally they large enough to measure with conventional methods yet small enough to simulate in detail. Characterizing somatic cell evolution in replicative units can lead to better understanding of tumor evolution because selection or drift first occurs at the cell-cell level.nnWe will sample multiple colon crypts from different aged individuals and multiple tumor glands from opposite sides of 20 colorectal tumors (adenomas and CRCs). Crypts from different species will also be compared with the human data. For each crypt or gland we will document genetic alterations (whole genome sequencing), epigenetic alterations (ATAC-seq), and expression. Combining epigenetic and genetic evolution is important because phenotypic plasticity can mimic clonal evolution when epigenetic modulation allows a single genome to express multiple phenotypes. This data will be modeled through simulations to better understand somatic cell proliferation (division and death) within small replicative units, specifically to determine whether selection or neutral drift are more common during normal human aging and tumor progression.nnThis Project will also compare the evolutionary biology of fibroblasts. We will test the predictions of Project 1 for the mutation rates, proliferation rates, apoptosis rates, DNA damage response, and stress responses of early passage, primary fibroblasts from species with a wide variety of life history traits. We will also test for functional differences in cancer associated pathways that have evidence of selection in specific species identified by Project 1.","4":"Heterogeneity","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645141","2":"Somatic Cell Evolution in Small Human Replicative Units","3":"![img3](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_HumanCrypts.jpg)nThis Project will study somatic cell evolution in distinct, small human replicative units (intestinal crypts and tumor glands). The compartmentalization of cells into small replicative units can modify evolution because selection and drift (random cell turnover) is limited to immediately adjacent cells. The advantages of analyzing small replicative units are that experimentally they large enough to measure with conventional methods yet small enough to simulate in detail. Characterizing somatic cell evolution in replicative units can lead to better understanding of tumor evolution because selection or drift first occurs at the cell-cell level.nnWe will sample multiple colon crypts from different aged individuals and multiple tumor glands from opposite sides of 20 colorectal tumors (adenomas and CRCs). Crypts from different species will also be compared with the human data. For each crypt or gland we will document genetic alterations (whole genome sequencing), epigenetic alterations (ATAC-seq), and expression. Combining epigenetic and genetic evolution is important because phenotypic plasticity can mimic clonal evolution when epigenetic modulation allows a single genome to express multiple phenotypes. This data will be modeled through simulations to better understand somatic cell proliferation (division and death) within small replicative units, specifically to determine whether selection or neutral drift are more common during normal human aging and tumor progression.nnThis Project will also compare the evolutionary biology of fibroblasts. We will test the predictions of Project 1 for the mutation rates, proliferation rates, apoptosis rates, DNA damage response, and stress responses of early passage, primary fibroblasts from species with a wide variety of life history traits. We will also test for functional differences in cancer associated pathways that have evidence of selection in specific species identified by Project 1.","4":"Epigenetics","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645141","2":"Somatic Cell Evolution in Small Human Replicative Units","3":"![img3](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_HumanCrypts.jpg)nThis Project will study somatic cell evolution in distinct, small human replicative units (intestinal crypts and tumor glands). The compartmentalization of cells into small replicative units can modify evolution because selection and drift (random cell turnover) is limited to immediately adjacent cells. The advantages of analyzing small replicative units are that experimentally they large enough to measure with conventional methods yet small enough to simulate in detail. Characterizing somatic cell evolution in replicative units can lead to better understanding of tumor evolution because selection or drift first occurs at the cell-cell level.nnWe will sample multiple colon crypts from different aged individuals and multiple tumor glands from opposite sides of 20 colorectal tumors (adenomas and CRCs). Crypts from different species will also be compared with the human data. For each crypt or gland we will document genetic alterations (whole genome sequencing), epigenetic alterations (ATAC-seq), and expression. Combining epigenetic and genetic evolution is important because phenotypic plasticity can mimic clonal evolution when epigenetic modulation allows a single genome to express multiple phenotypes. This data will be modeled through simulations to better understand somatic cell proliferation (division and death) within small replicative units, specifically to determine whether selection or neutral drift are more common during normal human aging and tumor progression.nnThis Project will also compare the evolutionary biology of fibroblasts. We will test the predictions of Project 1 for the mutation rates, proliferation rates, apoptosis rates, DNA damage response, and stress responses of early passage, primary fibroblasts from species with a wide variety of life history traits. We will also test for functional differences in cancer associated pathways that have evidence of selection in specific species identified by Project 1.","4":"Microenvironment","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645142","2":"Neoplastic Cell Evolution","3":"![img4](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_flowchart.jpg)nCancer is an evolutionary process where a single cell grows into a visible tumor after it has acquired multiple driver alterations. In this Project, we will develop predictive biomarkers for colorectal cancer (CRC) outcomes. The innovation is that the biomarkers will be direct measures of evolution. Such evolution-based biomarkers also provide mechanistic understanding for what aspects of evolution most impact survival. To fully characterize tumor evolution, it is necessary to measure both how tumor cells evolve and the host ecology.nnIn Aim 1, mutations detected by whole exome sequencing of CRC cohorts with long-term follow-up will be classified as public (clonal) and private (subclonal). CRCs will then be subclassified with a newly developed algorithm that can infer selection (positive, neutral, negative) based on private mutation frequencies, where selection preferentially increases (positive) or decreases (negative) subclone subsets. In Aim 2, we will scan microscope sections from the above tumors, using a unique automated platform that can identify cells and quantify tumor microenvironments with respect to lymphocytes and stromal cells. To determine if host ecological heterogeneity reflects responses to specific tumor subclones, we will overlay private mutation distributions on the same microscope slides.nWe will combine tumor evolution and the host reaction into a single evolution-ecology (Evo-Eco) index that summarizes the underlying evolutionary struggle. For example, patients with aggressive tumors (positive selection) and supportive environments are likely to have poorer outcomes relative to patients with tumors under negative selection and repressive environments. We will validate our Evo-Eco index on another cohort of CRCs. If successful, these studies will yield improved CRC predictive biomarkers.","4":"Evolution","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645142","2":"Neoplastic Cell Evolution","3":"![img4](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_flowchart.jpg)nCancer is an evolutionary process where a single cell grows into a visible tumor after it has acquired multiple driver alterations. In this Project, we will develop predictive biomarkers for colorectal cancer (CRC) outcomes. The innovation is that the biomarkers will be direct measures of evolution. Such evolution-based biomarkers also provide mechanistic understanding for what aspects of evolution most impact survival. To fully characterize tumor evolution, it is necessary to measure both how tumor cells evolve and the host ecology.nnIn Aim 1, mutations detected by whole exome sequencing of CRC cohorts with long-term follow-up will be classified as public (clonal) and private (subclonal). CRCs will then be subclassified with a newly developed algorithm that can infer selection (positive, neutral, negative) based on private mutation frequencies, where selection preferentially increases (positive) or decreases (negative) subclone subsets. In Aim 2, we will scan microscope sections from the above tumors, using a unique automated platform that can identify cells and quantify tumor microenvironments with respect to lymphocytes and stromal cells. To determine if host ecological heterogeneity reflects responses to specific tumor subclones, we will overlay private mutation distributions on the same microscope slides.nWe will combine tumor evolution and the host reaction into a single evolution-ecology (Evo-Eco) index that summarizes the underlying evolutionary struggle. For example, patients with aggressive tumors (positive selection) and supportive environments are likely to have poorer outcomes relative to patients with tumors under negative selection and repressive environments. We will validate our Evo-Eco index on another cohort of CRCs. If successful, these studies will yield improved CRC predictive biomarkers.","4":"Heterogeneity","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645142","2":"Neoplastic Cell Evolution","3":"![img4](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_flowchart.jpg)nCancer is an evolutionary process where a single cell grows into a visible tumor after it has acquired multiple driver alterations. In this Project, we will develop predictive biomarkers for colorectal cancer (CRC) outcomes. The innovation is that the biomarkers will be direct measures of evolution. Such evolution-based biomarkers also provide mechanistic understanding for what aspects of evolution most impact survival. To fully characterize tumor evolution, it is necessary to measure both how tumor cells evolve and the host ecology.nnIn Aim 1, mutations detected by whole exome sequencing of CRC cohorts with long-term follow-up will be classified as public (clonal) and private (subclonal). CRCs will then be subclassified with a newly developed algorithm that can infer selection (positive, neutral, negative) based on private mutation frequencies, where selection preferentially increases (positive) or decreases (negative) subclone subsets. In Aim 2, we will scan microscope sections from the above tumors, using a unique automated platform that can identify cells and quantify tumor microenvironments with respect to lymphocytes and stromal cells. To determine if host ecological heterogeneity reflects responses to specific tumor subclones, we will overlay private mutation distributions on the same microscope slides.nWe will combine tumor evolution and the host reaction into a single evolution-ecology (Evo-Eco) index that summarizes the underlying evolutionary struggle. For example, patients with aggressive tumors (positive selection) and supportive environments are likely to have poorer outcomes relative to patients with tumors under negative selection and repressive environments. We will validate our Evo-Eco index on another cohort of CRCs. If successful, these studies will yield improved CRC predictive biomarkers.","4":"Epigenetics","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645142","2":"Neoplastic Cell Evolution","3":"![img4](https://csbconsortium.org/wp-content/uploads/2018/06/ASU_flowchart.jpg)nCancer is an evolutionary process where a single cell grows into a visible tumor after it has acquired multiple driver alterations. In this Project, we will develop predictive biomarkers for colorectal cancer (CRC) outcomes. The innovation is that the biomarkers will be direct measures of evolution. Such evolution-based biomarkers also provide mechanistic understanding for what aspects of evolution most impact survival. To fully characterize tumor evolution, it is necessary to measure both how tumor cells evolve and the host ecology.nnIn Aim 1, mutations detected by whole exome sequencing of CRC cohorts with long-term follow-up will be classified as public (clonal) and private (subclonal). CRCs will then be subclassified with a newly developed algorithm that can infer selection (positive, neutral, negative) based on private mutation frequencies, where selection preferentially increases (positive) or decreases (negative) subclone subsets. In Aim 2, we will scan microscope sections from the above tumors, using a unique automated platform that can identify cells and quantify tumor microenvironments with respect to lymphocytes and stromal cells. To determine if host ecological heterogeneity reflects responses to specific tumor subclones, we will overlay private mutation distributions on the same microscope slides.nWe will combine tumor evolution and the host reaction into a single evolution-ecology (Evo-Eco) index that summarizes the underlying evolutionary struggle. For example, patients with aggressive tumors (positive selection) and supportive environments are likely to have poorer outcomes relative to patients with tumors under negative selection and repressive environments. We will validate our Evo-Eco index on another cohort of CRCs. If successful, these studies will yield improved CRC predictive biomarkers.","4":"Microenvironment","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645143","2":"Outreach","3":"The Outreach Unit of the Arizona Cancer and Evolution (ACE) Center will bring together students, researchers, and the general public to consider the evolutionary pathways and ecology of cancer. We have three aims within our Outreach Unit: (1) to integrate and synergize our interdisciplinary team to produce real innovation and ultimately impact the field of cancer research; (2) to connect the Center with the wider Cancer Systems Biology Consortium, other scientists and the public to promote collaboration; (3) to educate the next generation of scientists and communicators in cancer research methods and encourage them to work in integrative teams in order to stimulate new ideas.  We will achieve these aims through a comprehensive program that includes educational courses, online tutorial videos with accompanying monitored discussion boards, seminars, internships and public lectures and also an innovative creative activity <U+201A><U+00C4><U+00EC> a unique, immersive new media exhibit, based on the work of ACE Center researchers, that visualizes the fundamental forces of evolution: mutation, selection and drift in relation to the ecology of cancer cells. This project will explore the intersection of science, art and technology to promote new ways of imagining scientific concepts. It will be displayed in major public galleries and conferences.nnIMPACT: We will stimulate public interest in cancer theory research and educate students, scientists and the public about ACE advances and our drive to understand the nature of cancer and its evolutionary origins.  We will foster research and academic excellence and advance the goals of the National Cancer Institute.","4":"Evolution","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645143","2":"Outreach","3":"The Outreach Unit of the Arizona Cancer and Evolution (ACE) Center will bring together students, researchers, and the general public to consider the evolutionary pathways and ecology of cancer. We have three aims within our Outreach Unit: (1) to integrate and synergize our interdisciplinary team to produce real innovation and ultimately impact the field of cancer research; (2) to connect the Center with the wider Cancer Systems Biology Consortium, other scientists and the public to promote collaboration; (3) to educate the next generation of scientists and communicators in cancer research methods and encourage them to work in integrative teams in order to stimulate new ideas.  We will achieve these aims through a comprehensive program that includes educational courses, online tutorial videos with accompanying monitored discussion boards, seminars, internships and public lectures and also an innovative creative activity <U+201A><U+00C4><U+00EC> a unique, immersive new media exhibit, based on the work of ACE Center researchers, that visualizes the fundamental forces of evolution: mutation, selection and drift in relation to the ecology of cancer cells. This project will explore the intersection of science, art and technology to promote new ways of imagining scientific concepts. It will be displayed in major public galleries and conferences.nnIMPACT: We will stimulate public interest in cancer theory research and educate students, scientists and the public about ACE advances and our drive to understand the nature of cancer and its evolutionary origins.  We will foster research and academic excellence and advance the goals of the National Cancer Institute.","4":"Heterogeneity","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645143","2":"Outreach","3":"The Outreach Unit of the Arizona Cancer and Evolution (ACE) Center will bring together students, researchers, and the general public to consider the evolutionary pathways and ecology of cancer. We have three aims within our Outreach Unit: (1) to integrate and synergize our interdisciplinary team to produce real innovation and ultimately impact the field of cancer research; (2) to connect the Center with the wider Cancer Systems Biology Consortium, other scientists and the public to promote collaboration; (3) to educate the next generation of scientists and communicators in cancer research methods and encourage them to work in integrative teams in order to stimulate new ideas.  We will achieve these aims through a comprehensive program that includes educational courses, online tutorial videos with accompanying monitored discussion boards, seminars, internships and public lectures and also an innovative creative activity <U+201A><U+00C4><U+00EC> a unique, immersive new media exhibit, based on the work of ACE Center researchers, that visualizes the fundamental forces of evolution: mutation, selection and drift in relation to the ecology of cancer cells. This project will explore the intersection of science, art and technology to promote new ways of imagining scientific concepts. It will be displayed in major public galleries and conferences.nnIMPACT: We will stimulate public interest in cancer theory research and educate students, scientists and the public about ACE advances and our drive to understand the nature of cancer and its evolutionary origins.  We will foster research and academic excellence and advance the goals of the National Cancer Institute.","4":"Epigenetics","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21645143","2":"Outreach","3":"The Outreach Unit of the Arizona Cancer and Evolution (ACE) Center will bring together students, researchers, and the general public to consider the evolutionary pathways and ecology of cancer. We have three aims within our Outreach Unit: (1) to integrate and synergize our interdisciplinary team to produce real innovation and ultimately impact the field of cancer research; (2) to connect the Center with the wider Cancer Systems Biology Consortium, other scientists and the public to promote collaboration; (3) to educate the next generation of scientists and communicators in cancer research methods and encourage them to work in integrative teams in order to stimulate new ideas.  We will achieve these aims through a comprehensive program that includes educational courses, online tutorial videos with accompanying monitored discussion boards, seminars, internships and public lectures and also an innovative creative activity <U+201A><U+00C4><U+00EC> a unique, immersive new media exhibit, based on the work of ACE Center researchers, that visualizes the fundamental forces of evolution: mutation, selection and drift in relation to the ecology of cancer cells. This project will explore the intersection of science, art and technology to promote new ways of imagining scientific concepts. It will be displayed in major public galleries and conferences.nnIMPACT: We will stimulate public interest in cancer theory research and educate students, scientists and the public about ACE advances and our drive to understand the nature of cancer and its evolutionary origins.  We will foster research and academic excellence and advance the goals of the National Cancer Institute.","4":"Microenvironment","5":"Arizona Cancer and Evolution Center","6":"CSBC","7":"U54"},{"1":"syn21917484","2":"Identification of personalized adaptive response mechanisms in breast cancer by information theory and proteomics","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA"},{"1":"syn21917485","2":"Predictive Modeling of the EGFR-MAPK pathway for Triple Negative Breast Cancer Patients","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA"},{"1":"syn21917486","2":"Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA"},{"1":"syn21917487","2":"Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA"},{"1":"syn21917488","2":"Integrated mathematical and experimental analysis of immune system signaling in breast cancer","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA"},{"1":"syn21917489","2":"Systems analysis of aggressive prostate cancer pathology","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA"},{"1":"syn21917490","2":"Single-cell characterization of tumor and microenvironment coevolution in Peripheral T-cell Lymphomas","3":"NA","4":"NA","5":"NA","6":"NA","7":"NA"}],"options":{"columns":{"min":{},"max":[10],"total":[7]},"rows":{"min":[10],"max":[10],"total":[359]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_formatted_project_df &lt;- merged_project_df %&gt;%
  filter(!is.na(grantName)) %&gt;%
  group_by(projectName, description) %&gt;%
  summarize(grantName = str_c(unique(grantName), collapse = &quot;, &quot;),
            grantType = str_c(unique(grantType), collapse = &quot;, &quot;),
            theme = str_c(unique(theme), collapse = &quot;, &quot;),
            consortium = str_c(unique(consortium), collapse = &quot;, &quot;)) %&gt;%
  ungroup() %&gt;%
  # rowwise() %&gt;% 
  # mutate_at(proj_list_cols, ~ csv_str_to_json(.)) %&gt;%
  # ungroup() %&gt;% 
  distinct()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code># initial table creation (synIDs need to be integers)
# merged_proj_syntable &lt;- merged_formatted_proj_df %&gt;% 
#   mutate_at(vars(contains(&quot;Id&quot;)), ~ str_replace(., &quot;syn&quot;, &quot;&quot;)) %&gt;% 
#   synBuildTable(&quot;Portal - projs Merged&quot;, &quot;syn7080714&quot;, .) %&gt;% 
#   synStore()

# update/overwrite the table
merged_proj_syntable &lt;- merged_formatted_proj_df %&gt;% 
  # mutate(id = projName) %&gt;% 
  update_table(&quot;syn21868602&quot;, .)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
<div id="datasets---merged-table" class="section level2">
<h2>Datasets - merged table</h2>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGJfcHViX2RmIDwtIGdldF90YWJsZV9kZihcInN5bjIxNjUwNTM2XCIsIGNhY2hlID0gRkFMU0UpXG5cbmBgYCJ9 -->
<pre class="r"><code>db_pub_df &lt;- get_table_df(&quot;syn21650536&quot;, cache = FALSE)
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiXG4gWyMjIyMjIyMjIyMjIyMjIyMjIyMjXTEwMC4wMCUgICAxLzEgICBEb25lLi4uICAgIFxuRG93bmxvYWRpbmcgIFsjIyMjIyMjIyMjIyMjIyMjIyMjI10xMDAuMDAlICAgMzYzLjhrQi8zNjMuOGtCICg5OTUuNmtCL3MpIEpvYi0xMTIxMDQ4OTg3OTYxMzQ2OTE3NzUzMzQxODAuY3N2IERvbmUuLi4gICAgXG4ifQ== -->
<pre><code>
 [####################]100.00%   1/1   Done...    
Downloading  [####################]100.00%   363.8kB/363.8kB (995.6kB/s) Job-112104898796134691775334180.csv Done...    </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_dataset_df &lt;- db_dataset_df %&gt;% 
  select(-one_of(property_cols)) %&gt;% 
  rename(datasetId = id, datasetName = fullName, datasetAlias = displayName) %&gt;%
  mutate(datasetName = ifelse(datasetName == &quot;NA&quot;, datasetAlias, datasetName)) %&gt;% 
  left_join(db_description_dataset, by = &quot;datasetId&quot;) %&gt;% 
  left_join(db_link_dataset, by = &quot;datasetId&quot;) %&gt;%
  left_join(db_dataset_pub, by = &quot;datasetId&quot;) %&gt;% 
  left_join(
    db_grant_df %&gt;% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = &quot;grantId&quot;
  ) %&gt;% 
  left_join(db_theme_grant, by = &quot;grantId&quot;) %&gt;% 
  left_join(
    db_theme_df %&gt;% 
      select(themeId = id, theme = displayName),
    by = &quot;themeId&quot;
  ) %&gt;% 
  left_join(
    db_consortium_df %&gt;% 
      select(consortiumId = id, consortium = displayName)
  ) %&gt;% 
  left_join(
    db_pub_df %&gt;% 
      select(publicationId = id, publicationTitle = title, pubMedUrl)
  ) %&gt;% 
  mutate(pubMedId = str_extract(pubMedUrl, &quot;[0-9].*&quot;)) %&gt;%
  mutate_all(~ ifelse(str_detect(., &quot;^NA$&quot;), NA, .)) %&gt;% 
  mutate(externalLink = glue::glue(&quot;[{source}:{datasetAlias}]({url})&quot;)) %&gt;% 
  mutate(pubMedLink = glue::glue(&quot;[{publicationTitle} (PMID:{pubMedId})]({pubMedUrl})&quot;)) %&gt;% 
  mutate(tumorType = &quot;&quot;, assay = &quot;&quot;, species = &quot;&quot;) %&gt;% 
  mutate(overallDesign = ifelse(overallDesign == &quot;NA&quot;, NA, overallDesign)) %&gt;% 
  select(datasetId, datasetName, datasetAlias,
         description, publicationTitle, overallDesign, 
         tumorType, assay, species, externalLink, 
         publicationId, publication = pubMedLink,
         grantId, grantName, consortium, grantType, theme) %&gt;% 
  mutate_all(~ ifelse(. == &quot;[NA (PMID:NA)](NA)&quot;, NA, .)) %&gt;% 
  distinct()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiSm9pbmluZywgYnkgPSBcImNvbnNvcnRpdW1JZFwiXG5Kb2luaW5nLCBieSA9IFwicHVibGljYXRpb25JZFwiXG4ifQ== -->
<pre><code>Joining, by = &quot;consortiumId&quot;
Joining, by = &quot;publicationId&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWVyZ2VkX2RhdGFzZXRfZGZcbmBgYCJ9 -->
<pre class="r"><code>merged_dataset_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"ncol":17,"nrow":821},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["datasetId"],"name":[1],"type":["chr"],"align":["left"]},{"label":["datasetName"],"name":[2],"type":["chr"],"align":["left"]},{"label":["datasetAlias"],"name":[3],"type":["chr"],"align":["left"]},{"label":["description"],"name":[4],"type":["chr"],"align":["left"]},{"label":["publicationTitle"],"name":[5],"type":["chr"],"align":["left"]},{"label":["overallDesign"],"name":[6],"type":["chr"],"align":["left"]},{"label":["tumorType"],"name":[7],"type":["chr"],"align":["left"]},{"label":["assay"],"name":[8],"type":["chr"],"align":["left"]},{"label":["species"],"name":[9],"type":["chr"],"align":["left"]},{"label":["externalLink"],"name":[10],"type":["chr"],"align":["left"]},{"label":["publicationId"],"name":[11],"type":["chr"],"align":["left"]},{"label":["publication"],"name":[12],"type":["chr"],"align":["left"]},{"label":["grantId"],"name":[13],"type":["chr"],"align":["left"]},{"label":["grantName"],"name":[14],"type":["chr"],"align":["left"]},{"label":["consortium"],"name":[15],"type":["chr"],"align":["left"]},{"label":["grantType"],"name":[16],"type":["chr"],"align":["left"]},{"label":["theme"],"name":[17],"type":["chr"],"align":["left"]}],"data":[{"1":"syn21889513","2":"GSE100274","3":"GSE100274","4":"NA","5":"Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE100274](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100274)","11":"syn21648934","12":"[Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types (PMID:29871632)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29871632)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889513","2":"GSE100274","3":"GSE100274","4":"NA","5":"Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE100274](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100274)","11":"syn21648934","12":"[Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types (PMID:29871632)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29871632)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889514","2":"GSE101209","3":"GSE101209","4":"NA","5":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE101209](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101209)","11":"syn21648894","12":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","13":"syn10140998","14":"The Cancer Cell Map Initiative","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889514","2":"GSE101209","3":"GSE101209","4":"NA","5":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE101209](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101209)","11":"syn21648894","12":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","13":"syn10140998","14":"The Cancer Cell Map Initiative","15":"CSBC","16":"U54","17":"Evolution"},{"1":"syn21889514","2":"GSE101209","3":"GSE101209","4":"NA","5":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE101209](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101209)","11":"syn21648894","12":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","13":"syn10140998","14":"The Cancer Cell Map Initiative","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889515","2":"GSE101988","3":"GSE101988","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE101988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101988)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889515","2":"GSE101988","3":"GSE101988","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE101988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101988)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889515","2":"GSE101988","3":"GSE101988","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE101988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101988)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889515","2":"GSE101988","3":"GSE101988","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE101988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101988)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889516","2":"GSE102698","3":"GSE102698","4":"NA","5":"Unsupervised Trajectory Analysis of Single-Cell RNA-Seq and Imaging Data Reveals Alternative Tuft Cell Origins in the Gut","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE102698](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102698)","11":"syn21649125","12":"[Unsupervised Trajectory Analysis of Single-Cell RNA-Seq and Imaging Data Reveals Alternative Tuft Cell Origins in the Gut (PMID:29153838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29153838)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889517","2":"Mitotic chromosomes fold by condensin-dependent helical winding of chromatin loop arrays","3":"GSE102740","4":"Mitotic chromosome morphogenesis occurs through condensin-mediated disassembly of the interphase conformation and formation of extended prophase loop arrays that then shorten by condensin-dependent helical winding.","5":"A pathway for mitotic chromosome formation","6":"Chromosome organization investigation through Hi-C","7":"","8":"","9":"","10":"[GEO:GSE102740](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102740)","11":"syn21649214","12":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889517","2":"Mitotic chromosomes fold by condensin-dependent helical winding of chromatin loop arrays","3":"GSE102740","4":"Mitotic chromosome morphogenesis occurs through condensin-mediated disassembly of the interphase conformation and formation of extended prophase loop arrays that then shorten by condensin-dependent helical winding.","5":"A pathway for mitotic chromosome formation","6":"Chromosome organization investigation through Hi-C","7":"","8":"","9":"","10":"[GEO:GSE102740](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102740)","11":"syn21649214","12":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889517","2":"Mitotic chromosomes fold by condensin-dependent helical winding of chromatin loop arrays","3":"GSE102740","4":"Mitotic chromosome morphogenesis occurs through condensin-mediated disassembly of the interphase conformation and formation of extended prophase loop arrays that then shorten by condensin-dependent helical winding.","5":"A pathway for mitotic chromosome formation","6":"Chromosome organization investigation through Hi-C","7":"","8":"","9":"","10":"[GEO:GSE102740](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102740)","11":"syn21649214","12":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889519","2":"GSE103203","3":"GSE103203","4":"NA","5":"Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE103203](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103203)","11":"syn21681447","12":"[Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer (PMID:30389702)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30389702)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889519","2":"GSE103203","3":"GSE103203","4":"NA","5":"Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE103203](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103203)","11":"syn21681447","12":"[Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer (PMID:30389702)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30389702)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889520","2":"Single-Cell Transcriptome Analysis of Lineage Diversity and Microenvironment in High-Grade Glioma","3":"GSE103224","4":"Despite extensive molecular characterization, we lack a comprehensive picture of lineage identity, differentiation, and microenvironmental composition in high-grade gliomas (HGGs). We sampled the cellular milieu of HGGs with massively-parallel single-cell RNA-Seq.","5":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","6":"Performed single cell RNA-seq on tens of thousands of dissociated high-grade glioma tissue cells from 8 human patients.","7":"","8":"","9":"","10":"[GEO:GSE103224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103224)","11":"syn21648977","12":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889520","2":"Single-Cell Transcriptome Analysis of Lineage Diversity and Microenvironment in High-Grade Glioma","3":"GSE103224","4":"Despite extensive molecular characterization, we lack a comprehensive picture of lineage identity, differentiation, and microenvironmental composition in high-grade gliomas (HGGs). We sampled the cellular milieu of HGGs with massively-parallel single-cell RNA-Seq.","5":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","6":"Performed single cell RNA-seq on tens of thousands of dissociated high-grade glioma tissue cells from 8 human patients.","7":"","8":"","9":"","10":"[GEO:GSE103224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103224)","11":"syn21648977","12":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889520","2":"Single-Cell Transcriptome Analysis of Lineage Diversity and Microenvironment in High-Grade Glioma","3":"GSE103224","4":"Despite extensive molecular characterization, we lack a comprehensive picture of lineage identity, differentiation, and microenvironmental composition in high-grade gliomas (HGGs). We sampled the cellular milieu of HGGs with massively-parallel single-cell RNA-Seq.","5":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","6":"Performed single cell RNA-seq on tens of thousands of dissociated high-grade glioma tissue cells from 8 human patients.","7":"","8":"","9":"","10":"[GEO:GSE103224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103224)","11":"syn21648977","12":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889522","2":"The transcriptome effect of overexpressing EZH2 in MCF7","3":"GSE103242","4":"Purpose: Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in EZH2 overexpressed MCF-7 cells.","5":"NA","6":"Transcriptome profiles of tamoxifen sensitive MCF-7 infected with pLenti-CMV-hygro-GFP or pLento-HA-EZH2 were sequenced in at least duplicates using Illumina HiSeq 3000.","7":"","8":"","9":"","10":"[GEO:GSE103242](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103242)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889522","2":"The transcriptome effect of overexpressing EZH2 in MCF7","3":"GSE103242","4":"Purpose: Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in EZH2 overexpressed MCF-7 cells.","5":"NA","6":"Transcriptome profiles of tamoxifen sensitive MCF-7 infected with pLenti-CMV-hygro-GFP or pLento-HA-EZH2 were sequenced in at least duplicates using Illumina HiSeq 3000.","7":"","8":"","9":"","10":"[GEO:GSE103242](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103242)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889523","2":"GSE103243","3":"GSE103243","4":"NA","5":"Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE103243](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103243)","11":"syn21645251","12":"[Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis (PMID:29212856)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29212856)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889523","2":"GSE103243","3":"GSE103243","4":"NA","5":"Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE103243](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103243)","11":"syn21645251","12":"[Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis (PMID:29212856)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29212856)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889524","2":"GSE103990","3":"GSE103990","4":"NA","5":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE103990](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103990)","11":"syn21648885","12":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889524","2":"GSE103990","3":"GSE103990","4":"NA","5":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE103990](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103990)","11":"syn21648885","12":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889524","2":"GSE103990","3":"GSE103990","4":"NA","5":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE103990](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103990)","11":"syn21648885","12":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889525","2":"GSE104981","3":"GSE104981","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104981)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889525","2":"GSE104981","3":"GSE104981","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104981)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889525","2":"GSE104981","3":"GSE104981","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104981)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889525","2":"GSE104981","3":"GSE104981","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104981)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889526","2":"GSE104983","3":"GSE104983","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104983](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104983)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889526","2":"GSE104983","3":"GSE104983","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104983](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104983)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889526","2":"GSE104983","3":"GSE104983","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104983](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104983)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889526","2":"GSE104983","3":"GSE104983","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104983](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104983)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889527","2":"GSE104984","3":"GSE104984","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104984](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104984)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889527","2":"GSE104984","3":"GSE104984","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104984](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104984)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889527","2":"GSE104984","3":"GSE104984","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104984](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104984)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889527","2":"GSE104984","3":"GSE104984","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104984](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104984)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889528","2":"GSE104985","3":"GSE104985","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104985](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104985)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889528","2":"GSE104985","3":"GSE104985","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104985](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104985)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889528","2":"GSE104985","3":"GSE104985","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104985](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104985)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889528","2":"GSE104985","3":"GSE104985","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104985](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104985)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889529","2":"GSE104986","3":"GSE104986","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104986)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889529","2":"GSE104986","3":"GSE104986","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104986)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889529","2":"GSE104986","3":"GSE104986","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104986)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889529","2":"GSE104986","3":"GSE104986","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104986)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889530","2":"GSE104987","3":"GSE104987","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104987](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104987)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889530","2":"GSE104987","3":"GSE104987","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104987](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104987)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889530","2":"GSE104987","3":"GSE104987","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104987](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104987)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889530","2":"GSE104987","3":"GSE104987","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104987](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104987)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889531","2":"GSE104988","3":"GSE104988","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104988)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889531","2":"GSE104988","3":"GSE104988","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104988)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889531","2":"GSE104988","3":"GSE104988","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104988)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889531","2":"GSE104988","3":"GSE104988","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE104988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104988)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889532","2":"GSE106519","3":"GSE106519","4":"NA","5":"Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE106519](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106519)","11":"syn21648893","12":"[Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance (PMID:29251630)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29251630)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889532","2":"GSE106519","3":"GSE106519","4":"NA","5":"Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE106519](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106519)","11":"syn21648893","12":"[Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance (PMID:29251630)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29251630)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889533","2":"GSE107470","3":"GSE107470","4":"NA","5":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107470](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107470)","11":"syn21648884","12":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889533","2":"GSE107470","3":"GSE107470","4":"NA","5":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107470](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107470)","11":"syn21648884","12":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889533","2":"GSE107470","3":"GSE107470","4":"NA","5":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107470](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107470)","11":"syn21648884","12":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889534","2":"GSE107558","3":"GSE107558","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107558](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107558)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889534","2":"GSE107558","3":"GSE107558","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107558](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107558)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889534","2":"GSE107558","3":"GSE107558","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107558](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107558)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889536","2":"GSE107559","3":"GSE107559","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107559](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107559)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889536","2":"GSE107559","3":"GSE107559","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107559](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107559)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889536","2":"GSE107559","3":"GSE107559","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107559](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107559)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889537","2":"GSE107560","3":"GSE107560","4":"NA","5":"An anatomic transcriptional atlas of human glioblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107560](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107560)","11":"syn21648951","12":"[An anatomic transcriptional atlas of human glioblastoma (PMID:29748285)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29748285)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889537","2":"GSE107560","3":"GSE107560","4":"NA","5":"An anatomic transcriptional atlas of human glioblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107560](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107560)","11":"syn21648951","12":"[An anatomic transcriptional atlas of human glioblastoma (PMID:29748285)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29748285)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889537","2":"GSE107560","3":"GSE107560","4":"NA","5":"An anatomic transcriptional atlas of human glioblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE107560](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107560)","11":"syn21648951","12":"[An anatomic transcriptional atlas of human glioblastoma (PMID:29748285)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29748285)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889538","2":"GSE109089","3":"GSE109089","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109089](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109089)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889538","2":"GSE109089","3":"GSE109089","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109089](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109089)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889540","2":"GSE109092","3":"GSE109092","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109092](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109092)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889540","2":"GSE109092","3":"GSE109092","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109092](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109092)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889541","2":"GSE109309","3":"GSE109309","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109309)","11":"NA","12":"NA","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889541","2":"GSE109309","3":"GSE109309","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109309)","11":"NA","12":"NA","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889542","2":"GSE109457","3":"GSE109457","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109457](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109457)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889542","2":"GSE109457","3":"GSE109457","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109457](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109457)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889542","2":"GSE109457","3":"GSE109457","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109457](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109457)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889543","2":"GSE109458","3":"GSE109458","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109458](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109458)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889543","2":"GSE109458","3":"GSE109458","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109458](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109458)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889543","2":"GSE109458","3":"GSE109458","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109458](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109458)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889544","2":"GSE109459","3":"GSE109459","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109459](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109459)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889544","2":"GSE109459","3":"GSE109459","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109459](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109459)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889544","2":"GSE109459","3":"GSE109459","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE109459](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109459)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889545","2":"GSE110644","3":"GSE110644","4":"NA","5":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE110644](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110644)","11":"syn21681403","12":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889545","2":"GSE110644","3":"GSE110644","4":"NA","5":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE110644](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110644)","11":"syn21681403","12":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889545","2":"GSE110644","3":"GSE110644","4":"NA","5":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE110644](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110644)","11":"syn21681403","12":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889546","2":"GSE110704","3":"GSE110704","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE110704](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110704)","11":"NA","12":"NA","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889546","2":"GSE110704","3":"GSE110704","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE110704](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110704)","11":"NA","12":"NA","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889547","2":"GSE111075","3":"GSE111075","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE111075](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111075)","11":"NA","12":"NA","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889547","2":"GSE111075","3":"GSE111075","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE111075](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111075)","11":"NA","12":"NA","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889548","2":"GSE111076","3":"GSE111076","4":"NA","5":"Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE111076](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111076)","11":"syn21681553","12":"[Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence (PMID:30739799)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30739799)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889548","2":"GSE111076","3":"GSE111076","4":"NA","5":"Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE111076](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111076)","11":"syn21681553","12":"[Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence (PMID:30739799)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30739799)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889549","2":"GSE111653","3":"GSE111653","4":"NA","5":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE111653](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111653)","11":"syn21681401","12":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889549","2":"GSE111653","3":"GSE111653","4":"NA","5":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE111653](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111653)","11":"syn21681401","12":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889549","2":"GSE111653","3":"GSE111653","4":"NA","5":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE111653](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111653)","11":"syn21681401","12":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889550","2":"GSE112434","3":"GSE112434","4":"NA","5":"Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112434](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112434)","11":"syn21681640","12":"[Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF (PMID:30975481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30975481)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889551","2":"GSE112486","3":"GSE112486","4":"NA","5":"A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112486](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112486)","11":"syn21648960","12":"[A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development (PMID:29625070)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625070)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889552","2":"GSE112786","3":"GSE112786","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112786](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112786)","11":"NA","12":"NA","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889552","2":"GSE112786","3":"GSE112786","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112786](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112786)","11":"NA","12":"NA","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889552","2":"GSE112786","3":"GSE112786","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112786](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112786)","11":"NA","12":"NA","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889553","2":"GSE112829","3":"GSE112829","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112829](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112829)","11":"NA","12":"NA","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889553","2":"GSE112829","3":"GSE112829","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112829](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112829)","11":"NA","12":"NA","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889553","2":"GSE112829","3":"GSE112829","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112829](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112829)","11":"NA","12":"NA","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889555","2":"GSE112830","3":"GSE112830","4":"NA","5":"Patient derived organoids to model rare prostate cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112830](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112830)","11":"syn21648964","12":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889555","2":"GSE112830","3":"GSE112830","4":"NA","5":"Patient derived organoids to model rare prostate cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112830](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112830)","11":"syn21648964","12":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889555","2":"GSE112830","3":"GSE112830","4":"NA","5":"Patient derived organoids to model rare prostate cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE112830](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112830)","11":"syn21648964","12":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889556","2":"GSE113099","3":"GSE113099","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE113099](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113099)","11":"NA","12":"NA","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889558","2":"GSE113127","3":"GSE113127","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE113127](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113127)","11":"NA","12":"NA","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889559","2":"GSE113196","3":"GSE113196","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE113196](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113196)","11":"NA","12":"NA","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889560","2":"GSE113197","3":"GSE113197","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE113197](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113197)","11":"NA","12":"NA","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889561","2":"GSE113198","3":"GSE113198","4":"NA","5":"Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE113198](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113198)","11":"syn21649156","12":"[Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity (PMID:29795293)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29795293)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889562","2":"GSE113616","3":"GSE113616","4":"NA","5":"Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE113616](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113616)","11":"syn21681772","12":"[Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer (PMID:31155233)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31155233)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889563","2":"GSE114044","3":"GSE114044","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114044](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114044)","11":"NA","12":"NA","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889564","2":"GSE114071","3":"GSE114071","4":"NA","5":"Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114071](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114071)","11":"syn21681514","12":"[Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation (PMID:30626865)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30626865)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889565","2":"GSE114296","3":"GSE114296","4":"NA","5":"Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114296](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114296)","11":"syn21681436","12":"[Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs (PMID:30309298)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30309298)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889565","2":"GSE114296","3":"GSE114296","4":"NA","5":"Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114296](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114296)","11":"syn21681436","12":"[Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs (PMID:30309298)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30309298)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889566","2":"GSE114300","3":"GSE114300","4":"NA","5":"Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114300](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114300)","11":"syn21649081","12":"[Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival (PMID:29997286)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29997286)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889566","2":"GSE114300","3":"GSE114300","4":"NA","5":"Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114300](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114300)","11":"syn21649081","12":"[Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival (PMID:29997286)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29997286)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889567","2":"GSE114397","3":"GSE114397","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114397](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114397)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889567","2":"GSE114397","3":"GSE114397","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114397](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114397)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889567","2":"GSE114397","3":"GSE114397","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114397](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114397)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889567","2":"GSE114397","3":"GSE114397","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114397](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114397)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889568","2":"GSE114438","3":"GSE114438","4":"NA","5":"A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114438](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114438)","11":"syn21681409","12":"[A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine (PMID:30082792)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30082792)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889568","2":"GSE114438","3":"GSE114438","4":"NA","5":"A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114438](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114438)","11":"syn21681409","12":"[A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine (PMID:30082792)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30082792)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889568","2":"GSE114438","3":"GSE114438","4":"NA","5":"A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114438](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114438)","11":"syn21681409","12":"[A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine (PMID:30082792)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30082792)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889568","2":"GSE114438","3":"GSE114438","4":"NA","5":"A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114438](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114438)","11":"syn21681409","12":"[A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine (PMID:30082792)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30082792)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889569","2":"GSE114686","3":"GSE114686","4":"NA","5":"Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114686](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114686)","11":"syn21681737","12":"[Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming (PMID:31078528)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31078528)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889569","2":"GSE114686","3":"GSE114686","4":"NA","5":"Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114686](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114686)","11":"syn21681737","12":"[Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming (PMID:31078528)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31078528)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889570","2":"5' RNA sequencing and TCR sequencing of breast cancer tumor cells","3":"GSE114724","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on three patients using the 10x genomics TCR profiling kits. For each patient, populations of T-cells were assayed for both TCR sequence and trancriptome-wide RNA-sequence. Two donors have a replicate experiment.","7":"","8":"","9":"","10":"[GEO:GSE114724](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114724)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889570","2":"5' RNA sequencing and TCR sequencing of breast cancer tumor cells","3":"GSE114724","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on three patients using the 10x genomics TCR profiling kits. For each patient, populations of T-cells were assayed for both TCR sequence and trancriptome-wide RNA-sequence. Two donors have a replicate experiment.","7":"","8":"","9":"","10":"[GEO:GSE114724](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114724)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889570","2":"5' RNA sequencing and TCR sequencing of breast cancer tumor cells","3":"GSE114724","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on three patients using the 10x genomics TCR profiling kits. For each patient, populations of T-cells were assayed for both TCR sequence and trancriptome-wide RNA-sequence. Two donors have a replicate experiment.","7":"","8":"","9":"","10":"[GEO:GSE114724](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114724)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889570","2":"5' RNA sequencing and TCR sequencing of breast cancer tumor cells","3":"GSE114724","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on three patients using the 10x genomics TCR profiling kits. For each patient, populations of T-cells were assayed for both TCR sequence and trancriptome-wide RNA-sequence. Two donors have a replicate experiment.","7":"","8":"","9":"","10":"[GEO:GSE114724](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114724)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889571","2":"3' RNA Sequencing of breast cancer tumor cells","3":"GSE114725","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on eight donors using the InDrop v2 protocol. For each donor populations of CD45+ immune cells were assayed for trancriptome-wide RNA-sequence. At least one replicate was taken for each donor.","7":"","8":"","9":"","10":"[GEO:GSE114725](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114725)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889571","2":"3' RNA Sequencing of breast cancer tumor cells","3":"GSE114725","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on eight donors using the InDrop v2 protocol. For each donor populations of CD45+ immune cells were assayed for trancriptome-wide RNA-sequence. At least one replicate was taken for each donor.","7":"","8":"","9":"","10":"[GEO:GSE114725](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114725)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889571","2":"3' RNA Sequencing of breast cancer tumor cells","3":"GSE114725","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on eight donors using the InDrop v2 protocol. For each donor populations of CD45+ immune cells were assayed for trancriptome-wide RNA-sequence. At least one replicate was taken for each donor.","7":"","8":"","9":"","10":"[GEO:GSE114725](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114725)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889571","2":"3' RNA Sequencing of breast cancer tumor cells","3":"GSE114725","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"NA","6":"Single-cell RNA sequencing was performed on eight donors using the InDrop v2 protocol. For each donor populations of CD45+ immune cells were assayed for trancriptome-wide RNA-sequence. At least one replicate was taken for each donor.","7":"","8":"","9":"","10":"[GEO:GSE114725](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114725)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889572","2":"GSE114727","3":"GSE114727","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114727](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114727)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889572","2":"GSE114727","3":"GSE114727","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114727](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114727)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889572","2":"GSE114727","3":"GSE114727","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114727](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114727)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889572","2":"GSE114727","3":"GSE114727","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE114727](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114727)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889574","2":"GSE115501","3":"GSE115501","4":"NA","5":"Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115501](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115501)","11":"syn21681993","12":"[Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer (PMID:31805710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31805710)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889574","2":"GSE115501","3":"GSE115501","4":"NA","5":"Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115501](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115501)","11":"syn21681993","12":"[Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer (PMID:31805710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31805710)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889575","2":"GSE115531","3":"GSE115531","4":"NA","5":"Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115531](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115531)","11":"syn21681517","12":"[Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans (PMID:30638295)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30638295)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889575","2":"GSE115531","3":"GSE115531","4":"NA","5":"Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115531](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115531)","11":"syn21681517","12":"[Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans (PMID:30638295)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30638295)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889576","2":"GSE115542","3":"GSE115542","4":"NA","5":"Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115542](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115542)","11":"syn21681442","12":"[Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma (PMID:30355798)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30355798)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889576","2":"GSE115542","3":"GSE115542","4":"NA","5":"Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115542](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115542)","11":"syn21681442","12":"[Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma (PMID:30355798)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30355798)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889578","2":"GSE115635","3":"GSE115635","4":"NA","5":"Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115635](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115635)","11":"syn21681378","12":"[Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer (PMID:29860390)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29860390)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889578","2":"GSE115635","3":"GSE115635","4":"NA","5":"Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115635](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115635)","11":"syn21681378","12":"[Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer (PMID:29860390)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29860390)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889579","2":"GSE115832","3":"GSE115832","4":"NA","5":"The mammalian decidual cell evolved from a cellular stress response","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115832](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115832)","11":"syn21681412","12":"[The mammalian decidual cell evolved from a cellular stress response (PMID:30142145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30142145)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889579","2":"GSE115832","3":"GSE115832","4":"NA","5":"The mammalian decidual cell evolved from a cellular stress response","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115832](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115832)","11":"syn21681412","12":"[The mammalian decidual cell evolved from a cellular stress response (PMID:30142145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30142145)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889580","2":"GSE115870","3":"GSE115870","4":"NA","5":"Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115870](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115870)","11":"syn21649154","12":"[Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells (PMID:30044986)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30044986)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889580","2":"GSE115870","3":"GSE115870","4":"NA","5":"Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115870](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115870)","11":"syn21649154","12":"[Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells (PMID:30044986)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30044986)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889580","2":"GSE115870","3":"GSE115870","4":"NA","5":"Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE115870](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115870)","11":"syn21649154","12":"[Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells (PMID:30044986)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30044986)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889581","2":"GSE116011","3":"GSE116011","4":"NA","5":"SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116011](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116011)","11":"syn21681501","12":"[SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing (PMID:30583733)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30583733)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889581","2":"GSE116011","3":"GSE116011","4":"NA","5":"SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116011](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116011)","11":"syn21681501","12":"[SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing (PMID:30583733)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30583733)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889585","2":"GSE116348","3":"GSE116348","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116348](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116348)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889585","2":"GSE116348","3":"GSE116348","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116348](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116348)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889585","2":"GSE116348","3":"GSE116348","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116348](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116348)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889585","2":"GSE116348","3":"GSE116348","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116348](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116348)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889586","2":"GSE116466","3":"GSE116466","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116466](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116466)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889586","2":"GSE116466","3":"GSE116466","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116466](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116466)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889586","2":"GSE116466","3":"GSE116466","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116466](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116466)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889586","2":"GSE116466","3":"GSE116466","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116466](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116466)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889587","2":"GSE116468","3":"GSE116468","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116468](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116468)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889587","2":"GSE116468","3":"GSE116468","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116468](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116468)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889587","2":"GSE116468","3":"GSE116468","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116468](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116468)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889587","2":"GSE116468","3":"GSE116468","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116468](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116468)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889588","2":"GSE116561","3":"GSE116561","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116561](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116561)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889588","2":"GSE116561","3":"GSE116561","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116561](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116561)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889588","2":"GSE116561","3":"GSE116561","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116561](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116561)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889588","2":"GSE116561","3":"GSE116561","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE116561](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116561)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889589","2":"GSE117340","3":"GSE117340","4":"NA","5":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117340](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117340)","11":"syn21681441","12":"[Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity (PMID:30352428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30352428)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889589","2":"GSE117340","3":"GSE117340","4":"NA","5":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117340](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117340)","11":"syn21681441","12":"[Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity (PMID:30352428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30352428)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889589","2":"GSE117340","3":"GSE117340","4":"NA","5":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117340](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117340)","11":"syn21681441","12":"[Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity (PMID:30352428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30352428)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889590","2":"GSE117615","3":"GSE117615","4":"NA","5":"Quantitative assessment of cell population diversity in single-cell landscapes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117615](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117615)","11":"syn21649039","12":"[Quantitative assessment of cell population diversity in single-cell landscapes (PMID:30346945)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30346945)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889591","2":"GSE117824","3":"GSE117824","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117824](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117824)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889591","2":"GSE117824","3":"GSE117824","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117824](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117824)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889591","2":"GSE117824","3":"GSE117824","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117824](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117824)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889592","2":"GSE117825","3":"GSE117825","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117825](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117825)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889592","2":"GSE117825","3":"GSE117825","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117825](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117825)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889592","2":"GSE117825","3":"GSE117825","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117825](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117825)","11":"NA","12":"NA","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889593","2":"GSE117826","3":"GSE117826","4":"NA","5":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117826](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117826)","11":"syn21681828","12":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889593","2":"GSE117826","3":"GSE117826","4":"NA","5":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117826](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117826)","11":"syn21681828","12":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889593","2":"GSE117826","3":"GSE117826","4":"NA","5":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE117826](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117826)","11":"syn21681828","12":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889594","2":"GSE118303","3":"GSE118303","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118303](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118303)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889594","2":"GSE118303","3":"GSE118303","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118303](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118303)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889594","2":"GSE118303","3":"GSE118303","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118303](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118303)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889594","2":"GSE118303","3":"GSE118303","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118303](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118303)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889596","2":"GSE118389","3":"GSE118389","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118389)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889596","2":"GSE118389","3":"GSE118389","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118389)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889596","2":"GSE118389","3":"GSE118389","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118389)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889596","2":"GSE118389","3":"GSE118389","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118389)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889597","2":"GSE118390","3":"GSE118390","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118390](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118390)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889597","2":"GSE118390","3":"GSE118390","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118390](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118390)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889597","2":"GSE118390","3":"GSE118390","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118390](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118390)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889597","2":"GSE118390","3":"GSE118390","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE118390](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118390)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889599","2":"GSE119149","3":"GSE119149","4":"NA","5":"Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE119149](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119149)","11":"syn21681608","12":"[Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells (PMID:30910979)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30910979)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889600","2":"GSE119153","3":"GSE119153","4":"NA","5":"Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE119153](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119153)","11":"syn21681527","12":"[Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy (PMID:30664790)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30664790)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889601","2":"GSE119270","3":"GSE119270","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE119270](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119270)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889601","2":"GSE119270","3":"GSE119270","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE119270](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119270)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889602","2":"GSE119646","3":"GSE119646","4":"NA","5":"Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE119646](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119646)","11":"syn21681558","12":"[Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes (PMID:30755444)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30755444)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889603","2":"GSE120261","3":"GSE120261","4":"NA","5":"In situ 10-cell RNA sequencing in tissue and tumor biopsy samples","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE120261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120261)","11":"syn21681604","12":"[In situ 10-cell RNA sequencing in tissue and tumor biopsy samples (PMID:30894605)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30894605)","13":"syn17084062","14":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889603","2":"GSE120261","3":"GSE120261","4":"NA","5":"In situ 10-cell RNA sequencing in tissue and tumor biopsy samples","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE120261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120261)","11":"syn21681604","12":"[In situ 10-cell RNA sequencing in tissue and tumor biopsy samples (PMID:30894605)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30894605)","13":"syn17084062","14":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","15":"CSBC","16":"U01","17":"Evolution"},{"1":"syn21889604","2":"GSE121094","3":"GSE121094","4":"NA","5":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121094](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121094)","11":"syn21649183","12":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889604","2":"GSE121094","3":"GSE121094","4":"NA","5":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121094](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121094)","11":"syn21649183","12":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889604","2":"GSE121094","3":"GSE121094","4":"NA","5":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121094](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121094)","11":"syn21649183","12":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889605","2":"GSE121229","3":"GSE121229","4":"NA","5":"BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121229](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121229)","11":"syn21681667","12":"[BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells (PMID:30995943)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30995943)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889605","2":"GSE121229","3":"GSE121229","4":"NA","5":"BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121229](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121229)","11":"syn21681667","12":"[BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells (PMID:30995943)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30995943)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889606","2":"GSE121655","3":"GSE121655","4":"NA","5":"Linking single-cell measurements of mass, growth rate, and gene expression","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121655](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121655)","11":"syn21649021","12":"[Linking single-cell measurements of mass, growth rate, and gene expression (PMID:30482222)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30482222)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889606","2":"GSE121655","3":"GSE121655","4":"NA","5":"Linking single-cell measurements of mass, growth rate, and gene expression","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121655](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121655)","11":"syn21649021","12":"[Linking single-cell measurements of mass, growth rate, and gene expression (PMID:30482222)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30482222)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889607","2":"GSE121861","3":"GSE121861","4":"NA","5":"Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121861](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121861)","11":"syn21681451","12":"[Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics (PMID:30404002)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30404002)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889608","2":"GSE121937","3":"GSE121937","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121937](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121937)","11":"NA","12":"NA","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889609","2":"GSE121939","3":"GSE121939","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121939](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121939)","11":"NA","12":"NA","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889610","2":"GSE121940","3":"GSE121940","4":"NA","5":"Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE121940](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121940)","11":"syn21681992","12":"[Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach (PMID:31804471)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31804471)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889611","2":"GSE122041","3":"GSE122041","4":"NA","5":"A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122041](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122041)","11":"syn21649049","12":"[A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma (PMID:29590606)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29590606)","13":"syn17084070","14":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889611","2":"GSE122041","3":"GSE122041","4":"NA","5":"A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122041](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122041)","11":"syn21649049","12":"[A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma (PMID:29590606)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29590606)","13":"syn17084070","14":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889613","2":"GSE122050","3":"GSE122050","4":"NA","5":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122050](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122050)","11":"syn21681529","12":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889613","2":"GSE122050","3":"GSE122050","4":"NA","5":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122050](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122050)","11":"syn21681529","12":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889613","2":"GSE122050","3":"GSE122050","4":"NA","5":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122050](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122050)","11":"syn21681529","12":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889614","2":"GSE122233","3":"GSE122233","4":"NA","5":"Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122233](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122233)","11":"syn21681530","12":"[Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer (PMID:30674677)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674677)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889614","2":"GSE122233","3":"GSE122233","4":"NA","5":"Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122233](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122233)","11":"syn21681530","12":"[Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer (PMID:30674677)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674677)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889616","2":"GSE122404","3":"GSE122404","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122404](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122404)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889616","2":"GSE122404","3":"GSE122404","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE122404](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122404)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889617","2":"GSE124494","3":"GSE124494","4":"NA","5":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE124494](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124494)","11":"syn21681865","12":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889617","2":"GSE124494","3":"GSE124494","4":"NA","5":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE124494](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124494)","11":"syn21681865","12":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889617","2":"GSE124494","3":"GSE124494","4":"NA","5":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE124494](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124494)","11":"syn21681865","12":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889618","2":"GSE124854","3":"GSE124854","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE124854](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124854)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889618","2":"GSE124854","3":"GSE124854","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE124854](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124854)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889619","2":"GSE125014","3":"GSE125014","4":"NA","5":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125014](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125014)","11":"syn21681899","12":"[Molecular determinants for enzalutamide-induced transcription in prostate cancer (PMID:31501863)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31501863)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889619","2":"GSE125014","3":"GSE125014","4":"NA","5":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125014](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125014)","11":"syn21681899","12":"[Molecular determinants for enzalutamide-induced transcription in prostate cancer (PMID:31501863)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31501863)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889620","2":"GSE125215","3":"GSE125215","4":"NA","5":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125215](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125215)","11":"syn21681801","12":"[Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity (PMID:31178407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31178407)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889620","2":"GSE125215","3":"GSE125215","4":"NA","5":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125215](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125215)","11":"syn21681801","12":"[Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity (PMID:31178407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31178407)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889621","2":"GSE125587","3":"GSE125587","4":"NA","5":"Ex vivo Dynamics of Human Glioblastoma Cells in a Microvasculature-on-a-Chip System Correlates with Tumor Heterogeneity and Subtypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125587](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125587)","11":"syn21681676","12":"[Ex vivo Dynamics of Human Glioblastoma Cells in a Microvasculature-on-a-Chip System Correlates with Tumor Heterogeneity and Subtypes (PMID:31016107)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31016107)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889622","2":"GSE125588","3":"GSE125588","4":"NA","5":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125588](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125588)","11":"syn21681851","12":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889622","2":"GSE125588","3":"GSE125588","4":"NA","5":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125588](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125588)","11":"syn21681851","12":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889622","2":"GSE125588","3":"GSE125588","4":"NA","5":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125588](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125588)","11":"syn21681851","12":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889623","2":"GSE125594","3":"GSE125594","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125594](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125594)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889623","2":"GSE125594","3":"GSE125594","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125594](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125594)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889624","2":"GSE125606","3":"GSE125606","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125606](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125606)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889624","2":"GSE125606","3":"GSE125606","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125606](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125606)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889625","2":"GSE125607","3":"GSE125607","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125607](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125607)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889625","2":"GSE125607","3":"GSE125607","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125607](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125607)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889626","2":"GSE125609","3":"GSE125609","4":"NA","5":"A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125609](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125609)","11":"syn21681836","12":"[A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer (PMID:31303470)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31303470)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889626","2":"GSE125609","3":"GSE125609","4":"NA","5":"A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125609](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125609)","11":"syn21681836","12":"[A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer (PMID:31303470)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31303470)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889627","2":"GSE125688","3":"GSE125688","4":"NA","5":"Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125688](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125688)","11":"syn21681739","12":"[Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration (PMID:31080134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31080134)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889627","2":"GSE125688","3":"GSE125688","4":"NA","5":"Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125688](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125688)","11":"syn21681739","12":"[Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration (PMID:31080134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31080134)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889628","2":"GSE125802","3":"GSE125802","4":"NA","5":"Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125802](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125802)","11":"syn21681547","12":"[Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer (PMID:30718260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30718260)","13":"syn17083789","14":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","15":"PS-ON","16":"U01","17":"Metastasis"},{"1":"syn21889628","2":"GSE125802","3":"GSE125802","4":"NA","5":"Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE125802](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125802)","11":"syn21681547","12":"[Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer (PMID:30718260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30718260)","13":"syn17083789","14":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","15":"PS-ON","16":"U01","17":"Microenvironment"},{"1":"syn21889629","2":"Single-cell combinatorial indexing ATAC-seq of HCC1143 with MEK, PI3K, and BET inhibition","3":"GSE126261","4":"We performed single-cell combinatorial indexing ATAC-seq on the basal-like TNBC cell line HCC1143 under MEK, PI3K, BET and combination treatments as well as DMSO controls.","5":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","6":"Cells were cultured and exposed to inhibitors or vehicle for 72 hours and processed in a single batch of sci-ATAC-seq using transposition barcodes for sample tracking to eliminate batch effects downstream","7":"","8":"","9":"","10":"[GEO:GSE126261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126261)","11":"syn21649001","12":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889629","2":"Single-cell combinatorial indexing ATAC-seq of HCC1143 with MEK, PI3K, and BET inhibition","3":"GSE126261","4":"We performed single-cell combinatorial indexing ATAC-seq on the basal-like TNBC cell line HCC1143 under MEK, PI3K, BET and combination treatments as well as DMSO controls.","5":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","6":"Cells were cultured and exposed to inhibitors or vehicle for 72 hours and processed in a single batch of sci-ATAC-seq using transposition barcodes for sample tracking to eliminate batch effects downstream","7":"","8":"","9":"","10":"[GEO:GSE126261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126261)","11":"syn21649001","12":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889629","2":"Single-cell combinatorial indexing ATAC-seq of HCC1143 with MEK, PI3K, and BET inhibition","3":"GSE126261","4":"We performed single-cell combinatorial indexing ATAC-seq on the basal-like TNBC cell line HCC1143 under MEK, PI3K, BET and combination treatments as well as DMSO controls.","5":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","6":"Cells were cultured and exposed to inhibitors or vehicle for 72 hours and processed in a single batch of sci-ATAC-seq using transposition barcodes for sample tracking to eliminate batch effects downstream","7":"","8":"","9":"","10":"[GEO:GSE126261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126261)","11":"syn21649001","12":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889631","2":"GSE126770","3":"GSE126770","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE126770](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126770)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889631","2":"GSE126770","3":"GSE126770","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE126770](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126770)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889631","2":"GSE126770","3":"GSE126770","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE126770](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126770)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889631","2":"GSE126770","3":"GSE126770","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE126770](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126770)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889633","2":"GSE128313","3":"GSE128313","4":"NA","5":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE128313](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128313)","11":"syn21681723","12":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889633","2":"GSE128313","3":"GSE128313","4":"NA","5":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE128313](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128313)","11":"syn21681723","12":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889633","2":"GSE128313","3":"GSE128313","4":"NA","5":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE128313](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128313)","11":"syn21681723","12":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889634","2":"GSE129007","3":"GSE129007","4":"NA","5":"Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE129007](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129007)","11":"syn21681820","12":"[Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation (PMID:31229590)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31229590)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889637","2":"GSE129455","3":"GSE129455","4":"NA","5":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE129455](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129455)","11":"syn21681814","12":"[Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts (PMID:31197017)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31197017)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889637","2":"GSE129455","3":"GSE129455","4":"NA","5":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE129455](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129455)","11":"syn21681814","12":"[Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts (PMID:31197017)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31197017)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889638","2":"GSE129521","3":"GSE129521","4":"NA","5":"Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE129521](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129521)","11":"syn21681783","12":"[Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (PMID:31160565)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31160565)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889638","2":"GSE129521","3":"GSE129521","4":"NA","5":"Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE129521](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129521)","11":"syn21681783","12":"[Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (PMID:31160565)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31160565)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889639","2":"GSE129578","3":"GSE129578","4":"NA","5":"MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE129578](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129578)","11":"syn21681817","12":"[MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices (PMID:31209384)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31209384)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889640","2":"GSE130232","3":"GSE130232","4":"NA","5":"Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE130232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130232)","11":"syn21681618","12":"[Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer (PMID:30938713)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30938713)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889640","2":"GSE130232","3":"GSE130232","4":"NA","5":"Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE130232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130232)","11":"syn21681618","12":"[Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer (PMID:30938713)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30938713)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889640","2":"GSE130232","3":"GSE130232","4":"NA","5":"Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE130232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130232)","11":"syn21681618","12":"[Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer (PMID:30938713)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30938713)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889641","2":"GSE132926","3":"GSE132926","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE132926](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132926)","11":"NA","12":"NA","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889641","2":"GSE132926","3":"GSE132926","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE132926](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132926)","11":"NA","12":"NA","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889642","2":"GSE132959","3":"GSE132959","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE132959](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132959)","11":"NA","12":"NA","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889642","2":"GSE132959","3":"GSE132959","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE132959](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132959)","11":"NA","12":"NA","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889643","2":"GSE132960","3":"GSE132960","4":"NA","5":"Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE132960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132960)","11":"syn21681881","12":"[Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells (PMID:31442407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31442407)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889643","2":"GSE132960","3":"GSE132960","4":"NA","5":"Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE132960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132960)","11":"syn21681881","12":"[Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells (PMID:31442407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31442407)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889644","2":"GSE133747","3":"GSE133747","4":"NA","5":"Single-cell connectomic analysis of adult mammalian lungs","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE133747](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133747)","11":"syn21681999","12":"[Single-cell connectomic analysis of adult mammalian lungs (PMID:31840053)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31840053)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889644","2":"GSE133747","3":"GSE133747","4":"NA","5":"Single-cell connectomic analysis of adult mammalian lungs","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE133747](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133747)","11":"syn21681999","12":"[Single-cell connectomic analysis of adult mammalian lungs (PMID:31840053)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31840053)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889645","2":"GSE134139","3":"GSE134139","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134139](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134139)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889645","2":"GSE134139","3":"GSE134139","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134139](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134139)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889646","2":"GSE134385","3":"GSE134385","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134385](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134385)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889646","2":"GSE134385","3":"GSE134385","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134385](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134385)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889647","2":"GSE134413","3":"GSE134413","4":"NA","5":"PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134413](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134413)","11":"syn21681909","12":"[PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity (PMID:31527834)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31527834)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889647","2":"GSE134413","3":"GSE134413","4":"NA","5":"PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134413](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134413)","11":"syn21681909","12":"[PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity (PMID:31527834)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31527834)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889648","2":"GSE134583","3":"GSE134583","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134583](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134583)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889648","2":"GSE134583","3":"GSE134583","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134583](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134583)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889648","2":"GSE134583","3":"GSE134583","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134583](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134583)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889650","2":"GSE134997","3":"GSE134997","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134997](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134997)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889650","2":"GSE134997","3":"GSE134997","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134997](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134997)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889650","2":"GSE134997","3":"GSE134997","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE134997](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134997)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889651","2":"GSE135031","3":"GSE135031","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE135031](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135031)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889651","2":"GSE135031","3":"GSE135031","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE135031](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135031)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889651","2":"GSE135031","3":"GSE135031","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE135031](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135031)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889652","2":"GSE135578","3":"GSE135578","4":"NA","5":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE135578](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135578)","11":"syn21681944","12":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889652","2":"GSE135578","3":"GSE135578","4":"NA","5":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE135578](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135578)","11":"syn21681944","12":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889652","2":"GSE135578","3":"GSE135578","4":"NA","5":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE135578](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135578)","11":"syn21681944","12":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889653","2":"GSE136299","3":"GSE136299","4":"NA","5":"Evolution of placental invasion and cancer metastasis are causally linked","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE136299](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136299)","11":"syn21681987","12":"[Evolution of placental invasion and cancer metastasis are causally linked (PMID:31768023)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31768023)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889653","2":"GSE136299","3":"GSE136299","4":"NA","5":"Evolution of placental invasion and cancer metastasis are causally linked","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE136299](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136299)","11":"syn21681987","12":"[Evolution of placental invasion and cancer metastasis are causally linked (PMID:31768023)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31768023)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889655","2":"GSE137300","3":"GSE137300","4":"NA","5":"Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE137300](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137300)","11":"syn21681942","12":"[Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer (PMID:31591235)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31591235)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889656","2":"GSE138003","3":"GSE138003","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138003](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138003)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889656","2":"GSE138003","3":"GSE138003","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138003](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138003)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889656","2":"GSE138003","3":"GSE138003","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138003](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138003)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889657","2":"GSE138004","3":"GSE138004","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138004](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138004)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889657","2":"GSE138004","3":"GSE138004","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138004](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138004)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889657","2":"GSE138004","3":"GSE138004","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138004](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138004)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889658","2":"GSE138005","3":"GSE138005","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138005](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138005)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889658","2":"GSE138005","3":"GSE138005","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138005](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138005)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889658","2":"GSE138005","3":"GSE138005","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138005](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138005)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889659","2":"GSE138006","3":"GSE138006","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138006](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138006)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889659","2":"GSE138006","3":"GSE138006","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138006](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138006)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889659","2":"GSE138006","3":"GSE138006","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138006](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138006)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889660","2":"GSE138007","3":"GSE138007","4":"NA","5":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138007](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138007)","11":"syn21681890","12":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889660","2":"GSE138007","3":"GSE138007","4":"NA","5":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138007](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138007)","11":"syn21681890","12":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889660","2":"GSE138007","3":"GSE138007","4":"NA","5":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE138007](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138007)","11":"syn21681890","12":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889661","2":"RNA-array measurements of T-ALL with and without drug treatment","3":"GSE5827","4":"The NOTCH1 signaling pathway directly links extracellular signals with transcriptional responses in the cell nucleus and plays a critical role during T-cell development and in the pathogenesis over 50% of human T-cell lymphoblastic leukemia (T-ALL) cases. However, little is known about the transcriptional programs activated by NOTCH1. Using an integrative systems biology approach we show that NOTCH1 controls a feed-forward loop transcriptional network that promotes cell growth.","5":"NA","6":"Duplicated cultures of T-ALL cell lines were treated with Compound E, a gamma-secretase inhibitor or vehicle only (DMSO) for 24 h and analyzed using oligonucleotide microarrays. Gene expression changes were analyzed in the context of loss of NOTCH1 signaling induced by the gamma secretase inhibitor treatment.","7":"","8":"","9":"","10":"[GEO:GSE5827](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5827)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889661","2":"RNA-array measurements of T-ALL with and without drug treatment","3":"GSE5827","4":"The NOTCH1 signaling pathway directly links extracellular signals with transcriptional responses in the cell nucleus and plays a critical role during T-cell development and in the pathogenesis over 50% of human T-cell lymphoblastic leukemia (T-ALL) cases. However, little is known about the transcriptional programs activated by NOTCH1. Using an integrative systems biology approach we show that NOTCH1 controls a feed-forward loop transcriptional network that promotes cell growth.","5":"NA","6":"Duplicated cultures of T-ALL cell lines were treated with Compound E, a gamma-secretase inhibitor or vehicle only (DMSO) for 24 h and analyzed using oligonucleotide microarrays. Gene expression changes were analyzed in the context of loss of NOTCH1 signaling induced by the gamma secretase inhibitor treatment.","7":"","8":"","9":"","10":"[GEO:GSE5827](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5827)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889662","2":"GSE58423","3":"GSE58423","4":"NA","5":"Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE58423](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58423)","11":"syn21645611","12":"[Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state (PMID:25380226)](https://www.ncbi.nlm.nih.gov/pubmed/?term=25380226)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889663","2":"Methylation disorder in CLL","3":"GSE58889","4":"We performed RRBS and WGBS on primary human chronic lymphocytic leukemia and normal healthy donor B cell samples.","5":"NA","6":"cross-sectional/longitudinal","7":"","8":"","9":"","10":"[GEO:GSE58889](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58889)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889663","2":"Methylation disorder in CLL","3":"GSE58889","4":"We performed RRBS and WGBS on primary human chronic lymphocytic leukemia and normal healthy donor B cell samples.","5":"NA","6":"cross-sectional/longitudinal","7":"","8":"","9":"","10":"[GEO:GSE58889](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58889)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889663","2":"Methylation disorder in CLL","3":"GSE58889","4":"We performed RRBS and WGBS on primary human chronic lymphocytic leukemia and normal healthy donor B cell samples.","5":"NA","6":"cross-sectional/longitudinal","7":"","8":"","9":"","10":"[GEO:GSE58889](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58889)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889663","2":"Methylation disorder in CLL","3":"GSE58889","4":"We performed RRBS and WGBS on primary human chronic lymphocytic leukemia and normal healthy donor B cell samples.","5":"NA","6":"cross-sectional/longitudinal","7":"","8":"","9":"","10":"[GEO:GSE58889](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58889)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889664","2":"RNA-Seq of isolated stormal cells and tumor epithelial cells in mouse lung cancer","3":"GSE59831","4":"We sequenced mRNA from individual stormal cells (Macrophages, Monocytes, and Neutrophils) and tumor epithelial cells from KrasG12dD; p53-/- murine lung cancer model and WT control mouse to compare gene expressio profiles of lung cancer stroma and tumor cells to their counterparts of WT lugns.","5":"NA","6":"Examination of mRNA levels in individual stormal cells and tumor cells from tumor lungs compared to their counterparts from WT lungs","7":"","8":"","9":"","10":"[GEO:GSE59831](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59831)","11":"NA","12":"NA","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889664","2":"RNA-Seq of isolated stormal cells and tumor epithelial cells in mouse lung cancer","3":"GSE59831","4":"We sequenced mRNA from individual stormal cells (Macrophages, Monocytes, and Neutrophils) and tumor epithelial cells from KrasG12dD; p53-/- murine lung cancer model and WT control mouse to compare gene expressio profiles of lung cancer stroma and tumor cells to their counterparts of WT lugns.","5":"NA","6":"Examination of mRNA levels in individual stormal cells and tumor cells from tumor lungs compared to their counterparts from WT lungs","7":"","8":"","9":"","10":"[GEO:GSE59831](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59831)","11":"NA","12":"NA","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889665","2":"GSE61033","3":"GSE61033","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE61033](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61033)","11":"NA","12":"NA","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889666","2":"GSE61034","3":"GSE61034","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE61034](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61034)","11":"NA","12":"NA","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889668","2":"GSE61035","3":"GSE61035","4":"NA","5":"Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE61035](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61035)","11":"syn21645595","12":"[Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements (PMID:26748710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26748710)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889669","2":"GSE61198","3":"GSE61198","4":"NA","5":"Distinct EMT programs control normal mammary stem cells and tumour-initiating cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE61198](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61198)","11":"syn21645606","12":"[Distinct EMT programs control normal mammary stem cells and tumour-initiating cells (PMID:26331542)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26331542)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889670","2":"GSE63776","3":"GSE63776","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE63776](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63776)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889670","2":"GSE63776","3":"GSE63776","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE63776](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63776)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889672","2":"GSE64038","3":"GSE64038","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE64038](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64038)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889672","2":"GSE64038","3":"GSE64038","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE64038](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64038)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889673","2":"GSE64039","3":"GSE64039","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE64039](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64039)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889673","2":"GSE64039","3":"GSE64039","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE64039](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64039)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889674","2":"GSE65133","3":"GSE65133","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65133](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65133)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889674","2":"GSE65133","3":"GSE65133","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65133](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65133)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889674","2":"GSE65133","3":"GSE65133","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65133](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65133)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889675","2":"GSE65134","3":"GSE65134","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65134](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65134)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889675","2":"GSE65134","3":"GSE65134","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65134](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65134)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889675","2":"GSE65134","3":"GSE65134","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65134](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65134)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889676","2":"GSE65135","3":"GSE65135","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65135](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65135)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889676","2":"GSE65135","3":"GSE65135","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65135](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65135)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889676","2":"GSE65135","3":"GSE65135","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65135](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65135)","11":"NA","12":"NA","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889677","2":"GSE65136","3":"GSE65136","4":"NA","5":"Robust enumeration of cell subsets from tissue expression profiles","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65136](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65136)","11":"syn21681314","12":"[Robust enumeration of cell subsets from tissue expression profiles (PMID:25822800)](https://www.ncbi.nlm.nih.gov/pubmed/?term=25822800)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889677","2":"GSE65136","3":"GSE65136","4":"NA","5":"Robust enumeration of cell subsets from tissue expression profiles","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65136](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65136)","11":"syn21681314","12":"[Robust enumeration of cell subsets from tissue expression profiles (PMID:25822800)](https://www.ncbi.nlm.nih.gov/pubmed/?term=25822800)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889677","2":"GSE65136","3":"GSE65136","4":"NA","5":"Robust enumeration of cell subsets from tissue expression profiles","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE65136](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65136)","11":"syn21681314","12":"[Robust enumeration of cell subsets from tissue expression profiles (PMID:25822800)](https://www.ncbi.nlm.nih.gov/pubmed/?term=25822800)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889678","2":"GSE66357","3":"GSE66357","4":"NA","5":"Scalable microfluidics for single-cell RNA printing and sequencing","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE66357](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66357)","11":"syn21645574","12":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889678","2":"GSE66357","3":"GSE66357","4":"NA","5":"Scalable microfluidics for single-cell RNA printing and sequencing","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE66357](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66357)","11":"syn21645574","12":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889678","2":"GSE66357","3":"GSE66357","4":"NA","5":"Scalable microfluidics for single-cell RNA printing and sequencing","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE66357](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66357)","11":"syn21645574","12":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889679","2":"GSE67405","3":"GSE67405","4":"NA","5":"Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE67405](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67405)","11":"syn21645570","12":"[Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes (PMID:26883104)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26883104)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889679","2":"GSE67405","3":"GSE67405","4":"NA","5":"Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE67405](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67405)","11":"syn21645570","12":"[Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes (PMID:26883104)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26883104)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889679","2":"GSE67405","3":"GSE67405","4":"NA","5":"Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE67405](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67405)","11":"syn21645570","12":"[Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes (PMID:26883104)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26883104)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889680","2":"GSE67828","3":"GSE67828","4":"NA","5":"Distal Alternative Last Exons Localize mRNAs to Neural Projections","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE67828](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67828)","11":"syn21645610","12":"[Distal Alternative Last Exons Localize mRNAs to Neural Projections (PMID:26907613)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26907613)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889681","2":"GSE68078","3":"GSE68078","4":"NA","5":"The genetics of nodal marginal zone lymphoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68078](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68078)","11":"syn21645565","12":"[The genetics of nodal marginal zone lymphoma (PMID:27335277)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27335277)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889682","2":"GSE68795","3":"GSE68795","4":"NA","5":"Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68795](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68795)","11":"syn21681315","12":"[Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC (PMID:26046767)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26046767)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889682","2":"GSE68795","3":"GSE68795","4":"NA","5":"Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68795](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68795)","11":"syn21681315","12":"[Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC (PMID:26046767)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26046767)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889683","2":"GSE68858","3":"GSE68858","4":"NA","5":"Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68858](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68858)","11":"syn21681486","12":"[Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature (PMID:30548288)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30548288)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889683","2":"GSE68858","3":"GSE68858","4":"NA","5":"Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68858](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68858)","11":"syn21681486","12":"[Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature (PMID:30548288)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30548288)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889685","2":"GSE68975","3":"GSE68975","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68975](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68975)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889685","2":"GSE68975","3":"GSE68975","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68975](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68975)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889685","2":"GSE68975","3":"GSE68975","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68975](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68975)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889686","2":"GSE68976","3":"GSE68976","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68976](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68976)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889686","2":"GSE68976","3":"GSE68976","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68976](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68976)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889686","2":"GSE68976","3":"GSE68976","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68976](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68976)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889687","2":"GSE68977","3":"GSE68977","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68977](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68977)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889687","2":"GSE68977","3":"GSE68977","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68977](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68977)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889687","2":"GSE68977","3":"GSE68977","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68977](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68977)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889689","2":"GSE68978","3":"GSE68978","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68978](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68978)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889689","2":"GSE68978","3":"GSE68978","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68978](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68978)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889689","2":"GSE68978","3":"GSE68978","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE68978](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68978)","11":"NA","12":"NA","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889690","2":"RNA-Seq and DNAse-1 Hypersensitivty assays of Gefinitib-treated PANC1 cells","3":"GSE70810","4":"Small molecule screens are widely used to prioritize compounds for development of pharmaceuticals and to reveal pathways altered in biological processes.  However, interpreting the results of these screens is very challenging since in almost all cases, the compounds are highly promiscuous.","5":"Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE70810](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70810)","11":"syn21645600","12":"[Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens (PMID:29023490)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29023490)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889691","2":"Expression data from isogenic Pten WT or KO mouse T-ALLs treated with DBZ or DMSO","3":"GSE71087","4":"To investigate the underlying mechanisms mediating resistance to NOTCH inhibition in Pten-null T-ALL tumor cells we performed gene expression profiling of isogenic Pten-positive and Pten-deleted leukemia lymphoblasts after acute treatment with DBZ in vivo.","5":"NA","6":"We performed microarray gene expression analysis of GSI treatment in isogenic Pten KO or WT NOTCH1 induced leukemias","7":"","8":"","9":"","10":"[GEO:GSE71087](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71087)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889691","2":"Expression data from isogenic Pten WT or KO mouse T-ALLs treated with DBZ or DMSO","3":"GSE71087","4":"To investigate the underlying mechanisms mediating resistance to NOTCH inhibition in Pten-null T-ALL tumor cells we performed gene expression profiling of isogenic Pten-positive and Pten-deleted leukemia lymphoblasts after acute treatment with DBZ in vivo.","5":"NA","6":"We performed microarray gene expression analysis of GSI treatment in isogenic Pten KO or WT NOTCH1 induced leukemias","7":"","8":"","9":"","10":"[GEO:GSE71087](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71087)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889692","2":"Expression data from isogenic Pten WT mouse T-ALLs","3":"GSE71089","4":"To explore the mechanisms downstream of NOTCH1 and PTEN in the control of leukemia cell growth, we performed expression profiling on NOTCH1 induced and Pten-positive T-ALL tumor cells infected with constitutively active AKT (myristoylated-AKT). Constitutive activation of AKT rescues the transcriptional programs induced by NOTCH1 inhibition in Pten-positive T-ALL cells.","5":"NA","6":"We performed microarray gene expression analysis of GSI treatment in Pten WT NOTCH1 induced leukemias infected with constitutively active AKT (myristoylated-AKT) or empty vector.","7":"","8":"","9":"","10":"[GEO:GSE71089](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71089)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889692","2":"Expression data from isogenic Pten WT mouse T-ALLs","3":"GSE71089","4":"To explore the mechanisms downstream of NOTCH1 and PTEN in the control of leukemia cell growth, we performed expression profiling on NOTCH1 induced and Pten-positive T-ALL tumor cells infected with constitutively active AKT (myristoylated-AKT). Constitutive activation of AKT rescues the transcriptional programs induced by NOTCH1 inhibition in Pten-positive T-ALL cells.","5":"NA","6":"We performed microarray gene expression analysis of GSI treatment in Pten WT NOTCH1 induced leukemias infected with constitutively active AKT (myristoylated-AKT) or empty vector.","7":"","8":"","9":"","10":"[GEO:GSE71089](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71089)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889693","2":"GSE73628","3":"GSE73628","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE73628](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73628)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889693","2":"GSE73628","3":"GSE73628","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE73628](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73628)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889693","2":"GSE73628","3":"GSE73628","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE73628](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73628)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Evolution"},{"1":"syn21889693","2":"GSE73628","3":"GSE73628","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE73628](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73628)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889694","2":"Bisulfite-independent analysis of CpG island methylation across cancer cell lines","3":"GSE75346","4":"This set of data is for assessing and validation of a novel method, CGI-seq, as described in the corresponding paper, for profiling of single cell CpG methylome. We tested 4 different cell lines (K562, GM12878, 551 K1-iPSC, and Fibroblast ATCC-CCL-110) with a low quantity of cells (LQC, here including 100-cell or 10-cell) and with single cells (SC) separately. Briefly, the protocol include these steps. The intact gDNA of the cell(s) was released. This gDNA (i.e.","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"We designed 2 protocols (protocol option 1 - BstUI as RE2, and protocol option2 - ABH as RE2, while other steps were the same) for LQC processing (30 samples with 100Cell or 10cell), and the option 2 above was used for SC (8 samples for K562 and GM12878 separately, totally 16 samples). The corresponding Methylation Controls (MCs, for which no RE1 was applied but all other processes were the same as the TEST) were also generated corresponding to each set of TEST samples..","7":"","8":"","9":"","10":"[GEO:GSE75346](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75346)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889694","2":"Bisulfite-independent analysis of CpG island methylation across cancer cell lines","3":"GSE75346","4":"This set of data is for assessing and validation of a novel method, CGI-seq, as described in the corresponding paper, for profiling of single cell CpG methylome. We tested 4 different cell lines (K562, GM12878, 551 K1-iPSC, and Fibroblast ATCC-CCL-110) with a low quantity of cells (LQC, here including 100-cell or 10-cell) and with single cells (SC) separately. Briefly, the protocol include these steps. The intact gDNA of the cell(s) was released. This gDNA (i.e.","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"We designed 2 protocols (protocol option 1 - BstUI as RE2, and protocol option2 - ABH as RE2, while other steps were the same) for LQC processing (30 samples with 100Cell or 10cell), and the option 2 above was used for SC (8 samples for K562 and GM12878 separately, totally 16 samples). The corresponding Methylation Controls (MCs, for which no RE1 was applied but all other processes were the same as the TEST) were also generated corresponding to each set of TEST samples..","7":"","8":"","9":"","10":"[GEO:GSE75346](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75346)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889694","2":"Bisulfite-independent analysis of CpG island methylation across cancer cell lines","3":"GSE75346","4":"This set of data is for assessing and validation of a novel method, CGI-seq, as described in the corresponding paper, for profiling of single cell CpG methylome. We tested 4 different cell lines (K562, GM12878, 551 K1-iPSC, and Fibroblast ATCC-CCL-110) with a low quantity of cells (LQC, here including 100-cell or 10-cell) and with single cells (SC) separately. Briefly, the protocol include these steps. The intact gDNA of the cell(s) was released. This gDNA (i.e.","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"We designed 2 protocols (protocol option 1 - BstUI as RE2, and protocol option2 - ABH as RE2, while other steps were the same) for LQC processing (30 samples with 100Cell or 10cell), and the option 2 above was used for SC (8 samples for K562 and GM12878 separately, totally 16 samples). The corresponding Methylation Controls (MCs, for which no RE1 was applied but all other processes were the same as the TEST) were also generated corresponding to each set of TEST samples..","7":"","8":"","9":"","10":"[GEO:GSE75346](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75346)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889694","2":"Bisulfite-independent analysis of CpG island methylation across cancer cell lines","3":"GSE75346","4":"This set of data is for assessing and validation of a novel method, CGI-seq, as described in the corresponding paper, for profiling of single cell CpG methylome. We tested 4 different cell lines (K562, GM12878, 551 K1-iPSC, and Fibroblast ATCC-CCL-110) with a low quantity of cells (LQC, here including 100-cell or 10-cell) and with single cells (SC) separately. Briefly, the protocol include these steps. The intact gDNA of the cell(s) was released. This gDNA (i.e.","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"We designed 2 protocols (protocol option 1 - BstUI as RE2, and protocol option2 - ABH as RE2, while other steps were the same) for LQC processing (30 samples with 100Cell or 10cell), and the option 2 above was used for SC (8 samples for K562 and GM12878 separately, totally 16 samples). The corresponding Methylation Controls (MCs, for which no RE1 was applied but all other processes were the same as the TEST) were also generated corresponding to each set of TEST samples..","7":"","8":"","9":"","10":"[GEO:GSE75346](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75346)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889695","2":"GSE77142","3":"GSE77142","4":"NA","5":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77142](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77142)","11":"syn21645430","12":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889695","2":"GSE77142","3":"GSE77142","4":"NA","5":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77142](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77142)","11":"syn21645430","12":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889695","2":"GSE77142","3":"GSE77142","4":"NA","5":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77142](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77142)","11":"syn21645430","12":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889696","2":"GSE77450","3":"GSE77450","4":"NA","5":"BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic -Cell","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77450](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77450)","11":"syn21648846","12":"[BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic -Cell (PMID:27008626)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27008626)","13":"syn9775665","14":"CSBC U01 Project Boston University","15":"CSBC","16":"U01","17":"NA"},{"1":"syn21889697","2":"GSE77570","3":"GSE77570","4":"NA","5":"Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77570](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77570)","11":"syn21645592","12":"[Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia (PMID:27315426)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27315426)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889698","2":"GSE77967","3":"GSE77967","4":"NA","5":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77967](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77967)","11":"syn21645405","12":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889698","2":"GSE77967","3":"GSE77967","4":"NA","5":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77967](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77967)","11":"syn21645405","12":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889698","2":"GSE77967","3":"GSE77967","4":"NA","5":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE77967](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77967)","11":"syn21645405","12":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889699","2":"GSE78036","3":"GSE78036","4":"NA","5":"Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE78036](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78036)","11":"syn21645594","12":"[Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells (PMID:27146274)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27146274)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889700","2":"Gene expression profileing of CUTLL cell lines upon Withaferin A treatment","3":"GSE78187","4":"The clinical development of targeted therapies has been hampered by their limited intrinsic antitumor activity and the rapid emergence of resistance, highlighting the need to identify highly active and synergistic drug combinations. However, empirical synergistic drug screening approaches are challenging and elucidating the mechanisms that underlie such drug interactions is typically complex.","5":"NA","6":"CUTLL cell lines were treated with Withaferin A or DMSO control at 24hrs in 6 replicates.","7":"","8":"","9":"","10":"[GEO:GSE78187](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78187)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889700","2":"Gene expression profileing of CUTLL cell lines upon Withaferin A treatment","3":"GSE78187","4":"The clinical development of targeted therapies has been hampered by their limited intrinsic antitumor activity and the rapid emergence of resistance, highlighting the need to identify highly active and synergistic drug combinations. However, empirical synergistic drug screening approaches are challenging and elucidating the mechanisms that underlie such drug interactions is typically complex.","5":"NA","6":"CUTLL cell lines were treated with Withaferin A or DMSO control at 24hrs in 6 replicates.","7":"","8":"","9":"","10":"[GEO:GSE78187](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78187)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889701","2":"Gene expression profiling of CUTLL cell lines upon 17 drug treatments","3":"GSE78188","4":"The clinical development of targeted therapies has been hampered by their limited intrinsic antitumor activity and the rapid emergence of resistance, highlighting the need to identify highly active and synergistic drug combinations. However, empirical synergistic drug screening approaches are challenging and elucidating the mechanisms that underlie such drug interactions is typically complex.","5":"NA","6":"CUTLL cell lines were treated with drugs (Pyrvinium P, Vorinostat, Geldanamycin, Lanatoside C, Withaferin A, Prochlorperazine, Astemizole, Mefloquine, Trichostatin A, Rapamycin, Parthenolide, Valproic acid, Thioridazine, Trifluoperazine, Phenoxibenzamine, Wortmannin, Resveratrol) or DMSO control at 24hrs in 3 replicates.","7":"","8":"","9":"","10":"[GEO:GSE78188](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78188)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889701","2":"Gene expression profiling of CUTLL cell lines upon 17 drug treatments","3":"GSE78188","4":"The clinical development of targeted therapies has been hampered by their limited intrinsic antitumor activity and the rapid emergence of resistance, highlighting the need to identify highly active and synergistic drug combinations. However, empirical synergistic drug screening approaches are challenging and elucidating the mechanisms that underlie such drug interactions is typically complex.","5":"NA","6":"CUTLL cell lines were treated with drugs (Pyrvinium P, Vorinostat, Geldanamycin, Lanatoside C, Withaferin A, Prochlorperazine, Astemizole, Mefloquine, Trichostatin A, Rapamycin, Parthenolide, Valproic acid, Thioridazine, Trifluoperazine, Phenoxibenzamine, Wortmannin, Resveratrol) or DMSO control at 24hrs in 3 replicates.","7":"","8":"","9":"","10":"[GEO:GSE78188](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78188)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889703","2":"GSE78189","3":"GSE78189","4":"NA","5":"Synergistic antileukemic therapies in NOTCH1-induced T-ALL","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE78189](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78189)","11":"syn21645323","12":"[Synergistic antileukemic therapies in NOTCH1-induced T-ALL (PMID:28174276)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28174276)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889703","2":"GSE78189","3":"GSE78189","4":"NA","5":"Synergistic antileukemic therapies in NOTCH1-induced T-ALL","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE78189](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78189)","11":"syn21645323","12":"[Synergistic antileukemic therapies in NOTCH1-induced T-ALL (PMID:28174276)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28174276)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889704","2":"GSE78198","3":"GSE78198","4":"NA","5":"3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE78198](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78198)","11":"syn21681375","12":"[3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk (PMID:29785014)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29785014)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889704","2":"GSE78198","3":"GSE78198","4":"NA","5":"3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE78198](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78198)","11":"syn21681375","12":"[3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk (PMID:29785014)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29785014)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889705","2":"GSE81164","3":"GSE81164","4":"NA","5":"Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE81164](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81164)","11":"syn21681435","12":"[Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression (PMID:30306128)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30306128)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889705","2":"GSE81164","3":"GSE81164","4":"NA","5":"Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE81164](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81164)","11":"syn21681435","12":"[Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression (PMID:30306128)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30306128)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889707","2":"RNA-Sequencing of human basal-like breast cancer cell line HCC1143 treated with  JQ1,Trametinib, or BEZ235","3":"GSE82032","4":"The goal of this experiment was to understand the changes in gene expression in the human basal-like breast cancer cell line HCC1143 following treatment with the MEK inhibitor Trametinib (T), PI3K/mTOR inhibitor BEZ235 (B), the BET inhibition JQ1 (JQ), Trametinib + JQ1 (TJ), or BEZ235 + JQ1(BJ), compared to a DMSO control (D).","5":"NA","6":"The human basal-like breast cancer cell line HCC1143 was treated for 72hr with 1uM Trametinib (T), 1uM BEZ235, 1uM JQ1 (JQ), 1uM Trametinib + 1uM JQ1 (TJ), 1uM BEZ235 + 1uM JQ1 (BJ), or a 0.05% DMSO control. Total RNA was isolated using a QIAGEN total RNA RNeasy kit, libraries were generated with a Truseq kit, and samples were run on the Nextseq500, data processing is described below.","7":"","8":"","9":"","10":"[GEO:GSE82032](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82032)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889707","2":"RNA-Sequencing of human basal-like breast cancer cell line HCC1143 treated with  JQ1,Trametinib, or BEZ235","3":"GSE82032","4":"The goal of this experiment was to understand the changes in gene expression in the human basal-like breast cancer cell line HCC1143 following treatment with the MEK inhibitor Trametinib (T), PI3K/mTOR inhibitor BEZ235 (B), the BET inhibition JQ1 (JQ), Trametinib + JQ1 (TJ), or BEZ235 + JQ1(BJ), compared to a DMSO control (D).","5":"NA","6":"The human basal-like breast cancer cell line HCC1143 was treated for 72hr with 1uM Trametinib (T), 1uM BEZ235, 1uM JQ1 (JQ), 1uM Trametinib + 1uM JQ1 (TJ), 1uM BEZ235 + 1uM JQ1 (BJ), or a 0.05% DMSO control. Total RNA was isolated using a QIAGEN total RNA RNeasy kit, libraries were generated with a Truseq kit, and samples were run on the Nextseq500, data processing is described below.","7":"","8":"","9":"","10":"[GEO:GSE82032](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82032)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889707","2":"RNA-Sequencing of human basal-like breast cancer cell line HCC1143 treated with  JQ1,Trametinib, or BEZ235","3":"GSE82032","4":"The goal of this experiment was to understand the changes in gene expression in the human basal-like breast cancer cell line HCC1143 following treatment with the MEK inhibitor Trametinib (T), PI3K/mTOR inhibitor BEZ235 (B), the BET inhibition JQ1 (JQ), Trametinib + JQ1 (TJ), or BEZ235 + JQ1(BJ), compared to a DMSO control (D).","5":"NA","6":"The human basal-like breast cancer cell line HCC1143 was treated for 72hr with 1uM Trametinib (T), 1uM BEZ235, 1uM JQ1 (JQ), 1uM Trametinib + 1uM JQ1 (TJ), 1uM BEZ235 + 1uM JQ1 (BJ), or a 0.05% DMSO control. Total RNA was isolated using a QIAGEN total RNA RNeasy kit, libraries were generated with a Truseq kit, and samples were run on the Nextseq500, data processing is described below.","7":"","8":"","9":"","10":"[GEO:GSE82032](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82032)","11":"NA","12":"NA","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889708","2":"GSE82127","3":"GSE82127","4":"NA","5":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE82127](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82127)","11":"syn21645389","12":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889708","2":"GSE82127","3":"GSE82127","4":"NA","5":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE82127](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82127)","11":"syn21645389","12":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889708","2":"GSE82127","3":"GSE82127","4":"NA","5":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE82127](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82127)","11":"syn21645389","12":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889709","2":"GSE83083","3":"GSE83083","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE83083](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83083)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889709","2":"GSE83083","3":"GSE83083","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE83083](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83083)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889709","2":"GSE83083","3":"GSE83083","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE83083](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83083)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Evolution"},{"1":"syn21889709","2":"GSE83083","3":"GSE83083","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE83083](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83083)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889710","2":"RNA-sequencing of prostate tissues and fibroblasts","3":"GSE83298","4":"We report that a computational systems approach can identify cell type specification genes that act synergistically, and demonstrate its application for reprogramming of fibroblasts to prostate tissue. We have employed three such master regulators (FOXA1, NKX3.1, and androgen receptor, AR) in a primed conversion strategy to generate prostate tissue from mouse fibroblasts, involving expression of pluripotency factors, tissue recombination with embryonic urogenital mesenchyme, and renal grafting.","5":"A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue","6":"RNA-sequencing profiles of prostate tissues and fibroblasts were generated and compared to RNA-sequencing profiles of induced prostate tissue in tissue recombinants.","7":"","8":"","9":"","10":"[GEO:GSE83298](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83298)","11":"syn21645325","12":"[A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue (PMID:28429718)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28429718)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889710","2":"RNA-sequencing of prostate tissues and fibroblasts","3":"GSE83298","4":"We report that a computational systems approach can identify cell type specification genes that act synergistically, and demonstrate its application for reprogramming of fibroblasts to prostate tissue. We have employed three such master regulators (FOXA1, NKX3.1, and androgen receptor, AR) in a primed conversion strategy to generate prostate tissue from mouse fibroblasts, involving expression of pluripotency factors, tissue recombination with embryonic urogenital mesenchyme, and renal grafting.","5":"A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue","6":"RNA-sequencing profiles of prostate tissues and fibroblasts were generated and compared to RNA-sequencing profiles of induced prostate tissue in tissue recombinants.","7":"","8":"","9":"","10":"[GEO:GSE83298](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83298)","11":"syn21645325","12":"[A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue (PMID:28429718)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28429718)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889711","2":"GSE83584","3":"GSE83584","4":"NA","5":"Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE83584](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83584)","11":"syn21649111","12":"[Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation (PMID:27452175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27452175)","13":"syn7416710","14":"ECM geometrical and mechanical properties modulate RTK signaling","15":"PS-ON","16":"U01","17":"Heterogeneity"},{"1":"syn21889711","2":"GSE83584","3":"GSE83584","4":"NA","5":"Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE83584](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83584)","11":"syn21649111","12":"[Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation (PMID:27452175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27452175)","13":"syn7416710","14":"ECM geometrical and mechanical properties modulate RTK signaling","15":"PS-ON","16":"U01","17":"Microenvironment"},{"1":"syn21889712","2":"mRNA array profiling of response to mTOR and HDAC inhibitors","3":"GSE84205","4":"mTOR and HDAC inhibitors induce cell death of malignant peripheral nerve sheath tumors (MPNSTs) in vitro, and in vivo. We performed microarray analysis of mTOR and HDAC inhibition alone and in combination 24 hours after treatment, prior to induction of cell death, to identify transcriptional changes that might be mechanistic drivers of the therapeutic efficacy.","5":"mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors","6":"12 samples, in triplicate, 3X vehicle, 3X INK-128, 3X Vorinostat, 3X INK-128 + Vorinostat","7":"","8":"","9":"","10":"[GEO:GSE84205](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84205)","11":"syn21649213","12":"[mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors (PMID:28963352)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28963352)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889712","2":"mRNA array profiling of response to mTOR and HDAC inhibitors","3":"GSE84205","4":"mTOR and HDAC inhibitors induce cell death of malignant peripheral nerve sheath tumors (MPNSTs) in vitro, and in vivo. We performed microarray analysis of mTOR and HDAC inhibition alone and in combination 24 hours after treatment, prior to induction of cell death, to identify transcriptional changes that might be mechanistic drivers of the therapeutic efficacy.","5":"mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors","6":"12 samples, in triplicate, 3X vehicle, 3X INK-128, 3X Vorinostat, 3X INK-128 + Vorinostat","7":"","8":"","9":"","10":"[GEO:GSE84205](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84205)","11":"syn21649213","12":"[mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors (PMID:28963352)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28963352)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889712","2":"mRNA array profiling of response to mTOR and HDAC inhibitors","3":"GSE84205","4":"mTOR and HDAC inhibitors induce cell death of malignant peripheral nerve sheath tumors (MPNSTs) in vitro, and in vivo. We performed microarray analysis of mTOR and HDAC inhibition alone and in combination 24 hours after treatment, prior to induction of cell death, to identify transcriptional changes that might be mechanistic drivers of the therapeutic efficacy.","5":"mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors","6":"12 samples, in triplicate, 3X vehicle, 3X INK-128, 3X Vorinostat, 3X INK-128 + Vorinostat","7":"","8":"","9":"","10":"[GEO:GSE84205](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84205)","11":"syn21649213","12":"[mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors (PMID:28963352)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28963352)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889712","2":"mRNA array profiling of response to mTOR and HDAC inhibitors","3":"GSE84205","4":"mTOR and HDAC inhibitors induce cell death of malignant peripheral nerve sheath tumors (MPNSTs) in vitro, and in vivo. We performed microarray analysis of mTOR and HDAC inhibition alone and in combination 24 hours after treatment, prior to induction of cell death, to identify transcriptional changes that might be mechanistic drivers of the therapeutic efficacy.","5":"mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors","6":"12 samples, in triplicate, 3X vehicle, 3X INK-128, 3X Vorinostat, 3X INK-128 + Vorinostat","7":"","8":"","9":"","10":"[GEO:GSE84205](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84205)","11":"syn21649213","12":"[mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors (PMID:28963352)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28963352)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889713","2":"ATAC-Seq of embryonic vs extraembryonic lineages","3":"GSE84232","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of chromatin accessibility patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84232)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889713","2":"ATAC-Seq of embryonic vs extraembryonic lineages","3":"GSE84232","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of chromatin accessibility patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84232)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889713","2":"ATAC-Seq of embryonic vs extraembryonic lineages","3":"GSE84232","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of chromatin accessibility patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84232)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889713","2":"ATAC-Seq of embryonic vs extraembryonic lineages","3":"GSE84232","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of chromatin accessibility patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84232)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889714","2":"RNA-Seq of embryonic vs extraembryonic lineages","3":"GSE84234","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84234](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84234)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889714","2":"RNA-Seq of embryonic vs extraembryonic lineages","3":"GSE84234","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84234](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84234)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889714","2":"RNA-Seq of embryonic vs extraembryonic lineages","3":"GSE84234","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84234](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84234)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889714","2":"RNA-Seq of embryonic vs extraembryonic lineages","3":"GSE84234","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84234](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84234)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889715","2":"RRBS  of embryonic vs extraembryonic lineages","3":"GSE84235","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84235](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84235)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889715","2":"RRBS  of embryonic vs extraembryonic lineages","3":"GSE84235","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84235](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84235)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889715","2":"RRBS  of embryonic vs extraembryonic lineages","3":"GSE84235","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84235](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84235)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889715","2":"RRBS  of embryonic vs extraembryonic lineages","3":"GSE84235","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE84235](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84235)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889716","2":"GSE84236","3":"GSE84236","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE84236](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84236)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889716","2":"GSE84236","3":"GSE84236","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE84236](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84236)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889716","2":"GSE84236","3":"GSE84236","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE84236](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84236)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889716","2":"GSE84236","3":"GSE84236","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE84236](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84236)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889717","2":"GSE84389","3":"GSE84389","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE84389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84389)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889717","2":"GSE84389","3":"GSE84389","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE84389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84389)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889718","2":"GSE85047","3":"GSE85047","4":"NA","5":"Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE85047](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85047)","11":"syn21648926","12":"[Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma (PMID:29510988)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29510988)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889718","2":"GSE85047","3":"GSE85047","4":"NA","5":"Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE85047](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85047)","11":"syn21648926","12":"[Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma (PMID:29510988)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29510988)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889719","2":"GSE85224","3":"GSE85224","4":"NA","5":"Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE85224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85224)","11":"syn21649000","12":"[Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer (PMID:29161592)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29161592)","13":"syn17084062","14":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889719","2":"GSE85224","3":"GSE85224","4":"NA","5":"Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE85224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85224)","11":"syn21649000","12":"[Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer (PMID:29161592)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29161592)","13":"syn17084062","14":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","15":"CSBC","16":"U01","17":"Evolution"},{"1":"syn21889721","2":"GSE85575","3":"GSE85575","4":"NA","5":"An Automated Microwell Platform for Large-Scale Single Cell RNA-Seq","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE85575](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85575)","11":"syn21645316","12":"[An Automated Microwell Platform for Large-Scale Single Cell RNA-Seq (PMID:27670648)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27670648)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889722","2":"Immune escape in breast cancer during in situ to invasive carcinoma transition","3":"GSE87517","4":"To dissect mechanisms of immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils.","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"RNA-Seq: Gene expression analyses in leukocytes sorted from normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC).","7":"","8":"","9":"","10":"[GEO:GSE87517](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87517)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889722","2":"Immune escape in breast cancer during in situ to invasive carcinoma transition","3":"GSE87517","4":"To dissect mechanisms of immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils.","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"RNA-Seq: Gene expression analyses in leukocytes sorted from normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC).","7":"","8":"","9":"","10":"[GEO:GSE87517](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87517)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889722","2":"Immune escape in breast cancer during in situ to invasive carcinoma transition","3":"GSE87517","4":"To dissect mechanisms of immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils.","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"RNA-Seq: Gene expression analyses in leukocytes sorted from normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC).","7":"","8":"","9":"","10":"[GEO:GSE87517](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87517)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889722","2":"Immune escape in breast cancer during in situ to invasive carcinoma transition","3":"GSE87517","4":"To dissect mechanisms of immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils.","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"RNA-Seq: Gene expression analyses in leukocytes sorted from normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC).","7":"","8":"","9":"","10":"[GEO:GSE87517](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87517)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889724","2":"DNA Methylation of breast cancer treated with Bisphenol A and/or Genistein","3":"GSE89107","4":"Early postnatal exposures to Bisphenol A (BPA) and genistein (GEN) have been reported to predispose for and against mammary cancer, respectively, in adult rats. Since the changes in cancer susceptibility occurs in the absence of the original chemical exposure, we have investigated the potential of epigenetics to account for these changes. DNA methylation studies reveal that prepubertal BPA exposure alters signaling pathways that contribute to carcinogenesis.","5":"DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients","6":"We conducted MBDCap-seq on mammary glands procured from 100 day-old rats exposed prepubertally to vehicle control, BPA, GEN, or BPA + GEN (n = 5/ group)","7":"","8":"","9":"","10":"[GEO:GSE89107](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89107)","11":"syn21645258","12":"[DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients (PMID:28505145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28505145)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889724","2":"DNA Methylation of breast cancer treated with Bisphenol A and/or Genistein","3":"GSE89107","4":"Early postnatal exposures to Bisphenol A (BPA) and genistein (GEN) have been reported to predispose for and against mammary cancer, respectively, in adult rats. Since the changes in cancer susceptibility occurs in the absence of the original chemical exposure, we have investigated the potential of epigenetics to account for these changes. DNA methylation studies reveal that prepubertal BPA exposure alters signaling pathways that contribute to carcinogenesis.","5":"DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients","6":"We conducted MBDCap-seq on mammary glands procured from 100 day-old rats exposed prepubertally to vehicle control, BPA, GEN, or BPA + GEN (n = 5/ group)","7":"","8":"","9":"","10":"[GEO:GSE89107](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89107)","11":"syn21645258","12":"[DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients (PMID:28505145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28505145)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889725","2":"GSE89225","3":"GSE89225","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89225](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89225)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889725","2":"GSE89225","3":"GSE89225","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89225](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89225)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889725","2":"GSE89225","3":"GSE89225","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89225](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89225)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889725","2":"GSE89225","3":"GSE89225","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89225](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89225)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889726","2":"GSE89307","3":"GSE89307","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89307](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89307)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889726","2":"GSE89307","3":"GSE89307","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89307](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89307)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889726","2":"GSE89307","3":"GSE89307","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89307](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89307)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889726","2":"GSE89307","3":"GSE89307","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89307](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89307)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889727","2":"GSE89308","3":"GSE89308","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89308](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89308)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889727","2":"GSE89308","3":"GSE89308","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89308](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89308)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889727","2":"GSE89308","3":"GSE89308","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89308](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89308)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889727","2":"GSE89308","3":"GSE89308","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89308](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89308)","11":"NA","12":"NA","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889728","2":"GSE89309","3":"GSE89309","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89309)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889728","2":"GSE89309","3":"GSE89309","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89309)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889728","2":"GSE89309","3":"GSE89309","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89309)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889728","2":"GSE89309","3":"GSE89309","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89309)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889729","2":"GSE89409","3":"GSE89409","4":"NA","5":"Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE89409](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89409)","11":"syn21648917","12":"[Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma (PMID:29632085)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29632085)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889730","2":"Nm-seq finds thousands of modified 2'-methylation sites in mRNA with base precision","3":"GSE90164","4":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision The ribose of rna nucleotides can be 2<U+2032>-O-methylated (nm). despite advances in high-throughput detection, the inert chemical nature of nm still limits sensitivity and precludes mapping in mrna.","5":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","6":"we developed a conceptually distinct approach based on the different chemical properties of nucleosides with 2<U+2032>-OH and 2<U+2032>-OMe22<U+2013>25, combining enrichment with detection of a positive signal (rather than the lack of signal) to produce a sensitive method suited for discovery of Nm sites in rare RNA molecules or at low stoichiometry..","7":"","8":"","9":"","10":"[GEO:GSE90164](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90164)","11":"syn21645423","12":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889730","2":"Nm-seq finds thousands of modified 2'-methylation sites in mRNA with base precision","3":"GSE90164","4":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision The ribose of rna nucleotides can be 2<U+2032>-O-methylated (nm). despite advances in high-throughput detection, the inert chemical nature of nm still limits sensitivity and precludes mapping in mrna.","5":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","6":"we developed a conceptually distinct approach based on the different chemical properties of nucleosides with 2<U+2032>-OH and 2<U+2032>-OMe22<U+2013>25, combining enrichment with detection of a positive signal (rather than the lack of signal) to produce a sensitive method suited for discovery of Nm sites in rare RNA molecules or at low stoichiometry..","7":"","8":"","9":"","10":"[GEO:GSE90164](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90164)","11":"syn21645423","12":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889730","2":"Nm-seq finds thousands of modified 2'-methylation sites in mRNA with base precision","3":"GSE90164","4":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision The ribose of rna nucleotides can be 2<U+2032>-O-methylated (nm). despite advances in high-throughput detection, the inert chemical nature of nm still limits sensitivity and precludes mapping in mrna.","5":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","6":"we developed a conceptually distinct approach based on the different chemical properties of nucleosides with 2<U+2032>-OH and 2<U+2032>-OMe22<U+2013>25, combining enrichment with detection of a positive signal (rather than the lack of signal) to produce a sensitive method suited for discovery of Nm sites in rare RNA molecules or at low stoichiometry..","7":"","8":"","9":"","10":"[GEO:GSE90164](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90164)","11":"syn21645423","12":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889731","2":"GSE90780","3":"GSE90780","4":"NA","5":"Homeobox oncogene activation by pan-cancer DNA hypermethylation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE90780](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90780)","11":"syn21648978","12":"[Homeobox oncogene activation by pan-cancer DNA hypermethylation (PMID:30097071)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30097071)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889731","2":"GSE90780","3":"GSE90780","4":"NA","5":"Homeobox oncogene activation by pan-cancer DNA hypermethylation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE90780](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90780)","11":"syn21648978","12":"[Homeobox oncogene activation by pan-cancer DNA hypermethylation (PMID:30097071)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30097071)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889732","2":"The transcriptome effect of knocking down EZH2 with Taomifen Resistant-MCF7L","3":"GSE92316","4":"Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in tamoxifen-resistant (TamR) MCF-7 cells.","5":"NA","6":"Transcriptome profiles of tamoxifen sensitive MCF-7 infected with pLenti-CMV-hygro-GFP or pLento-HA-EZH2 were sequenced in at least duplicates using Illumina HiSeq 3000.","7":"","8":"","9":"","10":"[GEO:GSE92316](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92316)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889732","2":"The transcriptome effect of knocking down EZH2 with Taomifen Resistant-MCF7L","3":"GSE92316","4":"Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in tamoxifen-resistant (TamR) MCF-7 cells.","5":"NA","6":"Transcriptome profiles of tamoxifen sensitive MCF-7 infected with pLenti-CMV-hygro-GFP or pLento-HA-EZH2 were sequenced in at least duplicates using Illumina HiSeq 3000.","7":"","8":"","9":"","10":"[GEO:GSE92316](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92316)","11":"NA","12":"NA","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889733","2":"GSE92721","3":"GSE92721","4":"NA","5":"Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE92721](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92721)","11":"syn21645319","12":"[Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer (PMID:28411207)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28411207)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889733","2":"GSE92721","3":"GSE92721","4":"NA","5":"Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE92721](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92721)","11":"syn21645319","12":"[Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer (PMID:28411207)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28411207)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889734","2":"GSE93326","3":"GSE93326","4":"NA","5":"Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE93326](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93326)","11":"syn21681523","12":"[Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes (PMID:30658994)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30658994)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889734","2":"GSE93326","3":"GSE93326","4":"NA","5":"Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE93326](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93326)","11":"syn21681523","12":"[Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes (PMID:30658994)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30658994)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889735","2":"Metabolic origins of spatial organization in the tumor microenvironment","3":"GSE93702","4":"We report the transcriptional changes induced by hypoxia and/or lactate on bone marrow-derived macrophages (BMDMs)","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"Untreated macrophages as well as macrophages treated with lactate, cultured in hypoxia (1% oxygen) or both were cultured in vitro. Then total mRNA was sequenced.","7":"","8":"","9":"","10":"[GEO:GSE93702](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93702)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889735","2":"Metabolic origins of spatial organization in the tumor microenvironment","3":"GSE93702","4":"We report the transcriptional changes induced by hypoxia and/or lactate on bone marrow-derived macrophages (BMDMs)","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"Untreated macrophages as well as macrophages treated with lactate, cultured in hypoxia (1% oxygen) or both were cultured in vitro. Then total mRNA was sequenced.","7":"","8":"","9":"","10":"[GEO:GSE93702](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93702)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889735","2":"Metabolic origins of spatial organization in the tumor microenvironment","3":"GSE93702","4":"We report the transcriptional changes induced by hypoxia and/or lactate on bone marrow-derived macrophages (BMDMs)","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"Untreated macrophages as well as macrophages treated with lactate, cultured in hypoxia (1% oxygen) or both were cultured in vitro. Then total mRNA was sequenced.","7":"","8":"","9":"","10":"[GEO:GSE93702](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93702)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889735","2":"Metabolic origins of spatial organization in the tumor microenvironment","3":"GSE93702","4":"We report the transcriptional changes induced by hypoxia and/or lactate on bone marrow-derived macrophages (BMDMs)","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"Untreated macrophages as well as macrophages treated with lactate, cultured in hypoxia (1% oxygen) or both were cultured in vitro. Then total mRNA was sequenced.","7":"","8":"","9":"","10":"[GEO:GSE93702](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93702)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889737","2":"GSE93765","3":"GSE93765","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE93765](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93765)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889737","2":"GSE93765","3":"GSE93765","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE93765](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93765)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889737","2":"GSE93765","3":"GSE93765","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE93765](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93765)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889737","2":"GSE93765","3":"GSE93765","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE93765](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93765)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889738","2":"scRNA-sequencing of mESCs into motor neurons","3":"GSE94883","4":"Cellular lineage commitment and terminal cellular differentiation result from the induction of dynamically regulated transcriptional programs. We report an unbiased approach to studying this process that combines temporal single cell RNA-sequencing and topology-based computational analyses (single cell Topological Data Analysis (scTDA)).","5":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","6":"Single cell RNA sequencing of 2,744 individual cells, spanning 2 biological (non-technical) replicates. Cells were sampled daily across days 2 through 6 of the in vitro differentiation of mESCs into motor neurons.","7":"","8":"","9":"","10":"[GEO:GSE94883](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94883)","11":"syn21645558","12":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889738","2":"scRNA-sequencing of mESCs into motor neurons","3":"GSE94883","4":"Cellular lineage commitment and terminal cellular differentiation result from the induction of dynamically regulated transcriptional programs. We report an unbiased approach to studying this process that combines temporal single cell RNA-sequencing and topology-based computational analyses (single cell Topological Data Analysis (scTDA)).","5":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","6":"Single cell RNA sequencing of 2,744 individual cells, spanning 2 biological (non-technical) replicates. Cells were sampled daily across days 2 through 6 of the in vitro differentiation of mESCs into motor neurons.","7":"","8":"","9":"","10":"[GEO:GSE94883](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94883)","11":"syn21645558","12":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889738","2":"scRNA-sequencing of mESCs into motor neurons","3":"GSE94883","4":"Cellular lineage commitment and terminal cellular differentiation result from the induction of dynamically regulated transcriptional programs. We report an unbiased approach to studying this process that combines temporal single cell RNA-sequencing and topology-based computational analyses (single cell Topological Data Analysis (scTDA)).","5":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","6":"Single cell RNA sequencing of 2,744 individual cells, spanning 2 biological (non-technical) replicates. Cells were sampled daily across days 2 through 6 of the in vitro differentiation of mESCs into motor neurons.","7":"","8":"","9":"","10":"[GEO:GSE94883](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94883)","11":"syn21645558","12":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889739","2":"PDGF-driven glioblastoma mouse model scRNA-Seq","3":"GSE95157","4":"Generate scRNA-Seq profiles for PDGF-driven glioblastoma mouse model.","5":"NA","6":"Obtain 85 scRNA-Seq profiles from a de novo tumor-derived cell line.","7":"","8":"","9":"","10":"[GEO:GSE95157](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95157)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889739","2":"PDGF-driven glioblastoma mouse model scRNA-Seq","3":"GSE95157","4":"Generate scRNA-Seq profiles for PDGF-driven glioblastoma mouse model.","5":"NA","6":"Obtain 85 scRNA-Seq profiles from a de novo tumor-derived cell line.","7":"","8":"","9":"","10":"[GEO:GSE95157](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95157)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889740","2":"Cell Stiffness and Migration Gene Expression","3":"GSE95680","4":"Cell migration is central to many biological processes including embryonic development, wound healing, and cancer progression. Cell migration is sensitive to environmental stiffness, and many cell types exhibit a stiffness optimum at which migration is maximal. Here we present a cell migration simulator that predicts a stiffness optimum that can be shifted by altering the number of active molecular motors and clutches.","5":"Shifting the optimal stiffness for cell migration","6":"To collect enough mRNA for expression analysis on different stiffnesses, U251 cells were cultured on large polyacrylamide gels covering the surface of a one well chamber glass slide (Lab-Tek 154453). After one day of culture on the gels, mRNA was purified from the cells using an RNeasy Mini Kit (Qiagen 74104). mRNA samples were then analyzed at the University of Minnesota Genomics Center using a HumanHT-12 BeadChip microarray (Illumina BD 103-0204)..","7":"","8":"","9":"","10":"[GEO:GSE95680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95680)","11":"syn21645266","12":"[Shifting the optimal stiffness for cell migration (PMID:28530245)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28530245)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889740","2":"Cell Stiffness and Migration Gene Expression","3":"GSE95680","4":"Cell migration is central to many biological processes including embryonic development, wound healing, and cancer progression. Cell migration is sensitive to environmental stiffness, and many cell types exhibit a stiffness optimum at which migration is maximal. Here we present a cell migration simulator that predicts a stiffness optimum that can be shifted by altering the number of active molecular motors and clutches.","5":"Shifting the optimal stiffness for cell migration","6":"To collect enough mRNA for expression analysis on different stiffnesses, U251 cells were cultured on large polyacrylamide gels covering the surface of a one well chamber glass slide (Lab-Tek 154453). After one day of culture on the gels, mRNA was purified from the cells using an RNeasy Mini Kit (Qiagen 74104). mRNA samples were then analyzed at the University of Minnesota Genomics Center using a HumanHT-12 BeadChip microarray (Illumina BD 103-0204)..","7":"","8":"","9":"","10":"[GEO:GSE95680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95680)","11":"syn21645266","12":"[Shifting the optimal stiffness for cell migration (PMID:28530245)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28530245)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889740","2":"Cell Stiffness and Migration Gene Expression","3":"GSE95680","4":"Cell migration is central to many biological processes including embryonic development, wound healing, and cancer progression. Cell migration is sensitive to environmental stiffness, and many cell types exhibit a stiffness optimum at which migration is maximal. Here we present a cell migration simulator that predicts a stiffness optimum that can be shifted by altering the number of active molecular motors and clutches.","5":"Shifting the optimal stiffness for cell migration","6":"To collect enough mRNA for expression analysis on different stiffnesses, U251 cells were cultured on large polyacrylamide gels covering the surface of a one well chamber glass slide (Lab-Tek 154453). After one day of culture on the gels, mRNA was purified from the cells using an RNeasy Mini Kit (Qiagen 74104). mRNA samples were then analyzed at the University of Minnesota Genomics Center using a HumanHT-12 BeadChip microarray (Illumina BD 103-0204)..","7":"","8":"","9":"","10":"[GEO:GSE95680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95680)","11":"syn21645266","12":"[Shifting the optimal stiffness for cell migration (PMID:28530245)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28530245)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889742","2":"Protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309","3":"GSE96753","4":"11 BRAF inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"NA","6":"11 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","7":"","8":"","9":"","10":"[GEO:GSE96753](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96753)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889742","2":"Protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309","3":"GSE96753","4":"11 BRAF inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"NA","6":"11 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","7":"","8":"","9":"","10":"[GEO:GSE96753](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96753)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889742","2":"Protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309","3":"GSE96753","4":"11 BRAF inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"NA","6":"11 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","7":"","8":"","9":"","10":"[GEO:GSE96753](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96753)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889743","2":"GSE96760","3":"GSE96760","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE96760](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96760)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889743","2":"GSE96760","3":"GSE96760","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE96760](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96760)","11":"NA","12":"NA","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889744","2":"Protein levels in BRAF/MEK inhibitor resistance melanoma cells treated with PF3758309 [CR]","3":"GSE96902","4":"3 BRAF/MEK inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","6":"3 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","7":"","8":"","9":"","10":"[GEO:GSE96902](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96902)","11":"syn21649211","12":"[PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (PMID:28953887)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28953887)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889744","2":"Protein levels in BRAF/MEK inhibitor resistance melanoma cells treated with PF3758309 [CR]","3":"GSE96902","4":"3 BRAF/MEK inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","6":"3 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","7":"","8":"","9":"","10":"[GEO:GSE96902](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96902)","11":"syn21649211","12":"[PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (PMID:28953887)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28953887)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889744","2":"Protein levels in BRAF/MEK inhibitor resistance melanoma cells treated with PF3758309 [CR]","3":"GSE96902","4":"3 BRAF/MEK inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","6":"3 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","7":"","8":"","9":"","10":"[GEO:GSE96902](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96902)","11":"syn21649211","12":"[PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (PMID:28953887)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28953887)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889745","2":"GSE96931","3":"GSE96931","4":"NA","5":"Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE96931](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96931)","11":"syn21648871","12":"[Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma (PMID:29440233)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29440233)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889746","2":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","3":"GSE96979","4":"Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG island methylator phenotype (CIMP) and significantly longer patient survival time than wild-type IDH1/2 tumors. Although there are many factors underlying the differences in survival between these two tumor types, immune-related differences in cell content are potentially important contributors.","5":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","6":"Ntva_Ink4a/Arf-/- mice were used to generate mouse gliomas. The genetic backgrounds of tva mice are FVB/N, C57BL6, BALB/C, and 129. To generate wtIDH1- and muIDH1-expressing mouse gliomas, we used the RCAS/tva system as described previously. PDGFa-expressing DF1 cells were mixed with either wtIDH1-shp53- or muIDH1-shp53-expressing DF1 cells. These mixed DF1 cells were injected into Ntva_ Ink4a/Arf-/- mice. Whole tumor tissue was used for RNA extraction..","7":"","8":"","9":"","10":"[GEO:GSE96979](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96979)","11":"syn21648867","12":"[Mutant IDH1 regulates the tumor-associated immune system in gliomas (PMID:28465358)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28465358)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889746","2":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","3":"GSE96979","4":"Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG island methylator phenotype (CIMP) and significantly longer patient survival time than wild-type IDH1/2 tumors. Although there are many factors underlying the differences in survival between these two tumor types, immune-related differences in cell content are potentially important contributors.","5":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","6":"Ntva_Ink4a/Arf-/- mice were used to generate mouse gliomas. The genetic backgrounds of tva mice are FVB/N, C57BL6, BALB/C, and 129. To generate wtIDH1- and muIDH1-expressing mouse gliomas, we used the RCAS/tva system as described previously. PDGFa-expressing DF1 cells were mixed with either wtIDH1-shp53- or muIDH1-shp53-expressing DF1 cells. These mixed DF1 cells were injected into Ntva_ Ink4a/Arf-/- mice. Whole tumor tissue was used for RNA extraction..","7":"","8":"","9":"","10":"[GEO:GSE96979](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96979)","11":"syn21648867","12":"[Mutant IDH1 regulates the tumor-associated immune system in gliomas (PMID:28465358)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28465358)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889746","2":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","3":"GSE96979","4":"Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG island methylator phenotype (CIMP) and significantly longer patient survival time than wild-type IDH1/2 tumors. Although there are many factors underlying the differences in survival between these two tumor types, immune-related differences in cell content are potentially important contributors.","5":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","6":"Ntva_Ink4a/Arf-/- mice were used to generate mouse gliomas. The genetic backgrounds of tva mice are FVB/N, C57BL6, BALB/C, and 129. To generate wtIDH1- and muIDH1-expressing mouse gliomas, we used the RCAS/tva system as described previously. PDGFa-expressing DF1 cells were mixed with either wtIDH1-shp53- or muIDH1-shp53-expressing DF1 cells. These mixed DF1 cells were injected into Ntva_ Ink4a/Arf-/- mice. Whole tumor tissue was used for RNA extraction..","7":"","8":"","9":"","10":"[GEO:GSE96979](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96979)","11":"syn21648867","12":"[Mutant IDH1 regulates the tumor-associated immune system in gliomas (PMID:28465358)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28465358)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889746","2":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","3":"GSE96979","4":"Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG island methylator phenotype (CIMP) and significantly longer patient survival time than wild-type IDH1/2 tumors. Although there are many factors underlying the differences in survival between these two tumor types, immune-related differences in cell content are potentially important contributors.","5":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","6":"Ntva_Ink4a/Arf-/- mice were used to generate mouse gliomas. The genetic backgrounds of tva mice are FVB/N, C57BL6, BALB/C, and 129. To generate wtIDH1- and muIDH1-expressing mouse gliomas, we used the RCAS/tva system as described previously. PDGFa-expressing DF1 cells were mixed with either wtIDH1-shp53- or muIDH1-shp53-expressing DF1 cells. These mixed DF1 cells were injected into Ntva_ Ink4a/Arf-/- mice. Whole tumor tissue was used for RNA extraction..","7":"","8":"","9":"","10":"[GEO:GSE96979](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96979)","11":"syn21648867","12":"[Mutant IDH1 regulates the tumor-associated immune system in gliomas (PMID:28465358)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28465358)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889747","2":"GSE97460","3":"GSE97460","4":"NA","5":"PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE97460](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97460)","11":"syn21645322","12":"[PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens (PMID:28740083)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28740083)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889747","2":"GSE97460","3":"GSE97460","4":"NA","5":"PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE97460](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97460)","11":"syn21645322","12":"[PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens (PMID:28740083)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28740083)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889748","2":"RNA-seq of treated and untreated melanoma cells","3":"GSE97679","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","7":"","8":"","9":"","10":"[GEO:GSE97679](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97679)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889748","2":"RNA-seq of treated and untreated melanoma cells","3":"GSE97679","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","7":"","8":"","9":"","10":"[GEO:GSE97679](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97679)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889748","2":"RNA-seq of treated and untreated melanoma cells","3":"GSE97679","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","7":"","8":"","9":"","10":"[GEO:GSE97679](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97679)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889749","2":"ATAC-seq of treated and untreated melanoma cells","3":"GSE97680","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","7":"","8":"","9":"","10":"[GEO:GSE97680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97680)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889749","2":"ATAC-seq of treated and untreated melanoma cells","3":"GSE97680","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","7":"","8":"","9":"","10":"[GEO:GSE97680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97680)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889749","2":"ATAC-seq of treated and untreated melanoma cells","3":"GSE97680","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","7":"","8":"","9":"","10":"[GEO:GSE97680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97680)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889750","2":"Gene expression signature of vemurafenib resistance in WM989 and WM983B melanoma cells","3":"GSE97681","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed RNA sequencing on WM989 cells without vemurafenib, after 48 hours of treatment, and upon the development of resistance.","7":"","8":"","9":"","10":"[GEO:GSE97681](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97681)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889750","2":"Gene expression signature of vemurafenib resistance in WM989 and WM983B melanoma cells","3":"GSE97681","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed RNA sequencing on WM989 cells without vemurafenib, after 48 hours of treatment, and upon the development of resistance.","7":"","8":"","9":"","10":"[GEO:GSE97681](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97681)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889750","2":"Gene expression signature of vemurafenib resistance in WM989 and WM983B melanoma cells","3":"GSE97681","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"NA","6":"We performed RNA sequencing on WM989 cells without vemurafenib, after 48 hours of treatment, and upon the development of resistance.","7":"","8":"","9":"","10":"[GEO:GSE97681](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97681)","11":"NA","12":"NA","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889751","2":"GSE97682","3":"GSE97682","4":"NA","5":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE97682](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97682)","11":"syn21649208","12":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889751","2":"GSE97682","3":"GSE97682","4":"NA","5":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE97682](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97682)","11":"syn21649208","12":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889751","2":"GSE97682","3":"GSE97682","4":"NA","5":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE97682](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97682)","11":"syn21649208","12":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889752","2":"GSE98161","3":"GSE98161","4":"NA","5":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98161](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98161)","11":"syn21645422","12":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889752","2":"GSE98161","3":"GSE98161","4":"NA","5":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98161](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98161)","11":"syn21645422","12":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889752","2":"GSE98161","3":"GSE98161","4":"NA","5":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98161](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98161)","11":"syn21645422","12":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889753","2":"GSE98183","3":"GSE98183","4":"NA","5":"Chromosomal instability drives metastasis through a cytosolic DNA response","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98183](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98183)","11":"syn21645269","12":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889753","2":"GSE98183","3":"GSE98183","4":"NA","5":"Chromosomal instability drives metastasis through a cytosolic DNA response","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98183](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98183)","11":"syn21645269","12":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889753","2":"GSE98183","3":"GSE98183","4":"NA","5":"Chromosomal instability drives metastasis through a cytosolic DNA response","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98183](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98183)","11":"syn21645269","12":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889755","2":"CTCF ChIP-Seq and Hi-C of murine cell lines under various conditions","3":"GSE98671","4":"The molecular mechanisms underlying folding of mammalian chromosomes remain poorly understood. The transcription factor CTCF is a candidate regulator of chromosomal structure. Using the auxin-inducible degron system in mouse embryonic stem cells, we show that CTCF is absolutely and dose-dependently required for looping between CTCF target sites and insulation of topologically associating domains (TADs).","5":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","6":"mouse ES cells were engineered to harbor an auxin-inducible degron (AID) tag at both endogenous alleles of CTCF. A transgene encoding the auxin-binding F-box protein Tir1 was subsequently introduce, so that adding auxin to the culture media leads to rapid (hours) and reversible degradation of CTCF. Consequences of acute loss of CTCF and its restoration were investigated using ChIP-seq, RNA-seq and high-throughput Chromosome Conformation Capture (5C and Hi-C).","7":"","8":"","9":"","10":"[GEO:GSE98671](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98671)","11":"syn21649210","12":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889755","2":"CTCF ChIP-Seq and Hi-C of murine cell lines under various conditions","3":"GSE98671","4":"The molecular mechanisms underlying folding of mammalian chromosomes remain poorly understood. The transcription factor CTCF is a candidate regulator of chromosomal structure. Using the auxin-inducible degron system in mouse embryonic stem cells, we show that CTCF is absolutely and dose-dependently required for looping between CTCF target sites and insulation of topologically associating domains (TADs).","5":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","6":"mouse ES cells were engineered to harbor an auxin-inducible degron (AID) tag at both endogenous alleles of CTCF. A transgene encoding the auxin-binding F-box protein Tir1 was subsequently introduce, so that adding auxin to the culture media leads to rapid (hours) and reversible degradation of CTCF. Consequences of acute loss of CTCF and its restoration were investigated using ChIP-seq, RNA-seq and high-throughput Chromosome Conformation Capture (5C and Hi-C).","7":"","8":"","9":"","10":"[GEO:GSE98671](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98671)","11":"syn21649210","12":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889755","2":"CTCF ChIP-Seq and Hi-C of murine cell lines under various conditions","3":"GSE98671","4":"The molecular mechanisms underlying folding of mammalian chromosomes remain poorly understood. The transcription factor CTCF is a candidate regulator of chromosomal structure. Using the auxin-inducible degron system in mouse embryonic stem cells, we show that CTCF is absolutely and dose-dependently required for looping between CTCF target sites and insulation of topologically associating domains (TADs).","5":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","6":"mouse ES cells were engineered to harbor an auxin-inducible degron (AID) tag at both endogenous alleles of CTCF. A transgene encoding the auxin-binding F-box protein Tir1 was subsequently introduce, so that adding auxin to the culture media leads to rapid (hours) and reversible degradation of CTCF. Consequences of acute loss of CTCF and its restoration were investigated using ChIP-seq, RNA-seq and high-throughput Chromosome Conformation Capture (5C and Hi-C).","7":"","8":"","9":"","10":"[GEO:GSE98671](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98671)","11":"syn21649210","12":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889756","2":"GSE98894","3":"GSE98894","4":"NA","5":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98894](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98894)","11":"syn21681392","12":"[A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (PMID:29915428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29915428)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889756","2":"GSE98894","3":"GSE98894","4":"NA","5":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE98894](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98894)","11":"syn21681392","12":"[A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (PMID:29915428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29915428)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889760","2":"RNA-Seq perturbation of embryonic vs extraembryonic lineages","3":"GSE98960","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98960)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889760","2":"RNA-Seq perturbation of embryonic vs extraembryonic lineages","3":"GSE98960","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98960)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889760","2":"RNA-Seq perturbation of embryonic vs extraembryonic lineages","3":"GSE98960","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98960)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889760","2":"RNA-Seq perturbation of embryonic vs extraembryonic lineages","3":"GSE98960","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"NA","6":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98960)","11":"NA","12":"NA","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889762","2":"RRBS perturbation of embryonic vs extraembryonic lineages","3":"GSE98963","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98963](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98963)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889762","2":"RRBS perturbation of embryonic vs extraembryonic lineages","3":"GSE98963","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98963](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98963)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889762","2":"RRBS perturbation of embryonic vs extraembryonic lineages","3":"GSE98963","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98963](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98963)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889762","2":"RRBS perturbation of embryonic vs extraembryonic lineages","3":"GSE98963","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","7":"","8":"","9":"","10":"[GEO:GSE98963](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98963)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889763","2":"GSE99116","3":"GSE99116","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99116](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99116)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889763","2":"GSE99116","3":"GSE99116","4":"NA","5":"NA","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99116](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99116)","11":"NA","12":"NA","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889764","2":"GSE99330","3":"GSE99330","4":"NA","5":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99330](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99330)","11":"syn21648897","12":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889764","2":"GSE99330","3":"GSE99330","4":"NA","5":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99330](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99330)","11":"syn21648897","12":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889764","2":"GSE99330","3":"GSE99330","4":"NA","5":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99330](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99330)","11":"syn21648897","12":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889765","2":"GSE99378","3":"GSE99378","4":"NA","5":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99378](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99378)","11":"syn21649073","12":"[Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 (PMID:29844167)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29844167)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889765","2":"GSE99378","3":"GSE99378","4":"NA","5":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99378](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99378)","11":"syn21649073","12":"[Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 (PMID:29844167)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29844167)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889766","2":"GSE99790","3":"GSE99790","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99790](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99790)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889766","2":"GSE99790","3":"GSE99790","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99790](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99790)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889766","2":"GSE99790","3":"GSE99790","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99790](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99790)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889766","2":"GSE99790","3":"GSE99790","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99790](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99790)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889767","2":"GSE99795","3":"GSE99795","4":"NA","5":"Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99795](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99795)","11":"syn21645255","12":"[Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response (PMID:29233929)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29233929)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889767","2":"GSE99795","3":"GSE99795","4":"NA","5":"Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response","6":"NA","7":"","8":"","9":"","10":"[GEO:GSE99795](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99795)","11":"syn21645255","12":"[Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response (PMID:29233929)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29233929)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889768","2":"phs000669.v1.p1","3":"phs000669.v1.p1","4":"NA","5":"Hormone-related pathways and risk of breast cancer subtypes in African American women","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs000669.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000669.v1.p1)","11":"syn21648855","12":"[Hormone-related pathways and risk of breast cancer subtypes in African American women (PMID:26458823)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26458823)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889768","2":"phs000669.v1.p1","3":"phs000669.v1.p1","4":"NA","5":"Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER consortium","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs000669.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000669.v1.p1)","11":"syn21648853","12":"[Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER consortium (PMID:26650177)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26650177)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889768","2":"phs000669.v1.p1","3":"phs000669.v1.p1","4":"NA","5":"Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs000669.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000669.v1.p1)","11":"syn21648851","12":"[Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium (PMID:26743380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26743380)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889769","2":"phs001072.v1.p1","3":"phs001072.v1.p1","4":"NA","5":"Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001072.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001072.v1.p1)","11":"syn21645560","12":"[Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia (PMID:27655895)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27655895)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889770","2":"phs001231.v2.p1","3":"phs001231.v2.p1","4":"NA","5":"Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001231.v2.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001231.v2.p1)","11":"syn21645594","12":"[Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells (PMID:27146274)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27146274)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889770","2":"phs001231.v2.p1","3":"phs001231.v2.p1","4":"NA","5":"Revealing disease-associated pathways by network integration of untargeted metabolomics","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001231.v2.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001231.v2.p1)","11":"syn21645599","12":"[Revealing disease-associated pathways by network integration of untargeted metabolomics (PMID:27479327)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27479327)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889771","2":"phs001680.v1.p1","3":"phs001680.v1.p1","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001680.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001680.v1.p1)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889771","2":"phs001680.v1.p1","3":"phs001680.v1.p1","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001680.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001680.v1.p1)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889771","2":"phs001680.v1.p1","3":"phs001680.v1.p1","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001680.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001680.v1.p1)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889771","2":"phs001680.v1.p1","3":"phs001680.v1.p1","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001680.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001680.v1.p1)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889772","2":"phs001854.v1.p1","3":"phs001854.v1.p1","4":"NA","5":"Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells","6":"NA","7":"","8":"","9":"","10":"[dbGaP:phs001854.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001854.v1.p1)","11":"syn21681871","12":"[Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells (PMID:31427603)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31427603)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889773","2":"SRP043153","3":"SRP043153","4":"NA","5":"Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP043153](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP043153)","11":"syn21645611","12":"[Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state (PMID:25380226)](https://www.ncbi.nlm.nih.gov/pubmed/?term=25380226)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889774","2":"SRP046258","3":"SRP046258","4":"NA","5":"Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP046258](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP046258)","11":"syn21645595","12":"[Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements (PMID:26748710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26748710)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889775","2":"SRP046313","3":"SRP046313","4":"NA","5":"Distinct EMT programs control normal mammary stem cells and tumour-initiating cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP046313](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP046313)","11":"syn21645606","12":"[Distinct EMT programs control normal mammary stem cells and tumour-initiating cells (PMID:26331542)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26331542)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889777","2":"SRP050497","3":"SRP050497","4":"NA","5":"Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP050497](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP050497)","11":"syn21681486","12":"[Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature (PMID:30548288)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30548288)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889777","2":"SRP050497","3":"SRP050497","4":"NA","5":"Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP050497](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP050497)","11":"syn21681486","12":"[Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature (PMID:30548288)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30548288)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889778","2":"SRP055569","3":"SRP055569","4":"NA","5":"Scalable microfluidics for single-cell RNA printing and sequencing","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP055569](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP055569)","11":"syn21645574","12":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889778","2":"SRP055569","3":"SRP055569","4":"NA","5":"Scalable microfluidics for single-cell RNA printing and sequencing","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP055569](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP055569)","11":"syn21645574","12":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889778","2":"SRP055569","3":"SRP055569","4":"NA","5":"Scalable microfluidics for single-cell RNA printing and sequencing","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP055569](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP055569)","11":"syn21645574","12":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889780","2":"SRP057123","3":"SRP057123","4":"NA","5":"Distal Alternative Last Exons Localize mRNAs to Neural Projections","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP057123](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP057123)","11":"syn21645610","12":"[Distal Alternative Last Exons Localize mRNAs to Neural Projections (PMID:26907613)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26907613)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889781","2":"SRP058237","3":"SRP058237","4":"NA","5":"Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP058237](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP058237)","11":"syn21681315","12":"[Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC (PMID:26046767)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26046767)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889781","2":"SRP058237","3":"SRP058237","4":"NA","5":"Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP058237](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP058237)","11":"syn21681315","12":"[Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC (PMID:26046767)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26046767)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889782","2":"SRP058436","3":"SRP058436","4":"NA","5":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP058436](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP058436)","11":"syn21645430","12":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889782","2":"SRP058436","3":"SRP058436","4":"NA","5":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP058436](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP058436)","11":"syn21645430","12":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889782","2":"SRP058436","3":"SRP058436","4":"NA","5":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP058436](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP058436)","11":"syn21645430","12":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889783","2":"SRP060702","3":"SRP060702","4":"NA","5":"Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP060702](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP060702)","11":"syn21645600","12":"[Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens (PMID:29023490)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29023490)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889784","2":"SRP064353","3":"SRP064353","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP064353](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP064353)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889784","2":"SRP064353","3":"SRP064353","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP064353](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP064353)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889784","2":"SRP064353","3":"SRP064353","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP064353](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP064353)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Evolution"},{"1":"syn21889784","2":"SRP064353","3":"SRP064353","4":"NA","5":"Combating subclonal evolution of resistant cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP064353](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP064353)","11":"syn21645337","12":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889785","2":"SRP066615","3":"SRP066615","4":"NA","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP066615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP066615)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889785","2":"SRP066615","3":"SRP066615","4":"NA","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP066615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP066615)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889785","2":"SRP066615","3":"SRP066615","4":"NA","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP066615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP066615)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889785","2":"SRP066615","3":"SRP066615","4":"NA","5":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP066615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP066615)","11":"syn21649212","12":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889786","2":"SRP069293","3":"SRP069293","4":"NA","5":"Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP069293](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP069293)","11":"syn21645592","12":"[Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia (PMID:27315426)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27315426)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889787","2":"SRP070188","3":"SRP070188","4":"NA","5":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP070188](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070188)","11":"syn21645405","12":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889787","2":"SRP070188","3":"SRP070188","4":"NA","5":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP070188](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070188)","11":"syn21645405","12":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889787","2":"SRP070188","3":"SRP070188","4":"NA","5":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP070188](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070188)","11":"syn21645405","12":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889788","2":"SRP070460","3":"SRP070460","4":"NA","5":"Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP070460](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070460)","11":"syn21645594","12":"[Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells (PMID:27146274)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27146274)","13":"syn9772917","14":"Embryonal Brain Tumor Networks","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889789","2":"SRP070693","3":"SRP070693","4":"NA","5":"3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP070693](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070693)","11":"syn21681375","12":"[3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk (PMID:29785014)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29785014)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889789","2":"SRP070693","3":"SRP070693","4":"NA","5":"3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP070693](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070693)","11":"syn21681375","12":"[3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk (PMID:29785014)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29785014)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889790","2":"SRP074429","3":"SRP074429","4":"NA","5":"Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP074429](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP074429)","11":"syn21681435","12":"[Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression (PMID:30306128)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30306128)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889790","2":"SRP074429","3":"SRP074429","4":"NA","5":"Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP074429](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP074429)","11":"syn21681435","12":"[Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression (PMID:30306128)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30306128)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889791","2":"SRP075882","3":"SRP075882","4":"NA","5":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP075882](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075882)","11":"syn21649001","12":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889791","2":"SRP075882","3":"SRP075882","4":"NA","5":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP075882](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075882)","11":"syn21649001","12":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889791","2":"SRP075882","3":"SRP075882","4":"NA","5":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP075882](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075882)","11":"syn21649001","12":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889792","2":"SRP075973","3":"SRP075973","4":"NA","5":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP075973](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075973)","11":"syn21645389","12":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889792","2":"SRP075973","3":"SRP075973","4":"NA","5":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP075973](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075973)","11":"syn21645389","12":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889792","2":"SRP075973","3":"SRP075973","4":"NA","5":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP075973](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075973)","11":"syn21645389","12":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889793","2":"SRP076235","3":"SRP076235","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076235](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076235)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889793","2":"SRP076235","3":"SRP076235","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076235](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076235)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889793","2":"SRP076235","3":"SRP076235","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076235](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076235)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Evolution"},{"1":"syn21889793","2":"SRP076235","3":"SRP076235","4":"NA","5":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076235](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076235)","11":"syn21648903","12":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","13":"syn9771796","14":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889794","2":"SRP076484","3":"SRP076484","4":"NA","5":"A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076484](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076484)","11":"syn21645325","12":"[A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue (PMID:28429718)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28429718)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889794","2":"SRP076484","3":"SRP076484","4":"NA","5":"A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076484](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076484)","11":"syn21645325","12":"[A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue (PMID:28429718)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28429718)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889796","2":"SRP076871","3":"SRP076871","4":"NA","5":"Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076871](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076871)","11":"syn21649111","12":"[Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation (PMID:27452175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27452175)","13":"syn7416710","14":"ECM geometrical and mechanical properties modulate RTK signaling","15":"PS-ON","16":"U01","17":"Heterogeneity"},{"1":"syn21889796","2":"SRP076871","3":"SRP076871","4":"NA","5":"Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP076871](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076871)","11":"syn21649111","12":"[Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation (PMID:27452175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27452175)","13":"syn7416710","14":"ECM geometrical and mechanical properties modulate RTK signaling","15":"PS-ON","16":"U01","17":"Microenvironment"},{"1":"syn21889797","2":"SRP078495","3":"SRP078495","4":"NA","5":"Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP078495](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP078495)","11":"syn21648926","12":"[Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma (PMID:29510988)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29510988)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889797","2":"SRP078495","3":"SRP078495","4":"NA","5":"Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP078495](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP078495)","11":"syn21648926","12":"[Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma (PMID:29510988)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29510988)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889798","2":"SRP081644","3":"SRP081644","4":"NA","5":"An Automated Microwell Platform for Large-Scale Single Cell RNA-Seq","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP081644](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP081644)","11":"syn21645316","12":"[An Automated Microwell Platform for Large-Scale Single Cell RNA-Seq (PMID:27670648)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27670648)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889800","2":"SRP090689","3":"SRP090689","4":"NA","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP090689](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP090689)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889800","2":"SRP090689","3":"SRP090689","4":"NA","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP090689](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP090689)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889800","2":"SRP090689","3":"SRP090689","4":"NA","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP090689](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP090689)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889800","2":"SRP090689","3":"SRP090689","4":"NA","5":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP090689](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP090689)","11":"syn21649209","12":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889801","2":"SRP091986","3":"SRP091986","4":"NA","5":"DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP091986](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP091986)","11":"syn21645258","12":"[DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients (PMID:28505145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28505145)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889801","2":"SRP091986","3":"SRP091986","4":"NA","5":"DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP091986](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP091986)","11":"syn21645258","12":"[DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients (PMID:28505145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28505145)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889802","2":"SRP092158","3":"SRP092158","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092158](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092158)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889802","2":"SRP092158","3":"SRP092158","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092158](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092158)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889802","2":"SRP092158","3":"SRP092158","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092158](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092158)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889802","2":"SRP092158","3":"SRP092158","4":"NA","5":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092158](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092158)","11":"syn21645339","12":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889803","2":"SRP092280","3":"SRP092280","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092280](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092280)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889803","2":"SRP092280","3":"SRP092280","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092280](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092280)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889803","2":"SRP092280","3":"SRP092280","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092280](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092280)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889803","2":"SRP092280","3":"SRP092280","4":"NA","5":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP092280](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092280)","11":"syn21645338","12":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889804","2":"SRP093757","3":"SRP093757","4":"NA","5":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP093757](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP093757)","11":"syn21645423","12":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889804","2":"SRP093757","3":"SRP093757","4":"NA","5":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP093757](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP093757)","11":"syn21645423","12":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889804","2":"SRP093757","3":"SRP093757","4":"NA","5":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP093757](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP093757)","11":"syn21645423","12":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889805","2":"SRP094446","3":"SRP094446","4":"NA","5":"Homeobox oncogene activation by pan-cancer DNA hypermethylation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP094446](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP094446)","11":"syn21648978","12":"[Homeobox oncogene activation by pan-cancer DNA hypermethylation (PMID:30097071)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30097071)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889805","2":"SRP094446","3":"SRP094446","4":"NA","5":"Homeobox oncogene activation by pan-cancer DNA hypermethylation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP094446](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP094446)","11":"syn21648978","12":"[Homeobox oncogene activation by pan-cancer DNA hypermethylation (PMID:30097071)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30097071)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889808","2":"SRP095013","3":"SRP095013","4":"NA","5":"Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP095013](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP095013)","11":"syn21645251","12":"[Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis (PMID:29212856)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29212856)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889808","2":"SRP095013","3":"SRP095013","4":"NA","5":"Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP095013](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP095013)","11":"syn21645251","12":"[Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis (PMID:29212856)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29212856)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889810","2":"SRP095488","3":"SRP095488","4":"NA","5":"Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP095488](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP095488)","11":"syn21645319","12":"[Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer (PMID:28411207)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28411207)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889810","2":"SRP095488","3":"SRP095488","4":"NA","5":"Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP095488](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP095488)","11":"syn21645319","12":"[Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer (PMID:28411207)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28411207)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889811","2":"SRP096338","3":"SRP096338","4":"NA","5":"Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096338](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096338)","11":"syn21681523","12":"[Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes (PMID:30658994)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30658994)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889811","2":"SRP096338","3":"SRP096338","4":"NA","5":"Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096338](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096338)","11":"syn21681523","12":"[Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes (PMID:30658994)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30658994)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889812","2":"SRP096883","3":"SRP096883","4":"NA","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096883](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096883)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889812","2":"SRP096883","3":"SRP096883","4":"NA","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096883](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096883)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889812","2":"SRP096883","3":"SRP096883","4":"NA","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096883](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096883)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889812","2":"SRP096883","3":"SRP096883","4":"NA","5":"Metabolic origins of spatial organization in the tumor microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096883](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096883)","11":"syn21649207","12":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889813","2":"SRP096964","3":"SRP096964","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096964](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096964)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889813","2":"SRP096964","3":"SRP096964","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096964](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096964)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889813","2":"SRP096964","3":"SRP096964","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096964](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096964)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889813","2":"SRP096964","3":"SRP096964","4":"NA","5":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP096964](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096964)","11":"syn21648963","12":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889814","2":"SRP099648","3":"SRP099648","4":"NA","5":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP099648](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP099648)","11":"syn21645558","12":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889814","2":"SRP099648","3":"SRP099648","4":"NA","5":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP099648](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP099648)","11":"syn21645558","12":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889814","2":"SRP099648","3":"SRP099648","4":"NA","5":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP099648](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP099648)","11":"syn21645558","12":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889815","2":"SRP102315","3":"SRP102315","4":"NA","5":"Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP102315](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP102315)","11":"syn21648871","12":"[Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma (PMID:29440233)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29440233)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889816","2":"SRP103204","3":"SRP103204","4":"NA","5":"PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP103204](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103204)","11":"syn21645322","12":"[PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens (PMID:28740083)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28740083)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889816","2":"SRP103204","3":"SRP103204","4":"NA","5":"PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP103204](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103204)","11":"syn21645322","12":"[PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens (PMID:28740083)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28740083)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889818","2":"SRP103828","3":"SRP103828","4":"NA","5":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP103828](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103828)","11":"syn21649208","12":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889818","2":"SRP103828","3":"SRP103828","4":"NA","5":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP103828](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103828)","11":"syn21649208","12":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889818","2":"SRP103828","3":"SRP103828","4":"NA","5":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP103828](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103828)","11":"syn21649208","12":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889819","2":"SRP105181","3":"SRP105181","4":"NA","5":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP105181](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105181)","11":"syn21645422","12":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889819","2":"SRP105181","3":"SRP105181","4":"NA","5":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP105181](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105181)","11":"syn21645422","12":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889819","2":"SRP105181","3":"SRP105181","4":"NA","5":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP105181](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105181)","11":"syn21645422","12":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889821","2":"SRP105199","3":"SRP105199","4":"NA","5":"Chromosomal instability drives metastasis through a cytosolic DNA response","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP105199](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105199)","11":"syn21645269","12":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889821","2":"SRP105199","3":"SRP105199","4":"NA","5":"Chromosomal instability drives metastasis through a cytosolic DNA response","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP105199](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105199)","11":"syn21645269","12":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889821","2":"SRP105199","3":"SRP105199","4":"NA","5":"Chromosomal instability drives metastasis through a cytosolic DNA response","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP105199](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105199)","11":"syn21645269","12":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889822","2":"SRP106652","3":"SRP106652","4":"NA","5":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP106652](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP106652)","11":"syn21649210","12":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889822","2":"SRP106652","3":"SRP106652","4":"NA","5":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP106652](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP106652)","11":"syn21649210","12":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889822","2":"SRP106652","3":"SRP106652","4":"NA","5":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP106652](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP106652)","11":"syn21649210","12":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889823","2":"SRP107025","3":"SRP107025","4":"NA","5":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP107025](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107025)","11":"syn21681392","12":"[A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (PMID:29915428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29915428)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889823","2":"SRP107025","3":"SRP107025","4":"NA","5":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP107025](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107025)","11":"syn21681392","12":"[A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (PMID:29915428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29915428)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889824","2":"SRP107210","3":"SRP107210","4":"NA","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP107210](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107210)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889824","2":"SRP107210","3":"SRP107210","4":"NA","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP107210](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107210)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889824","2":"SRP107210","3":"SRP107210","4":"NA","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP107210](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107210)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889824","2":"SRP107210","3":"SRP107210","4":"NA","5":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP107210](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107210)","11":"syn21645383","12":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889829","2":"SRP108076","3":"SRP108076","4":"NA","5":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108076](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108076)","11":"syn21648897","12":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889829","2":"SRP108076","3":"SRP108076","4":"NA","5":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108076](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108076)","11":"syn21648897","12":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889829","2":"SRP108076","3":"SRP108076","4":"NA","5":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108076](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108076)","11":"syn21648897","12":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","13":"syn7349747","14":"Physical Science Oncology Center at Penn","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889833","2":"SRP108215","3":"SRP108215","4":"NA","5":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108215](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108215)","11":"syn21649073","12":"[Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 (PMID:29844167)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29844167)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889833","2":"SRP108215","3":"SRP108215","4":"NA","5":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108215](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108215)","11":"syn21649073","12":"[Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 (PMID:29844167)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29844167)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889834","2":"SRP108785","3":"SRP108785","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108785](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108785)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889834","2":"SRP108785","3":"SRP108785","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108785](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108785)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889834","2":"SRP108785","3":"SRP108785","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108785](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108785)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889834","2":"SRP108785","3":"SRP108785","4":"NA","5":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108785](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108785)","11":"syn21681326","12":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889835","2":"SRP108807","3":"SRP108807","4":"NA","5":"Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108807](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108807)","11":"syn21645255","12":"[Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response (PMID:29233929)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29233929)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889835","2":"SRP108807","3":"SRP108807","4":"NA","5":"Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP108807](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108807)","11":"syn21645255","12":"[Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response (PMID:29233929)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29233929)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889836","2":"SRP109858","3":"SRP109858","4":"NA","5":"Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP109858](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP109858)","11":"syn21648934","12":"[Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types (PMID:29871632)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29871632)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889836","2":"SRP109858","3":"SRP109858","4":"NA","5":"Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP109858](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP109858)","11":"syn21648934","12":"[Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types (PMID:29871632)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29871632)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889837","2":"SRP111555","3":"SRP111555","4":"NA","5":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP111555](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP111555)","11":"syn21648894","12":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","13":"syn10140998","14":"The Cancer Cell Map Initiative","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889837","2":"SRP111555","3":"SRP111555","4":"NA","5":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP111555](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP111555)","11":"syn21648894","12":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","13":"syn10140998","14":"The Cancer Cell Map Initiative","15":"CSBC","16":"U54","17":"Evolution"},{"1":"syn21889837","2":"SRP111555","3":"SRP111555","4":"NA","5":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP111555](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP111555)","11":"syn21648894","12":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","13":"syn10140998","14":"The Cancer Cell Map Initiative","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889838","2":"SRP113754","3":"SRP113754","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP113754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP113754)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889838","2":"SRP113754","3":"SRP113754","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP113754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP113754)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889838","2":"SRP113754","3":"SRP113754","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP113754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP113754)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889838","2":"SRP113754","3":"SRP113754","4":"NA","5":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP113754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP113754)","11":"syn21681382","12":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","13":"syn7349753","14":"H Lee Moffitt Cancer Center and Research Institute","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889839","2":"SRP115498","3":"SRP115498","4":"NA","5":"Unsupervised Trajectory Analysis of Single-Cell RNA-Seq and Imaging Data Reveals Alternative Tuft Cell Origins in the Gut","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP115498](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP115498)","11":"syn21649125","12":"[Unsupervised Trajectory Analysis of Single-Cell RNA-Seq and Imaging Data Reveals Alternative Tuft Cell Origins in the Gut (PMID:29153838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29153838)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889840","2":"SRP115572","3":"SRP115572","4":"NA","5":"A pathway for mitotic chromosome formation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP115572](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP115572)","11":"syn21649214","12":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889840","2":"SRP115572","3":"SRP115572","4":"NA","5":"A pathway for mitotic chromosome formation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP115572](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP115572)","11":"syn21649214","12":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889840","2":"SRP115572","3":"SRP115572","4":"NA","5":"A pathway for mitotic chromosome formation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP115572](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP115572)","11":"syn21649214","12":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889841","2":"SRP116341","3":"SRP116341","4":"NA","5":"Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP116341](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP116341)","11":"syn21681447","12":"[Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer (PMID:30389702)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30389702)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889841","2":"SRP116341","3":"SRP116341","4":"NA","5":"Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP116341](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP116341)","11":"syn21681447","12":"[Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer (PMID:30389702)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30389702)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889842","2":"SRP116382","3":"SRP116382","4":"NA","5":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP116382](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP116382)","11":"syn21648977","12":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889842","2":"SRP116382","3":"SRP116382","4":"NA","5":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP116382](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP116382)","11":"syn21648977","12":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889842","2":"SRP116382","3":"SRP116382","4":"NA","5":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP116382](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP116382)","11":"syn21648977","12":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889844","2":"SRP118077","3":"SRP118077","4":"NA","5":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP118077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP118077)","11":"syn21648885","12":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889844","2":"SRP118077","3":"SRP118077","4":"NA","5":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP118077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP118077)","11":"syn21648885","12":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889844","2":"SRP118077","3":"SRP118077","4":"NA","5":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP118077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP118077)","11":"syn21648885","12":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889845","2":"SRP119969","3":"SRP119969","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP119969](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP119969)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889845","2":"SRP119969","3":"SRP119969","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP119969](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP119969)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889845","2":"SRP119969","3":"SRP119969","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP119969](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP119969)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889845","2":"SRP119969","3":"SRP119969","4":"NA","5":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP119969](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP119969)","11":"syn21681468","12":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889847","2":"SRP125804","3":"SRP125804","4":"NA","5":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP125804](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP125804)","11":"syn21648884","12":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889847","2":"SRP125804","3":"SRP125804","4":"NA","5":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP125804](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP125804)","11":"syn21648884","12":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889847","2":"SRP125804","3":"SRP125804","4":"NA","5":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP125804](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP125804)","11":"syn21648884","12":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889848","2":"SRP128918","3":"SRP128918","4":"NA","5":"A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP128918](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP128918)","11":"syn21648960","12":"[A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development (PMID:29625070)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625070)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889849","2":"SRP132902","3":"SRP132902","4":"NA","5":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP132902](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP132902)","11":"syn21681403","12":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889849","2":"SRP132902","3":"SRP132902","4":"NA","5":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP132902](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP132902)","11":"syn21681403","12":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889849","2":"SRP132902","3":"SRP132902","4":"NA","5":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP132902](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP132902)","11":"syn21681403","12":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889850","2":"SRP132956","3":"SRP132956","4":"NA","5":"Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP132956](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP132956)","11":"syn21681553","12":"[Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence (PMID:30739799)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30739799)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889850","2":"SRP132956","3":"SRP132956","4":"NA","5":"Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP132956](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP132956)","11":"syn21681553","12":"[Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence (PMID:30739799)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30739799)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889851","2":"SRP134389","3":"SRP134389","4":"NA","5":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP134389](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP134389)","11":"syn21681401","12":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889851","2":"SRP134389","3":"SRP134389","4":"NA","5":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP134389](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP134389)","11":"syn21681401","12":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889851","2":"SRP134389","3":"SRP134389","4":"NA","5":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP134389](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP134389)","11":"syn21681401","12":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889852","2":"SRP136624","3":"SRP136624","4":"NA","5":"Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP136624](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP136624)","11":"syn21681640","12":"[Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF (PMID:30975481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30975481)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889854","2":"SRP137894","3":"SRP137894","4":"NA","5":"Patient derived organoids to model rare prostate cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP137894](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP137894)","11":"syn21648964","12":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889854","2":"SRP137894","3":"SRP137894","4":"NA","5":"Patient derived organoids to model rare prostate cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP137894](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP137894)","11":"syn21648964","12":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889854","2":"SRP137894","3":"SRP137894","4":"NA","5":"Patient derived organoids to model rare prostate cancer phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP137894](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP137894)","11":"syn21648964","12":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","13":"syn7349770","14":"Center on the Physics of Cancer Metabolism","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889855","2":"SRP140533","3":"SRP140533","4":"NA","5":"Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP140533](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP140533)","11":"syn21649156","12":"[Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity (PMID:29795293)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29795293)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889856","2":"SRP144614","3":"SRP144614","4":"NA","5":"Quantitative assessment of cell population diversity in single-cell landscapes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP144614](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP144614)","11":"syn21649039","12":"[Quantitative assessment of cell population diversity in single-cell landscapes (PMID:30346945)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30346945)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889857","2":"SRP144659","3":"SRP144659","4":"NA","5":"Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP144659](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP144659)","11":"syn21681514","12":"[Single-cell microRNA-mRNA co-sequencing reveals non-genetic heterogeneity and mechanisms of microRNA regulation (PMID:30626865)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30626865)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889858","2":"SRP144750","3":"SRP144750","4":"NA","5":"Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP144750](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP144750)","11":"syn21681772","12":"[Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer (PMID:31155233)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31155233)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889859","2":"SRP145267","3":"SRP145267","4":"NA","5":"Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145267](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145267)","11":"syn21681436","12":"[Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs (PMID:30309298)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30309298)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889859","2":"SRP145267","3":"SRP145267","4":"NA","5":"Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145267](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145267)","11":"syn21681436","12":"[Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs (PMID:30309298)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30309298)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889860","2":"SRP145321","3":"SRP145321","4":"NA","5":"Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145321](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145321)","11":"syn21649081","12":"[Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival (PMID:29997286)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29997286)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889860","2":"SRP145321","3":"SRP145321","4":"NA","5":"Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145321](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145321)","11":"syn21649081","12":"[Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival (PMID:29997286)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29997286)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889861","2":"SRP145597","3":"SRP145597","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145597](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145597)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889861","2":"SRP145597","3":"SRP145597","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145597](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145597)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889861","2":"SRP145597","3":"SRP145597","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145597](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145597)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889861","2":"SRP145597","3":"SRP145597","4":"NA","5":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP145597](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145597)","11":"syn21681394","12":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889863","2":"SRP148594","3":"SRP148594","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP148594](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148594)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889863","2":"SRP148594","3":"SRP148594","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP148594](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148594)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889863","2":"SRP148594","3":"SRP148594","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP148594](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148594)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889863","2":"SRP148594","3":"SRP148594","4":"NA","5":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP148594](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148594)","11":"syn21649215","12":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889864","2":"SRP148659","3":"SRP148659","4":"NA","5":"Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP148659](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148659)","11":"syn21681737","12":"[Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming (PMID:31078528)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31078528)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889864","2":"SRP148659","3":"SRP148659","4":"NA","5":"Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP148659](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148659)","11":"syn21681737","12":"[Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming (PMID:31078528)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31078528)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889865","2":"SRP150061","3":"SRP150061","4":"NA","5":"Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150061](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150061)","11":"syn21681993","12":"[Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer (PMID:31805710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31805710)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889865","2":"SRP150061","3":"SRP150061","4":"NA","5":"Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150061](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150061)","11":"syn21681993","12":"[Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer (PMID:31805710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31805710)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889867","2":"SRP150084","3":"SRP150084","4":"NA","5":"Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150084](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150084)","11":"syn21681517","12":"[Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans (PMID:30638295)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30638295)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889867","2":"SRP150084","3":"SRP150084","4":"NA","5":"Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150084](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150084)","11":"syn21681517","12":"[Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans (PMID:30638295)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30638295)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889868","2":"SRP150101","3":"SRP150101","4":"NA","5":"Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150101](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150101)","11":"syn21681442","12":"[Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma (PMID:30355798)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30355798)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889868","2":"SRP150101","3":"SRP150101","4":"NA","5":"Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150101](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150101)","11":"syn21681442","12":"[Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma (PMID:30355798)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30355798)","13":"syn9775595","14":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","15":"CSBC","16":"U01","17":"Microenvironment"},{"1":"syn21889869","2":"SRP150586","3":"SRP150586","4":"NA","5":"The mammalian decidual cell evolved from a cellular stress response","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150586](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150586)","11":"syn21681412","12":"[The mammalian decidual cell evolved from a cellular stress response (PMID:30142145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30142145)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889869","2":"SRP150586","3":"SRP150586","4":"NA","5":"The mammalian decidual cell evolved from a cellular stress response","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150586](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150586)","11":"syn21681412","12":"[The mammalian decidual cell evolved from a cellular stress response (PMID:30142145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30142145)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889870","2":"SRP150876","3":"SRP150876","4":"NA","5":"SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150876](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150876)","11":"syn21681501","12":"[SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing (PMID:30583733)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30583733)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889870","2":"SRP150876","3":"SRP150876","4":"NA","5":"SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP150876](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150876)","11":"syn21681501","12":"[SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing (PMID:30583733)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30583733)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889871","2":"SRP151472","3":"SRP151472","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP151472](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP151472)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889871","2":"SRP151472","3":"SRP151472","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP151472](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP151472)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889871","2":"SRP151472","3":"SRP151472","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP151472](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP151472)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889871","2":"SRP151472","3":"SRP151472","4":"NA","5":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP151472](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP151472)","11":"syn21649050","12":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889873","2":"SRP155570","3":"SRP155570","4":"NA","5":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP155570](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP155570)","11":"syn21681828","12":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889873","2":"SRP155570","3":"SRP155570","4":"NA","5":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP155570](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP155570)","11":"syn21681828","12":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889873","2":"SRP155570","3":"SRP155570","4":"NA","5":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP155570](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP155570)","11":"syn21681828","12":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","13":"syn7349759","14":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889874","2":"SRP157038","3":"SRP157038","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP157038](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP157038)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"},{"1":"syn21889874","2":"SRP157038","3":"SRP157038","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP157038](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP157038)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889874","2":"SRP157038","3":"SRP157038","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP157038](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP157038)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889874","2":"SRP157038","3":"SRP157038","4":"NA","5":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP157038](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP157038)","11":"syn21681417","12":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","13":"syn7349757","14":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889875","2":"SRP159023","3":"SRP159023","4":"NA","5":"Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP159023](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP159023)","11":"syn21681608","12":"[Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells (PMID:30910979)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30910979)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889876","2":"SRP159024","3":"SRP159024","4":"NA","5":"Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP159024](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP159024)","11":"syn21681527","12":"[Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy (PMID:30664790)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30664790)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889877","2":"SRP159185","3":"SRP159185","4":"NA","5":"PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP159185](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP159185)","11":"syn21681909","12":"[PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity (PMID:31527834)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31527834)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889877","2":"SRP159185","3":"SRP159185","4":"NA","5":"PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP159185](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP159185)","11":"syn21681909","12":"[PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity (PMID:31527834)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31527834)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889878","2":"SRP160142","3":"SRP160142","4":"NA","5":"Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP160142](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP160142)","11":"syn21681558","12":"[Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes (PMID:30755444)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30755444)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889879","2":"SRP162268","3":"SRP162268","4":"NA","5":"In situ 10-cell RNA sequencing in tissue and tumor biopsy samples","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP162268](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP162268)","11":"syn21681604","12":"[In situ 10-cell RNA sequencing in tissue and tumor biopsy samples (PMID:30894605)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30894605)","13":"syn17084062","14":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889879","2":"SRP162268","3":"SRP162268","4":"NA","5":"In situ 10-cell RNA sequencing in tissue and tumor biopsy samples","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP162268](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP162268)","11":"syn21681604","12":"[In situ 10-cell RNA sequencing in tissue and tumor biopsy samples (PMID:30894605)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30894605)","13":"syn17084062","14":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","15":"CSBC","16":"U01","17":"Evolution"},{"1":"syn21889880","2":"SRP164935","3":"SRP164935","4":"NA","5":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP164935](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP164935)","11":"syn21649183","12":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889880","2":"SRP164935","3":"SRP164935","4":"NA","5":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP164935](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP164935)","11":"syn21649183","12":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889880","2":"SRP164935","3":"SRP164935","4":"NA","5":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP164935](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP164935)","11":"syn21649183","12":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","13":"syn9773345","14":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889881","2":"SRP165726","3":"SRP165726","4":"NA","5":"BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP165726](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP165726)","11":"syn21681667","12":"[BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells (PMID:30995943)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30995943)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889881","2":"SRP165726","3":"SRP165726","4":"NA","5":"BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP165726](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP165726)","11":"syn21681667","12":"[BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells (PMID:30995943)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30995943)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889883","2":"SRP166447","3":"SRP166447","4":"NA","5":"Linking single-cell measurements of mass, growth rate, and gene expression","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP166447](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP166447)","11":"syn21649021","12":"[Linking single-cell measurements of mass, growth rate, and gene expression (PMID:30482222)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30482222)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889883","2":"SRP166447","3":"SRP166447","4":"NA","5":"Linking single-cell measurements of mass, growth rate, and gene expression","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP166447](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP166447)","11":"syn21649021","12":"[Linking single-cell measurements of mass, growth rate, and gene expression (PMID:30482222)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30482222)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889884","2":"SRP166967","3":"SRP166967","4":"NA","5":"Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP166967](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP166967)","11":"syn21681451","12":"[Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics (PMID:30404002)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30404002)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889886","2":"SRP167164","3":"SRP167164","4":"NA","5":"Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167164](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167164)","11":"syn21681992","12":"[Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach (PMID:31804471)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31804471)","13":"syn17084053","14":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889887","2":"SRP167389","3":"SRP167389","4":"NA","5":"A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167389](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167389)","11":"syn21649049","12":"[A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma (PMID:29590606)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29590606)","13":"syn17084070","14":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","15":"CSBC","16":"U01","17":"Drug Resistance/Sensitivity"},{"1":"syn21889887","2":"SRP167389","3":"SRP167389","4":"NA","5":"A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167389](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167389)","11":"syn21649049","12":"[A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma (PMID:29590606)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29590606)","13":"syn17084070","14":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","15":"CSBC","16":"U01","17":"Heterogeneity"},{"1":"syn21889888","2":"SRP167390","3":"SRP167390","4":"NA","5":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167390](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167390)","11":"syn21681529","12":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889888","2":"SRP167390","3":"SRP167390","4":"NA","5":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167390](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167390)","11":"syn21681529","12":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889888","2":"SRP167390","3":"SRP167390","4":"NA","5":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167390](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167390)","11":"syn21681529","12":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","13":"syn7349745","14":"Center for Modeling Tumor Cell Migration Mechanics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889889","2":"SRP167975","3":"SRP167975","4":"NA","5":"Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167975](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167975)","11":"syn21681530","12":"[Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer (PMID:30674677)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674677)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889889","2":"SRP167975","3":"SRP167975","4":"NA","5":"Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP167975](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167975)","11":"syn21681530","12":"[Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer (PMID:30674677)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674677)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889890","2":"SRP175077","3":"SRP175077","4":"NA","5":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP175077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP175077)","11":"syn21681865","12":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889890","2":"SRP175077","3":"SRP175077","4":"NA","5":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP175077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP175077)","11":"syn21681865","12":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889890","2":"SRP175077","3":"SRP175077","4":"NA","5":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP175077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP175077)","11":"syn21681865","12":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","13":"syn7315808","14":"Stanford University Center for Cancer Systems Biology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889895","2":"SRP178115","3":"SRP178115","4":"NA","5":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP178115](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP178115)","11":"syn21681801","12":"[Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity (PMID:31178407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31178407)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889895","2":"SRP178115","3":"SRP178115","4":"NA","5":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP178115](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP178115)","11":"syn21681801","12":"[Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity (PMID:31178407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31178407)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889897","2":"SRP178865","3":"SRP178865","4":"NA","5":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP178865](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP178865)","11":"syn21681899","12":"[Molecular determinants for enzalutamide-induced transcription in prostate cancer (PMID:31501863)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31501863)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889897","2":"SRP178865","3":"SRP178865","4":"NA","5":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP178865](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP178865)","11":"syn21681899","12":"[Molecular determinants for enzalutamide-induced transcription in prostate cancer (PMID:31501863)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31501863)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889898","2":"SRP181871","3":"SRP181871","4":"NA","5":"Ex vivo Dynamics of Human Glioblastoma Cells in a Microvasculature-on-a-Chip System Correlates with Tumor Heterogeneity and Subtypes","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP181871](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181871)","11":"syn21681676","12":"[Ex vivo Dynamics of Human Glioblastoma Cells in a Microvasculature-on-a-Chip System Correlates with Tumor Heterogeneity and Subtypes (PMID:31016107)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31016107)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889899","2":"SRP181911","3":"SRP181911","4":"NA","5":"A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP181911](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181911)","11":"syn21681836","12":"[A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer (PMID:31303470)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31303470)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889899","2":"SRP181911","3":"SRP181911","4":"NA","5":"A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP181911](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181911)","11":"syn21681836","12":"[A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer (PMID:31303470)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31303470)","13":"syn9773346","14":"Systems Analysis of Epigenomic Architecture in Cancer Progression","15":"CSBC","16":"U54","17":"Epigenetics"},{"1":"syn21889900","2":"SRP181952","3":"SRP181952","4":"NA","5":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP181952](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181952)","11":"syn21681851","12":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889900","2":"SRP181952","3":"SRP181952","4":"NA","5":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP181952](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181952)","11":"syn21681851","12":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889900","2":"SRP181952","3":"SRP181952","4":"NA","5":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP181952](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181952)","11":"syn21681851","12":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889901","2":"SRP182724","3":"SRP182724","4":"NA","5":"Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP182724](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP182724)","11":"syn21681739","12":"[Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration (PMID:31080134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31080134)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889901","2":"SRP182724","3":"SRP182724","4":"NA","5":"Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP182724](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP182724)","11":"syn21681739","12":"[Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration (PMID:31080134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31080134)","13":"syn9773338","14":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889902","2":"SRP182754","3":"SRP182754","4":"NA","5":"Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP182754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP182754)","11":"syn21681547","12":"[Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer (PMID:30718260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30718260)","13":"syn17083789","14":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","15":"PS-ON","16":"U01","17":"Metastasis"},{"1":"syn21889902","2":"SRP182754","3":"SRP182754","4":"NA","5":"Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP182754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP182754)","11":"syn21681547","12":"[Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer (PMID:30718260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30718260)","13":"syn17083789","14":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","15":"PS-ON","16":"U01","17":"Microenvironment"},{"1":"syn21889903","2":"SRP186300","3":"SRP186300","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP186300](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP186300)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Tumor-Immune"},{"1":"syn21889903","2":"SRP186300","3":"SRP186300","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP186300](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP186300)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889903","2":"SRP186300","3":"SRP186300","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP186300](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP186300)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889903","2":"SRP186300","3":"SRP186300","4":"NA","5":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP186300](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP186300)","11":"syn21681695","12":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","13":"syn7315805","14":"CSBC Research Center for Cancer Systems Immunology at MSKCC","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889905","2":"SRP188447","3":"SRP188447","4":"NA","5":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP188447](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP188447)","11":"syn21681723","12":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889905","2":"SRP188447","3":"SRP188447","4":"NA","5":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP188447](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP188447)","11":"syn21681723","12":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metastasis"},{"1":"syn21889905","2":"SRP188447","3":"SRP188447","4":"NA","5":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP188447](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP188447)","11":"syn21681723","12":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","13":"syn7349766","14":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889906","2":"SRP189782","3":"SRP189782","4":"NA","5":"Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP189782](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP189782)","11":"syn21681820","12":"[Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation (PMID:31229590)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31229590)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889907","2":"SRP191615","3":"SRP191615","4":"NA","5":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP191615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP191615)","11":"syn21681814","12":"[Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts (PMID:31197017)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31197017)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Heterogeneity"},{"1":"syn21889907","2":"SRP191615","3":"SRP191615","4":"NA","5":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP191615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP191615)","11":"syn21681814","12":"[Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts (PMID:31197017)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31197017)","13":"syn7315802","14":"Center for Cancer Systems Therapeutics (CaST)","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889908","2":"SRP192023","3":"SRP192023","4":"NA","5":"Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP192023](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP192023)","11":"syn21681783","12":"[Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (PMID:31160565)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31160565)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Drug Resistance/Sensitivity"},{"1":"syn21889908","2":"SRP192023","3":"SRP192023","4":"NA","5":"Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP192023](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP192023)","11":"syn21681783","12":"[Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (PMID:31160565)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31160565)","13":"syn12051865","14":"Center for Cancer Systems Pharmacology","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889910","2":"SRP192397","3":"SRP192397","4":"NA","5":"MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP192397](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP192397)","11":"syn21681817","12":"[MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices (PMID:31209384)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31209384)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889911","2":"SRP201838","3":"SRP201838","4":"NA","5":"Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP201838](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP201838)","11":"syn21681881","12":"[Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells (PMID:31442407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31442407)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889911","2":"SRP201838","3":"SRP201838","4":"NA","5":"Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP201838](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP201838)","11":"syn21681881","12":"[Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells (PMID:31442407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31442407)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889912","2":"SRP212810","3":"SRP212810","4":"NA","5":"Single-cell connectomic analysis of adult mammalian lungs","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP212810](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP212810)","11":"syn21681999","12":"[Single-cell connectomic analysis of adult mammalian lungs (PMID:31840053)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31840053)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889912","2":"SRP212810","3":"SRP212810","4":"NA","5":"Single-cell connectomic analysis of adult mammalian lungs","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP212810](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP212810)","11":"syn21681999","12":"[Single-cell connectomic analysis of adult mammalian lungs (PMID:31840053)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31840053)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889913","2":"SRP217843","3":"SRP217843","4":"NA","5":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP217843](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP217843)","11":"syn21681944","12":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889913","2":"SRP217843","3":"SRP217843","4":"NA","5":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP217843](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP217843)","11":"syn21681944","12":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Tumor-Immune"},{"1":"syn21889913","2":"SRP217843","3":"SRP217843","4":"NA","5":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP217843](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP217843)","11":"syn21681944","12":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","13":"syn7349762","14":"The Center for Immunotherapeutic Transport Oncophysics","15":"PS-ON","16":"U54","17":"Microenvironment"},{"1":"syn21889914","2":"SRP219234","3":"SRP219234","4":"NA","5":"Evolution of placental invasion and cancer metastasis are causally linked","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP219234](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP219234)","11":"syn21681987","12":"[Evolution of placental invasion and cancer metastasis are causally linked (PMID:31768023)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31768023)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Metastasis"},{"1":"syn21889914","2":"SRP219234","3":"SRP219234","4":"NA","5":"Evolution of placental invasion and cancer metastasis are causally linked","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP219234](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP219234)","11":"syn21681987","12":"[Evolution of placental invasion and cancer metastasis are causally linked (PMID:31768023)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31768023)","13":"syn7315810","14":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","15":"CSBC","16":"U54","17":"Microenvironment"},{"1":"syn21889915","2":"SRP221410","3":"SRP221410","4":"NA","5":"Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP221410](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP221410)","11":"syn21681942","12":"[Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer (PMID:31591235)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31591235)","13":"NA","14":"NA","15":"NA","16":"NA","17":"NA"},{"1":"syn21889917","2":"SRP223262","3":"SRP223262","4":"NA","5":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP223262](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP223262)","11":"syn21681890","12":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Metabolism"},{"1":"syn21889917","2":"SRP223262","3":"SRP223262","4":"NA","5":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP223262](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP223262)","11":"syn21681890","12":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Heterogeneity"},{"1":"syn21889917","2":"SRP223262","3":"SRP223262","4":"NA","5":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","6":"NA","7":"","8":"","9":"","10":"[SRA:SRP223262](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP223262)","11":"syn21681890","12":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","13":"syn7349742","14":"Chicago Region Physical Science Oncology Center","15":"PS-ON","16":"U54","17":"Evolution"}],"options":{"columns":{"min":{},"max":[10],"total":[17]},"rows":{"min":[10],"max":[10],"total":[821]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_formatted_dataset_df &lt;- merged_dataset_df %&gt;%
  filter(!is.na(grantName)) %&gt;%
  group_by(datasetId, datasetName, datasetAlias,
           description, overallDesign, externalLink, 
           publicationId, publicationTitle, publication, ) %&gt;%
  summarize(grantId = str_c(unique(grantId), collapse = &quot;, &quot;),
            grantName = str_c(unique(grantName), collapse = &quot;, &quot;),
            tumorType = str_c(unique(tumorType), collapse = &quot;, &quot;),
            assay = str_c(unique(assay), collapse = &quot;, &quot;),
            species = str_c(unique(species), collapse = &quot;, &quot;),
            grantType = str_c(unique(grantType), collapse = &quot;, &quot;),
            theme = str_c(unique(theme), collapse = &quot;, &quot;),
            consortium = str_c(unique(consortium), collapse = &quot;, &quot;)) %&gt;%
  ungroup() %&gt;%
  # rowwise() %&gt;% 
  # mutate_at(pub_list_cols, ~ csv_str_to_json(.)) %&gt;%
  # ungroup() %&gt;% 
  distinct()

merged_formatted_dataset_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["tbl_df","tbl","data.frame"],"ncol":17,"nrow":295},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["datasetId"],"name":[1],"type":["chr"],"align":["left"]},{"label":["datasetName"],"name":[2],"type":["chr"],"align":["left"]},{"label":["datasetAlias"],"name":[3],"type":["chr"],"align":["left"]},{"label":["description"],"name":[4],"type":["chr"],"align":["left"]},{"label":["overallDesign"],"name":[5],"type":["chr"],"align":["left"]},{"label":["externalLink"],"name":[6],"type":["chr"],"align":["left"]},{"label":["publicationId"],"name":[7],"type":["chr"],"align":["left"]},{"label":["publicationTitle"],"name":[8],"type":["chr"],"align":["left"]},{"label":["publication"],"name":[9],"type":["chr"],"align":["left"]},{"label":["grantId"],"name":[10],"type":["chr"],"align":["left"]},{"label":["grantName"],"name":[11],"type":["chr"],"align":["left"]},{"label":["tumorType"],"name":[12],"type":["chr"],"align":["left"]},{"label":["assay"],"name":[13],"type":["chr"],"align":["left"]},{"label":["species"],"name":[14],"type":["chr"],"align":["left"]},{"label":["grantType"],"name":[15],"type":["chr"],"align":["left"]},{"label":["theme"],"name":[16],"type":["chr"],"align":["left"]},{"label":["consortium"],"name":[17],"type":["chr"],"align":["left"]}],"data":[{"1":"syn21889513","2":"GSE100274","3":"GSE100274","4":"NA","5":"NA","6":"[GEO:GSE100274](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100274)","7":"syn21648934","8":"Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types","9":"[Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types (PMID:29871632)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29871632)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889514","2":"GSE101209","3":"GSE101209","4":"NA","5":"NA","6":"[GEO:GSE101209](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101209)","7":"syn21648894","8":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","9":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","10":"syn10140998","11":"The Cancer Cell Map Initiative","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889515","2":"GSE101988","3":"GSE101988","4":"NA","5":"NA","6":"[GEO:GSE101988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE101988)","7":"syn21681382","8":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","9":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","10":"syn7349753","11":"H Lee Moffitt Cancer Center and Research Institute","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Tumor-Immune","17":"PS-ON"},{"1":"syn21889517","2":"Mitotic chromosomes fold by condensin-dependent helical winding of chromatin loop arrays","3":"GSE102740","4":"Mitotic chromosome morphogenesis occurs through condensin-mediated disassembly of the interphase conformation and formation of extended prophase loop arrays that then shorten by condensin-dependent helical winding.","5":"Chromosome organization investigation through Hi-C","6":"[GEO:GSE102740](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102740)","7":"syn21649214","8":"A pathway for mitotic chromosome formation","9":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889519","2":"GSE103203","3":"GSE103203","4":"NA","5":"NA","6":"[GEO:GSE103203](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103203)","7":"syn21681447","8":"Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer","9":"[Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer (PMID:30389702)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30389702)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889520","2":"Single-Cell Transcriptome Analysis of Lineage Diversity and Microenvironment in High-Grade Glioma","3":"GSE103224","4":"Despite extensive molecular characterization, we lack a comprehensive picture of lineage identity, differentiation, and microenvironmental composition in high-grade gliomas (HGGs). We sampled the cellular milieu of HGGs with massively-parallel single-cell RNA-Seq.","5":"Performed single cell RNA-seq on tens of thousands of dissociated high-grade glioma tissue cells from 8 human patients.","6":"[GEO:GSE103224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103224)","7":"syn21648977","8":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","9":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889522","2":"The transcriptome effect of overexpressing EZH2 in MCF7","3":"GSE103242","4":"Purpose: Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in EZH2 overexpressed MCF-7 cells.","5":"Transcriptome profiles of tamoxifen sensitive MCF-7 infected with pLenti-CMV-hygro-GFP or pLento-HA-EZH2 were sequenced in at least duplicates using Illumina HiSeq 3000.","6":"[GEO:GSE103242](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103242)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889523","2":"GSE103243","3":"GSE103243","4":"NA","5":"NA","6":"[GEO:GSE103243](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103243)","7":"syn21645251","8":"Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis","9":"[Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis (PMID:29212856)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29212856)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889524","2":"GSE103990","3":"GSE103990","4":"NA","5":"NA","6":"[GEO:GSE103990](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103990)","7":"syn21648885","8":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","9":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889525","2":"GSE104981","3":"GSE104981","4":"NA","5":"NA","6":"[GEO:GSE104981](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104981)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889526","2":"GSE104983","3":"GSE104983","4":"NA","5":"NA","6":"[GEO:GSE104983](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104983)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889527","2":"GSE104984","3":"GSE104984","4":"NA","5":"NA","6":"[GEO:GSE104984](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104984)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889528","2":"GSE104985","3":"GSE104985","4":"NA","5":"NA","6":"[GEO:GSE104985](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104985)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889529","2":"GSE104986","3":"GSE104986","4":"NA","5":"NA","6":"[GEO:GSE104986](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104986)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889530","2":"GSE104987","3":"GSE104987","4":"NA","5":"NA","6":"[GEO:GSE104987](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104987)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889531","2":"GSE104988","3":"GSE104988","4":"NA","5":"NA","6":"[GEO:GSE104988](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104988)","7":"syn21681468","8":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","9":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889532","2":"GSE106519","3":"GSE106519","4":"NA","5":"NA","6":"[GEO:GSE106519](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106519)","7":"syn21648893","8":"Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance","9":"[Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance (PMID:29251630)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29251630)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889533","2":"GSE107470","3":"GSE107470","4":"NA","5":"NA","6":"[GEO:GSE107470](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107470)","7":"syn21648884","8":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","9":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889534","2":"GSE107558","3":"GSE107558","4":"NA","5":"NA","6":"[GEO:GSE107558](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107558)","7":"NA","8":"NA","9":"NA","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889536","2":"GSE107559","3":"GSE107559","4":"NA","5":"NA","6":"[GEO:GSE107559](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107559)","7":"NA","8":"NA","9":"NA","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889537","2":"GSE107560","3":"GSE107560","4":"NA","5":"NA","6":"[GEO:GSE107560](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE107560)","7":"syn21648951","8":"An anatomic transcriptional atlas of human glioblastoma","9":"[An anatomic transcriptional atlas of human glioblastoma (PMID:29748285)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29748285)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889538","2":"GSE109089","3":"GSE109089","4":"NA","5":"NA","6":"[GEO:GSE109089](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109089)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889540","2":"GSE109092","3":"GSE109092","4":"NA","5":"NA","6":"[GEO:GSE109092](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109092)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889541","2":"GSE109309","3":"GSE109309","4":"NA","5":"NA","6":"[GEO:GSE109309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109309)","7":"NA","8":"NA","9":"NA","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889542","2":"GSE109457","3":"GSE109457","4":"NA","5":"NA","6":"[GEO:GSE109457](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109457)","7":"NA","8":"NA","9":"NA","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889543","2":"GSE109458","3":"GSE109458","4":"NA","5":"NA","6":"[GEO:GSE109458](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109458)","7":"NA","8":"NA","9":"NA","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889544","2":"GSE109459","3":"GSE109459","4":"NA","5":"NA","6":"[GEO:GSE109459](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109459)","7":"NA","8":"NA","9":"NA","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889545","2":"GSE110644","3":"GSE110644","4":"NA","5":"NA","6":"[GEO:GSE110644](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110644)","7":"syn21681403","8":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","9":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889546","2":"GSE110704","3":"GSE110704","4":"NA","5":"NA","6":"[GEO:GSE110704](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110704)","7":"NA","8":"NA","9":"NA","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889547","2":"GSE111075","3":"GSE111075","4":"NA","5":"NA","6":"[GEO:GSE111075](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111075)","7":"NA","8":"NA","9":"NA","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889548","2":"GSE111076","3":"GSE111076","4":"NA","5":"NA","6":"[GEO:GSE111076](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111076)","7":"syn21681553","8":"Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence","9":"[Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence (PMID:30739799)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30739799)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889549","2":"GSE111653","3":"GSE111653","4":"NA","5":"NA","6":"[GEO:GSE111653](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111653)","7":"syn21681401","8":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","9":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","10":"syn7349766","11":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Metabolism","17":"PS-ON"},{"1":"syn21889552","2":"GSE112786","3":"GSE112786","4":"NA","5":"NA","6":"[GEO:GSE112786](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112786)","7":"NA","8":"NA","9":"NA","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889553","2":"GSE112829","3":"GSE112829","4":"NA","5":"NA","6":"[GEO:GSE112829](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112829)","7":"NA","8":"NA","9":"NA","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889555","2":"GSE112830","3":"GSE112830","4":"NA","5":"NA","6":"[GEO:GSE112830](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112830)","7":"syn21648964","8":"Patient derived organoids to model rare prostate cancer phenotypes","9":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889562","2":"GSE113616","3":"GSE113616","4":"NA","5":"NA","6":"[GEO:GSE113616](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113616)","7":"syn21681772","8":"Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer","9":"[Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer (PMID:31155233)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31155233)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889563","2":"GSE114044","3":"GSE114044","4":"NA","5":"NA","6":"[GEO:GSE114044](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114044)","7":"NA","8":"NA","9":"NA","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889565","2":"GSE114296","3":"GSE114296","4":"NA","5":"NA","6":"[GEO:GSE114296](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114296)","7":"syn21681436","8":"Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs","9":"[Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs (PMID:30309298)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30309298)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889566","2":"GSE114300","3":"GSE114300","4":"NA","5":"NA","6":"[GEO:GSE114300](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114300)","7":"syn21649081","8":"Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival","9":"[Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival (PMID:29997286)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29997286)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889567","2":"GSE114397","3":"GSE114397","4":"NA","5":"NA","6":"[GEO:GSE114397](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114397)","7":"syn21681394","8":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","9":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889568","2":"GSE114438","3":"GSE114438","4":"NA","5":"NA","6":"[GEO:GSE114438](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114438)","7":"syn21681409","8":"A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine","9":"[A PDGFR-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine (PMID:30082792)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30082792)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889569","2":"GSE114686","3":"GSE114686","4":"NA","5":"NA","6":"[GEO:GSE114686](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114686)","7":"syn21681737","8":"Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming","9":"[Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming (PMID:31078528)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31078528)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889570","2":"5' RNA sequencing and TCR sequencing of breast cancer tumor cells","3":"GSE114724","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"Single-cell RNA sequencing was performed on three patients using the 10x genomics TCR profiling kits. For each patient, populations of T-cells were assayed for both TCR sequence and trancriptome-wide RNA-sequence. Two donors have a replicate experiment.","6":"[GEO:GSE114724](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114724)","7":"NA","8":"NA","9":"NA","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889571","2":"3' RNA Sequencing of breast cancer tumor cells","3":"GSE114725","4":"Knowledge of immune cell phenotypes in the tumor microenvironment is essential for understanding mechanisms of cancer progression and immunotherapy response. We created an immune map of breast cancer using single-cell RNA-seq data from 45,000 immune cells from eight breast carcinomas, as well as matched normal breast tissue, blood, and lymph node.","5":"Single-cell RNA sequencing was performed on eight donors using the InDrop v2 protocol. For each donor populations of CD45+ immune cells were assayed for trancriptome-wide RNA-sequence. At least one replicate was taken for each donor.","6":"[GEO:GSE114725](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114725)","7":"NA","8":"NA","9":"NA","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889572","2":"GSE114727","3":"GSE114727","4":"NA","5":"NA","6":"[GEO:GSE114727](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114727)","7":"syn21649215","8":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","9":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889574","2":"GSE115501","3":"GSE115501","4":"NA","5":"NA","6":"[GEO:GSE115501](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115501)","7":"syn21681993","8":"Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer","9":"[Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer (PMID:31805710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31805710)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889575","2":"GSE115531","3":"GSE115531","4":"NA","5":"NA","6":"[GEO:GSE115531](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115531)","7":"syn21681517","8":"Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans","9":"[Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans (PMID:30638295)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30638295)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889576","2":"GSE115542","3":"GSE115542","4":"NA","5":"NA","6":"[GEO:GSE115542](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115542)","7":"syn21681442","8":"Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma","9":"[Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma (PMID:30355798)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30355798)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889578","2":"GSE115635","3":"GSE115635","4":"NA","5":"NA","6":"[GEO:GSE115635](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115635)","7":"syn21681378","8":"Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer","9":"[Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer (PMID:29860390)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29860390)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889579","2":"GSE115832","3":"GSE115832","4":"NA","5":"NA","6":"[GEO:GSE115832](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115832)","7":"syn21681412","8":"The mammalian decidual cell evolved from a cellular stress response","9":"[The mammalian decidual cell evolved from a cellular stress response (PMID:30142145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30142145)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889580","2":"GSE115870","3":"GSE115870","4":"NA","5":"NA","6":"[GEO:GSE115870](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115870)","7":"syn21649154","8":"Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells","9":"[Differential HDAC6 Activity Modulates Ciliogenesis and Subsequent Mechanosensing of Endothelial Cells Derived from Pluripotent Stem Cells (PMID:30044986)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30044986)","10":"syn7349766","11":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Metabolism","17":"PS-ON"},{"1":"syn21889581","2":"GSE116011","3":"GSE116011","4":"NA","5":"NA","6":"[GEO:GSE116011](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116011)","7":"syn21681501","8":"SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing","9":"[SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing (PMID:30583733)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30583733)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889585","2":"GSE116348","3":"GSE116348","4":"NA","5":"NA","6":"[GEO:GSE116348](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116348)","7":"NA","8":"NA","9":"NA","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889586","2":"GSE116466","3":"GSE116466","4":"NA","5":"NA","6":"[GEO:GSE116466](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116466)","7":"NA","8":"NA","9":"NA","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889587","2":"GSE116468","3":"GSE116468","4":"NA","5":"NA","6":"[GEO:GSE116468](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116468)","7":"NA","8":"NA","9":"NA","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889588","2":"GSE116561","3":"GSE116561","4":"NA","5":"NA","6":"[GEO:GSE116561](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116561)","7":"syn21649050","8":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","9":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889589","2":"GSE117340","3":"GSE117340","4":"NA","5":"NA","6":"[GEO:GSE117340](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117340)","7":"syn21681441","8":"Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity","9":"[Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity (PMID:30352428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30352428)","10":"syn7349762","11":"The Center for Immunotherapeutic Transport Oncophysics","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Tumor-Immune, Microenvironment","17":"PS-ON"},{"1":"syn21889590","2":"GSE117615","3":"GSE117615","4":"NA","5":"NA","6":"[GEO:GSE117615](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117615)","7":"syn21649039","8":"Quantitative assessment of cell population diversity in single-cell landscapes","9":"[Quantitative assessment of cell population diversity in single-cell landscapes (PMID:30346945)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30346945)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889591","2":"GSE117824","3":"GSE117824","4":"NA","5":"NA","6":"[GEO:GSE117824](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117824)","7":"NA","8":"NA","9":"NA","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889592","2":"GSE117825","3":"GSE117825","4":"NA","5":"NA","6":"[GEO:GSE117825](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117825)","7":"NA","8":"NA","9":"NA","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889593","2":"GSE117826","3":"GSE117826","4":"NA","5":"NA","6":"[GEO:GSE117826](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117826)","7":"syn21681828","8":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","9":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889594","2":"GSE118303","3":"GSE118303","4":"NA","5":"NA","6":"[GEO:GSE118303](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118303)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889596","2":"GSE118389","3":"GSE118389","4":"NA","5":"NA","6":"[GEO:GSE118389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118389)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889597","2":"GSE118390","3":"GSE118390","4":"NA","5":"NA","6":"[GEO:GSE118390](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118390)","7":"syn21681417","8":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","9":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889601","2":"GSE119270","3":"GSE119270","4":"NA","5":"NA","6":"[GEO:GSE119270](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119270)","7":"NA","8":"NA","9":"NA","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889603","2":"GSE120261","3":"GSE120261","4":"NA","5":"NA","6":"[GEO:GSE120261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120261)","7":"syn21681604","8":"In situ 10-cell RNA sequencing in tissue and tumor biopsy samples","9":"[In situ 10-cell RNA sequencing in tissue and tumor biopsy samples (PMID:30894605)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30894605)","10":"syn17084062","11":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Evolution","17":"CSBC"},{"1":"syn21889604","2":"GSE121094","3":"GSE121094","4":"NA","5":"NA","6":"[GEO:GSE121094](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121094)","7":"syn21649183","8":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","9":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889605","2":"GSE121229","3":"GSE121229","4":"NA","5":"NA","6":"[GEO:GSE121229](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121229)","7":"syn21681667","8":"BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells","9":"[BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells (PMID:30995943)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30995943)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889606","2":"GSE121655","3":"GSE121655","4":"NA","5":"NA","6":"[GEO:GSE121655](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121655)","7":"syn21649021","8":"Linking single-cell measurements of mass, growth rate, and gene expression","9":"[Linking single-cell measurements of mass, growth rate, and gene expression (PMID:30482222)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30482222)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889607","2":"GSE121861","3":"GSE121861","4":"NA","5":"NA","6":"[GEO:GSE121861](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121861)","7":"syn21681451","8":"Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics","9":"[Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics (PMID:30404002)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30404002)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889608","2":"GSE121937","3":"GSE121937","4":"NA","5":"NA","6":"[GEO:GSE121937](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121937)","7":"NA","8":"NA","9":"NA","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889609","2":"GSE121939","3":"GSE121939","4":"NA","5":"NA","6":"[GEO:GSE121939](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121939)","7":"NA","8":"NA","9":"NA","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889610","2":"GSE121940","3":"GSE121940","4":"NA","5":"NA","6":"[GEO:GSE121940](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121940)","7":"syn21681992","8":"Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach","9":"[Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach (PMID:31804471)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31804471)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889611","2":"GSE122041","3":"GSE122041","4":"NA","5":"NA","6":"[GEO:GSE122041](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122041)","7":"syn21649049","8":"A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma","9":"[A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma (PMID:29590606)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29590606)","10":"syn17084070","11":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity, Heterogeneity","17":"CSBC"},{"1":"syn21889613","2":"GSE122050","3":"GSE122050","4":"NA","5":"NA","6":"[GEO:GSE122050](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122050)","7":"syn21681529","8":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","9":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","10":"syn7349745","11":"Center for Modeling Tumor Cell Migration Mechanics","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Tumor-Immune","17":"PS-ON"},{"1":"syn21889614","2":"GSE122233","3":"GSE122233","4":"NA","5":"NA","6":"[GEO:GSE122233](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122233)","7":"syn21681530","8":"Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer","9":"[Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer (PMID:30674677)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674677)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889616","2":"GSE122404","3":"GSE122404","4":"NA","5":"NA","6":"[GEO:GSE122404](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122404)","7":"NA","8":"NA","9":"NA","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889617","2":"GSE124494","3":"GSE124494","4":"NA","5":"NA","6":"[GEO:GSE124494](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124494)","7":"syn21681865","8":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","9":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","10":"syn7315808","11":"Stanford University Center for Cancer Systems Biology","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889618","2":"GSE124854","3":"GSE124854","4":"NA","5":"NA","6":"[GEO:GSE124854](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124854)","7":"NA","8":"NA","9":"NA","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889619","2":"GSE125014","3":"GSE125014","4":"NA","5":"NA","6":"[GEO:GSE125014](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125014)","7":"syn21681899","8":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","9":"[Molecular determinants for enzalutamide-induced transcription in prostate cancer (PMID:31501863)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31501863)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889620","2":"GSE125215","3":"GSE125215","4":"NA","5":"NA","6":"[GEO:GSE125215](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125215)","7":"syn21681801","8":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity","9":"[Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity (PMID:31178407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31178407)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889622","2":"GSE125588","3":"GSE125588","4":"NA","5":"NA","6":"[GEO:GSE125588](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125588)","7":"syn21681851","8":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","9":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","10":"syn7349762","11":"The Center for Immunotherapeutic Transport Oncophysics","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Tumor-Immune, Microenvironment","17":"PS-ON"},{"1":"syn21889623","2":"GSE125594","3":"GSE125594","4":"NA","5":"NA","6":"[GEO:GSE125594](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125594)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889624","2":"GSE125606","3":"GSE125606","4":"NA","5":"NA","6":"[GEO:GSE125606](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125606)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889625","2":"GSE125607","3":"GSE125607","4":"NA","5":"NA","6":"[GEO:GSE125607](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125607)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889626","2":"GSE125609","3":"GSE125609","4":"NA","5":"NA","6":"[GEO:GSE125609](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125609)","7":"syn21681836","8":"A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer","9":"[A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer (PMID:31303470)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31303470)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889627","2":"GSE125688","3":"GSE125688","4":"NA","5":"NA","6":"[GEO:GSE125688](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125688)","7":"syn21681739","8":"Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration","9":"[Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration (PMID:31080134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31080134)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889628","2":"GSE125802","3":"GSE125802","4":"NA","5":"NA","6":"[GEO:GSE125802](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE125802)","7":"syn21681547","8":"Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer","9":"[Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer (PMID:30718260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30718260)","10":"syn17083789","11":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","12":"","13":"","14":"","15":"U01","16":"Metastasis, Microenvironment","17":"PS-ON"},{"1":"syn21889629","2":"Single-cell combinatorial indexing ATAC-seq of HCC1143 with MEK, PI3K, and BET inhibition","3":"GSE126261","4":"We performed single-cell combinatorial indexing ATAC-seq on the basal-like TNBC cell line HCC1143 under MEK, PI3K, BET and combination treatments as well as DMSO controls.","5":"Cells were cultured and exposed to inhibitors or vehicle for 72 hours and processed in a single batch of sci-ATAC-seq using transposition barcodes for sample tracking to eliminate batch effects downstream","6":"[GEO:GSE126261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126261)","7":"syn21649001","8":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","9":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889631","2":"GSE126770","3":"GSE126770","4":"NA","5":"NA","6":"[GEO:GSE126770](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE126770)","7":"syn21681695","8":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","9":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889633","2":"GSE128313","3":"GSE128313","4":"NA","5":"NA","6":"[GEO:GSE128313](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128313)","7":"syn21681723","8":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","9":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","10":"syn7349766","11":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Metabolism","17":"PS-ON"},{"1":"syn21889637","2":"GSE129455","3":"GSE129455","4":"NA","5":"NA","6":"[GEO:GSE129455](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129455)","7":"syn21681814","8":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","9":"[Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts (PMID:31197017)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31197017)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889638","2":"GSE129521","3":"GSE129521","4":"NA","5":"NA","6":"[GEO:GSE129521](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129521)","7":"syn21681783","8":"Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma","9":"[Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (PMID:31160565)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31160565)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889640","2":"GSE130232","3":"GSE130232","4":"NA","5":"NA","6":"[GEO:GSE130232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130232)","7":"syn21681618","8":"Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer","9":"[Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer (PMID:30938713)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30938713)","10":"syn7349762","11":"The Center for Immunotherapeutic Transport Oncophysics","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Tumor-Immune, Microenvironment","17":"PS-ON"},{"1":"syn21889641","2":"GSE132926","3":"GSE132926","4":"NA","5":"NA","6":"[GEO:GSE132926](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132926)","7":"NA","8":"NA","9":"NA","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889642","2":"GSE132959","3":"GSE132959","4":"NA","5":"NA","6":"[GEO:GSE132959](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132959)","7":"NA","8":"NA","9":"NA","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889643","2":"GSE132960","3":"GSE132960","4":"NA","5":"NA","6":"[GEO:GSE132960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132960)","7":"syn21681881","8":"Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells","9":"[Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells (PMID:31442407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31442407)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889644","2":"GSE133747","3":"GSE133747","4":"NA","5":"NA","6":"[GEO:GSE133747](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE133747)","7":"syn21681999","8":"Single-cell connectomic analysis of adult mammalian lungs","9":"[Single-cell connectomic analysis of adult mammalian lungs (PMID:31840053)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31840053)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889645","2":"GSE134139","3":"GSE134139","4":"NA","5":"NA","6":"[GEO:GSE134139](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134139)","7":"NA","8":"NA","9":"NA","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889646","2":"GSE134385","3":"GSE134385","4":"NA","5":"NA","6":"[GEO:GSE134385](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134385)","7":"NA","8":"NA","9":"NA","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889647","2":"GSE134413","3":"GSE134413","4":"NA","5":"NA","6":"[GEO:GSE134413](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134413)","7":"syn21681909","8":"PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity","9":"[PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity (PMID:31527834)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31527834)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889648","2":"GSE134583","3":"GSE134583","4":"NA","5":"NA","6":"[GEO:GSE134583](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134583)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889650","2":"GSE134997","3":"GSE134997","4":"NA","5":"NA","6":"[GEO:GSE134997](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134997)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889651","2":"GSE135031","3":"GSE135031","4":"NA","5":"NA","6":"[GEO:GSE135031](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135031)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889652","2":"GSE135578","3":"GSE135578","4":"NA","5":"NA","6":"[GEO:GSE135578](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135578)","7":"syn21681944","8":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","9":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","10":"syn7349762","11":"The Center for Immunotherapeutic Transport Oncophysics","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Tumor-Immune, Microenvironment","17":"PS-ON"},{"1":"syn21889653","2":"GSE136299","3":"GSE136299","4":"NA","5":"NA","6":"[GEO:GSE136299](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136299)","7":"syn21681987","8":"Evolution of placental invasion and cancer metastasis are causally linked","9":"[Evolution of placental invasion and cancer metastasis are causally linked (PMID:31768023)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31768023)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889656","2":"GSE138003","3":"GSE138003","4":"NA","5":"NA","6":"[GEO:GSE138003](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138003)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889657","2":"GSE138004","3":"GSE138004","4":"NA","5":"NA","6":"[GEO:GSE138004](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138004)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889658","2":"GSE138005","3":"GSE138005","4":"NA","5":"NA","6":"[GEO:GSE138005](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138005)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889659","2":"GSE138006","3":"GSE138006","4":"NA","5":"NA","6":"[GEO:GSE138006](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138006)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889660","2":"GSE138007","3":"GSE138007","4":"NA","5":"NA","6":"[GEO:GSE138007](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138007)","7":"syn21681890","8":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","9":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889661","2":"RNA-array measurements of T-ALL with and without drug treatment","3":"GSE5827","4":"The NOTCH1 signaling pathway directly links extracellular signals with transcriptional responses in the cell nucleus and plays a critical role during T-cell development and in the pathogenesis over 50% of human T-cell lymphoblastic leukemia (T-ALL) cases. However, little is known about the transcriptional programs activated by NOTCH1. Using an integrative systems biology approach we show that NOTCH1 controls a feed-forward loop transcriptional network that promotes cell growth.","5":"Duplicated cultures of T-ALL cell lines were treated with Compound E, a gamma-secretase inhibitor or vehicle only (DMSO) for 24 h and analyzed using oligonucleotide microarrays. Gene expression changes were analyzed in the context of loss of NOTCH1 signaling induced by the gamma secretase inhibitor treatment.","6":"[GEO:GSE5827](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5827)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889663","2":"Methylation disorder in CLL","3":"GSE58889","4":"We performed RRBS and WGBS on primary human chronic lymphocytic leukemia and normal healthy donor B cell samples.","5":"cross-sectional/longitudinal","6":"[GEO:GSE58889](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58889)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889664","2":"RNA-Seq of isolated stormal cells and tumor epithelial cells in mouse lung cancer","3":"GSE59831","4":"We sequenced mRNA from individual stormal cells (Macrophages, Monocytes, and Neutrophils) and tumor epithelial cells from KrasG12dD; p53-/- murine lung cancer model and WT control mouse to compare gene expressio profiles of lung cancer stroma and tumor cells to their counterparts of WT lugns.","5":"Examination of mRNA levels in individual stormal cells and tumor cells from tumor lungs compared to their counterparts from WT lungs","6":"[GEO:GSE59831](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59831)","7":"NA","8":"NA","9":"NA","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889665","2":"GSE61033","3":"GSE61033","4":"NA","5":"NA","6":"[GEO:GSE61033](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61033)","7":"NA","8":"NA","9":"NA","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889666","2":"GSE61034","3":"GSE61034","4":"NA","5":"NA","6":"[GEO:GSE61034](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61034)","7":"NA","8":"NA","9":"NA","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889668","2":"GSE61035","3":"GSE61035","4":"NA","5":"NA","6":"[GEO:GSE61035](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61035)","7":"syn21645595","8":"Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements","9":"[Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements (PMID:26748710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26748710)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889670","2":"GSE63776","3":"GSE63776","4":"NA","5":"NA","6":"[GEO:GSE63776](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63776)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889672","2":"GSE64038","3":"GSE64038","4":"NA","5":"NA","6":"[GEO:GSE64038](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64038)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889673","2":"GSE64039","3":"GSE64039","4":"NA","5":"NA","6":"[GEO:GSE64039](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64039)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889674","2":"GSE65133","3":"GSE65133","4":"NA","5":"NA","6":"[GEO:GSE65133](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65133)","7":"NA","8":"NA","9":"NA","10":"syn7315808","11":"Stanford University Center for Cancer Systems Biology","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889675","2":"GSE65134","3":"GSE65134","4":"NA","5":"NA","6":"[GEO:GSE65134](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65134)","7":"NA","8":"NA","9":"NA","10":"syn7315808","11":"Stanford University Center for Cancer Systems Biology","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889676","2":"GSE65135","3":"GSE65135","4":"NA","5":"NA","6":"[GEO:GSE65135](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65135)","7":"NA","8":"NA","9":"NA","10":"syn7315808","11":"Stanford University Center for Cancer Systems Biology","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889677","2":"GSE65136","3":"GSE65136","4":"NA","5":"NA","6":"[GEO:GSE65136](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65136)","7":"syn21681314","8":"Robust enumeration of cell subsets from tissue expression profiles","9":"[Robust enumeration of cell subsets from tissue expression profiles (PMID:25822800)](https://www.ncbi.nlm.nih.gov/pubmed/?term=25822800)","10":"syn7315808","11":"Stanford University Center for Cancer Systems Biology","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889678","2":"GSE66357","3":"GSE66357","4":"NA","5":"NA","6":"[GEO:GSE66357](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE66357)","7":"syn21645574","8":"Scalable microfluidics for single-cell RNA printing and sequencing","9":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889679","2":"GSE67405","3":"GSE67405","4":"NA","5":"NA","6":"[GEO:GSE67405](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE67405)","7":"syn21645570","8":"Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes","9":"[Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes (PMID:26883104)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26883104)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889682","2":"GSE68795","3":"GSE68795","4":"NA","5":"NA","6":"[GEO:GSE68795](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68795)","7":"syn21681315","8":"Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC","9":"[Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC (PMID:26046767)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26046767)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889683","2":"GSE68858","3":"GSE68858","4":"NA","5":"NA","6":"[GEO:GSE68858](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68858)","7":"syn21681486","8":"Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature","9":"[Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature (PMID:30548288)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30548288)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889685","2":"GSE68975","3":"GSE68975","4":"NA","5":"NA","6":"[GEO:GSE68975](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68975)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889686","2":"GSE68976","3":"GSE68976","4":"NA","5":"NA","6":"[GEO:GSE68976](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68976)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889687","2":"GSE68977","3":"GSE68977","4":"NA","5":"NA","6":"[GEO:GSE68977](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68977)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889689","2":"GSE68978","3":"GSE68978","4":"NA","5":"NA","6":"[GEO:GSE68978](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68978)","7":"NA","8":"NA","9":"NA","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889690","2":"RNA-Seq and DNAse-1 Hypersensitivty assays of Gefinitib-treated PANC1 cells","3":"GSE70810","4":"Small molecule screens are widely used to prioritize compounds for development of pharmaceuticals and to reveal pathways altered in biological processes.  However, interpreting the results of these screens is very challenging since in almost all cases, the compounds are highly promiscuous.","5":"NA","6":"[GEO:GSE70810](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70810)","7":"syn21645600","8":"Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens","9":"[Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens (PMID:29023490)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29023490)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889691","2":"Expression data from isogenic Pten WT or KO mouse T-ALLs treated with DBZ or DMSO","3":"GSE71087","4":"To investigate the underlying mechanisms mediating resistance to NOTCH inhibition in Pten-null T-ALL tumor cells we performed gene expression profiling of isogenic Pten-positive and Pten-deleted leukemia lymphoblasts after acute treatment with DBZ in vivo.","5":"We performed microarray gene expression analysis of GSI treatment in isogenic Pten KO or WT NOTCH1 induced leukemias","6":"[GEO:GSE71087](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71087)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889692","2":"Expression data from isogenic Pten WT mouse T-ALLs","3":"GSE71089","4":"To explore the mechanisms downstream of NOTCH1 and PTEN in the control of leukemia cell growth, we performed expression profiling on NOTCH1 induced and Pten-positive T-ALL tumor cells infected with constitutively active AKT (myristoylated-AKT). Constitutive activation of AKT rescues the transcriptional programs induced by NOTCH1 inhibition in Pten-positive T-ALL cells.","5":"We performed microarray gene expression analysis of GSI treatment in Pten WT NOTCH1 induced leukemias infected with constitutively active AKT (myristoylated-AKT) or empty vector.","6":"[GEO:GSE71089](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71089)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889693","2":"GSE73628","3":"GSE73628","4":"NA","5":"NA","6":"[GEO:GSE73628](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73628)","7":"syn21645337","8":"Combating subclonal evolution of resistant cancer phenotypes","9":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","10":"syn9771796","11":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Evolution, Metastasis","17":"CSBC"},{"1":"syn21889694","2":"Bisulfite-independent analysis of CpG island methylation across cancer cell lines","3":"GSE75346","4":"This set of data is for assessing and validation of a novel method, CGI-seq, as described in the corresponding paper, for profiling of single cell CpG methylome. We tested 4 different cell lines (K562, GM12878, 551 K1-iPSC, and Fibroblast ATCC-CCL-110) with a low quantity of cells (LQC, here including 100-cell or 10-cell) and with single cells (SC) separately. Briefly, the protocol include these steps. The intact gDNA of the cell(s) was released. This gDNA (i.e.","5":"We designed 2 protocols (protocol option 1 - BstUI as RE2, and protocol option2 - ABH as RE2, while other steps were the same) for LQC processing (30 samples with 100Cell or 10cell), and the option 2 above was used for SC (8 samples for K562 and GM12878 separately, totally 16 samples). The corresponding Methylation Controls (MCs, for which no RE1 was applied but all other processes were the same as the TEST) were also generated corresponding to each set of TEST samples..","6":"[GEO:GSE75346](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE75346)","7":"syn21649212","8":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","9":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889695","2":"GSE77142","3":"GSE77142","4":"NA","5":"NA","6":"[GEO:GSE77142](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77142)","7":"syn21645430","8":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","9":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889696","2":"GSE77450","3":"GSE77450","4":"NA","5":"NA","6":"[GEO:GSE77450](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77450)","7":"syn21648846","8":"BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic -Cell","9":"[BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic -Cell (PMID:27008626)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27008626)","10":"syn9775665","11":"CSBC U01 Project Boston University","12":"","13":"","14":"","15":"U01","16":"NA","17":"CSBC"},{"1":"syn21889697","2":"GSE77570","3":"GSE77570","4":"NA","5":"NA","6":"[GEO:GSE77570](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77570)","7":"syn21645592","8":"Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia","9":"[Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia (PMID:27315426)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27315426)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889698","2":"GSE77967","3":"GSE77967","4":"NA","5":"NA","6":"[GEO:GSE77967](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77967)","7":"syn21645405","8":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","9":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889699","2":"GSE78036","3":"GSE78036","4":"NA","5":"NA","6":"[GEO:GSE78036](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78036)","7":"syn21645594","8":"Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells","9":"[Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells (PMID:27146274)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27146274)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889700","2":"Gene expression profileing of CUTLL cell lines upon Withaferin A treatment","3":"GSE78187","4":"The clinical development of targeted therapies has been hampered by their limited intrinsic antitumor activity and the rapid emergence of resistance, highlighting the need to identify highly active and synergistic drug combinations. However, empirical synergistic drug screening approaches are challenging and elucidating the mechanisms that underlie such drug interactions is typically complex.","5":"CUTLL cell lines were treated with Withaferin A or DMSO control at 24hrs in 6 replicates.","6":"[GEO:GSE78187](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78187)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889701","2":"Gene expression profiling of CUTLL cell lines upon 17 drug treatments","3":"GSE78188","4":"The clinical development of targeted therapies has been hampered by their limited intrinsic antitumor activity and the rapid emergence of resistance, highlighting the need to identify highly active and synergistic drug combinations. However, empirical synergistic drug screening approaches are challenging and elucidating the mechanisms that underlie such drug interactions is typically complex.","5":"CUTLL cell lines were treated with drugs (Pyrvinium P, Vorinostat, Geldanamycin, Lanatoside C, Withaferin A, Prochlorperazine, Astemizole, Mefloquine, Trichostatin A, Rapamycin, Parthenolide, Valproic acid, Thioridazine, Trifluoperazine, Phenoxibenzamine, Wortmannin, Resveratrol) or DMSO control at 24hrs in 3 replicates.","6":"[GEO:GSE78188](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78188)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889703","2":"GSE78189","3":"GSE78189","4":"NA","5":"NA","6":"[GEO:GSE78189](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78189)","7":"syn21645323","8":"Synergistic antileukemic therapies in NOTCH1-induced T-ALL","9":"[Synergistic antileukemic therapies in NOTCH1-induced T-ALL (PMID:28174276)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28174276)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889704","2":"GSE78198","3":"GSE78198","4":"NA","5":"NA","6":"[GEO:GSE78198](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE78198)","7":"syn21681375","8":"3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk","9":"[3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk (PMID:29785014)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29785014)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889705","2":"GSE81164","3":"GSE81164","4":"NA","5":"NA","6":"[GEO:GSE81164](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81164)","7":"syn21681435","8":"Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression","9":"[Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression (PMID:30306128)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30306128)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889707","2":"RNA-Sequencing of human basal-like breast cancer cell line HCC1143 treated with  JQ1,Trametinib, or BEZ235","3":"GSE82032","4":"The goal of this experiment was to understand the changes in gene expression in the human basal-like breast cancer cell line HCC1143 following treatment with the MEK inhibitor Trametinib (T), PI3K/mTOR inhibitor BEZ235 (B), the BET inhibition JQ1 (JQ), Trametinib + JQ1 (TJ), or BEZ235 + JQ1(BJ), compared to a DMSO control (D).","5":"The human basal-like breast cancer cell line HCC1143 was treated for 72hr with 1uM Trametinib (T), 1uM BEZ235, 1uM JQ1 (JQ), 1uM Trametinib + 1uM JQ1 (TJ), 1uM BEZ235 + 1uM JQ1 (BJ), or a 0.05% DMSO control. Total RNA was isolated using a QIAGEN total RNA RNeasy kit, libraries were generated with a Truseq kit, and samples were run on the Nextseq500, data processing is described below.","6":"[GEO:GSE82032](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82032)","7":"NA","8":"NA","9":"NA","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889708","2":"GSE82127","3":"GSE82127","4":"NA","5":"NA","6":"[GEO:GSE82127](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82127)","7":"syn21645389","8":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","9":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889709","2":"GSE83083","3":"GSE83083","4":"NA","5":"NA","6":"[GEO:GSE83083](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83083)","7":"syn21648903","8":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","9":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","10":"syn9771796","11":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Evolution, Metastasis","17":"CSBC"},{"1":"syn21889710","2":"RNA-sequencing of prostate tissues and fibroblasts","3":"GSE83298","4":"We report that a computational systems approach can identify cell type specification genes that act synergistically, and demonstrate its application for reprogramming of fibroblasts to prostate tissue. We have employed three such master regulators (FOXA1, NKX3.1, and androgen receptor, AR) in a primed conversion strategy to generate prostate tissue from mouse fibroblasts, involving expression of pluripotency factors, tissue recombination with embryonic urogenital mesenchyme, and renal grafting.","5":"RNA-sequencing profiles of prostate tissues and fibroblasts were generated and compared to RNA-sequencing profiles of induced prostate tissue in tissue recombinants.","6":"[GEO:GSE83298](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83298)","7":"syn21645325","8":"A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue","9":"[A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue (PMID:28429718)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28429718)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889711","2":"GSE83584","3":"GSE83584","4":"NA","5":"NA","6":"[GEO:GSE83584](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83584)","7":"syn21649111","8":"Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation","9":"[Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation (PMID:27452175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27452175)","10":"syn7416710","11":"ECM geometrical and mechanical properties modulate RTK signaling","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"PS-ON"},{"1":"syn21889712","2":"mRNA array profiling of response to mTOR and HDAC inhibitors","3":"GSE84205","4":"mTOR and HDAC inhibitors induce cell death of malignant peripheral nerve sheath tumors (MPNSTs) in vitro, and in vivo. We performed microarray analysis of mTOR and HDAC inhibition alone and in combination 24 hours after treatment, prior to induction of cell death, to identify transcriptional changes that might be mechanistic drivers of the therapeutic efficacy.","5":"12 samples, in triplicate, 3X vehicle, 3X INK-128, 3X Vorinostat, 3X INK-128 + Vorinostat","6":"[GEO:GSE84205](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84205)","7":"syn21649213","8":"mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors","9":"[mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors (PMID:28963352)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28963352)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889713","2":"ATAC-Seq of embryonic vs extraembryonic lineages","3":"GSE84232","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Comparison of chromatin accessibility patterns in Extraembryonic Ectoderm and cancer","6":"[GEO:GSE84232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84232)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889714","2":"RNA-Seq of embryonic vs extraembryonic lineages","3":"GSE84234","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","6":"[GEO:GSE84234](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84234)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889715","2":"RRBS  of embryonic vs extraembryonic lineages","3":"GSE84235","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","6":"[GEO:GSE84235](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84235)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889716","2":"GSE84236","3":"GSE84236","4":"NA","5":"NA","6":"[GEO:GSE84236](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84236)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889717","2":"GSE84389","3":"GSE84389","4":"NA","5":"NA","6":"[GEO:GSE84389](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE84389)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889718","2":"GSE85047","3":"GSE85047","4":"NA","5":"NA","6":"[GEO:GSE85047](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85047)","7":"syn21648926","8":"Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma","9":"[Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma (PMID:29510988)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29510988)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889719","2":"GSE85224","3":"GSE85224","4":"NA","5":"NA","6":"[GEO:GSE85224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85224)","7":"syn21649000","8":"Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer","9":"[Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer (PMID:29161592)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29161592)","10":"syn17084062","11":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Evolution","17":"CSBC"},{"1":"syn21889722","2":"Immune escape in breast cancer during in situ to invasive carcinoma transition","3":"GSE87517","4":"To dissect mechanisms of immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils.","5":"RNA-Seq: Gene expression analyses in leukocytes sorted from normal breast tissues, ductal carcinomas in situ (DCIS), and HER2+ and triple negative invasive ductal carcinomas (IDC).","6":"[GEO:GSE87517](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87517)","7":"syn21649209","8":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","9":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889724","2":"DNA Methylation of breast cancer treated with Bisphenol A and/or Genistein","3":"GSE89107","4":"Early postnatal exposures to Bisphenol A (BPA) and genistein (GEN) have been reported to predispose for and against mammary cancer, respectively, in adult rats. Since the changes in cancer susceptibility occurs in the absence of the original chemical exposure, we have investigated the potential of epigenetics to account for these changes. DNA methylation studies reveal that prepubertal BPA exposure alters signaling pathways that contribute to carcinogenesis.","5":"We conducted MBDCap-seq on mammary glands procured from 100 day-old rats exposed prepubertally to vehicle control, BPA, GEN, or BPA + GEN (n = 5/ group)","6":"[GEO:GSE89107](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89107)","7":"syn21645258","8":"DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients","9":"[DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients (PMID:28505145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28505145)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889725","2":"GSE89225","3":"GSE89225","4":"NA","5":"NA","6":"[GEO:GSE89225](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89225)","7":"syn21645339","8":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","9":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889726","2":"GSE89307","3":"GSE89307","4":"NA","5":"NA","6":"[GEO:GSE89307](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89307)","7":"NA","8":"NA","9":"NA","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889727","2":"GSE89308","3":"GSE89308","4":"NA","5":"NA","6":"[GEO:GSE89308](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89308)","7":"NA","8":"NA","9":"NA","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889728","2":"GSE89309","3":"GSE89309","4":"NA","5":"NA","6":"[GEO:GSE89309](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89309)","7":"syn21645338","8":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","9":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889730","2":"Nm-seq finds thousands of modified 2'-methylation sites in mRNA with base precision","3":"GSE90164","4":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision The ribose of rna nucleotides can be 2<U+2032>-O-methylated (nm). despite advances in high-throughput detection, the inert chemical nature of nm still limits sensitivity and precludes mapping in mrna.","5":"we developed a conceptually distinct approach based on the different chemical properties of nucleosides with 2<U+2032>-OH and 2<U+2032>-OMe22<U+2013>25, combining enrichment with detection of a positive signal (rather than the lack of signal) to produce a sensitive method suited for discovery of Nm sites in rare RNA molecules or at low stoichiometry..","6":"[GEO:GSE90164](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90164)","7":"syn21645423","8":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","9":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889731","2":"GSE90780","3":"GSE90780","4":"NA","5":"NA","6":"[GEO:GSE90780](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90780)","7":"syn21648978","8":"Homeobox oncogene activation by pan-cancer DNA hypermethylation","9":"[Homeobox oncogene activation by pan-cancer DNA hypermethylation (PMID:30097071)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30097071)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889732","2":"The transcriptome effect of knocking down EZH2 with Taomifen Resistant-MCF7L","3":"GSE92316","4":"Increasing evidence suggests that epigenetic reprogramming contributes significantly to the development of endocrine therapy resistance in breast cancer. The goal of this work is to explore how the histone methyltransferase EZH2 interacts with ER signaling and drives the insensitiveness of breast cancer cells to the antagonistic effect of tamoxifen on ER activity. Therefore, we comprehensively analyzed the transcriptional program regulated by EZH2 in tamoxifen-resistant (TamR) MCF-7 cells.","5":"Transcriptome profiles of tamoxifen sensitive MCF-7 infected with pLenti-CMV-hygro-GFP or pLento-HA-EZH2 were sequenced in at least duplicates using Illumina HiSeq 3000.","6":"[GEO:GSE92316](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92316)","7":"NA","8":"NA","9":"NA","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889733","2":"GSE92721","3":"GSE92721","4":"NA","5":"NA","6":"[GEO:GSE92721](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92721)","7":"syn21645319","8":"Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer","9":"[Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer (PMID:28411207)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28411207)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889734","2":"GSE93326","3":"GSE93326","4":"NA","5":"NA","6":"[GEO:GSE93326](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93326)","7":"syn21681523","8":"Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes","9":"[Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes (PMID:30658994)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30658994)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889735","2":"Metabolic origins of spatial organization in the tumor microenvironment","3":"GSE93702","4":"We report the transcriptional changes induced by hypoxia and/or lactate on bone marrow-derived macrophages (BMDMs)","5":"Untreated macrophages as well as macrophages treated with lactate, cultured in hypoxia (1% oxygen) or both were cultured in vitro. Then total mRNA was sequenced.","6":"[GEO:GSE93702](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93702)","7":"syn21649207","8":"Metabolic origins of spatial organization in the tumor microenvironment","9":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889737","2":"GSE93765","3":"GSE93765","4":"NA","5":"NA","6":"[GEO:GSE93765](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93765)","7":"syn21648963","8":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","9":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889738","2":"scRNA-sequencing of mESCs into motor neurons","3":"GSE94883","4":"Cellular lineage commitment and terminal cellular differentiation result from the induction of dynamically regulated transcriptional programs. We report an unbiased approach to studying this process that combines temporal single cell RNA-sequencing and topology-based computational analyses (single cell Topological Data Analysis (scTDA)).","5":"Single cell RNA sequencing of 2,744 individual cells, spanning 2 biological (non-technical) replicates. Cells were sampled daily across days 2 through 6 of the in vitro differentiation of mESCs into motor neurons.","6":"[GEO:GSE94883](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94883)","7":"syn21645558","8":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","9":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889739","2":"PDGF-driven glioblastoma mouse model scRNA-Seq","3":"GSE95157","4":"Generate scRNA-Seq profiles for PDGF-driven glioblastoma mouse model.","5":"Obtain 85 scRNA-Seq profiles from a de novo tumor-derived cell line.","6":"[GEO:GSE95157](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95157)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889740","2":"Cell Stiffness and Migration Gene Expression","3":"GSE95680","4":"Cell migration is central to many biological processes including embryonic development, wound healing, and cancer progression. Cell migration is sensitive to environmental stiffness, and many cell types exhibit a stiffness optimum at which migration is maximal. Here we present a cell migration simulator that predicts a stiffness optimum that can be shifted by altering the number of active molecular motors and clutches.","5":"To collect enough mRNA for expression analysis on different stiffnesses, U251 cells were cultured on large polyacrylamide gels covering the surface of a one well chamber glass slide (Lab-Tek 154453). After one day of culture on the gels, mRNA was purified from the cells using an RNeasy Mini Kit (Qiagen 74104). mRNA samples were then analyzed at the University of Minnesota Genomics Center using a HumanHT-12 BeadChip microarray (Illumina BD 103-0204)..","6":"[GEO:GSE95680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE95680)","7":"syn21645266","8":"Shifting the optimal stiffness for cell migration","9":"[Shifting the optimal stiffness for cell migration (PMID:28530245)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28530245)","10":"syn7349745","11":"Center for Modeling Tumor Cell Migration Mechanics","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Tumor-Immune","17":"PS-ON"},{"1":"syn21889742","2":"Protein levels in BRAF inhibitor resistance melanoma cells treated with PF3758309","3":"GSE96753","4":"11 BRAF inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"11 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","6":"[GEO:GSE96753](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96753)","7":"NA","8":"NA","9":"NA","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889743","2":"GSE96760","3":"GSE96760","4":"NA","5":"NA","6":"[GEO:GSE96760](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96760)","7":"NA","8":"NA","9":"NA","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889744","2":"Protein levels in BRAF/MEK inhibitor resistance melanoma cells treated with PF3758309 [CR]","3":"GSE96902","4":"3 BRAF/MEK inhibitor resistance melanoma cells were treated with PAK inhibitor PF3758309 for 48 hr, the cell lysis were analyzed by RPPA profiling by protein array (RPPA)","5":"3 pair of samples were analyzed (control and PF3758309 treatment group) by RPPA, more than 200 of proteins were tested","6":"[GEO:GSE96902](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96902)","7":"syn21649211","8":"PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","9":"[PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (PMID:28953887)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28953887)","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889746","2":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","3":"GSE96979","4":"Gliomas harboring mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have the CpG island methylator phenotype (CIMP) and significantly longer patient survival time than wild-type IDH1/2 tumors. Although there are many factors underlying the differences in survival between these two tumor types, immune-related differences in cell content are potentially important contributors.","5":"Ntva_Ink4a/Arf-/- mice were used to generate mouse gliomas. The genetic backgrounds of tva mice are FVB/N, C57BL6, BALB/C, and 129. To generate wtIDH1- and muIDH1-expressing mouse gliomas, we used the RCAS/tva system as described previously. PDGFa-expressing DF1 cells were mixed with either wtIDH1-shp53- or muIDH1-shp53-expressing DF1 cells. These mixed DF1 cells were injected into Ntva_ Ink4a/Arf-/- mice. Whole tumor tissue was used for RNA extraction..","6":"[GEO:GSE96979](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96979)","7":"syn21648867","8":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","9":"[Mutant IDH1 regulates the tumor-associated immune system in gliomas (PMID:28465358)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28465358)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889747","2":"GSE97460","3":"GSE97460","4":"NA","5":"NA","6":"[GEO:GSE97460](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97460)","7":"syn21645322","8":"PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens","9":"[PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens (PMID:28740083)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28740083)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889748","2":"RNA-seq of treated and untreated melanoma cells","3":"GSE97679","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","6":"[GEO:GSE97679](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97679)","7":"NA","8":"NA","9":"NA","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889749","2":"ATAC-seq of treated and untreated melanoma cells","3":"GSE97680","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"We performed FACS to isolate EGFR-high populations of WM989 melanoma cells at three time points (untreated, 1 week in vemurafenib, 4 weeks in vemurafenib) for RNA sequencing and ATAC sequencing. Each sample has three biological replicates.","6":"[GEO:GSE97680](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97680)","7":"NA","8":"NA","9":"NA","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889750","2":"Gene expression signature of vemurafenib resistance in WM989 and WM983B melanoma cells","3":"GSE97681","4":"Therapies targeting signaling molecules mutated in cancers can often have striking short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can sometimes result from a secondary mutations in rare cells, but other times, there is no clear genetic cause, raising leaving the possibility of non-genetic rare cell variability.","5":"We performed RNA sequencing on WM989 cells without vemurafenib, after 48 hours of treatment, and upon the development of resistance.","6":"[GEO:GSE97681](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97681)","7":"NA","8":"NA","9":"NA","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889751","2":"GSE97682","3":"GSE97682","4":"NA","5":"NA","6":"[GEO:GSE97682](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97682)","7":"syn21649208","8":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","9":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889752","2":"GSE98161","3":"GSE98161","4":"NA","5":"NA","6":"[GEO:GSE98161](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98161)","7":"syn21645422","8":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","9":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889753","2":"GSE98183","3":"GSE98183","4":"NA","5":"NA","6":"[GEO:GSE98183](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98183)","7":"syn21645269","8":"Chromosomal instability drives metastasis through a cytosolic DNA response","9":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889755","2":"CTCF ChIP-Seq and Hi-C of murine cell lines under various conditions","3":"GSE98671","4":"The molecular mechanisms underlying folding of mammalian chromosomes remain poorly understood. The transcription factor CTCF is a candidate regulator of chromosomal structure. Using the auxin-inducible degron system in mouse embryonic stem cells, we show that CTCF is absolutely and dose-dependently required for looping between CTCF target sites and insulation of topologically associating domains (TADs).","5":"mouse ES cells were engineered to harbor an auxin-inducible degron (AID) tag at both endogenous alleles of CTCF. A transgene encoding the auxin-binding F-box protein Tir1 was subsequently introduce, so that adding auxin to the culture media leads to rapid (hours) and reversible degradation of CTCF. Consequences of acute loss of CTCF and its restoration were investigated using ChIP-seq, RNA-seq and high-throughput Chromosome Conformation Capture (5C and Hi-C).","6":"[GEO:GSE98671](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98671)","7":"syn21649210","8":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","9":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889756","2":"GSE98894","3":"GSE98894","4":"NA","5":"NA","6":"[GEO:GSE98894](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98894)","7":"syn21681392","8":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","9":"[A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (PMID:29915428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29915428)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889760","2":"RNA-Seq perturbation of embryonic vs extraembryonic lineages","3":"GSE98960","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Comparison of gene expression patterns in Extraembryonic Ectoderm and cancer","6":"[GEO:GSE98960](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98960)","7":"NA","8":"NA","9":"NA","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889762","2":"RRBS perturbation of embryonic vs extraembryonic lineages","3":"GSE98963","4":"Concerted efforts over past decades have established a thorough understanding of the canonical somatic DNA methylation landscape as well as its systematic misregulation across most human cancers.","5":"Comparison of DNA methylation patterns in Extraembryonic Ectoderm and cancer","6":"[GEO:GSE98963](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98963)","7":"syn21645383","8":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","9":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889763","2":"GSE99116","3":"GSE99116","4":"NA","5":"NA","6":"[GEO:GSE99116](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99116)","7":"NA","8":"NA","9":"NA","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889764","2":"GSE99330","3":"GSE99330","4":"NA","5":"NA","6":"[GEO:GSE99330](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99330)","7":"syn21648897","8":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","9":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889765","2":"GSE99378","3":"GSE99378","4":"NA","5":"NA","6":"[GEO:GSE99378](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99378)","7":"syn21649073","8":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","9":"[Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 (PMID:29844167)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29844167)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889766","2":"GSE99790","3":"GSE99790","4":"NA","5":"NA","6":"[GEO:GSE99790](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99790)","7":"syn21681326","8":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","9":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889767","2":"GSE99795","3":"GSE99795","4":"NA","5":"NA","6":"[GEO:GSE99795](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99795)","7":"syn21645255","8":"Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response","9":"[Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response (PMID:29233929)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29233929)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889770","2":"phs001231.v2.p1","3":"phs001231.v2.p1","4":"NA","5":"NA","6":"[dbGaP:phs001231.v2.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001231.v2.p1)","7":"syn21645594","8":"Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells","9":"[Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells (PMID:27146274)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27146274)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889770","2":"phs001231.v2.p1","3":"phs001231.v2.p1","4":"NA","5":"NA","6":"[dbGaP:phs001231.v2.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001231.v2.p1)","7":"syn21645599","8":"Revealing disease-associated pathways by network integration of untargeted metabolomics","9":"[Revealing disease-associated pathways by network integration of untargeted metabolomics (PMID:27479327)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27479327)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889771","2":"phs001680.v1.p1","3":"phs001680.v1.p1","4":"NA","5":"NA","6":"[dbGaP:phs001680.v1.p1](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001680.v1.p1)","7":"syn21645338","8":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","9":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889774","2":"SRP046258","3":"SRP046258","4":"NA","5":"NA","6":"[SRA:SRP046258](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP046258)","7":"syn21645595","8":"Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements","9":"[Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements (PMID:26748710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26748710)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889777","2":"SRP050497","3":"SRP050497","4":"NA","5":"NA","6":"[SRA:SRP050497](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP050497)","7":"syn21681486","8":"Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature","9":"[Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature (PMID:30548288)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30548288)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889778","2":"SRP055569","3":"SRP055569","4":"NA","5":"NA","6":"[SRA:SRP055569](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP055569)","7":"syn21645574","8":"Scalable microfluidics for single-cell RNA printing and sequencing","9":"[Scalable microfluidics for single-cell RNA printing and sequencing (PMID:26047807)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26047807)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889781","2":"SRP058237","3":"SRP058237","4":"NA","5":"NA","6":"[SRA:SRP058237](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP058237)","7":"syn21681315","8":"Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC","9":"[Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC (PMID:26046767)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26046767)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889782","2":"SRP058436","3":"SRP058436","4":"NA","5":"NA","6":"[SRA:SRP058436](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP058436)","7":"syn21645430","8":"Activation of proto-oncogenes by disruption of chromosome neighborhoods","9":"[Activation of proto-oncogenes by disruption of chromosome neighborhoods (PMID:26940867)](https://www.ncbi.nlm.nih.gov/pubmed/?term=26940867)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889783","2":"SRP060702","3":"SRP060702","4":"NA","5":"NA","6":"[SRA:SRP060702](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP060702)","7":"syn21645600","8":"Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens","9":"[Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens (PMID:29023490)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29023490)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889784","2":"SRP064353","3":"SRP064353","4":"NA","5":"NA","6":"[SRA:SRP064353](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP064353)","7":"syn21645337","8":"Combating subclonal evolution of resistant cancer phenotypes","9":"[Combating subclonal evolution of resistant cancer phenotypes (PMID:29093439)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29093439)","10":"syn9771796","11":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Evolution, Metastasis","17":"CSBC"},{"1":"syn21889785","2":"SRP066615","3":"SRP066615","4":"NA","5":"NA","6":"[SRA:SRP066615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP066615)","7":"syn21649212","8":"Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells","9":"[Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells (PMID:28126923)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28126923)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889786","2":"SRP069293","3":"SRP069293","4":"NA","5":"NA","6":"[SRA:SRP069293](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP069293)","7":"syn21645592","8":"Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia","9":"[Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia (PMID:27315426)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27315426)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889787","2":"SRP070188","3":"SRP070188","4":"NA","5":"NA","6":"[SRA:SRP070188](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070188)","7":"syn21645405","8":"A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations","9":"[A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations (PMID:27477909)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27477909)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889788","2":"SRP070460","3":"SRP070460","4":"NA","5":"NA","6":"[SRA:SRP070460](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070460)","7":"syn21645594","8":"Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells","9":"[Cell freezing protocol suitable for ATAC-Seq on motor neurons derived from human induced pluripotent stem cells (PMID:27146274)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27146274)","10":"syn9772917","11":"Embryonal Brain Tumor Networks","12":"","13":"","14":"","15":"U01","16":"Heterogeneity","17":"CSBC"},{"1":"syn21889789","2":"SRP070693","3":"SRP070693","4":"NA","5":"NA","6":"[SRA:SRP070693](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP070693)","7":"syn21681375","8":"3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk","9":"[3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk (PMID:29785014)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29785014)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889790","2":"SRP074429","3":"SRP074429","4":"NA","5":"NA","6":"[SRA:SRP074429](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP074429)","7":"syn21681435","8":"Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression","9":"[Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression (PMID:30306128)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30306128)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889791","2":"SRP075882","3":"SRP075882","4":"NA","5":"NA","6":"[SRA:SRP075882](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075882)","7":"syn21649001","8":"Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer","9":"[Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer (PMID:30232459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30232459)","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889792","2":"SRP075973","3":"SRP075973","4":"NA","5":"NA","6":"[SRA:SRP075973](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP075973)","7":"syn21645389","8":"Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping","9":"[Insights into Nucleosome Organization in Mouse Embryonic Stem Cells through Chemical Mapping (PMID:27889238)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27889238)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889793","2":"SRP076235","3":"SRP076235","4":"NA","5":"NA","6":"[SRA:SRP076235](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076235)","7":"syn21648903","8":"Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes","9":"[Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes (PMID:28446242)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28446242)","10":"syn9771796","11":"Cancer Systems Biology Center of HoPE (Heterogeneity of Phenotypic Evolution)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Evolution, Metastasis","17":"CSBC"},{"1":"syn21889794","2":"SRP076484","3":"SRP076484","4":"NA","5":"NA","6":"[SRA:SRP076484](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076484)","7":"syn21645325","8":"A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue","9":"[A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue (PMID:28429718)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28429718)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889796","2":"SRP076871","3":"SRP076871","4":"NA","5":"NA","6":"[SRA:SRP076871](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP076871)","7":"syn21649111","8":"Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation","9":"[Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation (PMID:27452175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27452175)","10":"syn7416710","11":"ECM geometrical and mechanical properties modulate RTK signaling","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"PS-ON"},{"1":"syn21889797","2":"SRP078495","3":"SRP078495","4":"NA","5":"NA","6":"[SRA:SRP078495](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP078495)","7":"syn21648926","8":"Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma","9":"[Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma (PMID:29510988)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29510988)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889800","2":"SRP090689","3":"SRP090689","4":"NA","5":"NA","6":"[SRA:SRP090689](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP090689)","7":"syn21649209","8":"Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition","9":"[Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition (PMID:28652380)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28652380)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889801","2":"SRP091986","3":"SRP091986","4":"NA","5":"NA","6":"[SRA:SRP091986](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP091986)","7":"syn21645258","8":"DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients","9":"[DNA Methylation Targets Influenced by Bisphenol A and/or Genistein Are Associated with Survival Outcomes in Breast Cancer Patients (PMID:28505145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28505145)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889802","2":"SRP092158","3":"SRP092158","4":"NA","5":"NA","6":"[SRA:SRP092158](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092158)","7":"syn21645339","8":"Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer","9":"[Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer (PMID:27851913)](https://www.ncbi.nlm.nih.gov/pubmed/?term=27851913)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889803","2":"SRP092280","3":"SRP092280","4":"NA","5":"NA","6":"[SRA:SRP092280](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP092280)","7":"syn21645338","8":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","9":"[Chromatin states define tumour-specific T cell dysfunction and reprogramming (PMID:28514453)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28514453)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889804","2":"SRP093757","3":"SRP093757","4":"NA","5":"NA","6":"[SRA:SRP093757](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP093757)","7":"syn21645423","8":"Nm-seq maps 2'-O-methylation sites in human mRNA with base precision","9":"[Nm-seq maps 2'-O-methylation sites in human mRNA with base precision (PMID:28504680)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28504680)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889805","2":"SRP094446","3":"SRP094446","4":"NA","5":"NA","6":"[SRA:SRP094446](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP094446)","7":"syn21648978","8":"Homeobox oncogene activation by pan-cancer DNA hypermethylation","9":"[Homeobox oncogene activation by pan-cancer DNA hypermethylation (PMID:30097071)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30097071)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889808","2":"SRP095013","3":"SRP095013","4":"NA","5":"NA","6":"[SRA:SRP095013](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP095013)","7":"syn21645251","8":"Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis","9":"[Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ER-GREB1 Transcriptional Axis (PMID:29212856)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29212856)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889810","2":"SRP095488","3":"SRP095488","4":"NA","5":"NA","6":"[SRA:SRP095488](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP095488)","7":"syn21645319","8":"Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer","9":"[Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer (PMID:28411207)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28411207)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889811","2":"SRP096338","3":"SRP096338","4":"NA","5":"NA","6":"[SRA:SRP096338](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096338)","7":"syn21681523","8":"Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes","9":"[Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes (PMID:30658994)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30658994)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889812","2":"SRP096883","3":"SRP096883","4":"NA","5":"NA","6":"[SRA:SRP096883](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096883)","7":"syn21649207","8":"Metabolic origins of spatial organization in the tumor microenvironment","9":"[Metabolic origins of spatial organization in the tumor microenvironment (PMID:28246332)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28246332)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889813","2":"SRP096964","3":"SRP096964","4":"NA","5":"NA","6":"[SRA:SRP096964](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP096964)","7":"syn21648963","8":"A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B","9":"[A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-B (PMID:29949764)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29949764)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889814","2":"SRP099648","3":"SRP099648","4":"NA","5":"NA","6":"[SRA:SRP099648](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP099648)","7":"syn21645558","8":"Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development","9":"[Single-cell topological RNA-seq analysis reveals insights into cellular differentiation and development (PMID:28459448)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28459448)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889816","2":"SRP103204","3":"SRP103204","4":"NA","5":"NA","6":"[SRA:SRP103204](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103204)","7":"syn21645322","8":"PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens","9":"[PLATE-Seq for genome-wide regulatory network analysis of high-throughput screens (PMID:28740083)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28740083)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889818","2":"SRP103828","3":"SRP103828","4":"NA","5":"NA","6":"[SRA:SRP103828](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP103828)","7":"syn21649208","8":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","9":"[Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance (PMID:28607484)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28607484)","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889819","2":"SRP105181","3":"SRP105181","4":"NA","5":"NA","6":"[SRA:SRP105181](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105181)","7":"syn21645422","8":"Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation","9":"[Hi-C 2.0: An optimized Hi-C procedure for high-resolution genome-wide mapping of chromosome conformation (PMID:28435001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28435001)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889821","2":"SRP105199","3":"SRP105199","4":"NA","5":"NA","6":"[SRA:SRP105199](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP105199)","7":"syn21645269","8":"Chromosomal instability drives metastasis through a cytosolic DNA response","9":"[Chromosomal instability drives metastasis through a cytosolic DNA response (PMID:29342134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29342134)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889822","2":"SRP106652","3":"SRP106652","4":"NA","5":"NA","6":"[SRA:SRP106652](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP106652)","7":"syn21649210","8":"Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization","9":"[Targeted Degradation of CTCF Decouples Local Insulation of Chromosome Domains from Genomic Compartmentalization (PMID:28525758)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28525758)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889823","2":"SRP107025","3":"SRP107025","4":"NA","5":"NA","6":"[SRA:SRP107025](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107025)","7":"syn21681392","8":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","9":"[A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors (PMID:29915428)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29915428)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889824","2":"SRP107210","3":"SRP107210","4":"NA","5":"NA","6":"[SRA:SRP107210](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP107210)","7":"syn21645383","8":"Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer","9":"[Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer (PMID:28959968)](https://www.ncbi.nlm.nih.gov/pubmed/?term=28959968)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889829","2":"SRP108076","3":"SRP108076","4":"NA","5":"NA","6":"[SRA:SRP108076](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108076)","7":"syn21648897","8":"Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH","9":"[Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH (PMID:29454938)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29454938)","10":"syn7349747","11":"Physical Science Oncology Center at Penn","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889833","2":"SRP108215","3":"SRP108215","4":"NA","5":"NA","6":"[SRA:SRP108215](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108215)","7":"syn21649073","8":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","9":"[Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 (PMID:29844167)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29844167)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889834","2":"SRP108785","3":"SRP108785","4":"NA","5":"NA","6":"[SRA:SRP108785](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108785)","7":"syn21681326","8":"The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation","9":"[The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation (PMID:29045536)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29045536)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889835","2":"SRP108807","3":"SRP108807","4":"NA","5":"NA","6":"[SRA:SRP108807](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP108807)","7":"syn21645255","8":"Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response","9":"[Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response (PMID:29233929)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29233929)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889836","2":"SRP109858","3":"SRP109858","4":"NA","5":"NA","6":"[SRA:SRP109858](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP109858)","7":"syn21648934","8":"Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types","9":"[Harnessing single-cell genomics to improve the physiological fidelity of organoid-derived cell types (PMID:29871632)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29871632)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889837","2":"SRP111555","3":"SRP111555","4":"NA","5":"NA","6":"[SRA:SRP111555](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP111555)","7":"syn21648894","8":"A global transcriptional network connecting noncoding mutations to changes in tumor gene expression","9":"[A global transcriptional network connecting noncoding mutations to changes in tumor gene expression (PMID:29610481)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29610481)","10":"syn10140998","11":"The Cancer Cell Map Initiative","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889838","2":"SRP113754","3":"SRP113754","4":"NA","5":"NA","6":"[SRA:SRP113754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP113754)","7":"syn21681382","8":"Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR","9":"[Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR (PMID:29861175)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29861175)","10":"syn7349753","11":"H Lee Moffitt Cancer Center and Research Institute","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Tumor-Immune","17":"PS-ON"},{"1":"syn21889840","2":"SRP115572","3":"SRP115572","4":"NA","5":"NA","6":"[SRA:SRP115572](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP115572)","7":"syn21649214","8":"A pathway for mitotic chromosome formation","9":"[A pathway for mitotic chromosome formation (PMID:29348367)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29348367)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"},{"1":"syn21889841","2":"SRP116341","3":"SRP116341","4":"NA","5":"NA","6":"[SRA:SRP116341](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP116341)","7":"syn21681447","8":"Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer","9":"[Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer (PMID:30389702)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30389702)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889842","2":"SRP116382","3":"SRP116382","4":"NA","5":"NA","6":"[SRA:SRP116382](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP116382)","7":"syn21648977","8":"Single-cell transcriptome analysis of lineage diversity in high-grade glioma","9":"[Single-cell transcriptome analysis of lineage diversity in high-grade glioma (PMID:30041684)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30041684)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889844","2":"SRP118077","3":"SRP118077","4":"NA","5":"NA","6":"[SRA:SRP118077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP118077)","7":"syn21648885","8":"Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer","9":"[Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer (PMID:29625057)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29625057)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889845","2":"SRP119969","3":"SRP119969","4":"NA","5":"NA","6":"[SRA:SRP119969](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP119969)","7":"syn21681468","8":"KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance","9":"[KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance (PMID:30472020)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30472020)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889847","2":"SRP125804","3":"SRP125804","4":"NA","5":"NA","6":"[SRA:SRP125804](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP125804)","7":"syn21648884","8":"Fenofibrate prevents skeletal muscle loss in mice with lung cancer","9":"[Fenofibrate prevents skeletal muscle loss in mice with lung cancer (PMID:29311302)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29311302)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889849","2":"SRP132902","3":"SRP132902","4":"NA","5":"NA","6":"[SRA:SRP132902](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP132902)","7":"syn21681403","8":"FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation","9":"[FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation (PMID:30046001)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30046001)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889850","2":"SRP132956","3":"SRP132956","4":"NA","5":"NA","6":"[SRA:SRP132956](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP132956)","7":"syn21681553","8":"Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence","9":"[Excessive Cell Growth Causes Cytoplasm Dilution And Contributes to Senescence (PMID:30739799)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30739799)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889851","2":"SRP134389","3":"SRP134389","4":"NA","5":"NA","6":"[SRA:SRP134389](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP134389)","7":"syn21681401","8":"Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes","9":"[Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes (PMID:30037853)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30037853)","10":"syn7349766","11":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Metabolism","17":"PS-ON"},{"1":"syn21889854","2":"SRP137894","3":"SRP137894","4":"NA","5":"NA","6":"[SRA:SRP137894](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP137894)","7":"syn21648964","8":"Patient derived organoids to model rare prostate cancer phenotypes","9":"[Patient derived organoids to model rare prostate cancer phenotypes (PMID:29921838)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29921838)","10":"syn7349770","11":"Center on the Physics of Cancer Metabolism","12":"","13":"","14":"","15":"U54","16":"Metabolism, Microenvironment, Metastasis","17":"PS-ON"},{"1":"syn21889856","2":"SRP144614","3":"SRP144614","4":"NA","5":"NA","6":"[SRA:SRP144614](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP144614)","7":"syn21649039","8":"Quantitative assessment of cell population diversity in single-cell landscapes","9":"[Quantitative assessment of cell population diversity in single-cell landscapes (PMID:30346945)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30346945)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889858","2":"SRP144750","3":"SRP144750","4":"NA","5":"NA","6":"[SRA:SRP144750](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP144750)","7":"syn21681772","8":"Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer","9":"[Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer (PMID:31155233)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31155233)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889859","2":"SRP145267","3":"SRP145267","4":"NA","5":"NA","6":"[SRA:SRP145267](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145267)","7":"syn21681436","8":"Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs","9":"[Decidualization of Human Endometrial Stromal Fibroblasts is a Multiphasic Process Involving Distinct Transcriptional Programs (PMID:30309298)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30309298)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889860","2":"SRP145321","3":"SRP145321","4":"NA","5":"NA","6":"[SRA:SRP145321](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145321)","7":"syn21649081","8":"Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival","9":"[Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival (PMID:29997286)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29997286)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889861","2":"SRP145597","3":"SRP145597","4":"NA","5":"NA","6":"[SRA:SRP145597](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP145597)","7":"syn21681394","8":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","9":"[Recovering Gene Interactions from Single-Cell Data Using Data Diffusion (PMID:29961576)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961576)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889863","2":"SRP148594","3":"SRP148594","4":"NA","5":"NA","6":"[SRA:SRP148594](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148594)","7":"syn21649215","8":"Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment","9":"[Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment (PMID:29961579)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29961579)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889864","2":"SRP148659","3":"SRP148659","4":"NA","5":"NA","6":"[SRA:SRP148659](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP148659)","7":"syn21681737","8":"Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming","9":"[Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming (PMID:31078528)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31078528)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889865","2":"SRP150061","3":"SRP150061","4":"NA","5":"NA","6":"[SRA:SRP150061](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150061)","7":"syn21681993","8":"Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer","9":"[Spatial EGFR Dynamics and Metastatic Phenotypes Modulated by Upregulated EphB2 and Src Pathways in Advanced Prostate Cancer (PMID:31805710)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31805710)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889867","2":"SRP150084","3":"SRP150084","4":"NA","5":"NA","6":"[SRA:SRP150084](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150084)","7":"syn21681517","8":"Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans","9":"[Microtubule regulators act in the nervous system to modulate fat metabolism and longevity through DAF-16 in C. elegans (PMID:30638295)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30638295)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889868","2":"SRP150101","3":"SRP150101","4":"NA","5":"NA","6":"[SRA:SRP150101](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150101)","7":"syn21681442","8":"Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma","9":"[Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma (PMID:30355798)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30355798)","10":"syn9775595","11":"Modeling and targeting stroma-tumor crosstalk in non small cell lung cancer","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889869","2":"SRP150586","3":"SRP150586","4":"NA","5":"NA","6":"[SRA:SRP150586](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150586)","7":"syn21681412","8":"The mammalian decidual cell evolved from a cellular stress response","9":"[The mammalian decidual cell evolved from a cellular stress response (PMID:30142145)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30142145)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889870","2":"SRP150876","3":"SRP150876","4":"NA","5":"NA","6":"[SRA:SRP150876](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP150876)","7":"syn21681501","8":"SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing","9":"[SCOPE-Seq: a scalable technology for linking live cell imaging and single-cell RNA sequencing (PMID:30583733)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30583733)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889871","2":"SRP151472","3":"SRP151472","4":"NA","5":"NA","6":"[SRA:SRP151472](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP151472)","7":"syn21649050","8":"The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types","9":"[The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types (PMID:30224821)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30224821)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889873","2":"SRP155570","3":"SRP155570","4":"NA","5":"NA","6":"[SRA:SRP155570](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP155570)","7":"syn21681828","8":"Somatic mutations and cell identity linked by Genotyping of Transcriptomes","9":"[Somatic mutations and cell identity linked by Genotyping of Transcriptomes (PMID:31270458)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31270458)","10":"syn7349759","11":"Columbia University Center for Topology of Cancer Evolution and Heterogeneity","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Evolution, Metastasis","17":"PS-ON"},{"1":"syn21889874","2":"SRP157038","3":"SRP157038","4":"NA","5":"NA","6":"[SRA:SRP157038](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP157038)","7":"syn21681417","8":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","9":"[Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq (PMID:30181541)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30181541)","10":"syn7349757","11":"Dana-Farber Cancer Institute Physical Sciences-Oncology Center","12":"","13":"","14":"","15":"U54","16":"Evolution, Drug Resistance/Sensitivity, Microenvironment, Heterogeneity","17":"PS-ON"},{"1":"syn21889877","2":"SRP159185","3":"SRP159185","4":"NA","5":"NA","6":"[SRA:SRP159185](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP159185)","7":"syn21681909","8":"PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity","9":"[PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity (PMID:31527834)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31527834)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889879","2":"SRP162268","3":"SRP162268","4":"NA","5":"NA","6":"[SRA:SRP162268](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP162268)","7":"syn21681604","8":"In situ 10-cell RNA sequencing in tissue and tumor biopsy samples","9":"[In situ 10-cell RNA sequencing in tissue and tumor biopsy samples (PMID:30894605)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30894605)","10":"syn17084062","11":"An Integrated Systems Approach for Incompletely Penetrant Onco-phenotypes","12":"","13":"","14":"","15":"U01","16":"Heterogeneity, Evolution","17":"CSBC"},{"1":"syn21889880","2":"SRP164935","3":"SRP164935","4":"NA","5":"NA","6":"[SRA:SRP164935](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP164935)","7":"syn21649183","8":"Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals","9":"[Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals (PMID:30366908)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30366908)","10":"syn9773345","11":"Measuring, Modeling and Controlling Heterogeneity (M2CH)","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Heterogeneity, Microenvironment","17":"CSBC"},{"1":"syn21889881","2":"SRP165726","3":"SRP165726","4":"NA","5":"NA","6":"[SRA:SRP165726](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP165726)","7":"syn21681667","8":"BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells","9":"[BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells (PMID:30995943)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30995943)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889883","2":"SRP166447","3":"SRP166447","4":"NA","5":"NA","6":"[SRA:SRP166447](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP166447)","7":"syn21649021","8":"Linking single-cell measurements of mass, growth rate, and gene expression","9":"[Linking single-cell measurements of mass, growth rate, and gene expression (PMID:30482222)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30482222)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889884","2":"SRP166967","3":"SRP166967","4":"NA","5":"NA","6":"[SRA:SRP166967](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP166967)","7":"syn21681451","8":"Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics","9":"[Analysis of Single-Cell RNA-Seq Identifies Cell-Cell Communication Associated with Tumor Characteristics (PMID:30404002)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30404002)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889886","2":"SRP167164","3":"SRP167164","4":"NA","5":"NA","6":"[SRA:SRP167164](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167164)","7":"syn21681992","8":"Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach","9":"[Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach (PMID:31804471)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31804471)","10":"syn17084053","11":"Systems approaches to understanding the relationships between genotype, signaling, and therapeutic efficacy","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889887","2":"SRP167389","3":"SRP167389","4":"NA","5":"NA","6":"[SRA:SRP167389](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167389)","7":"syn21649049","8":"A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma","9":"[A Nonquiescent \"Idling\" Population State in Drug-Treated, BRAF-Mutated Melanoma (PMID:29590606)](https://www.ncbi.nlm.nih.gov/pubmed/?term=29590606)","10":"syn17084070","11":"Phenotype Transitions in Small Cell Lung Cancer - CA215845","12":"","13":"","14":"","15":"U01","16":"Drug Resistance/Sensitivity, Heterogeneity","17":"CSBC"},{"1":"syn21889888","2":"SRP167390","3":"SRP167390","4":"NA","5":"NA","6":"[SRA:SRP167390](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167390)","7":"syn21681529","8":"Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors","9":"[Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors (PMID:30674530)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674530)","10":"syn7349745","11":"Center for Modeling Tumor Cell Migration Mechanics","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Tumor-Immune","17":"PS-ON"},{"1":"syn21889889","2":"SRP167975","3":"SRP167975","4":"NA","5":"NA","6":"[SRA:SRP167975](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP167975)","7":"syn21681530","8":"Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer","9":"[Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer (PMID:30674677)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30674677)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889890","2":"SRP175077","3":"SRP175077","4":"NA","5":"NA","6":"[SRA:SRP175077](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP175077)","7":"syn21681865","8":"Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils","9":"[Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils (PMID:31402260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31402260)","10":"syn7315808","11":"Stanford University Center for Cancer Systems Biology","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889895","2":"SRP178115","3":"SRP178115","4":"NA","5":"NA","6":"[SRA:SRP178115](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP178115)","7":"syn21681801","8":"Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity","9":"[Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity (PMID:31178407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31178407)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889897","2":"SRP178865","3":"SRP178865","4":"NA","5":"NA","6":"[SRA:SRP178865](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP178865)","7":"syn21681899","8":"Molecular determinants for enzalutamide-induced transcription in prostate cancer","9":"[Molecular determinants for enzalutamide-induced transcription in prostate cancer (PMID:31501863)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31501863)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889899","2":"SRP181911","3":"SRP181911","4":"NA","5":"NA","6":"[SRA:SRP181911](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181911)","7":"syn21681836","8":"A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer","9":"[A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer (PMID:31303470)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31303470)","10":"syn9773346","11":"Systems Analysis of Epigenomic Architecture in Cancer Progression","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Epigenetics","17":"CSBC"},{"1":"syn21889900","2":"SRP181952","3":"SRP181952","4":"NA","5":"NA","6":"[SRA:SRP181952](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP181952)","7":"syn21681851","8":"Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution","9":"[Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution (PMID:31335328)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31335328)","10":"syn7349762","11":"The Center for Immunotherapeutic Transport Oncophysics","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Tumor-Immune, Microenvironment","17":"PS-ON"},{"1":"syn21889901","2":"SRP182724","3":"SRP182724","4":"NA","5":"NA","6":"[SRA:SRP182724](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP182724)","7":"syn21681739","8":"Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration","9":"[Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration (PMID:31080134)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31080134)","10":"syn9773338","11":"Quantitative and Functional Characterization of Therapeutic Resistance in Cancer","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889902","2":"SRP182754","3":"SRP182754","4":"NA","5":"NA","6":"[SRA:SRP182754](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP182754)","7":"syn21681547","8":"Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer","9":"[Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer (PMID:30718260)](https://www.ncbi.nlm.nih.gov/pubmed/?term=30718260)","10":"syn17083789","11":"Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis","12":"","13":"","14":"","15":"U01","16":"Metastasis, Microenvironment","17":"PS-ON"},{"1":"syn21889903","2":"SRP186300","3":"SRP186300","4":"NA","5":"NA","6":"[SRA:SRP186300](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP186300)","7":"syn21681695","8":"Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells","9":"[Natural Genetic Variation Reveals Key Features of Epigenetic and Transcriptional Memory in Virus-Specific CD8T Cells (PMID:31027997)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31027997)","10":"syn7315805","11":"CSBC Research Center for Cancer Systems Immunology at MSKCC","12":"","13":"","14":"","15":"U54","16":"Tumor-Immune, Microenvironment, Drug Resistance/Sensitivity, Metastasis","17":"CSBC"},{"1":"syn21889905","2":"SRP188447","3":"SRP188447","4":"NA","5":"NA","6":"[SRA:SRP188447](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP188447)","7":"syn21681723","8":"A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens","9":"[A microfluidic assay for the quantification of the metastatic propensity of breast cancer specimens (PMID:31061459)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31061459)","10":"syn7349766","11":"Johns Hopkins Physical Sciences Oncology Center (PS-OC)","12":"","13":"","14":"","15":"U54","16":"Microenvironment, Metastasis, Metabolism","17":"PS-ON"},{"1":"syn21889907","2":"SRP191615","3":"SRP191615","4":"NA","5":"NA","6":"[SRA:SRP191615](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP191615)","7":"syn21681814","8":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts","9":"[Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts (PMID:31197017)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31197017)","10":"syn7315802","11":"Center for Cancer Systems Therapeutics (CaST)","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Drug Resistance/Sensitivity","17":"CSBC"},{"1":"syn21889908","2":"SRP192023","3":"SRP192023","4":"NA","5":"NA","6":"[SRA:SRP192023](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP192023)","7":"syn21681783","8":"Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma","9":"[Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma (PMID:31160565)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31160565)","10":"syn12051865","11":"Center for Cancer Systems Pharmacology","12":"","13":"","14":"","15":"U54","16":"Drug Resistance/Sensitivity, Microenvironment","17":"CSBC"},{"1":"syn21889911","2":"SRP201838","3":"SRP201838","4":"NA","5":"NA","6":"[SRA:SRP201838](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP201838)","7":"syn21681881","8":"Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells","9":"[Systematic Immunotherapy Target Discovery Using Genome-Scale InVivo CRISPR Screens in CD8T Cells (PMID:31442407)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31442407)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889912","2":"SRP212810","3":"SRP212810","4":"NA","5":"NA","6":"[SRA:SRP212810](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP212810)","7":"syn21681999","8":"Single-cell connectomic analysis of adult mammalian lungs","9":"[Single-cell connectomic analysis of adult mammalian lungs (PMID:31840053)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31840053)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889913","2":"SRP217843","3":"SRP217843","4":"NA","5":"NA","6":"[SRA:SRP217843](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP217843)","7":"syn21681944","8":"Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer","9":"[Targeting TGFR2-mutant tumors exposes vulnerabilities to stromal TGF blockade in pancreatic cancer (PMID:31609088)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31609088)","10":"syn7349762","11":"The Center for Immunotherapeutic Transport Oncophysics","12":"","13":"","14":"","15":"U54","16":"Heterogeneity, Tumor-Immune, Microenvironment","17":"PS-ON"},{"1":"syn21889914","2":"SRP219234","3":"SRP219234","4":"NA","5":"NA","6":"[SRA:SRP219234](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP219234)","7":"syn21681987","8":"Evolution of placental invasion and cancer metastasis are causally linked","9":"[Evolution of placental invasion and cancer metastasis are causally linked (PMID:31768023)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31768023)","10":"syn7315810","11":"Systems Analysis of Phenotypic Switch in Control of Cancer Invasion","12":"","13":"","14":"","15":"U54","16":"Metastasis, Microenvironment","17":"CSBC"},{"1":"syn21889917","2":"SRP223262","3":"SRP223262","4":"NA","5":"NA","6":"[SRA:SRP223262](https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP223262)","7":"syn21681890","8":"Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation","9":"[Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation (PMID:31495782)](https://www.ncbi.nlm.nih.gov/pubmed/?term=31495782)","10":"syn7349742","11":"Chicago Region Physical Science Oncology Center","12":"","13":"","14":"","15":"U54","16":"Metabolism, Heterogeneity, Evolution","17":"PS-ON"}],"options":{"columns":{"min":{},"max":[10],"total":[17]},"rows":{"min":[10],"max":[10],"total":[295]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWVyZ2VkX2RhdGFzZXRfdGFibGUgPC0gdXBkYXRlX3RhYmxlKFwic3luMjE4OTc5NjhcIiwgbWVyZ2VkX2Zvcm1hdHRlZF9kYXRhc2V0X2RmKVxuXG5gYGAifQ== -->
<pre class="r"><code>merged_dataset_table &lt;- update_table(&quot;syn21897968&quot;, merged_formatted_dataset_df)
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>
 [####################]100.00%   1/1   Done...    
Downloading  [####################]100.00%   159.3kB/159.3kB (565.1kB/s) Job-112109457489230437263223023.csv Done...    
Uploading [--------------------]0.00%   0.0bytes/2.6kB  tmpiupf1c05.csv     
Uploading [####################]100.00%   2.6kB/2.6kB (1.9kB/s) tmpiupf1c05.csv Done...    
 [####################]100.00%   1/1   Done...    
Uploading [--------------------]0.00%   0.0bytes/155.8kB  file65662988718     
Uploading [####################]100.00%   155.8kB/155.8kB (37.3kB/s) file65662988718 Done...    
 [####################]100.00%   1/1   Done...    </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
<div id="publications---merged-table" class="section level2">
<h2>Publications - merged table</h2>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>db_pub_df &lt;- get_table_df(&quot;syn21650536&quot;, cache = FALSE)
db_grant_pub &lt;- get_table_df(&quot;syn21682660&quot;, cache = FALSE)
db_person_pub &lt;- get_table_df(&quot;syn21792842&quot;, cache = FALSE)
db_assay_pub &lt;- get_table_df(&quot;syn21794722&quot;, cache = FALSE)
db_tissue_pub &lt;- get_table_df(&quot;syn21795296&quot;, cache = FALSE)
db_tumortype_pub &lt;- get_table_df(&quot;syn21795742&quot;, cache = FALSE)
db_link_pub &lt;- get_table_df(&quot;syn21868571&quot;, cache = FALSE)
db_dataset_pub &lt;- get_table_df(&quot;syn21895676&quot;, cache = FALSE)

db_dataset_df &lt;- get_table_df(&quot;syn21889931&quot;, cache = FALSE)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxucHViX2xpc3RfY29scyA8LSBjKFxuICBcImdyYW50TmFtZVwiLCBcbiAgXCJhc3NheVwiLCBcbiAgXCJ0aXNzdWVcIiwgXG4gIFwidHVtb3JUeXBlXCIsIFxuICBcImdyYW50VHlwZVwiLCBcbiAgXCJ0aGVtZVwiLCBcbiAgXCJjb25zb3J0aXVtXCJcbilcbmBgYCJ9 -->
<pre class="r"><code>pub_list_cols &lt;- c(
  &quot;grantName&quot;, 
  &quot;assay&quot;, 
  &quot;tissue&quot;, 
  &quot;tumorType&quot;, 
  &quot;grantType&quot;, 
  &quot;theme&quot;, 
  &quot;consortium&quot;
)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_pub_df &lt;- db_pub_df %&gt;% 
  select(-one_of(property_cols)) %&gt;% 
  rename(publicationId = id, publicationTitle = title) %&gt;%
  left_join(db_grant_pub, by = &quot;publicationId&quot;) %&gt;% 
  left_join(db_person_pub, by = &quot;publicationId&quot;) %&gt;% 
  left_join(db_assay_pub, by = &quot;publicationId&quot;) %&gt;% 
  left_join(db_tissue_pub, by = &quot;publicationId&quot;) %&gt;% 
  left_join(db_tumortype_pub, by = &quot;publicationId&quot;) %&gt;% 
  left_join(db_link_pub, by = &quot;publicationId&quot;) %&gt;% 
  left_join(db_dataset_pub, by = &quot;publicationId&quot;) %&gt;% 
  left_join(
    db_grant_df %&gt;% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = &quot;grantId&quot;
  ) %&gt;% 
  left_join(db_theme_grant, by = &quot;grantId&quot;) %&gt;% 
  left_join(
    db_theme_df %&gt;% 
      select(themeId = id, theme = displayName),
    by = &quot;themeId&quot;
  ) %&gt;% 
  left_join(
    db_consortium_df %&gt;% 
      select(consortiumId = id, consortium = displayName)
  ) %&gt;% 
  left_join(
    db_dataset_df %&gt;% 
      select(datasetId = id, dataset = displayName)
  ) %&gt;% 
  select(publicationId, doi, journal, 
         pubMedUrl, publicationTitle, publicationYear, keywords,
         authors = person, assay, tissue, tumorType,
         consortium, grantName, theme, grantType, datasetId, dataset) %&gt;% 
  distinct() %&gt;% 
  mutate_all(~ ifelse(str_detect(., &quot;Not Applicable&quot;), NA, .)) %&gt;% 
  mutate_all(~ ifelse(str_detect(., &quot;^NA$&quot;), NA, .))

merged_pub_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_formatted_pub_df &lt;- merged_pub_df %&gt;%
  filter(!is.na(grantName)) %&gt;%
  group_by(publicationId, doi, journal, pubMedUrl, 
           publicationTitle, publicationYear, keywords) %&gt;%
  summarize(grantName = str_c(unique(grantName), collapse = &quot;, &quot;),
            authors = str_c(unique(authors), collapse = &quot;, &quot;),
            assay = str_c(unique(assay), collapse = &quot;, &quot;),
            tissue = str_c(unique(tissue), collapse = &quot;, &quot;),
            tumorType = str_c(unique(tumorType), collapse = &quot;, &quot;),
            grantType = str_c(unique(grantType), collapse = &quot;, &quot;),
            theme = str_c(unique(theme), collapse = &quot;, &quot;),
            consortium = str_c(unique(consortium), collapse = &quot;, &quot;),
            datasetId = str_c(unique(datasetId), collapse = &quot;, &quot;),
            dataset = str_c(unique(dataset), collapse = &quot;, &quot;)
            ) %&gt;%
  ungroup() %&gt;%
  # rowwise() %&gt;% 
  # mutate_at(pub_list_cols, ~ csv_str_to_json(.)) %&gt;%
  # ungroup() %&gt;% 
  distinct()

merged_formatted_pub_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code># merged_pub_cols &lt;- list(
#   Column(name = &#39;authors&#39;, columnType = &#39;LARGETEXT&#39;),
#   Column(name = &#39;doi&#39;, columnType = &#39;STRING&#39;, maximumSize = 29),
#   Column(name = &#39;journal&#39;, columnType = &#39;STRING&#39;, maximumSize = 39),
#   Column(name = &#39;pubMedUrl&#39;, columnType = &#39;LINK&#39;, maximumSize = 50),
#   Column(name = &#39;publicationTitle&#39;, columnType = &#39;STRING&#39;, maximumSize = 203),
#   Column(name = &#39;publicationYear&#39;, columnType = &#39;INTEGER&#39;, maximumSize = 4),
#   Column(name = &#39;keywords&#39;, columnType = &#39;STRING&#39;, maximumSize = 243),
#   Column(name = &#39;theme&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 27),
#   Column(name = &#39;tumorType&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 50),
#   Column(name = &#39;tissue&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 26),
#   Column(name = &#39;assay&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 60),
#   Column(name = &#39;grantName&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 107),
#   Column(name = &#39;consortium&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 5),
#   Column(name = &#39;grantType&#39;, columnType = &#39;STRING&#39;, maximumSize = 3)
# )</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBtZXJnZWRfcHViX3NjaGVtYSA8LSBTY2hlbWEobmFtZSA9IFwiUG9ydGFsIC0gUHVibGljYXRpb25zIE1lcmdlZCAodGVzdCAzKVwiLCBcbiMgICAgICAgICAgICAgICAgICAgICAgICAgICAgIGNvbHVtbnMgPSBtZXJnZWRfcHViX2NvbHMsIFxuIyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgcGFyZW50ID0gXCJzeW43MDgwNzE0XCIpXG4jIG1lcmdlZF9wdWJfc2NoZW1hXG5gYGAifQ== -->
<pre class="r"><code># merged_pub_schema &lt;- Schema(name = &quot;Portal - Publications Merged (test 3)&quot;, 
#                             columns = merged_pub_cols, 
#                             parent = &quot;syn7080714&quot;)
# merged_pub_schema</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBtZXJnZWRfcHViX3RhYmxlIDwtIFRhYmxlKG1lcmdlZF9wdWJfc2NoZW1hLCBtZXJnZWRfZm9ybWF0dGVkX3B1Yl9kZilcbiMgbWVyZ2VkX3B1Yl90YWJsZSA8LSBzeW5TdG9yZShtZXJnZWRfcHViX3RhYmxlKVxuYGBgIn0= -->
<pre class="r"><code># merged_pub_table &lt;- Table(merged_pub_schema, merged_formatted_pub_df)
# merged_pub_table &lt;- synStore(merged_pub_table)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWVyZ2VkX3B1Yl90YWJsZSA8LSB1cGRhdGVfdGFibGUoXCJzeW4yMTg2ODU5MVwiLCBtZXJnZWRfZm9ybWF0dGVkX3B1Yl9kZilcbmBgYCJ9 -->
<pre class="r"><code>merged_pub_table &lt;- update_table(&quot;syn21868591&quot;, merged_formatted_pub_df)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
<div id="tools---merged-table" class="section level2">
<h2>Tools - merged table</h2>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGJfdG9vbF9kZiA8LSBnZXRfdGFibGVfZGYoXCJzeW4yMTY0NTIwOFwiLCBjYWNoZSA9IEZBTFNFKVxuXG5kYl9kZXNjcmlwdGlvbl90b29sIDwtIGdldF90YWJsZV9kZihcInN5bjIxOTE4MjczXCIsIGNhY2hlID0gRkFMU0UpXG5kYl9kYXRhdHlwZV90b29sIDwtIGdldF90YWJsZV9kZihcInN5bjIxNjgzNDg1XCIsIGNhY2hlID0gRkFMU0UpXG5kYl9sYW5ndWFnZV90b29sIDwtIGdldF90YWJsZV9kZihcInN5bjIxNjgzNDk3XCIsIGNhY2hlID0gRkFMU0UpXG5kYl9saW5rX3Rvb2wgPC0gZ2V0X3RhYmxlX2RmKFwic3luMjE5MzA1NTZcIiwgY2FjaGUgPSBGQUxTRSlcbmBgYCJ9 -->
<pre class="r"><code>db_tool_df &lt;- get_table_df(&quot;syn21645208&quot;, cache = FALSE)

db_description_tool &lt;- get_table_df(&quot;syn21918273&quot;, cache = FALSE)
db_datatype_tool &lt;- get_table_df(&quot;syn21683485&quot;, cache = FALSE)
db_language_tool &lt;- get_table_df(&quot;syn21683497&quot;, cache = FALSE)
db_link_tool &lt;- get_table_df(&quot;syn21930556&quot;, cache = FALSE)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxudG9vbF9saXN0X2NvbHMgPC0gYyhcbiAgXCJncmFudE5hbWVcIiwgXG4gIFwidGhlbWVcIiwgXG4gIFwiY29uc29ydGl1bVwiLFxuICBcImlucHV0RGF0YVR5cGVcIixcbiAgXCJvdXRwdXREYXRhVHlwZVwiXG4pXG5gYGAifQ== -->
<pre class="r"><code>tool_list_cols &lt;- c(
  &quot;grantName&quot;, 
  &quot;theme&quot;, 
  &quot;consortium&quot;,
  &quot;inputDataType&quot;,
  &quot;outputDataType&quot;
)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_tool_df &lt;- db_tool_df %&gt;% 
  select(-one_of(property_cols)) %&gt;% 
  rename(toolId = id, toolName = displayName) %&gt;%
  left_join(db_datatype_tool, by = &quot;toolId&quot;) %&gt;% 
  left_join(db_language_tool, by = &quot;toolId&quot;) %&gt;% 
  left_join(db_link_tool, by = &quot;toolId&quot;) %&gt;% 
  left_join(
    db_grant_df %&gt;% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = &quot;grantId&quot;
  ) %&gt;% 
  left_join(db_theme_grant, by = &quot;grantId&quot;) %&gt;% 
  left_join(
    db_theme_df %&gt;% 
      select(themeId = id, theme = displayName),
    by = &quot;themeId&quot;
  ) %&gt;% 
  left_join(
    db_consortium_df %&gt;% 
      select(consortiumId = id, consortium = displayName)
  ) %&gt;% 
  select(toolId, toolName, dataType, role, softwareLanguage,
         homepageUrl = url, toolType,
         theme, grantId, grantName, consortium) %&gt;%
  distinct() %&gt;% 
  pivot_wider(names_from = role, values_from = dataType) %&gt;% 
  select(-`NA`) %&gt;% 
  unnest(c(&quot;input&quot;)) %&gt;% 
  unnest(&quot;output&quot;) %&gt;% 
  rename_at(c(&quot;input&quot;, &quot;output&quot;), ~ str_c(., &quot;DataType&quot;, sep = &quot;&quot;)) 
    
merged_tool_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>merged_formatted_tool_df &lt;- merged_tool_df %&gt;%
  group_by(toolId, toolName, homepageUrl, toolType) %&gt;%
  summarize(
    grantId = str_c(unique(grantId), collapse = &quot;, &quot;),
    grantName = str_c(unique(grantName), collapse = &quot;, &quot;),
    inputDataType = str_c(unique(inputDataType), collapse = &quot;, &quot;),
    outputDataType = str_c(unique(outputDataType), collapse = &quot;, &quot;),
    softwareLanguage = str_c(unique(softwareLanguage), collapse = &quot;, &quot;),
    theme = str_c(unique(theme), collapse = &quot;, &quot;),
    consortium = str_c(unique(consortium), collapse = &quot;, &quot;)
  ) %&gt;%
  ungroup() %&gt;%
  # rowwise() %&gt;%
  # mutate_at(tool_list_cols, ~ csv_str_to_json(.)) %&gt;%
  # ungroup() %&gt;%
  distinct()

merged_formatted_tool_df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code># merged_tool_cols &lt;- list(
#    Column(name = &#39;toolName&#39;, columnType = &#39;STRING&#39;, maximumSize = 30),
#    Column(name = &#39;inputDataType&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 30),
#    Column(name = &#39;outputDataType&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 30),
#    Column(name = &#39;softwareLanguage&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 20),
#    Column(name = &#39;theme&#39;, columnType = &#39;STRING_LIST&#39;, maximumSize = 50),
#    Column(name = &#39;grantName&#39;, columnType = &#39;STRING&#39;, maximumSize = 160),
#    Column(name = &#39;consortium&#39;, columnType = &#39;STRING&#39;, maximumSize = 30),
#    Column(name = &#39;grantType&#39;, columnType = &#39;STRING&#39;, maximumSize = 10)
# )</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBtZXJnZWRfdG9vbF9zY2hlbWEgPC0gU2NoZW1hKG5hbWUgPSBcIlBvcnRhbCAtIFRvb2xzIE1lcmdlZFwiLFxuIyAgICAgICAgICAgICAgICAgICAgICAgICAgICBjb2x1bW5zID0gbWVyZ2VkX3Rvb2xfY29scyxcbiMgICAgICAgICAgICAgICAgICAgICAgICAgICAgcGFyZW50ID0gXCJzeW43MDgwNzE0XCIpXG4jIG1lcmdlZF90b29sX3NjaGVtYVxuYGBgIn0= -->
<pre class="r"><code># merged_tool_schema &lt;- Schema(name = &quot;Portal - Tools Merged&quot;,
#                            columns = merged_tool_cols,
#                            parent = &quot;syn7080714&quot;)
# merged_tool_schema</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBtZXJnZWRfdG9vbF90YWJsZSA8LSBUYWJsZShtZXJnZWRfdG9vbF9zY2hlbWEsIG1lcmdlZF90b29sX2RmKVxuIyBtZXJnZWRfdG9vbF90YWJsZSA8LSBzeW5TdG9yZShtZXJnZWRfdG9vbF90YWJsZSlcbmBgYCJ9 -->
<pre class="r"><code># merged_tool_table &lt;- Table(merged_tool_schema, merged_tool_df)
# merged_tool_table &lt;- synStore(merged_tool_table)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWVyZ2VkX3Rvb2xfc3ludGFibGUgPC0gdXBkYXRlX3RhYmxlKFwic3luMjE5MzA1NjZcIiwgbWVyZ2VkX2Zvcm1hdHRlZF90b29sX2RmKVxuYGBgIn0= -->
<pre class="r"><code>merged_tool_syntable &lt;- update_table(&quot;syn21930566&quot;, merged_formatted_tool_df)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
</div>

<div id="rmd-source-code">---
title: "CSBC/PS-ON Portal ETL"
output: html_notebook
---

The code in this notebook is used to take data from tables in the [CSBC/PS-ON Portal DB](https://www.synapse.org/#!Synapse:syn21498902/wiki/600349) and recombine them into denormalized, production tables hosted in the [CSBC/PS-ON Knowledge Portal Synapse project](https://www.synapse.org/csbcpson). 

```{r}
library(synapser)
library(syndccutils)
# Sys.setenv(RETICULATE_PYTHON="~/anaconda/envs/csbc-pson-dcc/bin/python")
# library(reticulate)
library(tidyverse)

source("../R/summary_viz.R")
source("../R/synapse_db.R")

synLogin()
# use_condaenv("csbc-pson-dcc")
# synapseclient <- reticulate::import("synapseclient")
# syn <- synapseclient$Synapse()
# syn$login()
```

```{r}
db_consortium_df <- get_table_df("syn21630133", cache = FALSE)
db_theme_df <- get_table_df("syn21630087", cache = FALSE)
db_grant_df <- get_table_df("syn21639712", cache = FALSE)
db_institution_df <- get_table_df("syn21905891", cache = FALSE)

db_theme_grant <- get_table_df("syn21639726", cache = FALSE)
db_institution_grant <- get_table_df("syn21905912", cache = FALSE)
db_person_grant <- get_table_df("syn21905932", cache = FALSE)

property_cols <- c("createdOn", "createdBy",
                   "modifiedOn", "modifiedBy",
                   "currentVersion")
```

## Grants - merged table

```{r}
merged_grant_df <- db_grant_df %>% 
  select(-one_of(property_cols)) %>% 
  rename(grantId = id, grantName = name) %>%
  left_join(db_theme_grant, by = "grantId") %>% 
  left_join(db_institution_grant, by = "grantId") %>% 
  left_join(db_person_grant, by = "grantId") %>% 
  left_join(
    db_theme_df %>% 
      select(themeId = id, theme = displayName),
    by = "themeId"
  ) %>% 
  left_join(
    db_consortium_df %>% 
      select(consortiumId = id, consortium = displayName)
  ) %>% 
  left_join(
    db_institution_df %>% 
      select(institutionId = id, institution = fullName)
  ) %>% 
  select(grantId, grantName, grantNumber, consortium, theme,
         institution, investigator = person,
         abstract = description, grantType) %>% 
  distinct() %>% 
  I

merged_grant_df
```

```{r}
merged_formatted_grant_df <- merged_grant_df %>%
  filter(!is.na(grantName)) %>%
  group_by(grantId, grantName, grantNumber, abstract, grantType) %>%
  summarize(institution = str_c(unique(institution), collapse = " | "),
            investigator = str_c(unique(investigator), collapse = ", "),
            theme = str_c(unique(theme), collapse = ", "),
            consortium = str_c(unique(consortium), collapse = ", ")) %>%
  ungroup() %>%
  distinct()

merged_formatted_grant_df
```

```{r}
# initial table creation (synIDs need to be integers)
# merged_grant_syntable <- merged_formatted_grant_df %>% 
#   mutate_at(vars(contains("Id")), ~ str_replace(., "syn", "")) %>% 
#   synBuildTable("Portal - Grants Merged", "syn7080714", .) %>% 
#   synStore()

# update/overwrite the table
merged_grant_syntable <- merged_formatted_grant_df %>% 
  # mutate(id = grantName) %>% 
  update_table("syn21918972", .)
```


## Projects - merged table

```{r}
db_project_df <- get_table_df("syn21645147", cache = FALSE)
db_description_project <- get_table_df("syn21868407", cache = FALSE)
```

```{r}
merged_project_df <- db_project_df %>% 
  rename(projectId = id, projectName = name) %>%
  left_join(
    db_description_project, by = "projectId"
  ) %>% 
  left_join(
    db_grant_df %>% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = "grantId"
  ) %>% 
  left_join(db_theme_grant, by = "grantId") %>% 
  left_join(
    db_theme_df %>% 
      select(themeId = id, theme = displayName),
    by = "themeId"
  ) %>% 
  left_join(
    db_consortium_df %>% 
      select(consortiumId = id, consortium = displayName)
  ) %>% 
  select(projectId, projectName = displayName, description, 
         theme, grantName, consortium, grantType) %>%
  distinct()

merged_project_df
```

```{r}
merged_formatted_project_df <- merged_project_df %>%
  filter(!is.na(grantName)) %>%
  group_by(projectName, description) %>%
  summarize(grantName = str_c(unique(grantName), collapse = ", "),
            grantType = str_c(unique(grantType), collapse = ", "),
            theme = str_c(unique(theme), collapse = ", "),
            consortium = str_c(unique(consortium), collapse = ", ")) %>%
  ungroup() %>%
  # rowwise() %>% 
  # mutate_at(proj_list_cols, ~ csv_str_to_json(.)) %>%
  # ungroup() %>% 
  distinct()
```

```{r}
# initial table creation (synIDs need to be integers)
# merged_proj_syntable <- merged_formatted_proj_df %>% 
#   mutate_at(vars(contains("Id")), ~ str_replace(., "syn", "")) %>% 
#   synBuildTable("Portal - projs Merged", "syn7080714", .) %>% 
#   synStore()

# update/overwrite the table
merged_proj_syntable <- merged_formatted_proj_df %>% 
  # mutate(id = projName) %>% 
  update_table("syn21868602", .)
```

## Datasets - merged table

```{r}
db_dataset_df <- get_table_df("syn21889931", cache = FALSE)
db_description_dataset <- get_table_df("syn21895659", cache = FALSE)
db_link_dataset <- get_table_df("syn21895656", cache = FALSE)
db_dataset_pub <- get_table_df("syn21895676", cache = FALSE)

db_pub_df <- get_table_df("syn21650536", cache = FALSE)
```

```{r}
merged_dataset_df <- db_dataset_df %>% 
  select(-one_of(property_cols)) %>% 
  rename(datasetId = id, datasetName = fullName, datasetAlias = displayName) %>%
  mutate(datasetName = ifelse(datasetName == "NA", datasetAlias, datasetName)) %>% 
  left_join(db_description_dataset, by = "datasetId") %>% 
  left_join(db_link_dataset, by = "datasetId") %>%
  left_join(db_dataset_pub, by = "datasetId") %>% 
  left_join(
    db_grant_df %>% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = "grantId"
  ) %>% 
  left_join(db_theme_grant, by = "grantId") %>% 
  left_join(
    db_theme_df %>% 
      select(themeId = id, theme = displayName),
    by = "themeId"
  ) %>% 
  left_join(
    db_consortium_df %>% 
      select(consortiumId = id, consortium = displayName)
  ) %>% 
  left_join(
    db_pub_df %>% 
      select(publicationId = id, publicationTitle = title, pubMedUrl)
  ) %>% 
  mutate(pubMedId = str_extract(pubMedUrl, "[0-9].*")) %>%
  mutate_all(~ ifelse(str_detect(., "^NA$"), NA, .)) %>% 
  mutate(externalLink = glue::glue("[{source}:{datasetAlias}]({url})")) %>% 
  mutate(pubMedLink = glue::glue("[{publicationTitle} (PMID:{pubMedId})]({pubMedUrl})")) %>% 
  mutate(tumorType = "", assay = "", species = "") %>% 
  mutate(overallDesign = ifelse(overallDesign == "NA", NA, overallDesign)) %>% 
  select(datasetId, datasetName, datasetAlias,
         description, publicationTitle, overallDesign, 
         tumorType, assay, species, externalLink, 
         publicationId, publication = pubMedLink,
         grantId, grantName, consortium, grantType, theme) %>% 
  mutate_all(~ ifelse(. == "[NA (PMID:NA)](NA)", NA, .)) %>% 
  distinct()

merged_dataset_df
```

```{r}
merged_formatted_dataset_df <- merged_dataset_df %>%
  filter(!is.na(grantName)) %>%
  group_by(datasetId, datasetName, datasetAlias,
           description, overallDesign, externalLink, 
           publicationId, publicationTitle, publication, ) %>%
  summarize(grantId = str_c(unique(grantId), collapse = ", "),
            grantName = str_c(unique(grantName), collapse = ", "),
            tumorType = str_c(unique(tumorType), collapse = ", "),
            assay = str_c(unique(assay), collapse = ", "),
            species = str_c(unique(species), collapse = ", "),
            grantType = str_c(unique(grantType), collapse = ", "),
            theme = str_c(unique(theme), collapse = ", "),
            consortium = str_c(unique(consortium), collapse = ", ")) %>%
  ungroup() %>%
  # rowwise() %>% 
  # mutate_at(pub_list_cols, ~ csv_str_to_json(.)) %>%
  # ungroup() %>% 
  distinct()

merged_formatted_dataset_df
```

```{r}
# initial table creation (synIDs need to be integers)
# merged_dataset_syntable <- merged_formatted_dataset_df %>% 
#   mutate_at(vars(contains("Id")), ~ str_replace(., "syn", "")) %>% 
#   synBuildTable("Portal - datasets Merged", "syn7080714", .) %>% 
#   synStore()

merged_dataset_table <- update_table("syn21897968", merged_formatted_dataset_df)
```

## Publications - merged table

```{r}
db_pub_df <- get_table_df("syn21650536", cache = FALSE)
db_grant_pub <- get_table_df("syn21682660", cache = FALSE)
db_person_pub <- get_table_df("syn21792842", cache = FALSE)
db_assay_pub <- get_table_df("syn21794722", cache = FALSE)
db_tissue_pub <- get_table_df("syn21795296", cache = FALSE)
db_tumortype_pub <- get_table_df("syn21795742", cache = FALSE)
db_link_pub <- get_table_df("syn21868571", cache = FALSE)
db_dataset_pub <- get_table_df("syn21895676", cache = FALSE)

db_dataset_df <- get_table_df("syn21889931", cache = FALSE)
```

```{r}
pub_list_cols <- c(
  "grantName", 
  "assay", 
  "tissue", 
  "tumorType", 
  "grantType", 
  "theme", 
  "consortium"
)
```


```{r, warning=FALSE, message=FALSE}
merged_pub_df <- db_pub_df %>% 
  select(-one_of(property_cols)) %>% 
  rename(publicationId = id, publicationTitle = title) %>%
  left_join(db_grant_pub, by = "publicationId") %>% 
  left_join(db_person_pub, by = "publicationId") %>% 
  left_join(db_assay_pub, by = "publicationId") %>% 
  left_join(db_tissue_pub, by = "publicationId") %>% 
  left_join(db_tumortype_pub, by = "publicationId") %>% 
  left_join(db_link_pub, by = "publicationId") %>% 
  left_join(db_dataset_pub, by = "publicationId") %>% 
  left_join(
    db_grant_df %>% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = "grantId"
  ) %>% 
  left_join(db_theme_grant, by = "grantId") %>% 
  left_join(
    db_theme_df %>% 
      select(themeId = id, theme = displayName),
    by = "themeId"
  ) %>% 
  left_join(
    db_consortium_df %>% 
      select(consortiumId = id, consortium = displayName)
  ) %>% 
  left_join(
    db_dataset_df %>% 
      select(datasetId = id, dataset = displayName)
  ) %>% 
  select(publicationId, doi, journal, 
         pubMedUrl, publicationTitle, publicationYear, keywords,
         authors = person, assay, tissue, tumorType,
         consortium, grantName, theme, grantType, datasetId, dataset) %>% 
  distinct() %>% 
  mutate_all(~ ifelse(str_detect(., "Not Applicable"), NA, .)) %>% 
  mutate_all(~ ifelse(str_detect(., "^NA$"), NA, .))

merged_pub_df
```

```{r}
merged_formatted_pub_df <- merged_pub_df %>%
  filter(!is.na(grantName)) %>%
  group_by(publicationId, doi, journal, pubMedUrl, 
           publicationTitle, publicationYear, keywords) %>%
  summarize(grantName = str_c(unique(grantName), collapse = ", "),
            authors = str_c(unique(authors), collapse = ", "),
            assay = str_c(unique(assay), collapse = ", "),
            tissue = str_c(unique(tissue), collapse = ", "),
            tumorType = str_c(unique(tumorType), collapse = ", "),
            grantType = str_c(unique(grantType), collapse = ", "),
            theme = str_c(unique(theme), collapse = ", "),
            consortium = str_c(unique(consortium), collapse = ", "),
            datasetId = str_c(unique(datasetId), collapse = ", "),
            dataset = str_c(unique(dataset), collapse = ", ")
            ) %>%
  ungroup() %>%
  # rowwise() %>% 
  # mutate_at(pub_list_cols, ~ csv_str_to_json(.)) %>%
  # ungroup() %>% 
  distinct()

merged_formatted_pub_df
```

```{r}
# merged_pub_cols <- list(
#   Column(name = 'authors', columnType = 'LARGETEXT'),
#   Column(name = 'doi', columnType = 'STRING', maximumSize = 29),
#   Column(name = 'journal', columnType = 'STRING', maximumSize = 39),
#   Column(name = 'pubMedUrl', columnType = 'LINK', maximumSize = 50),
#   Column(name = 'publicationTitle', columnType = 'STRING', maximumSize = 203),
#   Column(name = 'publicationYear', columnType = 'INTEGER', maximumSize = 4),
#   Column(name = 'keywords', columnType = 'STRING', maximumSize = 243),
#   Column(name = 'theme', columnType = 'STRING_LIST', maximumSize = 27),
#   Column(name = 'tumorType', columnType = 'STRING_LIST', maximumSize = 50),
#   Column(name = 'tissue', columnType = 'STRING_LIST', maximumSize = 26),
#   Column(name = 'assay', columnType = 'STRING_LIST', maximumSize = 60),
#   Column(name = 'grantName', columnType = 'STRING_LIST', maximumSize = 107),
#   Column(name = 'consortium', columnType = 'STRING_LIST', maximumSize = 5),
#   Column(name = 'grantType', columnType = 'STRING', maximumSize = 3)
# )
```

```{r}
# merged_pub_schema <- Schema(name = "Portal - Publications Merged (test 3)", 
#                             columns = merged_pub_cols, 
#                             parent = "syn7080714")
# merged_pub_schema
```

```{r}
# merged_pub_table <- Table(merged_pub_schema, merged_formatted_pub_df)
# merged_pub_table <- synStore(merged_pub_table)
```

```{r}
merged_pub_table <- update_table("syn21868591", merged_formatted_pub_df)
```



## Tools - merged table

```{r}
db_tool_df <- get_table_df("syn21645208", cache = FALSE)

db_description_tool <- get_table_df("syn21918273", cache = FALSE)
db_datatype_tool <- get_table_df("syn21683485", cache = FALSE)
db_language_tool <- get_table_df("syn21683497", cache = FALSE)
db_link_tool <- get_table_df("syn21930556", cache = FALSE)
```

```{r}
tool_list_cols <- c(
  "grantName", 
  "theme", 
  "consortium",
  "inputDataType",
  "outputDataType"
)
```

```{r}
merged_tool_df <- db_tool_df %>% 
  select(-one_of(property_cols)) %>% 
  rename(toolId = id, toolName = displayName) %>%
  left_join(db_datatype_tool, by = "toolId") %>% 
  left_join(db_language_tool, by = "toolId") %>% 
  left_join(db_link_tool, by = "toolId") %>% 
  left_join(
    db_grant_df %>% 
      select(grantId = id, grantName = name, grantType, consortiumId), 
    by = "grantId"
  ) %>% 
  left_join(db_theme_grant, by = "grantId") %>% 
  left_join(
    db_theme_df %>% 
      select(themeId = id, theme = displayName),
    by = "themeId"
  ) %>% 
  left_join(
    db_consortium_df %>% 
      select(consortiumId = id, consortium = displayName)
  ) %>% 
  select(toolId, toolName, dataType, role, softwareLanguage,
         homepageUrl = url, toolType,
         theme, grantId, grantName, consortium) %>%
  distinct() %>% 
  pivot_wider(names_from = role, values_from = dataType) %>% 
  select(-`NA`) %>% 
  unnest(c("input")) %>% 
  unnest("output") %>% 
  rename_at(c("input", "output"), ~ str_c(., "DataType", sep = "")) 
    
merged_tool_df
```

```{r}
merged_formatted_tool_df <- merged_tool_df %>%
  group_by(toolId, toolName, homepageUrl, toolType) %>%
  summarize(
    grantId = str_c(unique(grantId), collapse = ", "),
    grantName = str_c(unique(grantName), collapse = ", "),
    inputDataType = str_c(unique(inputDataType), collapse = ", "),
    outputDataType = str_c(unique(outputDataType), collapse = ", "),
    softwareLanguage = str_c(unique(softwareLanguage), collapse = ", "),
    theme = str_c(unique(theme), collapse = ", "),
    consortium = str_c(unique(consortium), collapse = ", ")
  ) %>%
  ungroup() %>%
  # rowwise() %>%
  # mutate_at(tool_list_cols, ~ csv_str_to_json(.)) %>%
  # ungroup() %>%
  distinct()

merged_formatted_tool_df
```

```{r}
# merged_tool_cols <- list(
#    Column(name = 'toolName', columnType = 'STRING', maximumSize = 30),
#    Column(name = 'inputDataType', columnType = 'STRING_LIST', maximumSize = 30),
#    Column(name = 'outputDataType', columnType = 'STRING_LIST', maximumSize = 30),
#    Column(name = 'softwareLanguage', columnType = 'STRING_LIST', maximumSize = 20),
#    Column(name = 'theme', columnType = 'STRING_LIST', maximumSize = 50),
#    Column(name = 'grantName', columnType = 'STRING', maximumSize = 160),
#    Column(name = 'consortium', columnType = 'STRING', maximumSize = 30),
#    Column(name = 'grantType', columnType = 'STRING', maximumSize = 10)
# )
```

```{r}
# merged_tool_schema <- Schema(name = "Portal - Tools Merged",
#                            columns = merged_tool_cols,
#                            parent = "syn7080714")
# merged_tool_schema
```

```{r}
# merged_tool_table <- Table(merged_tool_schema, merged_tool_df)
# merged_tool_table <- synStore(merged_tool_table)
```

```{r}
merged_tool_syntable <- update_table("syn21930566", merged_formatted_tool_df)
```


</div>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});

$(document).ready(function () {
  $('.knitsql-table').addClass('kable-table');
  var container = $('.kable-table');
  container.each(function() {

    // move the caption out of the table
    var table = $(this).children('table');
    var caption = table.children('caption').detach();
    caption.insertBefore($(this)).css('display', 'inherit');
  });
});

</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
